



### (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

# (19) World Intellectual Property Organization International Bureau

# A POOR

## T COLO BUNDOS O COLOR SUCO BUNDO BUNDO

### (43) International Publication Date 19 August 2004 (19.08.2004)

### **PCT**

# (10) International Publication Number WO 2004/070002 A2

(51) International Patent Classification7:

**C12N** 

(21) International Application Number:

PCT/US2003/037143

(22) International Filing Date:

18 November 2003 (18.11.2003)

(25) Filing Language:

English

(26) Publication Language:

(30) Priority Data:

60/427,464 60/482,604 18 November 2002 (18.11.2002) US 25 June 2003 (25.06.2003) US

English

(71) Applicant (for all designated States except US): THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION [US/US]; Technology Transfer Office, 4770 Buford Highway (K79), Atlanta, GA 30341

(US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): HODGE, Thomas, W. [US/US]; 9115 Twelvestones Dr., Roswell, GA 30076 (US). MOREY, Natalie, J. [US/US]; 3138 Caldwell Rd. NE, Atlanta, GA 30319-2918 (US). RUBIN, Don [US/US]; 1129 Hardinghill Lane, Nashville, TN 37215 (US). SHAW, Michael, W. [US/US]; 2614 Willow Cove,

Decatur, GA 30033-2200 (US). SANCHEZ, Anthony [US/US]; 1717 Red Fox Run, Lilburn, GA 30047 (US).

- (74) Agent: RYBAK, Sheree, Lynn; Klarquist Sparkman, LLP, Suite 1600, One World Trade Center, 121 SW Salmon Street, Portland, OR 97204 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

### Declaration under Rule 4.17:

- of inventorship (Rule 4.17(iv)) for US only

### Published:

 without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CELL LINES AND HOST NUCLEIC ACID SEQUENCES RELATED TO INFECTIOUS DISEASE

(57) Abstract: Host nucleic acids and host proteins that participate in viral infection, such as human immunodeficiency virus (HIV), influenza A, and Ebola virus, have been identified. Interfering with or disrupting the interaction between a host nucleic acid or host protein and a virus or viral protein confers an inhibition of or resistance to infection. Thus, interfering with such an interaction in a host subject can confer a therapeutic or prophylactic effect against a virus. The sequences identified can be used to identify agents that reduce or inhibit viral infection.

BEST AVAILABLE COPY

/O 2004/070002 A2



10

15

20

25

30

## CELL LINES AND HOST NUCLEIC ACID SEQUENCES RELATED TO INFECTIOUS DISEASE

### CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application Nos. 60/427,464 filed November 18, 2002 and 60/482,604 filed June 25, 2003, both herein incorporated by reference.

### FIELD

The present disclosure relates to host nucleic acid sequences, and proteins encoded by these sequences, that are involved in viral infection or are otherwise associated with the life cycle of a virus. Decreasing or inhibiting the interaction of these host sequences with a viral sequence can be used to decrease or inhibit infection by the virus.

### **BACKGROUND**

Infectious diseases affect the health of people and animals around the world, causing serious illness and death. Public health efforts have focused on behavioral modification and other public health efforts to reduce the incidences of infection, while treatment regimens for these diseases have focused on pharmaceuticals, such as antibiotics and anti-viral medications. However, educating people about modifying behavior can be difficult, and that approach alone rarely can significantly diminish the incidence of infection. Furthermore, modifying the behavior of domestic or wild animals would not result in diminished infections. Stopping the spread of infections in an animal population typically involves wholesale slaughter. Few vaccines are available or wholly effective, and they tend to be specific for particular conditions.

The rate of HIV (human immunodeficiency virus) infection is increasing. HIV and its associated acquired immune deficiency syndrome (AIDS) accounted for approximately 5% of all deaths in the United States in the year 2000, while over 313,000 persons were reported to be living with AIDS in that same year. Centers for Disease Control and Prevention, HIV/AIDS Surveillance Supplemental Report, 8(1):1-22 (2002). These increasing infection rates have occurred, even though the mode of HIV infection has been known for almost 20 years, and educational programs around the world have promoted behavioral modifications meant to reduce HIV infection. Incidence and death rates due to HIV disease have been decreasing since the mid-90's, in part due to aggressive antiviral therapies, which frequently have toxic side effects and strict dosage schedules. However, even with treatment, the patient is not cured of the disease, and to date, no effective vaccine therapy has been found.

In other diseases, such as infection by the Ebola virus, not only are treatments limited, but containment or prevention of infections is difficult because the life cycle of the virus is not well known. The natural reservoir for the Ebola virus, that is the place or population in nature where the virus resides between human outbreaks, has not yet been identified.

PCT/US2003/037143

5

10

15

20

25

30

35

Additionally, different viral strains can rapidly evolve in response to drug usage, producing drug-resistant strains. For example, strains of the influenza virus resistant to amantadine and rimantadine have recently arisen. A recent study of 80 newly-infected people conducted by the AIDS Research Center at Rockefeller University in New York, found that as many as 16.3% of these individuals had strains of HIV associated with resistance to some treatments, and 3.8% appeared to be resistant to several currently available anti-HIV drugs. Thus, a need exists for alternative treatments for infectious disease and methods of designing new drugs to combat infectious disease.

#### SUMMARY

Several host nucleic acid sequences involved in viral infection have been identified using gene trap methods. The identification of these host sequences and their encoded products permits the identification of sequences that can be targeted for therapeutic intervention.

The disclosed host sequences (including the target sequences associated with SEQ ID NOS: 1-227, 229, and 231, and the proteins encoded thereby (such as SEQ ID NOS: 228, 230, and 232), as well as variants, fusions, and fragments thereof that retain the appropriate biological activity) can mediate infection, and in some examples these host nucleic acids are required for infection. For example, the host nucleic acid can encode a cellular receptor or ligand or a fragment thereof that is recognized by a virus, such as the T-cell V-D-J beta 2.1 chain. In another example, the host nucleic acid encodes an enzyme that mediates viral infection, such as the β-chimerin rho-GTPase (referred to herein as β-chimerin). In another example, the host nucleic acid encodes a Ras oncogene family member such as Rab9. It is demonstrated herein that Rab9 is a host protein involved in infection by pathogens (such as viruses and bacteria) that use similar pathways for morphogenesis of infectious particles. In particular examples, Rab9 is involved in infection by pathogens (such as viruses and bacteria) that utilize lipid rafts. Thus, for example, interfering with the interaction between the disclosed host proteins and a viral or pathogen protein, for example by disrupting the expression of the host nucleic acid within a host cell, or by administering an agent that decreases binding between a host protein and a viral protein, can inhibit, or even prevent, infection of that host cell by the associated virus. Moreover, the identification of particular host enzymes or other host proteins involved in infection provides a method for developing new therapies targeted at inhibiting infection, at the protein or nucleic acid level.

In some examples, the nucleic acid itself mediates viral infection. For example, the nucleotide sequence of a host nucleic acid in the host genome can be recognized by the virus during integration of the viral genome into the host genome. The identification of nucleic acid sequences that are involved in the pathogenesis of infection therefore provides an important tool for interfering with infection.

This genomics-based discovery of nucleic acids and proteins involved in, or even required for, infection provides a new paradigm for identifying and validating various aspects of infectious disease, including assessing individual or population resistance to infection and finding novel

20

25

30

35

diagnostic and drug targets for infectious disease and altering the nucleotide sequence of the host nucleic acid.

Based on the identification of several host nucleic acid and protein sequences involved in viral infection, provided herein are methods for decreasing infection of a host cell by a virus, such as HIV, Ebola, or influenza A, or treating such a viral infection, by interfering with the activity or expression of one or more host proteins shown in Table 1 (including the target sequences associated with any of SEQ ID NOS: SEQ ID NOS: 1-232, as well as variants, fragments, and fusions thereof), such as at least two host proteins, or at least three host proteins. Also provided are methods for identifying agents that can decrease viral infection of a host cell, such as infection by HIV, Ebola, or influenza A. In addition, cells and non-human mammals are provided that have decreased susceptibility to viral infection, such as HIV, Ebola, or influenza A infection.

### BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 is a schematic illustration of the U3neoSV1 retroviral vector, which is capable of isolating the nucleic acids described herein using the gene-trap method.

FIG. 2 is a schematic illustration of the gene-trap method.

FIG. 3 is a schematic illustration of one method of identifying host genes described herein.

FIG. 4 is a flow chart illustrating a method for isolating cells resistant to HIV infection, including HIV-1 and HIV-2 infection.

FIG. 5 is a bar graph showing the relative amount of p24 in HIV-infected cells in the presence of various siRNAs. CHN (β-chimerin); KOX (similar to KOX4 (LOC131880) and LOC166140); RBB (retinoblastoma binding protein 1); RAB (Rab9); KIAA1259; F3 (tissue factor 3; thromboplastin); AXL (AXL receptor tyrosine kinase); Msleb (mammalian selenium binding protein).

FIG. 6 is a schematic drawing showing a model of Rab9 involvement in lipid raft formation.

### SEQUENCE LISTING

The nucleotide sequences of the nucleic acids described herein are shown using standard letter abbreviations for nucleotide bases, and three letter code for amino acids. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood as included by any reference to the displayed strand. Additionally, the nucleic acid sequences shown in SEQ ID NOS: 1-226 inherently disclose the corresponding polypeptide sequences of coding sequences (resulting translations of the nucleotide sequences), even when those polypeptide sequences are not explicitly provided herein.

SEQ ID NO: 1 is a nucleic acid sequence associated with viral, such as HIV, infection, and is the clone identified as Nucleotide Sequence 18E8, entire insert. The human homolog is the (-) strand of GenBank Accession No. NG\_001333.1, T-cell receptor V beta chain (T-cell receptor beta). Further information on the T-cell receptor V beta chain can be found in WO 01/23409, WO 01/55302, WO 01/57182, and WO 01/94629.

10

15

SEQ ID NO: 2 is a nucleic acid sequence associated with viral, such as HIV, infection, and is the clone identified as Nucleotide Sequence 18BA, distal end. The human homolog is the (-) strand of GenBank Accession No. AC104597.3, T-cell receptor V beta chain.

SEQ ID NO: 3 is a nucleic acid sequence associated with viral, such as HIV, infection, and is the clone identified as Nucleotide Sequence 18BA, proximal end. The human homolog is the (+) strand of GenBank Accession No. NG\_001333.1, T-cell receptor beta.

SEQ ID NO: 4 is a nucleic acid sequence associated with viral, such as HIV, infection, and is the clone identified as Nucleotide Sequence 18BE, distal end. The human homolog is the (+) strand of GenBank Accession No. AC00616.7, T-cell receptor beta.

SEQ ID NO: 5 is a nucleic acid sequence associated with viral, such as HIV, infection, and is the clone identified as Nucleotide Sequence 18BE, middle of insert. The human homolog is the (-) strand of GenBank Accession No. AC104597.3, T-cell receptor beta.

SEQ ID NO: 6 is a nucleic acid sequence associated with viral, such as HIV, infection, and is the clone identified as Nucleotide Sequence 18BE, proximal end. The human homolog is the (+) strand of GenBank Accession No. NG\_001333.1, T-cell receptor beta.

SEQ ID NO: 7 is a nucleic acid sequence associated with viral, such as HIV, infection which corresponds to the sequence identified as Nucleotide Sequence 18E6, proximal end. The human homolog is the (-) strand of GenBank Accession No. NG\_001333.1, T-cell receptor beta.

SEQ ID NO: 8 is a nucleic acid sequence associated with viral, such as HIV, infection, and is the clone identified as Nucleotide Sequence 2E21, proximal end. The human homolog is the (+) strand of GenBank Accession No. NG\_001333.1, T-cell receptor beta.

SEQ ID NO: 9 is a nucleic acid sequence associated with viral, such as HIV, infection which corresponds to the sequence identified as Nucleotide Sequence 2E22, proximal end. The human homolog is the (-) strand of GenBank Accession No. AC099395.2, T-cell receptor beta.

SEQ ID NO: 10 is a nucleic acid sequence associated with viral, such as HIV, infection, and is the clone identified as Nucleotide Sequence 2B13, proximal end. The human homolog is the (-) strand of GenBank Accession No. NG\_001333.1, T-cell receptor beta.

SEQ ID NO: 11 is a nucleic acid sequence associated with viral, such as HIV, infection, and is the clone identified as Nucleotide Sequence 2B14, proximal end. The human homolog is the (-) strand of GenBank Accession No. NG\_001333.1, T-cell receptor beta.

SEQ ID NO: 12 is a nucleic acid sequence associated with viral, such as HIV, infection, and is the clone identified as Nucleotide Sequence 2B15, distal end. The human homolog is the (+) strand of GenBank Accession No. NG\_001333.1, T-cell receptor beta.

SEQ ID NO: 13 is a nucleic acid sequence associated with viral, such as HIV, infection, and is the clone identified as Nucleotide Sequence 2B15, proximal end. The human homolog is the (-) strand of GenBank Accession No. NG\_001333.1, T-cell receptor beta.

SEQ ID NO: 14 is a nucleic acid sequence associated with viral, such as HIV, infection, and is the clone identified as Nucleotide Sequence 2B16, proximal end. The human homolog is the (-) strand of GenBank Accession No. NG\_001333.1, T-cell receptor beta.

20

25

35

30

10

15

20

25

30

35

SEQ ID NO: 15 is a nucleic acid sequence associated with viral, such as HIV, infection, and is the clone identified as Nucleotide Sequence 2E23, distal end. The human homolog is the (-) strand of GenBank Accession No. NG\_001333.1, T-cell receptor beta.

SEQ ID NO: 16 is a nucleic acid sequence associated with viral, such as HIV, infection, and is the clone identified as Nucleotide Sequence 2E23, proximal end. The human homolog is the (+) strand of GenBank Accession No. NG\_001333.1, T-cell receptor beta.

SEQ ID NO: 17 is a nucleic acid sequence associated with viral, such as HIV, infection, and is the clone identified as Nucleotide Sequence 2E24, proximal end. The human homolog is the (+) strand of GenBank Accession No. NG\_001333.1, T-cell receptor beta.

SEQ ID NO: 18 is a nucleic acid sequence associated with viral, such as HIV, infection, and is the clone identified as Nucleotide Sequence 2E25, proximal end. The human homolog is the (+) strand of GenBank Accession No. NG\_001333.1, T-cell receptor beta.

SEQ ID NO: 19 is a nucleic acid sequence associated with viral, such as HIV, infection, and is the clone identified as Nucleotide Sequence 2E26, proximal end. The human homolog is the (+) strand of GenBank Accession No. NG\_001333.1, T-cell receptor beta.

SEQ ID NO: 20 is a nucleic acid sequence associated with viral, such as HIV, infection, and is the clone identified as Nucleotide Sequence 18BD, proximal end. The human homolog is the (+) strand of GenBank Accession No. M16834.1, T-cell receptor V-D-J-beta 2.1 chain (described in WO 02/057414 and Reynolds et al., Cell 50(1):107-17, 1987).

SEQ ID NO: 21 is a nucleic acid sequence associated with viral, such as HIV, infection, and is the clone identified as Nucleotide Sequence 18E7, distal end. The human homolog is the (-) strand of GenBank Accession No. AC004593.1 including beta-chimaerin rho GTPase (CHN2) (for example see WO 01/12659).

SEQ ID NO: 22 is a nucleic acid sequence associated with viral, such as HIV, infection, and is the clone identified as Nucleotide Sequence 18E7, proximal end. The human homologs are the (-) strand of GenBank Accession No. NG\_001333.1, T-cell receptor beta; and the (+) strand of GenBank Accession No. AC004593.1 including beta-chimaerin (CHN2).

SEQ ID NO: 23 is a nucleic acid sequence associated with viral, such as HIV and influenza A, infection, and is the clone identified as Nucleotide Sequence 18E6, distal end. The human homolog is the (+) strand of GenBank Accession No. AL049699.8, including malic enzyme 1 (ME1) NADP(+)-dependent cytosolic. Further information on this gene can be found in WO 01/55301 and WO 01/53312.

SEQ ID NO: 24 is a nucleic acid sequence associated with viral, such as HIVand influenza A, infection, and is the clone identified as Nucleotide Sequence 18BD, distal end. The human homolog is the (+) strand of GenBank Accession No. AC123903.1, including hypothetical protein XP 174419.

SEQ ID NO: 25 is a nucleic acid sequence associated with viral, such as HIVand influenza A, infection, and is the clone identified as Nucleotide Sequence 18E9, distal end. The human

10

15

20

25

30

35

homolog is the (+) strand of GenBank Accession No. AC096736.3, a region of chromosome 4q31.3-32.

SEQ ID NO: 26 is a nucleic acid sequence associated with viral, such as HIVand influenza A, infection, and is the clone identified as Nucleotide Sequence 18E9, middle of insert. The human homolog is the (+) strand of GenBank Accession No. AC096736.3, a region of chromosome 4q31.3-32.

SEQ ID NO: 27 is a nucleic acid sequence associated with viral, such as HIVand influenza A, infection, and is the clone identified as Nucleotide Sequence 18E9, proximal end. The human homologs are the (-) strand of GenBank Accession No. NG\_001333.1, T-cell receptor beta; and (-) strand of GenBank Accession No. AC096736.3, a region of chromosome 4q31.3-32.

SEQ ID NO: 28 is a nucleic acid sequence associated with viral, such as HIV, infection, and is the clone identified as Nucleotide Sequence 2E21, distal end. The human homolog is the (-) strand of GenBank Accession No. M26920.1, alpha satellite DNA.

SEQ ID NO: 29 is a nucleic acid sequence associated with viral, such as HIV, infection, and is the clone identified as Nucleotide Sequence 2E22, distal end. The human homologs are the (+) strand of GenBank Accession No. AP004369.3, including LOC253788 (and neighboring similar to RIKEN cDNA 1700001L23 (LOC219938)); and the (+) strand of GenBank Accession No. AC093117.2, between coagulation factor III, thromboplastin, tissue factor (F3) and LOC91759.

SEQ ID NO: 30 is a nucleic acid sequence associated with viral, such as HIV, infection, and is the clone identified as Nucleotide Sequence 2B13, distal end. The human homolog is the (-) strand of GenBank Accession No. AC092043.2, between similar to zinc finger protein 7 KOX4 (LOC131880) and LOC166140.

SEQ ID NO: 31 is a nucleic acid sequence associated with viral, such as HIV, infection, and is the clone identified as Nucleotide Sequence 2B14, distal end. The human homologs are the (-) strand of GenBank Accession No. AL136963.17, between LOC222474 and similar to Rho guanine nucleotide exchange factor 4, isoform a, APC-stirmulated guanine nucleotide exchange factor (LOC221178); and the (+) strand of GenBank Accession No. NG\_001333.1, T-cell receptor beta.

SEQ ID NO: 32 is a nucleic acid sequence associated with viral, such as HIV, infection, and is the clone identified as Nucleotide Sequence 2B16, distal end. The human homolog is the (-) strand of GenBank Accession No. AL133293.28, between ribosomal protein L7A-like 4 (RPL7AL4) and v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian) (SRC).

SEQ ID NO: 33 is a nucleic acid sequence associated with viral, such as HIV, infection, and is the clone identified as Nucleotide Sequence 2E24, distal end. The human homolog is the (-) strand of GenBank Accession No. AL161417.17, KIAA0564.

SEQ ID NO: 34 is a nucleic acid sequence associated with viral, such as HIV, infection, and is the clone identified as Nucleotide Sequence 2E25, distal end. The human homologs are the (-) strand of GenBank Accession No. Z12006.1, alpha satellite DNA; and the (+) and (-) strands of GenBank Accession No. AC093577.2, M96 protein.

15

20

25

30

35 ·

SEQ ID NO: 35 is a nucleic acid sequence associated with viral, such as HTV, infection, and is the clone identified as Nucleotide Sequence 2E26, distal end. The human homologs are the (-) strand of GenBank Accession No. Z78022.1, hypothetical protein similar to G proteins, especially RAP-2A (LOC57826); and the (+) strand of GenBank Accession No. AL136220.14, between LOC161005 and osteoblast specific factor 2 (fasciclin I-like; OSF-2).

SEQ ID NO: 36 is a nucleic acid sequence associated with viral, such as influenza A, infection, and is the clone identified as Nucleotide Sequence B3B1, distal end. The canine homolog is the (+) and (-) strand portions of GenBank Accession No. AJ012166.1, Canis familiaris TCTA gene, AMT gene, DAG1 gene, and BSN gene.

SEQ ID NO: 37 is a nucleic acid sequence associated with viral, such as influenza A, infection, and is the clone identified as Nucleotide Sequence B5B5, distal end. The canine homolog is the (+) and (-) strand portions of GenBank Accession No. AJ012166.1, Canis familiaris TCTA gene, AMT gene, DAG1 gene, and BSN gene.

SEQ ID NO: 38 is a nucleic acid sequence associated with viral, such as influenza A, infection, and is the clone identified as Nucleotide Sequence B1B1, distal end. The human homolog is the (+) strand of GenBank Accession No. AC117507.5, including LIM domain containing preferred translocation partner in lipoma (LPP).

SEQ ID NO: 39 is a nucleic acid sequence associated with viral, such as influenza A, infection, and is the clone identified as Nucleotide Sequence B1B2, distal end. The human homolog is the (-) strand of GenBank Accession No. AC117507.5, including LIM domain containing preferred translocation partner in lipoma (LPP).

SEQ ID NO: 40 is a nucleic acid sequence associated with viral, such as influenza A, infection, and is the clone identified as Nucleotide Sequence B1B4, distal end. The human homolog is the (-) strand of GenBank Accession No. AC117507.5, including LIM domain containing preferred translocation partner in lipoma (LPP).

SEQ ID NO: 41 is a nucleic acid sequence associated with viral, such as influenza A, infection, and is the clone identified as Nucleotide Sequence B1B5, distal end. The human homolog is the (-) strand of GenBank Accession No. AC117507.5, including LIM domain containing preferred translocation partner in lipoma (LPP).

SEQ ID NO: 42 is a nucleic acid sequence associated with viral, such as influenza A, infection, and is the clone identified as Nucleotide Sequence B1B6, distal end. The human homolog is the (-) strand of GenBank Accession No. AC117507.5, including LIM domain containing preferred translocation partner in lipoma (LPP).

SEQ ID NO: 43 is a nucleic acid sequence associated with viral, such as influenza A, infection, and is the clone identified as Nucleotide Sequence B1E3, entire insert. The human homolog is the (+) strand of GenBank Accession No. AC117507.5, including LIM domain containing preferred translocation partner in lipoma (LPP).

SEQ ID NO: 44 is a nucleic acid sequence associated with viral, such as influenza A, infection, and is the clone identified as Nucleotide Sequence B1E5, proximal end. The human

homolog is the (-) strand of GenBank Accession No. AC117507.5, including LIM domain containing preferred translocation partner in lipoma (LPP).

SEQ ID NO: 45 is a nucleic acid sequence associated with viral, such as influenza A, infection, and is the clone identified as Nucleotide Sequence B6B1, entire insert. The human homolog is the (-) strand of GenBank Accession No. AC117507.5, including LIM domain containing preferred translocation partner in lipoma (LPP).

SEQ ID NO: 46 is a nucleic acid sequence associated with viral, such as influenza A, infection, and is the clone identified as Nucleotide Sequence B6E1, distal end. The human homolog is the (+) strand of GenBank Accession No. AC117507.5, including LIM domain containing preferred translocation partner in lipoma (LPP).

SEQ ID NO: 47 is a nucleic acid sequence associated with viral, such as influenza A, infection, and is the clone identified as Nucleotide Sequence B6E1, proximal end. The human homolog is the (-) strand of GenBank Accession No. AC117507.5, including LIM domain containing preferred translocation partner in lipoma (LPP).

SEQ ID NO: 48 is a nucleic acid sequence associated with viral, such as influenza A, infection, and is the clone identified as Nucleotide Sequence B6E3, proximal end. The human homolog is the (-) strand of GenBank Accession No. AC117507.5, including LIM domain containing preferred translocation partner in lipoma (LPP).

SEQ ID NO: 49 is a nucleic acid sequence associated with viral, such as influenza A, infection, and is the clone identified as Nucleotide Sequence B1E1, distal end. The human homolog is the (+) strand of GenBank Accession No. AC104036.8, between LOC253121 and hyaluronan synthase 2 (HAS2).

SEQ ID NO: 50 is a nucleic acid sequence associated with viral, such as influenza A, infection, and is the clone identified as Nucleotide Sequence B1E1, proximal end. The human homolog is the (-) strand of GenBank Accession No. AF260225.1, Testin 2 and Testin 3 (see WO 01/57270, WO 01/57271, WO 01/57273, WO 01/57274, WO 01/57275, WO 01/57276, WO 01/57277, WO 01/57278, or Tatarelli et al., Genomics 68(1):1-12, 2000).

SEQ ID NO: 51 is a nucleic acid sequence associated with viral, such as influenza A, infection, and is the clone identified as Nucleotide Sequence B1E4, distal end. The human homolog is the (+) strand of GenBank Accession No. AF260225.1, Testin 2 and Testin 3.

SEQ ID NO: 52 is a nucleic acid sequence associated with viral, such as influenza A, infection, and is the clone identified as Nucleotide Sequence B1E4, proximal end. The human homolog is the (-) strand of GenBank Accession No. AF260225.1, Testin 2 and Testin 3.

SEQ ID NO: 53 is a nucleic acid sequence associated with viral, such as influenza A, infection, and is the clone identified as Nucleotide Sequence B6E2, distal end. The human homolog is the (+) strand of GenBank Accession No. AF260225.1, Testin 2 and Testin 3.

SEQ ID NO: 54 is a nucleic acid sequence associated with viral, such as influenza A, infection, and is the clone identified as Nucleotide Sequence B6E2, proximal end. The human homolog is the (-) strand of GenBank Accession No. AF260225.1, Testin 2 and Testin 3.

15

5.

10

20

30

25

35

10

15

20

25

30

35

SEQ ID NO: 55 is a nucleic acid sequence associated with viral, such as influenza A, infection, and is the clone identified as Nucleotide Sequence B6E4, proximal end. The human homolog is the (-) strand of GenBank Accession No. AF260225.1, Testin 2 and Testin 3.

SEQ ID NO: 56 is a nucleic acid sequence associated with viral, such as influenza A, infection, and is the clone identified as Nucleotide Sequence B7E1, distal end. The human homolog is the (+) strand of GenBank Accession No. AF260225.1, Testin 2 and Testin 3.

SEQ ID NO: 57 is a nucleic acid sequence associated with viral, such as influenza A, infection, and is the clone identified as Nucleotide Sequence B7E1, proximal end. The human homolog is the (-) strand of GenBank Accession No. AF260225.1, Testin 2 and Testin 3.

SEQ ID NO: 58 is a nucleic acid sequence associated with viral, such as influenza A, infection, and is the clone identified as Nucleotide Sequence B5E2, distal end. The human homolog is the (-) strand of GenBank Accession No. AL133230.25, PTPN1 gene for protein tyrosine phosphatase, non-receptor type 1 (see Watanabe et al., Jpn. J. Cancer Res. 93:1114-22, 2002).

SEQ ID NO: 59 is a nucleic acid sequence associated with viral, such as influenza A, infection, and is the clone identified as Nucleotide Sequence B5E2, middle of insert. The human homolog is the (-) strand of GenBank Accession No. AL133230.25, PTPN1 gene for protein tyrosine phosphatase, non-receptor type 1.

SEQ ID NO: 60 is a nucleic acid sequence associated with viral, such as influenza A, infection, and is the clone identified as Nucleotide Sequence B3E11, distal end. The human homolog is the (+) strand of GenBank Accession No. AL445675.9, between LOC149360 and LOC253961.

SEQ ID NO: 61 is a nucleic acid sequence associated with viral, such as influenza A, infection, and is the clone identified as Nucleotide Sequence B3E11, proximal end. The human homolog is the (-) strand of GenBank Accession No. AL391986.12, between KIAA1560 and Tectorin beta (TECTB).

SEQ ID NO: 62 is a nucleic acid sequence associated with viral, such as influenza A, infection, and is the clone identified as Nucleotide Sequence B6E3, distal end. The human homolog is the (-) strand of GenBank Accession No. AC016826.9, including Cadherin related 23 (CDH23).

SEQ ID NO: 63 is a nucleic acid sequence associated with viral, such as influenza A, infection, and is the clone identified as Nucleotide Sequence B6E4, distal end. The human homolog is the (+) strand of GenBank Accession No. AL357372.12, Myeloid/lymphoma or mixed lineage leukemia, translocated to 10 (MMLT10).

SEQ ID NO: 64 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence ZV1-1B5, distal end. The human homolog is the (-) strand of GenBank Accession No. AL355802.13, between exportin 5 (XPO5) and DNA polymerase eta (POLH).

SEQ ID NO: 65 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence ZV1-1B5, proximal end. The human homolog is the (+) strand of GenBank Accession No. AL355802.13, between XPO5 and POLH.

10

20

25

30

35

SEQ ID NO: 66 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence ZV1-1E, proximal end. The human homolog is the (-) strand of GenBank Accession No. AL355802.13, between XPO5 and POLH.

SEQ ID NO: 67 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV1-2E1, proximal end. The human homolog is the (+) strand of GenBank Accession No. AL135744.4, including heterogenous nuclear riboprotein C (C1/C2) (HNRPC).

SEQ ID NO: 68 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV1-2E5, proximal end. The human homolog is the (+) strand of GenBank Accession No. AL135744.4, including HNRPC.

SEQ ID NO: 69 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV1-2E6, proximal end. The human homolog is the (+) strand of GenBank Accession No. AL135744.4, including HNRPC.

SEQ ID NO: 70 is a nucleic acid sequence associated with viral, such as Ebola, infection,
and is the clone identified as Nucleotide Sequence MV1-2B2, proximal end. The human homolog is
the (-) strand of GenBank Accession No. AL135744.4, including HNRPC.

SEQ ID NO: 71 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV1-2B13, proximal end. The human homolog is the (-) strand of GenBank Accession No. AL135744.4, including HNRPC.

SEQ ID NO: 72 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV1-2B14, proximal end. The human homolog is the (-) strand of GenBank Accession No. AL135744.4, including HNRPC.

SEQ ID NO: 73 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV1-2B21, proximal end. The human homolog is the (-) strand of GenBank Accession No. AL135744.4, including HNRPC.

SEQ ID NO: 74 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV1-2B25, proximal end. The human homolog is the (-) strand of GenBank Accession No. AL135744.4, including HNRPC.

SEQ ID NO: 75 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV1-2B35, proximal end. The human homolog is the (-) strand of GenBank Accession No. AL135744.4, including HNRPC.

SEQ ID NO: 76 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV1-2E5, distal end. The human homolog is the (+) and (-) strands of GenBank Accession No. AL050324.5, including alpha-endosulfine pseudogene (ENSAP) and LOC128741.

SEQ ID NO: 77 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV1-2E6, distal end. The human homolog is the (+) strand of GenBank Accession No. AC017060.7, including LOC222888.

10

15

20

25

30

35

SEQ ID NO: 78 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV1-2B13, distal end. The human homolog is the (+) strand of GenBank Accession No. AL161731.20, between LOC138421 and zinc finger protein 297B (ZNF297B).

SEQ ID NO: 79 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV1-2B14, distal end. The human homolog is the (-) strand of GenBank Accession No. AC012366.10, including sideroflexin 5 (SFXN5).

SEQ ID NO: 80 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV1-2B35, distal end. The human homolog is the (+) strand of GenBank Accession No. AL645504.10, including importin 9 (FLJ10402).

SEQ ID NO: 81 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence GV1-1B1, distal end. The human homolog is the (+) strand of GenBank Accession No. NG\_001333.1, T-cell receptor beta.

SEQ ID NO: 82 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence GV1-1B1, proximal end. The human homolog is the (+) strand of GenBank Accession No. NG\_001333.1, T-cell receptor beta.

SEQ ID NO: 83 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV2-B1, distal end. The human homolog is the (-) strand of GenBank Accession No. AC058791.4, adjacent to LOC135952.

SEQ ID NO: 84 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV2-E2, distal end. The human homolog is the (+) strand of GenBank Accession No. AC058791.4, adjacent to LOC135952.

SEQ ID NO: 85 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV2-E2, proximal end. The human homolog is the (-) strand of GenBank Accession No. AC058791.4, adjacent to LOC135952.

SEQ ID NO: 86 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV2-E3, proximal end. The human homolog is the (-) strand of GenBank Accession No. AC058791.4, adjacent to LOC135952.

SEQ ID NO: 87 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV2-E4, proximal end. The human homolog is the (-) strand of GenBank Accession No. AC058791.4, adjacent to LOC135952.

SEQ ID NO: 88 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV2-E5, distal end. The human homolog is the (+) strand of GenBank Accession No. AC058791.4, adjacent to LOC135952.

SEQ ID NO: 89 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV2-E5, proximal end. The human homolog is the (-) strand of GenBank Accession No. AC058791.4, adjacent to LOC135952.

10

15

20

25

30

35

SEQ ID NO: 90 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV3-B1, distal end. The human homolog is the (-) strand of GenBank Accession No. AC058791.4, adjacent to LOC135952.

SEQ ID NO: 91 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV3-E2, distal end. The human homolog is the (+) strand of GenBank Accession No. AC058791.4, adjacent to LOC135952.

SEQ ID NO: 92 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV3-E2, proximal end. The human homolog is the (-) strand of GenBank Accession No. AC058791.4, adjacent to LOC135952.

SEQ ID NO: 93 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV3-E4, proximal end. The human homolog is the (-) strand of GenBank Accession No. AC058791.4, adjacent to LOC135952.

SEQ ID NO: 94 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV6-B1, distal end. The human homolog is the (+) and (-) strand of GenBank Accession No. AC058791.4, adjacent to LOC135952.

SEQ ID NO: 95 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV6-E1, distal end. The human homolog is the (+) strand of GenBank Accession No. AC058791.4, adjacent to LOC135952.

SEQ ID NO: 96 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV6-E1, proximal end. The human homolog is the (-) strand of GenBank Accession No. AC058791.4, adjacent to LOC135952.

SEQ ID NO: 97 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV6-E4, proximal end. The human homolog is the (-) strand of GenBank Accession No. AC058791.4, adjacent to LOC135952.

SEQ ID NO: 98 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV6-E5, distal end. The human homolog is the (+) strand of GenBank Accession No. AC058791.4, adjacent to LOC135952.

SEQ ID NO: 99 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV6-E5, proximal end. The human homolog is the (-) strand of GenBank Accession No. AC058791.4, adjacent to LOC135952.

SEQ ID NO: 100 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV2-E1, distal end. The human homolog is the (+) strand of GenBank Accession No. AC021753.7, hypothetical protein KIAA1259.

SEQ ID NO: 101 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV2-E1, proximal end. The human homolog is the (-) strand of GenBank Accession No. AC021753.7, hypothetical protein KIAA1259.

SEQ ID NO: 102 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV2-E3, distal end. The human homolog is the

10

15

20

25

30

35

(+) and (-) strands of GenBank Accession No. AC107081.5, copper metabolism gene (MURR1) and chaperonin containing TCP1, subunit 4 (CCT4).

SEQ ID NO: 103 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV2-E4, distal end. The human homolog is the (-) strand of GenBank Accession No. AC099785.2, hypothetical protein FLJ40773 and similar to ribosomal protein L24-like (LOC149360).

SEQ ID NO: 104 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV2-E4, distal end. The human homolog is the (+) strand of GenBank Accession No. AF260225.1, Testin 2 and 3 (TES).

SEQ ID NO: 105 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV2-E4, proximal end. The human homolog is the (-) strand of GenBank Accession No. AF260225.1, Testin 2 and 3 (TES).

SEQ ID NO: 106 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV3-E7, distal end. The human homolog is the (+) strand of GenBank Accession No. AF260225.1, Testin 2 and 3 (TES).

SEQ ID NO: 107 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV3-E7, proximal end. The human homolog is the (-) strand of GenBank Accession No. AF260225.1, Testin 2 and 3 (TES).

SEQ ID NO: 108 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV3-B2, distal end. The human homolog is the (+) and (-) strands of GenBank Accession No. AC105934.2, polybromo 1 (PB1).

SEQ ID NO: 109 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV3-B4, distal end. The human homolog is the (+) strand of GenBank Accession No. AC022506.38, between DNA damage inducible transcript 3 (DDIT3) and KIAA1887.

SEQ ID NO: 110 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV3-B5, distal end. The human homolog is the (-) strand of GenBank Accession No. AL157834.12, PDZ and LIM domain 1 (elfin) (PDLIM1).

SEQ ID NO: 111 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV3-E1, distal end. The human homolog is the (+) strand of GenBank Accession No. AL110115.38, LOC284803.

SEQ ID NO: 112 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV3-E1, proximal end. The human homolog is the (-) strand of GenBank Accession No. AL110115.38, signal peptide peptidase (HM13) and LOC284803.

SEQ ID NO: 113 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV3-E3, distal end. The human homolog is the (-) strand of GenBank Accession No. AL117341.26, containing PRO0097 and adjacent to FLJ31958.

10

15

20

25

30

35

SEQ ID NO: 114 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV3-E3, proximal end. The human homolog is the (-) strand of GenBank Accession No. AP002076.3, small inducible cytokine E, member 1 (endothelial monocyte-activating) (SCYE1).

SEQ ID NO: 115 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV3-E6, distal end. The human homolog is the (+) strand of GenBank Accession No. AP002076.3, containing SCYE1.

SEQ ID NO: 116 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV3-E6, proximal end. The human homolog is the (-) strand of GenBank Accession No. AP002076.3, containing SCYE1.

SEQ ID NO: 117 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV3-E4, distal end. The human homolog is the (+) and (-) strands of GenBank Accession No. AC132812.9, between E3 ubiquitin ligase (SMURF2) and hypothetical protein MGC40489.

SEQ ID NO: 118 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV3-E5, distal end. The human homolog is the (+) strand of GenBank Accession No. AC079383.17, Ras oncogene family member Rab9.

SEQ ID NO: 119 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV3-E5, proximal end. The human homolog is the (-) strand of GenBank Accession No. AC079383.17, Ras oncogene family member Rab9.

SEQ ID NO: 120 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV6-E2, distal end. The human homolog is the (-) strand of GenBank Accession No. AL132989.5, between PRO1617 and retinoblastoma binding protein 1 (RBBP1).

SEQ ID NO: 121 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV6-E2, proximal end. The human homolog is the (+) strand of GenBank Accession No. AL132989.5, RBBP1.

SEQ ID NO: 122 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV6-E3, proximal end. The human homolog is the (+) strand of GenBank Accession No. AL132989.5, retinoblastoma binding protein 1 (RBBP1).

SEQ ID NO: 123 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV6-E3, distal end. The human homolog is the (+) and (-) strands of GenBank Accession No. AC096669.1, a region of chromosome 2q12.

SEQ ID NO: 124 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV6-E4, distal end. The human homolog is the (-) strands of GenBank Accession No. AF196968.4, elongation factor for selenoprotein translation (SELB).

10

15

20

25

SEQ ID NO: 125 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV13-B1, distal end. The human homolog is the (-) strand of GenBank Accession No. AC112218.2, transcription factor SMIF (HSA275986).

SEQ ID NO: 126 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV13-B1, proximal end. The human homolog is the (+) strand of GenBank Accession No. AC112218.2, transcription factor SMIF (HSA275986).

SEQ ID NO: 127 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV13-E1, proximal end. The human homolog is the (-) strand of GenBank Accession No. AC112218.2, transcription factor SMIF (HSA275986).

SEQ ID NO: 128 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV13-E1, distal end. The human homolog is the (+) strand of GenBank Accession No. AC112218.2, transcription factor SMIF (HSA275986).

SEQ ID NO: 129 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV13-E2, proximal end. The human homolog is the (-) strand of GenBank Accession No. AC112218.2, transcription factor SMIF (HSA275986).

SEQ ID NO: 130 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV13-E3, proximal end. The human homolog is the (-) strand of GenBank Accession No. AC112218.2, transcription factor SMIF (HSA275986).

SEQ ID NO: 131 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV13-E4, proximal end. The human homolog is the (-) strand of GenBank Accession No. AC112218.2, transcription factor SMIF (HSA275986).

SEQ ID NO: 132 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV13-E5, proximal end. The human homolog is the (-) strand of GenBank Accession No. AC112218.2, transcription factor SMIF (HSA275986).

SEQ ID NO: 133 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV13-E6, proximal end. The human homolog is the (-) strand of GenBank Accession No. AC112218.2, transcription factor SMIF (HSA275986).

SEQ ID NO: 134 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV13-E7, proximal end. The human homolog is the (-) strand of GenBank Accession No. AC112218.2, transcription factor SMIF (HSA275986).

SEQ ID NO: 135 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV13-E8, proximal end. The human homolog is the (-) strand of GenBank Accession No. AC112218.2, transcription factor SMIF (HSA275986).

SEQ ID NO: 136 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV13-E9, proximal end. The human homolog is the (-) strand of GenBank Accession No. AC112218.2, transcription factor SMIF (HSA275986).

SEQ ID NO: 137 is a nucleic acid sequence associated with viral, such as Ebola, infection. and is the clone identified as Nucleotide Sequence MV13-E10, proximal end. The human homolog is the (-) strand of GenBank Accession No. AC112218.2, transcription factor SMIF (HSA275986).

BNSDOCID: <WO \_\_\_ 2004070002A2 | ;

30

35

10

15

20

25

30

35

SEQ ID NO: 138 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV13-E2, distal end. The human homolog is the (+) strand of GenBank Accession No. AL031293.1, KIAA1026.

SEQ ID NO: 139 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV13-E3, distal end. The human homolog is the (+) strand of GenBank Accession No. AL035587.5, trinucleotide repeat containing 5 (TNRC5).

SEQ ID NO: 140 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV13-E4, distal end. The human homolog is the (-) strand of GenBank Accession No. AC126182.2, homogentisate 1,2-dioxygenase (HGD).

SEQ ID NO: 141 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV13-E5, distal end. The human homolog is the (+) strand of GenBank Accession No. AL591643.4, a region of chromosome Xq23-24.

SEQ ID NO: 142 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV13-E6, distal end. The human homolog is the (-) strand of GenBank Accession No. AC113603.3, a region of chromosome 4p15.3.

SEQ ID NO: 143 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV13-E7, distal end. The human homolog is the (+) strand of GenBank Accession No. AC011995.8, similar to LWamide neuropeptide precursor protein [Hydractinia echinata] (LOC129883).

SEQ ID NO: 144 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV13-E8, distal end. The human homolog is the (-) strand of GenBank Accession No. AC084208.5, a region of chromosome 2q21.

SEQ ID NO: 145 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV13-E9, distal end. The human homolog is the (-) strand of GenBank Accession No. AL391259.15, a region of chromosome Xp11.4, including ubiquitin specific protease 9 (USP9X).

SEQ ID NO: 146 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV13-E10, distal end. The human homolog is the (+) strand of GenBank Accession No. AC006397.1, LOC221829.

SEQ ID NO: 147 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV7-B2, distal end. The human homolog is the (+) strand of GenBank Accession No. X14945.1, U3 small nuclear RNA gene.

SEQ ID NO: 148 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV7-B2, proximal end. The human homolog is the (+) strand of GenBank Accession No. X14945.1, U3 small nuclear RNA gene.

SEQ ID NO: 149 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV7-E1, proximal end. The human homolog is the (-) strand of GenBank Accession No. X14945.1, U3 small nuclear RNA gene.

10

15

20

25

30

35 ·

SEQ ID NO: 150 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV7-E2, proximal end. The human homolog is the (-) strand of GenBank Accession No. X14945.1, U3 small nuclear RNA gene.

SEQ ID NO: 151 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV7-E2, distal end. The human homolog is the (-) strand of GenBank Accession No. X14945.1, U3 small nuclear RNA gene.

SEQ ID NO: 152 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV7-E5, proximal end. The human homolog is the (-) strand of GenBank Accession No. X14945.1, U3 small nuclear RNA gene.

SEQ ID NO: 153 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV8-E1, proximal end. The human homolog is the (-) strand of GenBank Accession No. X14945.1, U3 small nuclear RNA gene.

SEQ ID NO: 154 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV8-E1, distal end. The human homolog is the (+) strand of GenBank Accession No. X14945.1, U3 small nuclear RNA gene.

SEQ ID NO: 155 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV7-B3, distal end. The human homolog is the (+) strand of GenBank Accession No. AL365203.19, integrin, beta 1 (ITGB1).

SEQ ID NO: 156 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV7-B3, proximal end. The human homolog is the (-) strand of GenBank Accession No. AL365203.19, ITGB1.

SEQ ID NO: 157 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV7-E3, proximal end. The human homolog is the (+) strand of GenBank Accession No. AL365203.19, ITGB1.

SEQ ID NO: 158 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV7-E3, distal end. The human homolog is the (-) strand of GenBank Accession No. AL365203.19, ITGB1.

SEQ ID NO: 159 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV7-E1, distal end. The human homolog is the (+) strand of GenBank Accession No. AP001132.4, acrosomal vesicle protein 1 (ACRV1) and CHK1 checkpoint homolog (CHEK1).

SEQ ID NO: 160 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV7-E5, distal end. The human homolog is the (-) strand of GenBank Accession No. AK025453.1, prospero-related homeobox 1 (PROX1).

SEQ ID NO: 161 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV14-E1, proximal end. The human homolog is the (+) strand of GenBank Accession No. AL590543.8, hypothetical protein FLJ20627.

10

15

20

25

30

35

SEQ ID NO: 162 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV14-E2, proximal end. The human homolog is the (+) strand of GenBank Accession No. AL590543.8, hypothetical protein FLJ20627.

SEQ ID NO: 163 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV14-E3, proximal end. The human homolog is the (+) strand of GenBank Accession No. AL590543.8, hypothetical protein FLJ20627.

SEQ ID NO: 164 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV14-E4, proximal end. The human homolog is the (+) strand of GenBank Accession No. AL590543.8, hypothetical protein FLJ20627.

SEQ ID NO: 165 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV14-E4, distal end. The human homolog is the (-) strand of GenBank Accession No. AL590543.8, between hypothetical proteins FLJ20627 and FLJ12910.

SEQ ID NO: 166 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV14-E5, proximal end. The human homolog is the (+) strand of GenBank Accession No. AL590543.8, hypothetical protein FLJ20627.

SEQ ID NO: 167 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV14-E8, proximal end. The human homolog is the (+) strand of GenBank Accession No. AL590543.8, hypothetical protein FLJ20627.

SEQ ID NO: 168 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV14-E9, proximal end. The human homolog is the (+) strand of GenBank Accession No. AL590543.8, hypothetical protein FLJ20627.

SEQ ID NO: 169 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV14-E9, distal end. The human homolog is the (-) strand of GenBank Accession No. AL590543.8, between hypothetical proteins FLJ20627 and FLJ12910.

SEQ ID NO: 170 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV14-E10, proximal end. The human homolog is the (+) strand of GenBank Accession No. AL590543.8, hypothetical protein FLJ20627.

SEQ ID NO: 171 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV14-E10, distal end. The human homolog is the (-) strand of GenBank Accession No. AL590543.8, hypothetical protein FLJ20627.

SEQ ID NO: 172 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV19-E2, proximal end. The human homolog is the (+) strand of GenBank Accession No. AL590543.8, hypothetical protein FLJ20627.

SEQ ID NO: 173 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV19-E2, distal end. The human homolog is the (-) strand of GenBank Accession No. AL590543.8, between hypothetical proteins FLJ20627 and FLJ12910.

**(5**)

10

15

20

25

30

**35**.

SEQ ID NO: 174 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV14-E1, distal end. The human homolog is the (+) strand of GenBank Accession No. AC105001.3, between PIN2-interacting protein 1 (PINX1) and SRY (sex-determining region Y)-box7 (SOX7).

SEQ ID NO: 175 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV14-E2, distal end. The human homolog is the (-) strand of GenBank Accession No. AC009520.16, LOC131920.

SEQ ID NO: 176 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV14-E3, distal end. The human homolog is the (-) strand of GenBank Accession No. AL596329.5, a region of chromosome 13q14.

SEQ ID NO: 177 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV14-E5, distal end. The human homolog is the (+) strand of GenBank Accession No. AC023844.6, neurotrophic tyrosine kinase, receptor, type 3 (NTRK3).

SEQ ID NO: 178 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV14-E7, promimal end. The human homolog is the (-) strand of GenBank Accession No. AC024940.39, between TERA protein (TERA) and hypothetical protein FLJ13224.

SEQ ID NO: 179 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV14-E7, distal end. The human homolog is the (+) strand of GenBank Accession No. AC024940.39, flanking TERA protein (TERA) and hypothetical protein FLJ13224.

SEQ ID NO: 180 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV14-E8, distal end. The human homolog is the (-) strand of GenBank Accession No. AC084335.6, hypothetical gene LOC284260.

SEQ ID NO: 181 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV14-E11, proximal end. The human homolog is the (+) strand of GenBank Accession No. AC073108.9, POM (POM121 homolog) and ZP3 fusion (POMZP3).

SEQ ID NO: 182 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV14-E11, distal end. The human homolog is the (-) strand of GenBank Accession No. AC073108.9, POM (POM121 homolog) and ZP3 fusion (POMZP3).

SEQ ID NO: 183 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV19-E4, distal end. The human homolog is the (+) strand of GenBank Accession No. AC087650:12, between DEAD/H box polypeptide 8 (DDX8) and similar to ribosomal protein L29 (cell surface heparin binding protein HIP) (LOC284064).

SEQ ID NO: 184 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV20-E2, distal end. The human homolog is the

10

15

20

25

30

35

(-) strand of GenBank Accession No. AC105285.3, LOC345307 and UDP-N-acetyl-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 7 (GALNT7).

SEQ ID NO: 185 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV20-E2, proximal end. The human homolog is the (+) strand of GenBank Accession No. AC105285.3, LOC345307 and UDP-N-acetyl-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 7 (GALNT7).

SEQ ID NO: 186 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV20-B1, distal end. The human homolog is the (+) strand of GenBank Accession No. AC105285.3, LOC345307 and UDP-N-acetyl-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 7 (GALNI7).

SEQ ID NO: 187 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV20-E3, distal end. The murine homolog is the (+) strand of GenBank Accession No. NG\_001440.1, *Mus musculus* 5S rRNA pseudogene (Rn5s-ps1).

SEQ ID NO: 188 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV20-E5, proximal end. The human homolog is the (+) strand of GenBank Accession No. AL121886.22, between ribosomal protein L27a pseudogene (RPL27AP) and v-myb myeloblastosis viral oncogene homolog-like 2 (MYBL2).

SEQ ID NO: 189 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV28-E2, proximal end. The human homolog is the (+) strand of GenBank Accession No. AL121886.22, between RPL27AP and MYBL2.

SEQ ID NO: 190 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV28-E6, proximal end. The human homolog is the (+) strand of GenBank Accession No. AL121886.22, between RPL27AP and MYBL2.

SEQ ID NO: 191 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV28-E9, proximal end. The human homolog is the (+) strand of GenBank Accession No. AL121886.22, between RPL27AP and MYBL2.

SEQ ID NO: 192 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV28-E9, distal end. The human homolog is the (-) strand of GenBank Accession No. AL121886.22, between RPL27AP and MYBL2.

SEQ ID NO: 193 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV20-E6, distal end. The human homolog is the (+) strand of GenBank Accession No. AP000711.4, Down's syndrome cell adhesion molecule like 1 (DSCAML1).

SEQ ID NO: 194 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV20-E7, distal end. The human homolog is the (+) strand of GenBank Accession No. AL391555.19, LOC148529.

SEQ ID NO: 195 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV20-B4, distal end. The human homolog is the

10

15

20

25

30

35

(-) strand of GenBank Accession No. AC112129.4, Huntingtin-associated protein interacting protein (HAPIP).

SEQ ID NO: 196 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV22-E1, proximal end. The human homolog is the (-) strand of GenBank Accession No. Z69732.1, between LOC158525 and similar to RIKEN cDNA 1210001E11 (LOC347366).

SEQ ID NO: 197 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV22-E3, proximal end. The human homolog is the (-) strand of GenBank Accession No. Z69732.1, between LOC158525 and similar to RIKEN cDNA 1210001E11 (LOC347366).

SEQ ID NO: 198 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV22-E5, proximal end. The human homolog is the (-) strand of GenBank Accession No. Z69732.1, between LOC158525 and similar to RIKEN cDNA 1210001E11 (LOC347366).

SEQ ID NO: 199 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV22-E5, proximal end. The human homolog is the (-) strand of GenBank Accession No. Z69732.1, between LOC158525 and similar to RIKEN cDNA 1210001E11 (LOC347366).

SEQ ID NO: 200 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV22-E8, proximal end. The human homolog is the (-) strand of GenBank Accession No. Z69732.1, between LOC158525 and similar to RIKEN cDNA 1210001E11 (LOC347366).

SEQ ID NO: 201 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV22-E2, distal end. The human homolog is the (-) strand of GenBank Accession No. AL590543.8, hypothetical protein FLJ12910.

SEQ ID NO: 202 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV22-E2, proximal end. The human homolog is the (+) strand of GenBank Accession No. AL590543.8, hypothetical protein FLJ12910.

SEQ ID NO: 203 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV22-E6, distal end. The human homolog is the (-) strand of GenBank Accession No. AL590543.8, hypothetical protein FLJ12910.

SEQ ID NO: 204 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV22-E6, proximal end. The human homolog is the (+) strand of GenBank Accession No. AL590543.8, hypothetical protein FLJ12910.

SEQ ID NO: 205 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV22-E7, distal end. The human homolog is the (+) strand of GenBank Accession No. AC005284.1, LOC350411.

SEQ ID NO: 206 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV22-E9, proximal end. The human homolog is

10

15

20

25

30

35

the (+) strand of GenBank Accession No. AP000505.1, between allograft inflammatory factor 1 (AIF1) and HLA-B associated transcript 2 (BAT2).

SEQ ID NO: 207 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV27-E1, distal end. The human homolog is the (-) strand of GenBank Accession No. AC008755.8, C19orf7.

SEQ ID NO: 208 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV27-E2, distal end. The human homolog is the (+) strand of GenBank Accession No. AC058791.4, between LOC346658 and LOC340349.

SEQ ID NO: 209 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV27-E2, proximal end. The human homolog is the (-) strand of GenBank Accession No. AC058791.4, between LOC346658 and LOC340349.

SEQ ID NO: 210 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV27-E3, distal end. The human homolog is the (+) strand of GenBank Accession No. AC079030.13, a region of chromosome 12q21.

SEQ ID NO: 211 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV27-E3, proximal end. The human homolog is the (-) strand of GenBank Accession No. AC139138.2, between LOC339248 and hypothetical protein FLJ22659.

SEQ ID NO: 212 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV27-E4, distal end. The human homolog is the (-) strand of GenBank Accession No. AL513550.9, between SR rich protein DKFZp564B0769 and hypothetical protein MGC14793.

SEQ ID NO: 213 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV28-B1, distal end. The human homolog is the (-) strand of GenBank Accession No. AP001160.4, hypothetical protein FLJ10439.

SEQ ID NO: 214 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV28-B1, proximal end. The human homolog is the (+) strand of GenBank Accession No. AP001160.4, hypothetical protein FLJ10439.

SEQ ID NO: 215 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV28-B3, distal end. The human homolog is the (+) strand of GenBank Accession No. AC090826.15, between cytochrome P450, family 11, subfamily A, polypeptide 1 (CYP11A1) and sema domain, immunoglobulin domain (Ig) and GPI membrane anchor, (semaphoring) 7A.

SEQ ID NO: 216 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV28-B3, proximal end. The human homolog is the (-) strand of GenBank Accession No. AC090826.15, between cytochrome P450, family 11, subfamily A, polypeptide 1 (CYP11A1) and sema domain, immunoglobulin domain (Ig) and GPI membrane anchor, (semaphoring) 7A.

15

20

25

30

35

SEQ ID NO: 217 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV28-E11, proximal end. The human homolog is the (+) strand of GenBank Accession No. AC090826.15, between cytochrome P450, family 11, subfamily A, polypeptide 1 (CYP11A1) and sema domain, immunoglobulin domain (Ig) and GPI membrane anchor, (semaphoring) 7A.

SEQ ID NO: 218 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV28-E11, distal end. The human homolog is the (-) strand of GenBank Accession No. AC090826.15, between cytochrome P450, family 11, subfamily A, polypeptide 1 (CYP11A1) and sema domain, immunoglobulin domain (Ig) and GPI membrane anchor, (semaphoring) 7A.

SEQ ID NO: 219 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV28-E1, proximal end. The human homolog is the (-) strand of GenBank Accession No. AC011500.7, ribosomal protein S16 (RPS16).

SEQ ID NO: 220 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV28-E1, distal end. The human homolog is the (+) strand of GenBank Accession No. AC011500.7, ribosomal protein S16 (RPS16).

SEQ ID NO: 221 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV28-E4, distal end. The human homolog is the (-) strand of GenBank Accession No. AC091172.11, between hypothetical protein DKFZp434H0115 and ATP citrate lyase (ACLY).

SEQ ID NO: 222 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV28-E4, proximal end. The human homolog is the (+) strand of GenBank Accession No. AC091172.11, between hypothetical protein DKFZp434H0115 and ACLY.

SEQ ID NO: 223 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV28-E7, distal end. The human homolog is the (+) strand of GenBank Accession No. AL035594.7, protein tyrosine phosphatase, receptor type, K (PTPRK).

SEQ ID NO: 224 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV28-E7, proximal end. The human homolog is the (+) strand of GenBank Accession No. AC124857.2, calnexin (CANX) and (-) strand of GenBank Accession No. AL035594.7, protein tyrosine phosphatase, receptor type, K (PTPRK).

SEQ ID NO: 225 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV28-E8, distal end. The human homolog is the (+) strand of GenBank Accession No. AC009144.5, cyclin M2 (CNNM2).

SEQ ID NO: 226 is a nucleic acid sequence associated with viral, such as Ebola, infection, and is the clone identified as Nucleotide Sequence MV28-E8, proximal end. The human homolog is the (+) strand of GenBank Accession No. AC011510.7, AXL receptor tyrosine kinase (AXL).

20

30

SEQ ID NO: 227 is a nucleic acid sequence showing GenBank Accession No. BC008947, Homo sapiens chromosome 10 open reading frame 3, mRNA (cDNA clone MGC:3422 IMAGE:3028566). This sequence is associated with viral infection, such as Ebola infection.

SEQ ID NO: 228 is an amino acid sequence encoded by SEQ ID NO: 227.

SEQ ID NO: 229 is a nucleic acid sequence showing GenBank Accession No. NM\_018131, Homo sapiens chromosome 10 open reading frame 3 (C10orf3). This sequence is associated with viral infection, such as Ebola infection.

SEQ ID NO: 230 is an amino acid sequence encoded by SEQ ID NO: 229.

SEQ ID NO: 231 is a nucleic acid sequence showing GenBank Accession No. NM\_013451,

10 Homo sapiens fer-1-like 3, myoferlin (C. elegans) (FER1L3), transcript variant 1, mRNA. This sequence is associated with viral infection, such as Ebola infection.

SEQ ID NO: 232 is an amino acid sequence encoded by SEQ ID NO: 231.

SEQ ID NOS: 233 and 234 are exemplary complementary primers.

SEQ ID NOS: 235-237 are primer sequences used to sequence the shuttle clones as

15 described in Example 2.

SEQ ID NOS: 238-241 are Rab9 siRNA sequences.

SEQ ID NOS: 242-245 are AXL receptor tyrosine kinase siRNA sequences.

SEQ ID NOS: 246-295 are beta-chimerin receptor tyrosine kinase RNAi sequences.

SEQ ID NOS: 296-345 are retinoblastoma binding protein 1 RNAi sequences.

SEQ ID NOS: 346-395 are *Homo sapiens* chromosome 10 open reading frame 3 RNAi sequences.

SEQ ID NOS: 396-445 are *Homo sapiens* fer-1-like 3, myoferlin (C. elegans), transcript variant 1 RNAi sequences.

SEQ ID NOS: 446-495 are Homo sapiens chromosome 10 open reading frame 3 (C10orf3)

25 RNAi sequences.

SEQ ID NOS: 496-545 are malic enzyme RNAi sequences.

SEQ ID NOS: 546-595 are cadherin related 23 RNAi sequences.

SEQ ID NOS: 596-645 are sideroflexin 5 RNAi sequences.

SEQ ID NOS: 646-695 are polybromo 1 (PB1) RNAi sequences.

SEQ ID NOS: 696-720 are elongation factor for selenoprotein translation RNAi sequences.

SEQ ID NOS: 721-745 are integrin, beta 1 RNAi sequences.

SEQ ID NOS: 746-795 are huntingtin interacting protein 1 RNAi sequences.

SEQ ID NOS: 796-845 are cyclin M2 RNAi sequences.

### 35 DETAILED DESCRIPTION OF SEVERAL EMBODIMENTS

### Abbreviations and Terms

The following explanations of terms and methods are provided to better describe the present disclosure and to guide those of ordinary skill in the art in the practice of the present disclosure. The singular forms "a," "an," and "the" refer to one or more than one, unless the context clearly dictates



10

otherwise. For example, the term "comprising a nucleic acid" includes single or plural nucleic acids and is considered equivalent to the phrase "comprising at least one nucleic acid." The term "or" refers to a single element of stated alternative elements or a combination of two or more elements, unless the context clearly indicates otherwise. For example, the phrase "a first nucleic acid or a second nucleic acid" refers to the first nucleic acid, the second nucleic acid, or a combination of both the first and second nucleic acids. As used herein, "comprises" means "includes." Thus, "comprising a promoter and an open reading frame," means "including a promoter and an open reading frame," without excluding additional elements.

Unless explained otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this disclosure belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, suitable methods and materials are described below. The materials, methods, and examples are illustrative only and not intended to be limiting.

15 A = adenineC = cytosineDNA = deoxyribonucleic acid ds = double-stranded (for example, dsDNA) G = guanine20 mg = milligram ng = nanogram PCR = polymerase chain reaction Pu = purine Py = pyrimidine 25 RNA = ribonucleic acid mRNA = messenger RNA MOI = multiplicity of infection siRNA = short interfering or interrupting RNA ss = single-stranded (for example, ssDNA) 30 T = thymine $T_m = melting temperature$ U = uracilμg = microgram

μl = microliter

Amplification of a nucleic acid. To increase the number of copies of a nucleic acid.

Several methods can be used to amplify a nucleic acid, such as polymerase chain reaction (PCR).

Other examples of amplification include, but are not limited to, strand displacement amplification (U.S. Patent No: 5,744,311); transcription-free isothermal amplification (U.S. Patent No: 6,033,881);

35

10

15

20

25

30

35

repair chain reaction amplification (WO 90/01069); ligase chain reaction amplification (European Patent Appl. 320 308); gap filling ligase chain reaction amplification (U.S. Patent No: 5,427,930); and NASBATM RNA transcription-free amplification (U.S. Patent No: 6,025,134).

The amplification products ("amplicons") can be further processed, manipulated, or characterized by electrophoresis, restriction endonuclease digestion, hybridization, nucleic acid sequencing, ligation, or other molecular biology techniques. Standard protocols can be modified. For example, PCR can be modified by using reverse transcriptase PCR (RT-PCR) to amplify RNA molecules.

Antisense, Sense, and Antigene. Antisense molecules are molecules that are specifically hybridizable or specifically complementary to either RNA or the plus strand of DNA. Sense molecules are molecules that are specifically hybridizable or specifically complementary to the minus strand of DNA. Antigene molecules are either antisense or sense molecules directed to a particular dsDNA target. These molecules can be used to interfere with gene expression.

Double-stranded DNA (dsDNA) has two strands, a 5' to 3' strand, referred to as the plus (+) strand, and a 3' to 5' strand (the reverse complement), referred to as the minus (-) strand. Because RNA polymerase adds nucleic acids in a 5' to 3' direction, the minus strand of the DNA serves as the template for the RNA during transcription. Thus, the RNA formed will have a sequence complementary to the minus strand and virtually identical to the plus strand, except that U is substituted for T in RNA molecules.

Array. An arrangement of biological samples or molecules, such as an arrangement of tissues, cells, or biological macromolecules (including, but not limited to, peptides or nucleic acids) in addressable locations on or in a substrate. The arrangement of molecules within the array can be regular, such as being arranged in uniform rows and columns, or irregular. The number of addressable locations within the array can vary, for example from a few (such as two or three) to more than 50, 100, 200, 500, 1000, 10,000, or more. In certain examples, the array includes one or more molecules or samples occurring on the array a plurality of times (twice or more) to provide an added feature to the array, such as redundant activity or to provide internal controls. A "microarray" is an array that is miniaturized and evaluated or analyzed using microscopy.

Within an array, each arrayed sample or molecule is addressable, such that its location can be reliably and consistently determined within the at least two dimensions of the array. The location or address of each sample or molecule can be assigned when it is applied to the array, and a key or guide can be provided in order to correlate each location with the appropriate target sample or molecule position. Ordered arrays can be arranged in a symmetrical grid pattern or other patterns, for example, in radially distributed lines, spiral lines, or ordered clusters. Addressable arrays can be computer readable; a computer can be programmed to correlate a particular address on the array with information about the sample at that position, such as hybridization or binding data, including signal intensity. In some exemplary computer readable formats, the individual samples or molecules in the array are arranged regularly (for example, in a Cartesian grid pattern), which can be correlated to address information by a computer.

10

15

20

25

30

35

The sample or molecule addresses on an array can assume many different shapes. For example, substantially square regions can be used as addresses within arrays, but addresses can be differently shaped, for example, substantially rectangular, triangular, oval, irregular, or another shape. The term "spot" refers generally to a localized placement of molecules, tissue or cells, and is not limited to a round or substantially round region or address.

Examples of macroarrays include the Histo<sup>TM</sup>-array and INSTA-blot<sup>TM</sup> lines of products available from Imgenix, Inc. (San Diego, CA) and the Max Array<sup>TM</sup> line of products available from Zymed Laboratories, Inc. (South San Francisco, CA), while exemplary microarrays include the various GeneChip<sup>®</sup> technologies and products available from Affymetrix, Inc. (Santa Clara, CA) and the Hilight<sup>TM</sup>, Label Star<sup>TM</sup>, and Array-Ready Oligo Set lines of products available from Qiagen, Inc. (Valencia, CA).

 $\beta$ -chimerin. The term  $\beta$ -chimerin includes any  $\beta$ -chimerin gene, cDNA, RNA, or protein from any organism and is a  $\beta$ -chimerin that can function as a type of rho-GTPase. In some examples,  $\beta$ -chimerin is involved in viral infection.

Rho-GTPases are a family of small GTPases implicated as components of cellular signal transduction cascades. Signals that pass through rho-GTPase cascades can be initiated by the activation of cell surface proteins, such as growth factors. Functions of signaling cascades mediated by rho-GTPases, include, but are not limited to, alterations in cellular morphology which are linked to processes such as immune cell function, oncogenesis, metastasis and certain diseases (Peck, FEBS Lett. 528:27, 2002).

Examples of native  $\beta$ -chimerin nucleic acid sequences include, but are not limited to those shown in SEQ ID NOS: 21-22 (such as a target sequence associated with SEQ ID NOS: 21-22), as well as the protein sequence encoded thereby. This cell line remains CD4<sup>+</sup> after exposure to HIV 1 and HIV 2 and is resistant to HIV infection.  $\beta$ -chimerin also includes variants, fusions, and fragments of the disclosed nucleic acid and amino acid sequences that retain  $\beta$ -chimerin biological activity.

Examples of  $\beta$ -chimerin amino acid sequences include, but are not limited to: Genbank Accession Nos: NM\_004067 (mRNA) and NP\_004058.1 (protein). In one example, a  $\beta$ -chimerin sequence includes a full-length wild-type (or native) sequence, as well as  $\beta$ -chimerin allelic variants, variants, fragments, homologs or fusion sequences that retain the ability to function as a type of rho-GTPase. In certain examples,  $\beta$ -chimerin has at least 80% sequence identity, for example at least 85%, 90%, 95%, or 98% sequence identity to a native  $\beta$ -chimerin.

cDNA (complementary DNA). A piece of DNA lacking internal, non-coding segments (introns) and transcriptional regulatory sequences. A cDNA also can contain untranslated regions (UTRs) that are responsible for translational control in the corresponding RNA molecule. cDNA-can be produced using various methods, such as synthesis in the laboratory by reverse transcription from messenger RNA extracted from cells.

Complementary. Complementary binding occurs when the base of one nucleic acid molecule forms a hydrogen bond the base of another nucleic acid molecule. Normally, the base

10

15

20

25

30

35

adenine (A) is complementary to thymidine (T) and uracil (U), while cytosine (C) is complementary to guanine (G). For example, the sequence 5'-AFCG-3' of one ssDNA molecule can bond to 3'-TAGC-5' of another ssDNA to form a dsDNA.

Nucleic acid molecules can be complementary to each other even without complete hydrogen-bonding of all bases of each molecule. By way of example only (and without limitation), the ssDNA: 5'-GCTTGCCAAACCTACA-3' (SEQ ID NO: 233) is considered complementary to the ssDNA 3'-CGAACGGTCTGGATGT-5' (SEQ ID NO: 234) even though there is a mismatched base pair (A-C rather than A-T or G-C) at the ninth position.

Conservative substitution: A substitution of an amino acid residue for another amino acid residue having similar biochemical properties. Typically, conservative substitutions have little to no impact on the biological activity of a resulting polypeptide. In a particular example, a conservative substitution is an amino acid substitution in a peptide that does not substantially affect the biological function of the peptide. A peptide can include one or more amino acid substitutions, for example 2-10 conservative substitutions, 2-5 conservative substitutions, 4-9 conservative substitutions, such as 2, 5 or 10 conservative substitutions.

For example, a conservative substitution in a β-chimerin peptide (such as a peptide encoded by a target sequence associated with SEQ ID NO: 21 or 22) does not substantially affect the ability of β-chimerin to confer resistance to HIV infection. In another example, a conservative substitution in a Rab9 peptide (such as a peptide encoded by a target sequence associated with SEQ ID NOS: 118 or 119) is one that does not substantially affect the ability of Rab9 to confer resistance to infection by a pathogen that can hijack a lipid raft, such as HIV or Ebola.

A polypeptide can be produced to contain one or more conservative substitutions by manipulating the nucleotide sequence that encodes that polypeptide using, for example, standard procedures such as site-directed mutagenesis or PCR. Alternatively, a polypeptide can be produced to contain one or more conservative substitutions by using standard peptide synthesis methods. An alanine scan can be used to identify which amino acid residues in a protein can tolerate an amino acid substitution. In one example, the biological activity of the protein is not decreased by more than 25%, for example not more than 20%, for example not more than 10%, when an alanine, or other conservative amino acid (such as those listed below), is substituted for one or more native amino acids.

Examples of amino acids which can be substituted for an original amino acid in a protein and which are regarded as conservative substitutions include, but are not limited to: Ser for Ala; Lys for Arg; Gln or His for Asn; Glu for Asp; Ser for Cys; Asn for Gln; Asp for Glu; Pro for Gly; Asn or Gln for His; Leu or Val for Ile; Ile or Val for Leu; Arg or Gln for Lys; Leu or Ile for Met; Met, Leu or Tyr for Phe; Thr for Ser; Ser for Thr; Tyr for Trp; Trp or Phe for Tyr; and Ile or Leu for Val.

Further information about conservative substitutions can be found in, among other locations in, Ben-Bassat et al., (J. Bacteriol. 169:751-7, 1987), O'Regan et al., (Gene 77:237-51, 1989), Sahin-

15

20

25

30

35

Toth et al., (Protein Sci. 3:240-7, 1994), Hochuli et al., (Bio/Technology 6:1321-5, 1988) and in standard textbooks of genetics and molecular biology.

Ebola virus. A highly contagious hemorrhagic virus named after a river in the Democratic Republic of the Congo (formerly Zaire) in Africa, where it was first recognized. Ebola is one of two members of a family of RNA viruses called the Filoviridae. There are four identified subtypes of Ebola virus. Three of the four have caused disease in humans: Ebola-Zaire, Ebola-Sudan, and Ebola-Ivory Coast. The fourth, Ebola-Reston, has caused disease in nonhuman primates, but not in humans.

Ebola hemorrhagic fever (Ebola HF) is a severe, often fatal disease in humans and nonhuman primates (for example, monkeys, gorillas, and chimpanzees) that is caused by Ebola virus infection. Diagnosing Ebola HF in a recently infected individual can be difficult because early symptoms, such as red eyes and a skin rash, are nonspecific to the virus and are seen in other subjects with diseases that occur much more frequently. Antigen-capture enzyme-linked immunosorbent assay (ELISA) testing, IgM ELISA, PCR, and virus isolation can be used to diagnose a case of Ebola HF within a few days after the onset of symptoms. Subjects tested later in the course of the disease, or after recovery, can be tested for IgM and IgG antibodies. The disease also can be diagnosed retrospectively in deceased patients by using immunohistochemistry testing, virus isolation, or PCR.

Encodes: Unless evident from its context, includes DNA sequences that encode a polypeptide, as the term is typically used, as well as DNA sequences that are transcribed into inhibitory antisense molecules.

Expression: With respect to a gene sequence, refers to transcription of the gene and, as appropriate, translation of the resulting mRNA transcript to a protein. Thus, expression of a protein coding sequence results from transcription and translation of the coding sequence.

Functional deletion: A mutation, partial or complete deletion, insertion, or other variation made to a gene sequence that inhibits production of the gene product or renders the gene product non-functional. For example, a functional deletion of a Rab9 gene in a cell results in a cells having non-functional Rab9 protein, which results in the cell having an increase resistance to infection by a pathogen that uses a lipid raft.

Gene. A nucleic acid sequence that encodes a polypeptide under the control of a regulatory sequence, such as a promoter or operator. A gene includes an open reading frame encoding a polypeptide of the present disclosure, as well as exon and (optionally) intron sequences. An intron is a DNA sequence present in a given gene that is not translated into protein and is generally found between exons. The coding sequence of the gene is the portion transcribed and translated into a polypeptide (in vivo, in vitro or in situ) when placed under the control of an appropriate regulatory sequence. The boundaries of the coding sequence can be determined by a start codon at the 5' (amino) terminus and a stop codon at the 3' (carboxyl) terminus. If the coding sequence is intended to be expressed in a eukaryotic cell, a polyadenylation signal and transcription termination sequence can be included 3' to the coding sequence.

Transcriptional and translational control sequences include, but are not limited to, DNA regulatory sequences such as promoters, enhancers, and terminators that provide for the expression of

10

15

20

25

30

35

the coding sequence, such as expression in a host cell. A polyadenylation signal is an exemplary eukaryotic control sequence. A promoter is a regulatory region capable of binding RNA polymerase and initiating transcription of a downstream (3' direction) coding sequence. Additionally, a gene can include a signal sequence at the beginning of the coding sequence of a protein to be secreted or expressed on the surface of a cell. This sequence can encode a signal peptide, N-terminal to the mature polypeptide, which directs the host cell to translocate the polypeptide.

Host Cell. Any cell that can be infected with a virus or other pathogen, such as a bacterium. A host cell can be prokaryotic or eukaryotic, such as a cell from an insect, crustacean, mammal, bird, reptile, yeast, or a bacteria such as *E. coli*. Exemplary host cells include, but are not limited to, mammalian B-lymphocyte cells. Examples of viruses include, but are not limited to HIV, influenza A, and Ebola.

The host cell can be part of an organism, or part of a cell culture, such as a culture of mammalian cells or a bacterial culture. A host nucleic acid is a nucleic acid present in a host cell that expresses a host protein. Decreasing or inhibiting the interaction between a host polypeptide or host nucleic acid and a virus or viral protein can occur in vitro, in vivo, and in situ environments.

Human Immunodeficiency Virus (HIV). A retrovirus that causes immunosuppression in humans and leads to a disease complex known as acquired immunodeficiency syndrome (AIDS). This immunosuppression results from a progressive depletion and functional impairment of T lymphocytes expressing the CD4 cell surface glycoprotein. The loss of CD4 helper/inducer T cell function may underlie the loss of cellular and humoral immunity leading to the opportunistic infections and malignancies seen in AIDS.

Depletion of CD4 T cells results from the ability of HIV to selectively infect, replicate in, and ultimately destroy these T cells (for example see Klatzmann et al., Science 225:59, 1984). CD4 itself is an important component, and in some examples an essential component, of the cellular receptor for HIV.

HIV subtypes can be identified by particular number, such as HIV-1 and HIV-2. In the HIV life cycle, the virus enters a host cell in at least three stages: receptor docking, viral-cell membrane fusion, and particle uptake (D'Souza et al., JAMA 284:215, 2000). Receptor docking begins with a gp120 component of a virion spike binding to the CD4 receptor on the host cell. Conformational changes in gp120 induced by gp120-CD4 interaction promote an interaction between gp120 and either CCR5 or CXCR4 cellular co-receptors. The gp41 protein then mediates fusion of the viral and target-cell membranes. More detailed information about HIV can be found in Coffin et al., Retroviruses (Cold Spring Harbor Laboratory Press, 1997).

Hybridization. Hybridization of a nucleic acid occurs when two complementary nucleic acid molecules undergo an amount of hydrogen bonding to each other. The stringency of hybridization can vary according to the environmental conditions surrounding the nucleic acids, the nature of the hybridization method, and the composition and length of the nucleic acids used. For example, temperature and ionic strength (such as Na<sup>+</sup> concentration) can affect the stringency of hybridization. Calculations regarding hybridization conditions required for attaining particular

10

15

20

25

30

35

degrees of stringency are discussed in Sambrook et al., Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 2001); and Tijssen, Laboratory Techniques in Biochemistry and Molecular Biology—Hybridization with Nucleic Acid Probes Part I, Chapter 2 (Elsevier, New York, 1993).

The  $T_m$  is the temperature at which 50% of a given strand of nucleic acid is hybridized to its complementary strand. The  $T_m$  of a particular nucleic acid can be determined by various methods, such as observing the transition state between a single-stranded and double-stranded state during a temperature change, such as heating a dsDNA from about 30°C to about 100°C, and detecting when the dsDNA denatures to ssDNA. This can be accomplished by determining a melting profile for the nucleic acid. For longer nucleic acid fragments, such as PCR products, the nearest-neighbor method can be used to determine  $T_m$  (Breslauer et al., Proc. Natl. Acad. Sci. USA 83:3746-50, 1986).

Additionally, MeltCalc software can be used to determine  $T_m$  (Schütz and von Ahsen, Biotechniques 30:8018-24, 1999).

For purposes of this disclosure, "stringent conditions" encompass conditions under which hybridization only will occur if there is less than 25% mismatch between the hybridization molecule and the target sequence. "Moderate stringency" conditions are those under which molecules with more than 25% sequence mismatch will not hybridize; conditions of "medium stringency" are those under which molecules with more than 15% mismatch will not hybridize, and conditions of "high stringency" are those under which sequences with more than 10% mismatch will not hybridize. Conditions of "very high stringency" are those under which sequences with more than 5% mismatch will not hybridize.

Moderately stringent hybridization conditions are when the hybridization is performed at about 42°C in a hybridization solution containing 25 mM KPO<sub>4</sub> (pH 7.4), 5X SSC, 5X Denhart's solution, 50 μg/mL denatured, sonicated salmon sperm DNA, 50% formamide, 10% Dextran sulfate, and 1-15 ng/mL probe (about 5x10<sup>7</sup> cpm/μg), while the washes are performed at about 50°C with a wash solution containing 2X SSC and 0.1% sodium dodecyl sulfate.

Highly stringent hybridization conditions are when the hybridization is performed at about 42°C in a hybridization solution containing 25 mM KPO<sub>4</sub> (pH 7.4), 5X SSC, 5X Denhart's solution, 50 μg/mL denatured, sonicated salmon sperm DNA, 50% formamide, 10% Dextran sulfate, and 1-15 ng/mL probe (about 5x10<sup>7</sup> cpm/μg), while the washes are performed at about 65°C with a wash solution containing 0.2X SSC and 0.1% sodium dodecyl sulfate.

Infection. The entry, replication, insertion, lysis or other event or process involved with the pathogensis of a virus or other infectious agent into a host cell. Thus, decreasing infection includes decreasing entry, replication, insertion, lysis, or other pathogensis of a virus or other pathogen into a cell or subject, or combinations thereof. Infection includes the introduction of an infectious agent, such as a non-recombinant virus, recombinant virus, plasmid, bacteria, prion, eukaryotic microbe, or other agent capable of infecting a host, such as the cell of a subject.

In another example, infection is the introduction of a recombinant vector into a host cell via . transduction, transformation, transfection, or other method. Vectors include, but are not limited to,

viral, plasmid, cosmid, and artificial chromosome vectors. For example, a recombinant vector can include an antisense molecule, RNAi molecule, or siRNA that recognizes any target sequences associated with SEQ ID NOS: 1-227, 229, and 231, or variants, fusions, or fragments thereof, as well as SEQ ID NOS: 1-227, 229, and 231 themselves.

5

Influenza virus. A virus that causes respiratory disease or influenza ("the flu") and can lead to a secondary infection in the host, such as a bacterial infection of the lungs. Three types of influenza are currently known: influenza A, influenza B, and influenza C. Influenza A is the most common form of the virus and is capable of infection humans and non-human animals, such as pigs, horses, chickens, ducks and other birds.

10

The viral genome includes eight RNA molecules. HA, which encodes hemagglutinin (three hemagglutinin subtypes: H1, H2, and H3); M, which encodes two matrix proteins based on two different open reading frames within the nucleic acid sequence; NA encodes for neuraminidase; NP encodes the nucleoprotein; NS encodes two non-structural proteins based on different open reading frames within the nucleic acid sequence; and three genes that encode RNA polymerases (PA, PB1, PB2). The influenza virus can be categorized into subtypes on the bases of the surface glycoproteins.

15

The replication cycle of the influenza virus begins with binding of the viral hemagglutinin molecules to the surface carbohydrate of epithelial cell of a host cell, which draws the virus into the cell by receptor-mediated endocytosis. The viral membrane fuses with the endocytotic vesicle membrane, allowing the RNA molecules of the viral genome to enter the interior of the cell where these molecules later enter the cell nucleus and are replicated into viral-complementary RNA and new viral RNA and transcribed into viral mRNA, which are transported into the cytosol where they are translated into the proteins of new viral particles. After viral particles are assembled into new viruses, the neuraminidase glycoproteins proteins aid in the budding of the viruses from the cellular membrane of the host cell, thus releasing new viruses capable of infecting other host cells.

25

20

Isolated: An "isolated" biological component (such as a nucleic acid or protein) has been substantially separated, produced apart from, or purified away from other biological components in the cell of the organism in which the component naturally occurs, such as other chromosomal and extrachromosomal DNA and RNA, and proteins. Nucleic acids and proteins which have been "isolated" include nucleic acids and proteins purified by standard purification methods. The term also embraces nucleic acids and proteins prepared by recombinant expression in a host cell as well as chemically synthesized nucleic acids, proteins and peptides.

30

Nucleic acid. A deoxyribonucleotide or ribonucleotide polymer in either single (ss) or double stranded (ds) form, and can include analogues of natural nucleotides that hybridize to nucleic acids in a manner similar to naturally occurring nucleotides. In some examples, a nucleic acid is a nucleotide analog.

35

Unless otherwise specified, any reference to a nucleic acid molecule includes the reverse complement of nucleic acid. Except where single-strandedness is required by the text herein (for example, a ssRNA molecule), any nucleic acid written to depict only a single strand encompasses both strands of a corresponding double-stranded nucleic acid. For example, depiction of a plus-strand

15

20

25

30

35

of a dsDNA also encompasses the complementary minus-strand of that dsDNA. Additionally, reference to the nucleic acid molecule that encodes a specific protein, or a fragment thereof, encompasses both the sense strand and its reverse complement.

In particular examples, a nucleic acid includes a nucleotide sequence shown in any of SEQ ID NOS: 1-227, 229, and 231, or a variant, fragment, or fusion thereof. In other examples, a nucleic acid has a nucleotide sequence including a target sequence associated with SEQ ID NOS: 1-227, 229, and 231, or a variant, fragment, or fusion thereof, such as the corresponding cDNA or mRNA of SEQ ID NOS: 1-227, 229, and 231.

The fragment can be any portion of the nucleic acid corresponding to at least 5 contiguous bases from any target nucleic acid sequence associated with SEQ ID NOS: 1-227, 229, and 231, for example at least 20 contiguous bases, at least 50 contiguous bases, at least 100 contiguous bases, at least 250 contiguous bases, or even at least 500 or more contiguous bases. A fragment can be chosen from a particular portion of any of the target sequences associated with SEQ ID NOS: 1-227, 229, and 231, such as a particular half, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, or smaller portion of any of the target sequences associated with SEQ ID NOS: 1-227, 229, and 231. Fragments of the nucleic acids described herein can be used as probes and primers.

Oligonucleotide. A linear polynucleotide (such as DNA or RNA) sequence of at least 9 nucleotides, for example at least 15, 18, 24, 25, 30, 50, 100, 200 or even 500 nucleotides long. In particular examples, an oligonucleotide is about 6-50 bases, for example about 10-25 bases, such as 12-20 bases.

An oligonucleotide analog refers to moieties that function similarly to oligonucleotides, but have non-naturally occurring portions. For example, oligonucleotide analogs can contain non-naturally occurring portions, such as altered sugar moieties or inter-sugar linkages, such as a phosphorothicate oligodeoxynucleotide. Functional analogs of naturally occurring polynucleotides can bind to RNA or DNA, and include peptide nucleic acid (PNA) molecules.

Open reading frame (ORF). A series of nucleotide triplets (codons) coding for amino acids without any internal termination codons. These sequences are usually translatable into a peptide.

Operably linked. A first nucleic acid sequence is operably linked with a second nucleic acid sequence when the first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Generally, operably linked DNA sequences are contiguous and, where necessary to join two protein coding regions, in the same reading frame.

Pathogen: A disease-producing agent. Examples include, but are not limited to viruses, bacteria, and fungi.

Pharmaceutical agent or drug: A chemical compound or composition capable of inducing a desired therapeutic or prophylactic effect when administered to a subject, alone or in combination with another therapeutic agent(s) or pharmaceutically acceptable carriers. In a particular example, a

10

15

20

25

30

35

pharmaceutical agent decreases or even inhibits infection of a cell, such as the cell of a subject, by a pathogen, such as a virus.

Polymorphism. A polymorphism exists when two or more versions of a nucleic acid sequence exist within a population of subjects. For example, a polymorphic nucleic acid can be one where the most common allele has a frequency of 99% or less. Different alleles can be identified according to differences in nucleic acid sequences, and genetic variations occurring in more than 1% of a population (which is the commonly accepted frequency for defining polymorphism) are useful polymorphisms for certain applications.

The allelic frequency (the proportion of all allele nucleic acids within a population that are of a specified type) can be determined by directly counting or estimating the number and type of alleles within a population. Polymorphisms and methods of determining allelic frequencies are discussed in Hartl, D.L. and Clark, A.G., Principles of Population Genetics, Third Edition (Sinauer Associates, Inc., Sunderland Massachusetts, 1997), particularly in chapters 1 and 2.

Preventing or treating a disease: "Preventing" a disease refers to inhibiting the full development of a disease, for example preventing development of a viral infection. "Treatment" refers to a therapeutic intervention that ameliorates a sign or symptom of a disease or pathological condition related to a viral infection, such as inhibiting or decreasing viral infection.

Probes and primers. A probe includes an isolated nucleic acid attached to a detectable label or other reporter molecule. Typical labels include, but are not limited to radioactive isotopes, enzyme substrates, co-factors, ligands, chemiluminescent or fluorescent agents, haptens, and enzymes. Methods for labeling and guidance in the choice of labels appropriate for various purposes are discussed for example in Sambrook et al. (Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, New York, 1989) and Ausubel et al. (In Current Protocols in Molecular Biology, John Wiley & Sons, New York, 1998).

Primers are short nucleic acid molecules, such as DNA oligonucleotides ten nucleotides or more in length. Longer DNA oligonucleotides can be about 15, 20, 25, 30 or 50 nucleotides or more in length. Primers can be annealed to a complementary target DNA strand by nucleic acid hybridization to form a hybrid between the primer and the target DNA strand, and then the primer extended along the target DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification of a nucleic acid sequence, for example by the polymerase chain reaction (PCR) or other nucleic-acid amplification methods.

Nucleic acid probes and primers can be prepared based on the nucleic acid molecules of the target sequences associated with SEQ ID NOS: 1-227, 229, and 231, as indicators of resistance to infection. Probes and primers can be based on fragments or portions of these nucleic acid molecules, or on the reverse complement of these sequences, as well as probes and primers to 5' or 3' regions of the nucleic acids.

The specificity of a probe or primer increases with its length. Thus, for example, a primer that includes 30 consecutive nucleotides of a  $\beta$ -chimerin or Rab9 gene will anneal to a target sequence, such as another homolog of a  $\beta$ -chimerin or Rab9 gene, respectively, with a higher specificity than a

RINGOCOTO - WICH - SOMEOTOTOTO & S

 $j = \frac{1}{2},$ 

10

15

20

25

30

35

corresponding primer of only 15 nucleotides. Thus, to obtain greater specificity, probes and primers can be selected that include at least 20, 25, 30, 35, 40, 45, 50 or more consecutive nucleotides of a nucleic acid disclosed herein.

Protein coding sequence or a sequence that encodes a peptide: A nucleic acid sequence that is transcribed (in the case of DNA) and is translated (in the case of mRNA) into a peptide in vitro or in vivo when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxy) terminus. A coding sequence can include, but is not limited to, cDNA from procaryotic or eukaryotic mRNA, genomic DNA sequences from procaryotic or eukaryotic DNA, and even synthetic DNA sequences. A transcription termination sequence is usually be located 3' to the coding sequence.

Purified. The term purified does not require absolute purity; rather, it is a relative term. Thus, for example, a purified peptide preparation is one in which the peptide or protein is more enriched than the peptide or protein is in its environment within a cell, such that the peptide is substantially separated from cellular components (nucleic acids, lipids, carbohydrates, and other polypeptides) that may accompany it. In another example, a purified peptide preparation is one in which the peptide is substantially-free from contaminants, such as those that might be present following chemical synthesis of the peptide.

In one example, an peptide is purified when at least 60% by weight of a sample is composed of the peptide, for example when 75%, 95%, or 99% or more of a sample is composed of the peptide, such as a β-chimerin or Rab9 peptide. Examples of methods that can be used to purify proteins, include, but are not limited to the methods disclosed in Sambrook et al. (Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, New York, 1989, Ch. 17). Protein purity can be determined by, for example, polyacrylamide gel electrophoresis of a protein sample, followed by visualization of a single polypeptide band upon staining the polyacrylamide gel; high-pressure liquid chromatography; sequencing; or other conventional methods.

Rab9: The term Rab9 includes any Rab9 gene, cDNA, RNA, or protein from any organism and that is a Rab9 that can transport late endosomes to trans-golgi and function as a ras-like GTPase. In some examples, Rab9 is involved in lipid raft formation.

Examples of native Rab9 nucleic acid sequences include, but are not limited to, target sequences associated with SEQ ID NOS: 118 and 119. Examples of Rab9 amino acid sequences include, but are not limited to: Genbank Accession Nos: BC017265.2 and NM\_004251.3 (cDNA) as well as P51151 and AAH17265 (proteins). In one example, a Rab9 sequence includes a full-length wild-type (or native) sequence, as well as Rab9 allelic variants, variants, fragments, homologs or fusion sequences that retain the ability to transport late endosomes to trans-golgi. In certain examples, Rab9 has at least 80% sequence identity, for example at least 85%, 90%, 95%, or 98% sequence identity to a native Rab9.

In other examples, Rab9 has a sequence that hybridizes to a sequence set forth in GenBank Accession No. BC017265.2 or NM 004251.3, and retains Rab9 activity.

10

15

20

25

30

35

Recombinant. A recombinant nucleic acid or protein is one that has a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two otherwise separated segments of sequence. This artificial combination can be accomplished, for example, by chemical synthesis or by the artificial manipulation of isolated segments of nucleic acids or proteins, for example, by genetic engineering techniques.

RNA interference (RNAi): A post-transcriptional gene silencing mechanism mediated by double-stranded RNA (dsRNA). Introduction of dsRNA into cells, such as RNAi compounds or siRNA compounds, induces targeted degradation of RNA molecules with homologous sequences. RNAi compounds are typically longer than an siRNA molecule. For example, an RNAi molecule can be at least about 25 nucleic acids, at least about 27 nucleic acids, or even at least about 400 nucleotides in length.

RNAi compounds can be used to modulate transcription, for example, by silencing genes, such as Rab9, β-chimerin, or combinations thereof. In certain examples, an RNAi molecule is directed against a certain target gene, such as Rab9, β-chimerin, or combinations thereof, and is used to decrease viral infection.

Sequence identity: The similarity between nucleic acid or amino acid sequences is expressed in terms of the similarity between the sequences. Sequence identity is frequently measured in terms of percentage identity (or similarity or homology); the higher the percentage, the more similar the two sequences are. Homologs or variants of a protein or nucleic acid disclosed herein, such as target sequences associated with SEQ ID NOS: 1-232, and their corresponding cDNA and protein sequences, will possess a relatively high degree of sequence identity when aligned using standard methods.

Methods of alignment of sequences for comparison are well known in the art. Various programs and alignment algorithms are described in: Smith and Waterman, Adv. Appl. Math. 2:482, 1981; Needleman and Wunsch, J. Mol. Biol. 48:443, 1970; Pearson and Lipman, Proc. Natl. Acad. Sci. U.S.A. 85:2444, 1988; Higgins and Sharp, Gene 73:237-44, 1988; Higgins and Sharp, CABIOS 5:151-3, 1989; Corpet et al., Nucl. Acids Res. 16:10881-90, 1988; Pearson and Lipman, Proc. Natl. Acad. Sci. U.S.A. 85:2444, 1988; and Altschul et al., Nature Genet. 6:119-29, 1994.

The NCBI Basic Local Alignment Search Tool (BLAST<sup>TM</sup>) (Altschul et al., J. Mol. Biol. 215:403-10, 1990) is available from several sources, including the National Center for Biotechnology Information (NCBI, Bethesda, MD) and on the Internet, for use in connection with the sequence analysis programs blastp, blastn, blastn, tblastn and tblastn.

Variants of a peptide, such as a peptide encoded by any target sequence associated with SEQ ID NOS: 1-227, 229, and 231, as well as any target sequence associated with SEQ ID NOS: 228, 230, and 232, are typically characterized by possession of at least 70% sequence identity counted over the full length alignment with the amino acid sequence encoded by any target sequence associated with SEQ ID NOS: 1-227, 229, or 231, using the NCBI Blast 2.0, gapped blastp set to default parameters. For comparisons of amino acid sequences of greater than about 30 amino acids, the Blast 2 sequences function is employed using the default BLOSUM62 matrix set to default parameters, (gap existence



10

15

20

25

30

cost of 11, and a per residue gap cost of 1). When aligning short peptides (fewer than around 30 amino acids), the alignment is performed using the Blast 2 sequences function, employing the PAM30 matrix set to default parameters (open gap 9, extension gap 1 penalties). Proteins with even greater similarity to the reference sequences will show increasing percentage identities when assessed by this method, such as at least 80%, at least 90%, at least 95%, at least 98%, or even at least 99% sequence identity. When less than the entire sequence is being compared for sequence identity, homologs and variants will typically possess at least 80% sequence identity over short windows of 10-20 amino acids, and may possess sequence identities of at least 85%, at least 90%, at least 95%, or at least 98% depending on their similarity to the reference sequence. Methods for determining sequence identity over such short windows are described at the website that is maintained by the National Center for Biotechnology Information in Bethesda, Maryland. One of skill in the art will appreciate that these sequence identity ranges are provided for guidance only; it is entirely possible that strongly significant homologs could be obtained that fall outside of the ranges provided.

Similar methods can be used to determine the sequence identity between two or more nucleic acids. To compare two nucleic acid sequences, the BLASTN options can be set as follows: -i is set to a file containing the first nucleic acid sequence to be compared (such as C:\seq1.txt); -j is set to a file containing the second nucleic acid sequence to be compared (such as C:\seq2.txt); -p is set to blastn; -o is set to any desired file name (such as C:\output.txt); -q is set to -1; -r is set to 2; and all other options are left at their default setting. For example, the following command can be used to generate an output file containing a comparison between two sequences: C:\Bl2seq -i c:\seq1.txt -j c:\seq2.txt -p blastn -o c:\output.txt -q -1 -r 2.

Once aligned, the number of matches is determined by counting the number of positions where an identical nucleotide or amino acid residue is presented in both sequences. The percent sequence identity is determined by dividing the number of matches either by the length of the sequence set forth in the identified sequence, or by an articulated length (for example, 100 consecutive nucleotides or amino acid residues from a sequence set forth in an identified sequence), followed by multiplying the resulting value by 100. For example, a nucleic acid sequence that has 1166 matches when aligned with a test sequence having 1154 nucleotides is 75.0 percent identical to the test sequence (for example, 1166+1554°100=75.0). The percent sequence identity value is rounded to the nearest tenth. For example, 75.11, 75.12, 75.13, and 75.14 are rounded down to 75.1, while 75.15, 75.16, 75.17, 75.18, and 75.19 are rounded up to 75.2. The length value will always be an integer. In another example, a target sequence containing a 20-nucleotide region that aligns with 20 consecutive nucleotides from an identified sequence as follows contains a region that shares 75 percent sequence identity to that identified sequence (for example, 15+20\*100=75).

35 1 20

Target Sequence: AGGTCGTGTACTGTCAGTCA

Identified Sequence: ACGTGGTGAACTGCCAGTGA

10

15

20

25

30

35

The nucleic acids disclosed herein include nucleic acids have nucleotide sequences that are at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identical to the nucleotide sequence of any target sequence associated with SEQ ID NOS: 1-227, 229, and 231. In particular examples, a nucleic acid is substantially similar to the nucleotide sequence of any target sequence associated with SEQ ID NOS: 1-227, 229, and 231. A first nucleic acid is "substantially similar" to a second nucleic acid if, when the first nucleic acid is optimally aligned (with appropriate nucleotide deletions or gap insertions) with the second nucleic acid (or its complementary strand) and there is nucleotide sequence identity of at least about 90%, for example at least about 95%, at least 98% or at least 99% identity. An alternative indication that two nucleic acid molecules are closely related is that the two molecules hybridize to each other under stringent conditions.

Nucleic acid sequences that do not show a high degree of identity may nevertheless encode similar amino acid sequences, due to the degeneracy of the genetic code. It is understood that changes in nucleic acid sequence can be made using this degeneracy to produce multiple nucleic acid molecules that all encode substantially the same protein.

Short interfering or interrupting RNA (siRNA). Double-stranded RNAs that can induce sequence-specific post-transcriptional gene silencing, thereby decreasing or even inhibiting gene expression. In some examples, siRNA molecules are about 19-23 nucleotides in length, such as at least 21 nucleotides, for example at least 23 nucleotides.

In one example, siRNA triggers the specific degradation of homologous RNA molecules, such as mRNAs, within the region of sequence identity between both the siRNA and the target RNA. For example, WO 02/44321 discloses siRNAs capable of sequence-specific degradation of target mRNAs when base-paired with 3' overhanging ends. The direction of dsRNA processing determines whether a sense or an antisense target RNA can be cleaved by the produced siRNA endonuclease complex. Thus, siRNAs can be used to modulate transcription, for example, by silencing genes, such as Rab9, β-chimerin, or combinations thereof. The effects of siRNAs have been demonstrated in cells from a variety of organisms, including *Drosophila*, *C. elegans*, insects, frogs, plants, fungi, mice and humans (for example, WO 02/44321; Gitlin et al., Nature 418:430-4, 2002; Caplen et al., Proc. Natl. Acad. Sci. 98:9742-9747, 2001; and Elbashir et al., Nature 411:494-8, 2001).

In certain examples, siRNAs are directed against certain target genes, such as Rab9, β-chimerin, or combinations thereof, to confirm results of the gene-trap method used against the same nucleic acid sequence.

Specific binding agent. An agent that binds substantially only to a defined target. For example, a protein-specific binding agent binds substantially only the specified protein and a nucleic acid specific binding agent binds substantially only the specified nucleic acid.

As used herein, the term "protein [X] specific binding agent" includes anti-[X] protein antibodies (including polyclonal or monoclonal antibodies and functional fragments thereof) and other agents (such as soluble receptors) that bind substantially only to the [X] protein. In this context, [X] refers to any specific or designated protein, for instance  $\beta$ -chimerin, Rab9, or any protein listed in Table

15

20

25

30

35

1 or encoded by a target sequence associated with SEQ ID NOS: 1-227, 229, and 231 (including variants, fragments, and fusions thereof).

Anti-[X] protein antibodies can be produced using standard procedures such as those described in Harlow and Lane (*Using Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory Press: Cold Spring Harbor, 1998). Antibodies can be polyclonal or monoclonal antibodies, humanized antibodies, Fab fragments, F(ab')2 fragments, single chain antibodies, or chimeric antibodies. For example, polyclonal antibodies can be produced by immunizing a host animal by injection with polypeptides described herein, including the target sequences associated with SEQ ID NOS: 1-227, 229, 231 (or variants, fragments, or fusions thereof). The production of monoclonal antibodies can be accomplished by a variety of methods, such as the hybridoma technique (Kohler and Milstein, *Nature* 256:495-7, 1975), the human B-cell technique (Kosbor et al., *Immunology Today* 4:72, 1983), or the EBV-hybridoma technique (Cole et al., in *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96, 1983). Additionally, chimeric antibodies can be produced (for example, see Morrison et al., *J. Bacteriol.* 159:870, 1984; Neuberger et al., *Nature* 312:604-8, 1984; and Takeda et al., *Nature* 314:452-4, 1985), as well as single-chain antibodies (for example, see U.S. Pat. Nos: 5,476,786; 5,132,405; and 4,946,778).

The determination that a particular agent binds substantially only to the specified protein readily can be made by using or adapting routine procedures. For example, Western blotting can be used to determine that a given protein binding agent, such as an anti-[X] protein monoclonal antibody, binds substantially only to the [X] protein. Other assays include, but are not limited to, competitive and non-competitive homogenous and heterogeneous enzyme-linked immunosorbent assays (ELISA) as symmetrical or asymmetrical direct or indirect detection formats; "sandwich" immunoassays; immunodiffusion assays; in situ immunoassays (for example, using colloidal gold, enzyme or radioisotope labels); agglutination assays; complement fixing assays; immunoelectrophorectic assays; enzyme-linked immunospot assays (ELISPOT); radioallergosorbent tests (RAST); fluorescent tests, such as used in fluorescent microscopy and flow cytometry; Western, grid, dot or tissue blots; dip-stick assays; halogen assays; or antibody arrays (for example, see O'Meara and Tovey, Clin. Rev. Allergy Immunol., 18:341-95, 2000; Sambrook et al., 2001, Appendix 9; Simonnet and Guilloteau, in: Methods of Immunological Analysis, Masseyeff et al. (Eds.), VCH, New York, 1993, pp. 270-388).

A specific binding agent also can be labeled for direct detection (see Chapter 9, Harlow and Lane, Antibodies: A Laboratory Manual. 1988). Suitable labels include (but are not limited to) enzymes (such as alkaline phosphatase (AP) or horseradish peroxidase (HRP)), fluorescent labels, colorimetric labels, radioisotopes, chelating agents, dyes, colloidal gold, ligands (such as biotin), and chemiluminescent agents.

Shorter fragments of antibodies can also serve as specific binding agents. For instance, Fabs, Fvs, and single-chain Fvs (SCFvs) that bind to a specified protein would be specific binding agents. These antibody fragments include: (1) Fab, the fragment containing a monovalent antigen-binding fragment of an antibody molecule produced by digestion of whole antibody with the enzyme papain to yield an intact light chain and a portion of one heavy chain; (2) Fab', the fragment of an

10

15

20

25

30

35

antibody molecule obtained by treating whole antibody with pepsin, followed by reduction, to yield an intact light chain and a portion of the heavy chain; two Fab' fragments are obtained per antibody molecule; (3) (Fab')2, the fragment of the antibody obtained by treating whole antibody with the enzyme pepsin without subsequent reduction; (4) F(ab')2, a dimer of two Fab' fragments held together by two disulfide bonds; (5) Fv, a genetically engineered fragment containing the variable region of the light chain and the variable region of the heavy chain expressed as two chains; and (6) single chain antibody ("SCA"), a genetically engineered molecule containing the variable region of the light chain, the variable region of the heavy chain, linked by a suitable polypeptide linker as a genetically fused single chain molecule. Methods of making these fragments are routine. For example, construction of Fab expression libraries permits the rapid and easy identification of monoclonal Fab fragments with the desired specificity for a protein described herein.

Subject: Living multi-cellular vertebrate organisms, including human and veterinary subjects, such as cows, pigs, horses, dogs, cats, birds, reptiles, and fish.

Target sequences associated with SEQ ID NO: When used herein, this phrase refers to any nucleic acid sequence, amino acid sequence, or combination of nucleic acid and amino acid sequences, that are involved in viral infection, and therefore serve as targets for inhibiting viral infection, and which are or include a specified SEQ ID NO, are involved in the expression of the SEQ ID NO, or are peptide (including protein) sequences that are expressed by such specified SEQ ID NO. Although a target sequence may refer to a SEQ ID NO of a sequence obtained from a particular species, the target sequences also include homologues of the sequence from other related species, such as other mammals. For example, the phrase "target sequences associated with SEQ ID NO. X" can refer to the entire gene sequence of which the particular SEQ ID NO X is a part, the appropriate coding sequence, a promoter sequence associated with the gene, or the corresponding protein sequence, as well as variants, fragments, homologues, and fusions thereof that retain the activity of the native sequence.

For example, when using the phrase "sequences associated with SEQ ID NOS: 21-22," this term encompases β-chimerin genomic sequences, endogenous promoter sequences that promote the expression of β-chimerin, coding sequences, and β-chimerin proteins, as well as variants, fragments homologues and fusions thereof that retain the activity of the native sequence. A particular cDNA sequence associated with SEQ ID NOS: 21-22 is provided in GenBank Accession No. NM\_004067, and a particular protein sequence associated with SEQ ID NOS: 21-22 is provided in NP\_004058.1.

The term "a GenBank Accession No. associated with SEQ ID NO. X" refers to a-GenBank Accession No. that includes SEQ ID NO. X, or is a homolog of SEQ ID NO: X from another mammal, for example a human homolog. The GenBank Accession No. may, in some examples, also identify a coding sequence of an open reading frame, and the sequence of the protein encoded by SEQ ID NO. X.

Although sequences are provided herein that encode (or are included within sequences that encode) host proteins that are involved in viral infection, it should be understood that the ultimate goal is to interfere with the activity of the protein that has been identified to be involved in viral

pathogenesis. Such interference can be at either the level of the nucleic acid that encodes the protein (for example by reducing or otherwise disrupting expression of the protein), or at the level of the protein itself (for example by interfering with the activity of the protein, or its interaction with the virus). The disclosure of specific techniques for achieving these goals in particular species should not be interpreted to limit the method to these particular techniques, or to particular species in which the viral interaction is first identified. The identification of the viral interaction in one species indicates the importance of the interaction between the virus and the protein in that species, as well as the interaction of the virus with homologues of that protein in other species.

Target sequence of a nucleic acid: A portion of a nucleic acid that, upon hybridization to a therapeutically effective oligonucleotide or oligonucleotide analog, results in reduction or even inhibition of infection by an infectious agent. An antisense or a sense molecule can be used to target a portion of dsDNA, since either can interfere with the expression of that portion of the dsDNA. The antisense molecule can bind to the plus strand, and the sense molecule can bind to the minus strand. Thus, target sequences can be ssDNA, dsDNA, and RNA.

Therapeutically active molecule: An agent, such as a protein, antibody or nucleic acid, that can decrease expression of a host protein involved in viral infection (such as those listed in Table 1 or target sequences associated with any of SEQ ID NOS: 1-232, or can decrese an interaction between a host protein involved in viral infection and a viral protein, such as HIV, Ebola, or influenza A, as measured by clinical response (for example, a decrease in infection by a virus, such as an inhibition of infection). Therapeutically active agents also include organic or other chemical compounds that mimic the effects of the therapeutically effective peptide or nucleic acids.

Therapeutically Effective Amount: An amount of a pharmaceutical preparation that alone, or together with an additional therapeutic agent(s), induces the desired response. The preparations disclosed herein are administered in therapeutically effective amounts.

In one example, a desired response is to decrease or inhibit viral infection of a cell, such as a cell of a subject. Viral infection does not need to be completely inhibited for the pharmaceutical preparation to be effective. For example, a pharmaceutical preparation can decrease viral infection by a desired amount, for example by at least 20%, at least 50%, at least 60%, at least 70%, at least 80%, at least 95%, at least 98%, or even at least 100%, as compared to an amount of viral infection in the absence of the pharmaceutical preparation. This decrease or inhibition can result in halting or slowing the progression of, or inducing a regression of a pathological condition caused by the viral infection, or which is capable of relieving signs or symptoms caused by the condition.

In another or additional example, it is an amount sufficient to partially or completely alleviate symptoms of viral infection within a host subject. Treatment can involve only slowing the progression of the infection temporarily, but can also include halting or reversing the progression of the infection permanently.

Effective amounts of the therapeutic agents described herein can be determined in many different ways, such as assaying for a reduction in the rate of infection of cells or subjects, a reduction in the viral load within a host, improvement of physiological condition of an infected subject, or

15

10

5

20

25

30

35

BNSDOCID: <WO\_\_\_\_2004070002A2\_1\_>

increased resistance to infection following exposure to the virus. Effective amounts also can be determined through various in vitro, in vivo or in situ assays, including the assays described herein.

The disclosed therapeutic agents can be administered in a single dose, or in several doses, for example daily, during a course of treatment. However, the effective amount of can be dependent on the source applied (for example a nucleic acid isolated from a cellular extract versus a chemically synthesized and purified nucleic acid), the subject being treated, the severity and type of the condition being treated, and the manner of administration. In addition, the disclosed therapeutic agents can be administered alone, or in the presence of a pharmaceutically acceptable carrier, or in the presence of other therapeutic agents, for example other anti-viral agents.

Transduced and Transformed: A virus or vector "transduces" or "transfects" a cell when it transfers nucleic acid into the cell. A cell is "transformed" by a nucleic acid transduced into the cell when the DNA becomes stably replicated by the cell, either by incorporation of the nucleic acid into the cellular genome, or by episomal replication. As used herein, the term transformation encompasses all techniques by which a nucleic acid molecule might be introduced into such a cell, including transfection with viral vectors, transformation with plasmid vectors, and introduction of naked DNA by electroporation, lipofection, and particle gun acceleration.

Transfected: A transfected cell is a cell into which has been introduced a nucleic acid molecule by molecular biology techniques. The term transfection encompasses all techniques by which a nucleic acid molecule can be introduced into such a cell, including transfection with viral vectors, transformation with plasmid vectors, and introduction of naked DNA by electroporation, lipofection, and particle gun acceleration.

Transgene: An exogenous nucleic acid sequence supplied by a vector. In one example, a transgene includes any target sequence associated with SEQ ID NOS: 1-227, 229, 231 (or variants, fragments, or fusions thereof), for example a nucleic acid that encodes a beta-chimerin or Rab9.

Variants, fragments or fusions: The disclosed nucleic acid sequences, such as target sequences associated with SEQ ID NOS: 1-227, 229, and 231, and the proteins encoded thereby, include variants, fragments, and fusions thereof that retain the native biological activity (such as playing a role in viral infection). DNA sequences which encode for a protein or fusion thereof, or a fragment or variant of thereof can be engineered to allow the protein to be expressed in eukaryotic cells or organisms, bacteria, insects, and/or plants. To obtain expression, the DNA sequence can be altered and operably linked to other regulatory sequences. The final product, which contains the regulatory sequences and the therapeutic protein, is referred to as a vector. This vector can be introduced into eukaryotic, bacteria, insect, and/or plant cells. Once inside the cell the vector allows the protein to be produced.

One of ordinary skill in the art will appreciate that the DNA can be altered in numerous ways without affecting the biological activity of the encoded protein. For example, PCR can be used to produce variations in the DNA sequence which encodes a protein. Such variants can be variants optimized for codon preference in a host cell used to express the protein, or other sequence changes that facilitate expression.

10

15


5

20

25

35

30



10

15

Vector: A nucleic acid molecule as introduced into a host cell, thereby producing a transformed host cell. A vector can include nucleic acid sequences that permit it to replicate in a host cell, such as an origin of replication, and can also include one or more selectable marker genes and other genetic elements. An insertional vector is capable of inserting itself into a host nucleic acid. For example, recombinant lambda-phage vectors of host genomes (Coffin et al., Retroviruses, Chapter 5).

Wild-type. A naturally occurring, non-mutated version of a nucleic acid sequence. Among multiple alleles, the allele with the greatest frequency within the population is usually (but not necessarily) the wild-type. The term "native" can be used as a synonym for "wild-type."

### Nucleic Acids and Proteins Involved in Viral Infection

Examples of host nucleic acids and proteins that play a role in viral infection have been identified and are summarized in Table 1. These nucleic acids and proteins offer new targets for therapies that reduce or even inhibit or prevent viral infection, and offer new strategies for assessing the risk of infection among certain populations. While the target genes were identified in an assay using the recited virus, it is appreciated that infections agents such as viruses will share common pathways. Thus, the host sequences set forth below can be interfered with to decrease infection in a host cell.

Examples of viruses that can be inhibited are described in Virology, Volumes 1 and 2 by Bernard Fields, Second Edition, 1990, Raven Press. Exemplary viruses include, but are not limited to 20 members of the family: Picornaviridae (such as Poliovirus, Coxsackievirus, Echovirus ,Rhinovirus, and Hepatitis A and E); Calciviridae (such as Norwalk and related viruses); Togaviridae and Flavivirdae (such as hepatitis C, Alphavirus, and Rubella); Coronaviridae (such as SARS); Rhabdoviridae (such as Rabies); Filoviridae (such as Marburg and Ebola); Paramyxoviridae (such as Parainfluenza, Mumps, Measles, Hydra and Respiratory Synctial virus); Orthomyxoviridae; 25 Bunyaviridae (including all subtypes and strains); Arenaviridae (such as lymphocytic choreomeningitis virus and lassa fever and related viruses); Reoviridae (such as Reovirus and Rotavirus); Retroviridae (such as HTLV, HIV, and Lentivirus); Papoviridae (such as Polyoma and Papilloma); Adenoviridae (such as Adenovirus); Parvoviridae (such as Parvovirus); Herpesviridae (such as Herpes 1 and 2, Cytomegalovirus, Varicella-Zoster, Kaposi sarcoma related virus (HHV9), 30 Epstein Barr Virus, and HHV6-7 (roseolavirus)); Poxviridae (such as Pox); Hepadnaviridae (such as Hepatitis B); as well as Hepatitis D virus, Hanta virus, and newly identified infectious agents.

Table 1: Examples of Host Genes and Protiens Implicated in Pathogenesis

Nucleic Acid or Protein	Associated Virus	SEQ ID NO:	GenBank Accession Nos for cDNA and Protein
T-cell receptor V beta chain	HIV	1-19	

T-cell receptor V-D-J beta 2.1 chain	HIV	20	
β-chimerin (CHN2)	HIV	21-22	NM_004067; NP_004058.1
Malic enzyme 1 (ME1)	HIV and Influenza A	23	BC025246; AAH25246.1
Hypothetical protein XP_174419	HIV and Influenza A	24	
sequence from Chromosome 4q31.3-32	HIV and Influenza A	25-27	
alpha satellite DNA	HIV	28	
LOC253788 and LOC219938; coagulation factor III (F3) and LOC91759	HIV	29	
similar to KOX4 (LOC131880) and LOC166140	HIV	30	
LOC222474 and similar to Rho guanine nucleotide exchange factor 4, isoform a, APC-stimulated guanine nucleotide exchange factor (LOC221178); T-cell receptor beta	HIV	31	
ribosomal protein L7A-like 4 (RPL7ALA) and v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian) (SRC)	HIV	32	
KIAA0564	HIV	33	
alpha satellite DNA; M96 protein	HIV	34	,
hypothetical protein similar to G proteins, especially RAP-2A (LOC57826); LOC161005 and osteoblast specific factor 2 (fasciclin I-like; OSF-2)	ні∨	35	
Canis familiaris T-cell leukemia translocation-associated (TCTA) gene, aminomethyltransferase (AMT) gene, dystroglycan (DAG1) gene, and bassoon (BSN) gene	Influenza A	36-37	
LIM domain containing preferred translocation partner in lipoma (LPP)	Influenza A	38-48	
sequence between LOC253121 and hyaluronan synthase 2 (HAS2)	Influenza A	49	
Testin 2 and Testin 3 (TES)	Influenza A	50-57	<u> </u>
PTPN1 gene for protein tyrosine phosphatase, non-receptor type 1	Influenza A	58-59	
sequence between LOC149360 and LOC253961	Influenza A	60	
sequence between KIAA1560 and Tectorin beta (TECTB)	Influenza A	61	
Cadherin related 23 (CDH23)	Influenza A	62	BC032581; AAH32581.1-
Myeloid/lymphoma or mixed lineage leukemia, translocated to 10 (MMLT10)	Influenza A	63	
	<u></u>		<u> </u>

WO 2004/070002

	201 1	· · · · · · · · · · · · · · · · · · ·	
exportin 5 (XPO5) and DNA polymerase eta (POLH)	Ebola	64-66	
heterogenous nuclear riboprotein C (C1/C2) (HNRPC)	Ebola	67-75	
alpha-endosulfine pseudogene (ENSAP) and LOC128741	Ebola	76	
LOC222888	Ebola	77	
LOC138421 and zinc finger protein 297B (ZNF297B)	Ebola	78	
sideroflexin 5 (SFXN5)	Ebola	79	AY044437; AAK95826
importin 9 (FLJ10402)	Ebola	80	
T-cell receptor beta	Ebola	81-82	
similar to murine putative transcription factor ZNF131 (LOC135952)	Ebola	83-99	
KIAA1259	Ebola	100-101	AB033085; NP_115572
MURR1 and CCT4	Ebola	102	
FLJ40773 and similar to ribosomal protein L24-like (LOC149360)	Ebola	103	
Testin 2 and 3 (TES)	Ebola	104-107	See above
polybromo 1 (PB1)	Ebola	108	NM_018165.2; NP_060635
DNA damage inducible transcript 3 (DDIT3) and KIAA1887	Ebola	109	
PDZ and LIM domain 1 (elfin) (PDLIM1)	Ebola	110	
LOC284803	Ebola	111-112	
PRO0097 and FLJ31958	Ebola	113	
small inducible cytokine E, member 1 (endothelial monocyte-activating) (SCYE1)	Ebola	114-116	
E3 ubiquitin ligase (SMURF2) and MGC40489	Ebola	117-119	
Ras oncogene family member Rab9	Ebola	118-119	
PRO1617 and retinoblastoma binding protein 1 (RBBP1)	Ebola	120-122	NM_000321; NP_000312.1
region of chromosome 2q12	Ebola	123	
elongation factor for selenoprotein translation	. Ebola .	124	NM_021937.1 NP 068756.1
Transcription factor SMIF (HSA275986)	Ebola	125-137	
KIAA1026	Ebola	138	
trinucleotide repeat containing 5 (TNRC5)	Ebola	139	1
homogentisate 1,2-dioxygenase (HGD)	Ebola	140	1
region of chromosome Xq23-24	Ebola	141	1
region of chromosome 4p15.3	Ebola	142	1
similar to LWamide neuropeptide precursor protein [Hydractinia echinata] (LOC129883)	Ebola	143	

•			
region of chromosome 2q21	Ebola .	144	
region of chromosome Xp11.4, including UPS9X	Ebola	145	
LOC221829	Ebola	146	
U3 small nuclear RNA	Ebola	147-154	
integrin, beta 1 (ITGB1)	Ebola		BC020057; AAH20057.1
acrosomal vesicle protein 1 (ACRV1) and CHK1 checkpoint homolog (CHEK1)	Ebola	159	
prospero-related homeobox 1 (PROX1)	Ebola	160	
FLJ20627 and FLJ12910	Ebola	161-173	
PIN2-interacting protein (PINX1) and SRY (sex-determining region Y)-box 7 (SOX7)	Ebola	174	
LOC131920	Ebola	175	
region of chromosome 13q14	Ebola	176	
neurotrophic tyrosine kinase, receptor, type 3 (NTRK3)	Ebola	177	
TERA protein and FLJ13224	Ebola	178-179	
LOC284260	Ebola	180	
POM (POM121 homolog) and ZP3 fusion (POMZP3)	Ebola	181-182	·
DEAD/H box polypeptide 8 (DDX8) and similar to ribosomal protein L29 (cell surface heparin binding protein HIP) (LOC284064)	Ebola	183	
LOC345307 and UDP-N-acetyl-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 7 (GALNT7)	Ebola	184-186	
Mus musculus 5S rRNA pseudogene (Rn5s-ps1)	Ebola	187	
ribosomal protein L27a pseudogene (RPL27AP) and v-myb myeloblastosis viral oncogene homolog-like 2 (MYBL2)	Ebola .	188-192	
Down's syndrome cell adhesion molecule like 1 (DSCAML1)	Ebola	193	
LOC148529	Ebola	194	<u> </u>
Huntingtin-associated protein interacting protein (HAPIP)	Ebola	195	NM_005338.4; NP_005329.3
LOC158525 and similar to RIKEN cDNA 1210001E11 (LOC347366)	Ebola	196-200	
hypothetical protein FLJ12910	Ebola	201-204	
LOC350411	Ebola	205	
allograft inflammatory factor 1 (AIF1) and HLA-B associated transcript 2 (BAT2)	Ebola	206	
C10orf7	Ebola	207	
LOC346658 and LOC340349	Ebola .	208-209	
region of chromosome 12q21	Ebola	210	. [
LOC339248 and FLJ22659	Ebola	211	1
1 1.()(339248 and FLJ22029			

hypothetical protein MGC14793			
FLJ10439	Ebola	213-214	NM_018093.1; NP_060563.1
cytochrome P450, family 11, subfamily A, polypeptide 1 (CYP11A1) and sema domain, immunoglobulin domain (Ig) and GPI membrane anchor, (semaphoring) 7A	Ebola	215-218	
ribosomal protein S16 (RPS16)	Ebola	219-220	BC004324.2; AAH04324.1
hypothetical protein DKFZp434H0115 and ATP citrate lyase (ACLY)	Ebola	221-222	
calnexin (CANX); protein tyrosine phosphatase, receptor type, K (PTPRK)	Ebola	223-224	
cyclin M2 (CNNM2)	Ebola	225	NM_017649.2; NP_060119.2
AXL receptor tyrosine kinase (AXL)	Ebola	226	BC032229; AAH32229.1
Homo sapiens chromosome 10 open reading frame 3	Ebola	227-228	
Homo sapiens chromosome 10 open reading frame 3 (C10orf3)	Ebola	229-230	
Homo sapiens fer-1-like 3, myoferlin (C. elegans)	Ebola	231-232	NM_013451.; NP_038479.1

Some of the host nucleic acids described in Table 1 and target sequences associated with SEQ ID NOS: 1-227, 229, and 231 encode polypeptides that are receptors or ligands recognized by a particular virus, such as HIV, influenza A, or the Ebola virus. For example, the T-cell receptor V beta and V-D-J beta 2.1 chain polypeptides are part of the T-cell receptor complex that are recognized by certain glycoproteins in the HIV envelope. Other host nucleic acids encode polypeptides that provide an enzymatic function related to a viral life cycle, such as the signaling pathways controlling viral packaging or enzymes involved in viral replications. For example, the β-chimerin rho-GTPase may mediate a cellular signal that initiates or triggers a process leading to passage of an HIV viral particle into the host cell. The data presented herein indicate that Rab9 is involved in pathogen infectivity, for example by interfering with trafficking of proteins and lipids within cells. In particular examples, it is demonstrated that Rab9 is involved in lipid raft formation, and that decreasing functional Rab9 and lipid rafts decreases the ability of pathogens, such as viruses and bacteria, that hijack lipid rafts to bud or be infectious.

Still other host nucleic acids participate in the life cycle of a virus. For example, a certain nucleotide sequence of a host nucleic acid, such as a gene within the host genome can be recognized during insertion and integration of a viral genome (reverse transcribed into DNA from the viral RNA genomic template) into the host genome. Viral integration is described in, for example, Coffin et al., Retroviruses, Chapter 5.

The nucleic acids and proteins disclosed herein can be identified, isolated, and characterized using any number of techniques of molecular biology, including the specific methods and protocols described herein, such as in the examples below. In some examples, the nucleic acids were identified

5

10

15

10

15

20

25

30

35

and isolated using the Lexicon Genetics, Inc. (The Woodlands, TX) "gene trap" technology disclosed in U.S. Pat. Nos: 6,080,576; 6,136,566; 6,207,371; 6,139,833; 6,218,123 and 6,448,000.

Gene trap technology is a powerful method for cloning and identifying functional genes, as it marks a gene with a tag and simultaneously generates a corresponding genetic variation for that particular locus. The method involves introducing into a cell a DNA construct that can monitor and potentially disrupt the transcriptional activity of the region of the cell's genome into which it is inserted. The gene-trap method used to identify the host sequences is disclosed in U.S. Patent No. 6,448,000 (herein incorporated by reference).

Briefly, the gene trap protocol involves infecting a host cell (for example, a cell of a Sup T-1 cell line (human), MDCK cells (canine), or Vero cells (monkey)) with a recombinant vector (for example, U3neoSV1, FIG. 1). The recombinant vector includes a selectable marker or other sequence capable of being used to select infected host cells. However, the selectable marker or other sequence does not have a promoter at its 5' end. An exemplary selectable marker is a nucleic acid encoding resistance to an antibiotic (such as neomycin). A summary of the gene trap method is provided in FIGS. 2 and 3. Infection of the host cell is performed in culture under conditions that yield about one copy of the vector per cell. The vector incorporates into the host cell genome adjacent to an active promoter and interrupts or disrupts the transcription of a nucleic acid in the host cell (FIG. 2). The host promoter drives expression of the selectable marker or other sequence on the vector, and infected cells can then be selected. For example, if the vector carries a nucleic acid encoding neomycin resistance, cells can be selected on a medium that contains neomycin or G418, the neomycin analog for mammalian cells, depending on the type of host cell used.

The selected host cells are expanded in culture to form a library of cells that contain randomly disrupted host genes (FIG. 3). An aliquot of the library of cells is exposed to the appropriate virus, such as HIV, influenza A, or Ebola, to determine the effect of the disrupted host sequence on viral infection of the host cells. Host cells that survive the viral infection, or are relatively resistant to such infection (such as those cells that survive for a longer period of time than about at least 50% of the infected cells), can include one or more disrupted genes involved in viral infection. Thus, by using the vector one can decrease viral or pathogenic infection of a host cell or in a subject. Therefore, by identifying these disrupted genes that decreased or otherwise interfered with viral infection of the host cell, candidate sequences are identified that can be used as targets to decrease or inhibit viral infection.

Those host cells that survive viral infection, or are relatively resistant to such infection, are cloned, for example, by limit dilution using a chambered plate or by growth on methylcellulose. The interrupted host nucleic acid is identified using standard molecular biology methods. For example, host DNA can be isolated from the cell and digested using an appropriate restriction enzyme to free the 5' and 3' sequences adjacent the incorporated vector. The isolated DNA fragment can then be amplified, for example using PCR or by introducing the DNA fragment into a bacterial host cell then growing the bacteria. Once isolated, the host nucleic acid can be further characterized and analyzed.

10

15

20

25

**30** °

35

For example, the nucleic acid can be sequenced and compared to other similar nucleic acids. Methods of using these nucleic acids, and the proteins encoded thereby, are discussed below.

Using these gene trap methods, several host molecules were identified that were previously not known to be involved in viral pathogenesis (SEQ ID NOS: 1-232, Table 1, and target sequences associated with SEQ ID NOS: 1-232). For example, the AMT gene (target sequences associated with SEQ ID NOS: 36 and 37) participates in influenza A infection of host cells. Fragments of host sequences involved in viral infection and pathogenesis can now be identified, even including fragments or sequences that were previously known to be important in the pathogenesis of intracellular pathogens. For example, although the T-cell receptor was previously implicated in HIV infection, the results disclosed herein demonstrate that the T-cell receptor V-D-J beta 2.1 chain (target sequences associated with SEQ ID NO: 20) is involved and in some examples required for HIV infection, and host cells lacking the T-cell receptor V-D-J beta 2.1 chain are unexpectedly highly resistant to HIV infection. Hence the V-D-J beta 2.1 chain is a target for anti-viral therapy at the DNA or polypeptide level, and other pathogenically active subcomponents of other known pathogenic sequences can also be identified with this method.

Examples of these host nucleic acid molecules are target sequences associated with SEQ ID NOS: 1-227, 229, and 231 (including variants, fragments, and fusions thereof) and summarized in Table 1. In addition to these specifically disclosed nucleotide sequences, a host nucleic acid can include nucleotide sequences that are similar to any of the target sequences associated with SEQ ID NOS: 1-227, 229, and 231, such as having at least 70% identity, at least 80% identity, at least 85% identity, at least 90% identity, at least 95% identity, at least 98% identity, or even at least 99% identity to any of the target sequences associated with SEQ ID NOS: 1-227, 229, and 231. The disclosed host nucleic acid sequences, and methods of using them, may comprise, consist, or consist essentially of any of the disclosed nucleic acid sequences shown in SEQ ID NOS: 1-227, 229, and 231, as well as target sequences associated with SEQ ID NOS: 1-227, 229, and 231, or variants or fragments thereof, or sequences that hybridize to the identified sequences under stringent or moderately stringent conditions.

The host nucleic acid molecules also include a fragment of any target sequence associated with SEQ ID NOS: 1-227, 229, and 231, such as a probe or primer as described below.

Host polypeptides corresponding to these nucleic acids also can be used to practice the disclosed methods. In some examples, the polypeptide includes an amino acid sequence that corresponds to a coding sequence of any target sequence associated with SEQ ID NOS: 1-227, 229, and 231, or a target protein sequence associated with SEQ ID NOS: 228, 230, and 232. However, host polypeptides can also include those having similar amino acid sequences, such as polypeptides that are at least 70% identical, at least 80% identical, at least 90% identical, at least 95% identical, at least 98% identical, or at least 99% identical to the amino acid sequences corresponding to translations of the coding sequence of any target sequence associated with SEQ ID NOS: 1-227, 229, and 231, or a target protein sequence associated with SEQ ID NOS: 228, 230, and 232. For example, the disclosed host polypeptides and methods of using them, may comprise, consist, or consist

10

15

20

25

30

35

essentially of an amino acid sequence corresponding to a translation of the nucleotide sequence in any target sequence associated with SEQ ID NOS: 1-227, 229, and 231, a target protein sequence associated with SEQ ID NOS: 228, 230, and 232, or any of the protein sequences listed in Table 1. Alternatively, the polypeptides include homologous polypeptides from other mammals (for example human, monkeys, and dogs).

The host polypeptide can have an amino acid sequence that varies by one or more conservative substitutions from the amino acid sequences of the proteins encoded by target sequences associated with SEQ ID NOS: 1-227, 229, and 231, or from the target amino acid sequences associated with SEQ ID NOS: 228, 230, and 232. In one example, there is no more than 1, 2, 3, 4, 5, or 10 conservative amino acid substitutions. In another example, there are 1, 2, 3, 4, 5 or 10 conservative amino acid substitutions. The effects of these amino acid substitutions, deletions, or additions on host polypeptides can be assayed, for example, by analyzing the ability of cells transformed with the derivative proteins to resist infection by the corresponding virus.

Also included are fragments of any host polypeptide encoded by any of the target sequences associated with SEQ ID NOS: 1-227, 229, and 231, as well as fragments of the target amino acid sequences associated with SEQ ID NOS: 228, 230, and 232. For example, a protein can include at least 5-500 contiguous amino acids of the protein, such as at least 6-200, at least 6-100, at least 10-100, at least 10-50, or at least 20-50 contiguous amino acids of the protein. A host polypeptide fragment can be at least 5, at least 10, at least 15, at least 25, at least 50, at least 100, at least 200, at least 500, or more amino acids of a polypeptide having an amino acid sequence corresponding to a coding region of the nucleotide sequence in any of the target sequences associated with SEQ ID NOS: 1-227, 229, and 231, or a conservative variant thereof, as well as target amino acid sequences associated with SEQ ID NOS: 228, 230, and 232.

Fragments of a nucleic acid target sequences associated with SEQ ID NOS: 1-227, 229, and 231 can include 10-5000 contiguous nucleic acids, such as 12-1000, 12-500, 15-100, or 18-50 contiguous nucleic acids. A host nucleic acid fragment can be at least at least 5, at least 10, at least 15, at least 20, at least 25, at least 50, at least 100, at least 200, at least 500, at least 1000, at least 2000, at least 5000 or more contiguous nucleic acids in any target sequence associated with SEQ ID NOS: 1-227, 229, and 231, or a variant or fusion thereof.

Also included are host nucleic acids that encode the same polypeptide encoded by any target sequence associated with SEQ ID NOS: 1-227, 229, and 231, or a conservative variant of the polypeptide, or a fragment thereof. For example, a host nucleic acid provided by target sequences associated with SEQ ID NOS: 36-37 encodes AMT. A second host nucleic acid also can encode an AMT having the same amino acid sequence as the AMT encoded by target sequences associated with SEQ ID NOS: 36-37, a conservative variant of this AMT, or a fragment thereof, yet this second host nucleic acid can have a different nucleotide sequence than a target sequence associated with SEQ ID NOS: 36-37 due to the degeneracy of the genetic code.

10

15

20

51

#### Methods of Using Host Sequences to Decrease Viral Infection

The interaction between a host nucleic acid or polypeptide (such as target sequences associated with SEQ ID NOS: 1-232 and those shown in Table 1) and a virus or viral protein can be decreased or inhibited using the methods provided. Decreasing or inhibiting this interaction can be used to decrease viral infection of a host cell, and/or to decrease symptoms associated with a viral infection in a subject. For example, decreasing or even inhibiting the interaction of a host nucleic acid or polypeptide and a virus can decrease, inhibit, or even prevent infection of a host cell by that virus, or otherwise inhibit the progression or clinical manifestation of the viral infection. In addition, decreasing the interaction of a host nucleic acid or polypeptide and a virus can reduce or alleviate one or more symptoms associated with viral infection, such as a fever.

Several methods can be used to decrease or inhibit the interaction between a viral protein and a host protein or nucleic acid. The viral and host proteins or nucleic acids can be part of an in vitro solution, an in vivo expression system, or in situ with a host tissue or subject. The viral protein can be part of a larger molecule or complex, such as an envelope protein on the envelope of a mature virus or a fragment of a viral envelope. The host protein also can be part of a larger molecule or complex, such as a host polypeptide expressed as part of a fusion protein or contained as one subunit of a larger protein, such as a transport protein, cell receptor, structural protein, or an enzyme. A host nucleic acid can be part of a larger molecule, complex, organism or microorganism such as a host nucleic acid contained within its host genome, a recombinant vector, or a transgenic organism or microorganism (including both extrachromosomal molecules or genomic insertions).

In accordance with the disclosed methods, interaction is decreased or inhibited between a virus or viral protein and more than one (such as 2 or more, such as 3 or more) host nucleic acids or polypeptides. Decreasing or inhibiting the interactions of one or more host nucleic acids or polypeptides with one or more viral proteins can have additive or exponentially increasing effects. For example, it is believed that decreasing the interaction between a host T-cell receptor V-D-J beta 2.1 chain and HIV, or decreasing the activity of a host β-chimerin, within a host cell can enhance the inhibitory effect on HIV infection of that host cell compared to inhibiting the interaction of only one of the host polypeptides. Hence, the methods include interfering with an interaction between the virus or viral protein and more than one of the proteins associated with infection by the same virus.

For example, for infection with HIV, the method could interfere with one, or two or more (such as three or more) of the following: T-cell receptor V beta chain; T-cell receptor V-D-J beta 2.1 chain; β-chimerin (CHN2); malic enzyme 1; Hypothetical protein XP\_174419; sequence from Chromosome 4q31.3-32; alpha satellite DNA; LOC253788; LOC219938; coagulation factor III (F3); LOC91759; similar to KOX4 (LOC131880); LOC166140; LOC222474; similar to Rho guanine nucleotide exchange factor 4, isoform a; APC-stimulated guanine nucleotide exchange factor (LOC221178); T-cell receptor beta; ribosomal protein L7A-like 4 (RPL7ALA); v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian) (SRC); KIAA0564; alpha satellite DNA; M96 protein; hypothetical protein similar to G proteins (such as RAP-2A; LOC57826); LOC161005 and osteoblast specific factor 2 (fasciclin I-like).

30

35

25

BNSDOCID: <WO\_\_\_\_2004070002A2\_I\_>

For Ebola virus, examples of targets include one, or two or more (such as three or more) of the following: exportin 5; DNA polymerase eta (POLH); heterogenous nuclear riboprotein C (C1/C2); alpha-endosulfine pseudogene; LOC128741; LOC222888; LOC138421; zinc finger protein 297B; sideroflexin 5; importin 9; T-cell receptor beta; similar to murine putative transcription factor ZNF131 (LOC135952); KIAA1259; MURR1; CCT4; FLJ40773 and similar to ribosomal protein 5 I.24-like (LOC149360); testin 2; testin 3; polybromo 1; DNA damage inducible transcript 3 (DDIT3); KIAA1887; PDZ and LIM domain 1 (elfin) (PDLIM1); LOC284803; PRO0097 and FLJ31958; small inducible cytokine E, member 1 (endothelial monocyte-activating); E3 ubiquitin ligase (SMURF2) and MGC40489; Rab9; PRO1617 and retinoblastoma binding protein 1 (RBBP1); region of chromosome 2q12; elongation factor for selenoprotein translation; transcription factor SMIF 10 (HSA275986); KIAA1026; trinucleotide repeat containing 5; homogentisate 1,2-dioxygenase; region of chromosome Xq23-24; region of chromosome 4p15.3; similar to LWamide neuropeptide precursor protein [Hydractinia echinata] (LOC129883); region of chromosome 2q21; region of chromosome Xp11.4, including UPS9X; LOC221829; U3 small nuclear RNA; integrin, beta 1; acrosomal vesicle protein 1 (ACRV1) and CHK1 checkpoint homolog (CHEK1); prospero-related homeobox 1 15 (PROX1); FLJ20627 and FLJ12910; PIN2-interacting protein (PINX1) and SRY (sex-determining region Y)-box 7 (SOX7); LOC131920; region of chromosome 13q14; neurotrophic tyrosine kinase, receptor, type 3 (NTRK3); TERA protein; FLJ13224; LOC284260; POM (POM121 homolog) and ZP3 fusion (POMZP3); DEAD/H box polypeptide 8 (DDX8) and similar to ribosomal protein L29 (cell surface heparin binding protein HIP) (LOC284064); LOC345307 and UDP-N-acetyl-D-20 galactosarmine:polypeptide N-acetylgalactosarminyltransferase 7 (GALNT7); 5S rRNA pseudogene; ribosomal protein L27a pseudogene (RPL27AP) and v-myb myeloblastosis viral oncogene homologlike 2 (MYBL2); Down's syndrome cell adhesion molecule like 1; LOC148529; Huntingtinassociated protein interacting protein; LOC158525 and similar to RIKEN cDNA 1210001E11 (LOC347366); hypothetical protein FLJ12910; LOC350411; allograft inflammatory factor 1 (AIF1); 25 HLA-B associated transcript 2 (BAT2); C10orf7 ;LOC346658; LOC340349; region of chromosome 12q21; LOC339248; FLJ22659; SR rich protein DKFZp564B0769; hypothetical protein MGC14793; FLJ10439; cytochrome P450, family 11, subfamily A, polypeptide 1; sema domain, immunoglobulin domain (Ig) and GPI membrane anchor, (semaphoring) 7A; ribosomal protein S16; hypothetical protein DKFZp434H0115; ATP citrate lyase; calnexin; protein tyrosine phosphatase, receptor type, K 30 (PTPRK); cyclin M2; AXL receptor tyrosine kinase; Homo sapiens chromosome 10 open reading frame 3, mRNA (cDNA clone MGC:3422 IMAGE:3028566); Homo sapiens chromosome 10 open reading frame 3.(C10orf3); and Homo sapiens fer-1-like 3, myoferlin-(C. elegans) (FER1L3), transcript variant 1.

For influenza, examples of targets include one, or two or more (such as three or more) of the following: T-cell leukemia translocation-associated (TCTA) gene, aminomethyltransferase; dystroglycan; BSN; LIM domain containing preferred translocation partner in lipoma (LPP); sequence between LOC253121 and hyaluronan synthase 2 (HAS2); testin 2; testin 3; PTPN1 gene for protein tyrosine phosphatase, non-receptor type 1; sequence between LOC149360 and LOC253961;

**WO 2004/07000** 

5

10

15

20

25

30

35

sequence between KIAA1560 and tectorin beta; cadherin related 23; myeloid/lymphoma or mixed lineage leukemia, translocated to 10; malic enzyme 1; hypothetical protein XP\_174419; and sequence from chromosome 4q31.3-32.

In examples where a host polypeptide is a cell receptor or part of a cell receptor, decreasing or preventing expression of the polypeptide, or altering the three-dimensional structure of the polypeptide, can reduce or inhibit the interaction between the host cell receptor and a viral protein. Similarly, decreasing, inhibiting or preventing expression of a host ligand polypeptide (or altering the structure of such a ligand) can decrease or inhibit an interaction between the viral protein and the ligand. For example, decreasing or inhibiting expression of one or more enzymes involved in viral pathogenesis, such as those listed in Table 1 and those target sequences associated with SEQ ID NOS: 1-232, can block a component of the viral life cycle, such as blocking a signal pathway leading to transcription or translation of the viral genome, or assembly of viral sub-parts. Decreasing or inhibiting the enzymatic activity of an enzyme (rather than its expression) can have a similar effect.

Altering the nucleotide sequence of a host nucleic acid, for example by targeting disruption of the nucleotide sequence using complementary nucleic acid sequences, can decrease, inhibit or prevent integration of a viral nucleic acid into the host nucleic acid. Methods that can be used to interrupt or alter translation of a host nucleic acid include, but are not limited to, using an antisense RNA, RNAi molecule, or an siRNA that binds to a messenger RNA transcribed by the nucleic acid encoding a host polypeptide as described herein. Decreasing or inhibiting the expression of the host nucleic acid can also alter the course of the disease. In one example, altering the nucleotide sequence of a host gene that is targeted by a virus for viral integration can decrease, inhibit, or even prevent, integration of that virus into the host genome.

A host nucleic acid involved in viral infection, including variants, fusions and fragments thereof, can be used to design agents that bind to a target sequence of that nucleic acid, such as antisense nucleic acids or siRNAs. Such nucleic acid binding agents can be used to decrease or inhibit expression of the nucleic acid, to reduce the incidence of viral infection. For example, an expression vector that transcribes antisense RNA or siRNA that recognizes human β-chimerin mRNA is used to transform cell lines obtained from simians. These transformed cell lines are analyzed for infection by simian immunodeficiency virus (SIV), which is related to HIV. If those cells are resistant to SIV infection, the disrupted gene is identified, sequenced, and compared to the human β-chimerin gene. Sequence similarities between the two genes will offer insight into common molecular mechanisms for infection by HIV and SIV, for example, common structural regions within their respective translated proteins.

A binding agent that recognizes a host nucleic acid involved in viral infection can be used for prophylactic or therapeutic purposes. For example, expression vectors having antisense RNA, RNAi molecules, or siRNA molecules that target a host nucleic acid involved in viral infection, such as β-chimerin, are introduced into the bone marrow of a subject. Uptake of the vector and expression of the antisense RNA, RNAi, or siRNA within cells infected by HIV offers a prophylactic or therapeutic effect by disrupting the β-chimerin genes within those cells, thus decreasing or inhibiting

10

15

20

25

30

35

HIV infection. Similarly, expression vectors including Rab9 antisense RNA, RNAi, or siRNA molecules can be introduced into the bone marrow of a subject. Uptake of the vector and expression of Rab9 antisense RNA, RNAi, or siRNA within cells infected by a pathogen that can hijack a lipid raft, such as HIV or Ebola, offers a prophylactic or therapeutic effect by disrupting the Rab9 genes within those cells, thus decreasing or even inhibiting infection by a pathogen that can hijack a lipid raft. The vector, or other nucleic acid carrying the nucleic acid specific binding agent, is introduced into a subject by any standard molecular biology method and can be included in a composition containing a pharmaceutically acceptable carrier.

Decreasing or inhibiting the interaction between a viral protein and a host protein can decrease or inhibit viral infection. Methods that can be used to decrease an interaction between a viral protein and one or more host proteins (such as at least 2 host proteins, or at least 3 host proteins), include but are not limited to, disrupting expression of a host nucleic acid sequence encoding the host protein, (for example by functionally deleting the coding sequence, such as by a mutation, insertion, or deletion), altering the amino acid sequence or overall shape of the host protein, degrading the host protein, employing an agent that interferes with the viral protein or host protein (such as a specific binding agent, for example an antibody or small molecule), or a combination thereof.

For example, expression of a host protein can occur during transcription or translation of a nucleic acid encoding the host protein, or as a result of post-translational modification of a host protein. Methods that can be used to interrupt or alter transcription of a nucleic acid include, but are not limited to, site-directed mutagenesis, including mutations caused by a transposon or an insertional vector; and providing a DNA-binding protein that binds to the coding region of the host protein, thus blocking or interfering with RNA polymerase or another protein involved in transcription. Various inactive and recombinant DNA-binding proteins, and their effects on transcription, are discussed in Lewin, Genes VII. Methods that can be used to interrupt or alter translation of a nucleic acid include, but are not limited to, using an antisense RNA or an siRNA that binds to a messenger RNA transcribed by the nucleic acid encoding the host polypeptide as described herein.

For example, exemplary host T-cell receptor polypeptides are encoded by target sequences associated with SEQ ID NOS: 1-20. Disrupting the expression of a nucleic acid including any target sequence associated with SEQ ID NOS: 1-20 can reduce or prevent production of the corresponding T-cell receptor polypeptide, and without access to the T-cell receptor polypeptide, an HIV virus cannot infect the host cell. Even if expression of the host nucleic acid is not completely blocked or disrupted, virus infection can still be inhibited. For example, interference with a host protein encoded by any target sequence associated with SEQ ID NOS: 1-20 reduces the number of T-cell receptors within that host cell available for recognition by an HIV virus, thus inhibiting HIV infection.

It is shown herein that inhibiting the interaction or activity between host Rab9 and HIV and Ebola using Rab9 siRNA molecules decreases infection of a host cell by the virus compared to the amount of infection in the absence of the siRNA molecules.

5.

10

15

20

25

30

35 '

Host proteins involved in viral infection, such as those encoded by target cDNA sequences associated with SEQ ID NOS: 1-227, 229, and 231, as well as target sequences associated with SEQ ID NOS: 228, 230, and 232, can be used to generate specific binding agents to those proteins. The specific binding agent can be an anti-protein binding agent, such as a monoclonal or polyclonal antibody. Anti-protein binding agents can provide a prophylactic or therapeutic effect, for example by interfering with viral infection. Assays to determine whether an antibody interferes with viral infection are described herein. Antibodies that recognize a host protein involved in viral infection can prevent a virus or portion thereof (such as a viral protein) from binding to a host protein involved in viral infection. For example, a monoclonal or polyclonal antibody that binds to a V beta T-cell receptor on a cell can block the binding of HIV to that T-cell receptor, thus blocking infection of that cell. Effective amounts of such specific binding agents can be administered alone to a subject, or as part of a pharmaceutical composition, for the treatment of viral infection or as a prophylactic measure prior to the time the subject is exposed to the virus. In another example, specific binding agents that recognize a host protein involved in viral infection, such as β-chimerin or Rab9, can be used can be used to screen for the presence of the host protein, in other cells, tissues or lysates, including a biological sample obtained from a subject.

Host nucleic acids and polypeptides described herein, such as target sequences associated with SEQ ID NOS: 1-232, can be used for prophylactic or therapeutic uses. For example, polypeptides with structures mimicking a protein recognized by a virus can be administered to a subject as a pharmaceutical composition. These polypeptides interact with a virus already infecting that subject, or provide a prophylactic defense mechanism against infection if the subject is at risk of exposure to a virus. For example, polypeptides structurally similar to the T-cell receptor V beta 2.1 chain are recognized by HIV. If such polypeptides are administered to an HIV-positive subject, the viruses already present in the subject interact with those polypeptides in addition to that subject's T-cell receptors, thus inhibiting the rate at which HIV infects T-cells. The administered polypeptides act as "decoys" to block HIV from interacting with T-cell receptors. As another example, an agent that otherwise interferes with the interaction between a virus and a host protein can provide a similar prophylactic effect. For example, a chemical compound or anti-AMT binding agent (such as an antibody) that interferes with the interaction between AMT and an influenza virus (including an enzymatic inhibitor of AMT) provides a prophylactic or therapeutic effect against influenza A infection when provided to a host cell or administered to a host subject.

Additionally, the proteins described herein can be used to screen samples for the presence or absence of a particular antibody. For example, a β-chimerin or Rab9 protein can be used in an ELISA to screen a sample obtained from an individual for the presence of anti-β-chimerin or anti-Rab9 antibodies generated by that individual, such as a blood sample.

Using a method similar to that described for nucleic acid binding agents above, protein binding agents (such as agents that specifically bind β-chimerin, Rab9, or V beta T-cell receptor proteins) can be used to screen cells, individuals or populations for the presence or absence of

3.

5

10

15 .

20

25

30

35

polypeptides related to infection (such as HIV, Ebola, or influenza infection), thus providing information about the susceptibility or resistance of that individual or population to viral infection.

The host nucleic acids, proteins, and related specific binding agents described herein can be used as models for the design of anti-viral drugs. For example, the three-dimensional structure of a protein described herein, such as β-chimerin, can be used in computer modeling of chemotherapeutic agents that block the activity of that moiety, for example by binding the protein. As another example, a monoclonal antibody can be used in a competitive binding assay to screen for other compounds that bind the same antigen.

#### Screening for Resistance to Infection

Also provided herein are methods of screening host subjects for resistance to infection by characterizing a nucleotide sequence of a host nucleic acid or the amino acid sequence of a host polypeptide (such as those shown in Table 1, or any target sequence associated with SEQ ID NOS: 1-232).

For example, the T-cell receptor V beta 2.1 chain nucleic acid of a subject can be isolated, sequenced, and compared to SEQ ID NO: 20 (or a target sequence associated with SEQ ID NO: 20). The greater the similarity between that subject's V beta 2.1 chain nucleic acid and the sequence shown in SEQ ID NO: 20 (or a target sequence associated with SEQ ID NO: 20), the more susceptible that person is to HIV infection, while a decrease in similarity between that subject's V beta 2.1 chain nucleic acid and SEQ ID NO: 20 (or a target sequence associated with SEQ ID NO: 20), the more resistant that subject can be to HIV infection.

In another example, the aminomethyltransferase (AMT) nucleic acid of a subject can be isolated, sequenced, and compared to SEQ ID NOS: 36-37 (or a target sequence associated with SEQ ID NOS: 36-37). The greater the similarity between that subject's AMT nucleic acid and the sequence shown in SEQ ID NOS: 36-37 (or a target sequence associated with SEQ ID NOS: 36-37), the more susceptible that person is to influenza A infection, while a decrease in similarity between that subject's AMT nucleic acid and SEQ ID NOS: 36-37 (or a target sequence associated with SEQ ID NOS: 36-37), the more resistant that subject can be to influenza A infection.

In yet another example, the Ras oncogene family member Rab9 nucleic acid of a subject can be isolated, sequenced, and compared to SEQ ID NOS: 118-119 (or a target sequence associated with SEQ ID NOS: 118-119). The greater the similarity between that subject's Rab9 nucleic acid and the sequence shown in SEQ ID NOS: 118-119 (or a target sequence associated with SEQ ID NOS: 118-119), the more susceptible that person is to infection by a pathogen that uses lipid rafts, such as those listed in Table 2, while a decrease in similarity between that subject's Rab9 nucleic acid and SEQ ID NOS: 118-119 (or a target sequence associated with SEQ ID NOS: 118-119), the more resistant that subject may be to infection by a pathogen that uses lipid rafts.

Assessing the genetic characteristics of a population can provide information about the susceptibility or resistance of that population to viral infection. For example, polymorphic analysis of AMT alleles in a particular human population, such as the population of a particular city or

10

15

25

30

35

geographic area, can indicate how susceptible that population is to influenza A infection. A higher percentage of AMT alleles substantially similar to SEQ ID NOS: 36-37 (or a target sequence associated with SEQ ID NOS: 36-37) indicates that the population is more susceptible to influenza A infection, while a large number of polymorphic alleles that are substantially different than SEQ ID NOS: 36-37 (or a target sequence associated with SEQ ID NOS: 36-37) indicates that a population is more resistant to influenza A infection. Such information can be used, for example, in making public health decisions about vaccinating susceptible populations.

#### Transgenic Cells and Non-Human Mammals

Transgenic animal models, including recombinant and knock-out animals, can be generated from the host nucleic acids described herein. Exemplary transgenic non-human mammals include, but are not limited to, mice, rats, chickens, cows, and pigs. In certain examples, a transgenic nonhuman mammal has a knock-out of one or more of the target sequences associated with SEQ ID NOS: 1-35, and has a decreased viral susceptibility, for example infection by HIV. In certain embodiments, a transgenic non-human mammal has a knock-out of any of the target sequences associated with SEQ ID NOS: 36-63, and has a decreased viral susceptibility, for example infection by influenza A. In certain examples, a transgenic non-human mammal has a knock-out of any of the target sequences associated with SEQ ID NOS: 64-232, and has a decreased viral susceptibility, for example infection by Ebola. In certain examples, a transgenic non-human mammal has a knock-out of any target sequence associated with SEQ ID NOS: 118-119, and has a decreased susceptibility to **20** 1 infection by a pathogen that uses a lipid raft, such as those listed in Table 2. Such knock-out animals are useful for reducing the transmission of viruses from animals to humans. In addition, animal viruses that utilize the same targets provided herein can be decreased in the animals.

Expression of the sequence used to knock-out or functionally delete the desired gene can be regulated by chosing the appropriate promoter sequence. For example, constitutive promoters can be used to ensure that the functionally deleted gene is never expressed by the animal. In contrast, an inducible promoter can be used to control when the transgenic animal does or does not express the gene of interest. Exemplary inducible promoters include tissue-specific promoters and promoters responsive or unresponsive to a particular stimulus (such as light, oxygen, chemical concentration, such as a tetracycline inducible promoter).

For example, a transgenic mouse including an AMT gene (such as a target sequence associated with SEQ ID NOS: 36-37), or a mouse having a disrupted AMT gene, can be examined during exposure to various mammalian viruses related to influenza A. Comparison data can provide insight into the life cycles of influenza and related viruses. Moreover, knock-out animals (such as pigs) that are otherwise susceptible to an infection (for example influenza) can be made to determine the resistance to infection conferred by disruption of the gene.

Transgenic pigs having a disrupted human protein tyrosine phosphatase gene can be produced and used as an animal model to determine other types of infections, including viral infections in mammals related to influenza A. A transgenic pig resistant to infection by viruses other 5.

10

15

20

25

30

35

than influenza A is used to demonstrate the relatedness of influenza and those other viruses. Transgenic animals, including methods of making and using transgenic animals, are described in various patents and publication, such as WO 01/43540; WO 02/19811; U.S. Pub. Nos: 2001-0044937 and 2002-0066117; and U.S. Pat. Nos: 5,859,308; 6,281,408; and 6,376,743; and the references cited therein.

Cells including an altered or disrupted host nucleic acid or polypeptide having a role in viral infection (such as a target sequence associated with SEQ ID NOS: 1-232), are resistant to infection by a virus (see Example 2). Such cells may therefore include cells having decreased susceptibility to HIV infection (such as cells having altered or disrupted target sequence associated with SEQ ID NOS: 1-35), Ebola infection (such as cells having altered or disrupted target sequence associated with SEQ ID NOS: 64-232), or influenza A (such as cells having altered or disrupted target sequence associated with SEQ ID NOS: 36-63). For example, cells in which a  $\beta$ -chimerin gene was disrupted using the gene-trap method remain CD4<sup>+</sup> after HIV infection and do not produce further detectable HIV virus particles. Thus, disrupting the expression of  $\beta$ -chimerin can confer resistance on the cell to infection by HIV. Additionally, interfering with the activity of  $\beta$ -chimerin, such as contacting a  $\beta$ -chimerin with an enzymatic inhibitor or an anti- $\beta$ -chimerin binding agent, can confer a similar resistance to HIV infection.

### Screening for Agents that Decrease Viral Infection

A host nucleic acid or polypeptide involved in viral infection, such as a target sequence associated with SEQ ID NOS: 1-232, and peptides listed in Table 1, can be used to identify agents that inhibit the binding of a virus or viral protein to a host nucleic acid, a host protein, or another target protein capable of binding to the virus or viral protein. In some examples, a host molecule, such as a host protein or nucleic acid is contacted with a viral molecule, such as a virus or portion thereof, for example as a viral protein. One or more test agents are contacted with the host molecule, the viral molecule, both both molecules, before, during or after contacting the host and viral molecules. Subsequently, it is determined whether binding of the viral molecule to the host molecule is decreased in the presence of the test agent, wherein a decrease in binding is an indication that the test agent decreases the binding of viral protein to the target protein.

In other examples, a cell-based assay is used to identify proteins that decrease viral infection, for example using the yeast two-hybrid system.

For example, the binding of the T-cell receptor V-D-J beta 2.1 chain polypeptide to HIV-(or an HIV envelope glycoprotein) can be determined in the presence of a test agent. A decrease in binding activity between the T-cell receptor V-D-J beta 2.1 chain polypeptide and HIV indicates that the test agent decreases the binding of HIV to the T-cell receptor V-D-J beta 2.1 chain, and the agent is a candidate for use as an anti-HIV agent. A decrease in binding activity can be determined by a comparison to a reference standard, such as a binding activity reported in the scientific literature, or to a control. Any suitable compound or composition can be used as a test agent, such as organic or inorganic chemicals, including aromatics, fatty acids, and carbohydrates; peptides, including

15

20

25

30

**'59** 

monoclonal antibodies, polyclonal antibodies, and other specific binding agents; or nucleic acids.

The virus or viral molecule can be obtained from any suitable virus, such as HIV, influenza A, Ebola, and related viruses.

Therapeutic agents identified with the disclosed approaches can be used as lead compounds to identify other agents having even greater antiviral activity. For example, chemical analogs of identified chemical entities, or variant, fragments of fusions of peptide agents, are tested for their ability to decrease viral infection using the disclosed assays. Candidate agents are also tested tested for safety in animals and then used for clinical trials in animals or humans.

10 Microarrays

The host nucleic acids or proteins disclosed herein having a role in viral infection, such as a target sequence associated with SEQ ID NOS: 1-232, can be used in an array. The array can be a microarray, such as a nucleic acid array that includes probes to different polymorphic alleles of a human AMT gene (for example target sequence associated with SEQ ID NOS: 36-37) or a human Rab9 gene (for example target sequence associated with SEQ ID NOS: 118-119). Kits can be generated, such as diagnostic kits or kits for screening for the presence or absence of a host nucleic acid within a biological sample obtained from a subject or kits for administering an effective amount of a specific binding agent to a subject for a therapeutic or prophylactic purpose.

The following examples are provided to illustrate particular features of certain embodiments, but the scope of the claims should not be limited to those features exemplified.

#### Example 1

#### Generation of Cells with Increased Resistance to Viral Infection

The gene-trap method was used to identify cellular genes needed for viral propagation but whose inactivation is not lethal to the host cell. This was accomplished by using a Moloney murine leukemia virus-derived shuttle vector that encodes for a promoterless neomycin-resistance gene (FIG. 1). This vector integrates into the host genome at transcriptionally active genes, thereby disrupting the host gene but utilizing the host promoter to drive neomycin resistance carried by the vector. The cells are then infected with the desired virus. Cells surviving the viral infection carry an interrupted host gene that is needed during the viral life cycle. Since the construct is a shuttle vector, it can function as a plasmid and can be moved from mammalian to bacterial systems, facilitating subcloning and DNA sequencing. Using this approach, loci involved in, and in some cases required for viral infection, for example by HIV-1 and HIV-2, influenza A and Ebola virus were identified.

35

#### Tissue culture

Sup-T1 human lymphoblastic leukemia cells were cultured in RPMI-1640 medium supplemented with 10% heat-inactivated fetal-calf serum (FCS), penicillin, streptomycin and Fungisome. MDCK normal canine kidney-cells were cultured in DMEM supplemented with 10%

fetal bovine serum (FBS), penicillin, streptomycin. Vero African green monkey kidney cells were cultured in DMEM supplemented with 10% FBS, amphotericin B, streptomycin, and Glutamine. All cultures were grown under 5% CO<sub>2</sub>. Selection by all media was done in the presence of either 1 mg/ml (Sup-T1 and MDCK cells) or 400 mg/ml G418 (Geneticin; Vero cells).

5

10

15

20

25

# Generation of gene-trapped library of cells

Parental, virus sensitive cells were plated and infected with U3neoSV1 as follows.

Retrovirus vectors were obtained from H. Earl Ruley (Department of Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN). Stocks of the U3neoSV1 virus were prepared as described (Chen et al., Gene trap retroviruses in Methods in Molecular Genetics (1994), page 123, herein incorporated by reference).

FIG. 1 illustrates the U3neoSV1 retroviral vector, which contains a promoterless neomycin phosphotransferase gene ( $Neo^R$ ) within the U3 unique sequence of the 5' long terminal repeat (LTR) of MMLV. Additionally, a second mutationally inactivated copy of neo is present in the 3' LTR. Portions of the MMLV genome were removed to impair replication, and were replaced with the  $\beta$ -lactamase gene which confers ampicillin resistance ( $Amp^R$ ) to  $E.\ coli$  as well as an  $E.\ coli$  origin of replication (ori), flanked by two unique restriction sites for BamHI (position 2570) and EcoRI (position 4175). Sites and orientations of primers used for sequence analysis of cloned genomic fragments are indicated by the triangular arrowheads.

Parental, virus sensitive cells (106 Sup-T1 for HIV, Madin-Darby canine kidney, (MDCK) for influenza A, or Vero cells for Ebola) were plated for 12 hours before infection, after which U3neoSV1 was added at a multiplicity of infection (MOI) of 0.1, as titered by adding 1 ml of diluted stocks to cultured cells in the presence of 4 µg/ml polybrene. The cells were incubated at 37°C for one hour, 10 ml of fresh medium added, and the cells were incubated overnight at 37°C. The next day, the medium was replaced with the appropriate media containing 1 mg/ml G418 and maintained until surviving cells approached confluence, which was usually about two weeks.

Upon random integration of the U3neoSV1 vector into the host genome, endogenous promoters result in expression of *Neo<sup>R</sup>*, while expression of the exons 3' to the site of integration is disrupted. Therefore, only those events occurring at transcriptionally active promoters of non-essential genes are selected.

A pool of the surviving cells, termed a library, including many cells bearing different disrupted genes was then exposed to the pathogen of interest. The resulting Sup-T1 library cells, MDCK library cells, and Vero library cells were infected HIV-1 and HIV-2; the A/PR/8/34 virus reassortant having A/Johannesburg/82/96 glycoproteins (H1N1); and Ebola, respectively, as follows.

An aliquot of the cell library was infected with three rounds of HIV-1 and three rounds of HIV-2 (3Bx in BC7 cells), normally a lethal event for Sup T-1 cells (FIG. 4). Approximately 3 x 10<sup>8</sup> actively growing Sup-T1 library cells were infected with the CXCR4 cytopathic HIV-1 strain LAI at an MOI of 10, approximately 100 fold greater that that normally used for spreading infection in culture. The cells were incubated with the virus for four hours in 2 ml of medium, then grown in bulk

35

30

;

5

10

15

20

25

**30**-

35

at 10<sup>6</sup> cells/ml for two weeks, at which time G418 was added to a final concentration of 1 mg/ml and the cultures continued for an additional two weeks. The surviving cells were exposed to two further rounds of HIV-1 infection as described above and shown in FIG. 4.

Following HIV-1 infection, surviving cells were incubated 1:100 with BC7 T cells constitutively expressing the HIV-2 strain 3BX, which was modified to infect regardless of CD4 status, solely using the CXCR4 receptor. Cells were coincubated for two weeks followed by selection with 1 mg/ml G418 (same as FIG. 4, but with HIV-2 instead of HIV-1). The surviving cells were exposed to two further rounds of HIV-2 infection.

The final cell culture was selected using anti-CD4 magnetic microbeads (Miltyni) and divided into 2.0 ml cultures containing 1000 cells each. These were then infected with LAI at an MOI of 10. Surviving cells from each culture were subjected to limit dilution, or growth on methylcellulose, and expanded in selection medium. The isolated clones were identified as being CD4 and CXCR4 positive following flow cytometry analysis using standard protocols. Several cell isolates were resistant to further HIV infection with unique expression of CD4 cell surface antigen.

For influenza infection, approximately 10<sup>7</sup> actively growing MDCK library cells were washed with phosphate buffered saline (Gibco) and infected with the A/PR/8/34 virus reassortant having A/Johannesburg/82/96 glycoproteins (H1N1) at an MOI of 20-30 in 250 µl DMEM in a T-25 flask. The cells were incubated with the virus for two hours, and the inoculum was subsequently replaced with DMEM, supplemented with 2% FBS and 1 µg/ml TPCK trypsin (to cleavage-activate HA of new progeny virus). The cells were incubated for 18 hours to provide 2-3 rounds of infection. The maintenance medium was removed and replaced with selection medium (DMEM with 10% FBS and 1 mg/ml neomycin) and survivors allowed to expand. The surviving cells were exposed to one additional round of infection as described.

For filovirus infection, vero library cells were infected with either the Gulu 2000 or Zaire 1976 Ebola (EBO) strains, or the Voege 1967 strain of Marburg (MBG) at an MOI of greater than one in T-75 flasks in medium supplemented with 400 mg/ml G418. After a cytopathic effect (CPE) of 4+ was attained (greater than one week), survivors were harvested and reseeded undiluted and at 1:16 and 1:256 dilutions in selection medium. Wells with growth after 10 or more days were reinoculated into T12.5 flasks in selection medium and allowed to expand.

Cells surviving Ebola or influenza infection were cloned by either limiting dilution or growth on methylcellulose. The isolates were characterized phenotypically by flow cytometry and the interrupted gene determined by inverse PCR, cloning into BAC, or by the use of the shuttle feature of the vector followed by DNA sequence analysis.

### Example 2

### Cloning and Sequencing of Trapped Genes

This example describes the methods used to clone the sequences conferring resistance to the library of cells surviving viral infection. The identified sequences (SEQ ID NOS: 1-227, 229, 231)

5.

10

15

20

25

30

encode host proteins that are involved in pathogen infection, and in some cases are required for the infectivity by the pathogen.

# Isolation of trapped genes

The genomic DNA from actively growing virus-resistant isolates was extracted, prepared, and electroporated into cells as follows. Cellular DNA from actively growing virus-resistant isolates was extracted from one million cells using the QIAamp DNA Blood Mini Kit (Qiagen, Inc.) according to the manufacturer's instructions. Genomic DNA was digested at a final concentration of 150 µg/ml with either EcoRI or BamHI (New England Biolabs) at 1.5 or 2 units/µl, respectively (see FIG. 1). Digested DNA was ethanol precipitated using oyster glycogen (Sigma) as a carrier, resuspended to a final concentration of 60 ng/µl and ligated using T4 DNA ligase (New England Biolabs). Genomic digestion resulted in the fragmentation of the retrovirus and the genomic DNA. Ligations were subsequently ethanol precipitated in the presence of glycogen, resuspended in 3 µl water and used directly to transform E. coli.

A 1.5 µl aliquot of each precipitated ligation was added to thawed Genehog cells (Invitrogen) or SURE cells (Stratagene), electroporated using a GenePulser (BioRad) according to the manufacturer's instructions, and plated onto Luria broth (LB) agar (1% tryptone, 0.5% yeast extract, 0.5% NaCl, 2% agar) containing 100 µg/µl carbenicillin (Sigma). Clones were isolated after 24 hours and used to inoculate 3 ml LB containing 100 µg/µl carbenicillin. Plasmid DNA was prepared after overnight growth using the QIAprep Spin Miniprep Kit (QIAGEN, Inc.) according to the manufacturer's instructions and eluted in water.

# Sequencing of Shuttle Clones

Due to the position of the unique sites in U3neoSV1, BamHI digestion facilitates cloning of DNA 3' to the site of integration, while EcoRI digestion results in the cloning of genomic DNA 5' to the site of integration. Using oligonucleotides homologous to the U3neoSV1 fragment, the sequence of the disrupted genomic DNA flanking the gene-trap insertion site was determined as follows.

Sequencing reactions were performed using the ABI BigDye terminator cycle sequencing kit with reaction products resolved on either an ABI 3100 Genetic Analyzer or an ABI 377 DNA Sequencer (Applied Biosystems, Foster City, CA). Sequences were obtained by using oligonucleotides 5'-ATCTTGTTCAATCATGCG (SEQ ID NO: 235) and 5'-GGGTCTGACGCTCATG (SEQ ID NO: 236) for *EcoRI*-generated shuttle clones, or 5'-GATAGGTGCCTCACTG (SEQ ID NO: 237) for *Bam*HI-generated shuttle clones.

# 35 Sequence analysis

Sequences obtained from shuttle clones were analyzed by the Repeatmasker Web Server, available on the Internet at the website for the Department of Molecular Biotechnology, University of Washington, followed by standard nucleotide-nucleotide BLAST (blastn) against the National Center for Biotechnology Information databases, including nr (non-redundant

15

20

63

GenBank+EMBL+DDBJ+PDB sequences), est (expressed sequence tags) and htgs (unfinished High Throughput Genomic Sequences: phases 0, 1 and 2). Additionally, a nucleotide-protein database (blastx) analysis was performed against the nr database.

### 5 Candidate Host Genes Required for Pathogenesis

Candidate host genes required for the indicated pathogen, which were cloned via the genetrap method and sequenced, are presented in Table 1 and in SEQ ID NOS: 1-226. The CD4<sup>+</sup>, latently infected, noninfectious HIV-resistant isolates 18B, 18E, 2B, and 2E were used to recover the genes involved in HIV-1 and HIV-2 pathogenesis, influenza A-resistant isolates B1, B3, B5, B6, and B7 were use to recover the host genes involved in influenza A pathogenesis, and Ebola-resistant isolates ZV and MV were used to recover the host genes involved in Ebola pathogenesis. Candidate genes can be validated by siRNA and cDNA complementation, as described in Example 3.

In summary, using the U3neoSV1 gene-trap, sixteen HIV-1 and -2 resistant Sup-T1 cell lines, and fifteen influenza A resistant MDCK cell lines were isolated and characterized. Twenty-three EBO-Zaire resistant Vero cell line pools, twenty-four EBO-Gulu resistant pools, and thirty MBG resistant pools were screened. The shuttle-vector design of the U3neoSV1 gene-trap allowed identification of multiple host genes involved in the pathogenesis of HIV-1, HIV-2, influenza A, and Ebola, which are described herein and summarized in Table 1 and sequences provided in SEQ ID NOS: 1-232. Cross-resistance of resistant isolates to multiple pathogens can be quickly examined to reveal common pathways in the viral life cycles.

#### Example 3

#### siRNA Molecules Decrease Viral Infection

This example describes methods used to express siRNAs that recognize Rab9 (such as a target sequence associated with SEQ ID NOS: 118-119), AXL (AXL receptor tyrosine kinase; such as a target sequence associated with SEQ ID NO: 226), CHN (beta-chimerin; such as a target sequence associated with SEQ ID NOS: 21-22), KOX (such as a target sequence associated with SEQ ID NO: 30), RBB (retinoblastoma binding protein 1; such as a target sequence associated with SEQ ID NOS: 120-122), KIAA1259; F3 (such as a target sequence associated with SEQ ID NO: 29), and Mselb (mammalian selenium binding protein; such as a target sequence associated with SEQ ID NO: 124).

The following Rab9 siRNA sequences were generated by Dharmacon, RNA Technologies (Lafayette, CO) using chemical synthesis: GGGAAGAGTTCACTTATGA (SEQ ID NO: 238); TCACAAAGCTTCCAGAACT (SEQ ID NO: 239); GTAACAAGATTGACATAAG (SEQ ID NO: 240); and GGAAGTGGATGGACATTTT (SEQ ID NO: 241).

The following AXL (AXL receptor tyrosine kinase) siRNA sequences were generated by Dharmacon, RNA Technologies using chemical synthesis: GGUCAGAGCUGGAGGAUUU (SEQ ID NO: 242); GAAAGAAGGAGCCCGUUA (SEQ ID NO: 243);

35

10

15

20

25

30

35

CCAAGAAGAUCUACAAUGG (SEQ ID NO: 244); and GGAACUGCAUGCUGAAUGA (SEQ ID NO: 245).

siRNA sequences were also used that recognized CHN (beta-chimerin); KOX (similar to KOX4 (LOC131880) and LOC166140); RBB (retinoblastoma binding protein 1); KIAA1259; F3 and mammalian selenium binding protein. One skilled in the art will understand that siRNA sequences that recognize other sequences involved in viral infection (such as a target sequence associated with any of SEQ ID NOS: 1-232) can be desiged and prepared by commercial entities, such as Dharmacon, RNA Technologies.

The four siRNA sequences for each gene (CHN, KOX, RBB, RAB, KIAA1259, F3, ASL and Mselb) were separately pooled. Each of the eight pools of siRNAs, hybridized to its appropriate complement sequence, were used to transfect IC53 (HeLa cells modified to accept HIV), Vero (monkey kidney cells), MDCK (dog kidney cells), or HEK (human kidney cells). All cells were obtained from American Type Culture Collection (ATCC, Mannassas, VA). GFP siRNA sequences were used as a negative control.

Cells (20,000 to 250,000) were incubated in serum free media for 24 hours. Cocktails were made by mixing the appropriate duplex siRNAs (50-100 pmoles) with lipofectamine 2000 (4-16 µl) and RNAse Inhibitor (1-4 µl) in a solution of Optimem (serum free medium) in a total volume of 200-2000 µl. The lipofectamine was allowed to incubate at room temperature for 5 minutes before the addition of siRNA. Aliquots (50-500 µl) of the cocktail were added to the cells which were incubated at 37°C for 48 hours. The cells were then infected with HIV, Ebola, or influenza and the incubation continued for 3-7 days. Following transfection, several assays were conducted to confirm transfection efficiency, and to determine the resistance of the cells to infection by various agents.

Quantitation of p24 levels in HTV infected JC53 cells was determined using the Coulter HIV-1 pz4 Antigen Neutralization Kit according to the manufacturers recommendation. As shown in FIG. 5, Rab9 siRNAs and mammalian selenium binding protein siRNAs each decreased HIV infection by about 50% on day 4 post infection (day 7 post addition of siRNA). In addition, HIV infection decreased by about 80-90% in the presence of beta-chimerin siRNAs, KOX (similar to KOX4 (LOC131880) and LOC166140) siRNAs, or retinoblastoma binding protein 1 siRNAs. However, HIV infection did not decrease in the presence of siRNAs that recognize KIAA1259, tissue factor 3, or AXL receptor tyrosine kinase. It is possible that apoptosis is interrupted by the siRNAs, so the cell lives through the infection but still makes virus. It is also possible that the p24 levels are elevated but is not associated with infectious particles.

To determine the level of Ebola infection in HEK293 cells transfected with Rab9 or AXL siRNA, the presence of gpl antigen was determined by using a fluorescent antibody to gpl envelope protein. Infection by Ebola decreased by at least about 90-95% in the presence of Rab9 siRNA, as compared to the amount of infection in the absence of Rab9 siRNA. Infection by Ebola decreased by at least about 80% in the presence of AXL siRNA, as compared to the amount of infection in the absence of AXL siRNA.

15

### Example 4

### Expression of Rab9 siRNA Decreases Lipid Raft Formation

As described in Example 3, siRNA molecules that recognize Rab9 decrease viral infection. Rab9 transports late endosomes to trans-golgi. Based on these results, a model is proposed whereby Rab9 plays a role in lipid raft formation (FIG. 6). Lipid rafts are liquid-ordered microdomains enriched in sphingolipds and cholesterol, and are involved in biosynthetic traffic, signal transduction, and endocytosis. Viruses take advantage of ("hijack") rafts for completion of some steps of their replication cycle, such as entry into their cell host, assembly, and budding. Without wishing to be bound to a particular theory, it is proposed that Rab9 trafficks cholesterol, the dynamic glue that holds lipid rafts together. Further evidence for this hypothesis is based on observations of Neimann-Pick type C disease cells. Neimann-Pick type C is a genetic disease that results in accumulation of abnormally high levels of intracellular cholesterol. However, over expression of Rab9 in Neimann-Pick type C disease cells, decreases the level of cholesterol.

Examples of pathogens that hijack lipid rafts include, but are not limited to those shown in Table 2. In the absence of functional Rab9 and lipid rafts (or a decrease in the number of rafts), viruses may not be able to bud or be infectious. Therefore, the use of agents that decrease or inhibit Rab9 expression or activity can be used to decrease infection by other pathogens, as well as toxins such as anthrax, that hijack lipid rafts, such as those shown in Table 2.

20 Table 2: Pathogens that hijack lipid rafts.

	Bacteria		
Intracellular survival	Toxin binding/oligomerization	Viruses	Protozoa
Campylobacter jujuni	Vibrio cholerae	SV40	Toxoplasma gondii
Legionella pneumophila	Aeromonas hydrophilia	Echovirus 1 and 11	Plasmodium falciparum
Brucella spp	Clostridium spp.	Avian sarcoma and leukosis virus	
FimH and Dr Escherichia coli	Streptcoccus pyogenes	Semiliki forest virus	·
Salmonella typhimurium	Bacillus anthracis	Ecotropic mouse leukaemia virus	
Shigella flexneri	Bacillus thuringiensis	HTLV-1	
Chlamydia spp.	Helicobacter pylori	HIV-1	
Mycobacterium spp.	Lysteria monocytogenes	Ebola and Marburg viruses	
· • • • · · · · · · · · · · · · · · · ·		Measles virus	
		Herpes Simplex virus	
		Influenza virus	
		Epstein-Barr virus	

This example therefore illustrates that identification of an agent (such as a small molecule or siRNA) that inhibits a particular pathogen can be used to inhibit other pathogens that have a similar mechanism of action.

10

15

#### Example 5

#### **RNAi Molecules**

This example describes methods that can be used to decrease or inhibit expression of any of the genes listed in Table 1, or target sequences associated with SEQ ID NOS: 1-232, to decrease viral infection, such as infection by HIV, Ebola, or influenza. Exemplary RNAi compounds are provided for several different genes, such as beta-chimerin receptor tyrosine kinase, retinoblastoma binding protein 1, Homo sapiens chromosome 10 open reading frame 3, Homo sapiens fer-1-like 3, myoferlin (C. elegans), transcript variant 1, Homo sapiens chromosome 10 open reading frame 3 (C10orf3), malic enzyme, cadherin related 23, sideroflexin 5, polybromo 1, elongation factor for selenoprotein translation, integrin, beta 1, huntingtin interacting protein 1 and cyclin M2.

One skilled in the art will understand that RNAi molecules can be generated to any of the genes listed in Table 1. Although only 27mers are shown in SEQ ID NOS: 246-845, this disclosure is not limited to RNAi compounds of a particular length. An RNAi molecule can be any length, such as at least about about 25 nucleotides, or even as many as 400 nucleotides. One skilled in the art will also understand that RNAi sequences that recognize other sequences involved in viral infection (such as a target sequence associated with any of SEQ ID NOS: 1-232) can be desiged and prepared by commercial entities, such as Sequitur, Inc. (Natick, MA).

Using the methods described in Example 3, the disclosed RNAi compounds are used to decrease viral infection. For example, a 27mer RNAi compound shown in any of SEQ ID NOS: 246-845 is incubated with its reverse complement, allowing hybridization of the two molecules. In particular examples, two or more, such as three or more, 27mer RNAi compounds are transfected into a cell. This duplex molecule is contacted with a cell, such as a cell of a subject in whom decreased viral infection is desired, under conditions that allow the duplex to enter the cell.

### 25

30

35

20

### Example 6

# Disruption of Gene Expression

This example describes methods that can be used to disrupt expression of a host gene, such as those shown in Table 1 and target sequences associated with SEQ ID NOS: 1-232, and thereby decrease activity of the proteins encoded by these sequences. Such methods are useful when it is desired to decrease or inhibit viral infection. In a particular example, disrupted expression of at least one target sequence associated with SEQ ID NOS: 1-232 in a host cell is used to treat a subject having a viral infection, or susceptible to a viral infection. Methods useful for disrupting gene function or expression are the use of antisense oligonucleotides, siRNA molecules (see Example 3), RNAi molecules (see Example 5), ribozymes, and triple helix molecules. Techniques for the production and use of such molecules are well known to those of skill in the art.

Antisense Methods

10

15

20

25

30

35

To design antisense oligonucleotides, a host mRNA sequence is examined. Regions of the sequence containing multiple repeats, such as TTTTTTTT, are not as desirable because they will lack specificity. Several different regions can be chosen. Of those, oligos are selected by the following characteristics: those having the best conformation in solution; those optimized for hybridization characteristics; and those having less potential to form secondary structures. Antisense molecules having a propensity to generate secondary structures are less desirable.

Plasmids including antisense sequences that recognize one or more of the target sequences associated with SEQ ID NOS: 1-232 (such as a sequence that encodes a protein listed in Table 1) can be generated using standard methods. For example, cDNA fragments or variants coding for a host protein involved in viral infection are PCR amplified. The nucleotides are amplified using Pfu DNA polymerase (Stratagene) and cloned in antisense orientation a vector, such as pcDNA vectors (InVitrogen, Carlsbad, CA). The nucleotide sequence and orientation of the insert can be confirmed by sequencing using a Sequenase kit (Amersham Pharmacia Biotech).

Generally, the term "antisense" refers to a nucleic acid capable of hybridizing to a portion of a host RNA sequence (such as mRNA) by virtue of some sequence complementarity. The antisense nucleic acids disclosed herein can be oligonucleotides that are double-stranded or single-stranded, RNA or DNA or a modification or derivative thereof, which can be directly administered to a cell, or which can be produced intracellularly by transcription of exogenous, introduced sequences.

Antisense nucleic acids are polynucleotides, and can be oligonucleotides (ranging from about 6 to about 100 oligonucleotides). In one example, an antisense polynucleotide recognizes one or more of the target nucleic acid sequences associated with SEQ ID NOS: 1-227, 229, or 231. In specific examples, the oligonucleotide is at least 10, 15, or 100 nucleotides, or a polynucleotide of at least 200 nucleotides. However, antisense nucleic acids can be much longer. The nucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone, and can include other appending groups such as peptides, or agents facilitating transport across the cell membrane (Letsinger et al., Proc. Natl. Acad. Sci. USA 1989, 86:6553-6; Lemaitre et al., Proc. Natl. Acad. Sci. USA 1987, 84:648-52; WO 88/09810) or blood-brain barrier (WO 89/10134), hybridization triggered cleavage agents (Krol et al., BioTechniques 1988, 6:958-76) or intercalating agents (Zon, Pharm. Res. 5:539-49, 1988).

An antisense polynucleotide (including oligonucleotides) that recognizes one or more of the target sequences associated with SEQ ID NOS: 1-227, 229, or 231, can be modified at any position on its structure with substituents generally known in the art. For example, a modified base moiety can be 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, acetylcytosine, 5-(carboxyhydroxylmethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N-6-sopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methylguanine, 5-methylguanine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, methoxyarninomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-

3NSDOCID:.<WO\_\_\_\_2004070002A2\_l\_>

10

15

20

25

30

35

oxyacetic acid, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-S-oxyacetic acid, 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, and 2,6-diaminopurine.

An antisense polynucleotide that recognizes one or more of the target sequences associated with SEQ ID NOS: 1-227, 229, or 231, can include at least one modified sugar moiety such as arabinose, 2-fluoroarabinose, xylose, and hexose, or a modified component of the phosphate backbone, such as phosphorothioate, a phosphorodithioate, a phosphoramidate, a phosphoramidate, a phosphoramidate, a phosphoramidate, a formacetal or analog thereof.

In a particular example, an antisense polynucleotide that recognizes one or more of the target sequences associated with SEQ ID NOS: 1-227, 229, or 231 is an α-anomeric oligonucleotide. An α-anomeric oligonucleotide forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual β-units, the strands run parallel to each other (Gautier *et al.*, *Nucl. Acids Res.* 15:6625-41, 1987). The oligonucleotide can be conjugated to another molecule, such as a peptide, hybridization triggered cross-linking agent, transport agent, or hybridization-triggered cleavage agent. Oligonucleotides can include a targeting moiety that enhances uptake of the molecule by host cells. The targeting moiety can be a specific binding molecule, such as an antibody or fragment thereof that recognizes a molecule present on the surface of the host cell.

Polynucleotides disclosed herein can be synthesized by standard methods, for example by use of an automated DNA synthesizer. As examples, phosphorothioate oligos can be synthesized by the method of Stein et al. (Nucl. Acids Res. 1998, 16:3209), methylphosphonate oligos can be prepared by use of controlled pore glass polymer supports (Sarin et al., Proc. Natl. Acad. Sci. USA 85:7448-51, 1988). In a specific example, antisense oligonucleotide that recognizes one or more of the target sequences associated with SEQ ID NOS: 1-227, 229, or 231 includes catalytic RNA, or a ribozyme (see WO 90/11364, Sarver et al., Science 247:1222-5, 1990). In another example, the oligonucleotide is a 2'-0-methylribonucleotide (Inoue et al., Nucl. Acids Res. 15:6131-48, 1987), or a chimeric RNA-DNA analogue (Inoue et al., FEBS Lett. 215:327-30, 1987).

The antisense polynucleic acids disclosed herein include a sequence complementary to at least a portion of an RNA transcript of a gene, such as a target sequence associated with SEQ ID NOS: 1-227, 229, or 231. However, absolute complementarity, although advantageous, is not required. A sequence can be complementary to at least a portion of an RNA, meaning a sequence having sufficient complementarily to be able to hybridize with the RNA, forming a stable duplex; in the case of double-stranded antisense nucleic acids, a single strand of the duplex DNA may thus be tested, or triplex formation can be assayed. The ability to hybridize depends on the degree of complementarity and the length of the antisense nucleic acid. Generally, the longer the hybridizing nucleic acid, the more base mismatches with an RNA it may contain and still form a stable duplex (or triplex, as the case may be). One skilled in the art can ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex.

10

15

20

25

30

35

169

The relative ability of polynucleotides (such as oligonucleotides) to bind to complementary strands is compared by determining the  $T_m$  of a hybridization complex of the poly/oligonucleotide and its complementary strand. The higher the  $T_m$  the greater the strength of the binding of the hybridized strands. As close to optimal fidelity of base pairing as possible achieves optimal hybridization of a poly/oligonucleotide to its target RNA.

The amount of antisense nucleic acid that is effective in the treatment of a particular disease or condition (the therapeutically effective amount) depends on the nature of the disease or condition, and can be determined by standard clinical techniques. For example, it can be useful to use compositions to achieve sustained release of an antisense nucleic acid, for example an antisense molecule that recognizes one or more target sequences associated with SEQ ID NOS: 1-227, 229, or 231. In another example, it may be desirable to utilize liposomes targeted via antibodies to specific cells.

As an alternative to antisense inhibitors, catalytic nucleic acid compounds, such as ribozymes or anti-sense conjugates, can be used to inhibit gene expression. Ribozymes can be synthesized and administered to the subject, or can be encoded on an expression vector, from which the ribozyme is synthesized in the targeted cell (as in WO 9523225, and Beigelman et al. Nucl. Acids Res. 1995, 23:4434-42). Examples of oligonucleotides with catalytic activity are described in WO 9506764. Conjugates of antisense with a metal complex, such as terpyridylCu (II), capable of mediating mRNA hydrolysis, are described in Bashkin et al. (Appl. Biochem Biotechnol. 54:43-56, 1995).

#### Ribozymes

Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA. The mechanism of ribozyme action involves sequence specific hybridization of the ribozyme molecule to complementary target RNA, followed by a endonucleolytic cleavage. Methods of using ribozymes to decrease or inhibit RNA expression are known in the art. An overview of ribozymes and methods of their use is provided in Kashani-Sabet (*J. Imvestig. Dermatol. Symp. Proc.*, 7:76-78, 2002).

Ribozyme molecules include one or more sequences complementary to the target host mRNA and include the well-known catalytic sequence responsible for mRNA cleavage (see U.S. Pat. No. 5,093,246, herein incorporated by reference).

A ribozyme gene directed against any of the target sequences associated with SEQ ID NOS: 1-227, 229, or 231 can be delivered to a subject endogenously (where the ribozyme coding gene is transcribed intracellularly) or exogenously (where the ribozymes are introduced into a cell, for example by transfection). Methods describing endogenous and exogenous delivery are provided in Marschall et al. (Cell Mol. Neurobiol. 14:523-38, 1994).

Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites that include the following sequence: GUA, GUU and GUC. Once identified, short RNA sequences of between 15 and ribonucleotides

corresponding to the region of the target gene containing the cleavage site may be evaluated for predicted structural features, such as secondary structure, that may render the oligonucleotide sequence unsuitable. The suitability of candidate targets may also be evaluated by testing their accessibility to hybridization with complementary oligonucleotides, using ribonuclease protection assays.

For example, a plasmid that contains a riboyzme gene directed against a β-chimerin rho-GTPase, placed behind a promoter, can be transfected into the cells of a subject, for example a subject susceptible to HIV infection. Expression of this plasmid in a cell will decrease or inhibit β-chimerin rho-GTPase RNA expression in the cell. In another example, a plasmid that contains a riboyzme gene directed against Rab9 placed behind a promoter, can be transfected into the cells of a subject, for example a subject susceptible to infection by a pathogen that utilizes lipid rafts, such as Ebola. Expression of this plasmid in a cell will decrease or inhibit Rab9 RNA expression in the cell. Other examples of using ribozymes to decrease or inhibit RNA expression can be found in WO 01/83754 (herein incorporated by reference).

15

20

25

30

10

5

### Triple helix molecules

Nucleic acid molecules used in triplex helix formation should be single stranded and composed of deoxynucleotides. The base composition of these oligonucleotides is ideally designed to promote triple helix formation via Hoogsteen base pairing rules, which generally require sizeable stretches of either purines or pyrimidines to be present on one strand of a duplex. Nucleotide sequences may be pyrimidine-based, which will result in TAT and CGC+ triplets across the three associated strands of the resulting triple helix. The pyrimidine-rich molecules provide base complementarity to a purine-rich region of a single strand of the duplex in a parallel orientation to that strand. In addition, nucleic acid molecules may be chosen that are purine-rich, for example, contain a stretch of guanidine residues. These molecules will form a triple helix with a DNA duplex that is rich in GC pairs, in which the majority of the purine residues are located on a single strand of the targeted duplex, resulting in GGC triplets across the three strands in the triplex.

Alternatively, the potential sequences that can be targeted for triple helix formation may be increased by creating a so called "switchback" nucleic acid molecule. Switchback molecules are synthesized in an alternating 5'-3', 3'-5' manner, such that they base pair with one strand of a duplex first and then the other, eliminating the necessity for a sizeable stretch of either purines or pyrimidines to be present on one strand of a duplex.

### Example 7

35

### Methods of Treatment

When the activity of a host cell protein or nucleic acid involved in viral infection is decreased by prematurely downregulating their levels of expressing using antisense molecules, a reduction in viral infection can be achieved. Antisense oligonucleotides, RNAi molecules, ribozymes, and siRNA molecules that recognize a host nucleic acid involved in viral infection

į

5

10

15

20

(Example 6) can therefore be used to disrupt cellular expression of a host protein involved in viral infection. The disclosed antisense, ribozyme, RNAi molecules and siRNA molecules can be administered to a subject alone, or in combination with other therapeutic agents such as anti-viral compounds.

A subject susceptible to or suffering from a viral infection, wherein decreased amounts of infection by the virus is desired, can be treated with a therapeutically effective amount of antisense, ribozyme, RNAi molecule or siRNA molecule (or combinations thereof) that recognizes a host sequence involved in viral infection, such as those shown in Table 1 or target sequences associated with SEQ ID NOS: 1-232. After the antisense, ribozyme, RNAi molecule or siRNA molecule has produced an effect (a decreased level of viral infection is observed, or symptoms associated with viral infection decrease), for example after 24-48 hours, the subject can be monitored for diseases associated with viral infection.

Similarly, other agents, such as an antibody that recognizes a host protein involved in viral infection and prevents the protein from interacting with a viral protein, can also be used to decrease or inhibit viral infection. Other exemplary agents are those identified using the methods described in the Examples below. These agents, such as antibodies, peptides, nucleic acids, organic or inorganic compounds, can be can be administered to a subject in a therapeutically effective amount. After the agent has produced an effect (a decreased level of viral infection is observed, or symptoms associated with viral infection decrease), for example after 24-48 hours, the subject can be monitored for diseases associated with viral infection.

The treatments disclosed herein can also be used prophylactically, for example to inhibit or prevent a viral infection. Such administration is indicated where the treatment is shown to have utility for treatment or prevention of the disorder. The prophylactic use is indicated in conditions known or suspected of progressing to disorders associated with a viral infection.

25

30

35

#### Example 8

#### **Recombinant Expression**

With the disclosed host sequences involved in viral infection, native and variant sequences can be generated. Expression and purification by standard laboratory techniques of any variant, such as a polymorphism, mutant, fragment or fusion of a sequence involved in viral infection, such as a target sequence associated with SEQ ID NOS: 1-232, is enabled. One skilled in the art will understand that the sequences involved in viral infection, as well as variants thereof, can be produced recombinantly in any cell or organism of interest, and purified prior to use.

Methods for producing recombinant proteins are well known in the art. Therefore, the scope of this disclosure includes recombinant expression of any host protein or variant or fragment thereof involved in viral infection. For example, see U.S. Patent No: 5,342,764 to Johnson et al.; U.S. Patent No: 5,846,819 to Pausch et al.; U.S. Patent No: 5,876,969 to Fleer et al. and Sambrook et al. (Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, New York, 1989, Ch. 17, herein incorporated by reference).

10

15

20

25

30

35

Briefly, partial, full-length, or variant cDNA sequences that encode for a protein involved in viral infection, such as a target sequence associated with SEQ ID NOS: 1-232, can be ligated into an expression vector, such as a bacterial expression vector. Proteins or peptides can be produced by placing a promoter upstream of the cDNA sequence. Examples of promoters include, but are not limited to *lac*, *trp*, *tac*, *trc*, major operator and promoter regions of phage lambda, the control region of fd coat protein, the early and late promoters of SV40, promoters derived from polyoma, adenovirus, retrovirus, baculovirus and simian virus, the promoter for 3-phosphoglycerate kinase, the promoters of yeast acid phosphatase, the promoter of the yeast alpha-mating factors and combinations thereof.

Vectors suitable for the production of intact proteins include pKC30 (Shimatake and Rosenberg, 1981, Nature 292:128), pKK177-3 (Amann and Brosius, 1985, Gene 40:183) and pET-3 (Studiar and Moffatt, 1986, J. Mol. Biol. 189:113). A DNA sequence can be transferred to other cloning vehicles, such as other plasmids, bacteriophages, cosmids, animal viruses and yeast artificial chromosomes (YACs) (Burke et al., 1987, Science 236:806-12). These vectors can be introduced into a variety of hosts including somatic cells, and simple or complex organisms, such as bacteria, fungi (Timberlake and Marshall, 1989, Science 244:1313-7), invertebrates, plants (Gasser and Fraley, 1989, Science 244:1293), and mammals (Pursel et al., 1989, Science 244:1281-8), that are rendered transgenic by the introduction of the heterologous cDNA.

For expression in mammalian cells, a cDNA sequence, such as a coding sequence of any target sequence associated with SEQ ID NOS: 1-227, 229, or 231, can be ligated to heterologous promoters, such as the simian virus SV40, promoter in the pSV2 vector (Mulligan and Berg, 1981, *Proc. Natl. Acad. Sci. USA* 78:2072-6), and introduced into cells, such as monkey COS-1 cells (Gluzman, 1981, *Cell* 23:175-82), to achieve transient or long-term expression. The stable integration of the chimeric gene construct may be maintained in mammalian cells by biochemical selection, such as neomycin (Southern and Berg, 1982, *J. Mol. Appl. Genet.* 1:327-41) and mycophoenolic acid (Mulligan and Berg, 1981, *Proc. Natl. Acad. Sci. USA* 78:2072-6).

The transfer of DNA into eukaryotic, such as human or other mammalian cells is a conventional technique. The vectors are introduced into the recipient cells as pure DNA (transfection) by, for example, precipitation with calcium phosphate (Graham and vander Eb, 1973, Virology 52:466) strontium phosphate (Brash et al., 1987, Mol. Cell Biol. 7:2013), electroporation (Neumann et al., 1982, EMBO J. 1:841), lipofection (Felgner et al., 1987, Proc. Natl. Acad. Sci USA 84:7413), DEAE dextran (McCuthan et al., 1968, J. Natl. Cancer Inst. 41:351), microinjection (Mueller et al., 1978, Cell 15:579), protoplast fusion (Schafner, 1980, Proc. Natl. Acad. Sci. USA 77:2163-7), or pellet guns (Klein et al., 1987, Nature 327:70). Alternatively, the cDNA can be introduced by infection with virus vectors, for example retroviruses (Bernstein et al., 1985, Gen. Engrg. 7:235) such as adenoviruses (Ahmad et al., J. Virol. 57:267, 1986) or Herpes (Spaete et al., Cell 30:295, 1982).

10

15

20

25

30

35

#### Pharmaceutical Compositions and Modes of Administration

Various delivery systems for administering the therapies disclosed herein are known, and include encapsulation in liposomes, microparticles, microcapsules, expression by recombinant cells, receptor-mediated endocytosis (Wu and Wu, J. Biol. Chem. 1987, 262:4429-32), and construction of therapeutic nucleic acids as part of a retroviral or other vector. Methods of introduction include, but are not limited to, topical, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, and oral routes. The compounds can be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (for example, oral mucosa, rectal, vaginal and intestinal mucosa, etc.) and can be administered together with other biologically active agents. Administration can be systemic or local. Pharmaceutical compositions can be delivered locally to the area in need of treatment, for example by topical application.

Pharmaceutical compositions are disclosed that include a therapeutically effective amount of an RNA, DNA, antisense molecule, ribozyme, RNAi molecule, siRNA molecule, specific-binding agent, or other therapeutic agent, alone or with a pharmaceutically acceptable carrier. Furthermore, the pharmaceutical compositions or methods of treatment can be administered in combination with (such as before, during, or following) other therapeutic treatments, such as other antiviral agents.

#### Delivery systems

The pharmaceutically acceptable carriers useful herein are conventional. Remington's Pharmaceutical Sciences, by Martin, Mack Publishing Co., Easton, PA, 15th Edition (1975), describes compositions and formulations suitable for pharmaceutical delivery of the therapeutic agents herein disclosed. In general, the nature of the carrier will depend on the mode of administration being employed. For instance, parenteral formulations usually include injectable fluids that include pharmaceutically and physiologically acceptable fluids such as water, physiological saline, balanced salt solutions, aqueous dextrose, sesame oil, glycerol, ethanol, combinations thereof, or the like, as a vehicle. The carrier and composition can be sterile, and the formulation suits the mode of administration. In addition to biologically-neutral carriers, pharmaceutical compositions to be administered can contain minor amounts of non-toxic auxiliary substances, such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example sodium acetate or sorbitan monolaurate.

The composition can be a liquid solution, suspension, emulsion, tablet, pill, capsule, sustained release formulation, or powder. For solid compositions (for example powder, pill, tablet, or capsule forms), conventional non-toxic solid carriers can include, for example, pharmaceutical grades of mannitol, lactose, starch, sodium saccharine, cellulose, magnesium carbonate, or magnesium stearate. The composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides.

ŝ.

5.

10

15

20

25

Embodiments of the disclosure including medicaments can be prepared with conventional pharmaceutically acceptable carriers, adjuvants and counterions as would be known to those of skill in the art.

The amount of therapeutic agent effective in decreasing or inhibiting viral infection can depend on the nature of the virus and its associated disorder or condition, and can be determined by standard clinical techniques. In addition, in vitro assays can be employed to identify optimal dosage ranges. The precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each subject's circumstances. Effective doses can be extrapolated from dose-response curves derived from in vitro or animal model test systems.

The disclosure also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. Instructions for use of the composition can also be included.

#### Administration of Nucleic Acids

In an example in which a nucleic acid is employed to reduce viral infection, such as an antisense, RNAi molecule, or siRNA molecule, the nucleic acid can be delivered intracellularly (for example by expression from a nucleic acid vector or by receptor-mediated mechanisms), or by an appropriate nucleic acid expression vector which is administered so that it becomes intracellular, for example by use of a retroviral vector (see U.S. Patent No. 4,980,286), or by direct injection, or by use of microparticle bombardment (such as a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, or by administering it in linkage to a homeobox-like peptide which is known to enter the nucleus (for example Joliot et al., Proc. Natl. Acad. Sci. USA 1991, 88:1864-8). The present disclosure includes all forms of nucleic acid delivery, including synthetic oligos, naked DNA, plasmid and viral, integrated into the genome or not.

30 Example 10
in vitro Screening Assay for Agents that Decrease Viral Infection

13

20

25

30

35

This example describes in vitro methods that can be used to screen test agents for their ability to interfere with or even inhibit viral infection of a host cell. As disclosed in the Examples above, the disclosed host proteins (such as those listed in Table 1 and the target protein sequences associated with SEQ ID NOS: 1-232, as well as variants, fragments, and fusions thereof) are involved in viral infection (such as infection by HIV, Ebola, and influenza A), and the host protein/viral protein interaction is a component in the ability of a virus to infect a cell. Therefore, screening assays can be used to identify and analyze agents that decrease or interfere with this interaction. For example, the following assays can be used to identify agents that interfere with the interaction of the disclosed host proteins (such as those listed in Table 1 and the target protein sequences associated with SEQ ID NOS: 1-232) with a viral protein sequence. However, the present disclosure is not limited to the particular methods disclosed herein.

Agents identified via the disclosed assays can be useful, for example, in decreasing or even inhibiting viral infection by more than an amount of infection in the absence of the agent, such as a decrease of at least about 10%, at least about 20%, at least about 50%, or even at least about 90%. This decrease in viral infection can serve to ameliorate symptoms associated with viral infection, such as fever. Assays for testing the effectiveness of the identified agents, are discussed below.

Exemplary test agents include, but are not limited to, any peptide or non-peptide composition in a purified or non-purified form, such as peptides made of D-and/or L-configuration amino acids (in, for example, the form of random peptide libraries; see Lam et al., Nature 354:82-4, 1991), phosphopeptides (such as in the form of random or partially degenerate, directed phosphopeptide libraries; see, for example, Songyang et al., Cell 72:767-78, 1993), antibodies, and small or large organic or inorganic molecules. A test agent can also include a complex mixture or "cocktail" of molecules.

The basic principle of the assay systems used to identify agents that interfere with the interaction between a host protein, such as those listed in Table 1 and the target protein sequences associated with SEQ ID NOS: 1-232, and its viral protein binding partner or partners, involves preparing a reaction mixture containing the host protein and a viral protein under conditions and for a time sufficient to allow the two proteins to interact and bind, thus forming a complex. In order to test an agent for inhibitory activity, the reaction is conducted in the presence and absence of the test agent. The test agent can be initially included in the reaction mixture, or added at a time subsequent to the addition of a host protein and a viral protein. Controls are incubated without the test agent or with a placebo. Exemplary controls include agents known not to bind to viral or host proteins. The formation of any complexes between the host protein and the viral protein is then detected. The formation of a complex in the control reaction, but not in the reaction mixture containing the test agent, indicates that the agent interferes with the interaction of the host protein and the viral protein, and is therefore possibly an agent that can be used to decrease viral infection.

The assay for agents that interfere with the interaction of host and viral proteins can be conducted in a heterogeneous or homogeneous format. Heterogeneous assays involve anchoring the host protein or the viral protein onto a solid phase and detecting complexes anchored on the solid

10

15

20

25

30

35

phase at the end of the reaction. In some examples, the method further involves quantitating the amount of complex formation or inhibition. Exemplary methods that can be used to detect the presence of complexes, when one of the proteins is labeled, include ELISA, spectrophotometry, flow cytometry, and microscopy. In homogeneous assays, the entire reaction is performed in a liquid phase. In either method, the order of addition of reactants can be varied to obtain different information about the agents being tested. For example, test agents that interfere with the interaction between the proteins, such as by competition, can be identified by conducting the reaction in the presence of the test agent, for example by adding the test agent to the reaction mixture prior to or simultaneously with the host protein and viral protein. On the other hand, test agents that disrupt preformed complexes, such as agents with higher binding constants that displace one of the proteins from the complex, can be tested by adding the test agent to the reaction mixture after complexes have been formed. The various formats are described briefly below.

Once identified, test agents found to inhibit or decrease the interaction between a host protein and a viral protein can be formulated in therapeutic products (or even prophylactic products) in pharmaceutically acceptable formulations, and used for specific treatment or prevention of a viral disease, such as HIV, Ebola, or influenza A.

#### Heterogeneous assay system

In a heterogeneous assay system, one binding partner, either the host protein (such as those listed in Table 1 and target protein sequences associated with SEQ ID NOS: 1-232) or the viral protein (such as an HIV, Ebola, or influenza A virus preparation) is anchored onto a solid surface (such as a microtiter plate), and its binding partner, which is not anchored, is labeled, either directly or indirectly. Exemplary labels include, but are not limited to, enzymes, fluorophores, ligands, and radioactive isotopes. The anchored protein can be immobilized by non-covalent or covalent attachments. Non-covalent attachment can be accomplished simply by coating the solid surface with a solution of the protein and drying. Alternatively, an immobilized antibody (such as a monoclonal antibody) specific for the protein can be used to anchor the protein to the solid surface. The surfaces can be prepared in advance and stored.

To conduct the assay, the binding partner of the immobilized species is added to the coated surface with or without the test agent. After the reaction is complete, unreacted components are removed (such as by washing) and any complexes formed will remain immobilized on the solid surface. The detection of complexes anchored on the solid surface can be accomplished in a number of ways. Where the binding partner was pre-labeled, the detection of label immobilized on the surface indicates that complexes were formed. Where the binding partner is not pre-labeled, an indirect label can be used to detect complexes anchored on the surface; for example by using a labeled antibody specific for the binding partner (the antibody, in turn, may be directly labeled or indirectly labeled with a labeled anti-Ig antibody). Depending upon the order of addition of reaction components, test compounds which inhibit complex formation or which disrupt preformed complexes can be detected.

O 2004/07000

5

10

15

20

25

30

35

Alternatively, the reaction can be conducted in a liquid phase in the presence or absence of the test agent, the reaction products separated from unreacted components, and complexes detected; for example by using an immobilized antibody specific for one binding partner to anchor any complexes formed in solution, and a labeled antibody specific for the other binding partner to detect anchored complexes. Again, depending upon the order of addition of reactants to the liquid phase, test agents which inhibit complex or which disrupt preformed complexes can be identified.

#### Homogenous assays

In an alternate example, a homogeneous assay can be used. In this method, a preformed complex of the host protein and the viral protein is prepared in which one of the proteins is labeled, but the signal generated by the label is quenched due to complex formation (for example, see U.S. Pat. No. 4,109,496 by Rubenstein which utilizes this approach for immunoassays). The addition of a test substance that competes with and displaces one of the binding partners from the preformed complex will result in the generation of a signal above background. In this way, test agents that disrupt host protein-viral protein interactions are identified.

#### Immobilization of Proteins

In a particular example, a host protein involved in viral infection (such as those listed in Table 1 and the target protein sequences associated with SEQ ID NOS: 1-232) can be prepared for immobilization using recombinant DNA techniques. For example, a coding region of a protein listed in Table 1, or any target sequence associated with SEQ ID NOS: 1-232, can be fused to a glutathione-S-transferase (GST) gene using the fusion vector pGEX-5X-1, in such a manner that its binding activity is maintained in the resulting fusion protein. The viral protein (such as an Ebola, HIV, or influenza A protein or viral preparation) can be purified and used to raise a monoclonal antibody, using methods routinely practiced in the art and described above. This antibody can be labeled with the radioactive isotope 125 I using methods routinely practiced in the art.

In a heterogeneous assay, for example, the GST-host fusion protein can be anchored to glutathione-agarose beads. The viral protein preparation can then be added in the presence or absence of the test agent in a manner that allows interaction and binding to occur. At the end of the reaction period, unbound material can be washed away, and the labeled monoclonal antibody can be added to the system and allowed to bind to the complexed binding partners. The interaction between the host protein and the viral protein can be detected by measuring the amount of radioactivity that remains associated with the glutathione-agarose beads. A successful inhibition of the interaction by the test compound will result in a decrease in measured radioactivity.

Alternatively, the GST-host fusion protein and the viral protein can be mixed together in liquid in the absence of the solid glutathione agarose beads. The test agent can be added either during or after the binding partners are allowed to interact. This mixture can then be added to the glutathione-agarose beads and unbound material is washed away. Again, the extent of inhibition of

10

15

20

25

30

35

the binding partner interaction can be detected by adding the labeled antibody and measuring the radioactivity associated with the beads.

In another example, these same techniques can be employed using peptide fragments that correspond to the binding domains of the host protein and the viral protein, respectively, in place of one or both of the full length proteins. Any number of methods routinely practiced in the art can be used to identify and isolate the protein's binding site. These methods include, but are not limited to, mutagenesis of one of the genes encoding the proteins and screening for disruption of binding in a co-immunoprecipitation assay. Compensating mutations in a host gene can be selected. Sequence analysis of the genes encoding the respective proteins will reveal the mutations that correspond to the region of the protein involved in interactive binding. Alternatively, one protein can be anchored to a solid surface using methods described in above, and allowed to interact with and bind to its labeled binding partner, which has been treated with a proteolytic enzyme, such as trypsin. After washing, a short, labeled peptide comprising the binding domain may remain associated with the solid material, which can be isolated and identified by amino acid sequencing. Also, once the gene coding for the for the cellular or extracellular protein is obtained, short gene segments can be engineered to express peptide fragments of the protein, which can then be tested for binding activity and purified or synthesized.

For example, a host protein can be anchored to a solid material as described above by making a GST-host protein fusion protein and allowing it to bind to glutathione agarose beads. The viral protein can be labeled with a radioactive isotope, such as <sup>35</sup>S, and cleaved with a proteolytic enzyme such as trypsin. Cleavage products can then be added to the anchored GST-host protein fusion protein and allowed to bind. After washing away unbound peptides, labeled bound material, representing the cellular or extracellular protein binding domain, can be eluted, purified, and analyzed for amino acid sequence. Peptides so identified can be produced synthetically or fused to appropriate facilitative proteins using recombinant DNA technology.

#### Example 11

# Cell-Based Screening Assay for Agents that Decrease Viral Infection

This example describes methods using intact cells that can be used to screen test agents for their ability to interfere with or even inhibit viral infection of a host cell. For example, a yeast two-hybrid assay or the inverse two-hybrid assay method of Schreiber and coworkers (*Proc. Natl. Acad. Sci., USA* 94:13396, 1977) is used to screen for an agent that disrupts the association between a host protein (such as those listed in Table 1, proteins encoded by any target sequence associated with SEQ ID NOS: 1-227, 229, and 231, and any target sequence associated with SEQ ID NOS: 229, 230, and 232) and a viral protein (such as HIV, Ebola, or influenza A virus). Similar to Example 10, therapeutic agents identified by these approaches are tested for their ability to decrease or inhibit infection of a host cell, such as a human cell, by HIV, Ebola, or influenza A.

In one example, the yeast two-hybrid system is used to identify anti-viral agents. One version of this system has been described (Chien et al., Proc. Natl. Acad. Sci. USA, 88:9578-82.

15

20

25

30

79

1991) and is commercially available from Clontech (Palo Alto, CA). Briefly, utilizing such a system, plasmids are constructed that encode two hybrid proteins: one includes the DNA-binding domain of a transcription activator protein fused to one test protein "X" and the other includes the activator protein's activation domain fused to another test protein "Y". Thus, either "X" or "Y" in this system can be a host protein (such as those listed in Table 1 and any target sequences associated with SEQ ID NOS: 1-232), while the other can be a test protein or peptide. The plasmids are transformed into a strain of Saccharomyces cerevisiae that contains a reporter gene (such as lacZ) whose regulatory region contains the activator's binding sites. Either hybrid protein alone cannot activate transcription of the reporter gene, the DNA-binding domain hybrid because it does not provide activation function and the activation domain hybrid because it cannot localize to the activator's binding sites.

Interaction of the two proteins reconstitutes the functional activator protein and results in expression of the reporter gene, which is detected by an assay for the reporter gene product.

The two-hybrid system or related methodology can be used to screen activation domain libraries for proteins that interact with a host protein involved in viral infection. Total genomic or cDNA sequences are fused to the DNA encoding an activation domain. This library and a plasmid encoding a hybrid of the host protein involved in viral infection fused to the DNA-binding domain are cotransformed into a yeast reporter strain, and the resulting transformants are screened for those that express the reporter gene. These colonies are purified and the plasmids responsible for reporter gene expression are isolated. DNA sequencing is then used to identify the proteins encoded by the library plasmids.

For example, and not by way of limitation, a host gene encoding a protein involved in viral infection (such as those listed in Table 1 and target sequences associated with SEQ ID NOS: 1-232) can be cloned into a vector such that it is translationally fused to the DNA encoding the DNA-binding domain of the GALA protein. A cDNA library of the cell line from which proteins that interact with the host protein are to be detected can be made using methods routinely practiced in the art. In this particular system, the cDNA fragments can be inserted into a vector such that they are translationally fused to the activation domain of GALA. This library can be co-transformed along with the host-GALA DNA binding domain fusion plasmid into a yeast strain which contains a lacZ gene driven by a promoter which contains GALA activation sequences. A cDNA encoded protein, fused to GALA activation domain, that interacts with the host protein will reconstitute an active GALA protein and thereby drive expression of the lacZ gene. Colonies which express lacZ can be detected by their blue color in the presence of X-gal. The cDNA can then be extracted from strains derived from these and used to produce and isolate the host protein-interacting protein using techniques routinely practiced in the art.

35

### Example 12

### Rapid Screening Assays

Prior to performing any assays to detect interference with the association of a host protein involved in viral infection and a viral protein such as an HIV, Ebola, or influenza A protein, rapid

screening assays can be used to screen a large number of agents to determine if they bind to the host or viral protein. Rapid screening assays for detecting binding to HIV proteins have been disclosed, for example in U.S. Patent No. 5,230,998, which is incorporated by reference. In that assay, a host protein (such as those listed in Table 1 and target protein sequences associated with SEQ ID NOS: 1-232) or a viral protein, such as an HIV protein, is incubated with a first antibody capable of binding to the host or viral protein, and the agent to be screened. Excess unbound first antibody is washed and removed, and antibody bound to the host or viral protein is detected by adding a second labeled antibody which binds the first antibody. Excess unbound second antibody is then removed, and the amount of the label is quantitated. The effect of the binding effect is then determined in percentages by the formula: (quantity of the label in the absence of the test agent) - (quantity of the label in the presence of the test agent) / (quantity of the label in the absence of the test agent) x 100.

Agents that are found to have a high binding affinity to the host or viral protein can then be used in other assays more specifically designed to test inhibition of the host protein/viral protein interaction, or inhibition of viral replication.

15

10

5

#### Example 13

### Assays for Measuring Inhibition of Viral Infection

Any of the test agents identified in the foregoing assay systems can be tested for their ability to decrease or inhibit infection by a pathogen or virus such as HIV, Ebola, or influenza A.

20

25

30

35

#### Cell-based assays

Exemplary methods are provided in Example 3 above. Briefly, cells (20,000 to 250,000) are infected with the desired pathogen, such as HIV, Ebola, or influenza A, and the incubation continued for 3-7 days. The test agent can be applied to the cells before, during, or after infection with the virus. The amount of virus and agent administered can be determined by skilled practitioners. In some examples, several different doses of the potential therapeutic agent can be administered, to identify optimal dose ranges. Following transfection, assays are conducted to determine the resistance of the cells to infection by various agents.

For example, the presence of a viral antigen can be determined by using antibody specific for the viral protein then detecting the antibody. In one example, the antibody that specifically binds to the viral protein is labeled, for example with a detectable marker such as a flurophore. In another example, the antibody is detected by using a secondary antibody containg a label. The presence of bound antibody is then detected, for example using microscopy, flow cytometry, and ELISA.

Alternatively or in addition, the ability of the cells to survive viral infection is determined, for example by performing a cell viability assay, such as trypan blue exclusion.

#### Animal model assays

The ability of an agent, such as those identified using the methods provide above, to prevent or decrease infection by a virus, such as HIV, Ebola, or influenza A, can be assessed in animal

**5**.

10

15

**20** 1

models. Several animal models for viral infection are known in the art. For example, mouse HIV models are disclosed in Sutton et al. (Res. Initiat Treat. Action, 8:22-4, 2003) and Pincus et al. (AIDS Res. Hum. Retroviruses 19:901-8, 2003); guinea pig models for Ebola infection are disclosed in Parren et al. (J. Virol. 76:6408-12, 2002) and Xu et al. (Nat. Med. 4:37-42, 1998); and cynomolgus monkey (Macaca fascicularis) models for influenza infection are disclosed in Kuiken et al. (Vet. Pathol. 40:304-10, 2003). Such animal models can also be used to test agents for an ability to ameliorate symptoms associated with viral infection. In addition, such animal models can be used to determine the LD50 and the ED50 in animal subjects, and such data can be used to determine the in vivo efficacy of potential agents.

Animals of any species, including, but not limited to, mice, rats, rabbits, guinea pigs, pigs, micro-pigs, goats, and non-human primates, such as baboons, monkeys, and chimpanzees, can be used to generate an animal model of viral infection if needed.

The appropriate animal is inoculated with the desired virus, in the presence or absence of the test agents identified in the examples above. The amount of virus and agent administered can be determined by skilled practitioners. In some examples, several different doses of the potential therapeutic agent can be administered to different test subjects, to identify optimal dose ranges. The therapeutic agent can be administered before, during, or after infection with the virus. Subsequent to the treatment, animals are observed for the development of the appropriate viral infection and symptoms associated therewith. A decrease in the development of the appropriate viral infection, or symptoms associated therewith, in the presence of the test agent provides evidence that the test agent is a therapeutic agent that can be used to decrease or even inhibit viral infection in a subject.

Having illustrated and described the principles of the invention by several examples, it should be apparent that those embodiments can be modified in arrangement and detail without departing from the principles of the invention. Thus, the invention includes all such embodiments and variations thereof, and their equivalents.

#### We claim:

1. A method of decreasing infection of a host cell by a virus, comprising interfering with an activity or expression of one or more host proteins or interfering with an activity of one or more host nucleic acids, wherein the host protein or host nucleic acid is a T-cell receptor V beta chain; T-cell receptor V-D-J beta 2.1 chain; β-chimerin; malic enzyme 1; hypothetical protein XP\_174419; sequence from chromosome 4q31.3-32; alpha satellite DNA; LOC253788; LOC219938; coagulation factor III (F3); LOC91759; similar to KOX4 (LOC131880); LOC166140; LOC222474; similar to Rho guanine nucleotide exchange factor 4, isoform a; APC-stimulated guanine nucleotide exchange factor (LOC221178); T-cell receptor beta; ribosomal protein L7A-like 4; v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian) (SRC); KIAA0564; alpha satellite DNA; M96 protein; 10 hypothetical protein similar to G proteins (LOC57826); LOC161005; osteoblast specific factor 2; Canis familiaris T-cell leukemia translocation-associated protein; aminomethyltransferase; dystroglycan; bassoon; LIM domain containing preferred translocation partner in lipoma; sequence between LOC253121 and hyaluronan synthase 2; testin 2, testin 3; protein tyrosine phosphatase, nonreceptor type 1; sequence between LOC149360 and LOC253961; sequence between KIAA1560 and 15 tectorin beta; cadherin related 23; myeloid/lymphoma or mixed lineage leukemia, translocated to 10; exportin 5; DNA polymerase eta (POLH); heterogenous nuclear riboprotein C (C1/C2); alphaendosulfine pseudogene; LOC128741; LOC222888; LOC138421; zinc finger protein 297B; sideroflexin 5; importin 9 (FLJ10402); T-cell receptor beta; similar to murine putative transcription factor ZNF131 (LOC135952); KIAA1259; MURR1; CCT4; FLJ40773; similar to ribosomal protein 20 L24-like (LOC149360); polybromo 1; DNA damage inducible transcript 3; KIAA1887; PDZ; LIM domain 1 (elfin); LOC284803; PRO0097; FLJ31958; small inducible cytokine E, member 1 (endothelial monocyte-activating); E3 ubiquitin ligase (SMURF2); MGC40489; Rab9; PRO1617; retinoblastoma binding protein 1; region of chromosome 2q12; elongation factor for selenoprotein translation; Transcription factor SMIF (HSA275986); KIAA1026; trinucleotide repeat containing 5 25 (TNRC5): homogentisate 1.2-dioxygenase (HGD); region of chromosome Xq23-24; region of chromosome 4p15.3; similar to LWamide neuropeptide precursor protein [Hydractinia echinata] (LOC129883); region of chromosome 2q21; region of chromosome Xp11.4, including UPS9X; LOC221829: U3 small nuclear RNA; integrin, beta 1 (ITGB1); acrosomal vesicle protein 1 (ACRV1) and CHK1 checkpoint homolog (CHEK1); prospero-related homeobox 1 (PROX1); 30 FLJ20627 and FLJ12910; PIN2-interacting protein (PINX1) and SRY (sex-determining region Y)box 7 (SOX7); LOC131920; region of chromosome 13q14; neurotrophic tyrosine kinase, receptor. type 3 (NTRK3); TERA protein and FLJ13224; LOC284260; POM (POM121 homolog) and ZP3 fusion (POMZP3); DEAD/H box polypeptide 8 (DDX8) and similar to ribosomal protein L29 (cell surface heparin binding protein HIP) (LOC284064); LOC345307 and UDP-N-acetyl-D-35 galactosamine:polypeptide N-acetylgalactosaminyltransferase 7 (GALNT7); Mus musculus 3S rRNA pseudogene (Rn5s-ps1); ribosomal protein L27a pseudogene (RPL27AP) and v-myb myeloblastosis. viral oncogene homolog-like 2 (MYBL2); Down's syndrome-cell adhesion molecule like 1 (DSCAML1); LOC148529; Huntingtin-associated protein interacting protein (HAPIP); LOC158525

and similar to RIKEN cDNA 1210001E11 (LOC347366); hypothetical protein FLJ12910; LOC350411; allograft inflammatory factor 1 (AIF1) and HLA-B associated transcript 2 (BAT2); C10orf7; LOC346658 and LOC340349; region of chromosome 12q21; LOC339248 and FLJ22659; SR rich protein DKFZp564B0769 and hypothetical protein MGC14793; FLJ10439; cytochrome P450, family 11, subfamily A, polypeptide 1 (CYP11A1) and sema domain, immunoglobulin domain (Ig) and GPI membrane anchor, (semaphoring) 7A; ribosomal protein S16 (RPS16); hypothetical protein DKFZp434H0115 and ATP citrate lyase (ACLY); calnexin (CANX); protein tyrosine phosphatase, receptor type, K (PTPRK); cyclin M2 (CNNM2); or AXL receptor tyrosine kinase (AXL), and wherein interfering with the activity or expression of the one or more host proteins decreases infection of the host cell by the virus.

2. The method of claim 1, wherein the one or more host proteins is encoded by one or more host nucleic acids comprising at least 90% identity to any target nucleic acid sequence associated with SEO ID NOS: 1-227, 229 or 231.

15

- 3. The method of claim 2, wherein the one or more host nucleic acids comprises any target nucleic acid sequence associated with SEQ ID NOS: 1-227, 229 or 231.
- 4. The method of claim 1, wherein the method comprises interfering with an activity or expression of more than one of the host proteins.
  - 5. The method of claim 1, wherein the method comprises interfering with an activity or expression of at least three of the host proteins.
- 6. The method of claim 1 wherein the virus is HIV-1 or HIV-2, and the host protein or host nucleic acid is a T-cell receptor V beta chain; T-cell receptor V-D-J beta 2.1 chain; β-chimerin; malic enzyme 1; hypothetical protein XP\_174419; sequence from chromosome 4q31.3-32; alpha satellite DNA; LOC253788; LOC219938; coagulation factor III; LOC91759; similar to KOX4 (LOC131880); LOC166140; LOC222474; similar to Rho guanine nucleotide exchange factor 4, isoform a; APC-stimulated guanine nucleotide exchange factor (LOC221178); T-cell receptor beta; ribosomal protein L7A-like 4 (RPL7ALA); v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian) (SRC); KIAA0564; alpha satellite DNA; M96 protein; hypothetical protein similar to G proteins; RAP-2A (LOC57826); LOC161005; Rab9, or osteoblast specific factor 2.
- 7. The method of claim 6, wherein the method comprises interfering with an activity or expression of more than one of the host proteins.
  - 8. The method of claim 6, wherein the method comprises interfering with expression of one or more of the host nucleic acids.

9. The method of claim 1 wherein the virus is influenza A, and the host protein is a Canis familiaris T-cell leukemia translocation-associated protein, aminomethyltransferase; dystroglycan; bassoon; LIM domain containing preferred translocation partner in lipoma; sequence between LOC253121 and hyaluronan synthase 2; testin 2; testin 3; PTPN1 gene for protein tyrosine phosphatase, non-receptor type 1; sequence between LOC149360 and LOC253961; sequence between KIAA1560 and tectorin beta; cadherin related 23; malic enzyme 1; hypothetical protein XP\_174419; sequence from chromosome 4q31.3-32; Rab9, or a myeloid/lymphoma or mixed lineage leukemia, translocated to 10.

10


20

25

30

35

- 10. The method of claim 9, wherein the method comprises interfering with an activity or expression of more than one of the host proteins.
- 11. The method of claim 9, wherein the method comprises interfering with expression ofone or more of the host nucleic acids.
  - 12. The method of claim 1 wherein the virus is Ebola, and the host protein is a exportin 5; DNA polymerase eta (POLH); heterogenous nuclear riboprotein C; alpha-endosulfine pseudogene; LOC128741; LOC222888; LOC138421; zinc finger protein 297B; sideroflexin 5; importin 9 (FLJ10402); T-cell receptor beta; similar to murine putative transcription factor ZNF131 (LOC135952); KIAA1259; MURR1; CCT4; FLJ40773; ribosomal protein L24-like (LOC149360); testin 2; testin 3; polybromo 1; DNA damage inducible transcript 3; KIAA1887; PDZ; LIM domain 1 (elfin); LOC284803; PRO0097; FLJ31958; small inducible cytokine E, member 1 (endothelial monocyte-activating); E3 ubiquitin ligase; MGC40489; Rab9; PRO1617; retinoblastoma binding protein 1; region of chromosome 2q12; elongation factor for selenoprotein translation; Transcription factor SMIF (HSA275986); KIAA1026; trinucleotide repeat containing 5 (TNRC5); homogentisate 1,2-dioxygenase (HGD); region of chromosome Xq23-24; region of chromosome 4p15.3; similar to LWamide neuropeptide precursor protein [Hydractinia echinata] (LOC129883); region of chromosome 2q21; region of chromosome Xp11.4, including UPS9X; LOC221829; U3 small nuclear RNA; integrin, beta 1 (ITGB1); acrosomal vesicle protein 1 (ACRV1) and CHK1 checkpoint homolog (CHEK1); prospero-related homeobox 1 (PROX1); FLJ20627 and FLJ12910; PIN2interacting protein (PINX1) and SRY (sex-determining region Y)-box 7 (SOX7); LOC131920; region of chromosome 13q14; neurotrophic tyrosine kinase, receptor, type 3 (NTRK3); TERA protein and FLJ13224; LOC284260; POM (POM121 homolog) and ZP3 fusion (POMZP3); DEAD/H box polypeptide 8 (DDX8) and similar to ribosomal protein L29 (cell surface heparin binding protein HIP) (LOC284064); LOC345307 and UDP-N-acetyl-D-galactosamine:polypeptide Nacetylgalactosaminyltransferase 7 (GALNT7); Mus musculus SS rRNA pseudogene (RnSs-ps1); ribosomal protein L27a pseudogene (RPL27AP) and v-myb myeloblastosis viral oncogene homologlike 2 (MYBL2); Down's syndrome cell adhesion molecule like 1 (DSCAML1); LOC148529;



Huntingtin-associated protein interacting protein (HAPIP); LOC158525 and similar to RIKEN cDNA 1210001E11 (LOC347366); hypothetical protein FLJ12910; LOC350411; allograft inflammatory factor 1 (AIF1) and HLA-B associated transcript 2 (BAT2); C10orf7; LOC346658 and LOC340349; region of chromosome 12q21; LOC339248 and FLJ22659; SR rich protein DKFZp564B0769 and hypothetical protein MGC14793; FLJ10439; cytochrome P450, family 11, subfamily A, polypeptide 1 (CYP11A1) and sema domain, immunoglobulin domain (Ig) and GPI membrane anchor, (semaphoring) 7A; ribosomal protein S16 (RPS16); hypothetical protein DKFZp434H0115 and ATP citrate lyase (ACLY); calnexin (CANX); protein tyrosine phosphatase, receptor type, K (PTPRK); cyclin M2 (CNNM2); or AXL receptor tyrosine kinase.

10

15

- 13. The method of claim 12, wherein the method comprises interfering with an activity or expression of more than one of the host proteins.
- 14. The method of claim 12, wherein the method comprises interfering with expression of one or more of the host nucleic acids.
- 15. The method of claim 6, wherein the one or more host proteins are encoded by one or more nucleic acid sequences comprising at least 90% identity to any target nucleic acid sequence associated with SEQ ID NOS: 1-35.

20

16. The method of claim 6, wherein one or more host proteins is encoded by one or more nucleic acid sequences comprising any target nucleic acid sequence associated with SEQ ID NOS: 1-35.

25

- 17. The method of claim 9, wherein the one or more host proteins are encoded by one or more nucleic acid sequences comprising at least 90% identity to any of SEQ ID NOS: 36-63 or a coding sequence of any of SEQ ID NOS: 36-63.
- 18. The method of claim 9, wherein the one or more host proteins are encoded by one or more nucleic acid sequences comprising any target nucleic acid sequence associated with SEQ ID NOS: 36-63.
  - 19. The method of claim 12, wherein the one or more host proteins are encoded by one or more nucleic acid sequences comprising at least 90% identity to any target nucleic acid sequence associated with SEQ ID NOS: 64-227, 229, and 231.
  - 20. The method of claim 12, wherein one or more host proteins are encoded by one or more nucleic acid sequences comprising any target nucleic acid sequence associated with SEQ ID NOS: 64-227, 229, and 231.

21. The method of claim 1, wherein interfering with the activity of the one or more host proteins comprises decreasing an interaction of a viral protein and the one or more host proteins by disrupting or decreasing expression of the one or more host proteins.

5

- 22. The method of claim 21, wherein the viral protein comprises a virus and decreasing the interaction of the viral protein and the one or more host proteins decreases or inhibits infection of a host cell by the virus.
- 23. The method of claim 21, wherein disrupting or decreasing expression of the host protein comprises disrupting or decreasing transcription of an mRNA encoding the host protein.
  - 24. The method of claim 23, wherein disrupting or decreasing transcription of the mRNA comprises inserting a transposon or insertional vector into a coding region of the nucleic acid encoding the host protein.
  - 25. The method of claim 23, wherein disrupting or decreasing the transcription of the mRNA comprises contacting the mRNA with an antisense RNA, RNAi, ribozyme, or siRNA that recognizes the mRNA.

20

15

26. The method of claim 1 wherein interfering with the activity of the host protein comprises decreasing an interaction of a viral protein and the host protein by contacting the cell with an agent that decreases or inhibits the activity or expression of the host protein or that disrupts expression of the host protein.

25

- 27. The method of claim 26, wherein the host cell is present in a host subject and wherein contacting the cell with the agent comprises administering the agent to the subject.
  - 28. The method of claim 1, wherein the host cell is a mammalian host cell.

30

29. A method of decreasing HIV, Ebola, or influenza A infection of a host cell, comprising, decreasing an interaction between a viral nucleic acid and a host nucleic acid by decreasing the integration of the viral nucleic acid into the host nucleic acid, wherein the host nucleic acid comprises at least 90% identity to any target sequence associated with SEQ ID NOS: 1-227, 229, and 231.

35

30. The method of claim 29, wherein the viral nucleic acid comprises a viral genome and the host nucleic acid comprises a host genome.

- 31. A method of treating an HIV, Ebola, or influenza A viral infection in a host subject, comprising administering to a subject having a viral infection an effective amount of an agent that interferes with the interaction of a virus and host protein, wherein the host protein is encoded by a nucleic acid comprising at least 90% identity to any target sequence associated with SEQ ID NOS: 1-227, 229, and 231.
- 32. The method of claim 31, wherein the agent disrupts expression of the nucleic acid encoding the host protein.
- 33. The method of claim 32, wherein the agent is an antisense, ribozyme, or siRNA molecule that recognizes the nucleic acid sequence comprising at least 90% identity to any target sequence associated with SEQ ID NOS: 1-227, 229, and 231.
- 34. The method of claim 31, wherein the effective amount induces a prophylactic effect in the host, which inhibits infection of the host by a virus.
  - 35. The method of claim 31, wherein the host was previously infected by a virus and the effective amount induces a therapeutic effect in the host.
- 20 36. A method of determining resistance or susceptibility to viral infection in a subject, comprising comparing a first nucleic acid sequence of a subject to a second nucleic acid sequence comprising any target sequence associated with SEQ ID NOS: 1-227, 229, and 231, wherein a higher similarity between the first and second nucleic acid sequence indicates the subject is more susceptible to viral infection, and wherein a lesser similarity between the first and second nucleic acid sequence indicates the subject is more resistant to viral infection.
  - 37. The method of claim 36, wherein the first nucleic acid sequence is obtained from a biological sample of the subject.
  - 38. The method of claim 37, wherein the first nucleic acid sequence comprises a plurality of nucleic acid sequences, wherein each nucleic acid sequence is obtained from a different subject.
  - 39. The method according to claim 36, further comprising determining a polymorphic variation within a population.
  - 40. A method of decreasing HIV, Ebola, or influenza A infection of a host cell, comprising: contacting the host cell with an anti-protein binding agent that selectively or specifically binds to a host protein encoded by any target sequence associated with SEQ ID NOS: 1-227, 229, and 231 or a protein sequence shown in any of SEQ ID NOS: 228, 230, or 232, wherein the anti-protein

30

**35**°

10

15

20

25

35

binding agent inhibits an interaction between the host protein and the HIV, Ebola, or influenza A virus.

- 41. The method of claim 40, wherein the host cell is present in a subject, and contacting the host cell with the anti-protein binding agent comprises administering the anti-protein binding agent to the subject.
  - 42. The method of claim 40, wherein the anti-protein binding agent is an antibody or chemical compound.
  - 43. A method of identifying a compound that decreases binding of a viral protein to a host protein and decreases viral infection, comprising:

contacting the host protein with the viral protein and a test compound, wherein the host protein is a protein in Table 1, and the viral protein is an HIV, Ebola, or influenza A protein; and


- determining whether binding of the viral protein to the host protein is decreased in the presence of the test compound, the decrease in binding being an indication that the test compound decreases the binding of viral protein to the target protein, and decreases viral infection.
  - 44. The method of claim 43, wherein the viral protein comprises a virus.
  - 45. The method of claim 43, wherein the viral protein is a viral envelope protein.
- 46. The method of claim 43, wherein the viral protein is an HIV protein and the host protein is a protein encoded by a target sequence associated with SEQ ID NOS: 1-35.
- 47. The method of 43, wherein the viral protein is an influenza A protein and the host protein is a protein encoded by a target sequence associated with SEQ ID NOS: 36-63.
- 48. The method of claim 43, wherein the viral protein is an Ebola protein and the host protein is a protein encoded by a target sequence associated with SEQ ID NOS: 64-227, 229, and 231.
  - 49. The method of claim 43, wherein the method comprises expressing the host protein in a cell, and contacting the host protein with the viral protein and a test compound comprises exposing the cell to the viral protein and the test compound.
  - 50. The method of claim 43, wherein the host protein or the viral protein comprises a label, and determining whether binding is decreased comprises detecting an amount of label present.




- 51. A method of decreasing infection of a host cell by a pathogen, comprising interfering with an activity or expression of a Rab9 in the host cell, wherein interfering with Rab9 activity or expression decreases infection of the host cell by the pathogen.
  - 52. The method of claim 51, wherein the pathogen hijacks a lipid raft.
- 53. The method of claim 51, wherein the pathogen is a Campylobacter jujuni, Vibrio cholerae, SV40, Legionella pneumophila, Aeromonas hydrophilia, Echovirus 1, Echovirus 11, Brucella spp, Clostridium spp., Avian sarcoma and leukosis virus, FimH, Dr Escherichia coli, Streptcoccus pyogenes, Semiliki forest virus, Salmonella typhimurium, Bacillus anthracis, Ecotropic mouse leukaemia virus, Shigella flexneri, Bacillus thuringiensis, HTLV-1, Chlamydia spp., Helicobacter pylori, HIV-1, Mycobacterium spp., Lysteria monocytogenes, Ebola, Marburg, Measles, Herpes Simplex virus, influenza virus, or Epstein-Barr virus.
- 54. The method of claim 51, wherein the Rab9 host protein is encoded by a host nucleic acid comprising at least 90% identity to a target sequence associated with any of SEQ ID NOS: 118-119.
- 55. The method of claim 54, wherein the host nucleic acid comprises a target sequence associated with any of SEQ ID NOS: 118-119.
  - 56. The method of claim 51, wherein interfering with expression of Rab9 comprises disrupting or decreasing transcription of an mRNA encoding the Rab9 protein.
- 25 57. The method of claim 56 wherein disrupting or decreasing the transcription of the mRNA comprises contacting the mRNA with an antisense RNA, ribozyme, or siRNA that recognizes the mRNA.
- 58. The method of claim 57, wherein the siRNA sequence comprises any of SEQ ID NOS: 30 232-235.
  - 59. The method of claim 57, wherein the host cell is present in a subject, and contacting the mRNA with an antisense RNA, ribozyme, or siRNA that recognizes the mRNA comprises administering the antisense RNA, ribozyme, or siRNA to the subject.
  - 60. A cell comprising a functional deletion of one or more target sequences associated with any of SEQ ID NOS: 1-35, wherein the cell has a decreased susceptibility to HIV infection.

35.

- 61. A cell comprising a functional deletion of one or more target sequences associated with any of SEQ ID NOS: 36-63, wherein the cell has a decreased susceptibility to influenza infection.
- 62. A cell comprising a functional deletion of one or more target sequences associated with any of SEQ ID NOS: 64-232, wherein the cell has a decreased susceptibility to Ebola infection.
  - 63. A cell comprising a functional deletion of a Rab9 gene, wherein the cell has a decreased susceptibility to infection by a pathogen that uses lipid rafts.
- 10 64. A non-human transgenic mammal comprising a functional deletion of one or more target sequences associated with any of SEQ ID NOS: 1-35, wherein the mammal has decreased suseptibility to infection by HIV.
- 65. A non-human transgenic mammal comprising a functional deletion of one or more target sequences associated with any of SEQ ID NOS: 36-63, wherein the mammal has decreased suseptibility to infection by influenza.
  - 66. A non-human transgenic mammal comprising a functional deletion of one or more target sequences associated with any of SEQ ID NOS: 64-232, wherein the mammal has decreased suseptibility to infection by Ebola.
  - 67. A non-human transgenic mammal comprising a functional deletion of a Rab9 gene, wherein the mammal has decreased suseptivlity to infection by a pathogen that uses a lipid raft.
- 25 68. The method of claim 1, wherein interfering with an activity of the host nucleic acid comprising administering one or more of SEQ ID NOS: 246-845 to the host cell.





Recover clones by transformation into bacteria and sequence

יו בפכתתתחותה מאוי יחוייתיםות






FIG. 5






WO 2004/070002 PCT/US2003/037143

# STATEMENT ACCOMPANYING SEQUENCE LISTING

The sequence listing does not include matter that goes beyond the disclosure in the international application.

The printout of the attached Sequence Listing is identical to the computer readable sequence listing on the enclosed computer disk.

RNSDOCID: <WO 2004070002A2 1 >



### SEQUENCE LISTING

<110> The Government of the United States of	America		•
<120> CELL LINES AND HOST NUCLEIC ACIDS RELAT	TED TO INFE	ECTIOUS DISEASE	2S
<130> 6395-66741			
<150> US 60/482,604 <151> 2003-06-25			
<150> US 60/427,464			
<160> 845			
<170> PatentIn version 3.2			
<210> 1 <211> 937 <212> DNA <213> Homo sapiens		•	
<220> <221> misc_feature <222> (1)(937) <223> n is a, g, c, or t			
<400> 1 gaanageetn tecacecaag ngneggagaa ceagngngea a	attenttttg	ttcaatcatg	60
cgaaacgatc ctyrgstacc gcttgccaaa cctacaggtg g	ggtctttca	agaggtctcc	120
agacctaggg gagcatctca gcgtcactcg ctgtccagtt g	gctgtgatca	ggtgctttgg	180
ggtttgtgtg actccagaat ccactgggcc tgtgtgtcag a	aagacaaaag	ttaaccataa	240
ggcacagaag aaagcctcct gctgaagcca tcgttggccc a	acatgcattt	cagggacaag	300
aaatgaagat cggagacttt caagttgtgc ccaggactca c	cctgctccca	ggagacaaaa	360
ggccacacag cagaggagcc tgaagcccat ggcaggatct c	cctagcttgg	ggctggtgtc	420
totgtagtaa gcattotgaa gttoctaago toccttotto o	ctgataggag	cattgacctg	480
tgatgtcacc acactgacat actttcccct gcaggccact c	ccagcccact	gtactctttg	540
gcaggectca ggttctgcta ctccatgtac tattcctgtc t	ttgcacaggc	cagaagctaa	600
aggtgaggag gactgaacac agtaccaaca tacccacatc	acaccttact	ttcctctgcc	660
cgccctgtcc ctgccctgac actgattccc cageccttgc	caceccagec	ccttcaccct	720
ccactgcccg tgcagcagca gagacactcc ctccttgatg	caaactgagg	cctctggcac	780
cccaactctt tcaaggcaat gatagtctgt gcttaactct	acatggecag	gccccactc	840
agggaattnc tgtgtgaaat tgttatccgc tgsacaattc	cacacaacat	ggnncgtcag	900
accccgaaga aaagaancaa nggatetttt ggnnacc			937

<210> 2 <211> 1515 <212> DNA <213> Homo sapiens

<220>

<221> misc\_feature

<222> (1)..(1515)

<223> n is a, c, g, or t

**<400> 2** eccgtgttga cgccgggcaa gngcaactcg gtcgccgcat acactattct cagaatgact 60 tggttgagta ctcaccagtc acagaaaagc atcttacgga tggcatgaca gtaagagaat 120 tatgcagtgc tgccataacc atgagtgata acactgcggc caacttactt ctgacaacga 180 teggaggace gaaggageta accgettttt tgcacaacat gggggateat gtaactegee 240 ttgatcgttg ggaaccggag ctgaatgaag ccataccaaa cgacgagcgt gacaccacga 300 tgcctgcagc aatggcaaca acgttgcgca aactattaac tggcgaacta cttactctag 360 cttcccggca acaattaata gactggatgg aggcggataa agttgcagga ccacttctgc 420 gctcggccct tccggctggc tggtttattg ctgataaatc tggagccggt gagcgtgggt 480 ctcgcggtat cattgcagca ctggggccag atggtaagcc ctcccgtatc gtagttatct 540 acacgacggg gagtcaggca actatggatg aacgaaatag acagatcgct gagataggtg 600 cctcactgat taagcattng gkaanctgtc agaccattkt ttactgcata tacsgateca 660 ttgcccttat ctcaaactct tattatgaaa tcactnccct tgagagaraa aaagcctttt 720 tetettnngg atkgteccag magytyeega meatecceae tyeecaacet tatgkggece 780 840 agcaatgans cctagtagta ggaaaatcty tatggatacy ggkgnctgak gggaarattc 900 ttcytctcat gaarwgatgg kgactggggc tytgggatgc tcacgggaat ccctatttcc cccacaaaga agttatttta ttacacaacc atttggatga cccccttttt cttccaattn 960 nccaaataaa totgtaaagg toacaggtga agttottoto tttaagagot actocatgot 1020 1080 aagttcagcg agaacttggg gtaccctaga cattcttcca gagatgcttt tcttgtaact cttttcaata agtaagcatg ctttgctctg cactgggtgt cacctgtgtt ggatgctgtt 1140 gtecetgeet tgeectatat tetgtecaca tggtttette ataggatgat gettaggtea 1200 gccctgaggt ttgaaccagt caacaagtcc aggttggtgt ggagtccctt tagtacctcc 1260 ctttgcagga ataatgctgc acccagaaac tccctcagag cctctccact gggaggggcc 1320 ttgtgaccat tcctggttta ctcctcttgt tccagcatcc catgtggcca atgggcccct 1380 ttcattttca atggtatctc antinttaca gtaagttata ttattgccct acatngaact 1440 **WO 2004/0700**0 PCT/US2003/037143

1500

catcttttt cantgttacc tgnngaagaa tggnnaagga tgcccnaaan tnggcccaaa anaatccact tcgnn 1515 <210> 3 <211> 885 <212> DNA <213> Homo sapiens <220> <221> misc\_feature <222> (1)..(885)<223> n is a, g, c, or t <400> 3 tgtggtttnc ggtatcgccg cttccgattc gcagcgcatc gccttctatc gccttcttga 60 cgagttette tgagegggae tetggggtte gaaatgaget ageeettaag taacgeeatt 120 ttgcaaggca tggaaaaata cataactgag aatagaaaag ttcagatcga ggtcaggaac 180 agatggaaca gggtcgaccg gtcgaccggt cgaccctaga gaaccatcag atgtttccag 240 300 ggtgocccaa ggacctgaaa tgaccctgtg ccttatttga actaaccaat cagttcgctt 360 ctegettetg ttegegeget tetgeteece gageteaata aaagageeca caaccectea 420 cteggggege cagtecteeg attgactgag tegecegggt acceptgtat ceaataaace ctcttgcagt tgcatccgac ttgtggtctc gctgttcctt gggagggtct cctctgagtg 480 attgactacc cgtcagcggg ggtctttcac tctctgtgta ctggtaccaa cagagcctgg 540 accagggect ecagtteete atteagtatt ataatggaga agagagagea aaaggaaaca 600 ttcttgaacg attctccgca caacagttcc ctgacttgca ctctgaacta aacctgagct **660** 720 ctctggagct gggggactca gctttgtatt tctgtgccag cagcgtaggt ggtagcttga aacagttett egggecaggg acaeggetea eegtgetagg taagaagggg getecagtgg 780 gagagaggt gagcagccca ncctgnncga ceccanance tgttnttagg ggagtggnca 840 885 ctgggcatcc aggccctnct cnaggaancg ggttncgccn ggncc <210> <211> 900 <212> DNA

```
<213> Homo sapiens
<220>
<221> misc_feature
<222>
      (1)..(900)
<223> n is a, g, c, or t
<400> 4
```

#### PCT/US2003/037143

ttggtaactg	tcagaccaag	tttactcata	tcggatccag	ttggagccat	aagecgtcag	760
acatagaaaa	aaatctgaaa	agatatctca	aaagcccaga	catttattca	cactaacggt	120
gaaaagcata	ccccacagtg	tcagtggagg	caacatgggg	tcctggattt	ectetteace	180
ctcagtggta	gtgaggtgtt	cctctcactc	cttctgagta	gaggaagcca	agaggaaagc	240
•				ccctccacct		300
ttatcagtgg	caaccacatg	gctagtggta	-cecebecege	tectagecag	aatgatatca	360
gcagaggcct	agagagtagc	ccaaaaactc	atctgcaccc	agcaggactg	aggtttccta	420
ccccaccaa	tggaagccaa	gtgaggaacc	taageettea	cctctcactc	agcaggaacc	480
agacaacacc	ccctaacaca	cacacacaca	cacacacaca	cacacccttc	tgttagtgtg	540
gtatcaagga	ggcttgataa	aatagaagat	ttaaatagga	tccattgccc	ttatctcaaa	600
ctcttattat	gaaatcactc	ccttgagaga	gaaaaaagcc	tttttctctt	ggattgtccc	660
agcagctccc	gaccatecce	actccccaac	cttatgtggc	cccagcaatg	agcctagtag	720
taggaaaatc	tctatggata	ctggtgctga	tgggaagatt	cttcctctca	ngaagtgatg	780
gtgactgggg	ctctgggatg	ctcacgggaa	tnccatttcc	cccacaagaa	nttattttat	840
naccaaccat	ttggatgacc	cctttttntt	ccatttncca	annaatttgt	aaggncaaag	900

<sup>&</sup>lt;210> 5

WO 2004/070002

<220>

<400> 5

ttgggnancc ccccacaaag naagttattt tattacacaa ccatttggat gaccccttt 60 ttcttccaat ttcccaaata aatctgtaaa ggtcacaggt gaagttcttc tctttaagag 120 ctactccatg ctaagttcag cgagaacttg gggtacccta gacattcttc cagagatgct 180 tttcttgtaa ctcttttcaa taagtaagca tgctttgctc tgcactgggt gtcacctgtg 240 ttggatgetg ttgteeetge ettgeeetat attetgteea catggtttet teataggatg 300 atgcttaggt cagccctgag gtttgaacca gtcaacaagt ccaggttggt gtggagtccc 360 tttagtacct ccctttgcag gaataatgct gcacccagaa actccctcag agcctctcca 420 ctggaggggc cttgtgacca ttcctggttt actcctcttg ttccagcatc ccatgtggcc 480 aatgggcccc ttecattttc aatggtatct caattcttac agtaagttat attattgccc 540 tacatcgaac tcatcttttc tcagtgttac ctgaggaaga atggagagga tgcccagaat 600

<sup>&</sup>lt;211> 869

<sup>&</sup>lt;212> DNA

<sup>&</sup>lt;213> Homo sapiens

<sup>&</sup>lt;221> misc\_feature

<sup>&</sup>lt;222> (1)..(869)

<sup>&</sup>lt;223> n is a, g, c, or t

# WO 2004/070002

### PCT/US2003/037143

tggcccagaa gaatccactt cgattctaga gaaaaaggca ggtagaggca gaagagattc	660
acttcccagt gcatgcgtgc tgaatgttgg gggtgttgtt tgagagagac aaggaaatgg	720
ctgtaaaact tgggaagagg aacctgccct gggtcaagta gggtgttggg aggaccagat	780
ggagettgaa geteteteea tetttgteaa gteeeetgga etgagagggn aaaatnacat	840
ggcctttatc ctccagagga aantnattc	869
<210> 6 <211> 850 <212> DNA <213> Homo sapiens	
<220> <221> misc_feature <222> (1)(850) <223> n is a, g, c, or t	•
<400> 6 tgggggttcc ggtatcgccg cttcgattcg cagcgcatcg ccttctatcg ccttcttgac	60
gagttettet gagegggaet etggggtteg aaatgageta geeettaagt aacgeeattt	120
tgcaaggcat ggaaaaatac ataactgaga atagaaaagt tcagatcgag gtcaggaaca	180
gatggaacag ggtcgaccgg tcgaccggtc gaccctagag aaccatcaga tgtttccagg	240
gtgccccaag gacctgaaat gaccctgtgc cttatttgaa ctaaccaatc agttcgcttc	300
tegettetgt tegegegett etgeteeceg ageteaataa aagageecac aacceeteac	360
teggggegee agteeteega ttgaetgagt egeeegggta coegtgtate caataaacee	420
tettgeagtt geateegact tgtggteteg etgtteettg ggagggtete etetgagtga	480
ttgactaccc gtcagcgggg gtctttcact ctctgtgtac tggtaccaac agagcctgga	540
ccagggcctc cagttcctca ttcagtatta taatggagaa gagagagcaa aaggaaacat	600
tcttgaacga ttctccgcac aacagttccc tgacttgcac tctgaactaa acctgagctc	660
tetggagetg ggggaeteag etttgtattt etgtgeeage agegtaggtg gtagettgaa	720
acagttette gggccaggga caeggeteae egtgetaggt aagaaggggg etecaggtgg	780
gagagagggt gagcagecea neetgeaega eeecanaaee etgttettag gggagnggae	840
actgggncat	850

<sup>&</sup>lt;210> 7

<sup>&</sup>lt;211> 847 <212> DNA <213> Homo sapiens

# WO 2004/070002 PCT/US2003/037143

<220> <221> misc_feature <222> (1)(847) <223> n is a, g, c, or t	
<400> 7 ttgggggacc gcttgccaaa cctacaggtg gggtctttca agaggtctcc agacctaggg	60
gagcatotoa gogtoactog otgtocagtt gotgtgatoa ggtgotttgg ggtttgtgtg	120
actecagaat ccactgggcc tgtgtgtcag aagacaaaag ttaaccataa ggcacagaag	180
aaagcctcct gctgaagcca tcgttggccc acatgcattt cagggacaag aaatgaagat	240
cggagacttt caagttgtgc ccaggactca cctgctccca ggagacaaaa ggccacacag	300
cagaggagec tgaageceat ggeaggatet cetagettgg ggetggtgte tetgtagtaa	360
gcattctgaa gttcctaagc tcccttcttc ctgataggag cattgacctg tgatgtcacc	r420
acactgacat actttcccct gcaggccact ccagcccact gtactctttg gcaggcctca	480
ggttctgcta ctccatgtac tattcctgtc ttgcacaggc cagaagctaa aggtgaggag	540
gactgaacac agtaccaaca tacccacatc acaccttact tteetetgee egecetgtee	600
ctgccctgac actgattccc cagcccttgc caccccagcc cettcaccct ccactgcccg	660
tgcagcagca gagacactcc creettgatg caaactgagg cetetggcac cecaactett	720
tcagggcaat gatagtctgt gcttaactct acatggccag gccccactca gggaattctc	780
acctagaatt tcatatncag ccaaactaag cttcataagt gaaggggaaa taaaatgctt	840
tacagac	847
<210> 8 <211> 755 <212> DNA <213> Homo sapiens	
<220> <221> misc_feature <222> (1)(755) <223> n is a, g, c, or t	
<400> 8 ttcactncaa ggatnttaca acaggacatt ttttaaaaacc tcaaacatca ccaaaatttc	60
taagtgcaag titatitita titititit tititigaga cagagtotog cicigicaco	120
caggetagag tgcagtggca tgatettgge teactgcaac etceacetee caggitcaag	180
tgattetett geeteageet eecaagtage tagtattaca gaegeetgee accaegeeeg	240
gttaattttt gtacttttag tagagacagg tttcaccata ttggccaggc tggtctcaaa	300
3	

ctcctgacct caggtgatcc tectgectca geoteccaaa gtgctgggat tacaggcatg 360

WO 2004/070002 PCT/0	US2003/037143
agetaccaeg tetggeetaa gtgeatgtta estataetaa caaaaccaea ettet	geete 420
gaatgagaac agtotootga acatottgoo totttgootg actoaaagco toagg gootooccat aatttotagt otoagcagaa agatoaatga caggagacto tooag	
gaaattaacc aattaagtaa cctgggttgg catcctcccg tttgttcacc agctc	acctn 600
ctgccacagg tatatecttt etetcaneca tatatgcaca aacecectne ecaeg	gnaca 660
catannaana atttggaaga ctanaaaatc aggcanggtn tancncacct tgngg	getgg 720
agtatggnan cctgggccgg nacatncata cattg	755
<210> 9 <211> 839 <212> DNA <213> Homo sapiens	
<220> <221> misc_feature <222> (1)(839) <223> n is a, g, c, or t	
<400> 9 cnntntttgn gnngnnnaag aaantnenga entnngeene caaatnaact tgggg	gggna 60
accttcacta caaggatatt acaacaggac atttttaaa acctcaaaca tcacc	caaaat 120
ttctaagtgc aagtttattt ttatttttt tttttttt gagacagagt otcgo	etetgt 180
cacccagget agagtgcagt ggcatgatet tggctcactg caacctccac etce	caggtt 240
caagtgattc tcttgcctca gcctcccaag tagctagtat tacagacgcc tgcca	accacg 300
-cccggttaat ttttgtactt ttagtagaga caggtttcac catattggcc aggct	tggtct 360
caaactcctg acctcaggtg atcctcctgc ctcagcctcc caaagtgctg ggat	tacagg 420
catgagetae caegtetgge etaagtgeat gttacetata etaacaaaac caea	cttctg 480
cctcgaatga gaacagtctc ctgaacatct tgcctctttg cctgactcaa agcc	tcaggt 540
ctaageetee ccataattte tagteteage agaaagatea atgacaggag acte	tecagg 600
tgatgaaatt aaccaattaa gtaacctggg ttggcatcct cccgtttgtt cacca	agctca 660
ceteetgeca caggiatate etteeteta gecatatatg cacaaacee etce	ccacgg 720
cacacataga aanaatttgg aagactagaa aatcaggcna gggnttanca cacc	ttngag 780
ggetggagta tggnanceng ggneegggan atneathenn tngaaaaett gaet	atggg 839
<210> 10 <211> 829 <212> DNA <213> Homo sapiens	. •

<sup>7</sup> 

#### PCT/US2003/037143

#### WO 2004/070002

<220>
<221> misc\_feature
<222> (1)..(829)
<223> n is a, g, c, or t
<400> 10

tegeetteaa tegtettatt nacgagttet tetgageggg actetggggt tegaaatgag 60 ctagecetta agtaacgeca ttttgcaagg catggaaaaa tacataactg agaatagaaa 120 agttcagatc gaggtcagga acagatggaa cagggtcgac cggtcgaccg gtcgacccta 180 gagaaccatc agatgtttcc agggtgcccc aaggacctga aatgaccctg tgccttattt 240 gaactaacca atcagttcgc ttctcgcttc tgttcgcgcg cttctgctcc ccgagctcaa 300 taaaagagcc cacaacccct cactcggggc gccagtcctc cgattgactg agtcgcccgg 360 gtacccgtgt atccaataaa ccctcttgca gttgcatccg acttgtggtc tcgctgttcc 420 ttgggagggt ctcctctgag tgattgacta cccgtcagcg ggggtctttc agtagccctt 480 cctttgtagc aaagacagac agatggtgat ccaagagata cgcaagaaga ggaccgtgtg 540 600 tgtcatggtt gagctctaaa aaagagaaat cacttggatg gaantgaagg agaggaaaag gctgatgtgg atggcctgga agangttcga ttggttacct tggcaccgag cttccttcct 660 catecteatn cetecetagt cettgttett aaaaanantt ttettetaa ngteeettee 720 780 ccctccncaa gggggcacaa ggatntttaa aaaacncctt tccgggcnta attttaacct angatecate ecagnecegt ncenntttte nnagatteat ttaaacnng 829

<210> 11 <211> 710 <212> DNA

<213> Homo sapiens

<220>
<221> misc\_feature
<222> (1)..(710)
<223> n is a, g, c, or t

<400> 11
ttttttgcnn taccgtatcg ccgctntcga ttcgcagcnc atcgccttct atcgccttct 60
tgacgagttc ttctgagcgg gactctgggg ttcgaaatga gctagccctt aagtaacgcc 120
attttgcaag gcatggaaaa atacataact gagaatagaa aagttcagat cgaggtcagg 180
aacagatgga acagggtcga ccggtcgacc ggtcgaccct agagaaccat cagatgttc 240
cagggtgccc caaggacctg aaatgaccct gtgccttatt tgaactaacc aatcagttcg 300
cttctcgctt ctgttcgcgc gcttctgctc cccgagctca ataaaagagc ccacaacccc 360
tcactcgggg cgccagtcct ccgattgact gagtcgccg ggtacccgtg tatccaataa 420

WO 2004/070002	PCT/US2003/037	143
accetettge agttgcatee gaettgtggt etegetgtte ettgggaggg	tetectetga	480
gtgattgact accepteage gggggtettt cagtagecet teetttgtag	caaagacaga	540
cagatggtga tocaagagat acgcaagaag aggaccgtgt gtgtaatggt	tgagctctaa	600
aaagagaaat cacttggatg gaaatgaagg agaggaaagg ctgatgtgga	tggctgggaa	660
gaggttcgat ggttaccttg gcanccganc ttcnttnctn atncccatcc		710
		•
∵<210> 12 <211> 752		
<212> DNA <213> Homo sapiens		
<pre>&lt;220&gt; &lt;221&gt; misc_feature</pre>		
<222> (1)(752)		
<223> n is a, g, c, or t		
<pre>&lt;400&gt; 12 ttgggaaccg tcagnaccaa gttttnctca tatcggctcc cttctggtcc</pre>	cacatcactc	60
aggcaactet etetteecae etgeceeca aactecette caceteecte	cacatgtatc	120
ctcccacttc cttccactca tgtaatgaga ggtgctgatg agtcacagga	gaggtagecc	180
tagataacca acagactgca aaacggacag teeetggatg tetgagecag	tgtttgtgca	240
ctgcattgac tggctcctcg tagttttttc ctgtagttgc taaagcctgt	aaggtctgtg	300
tgatgaatat tttctaacac atcttagaag aacataatgc aagacagaat	gaaaaactag	3 <del>6</del> 0
agaggcagaa acccccaaag taagtagtgg gaaattacca ggtatataat	aggtcaagcc	420
tgctctgcag gagctcaagg gattgtagca ttcttatccc aaaccactga	atcctgggca	480
aaaataagaa gtegeetaat tttagtatta eeagetteee aaceeeggge	: attetteate	540
ttactcaagc tgtccagagg ccccagggtg actccctata agtcccatgg	gtggctgaga	600
tctatttaga ggcacaaggg tatctnctta taagtccaat ggggnggctg	, agatetatga	660
gaagcatctt gggggagagt gccntttggc caccagcatg tggnccctna	attttncatg	720
nnncaactgg nccngggaag gaaaantttt ga		752
010. 13		
<210> 13 <211> 749		
<212> DNA		
<213> Homo sapiens		
<220>		
<221> misc_feature		
<222> (1)(749) <223> n is a, g, c, or t		

WO,2004/070002 PCT/US2003/037143

13						
gcg	ntaccgtatc	gecgetntng	attcgcagcg	catcgccttc	tategeette	€0
agtt	cttctgagcg	ggactctggg	gttcgaaatg	agctagccct	taagtaacgc	120
gcaa	ggcatggaaa	aatacataac	tgagaataga	aaagttcaga	tcgaggtcag	180
atgg	aacagggtcg	accggtcgac	cggtcgaccc	tagagaacca	tcagatgttt	240
tgcc	ccaaggacct	gaaatgaccc	tgtgccttat	ttgaactaac	caatcagttc	300
cgct	tetgbtegeg	cgcttctgct	ccccgagctc	aataaaagag	cocacaaccc	360
cggg	gcgccagtcc	tccgattgac	tgagtcgccc	gggtacccgt	gtatccaata	420
cttg	cagttgcatc	cgacttgtgg	tctcgctgtt	ccttgggagg	gteteetetg	480
tgac	tacccgtcag	cgggggtctt	tcagtagccc	ttcctttgta	gcaaagacag	540
ggtg	atcçaagaga	tacgcaagaa	gaggaccgtg	tgtgtaatgg	ttgagcttta	600
gaga	aatcacttgg	atggaaatga	agganaggaa	aaggcntgat	ntngatngcn	660
nagg	ttccatnggt	nnctttggnn	ancegannet	tnettteetn	ateccentne	720
tann	necntnnttn	ttaaaaaag				749
	ggcg agtt gcaa atgg tgcc cgct cggg ttgac ggtg gaga nagg	ageg ntacegtate agtt cttetgageg geaa ggeatggaaa atgg aacagggteg tgee ceaaggacet eget tetgtegeg eggg gegeeagtee ettg cagttgeate tgae tacegteag ggtg atecaagaga gaga aateaettgg nagg ttecatnggt	ageg ntacegtate geogething agtt ettetgageg ggactetggg gcaa ggeatggaaa aatacataac atgg aacagggteg aceggtegac teeggtegeet tetgteegeg egettetget eggg gegeeagtee teegategac ettg cagttgcate egggtgatett egge taceegteag egggggtett gge atccaagaa tacgcaagaa gaga aatcacttgg atggaaatga	ageg ntacegtate geogething attegrageg aget ettetgageg ggaetetgag gttegaaatg geaa ggeatggaaa aatacataac tgagaataga attgg aacagggteg aceggtegac eggtegacee tgtgee ecaaggacet gaaatgacee tgtgeettat eggt tetgategeg egettetget eeeggg gegecagtee teegattgae tgagtegeee ettg eagttgeate eggtgggtet teegetgt tetgae taceegteag eggtggtett teagtageee eggtg atecaagaga tacgcaagaa gaggaeegtg gaga aateaettgg atggaaatga agganaggaa nagg tteeatnggt nnetttggnn aneegannet	ageg ntacegtate geogething attegrages categorite aget citetages gracetry gitegraat agetageert graa graatgaaa aatacataac tragaataga aaagticaga attegraa aacaggeteg aceggitegrace tragagaacea tragec ccaargacet graatgacec tragagacea tragec ccaargacet graatgacec tragagacea aataaaagag geogg geogragice teegategrace tragagacec tragagacea coggi geogragice teegategrace tragagacec graatgace tragagacec graatgacec tragagacec graatgacec tragagacec graatgacec tragagacec graatgacec tragagacec graatgacec tragagacec graatgacec tragagacec graatgacec tragagacec tragagacec graatgacec aataaaagagacec graatgacec tragagacec tragagacec graatgacec aacagagacec graatgacec graatgacec tragagacec graatgacec graatgacec aacagagacec graatgacec aacagagacec graatgacec aacagagacec graatgacec aacagagacec graatgacec aacagagacec graatgacec aacagagacec graatgacec aacacagagacec graatgacec aacagagacec graatgacec aacagagacec graatgacec aacagagacec aacagagacec graatgacec aacagagacec graatgacec aacagagacec graatgacec aacagagacec graatgacec graatgacec aacagagagacec graatgacec g	aged ntacegtate geogething attegraged categorite tategorite aget citetagged gracetrong grands agetageorite tategorite aget citetagged gracetrong grands agetageorite tategorite agetageorite agetageorite tategorite agetageorite accaded to agetageorite tategorite accaded to agetageorite tategorite accaded to agetageorite tategorite aget to agetageorite aget

<210> 14 <211> 794

<212> DNA

<213> Homo sapiens

<220>

<221> misc\_feature

<222> (1)..(794)

<223> n is a, g, c, or t

<400> 14 tttttttgcg ntaccgtatc gccgctntcg attcgcagen catcgccttc tatcgccttc 60 ttgacgagtt cttctgagcg ggactctggg gttcgaaatg agctagccct taagtaacgc 120 cattttgcaa ggcatggaaa aatacataac tgagaataga aaagttcaga tcgaggtcag 180 gaacagatgg aacagggtcg accggtcgac cggtcgaccc tagagaacca tcagatgttt 240 ccagggtgcc ccaaggacct gaaatgaccc tgtgccttat ttgaactaac caatcagttc 300 getteteget tetgttegeg egettetget eecegagete aataaaagag eecacaacee 360 ctcactcggg gcgccagtcc tccgattgac tgagtcgccc gggtacccgt gtatccaata 420 aaccetettg cagttgcate cgaettgtgg tetegetgtt cettgggagg gteteetetg 480 agtgattgac tacccgtcag cgggggtctt tcagtagccc ttcctttgta gcaaagacag 540 acagatggtg atccaagaga tacgcaagaa gaggaccgtg tgtgtaatgg ttgagctcta 600 aaaaagagaa atcacttgga tggaaatgaa ggagaggaaa aggctgatgt ggatggctgg 660

# PCT/US2003/037143

gaagaggttc gatggttacc ttggcaaccg agctecettn ctcatnccca tecetnecta	720
gtccttgttc tttaaaaaga ttttntttnt aatgtccctt nccctccaca agggggcaca	780
agatgttttn aaac	794
<210> 15 <211> 784 <212> DNA <213> Homo sapiens	
<220> <221> misc_feature <222> (1)(784) <223> n is a, g, c, or t	
<400> 15 ccttggnggg naanacggnt aacaatttt acacaggaat tactacaaaa gactctacta	· ·•60
agttctcagg gngascaaaa aattgtatgt gtgcagaacc tgtgatttgc ctgcacatag	120
tcaagttctc aatgtatgga tgtcccggcc caggctacca tactccagcc ctcaaggtgt	180
gctatacett gcctgatttt ctagtettee aaattettet atgtgtgeeg tggggagggg	240
gtttgtgcat atatggctga gagaaaggat atacctgtgg caggaggtga gctggtgaac	300
aaacgggagg atgccaaccc aggttactta attggttaat ttcatcacct ggagagtctc	360
ctgtcattga tctttctgct gagactagaa attatgggga ggcttagacc tgaggctttg	420
agtcaggcaa agaggcaaga tgttcaggag actgttctca ttcgaggcag aagtgtggtt	480
ttgttagtat aggtaacatg cacttaggcc agacgtggta gctcatgcct gtaatcccag	540
cactttggga ggctgaggca ggaggatcac ctgaggtcag gagttttgag accagectgg	600
ccaatatggg ggaaaacctg tetetactaa aaagtacaaa aattaacccg gncgtnggng	660
gcaggnnntc tgtaatacta nnctacttgg ggngntgnag gcaanaaaat cantttgaac	720
ctnggnaggg gggngnttgc aatnnnccna aaaanatgcc cnntggncct ttaaccntgg	780
gngn	784
<210> 16 <211> 757 <212> DNA <213> Homo sapiens	
<220> <221> misc_feature <222> (1)(757) <223> n is a, g, c, or t	
<400> 16	

# WO 2004/070002 PCT/US2003/037143

tcctgggccc	ncttgccaaa	ccttcaggtg	gggtctttca	ctacaagata	gtacaacagg	40
acattttta	aaacctcaaa	catcaccaaa	atttctaagt	gcaagtttat	ttttatttt	120
ttttttt	ttttgagaca	gagtctcgct	ctgtcaccca	ggctagagtg	cagtggcatg	180
atcttggctc	actgcaacct	ccacctccca	ggttcaagtg	attctcttgc	ctcagcctcc	240
caagtagcta	gtattacaga	cgcctgccac	cacgcccggt	taatttttgt	acttttagta	300
gagacaggtt	tcaccatatt	ggccaggctg	gtctcaaact	ectgacetca	ggtgatcctc	360
-ctgcctcagc	ctcccaaagt	gctgggatta	caggcatgag	ctaecaegte	tggcctaagt	420
gcatgttacc	tatactaaca	aaaccacact	tctgcctcga	atgagaacag	tctcctgaac	480
atcttgcctc	tttgcctgac	tcaaagcctc	aggtctaagc	ctccccataa	tttctagtct	540
					•	,
tgggttggca	tectecegtt	tgttcaccag	ctcacctnct	gncacaggta	tatnetttt	660
tetnagecat	atatgcccaa	ancecetne	ccacggnaca	catngaagaa	nttnggaaga	720
ctngaaaatc	aggccagggt	tnngcccacc	ttgnggg			757

<sup>&</sup>lt;210> 17

<220>

<221> misc\_feature

<222> (1)..(783)

<223> n is a, g, c, or t

<400> 17 annaacttga atgacccctc tngccaaatc cttagggggg ggtccttcac tacaagatag 60 tacaacagga cattititt aaccinaaac attaccacaa attictaagi gcaagiitat 120 ttttattttt tttttttt ttgagacaga gtctcgctct gtcacccagg ctagagtgca 180 gtggcatgat cttggctcac tgcaacctcc acctcccagg ttcaagtgat tctcttgcct 240 cagoctocca agtagotagt attacagacy cotgocacca cgcccggtta atttttgtac 300 ttttagtaga gacaggtttc accatattgg ccaggctggt ctcaaactcc tgacctcagg 360 tgatcctcct gcctcagcct cccaaagtgc tgggattaca ggcatgagct accacgtctg 420 gectaagtge atgttaceta tactaacaaa accacaette tgeetegaat gagaacagte 480 tectgaacat ettgeetett tgeetgaete aaageeteag gtetaageet eeccataatt tctagtctca gcagaaagat caatgacagg agactctcca ggtgatgaaa ttaaccaatt 600 aagtaacctg ggttggcatc ctcccgtttg ttcaccagct cacctcctgc cacaggtata 660 tecttetet cagecatata tgcacaaace ecetneceae ggcacacata gaagaatttg 720

<sup>&</sup>lt;211> 783

<sup>&</sup>lt;212> DNA

<sup>&</sup>lt;213> Homo sapiens

	gaagactaga aaatcaggca nggtatagca cacettggag ggctggagta tggtageetg '	780
:	, , , , , , , , , , , , , , , , , , ,	783
,	<210> 18 <211> 770	
	<212> DNA	
: (	<213> Homo sapiens	
:	<pre>&lt;220&gt;</pre>	
	<221> misc_feature	
	<222> (1)(770) <223> n is a, g, c, or t	
	<400> 18	
	teegggnnee gettgeeaaa eetteaggtg gggtetttea etacaagata gtacaacagg	60
	acatttttta aaacetcaaa catcaccaaa atttctaagt gcaagtttat ttttattttt	120
	ttttttttt ttgagacaga gtctcgctct gtcacccagg ctagagtgca gtggcatgat	180
	cttggeteac tgcaacetec aceteceagg ttcaagtgat tetettgeet cageeteeca	240
	agtagctagt attacagacg cctgccacca cgcccggtta atttttgtac ttttagtaga	300
	gacaggtttc accatattgg ccaggctggt ctcaaactcc tgacctcagg tgatcctcct	360
		420
	atgttaccta tactaacaaa accacacttc tgcctcgaat gagaacagtc tcctgaacat	480
	cttgcctctt tgcctgactc aaagcctcag gtctaagcct ccccataatt tctagtctca	540
	gcagaaagat caatgacagg agactctcca ggtgatgaaa ttaaccaatt aagtaacctg	600
	ggttggcatc ctcccgtttg ttcaccagct cacctnctgc cacaggtata tccttttct	660
	tagecatata tgeacaaace ceetteecac ggnacacata gaaaaatttn ggaagactag	720
	aaaatcaggc agggtntagc acaccttngn gggctnggag tntnggtanc	770
	<210> 19	
	<211> 774	
	<212> DNA <213> Homo sapiens	
	·	
	<220> <221> misc_feature	
	<222> (1)(774)	
	<223> n is a, g, c, or t	
	<pre>&lt;400&gt; 19 tccgggmcnc gcttgccaaa ccttcaggtg gggtctttca ctacaagata gtacaacagg</pre>	60
	acattttta aaacctcaaa catcaccaaa atttctaagt gcaagtttat ttttatttt	120
	ttttttttt ttgagacaga gtctcgctct gtcacecagg ctagagtgca gtggcatgat	180
		🕶

WO,2004/070002 PCT/US2003/037143

4	cttggctcac	tgcaacctcc	acctcccagg	ttcaagtgat	tetettgeet	cagcetecca	240
ŕ	igtagetagt	attacagacg	cctgccacca	.cgcccggtta	atttttgtac	ttttagtaga	300
•	gacaggtttc	accatattgg	ccaggctggt	ctcaaactcc	tgacctcagg	tgatcctcct	360
•	geeteageet	cccaaagtgc	tgggattaca	ggcatgagct	accacgtetg	gcctaagtgc	420
i	atgttaccta	tactaacaaa	accacacttc	tgcctcgaat	gagaacagtc	tectgaacat	480
•	cttgcctctt	tgcctgactc	aaagcctcag	gtctaagcct	ncccataatt	tctagtctca	540
	gcagaaagat	caatgacagg	agactctnca	ggtgatgaaa	ttaaccaatt	aagtaacctg	600
:	ggttggcatc	ctcccgtttg	ntcaccagnc	tnacctnctg	ncacaggnat	atnettttnt	660
	ttnagccata	tntgcacaaa	cccctnccc	acggnacaca	tagaaaaant	tnggnagact	720
	ngaaaattca	ggncagggnt	tagenenece	ttgggggnnt	ggnntntngg	aacc	774

<210> 20

<211> 914

<212> DNA

<213> Homo sapiens

<220>

<221> misc\_feature

<222> (1)..(914)

<223> n is a, g, c, or t

tggggntncc ggtatcgccg cttccgattc gcagcgcatc gccttctatc gccttcttga 60 cgagttcttc tgagcgggac tctggggttc gaaatgagct agcccttaag taacgccatt 120 ttgcaaggca tggaaaaata cataactgag aatagaaaag ttcagatcga ggtcaggaac 180 agatggaaca gggtcgaccg gtcgaccggt cgaccctaga gaaccatcag atgtttccag 240 ggtgececaa ggacetgaaa tgaceetgtg cettatttga actaaccaat cagttegett 300 360 ctcgcttctg ttcgcgcgct tctgctcccc gagctcaata aaagagccca caacccctca 420 cteggggcgc cagtectecg attgactgag tegecegggt accegtgtat ecaataaace 480 ctcttgcagt tgcatccgac ttgtggtctc gctgttcctt gggagggtct cctctgagtg attgactacc cgtcagcggg ggtctttcac tctctgtgta ctggtaccaa cagagcctgg 540 accagggcct ccagttcctc attcagtatt ataatggaga agagagagca aaaggaaaca 600 660 ttettgaacg atteteegea caacagttee etgacttgea etetgaacta aacetgaget ctctggagct gggggactca gcttttgtat ttctgtgcca gcagcgtagg tggtagcttg 720 aaacagttct tcngggccag gggacncggc tnaccgggnn aggtaagaag ggggcctcca 780

840

ggtgggaaan aagggtgagc agnccanccc tgcacgaccc nnnaaccnin tictagggg

WO 2004/070002 PCT/US2003/037143

gagggmnca	ctgggncatn	ncagggccnt	cntngnggaa	nnggggtttg	cgccnagggt	900
ccccagggct	gngc					914

<210> 21

<211> 1604

<213> Homo sapiens

<220>

<221> misc\_feature

<222> (1)..(1604)

<223> n is a, g, c, or t

<400> 21

60	tgatgtcaca	cagtaaatgt	cacagnaatt	aacaatttca	gtgagcggat	gngtggnatt
120	tagtataagc	aactggcttt	tctacctgaa	tacattcaac	cagctctagc	ttgggggcag
180	ttggataatt	ttcagcattt	aacaagtaat	gctagtttac	taacacatag	catggatcca
240	agaaaatagg	gaactgtgtc	gcatgatact	taaggagcct	cgacaatttc	acattccctc
300	agtaaaatgc	atggaattat	cttttttact	tctaatcagg	aatatgtgat	tgctacagtg
360	aagggaagca	atctctaatg	gectatactt	attgctctgt	actcatataa	actataatca
420	tttataggca	ggtatggaag	tgattacaaa	taaaagaaaa	cctgaaatta	aattgcctta
480	tatttatcca	aaaaaattcc	tatagatggc	ttatgcatta	cctgatttta	tcttataaga
540	tttttatgtg	tgggaatttg	atgtgtttca	ctcaaataaa	gaccaggaag	gaatctaaat
600	tgctcacaca	gaaacatgaa	gatcatcaaa	gggtctttaa	agatcctgaa	ctgaattgca
660	tgacagctgc	cctgtccatt	catggcccaa	gtggagttca	tgtaagaggt	actttagagc
720	cgagacctgg	tgtgacaaag	ccaatgaatt	catggcttgc	caggggagag	gtgctgagcc
780	ctaggkgnaa	ttgtgctcta	aaatgggtct	yataccccac	cagtttccct	rgnnaccttt
840	cctaatttat	ttagaaattt	ttctaantyc	cttttgtgta	taccacagne	tggtattaaa
900	getecettee	atatcttaga	atacaccatg	aaatttcagc	mcccttgcta	gcatgggycc
960	ttccccatta	atcatctgta	atttaaaaaa	cattttcacg	tctctcttag	cacttaatct
1020	gaatcaccta	attcactgct	tttttttt	caaataactt	ttcctaagga	gcaggcaaga
1080	aaaaaaaatg	gttgaatgaa	agaaatagtt	tgagaggttg	cagcacaaag	gaacggtacc
1140	cattttttat	cagaataccc	actgcattat	aaatcccatc	gataatcctc	aatcgtttat
1200	aaggctgagg	ggcattttac	tgatgtgcca	ccagaacttc	tgacactttt	gtcatctatt
1260	aggtgatect	gcttaattta	cattcaggga	ttattttatt	agtaataggo	tgaaccacag
1320	agactgtagc	ttaattctgc	tcttatcago	caatgtcatc	cctcctaatg	attattgtaa

WO,2004/070002 PCT/US2003/03	7143
tatgtattac tecctgaagg aattattttc aocttcaacc tgaagttagg actcatgatt	1380
dagcaatotg ottootggga toatacaagg gaaattgcaa totttgtgot tgottgccaa	1440
agctgagaaa gatggagcag natcaaaata agcaggattt gccaggcaat tttgacatat	1500
tetteetete acatataace ateacaaagt aatgeattte ataatgagaa ganeettgea	1560
ctagaagcat acatagtatc acatgnetea tettetngnt tetn	1604
<210> 22	
<212> DNA	
<213> Homo sapiens	
<pre>&lt;220&gt; &lt;221&gt; misc_feature</pre>	
<222> (1)(844)	
<223> n is a,'g, c, or t	
<400> 22	
ttggggance gettgeeaaa entteaggtg gggtetttea agaggtetee agaeetaggg	60
gagcatctca gcgtcactcg ctgtccagtt gctgtgatca ggtgctttgg ggtttgtgtg	120
actccagaat ccactgggcc tgtgtgtcag aagacaaaag ttaaccataa ggcacagaag	180
aaagcctcct gctgaagcca tcgttggccc acatgcattt cagggacaag aaatgaagat	240
cggagacttt caagttgtgc ccaggactca cctgctccca ggagacaaaa ggccacacag	300
cagaggagee tgaageeeat ggeaggatet eetagettgg ggetggtgte tetgtagtaa	360
gcattctgaa gttcctaagc tcccttcttc ctgataggag cattgacctg tgatgtcacc	420
acactgacat actiteccet geaggeeact ecageeeact gtactetitg geaggeetea	480
ggttctgcta ctccatgtac tattcctgtc ttgcacaggc cagaagctaa aggtgaggag	540
ctgccctgac actgattccc cagcccttgc accccagccc cttcaccctc cactgcccgt	660
gcagcagcag agacactece teettgatge aaactgagge etetggcace enactetite	720
agggcaatga tagtotgtgo ttaactotac atggccaggo cocactoagg gaattottat	780
gaaattatta tittitinta titcigggaa acaaagcgat gtatitatit cigitinggg	840
gata	844
<del>5</del>	
<210> 23	
<211> 1562	
<212> DNA <213> Homo sapiens	
-513. Homo adviena	
<220>	•
<221> misc_feature	

# WO 2004/070002

<222> (1)..(1562)

<223> n is a, g, c, or t

<400> 23 60 ttttacanaa ctnnccccc tnaatcaaca gaatatacat tttnttnagc cccncaatac acttattcta aantgnccca cataatngga agtaaaccac tcagcaaata taaagancag 120 aaatcccanc aaactgtctc tcagaccaca gtgcaatcaa attagaactc agggttaaga 180 240 atcacactca aaaccacaca actacatgga aactgaacaa octgctcctg aatgactact gggtaaataa tgaaatgaag gcagaaataa acacgttett tgaaaccaac tagaacaaag 300 acacaatgta ccagaatctc tgggacacat ttaaagcagt gtgtagaggg aaatttatag 360 cactaaatgc ccacaagaga aagcaggaga gatctaaaat cgacatccta acatcacaat 420 taaaagaact agagaagcaa gagcaaacat attcaaaagc tagcagaaga cgagadataa 480 540 ctaagatcag agcagaactg aaggagatag agacacaaaa aaaaccttca aaaattaatg aatgcaggag ctggtttttt gaaaagatca acaaaatagc cctctagcaa gactaataaa 600 660 ggataaaaga gggaagaatc aaatagatgc aataaaaatg ataaagggga tatcaccacc aatcccmcmg aaatacaaac taccmtcaga gaatactata aacmcctgta tgcaaataaa 720 ctagaaaatc tagaagaagc agataaattc ctggacacat acaacctccc aagactaaac 780 840 . caggaagaag ttgaatctct gaatagacca ataataggtt ctgaaattga ggcaataatt 900 aataqcctac caaccaaraa aagtcgagga ccagatggat tcacagccgt attctaccag 960 aggtacaaag aggagctggt accatteett etgaaactat tetgateaat gagaaaaaag 1020 ggaatectee etaacteatt tatgaggeta geateateet gataceaaag eetggeagag acacaacaaa aaaagaaaat ttcaggccaa tatccctgat gaacattgat gtgaaaatcc 1080 tcaatacaat actggcaaat caaaaagctt atccaccacg atcaagtcag cttcatcgct 1140 1200 gggatgcaag totggttcaa catatgcaaa toaataaaca aaatccatca cataaacaga 1260 accaatgaca aaaaccacat gattatctca atagatgcag aaaaggcctt caacaatatt caacagcett teatgetaaa aacteteaat aaactagata ttgatggaac atateteaac 1320 1380 ataataagag ctatttatga caaacccata gccaatatca tactgaatgg gcaaaaaactg 1440 gaagcattcc ctttgaaaac cagcacaaga caaggatgcc ctctttcacc acttcgattc aacctagtat tggaagttet ggccagggcc atcaagcaag agaaagcaat aaggggtatt 2500 caagtaggaa gagaggggnt ttctgtgtga aaangttanc cgctggnnan ccccaaanan 1560 1562 aa

<210> 24 <211> 1446

#### WO 2004/070002

<212> DNA

<213> Homo sapiens

<220>

<221> misc\_feature

<222> (1)..(1446)

<223> n is a, g, c, or t

<400> 24 60 ttggtactgt cagaccaagt ttactcatat cggatccgag gagcaggcgg gcctgaggcc gagtcagctg cgcgggcccc cggatoctgg gctgtcatgt aacatcttcc aataaatgtg 120 atcttgggag gagaccattt tgggccttgg tttccacatc tgcgaaatgt tattatagcc 180 atgaacactt actgaaagct taccccatat gccagacaca tcttccaatc aacttatgtg 240 agttatetea tttaatttte acaacaatae aaagtagegg ggaaaaette tggettetet ,300 tgaaaactca gaaaatctaa caatgttgag tatgagtcca aaatgtcagc aagaagccag 360 agctgaatag ggaaggctgt tttagatgag accattagcc acagacctca ccactcttct 420 tactgtgcta cttatttcct ttatagtacc tgagtggttc ctgctgcgtg tgggtttgtg 480 gcccctgcat tagatggncc ttnatnattc ctcttcaccc ctgagctttg atgttttttg 540 600 ctccatgtca ccttcaccag agtggtcagg ccattcttca atattcwkac ctrggcaaaa 660 ggtgcatgac tttgaactcc cctagttaag ttaaggcttc takaawgaac angannangc tttgggagct gaggaagggt gctcactgtg ccctataaaa tagagtttca atagacactg 720 ggtectetgt ggeetgaeet eccetgtgte ageaacttga gteteaettg aatggggaaa 780 gaaagtawtg arangaaakg aacwwkgaam ytcwgaaaca ngacctettm akanswarcm 840 aggreectms tagtetanyt wrggtaaage caagtgtgae eetaaggeaa gttaettaae 900 ctctgcgtct cagtttcctc atctataagt taatgacaac ctctacccca taagggagct 960 tgaaagaaaa tccaaaaaag aaagaatctc tttgagttgc taatgactct taagtttctg 1020 1080 gttctagtcc tttgaccatc atgacagtcc tatggtttta cgaaagaact atccatctct atttaaaaaa caaaaaacac aaagaccttt tttgcttaag ctaacttgtg ttgggtttca 1140 tecaecagga agttagagag agaaattaet tagagataaa ettaeacatt acaaateett 1200 ctgttctgtg tgcttttaaa aatgttcaat ttctaaatgg gcctctggtg aagataatga 1260 tracetratt gatttgtter caggagaara gggtaaaatg aagteetget gatcacattt 1320 1380 tetaaatett tttanteeca ttgetttggg aaagttteta caecagtnat eettntacag cctcctctt teccatggtt cnttctctgc accaccagga aaggaggaat cccanancag 1440 1446 tcttgc

60 .

, s		
<b>&lt;210&gt;</b>	25	
<211>	840	
<212>	DNA	

WO 2004/07000

· <220>

<213>

<221> misc\_feature

<222> (1)..(840)

:<223> n is a, g, c, or t

Homo sapiens

<400> 25

ggaattgnna gcggntaaca atttcacaca gnaattctta ttatggtaag ttcctgagat ttgagatggt ttgttataca acagggaact gataggctta ttcttcaaga ggagcaaaac 120 agggatgatt getattetet teaatgggtt gaggaaagaa gaaattatgt gaacatttat 180 acactaataa tttattctgt catatttcag tcagattaaa gcaaacagcc aaaaacaagg 240 acaaagtcca aggtaagaga ctgatgataa gtggcctgtt tacaaggaaa ataagatcac 300 tagetetaet taeagetgat teagaataae tteattttta aageetaaaa ttttaeagte 360 aagctettga gtgcaattte ettaacattt tetaaaccat acagaaaate ataaagaaac 420 aatatttctt tgtttgagtt tootttttag gagttaggto ttattttaaa aatattttot 480 agcctgttta ggctcttatt taaaattatc tacttttctc aaagtctttc tcatacttga 540 gatatecaaa atattgaatg agtgatgtaa actataccag ataaactatg agtetatatt 600 tttaccctga ttcagtcagt ttccaaggag aactttgaac aactaaaaat gtgtattact 660 ataatctctc tgaaatattn ctnattaatt ttttgggggn aaaatgagtc attctgagcc 720 aaaaaaaaa anggtnacca gacantttcc actnctaact tgnntgggcg attncagcag 780 attcaanttc cagcatnggn agatncggna gatnnnggnc ctaccatgan cttaccttcc 840

<210> 26

<211> 861

<212> DNA

<213> Homo sapiens

<220>

<221> misc\_feature

<222> (1)..(861)

<223> n is a, g, c, or t

**<400> 26** 

ttttnctcct aacttgagtt ggcgatatca gcagattcaa attaccagca atgggaagat 60 acaggaagat gtaggtacct accaatgagc ttaccttecc agtgetetat ataaccteac 120 ttctatagcc caaagtatta aaaagaagaa aaaataataa ttcaggctta ctatttaaaa 180 atacagtgat tetggeeggg caeggtgget caegaetgea ateceageae tttgggagge 240

),2004/070002 PCT	CT/US2003/037143
-------------------	------------------

ggatcacgtg	aggecaggag	tttgagacca	gcctggccaa	tgtggtgaaa	300
actaaaaata	caaaaattag	ctgggcatgg	tggcgggcgc	ctgtaatecc	360
gaggttgaga	tgggagaatt	gcttggaccc	aggaggcaga	gcttgcagtg	420
gcaccactgc	attccaecct	gggtgacaga	gtgagaccct	gtctcaaaaa	480
atacagtgat	tctgagaggc	cttccctttc	cacaecaect	cctacttgtt	540
catcccattt	tcctcaactg	ccacatatgg	ccaggacttc	cacagtgtat	600
ctttggacaa	gagaaatttc	actgaagcaa	tgagtgtaga	agttattagc	660
gactgatgct	ggcacacaaa	tagggagaca	catcaatata	atgacctaat	720
atagcttcan	gaantntgga	aaagtagatg	tgataaaagn	-tgcatttnaa	780
aagtnttaat	anaattgaga	cacctatgtn	gctattngga	aacattaang	840
antngaaact	t				861
	actaaaaata gaggttgaga gcaccactgc atacagtgat catccattt ctttggacaa gactgatgct atagcttcan aagtnttaat	actaaaata caaaaattag gaggttgaga tgggagaatt gcaccactgc attccaccct atacagtgat tctgagaggc catcccattt tcctcaactg ctttggacaa gagaaattcc gactgatgct ggcacacaaa atagcttcan gaantntgga	actaaaata caaaaattag ctgggcatgg gaggttgaga tgggagaatt gcttggaccc gcaccactgc attccaccct gggtgacaga atacagtgat tctgagaggc cttccctttc catccattt tcctcaactg ccacatatgg ctttggacaa gagaaatttc actgaagcaa gactgatgct ggcacacaaa tagggagaca atagcttcan gaantntgga aaagtagatg aagtnttaat anaattgaga cacctatgtn	actaaaata caaaaattag ctgggcatgg tggcgggcgc gaggttgaga tgggagaatt gcttggaccc aggaggcaga gcaccactgc attccacct gggtgacaga gtgagaccct atacagtgat tctgagaggc cttccctttc cacaccacct catccattt tcctcaactg ccacatatgg ccaggacttc ctttggacaa gagaaatttc actgaagcaa tgagtgtaga gactgatgct ggcacacaaa tagggagaca catcaatata atagcttcan gaantntgga aaagtagatg tgataaaagn aagtnttaat anaattgaga cacctatgtn gctattngga	ggatcacgtg aggecaggag tttgagacca gectggecaa tgtggtgaaa actaaaaata caaaaattag ctgggcatgg tggcgggege ctgtaatecc gaggttgaga tgggagaatt gettggacce aggaggcaga gettgeagtg geaceaetge attecaeet gggtgacaga gtgagaeeet gteteaaaaa atacagtgat tetgagagge etteeettte cacaeeaeet eetaettgtt cateeatt teeteaaetg eeacatatgg eeaggaette eacagtgat ettggacaa gagaaatte aetgaageaa tgagtgtaga agttattage gactgatget ggeacacaaa tagggagaea eateaataa atgaeetaat atagettean gaantntgga aaagtagatg tgataaaaagn tgeattnaa aagtnttaat anaattgaga eacetatgtn getattngga aacattaang antngaaaet t

<210> 27 <211> 875

<212> DNA .

<213> Homo sapiens

<220>

<221> misc\_feature

<222> (1)..(875)

<223> n is a, g, c, or t

<400> 27 ttgggnnacc gcttgccaaa cctacaggtg gggtcttca agaggtctcc agacctaggg 60 gagcatetea gegteacteg etgtecagtt getgtgatea ggtgetttgg ggtttgtgtg 120 actccagaat ccactgggcc tgtgtgtcag aagacaaaag ttaaccataa ggcacagaag 180 aaageeteet getgaageea tegttggeee acatgeattt cagggacaag aaannnagat 240 cggagacttt caagttgtgc ccaggactca cctgctccca ggagacaaaa ggccacacag 300 cagaggagcc tgaagcccat ggcaggatct cctagcttgg ggctggtgtc tctgtagtaa 360 gcattctgaa gttcctaagc tcccttcttc ctgataggag cattgacctg tgatgtcacc 420 acactgacat actttcccct gcaggccact ccagcccact gtactctttg gcaggcctca 480 ggttctgcta ctccatgtac tattcctgtc ttgcacaggc cagaagctaa aggtgaggag 540 gactgaacac agtaccaaca tacccacatc acaccttact ttectctgcc cgccctgtcc 600 etgecetgae actgattece cagecettge caececagee cetteacect ecactgeceg 660 tgcagcagca gagacactcc ctccttgatg caaactgagg cctctggcac cocaactctt 720 tcagggcaat gatagtctgt gcttaactct acatggccag gcccccactc agggaattct 780

# WO 2004/070002 PCT/US2003/037143

aatatgaatg taaactncag gtgttgncag ctagtgcttc cntggaaaan cccctgttnc	840
agetnetaca catgetetta tetntagetn ganca	875
<210> 28 <211> 901 <212> DNA <213> Homo sapiens	
<220> <221> misc_feature <222> (1)(901) <223> n is a, g, c, or t	
<400> 28 ctnettetng ggngtnnnnn nacnatntan nnnnategne tenacantnn nttnennggg	60
aaaaacctct gtctaacctt acatgaaaaa acccgtttcc aacgaaggcc tctaagaggc	120
caagatatcc acttgcagac tttacaaaca gagtgtttcc aaactgctga atgaaaagaa	180
aagttaaact ctgtgagttg aacgcacaca tcacagagca gtttctgaga atgattctgt	240
cgggttttta tacgaagata ttcccttttc tgcctttggc ctcaaagcgc ttgaagtctc	300
cacttgcaaa ttgcagaaaa agagtgtttc gaatctgctc tgtctaaaag aaggttcaac	360
tetgteagtt gaatacacae aacaeaagga agttactgag atttettetg tetageetta	420
catgaaaaaa acccgtttcc aacgaaggcc tcaaagaggt caaaatatcc acgtgcagac	480
tttccaaaca gagtgtttcc aaactgctga atgaaaagaa aagttaaact ctgtgagttg	540
aacgcacaca tcccagagca gtttctgaga aagattctgt ctagttttta taggaaaata	600
tttccttttc tgcttttggc ctcaaagtgc ttgaaatctc cacttgcaaa ttccacaaaa	660
agagtgtttc aaatctgctc tgtctaaagg aaggttgaac tctgtgagtt gcatacacac	720
aacacaaaga agttactgag aaatcttctg tctagcataa tatgaagaaa tcccgtttcc	.780
acgaaggeet caagaggnee aatatneact ggeaggettn caacagagtg tinetactge	840
tctgtgaaag aangntaact ttgnngttga ccaccatnan aagnnttttg naanatttgn	900
n	901
<210> 29 <211> 856 <212> DNA <213> Homo sapiens  <220>	
<221> misc_feature	
<223> n is a. c. or +	

<223> n is a, g, c, or t

WO 2004/070002 PCT/US2003/037143

<400> 29						60
cntttggnng	tttaaaangg	gcnganatat	gcttnacatc	nattgggggn	aaacoccccg	
cgtgagtatt	caagaaccct	ctcttgggat	ctggatcggg	accepttec	tgtaacatat	120
gcaaggaaag	aaatgcagag	gaatggaact	gagccatgga	acagacattt	ggggttgggc	180
aggaggagtt	agcagagaga	tctgcatagc	tcttatccta	cttagcacta	gtgctgttca	240
aggtagaact	cacagcataa	gaattctagc	atctgcataa	atttggagag	caacttgect	300
tctccttaga	tacacgaata	tggaaaatgc	aatagaagtt	gcttatcatg	cactcaggtt	360
gagtgaagtt	ttatcataat	gaagctaaat	gaaattccca	aattgctctg	gtggagagga	420
acgccttgat	attccacttg	tggaaaaatg	gctctatgcc	aaaaataaag	ttacatcaac	480
ctcagtacag	gagaaatcag	agtttctgct	cacagcagca	gcagaggaat	catctgcaac	540
acagagactt	ttgggttgta	tgtaaggcag	ccttgctgga	tggtctttaa	cagggttttg	่∗600
gtagggacat	ggtagaggct	ggttcctaaa	ctcttcaaac	gtttcttccc	agccctttag	660
ctttgaccto	: acgtgcagag	ttgagttaat	tataagcctt	atttatgggc	acactttcac	720
cattaagtto	: atacacagec	: ccatttttgt	gccattctt	actcctatgt	: ccttttctcc	780
cctaagcaac	catgtaaaca	tgttagagng	ggngagcgtg	g cacacnecat	acacacacat	840
tcatttacac	atgatt				•	856

<210> 30

<211> 890 <212> DNA

<213> Homo sapiens

<220>

<221> misc\_feature

<222> (1)..(890)

<223> n is a, g, c, or t

<400> 30 cnnnttctgg gggngtannn aactaannna nntnaatncc ncccaatnnn ttcggggggg 60 aaaancccca gnactccata attcncaagn atcacatgna tcacaggaga ggagactggg 120 ggagtcaatg gatagaggat ttataagcca agaaaaaaaa atggagcccc aaactgtgaa 180 atccaagaag ggggtcatgt gaaccccaat ttatagccag tttttcagaa gaataagtga 240 caacctacta cttgtgattg gcacttgaag tgggaggcag tcgtgaggga gttaatatgt 300 gggaactaac cctactctag gtagtgttga attgaatcaa atcataggac atctagttgg 360 tgtttgctgg aaaactggtt gttggtggag tgaaacccct acatattttg gtgatcagag 420 gtgaagtgtt gtgttaagtg gtatgagact gggaaaaaca ctttggtttt «tectgtetet 480 cacagaatta aagtttccaa gagaagcatc agaagagtgg aaggttggga ccagcaaacc 540 VO 2004/070002 PCT/US2003/037143

acaageeeta	ggccccaaac	tagggtcaag	tggaaaa <b>gc</b> a	gggtataata	gtgaaatggc	600
cetectete	acttctgcag	ctccagtgac	gctgttccta	ctcattgtca	cactggaatg	660
gttgcaggat	gaacacgatc	ctctggaaat	ggagacatct	tctgaaggta	gaggaaactg	720
cagtcttect	gecccegacc	gccactcgca	gaggttggga	atgtcagect	nctecaaccc	780
antcttttnt	atgggatttt	ccttactttg	gggggggact	gnaatgntac	ctatctttt	840
tttacaantt	gggggggntc	cnceccactt	anngaccong	nttnnccnng		890

<210> 31 <211> 732 <212> DNA <213> Homo sapiens

<220>
<221> misc\_feature
<222> (1)..(732)

<223> n is a, g, c, or t

<400> 31 60 attettttgg gnacegteag naceaagttt tacteatate ggeatectet eteggtgget gctgcagcgg ggctggtgtg ctgcaacccg gacggagctg agtgaggggc acaatggcag 120 caacctgcag gcaccaaaga gcccccaaga gctgctcagc ggtgcctgat caaagtttgt 180 240 ctgggccagt gcttgtgcat tgtgtacgct gtgcgacaac caggaaggag agctgggttt 300 tgccatcctc caacgcttct taaataggaa actttttggg tagcacctgg cctagttcct ggaacacaga aggtgctgag tgatgttagt ttcattcgct catcttgtct cttgggcatg 360 gaaaagagtt tacaagtgct ctttcattat ccatcttgat gtgggaaggt ggggcagggg 420 aaqatqaqta cccgctctcg ccctttggtg tgatgtttgt gacgtacatg aggcatgtgg 480 gagagtggat cacagcattg gacagactgg atcocttctg gtcccacatc actcaggcaa 540 600 ctctctcttc ccacctgccc cccaaactcc cttncacctc cctccacatg tatcctccca cttncttcca ctcatgtaat gagaggtgct gatgagtcac aggaagaggt agccctagat 660 720 aaccaacaga ctgcaaaacg ggacagtncc ntggatgtct gagccagtgt ttngngcact 732 gcattgactg gc

<210> 32 <211> 672 <212> DNA <213> Homo sapiens

<220> <221> misc\_feature

### WO 2004/070002

<222> (1)..(672) <223> n is a, g, c, or t

<400> 32 60 tttggnaacc gtcagaccaa gtttactcat atcggatccc aggagacacg ctccaagggc tgggtgggaa aagccccaga aaggggaggg ctgcggggag tgagaatcgg gatggacctc 120 acagacgaca aacagatgga caaaaagctt ctctccctgc cgctccctcc ccgccaccaa 180 ctccagcccc tetgteteca toccetttte etgtetgtee tgtetgaate tetgaatete 240 tgcctgtttn tttttctctc tatgaatcac agcgtttcag agcctctgag agaaaaatgg 300 gaaaagaaga cagagatgat agaaaatgca gagtgtgcgt gtgtgtgtgt gtgtgtgcat 360 gtgtatgcgc gcgtgtgtgt gtgtgtctgt gcatgcgtgc acccagcatg aagtctggtc 420 tggagaatgt aactagggag ggaggaagag aggggacgag agaagcagag gatgaacaaa 480 . gagactttcg aagctcatag gaaaaagcct gggaggcaac agcagcaggg acacgcatat 540 geogeacace ectacacaca ecacacaca cacaccacac acaceetgea tgeaceetgg 600 660 agacatgocc cagactccag gcgggagggg tggagcaggg ggtgtgaaat atggttggtt 672 gggttgggtt tg

<210> 33 <211> 770 <212> DNA

<213> Homo sapiens

<220>
<221> misc\_feature
<222> (1)..(770)
<223> n is a, g, c, or t

<400> 33 nttttgnant gtncgcggnt aacaatttca cacagnaatt cattttaacg ttgtacatat 60 ttattataca agaaatattt tttccatcaa aaagtactca ttcaaaaaat atttaatcta 120 gaatagagat tataaatttt taacttaatt ttatttttt cttaaggaaa actctaagat 180 atcattacca ttttcaaaac tgtcaagtag tggtgaatga cacttcttat atgttaattt 240 ttaaaagaat atttctaaca cacattctta atggagaatt atatcttata cagaatgata 300 cattctaagg gtgatgttta tgaaagaaat ttaagcttgg ttaacatgct tagtaaaatt 360 ttttaataca aataaaattc agagtatatg gtgtgaagtg agttatatgg tgcaaatact 420 attttaattc ttgaacactt ccacaaaatt agcttgtaaa ataaaattaa acccacactg 480 agatgctaga tttgcagatg aatcattcat ttttttacat ttcttttat ttctctaact 540 aaattatatg acagaaggca agggtcatga ttaattcatt gttgtattct ttatatatta 600 WO 2004/070002 PCT/US2003/037143

٠,		
	itataaget eeteaataaa tattatggaa aaaatgaaca aacaetteae attttattgt (	560
:	totatatt titcaaggit titattaatt citcatgigc titgigaott tatticicc 7	720
•	agaaatto ttottgaaat gaaaagttoa caanagttag gataactgga	770
•	210> 34	
	211> 777	
	212> DNA	
;	213> Homo sapiens	
•		
	18 200.	
	220> 221> misc_feature	
	222> (1)(777)	
	223> n is a, g, c, or t	
•		
	400> 34	
	ttttgnatt gtngcgcggn taacaatttt cacacagnaa ttcttttgtc aagaattata	60
	gaagaaatc ccgtttccaa cgaaggcctc aaagagttcc aaatatccac ttgcacactg	120
	gaagaaatt tegetteeaa egaaggeete aaagageete aaatateeae eegeacaesg	120
	acaaactaa gtettteeaa actgetetat geaaagaaat gtteaactet gtgagtttaa	180
	acacacatc acaaagcagt ttctgagaat gatactgtct agtttttata cgaagatatt	240
	ccttttgta ccattggcct catactgcta gaattttcca cttgcaaatt ccacaaaaag	300
	celetyta wateggeet catactgra gaatettota eetgeaaat soutaaaag	500
	gtgtttcca atccgctctg tctaaaggaa ggttcaactc tctgatttga atacatacat	360
		400
	aatataaaa cgtagattgt cacttcaaga aaatacctgc cttatacaga actaagtggc	480
	gtttcaagt aaaaatggtg ttccatgaaa aagctgctag ttcagctggc aactcaaaca	540
	tggcacaag tgccttatgc catttctatt ttatcacaca tattaaaaac ctggccagca	600
		660
	ggtggctca tgcctgtaat tccagcattt tggnaaggcc gaggcaggtg gatcatttga	000
	gccagnagt tcaagacang cctggccaac atagcaaaac ccccatttt actaaaatac	720
	aaattagee aggentgggg gegegtgeet gtanteenne ttetegggag getgagg	777
	210> 35	
	211> 799	
	212> DNA	
	213> Homo sapiens	
	220>	

60

120

tnnttttgga gtgancgcgg ntaacaattt tacacaggaa ttctagggtt ggttcatggt

ttgagacttg agagtggaca ggtgcctagt tagacctgct ctggatgtgg aggtgtctgg

<221> misc\_feature <222> (1)..(799)

<400> 35

<223> n is a, g, c, or t

<b>WO</b> ,2004/070002	PCT/US2003/037143

tgattagaat	gactctttgt	atatctgttc	cctctttaat	tgcttccttt	taacctcaag	180
attaggettt	tattgcataa	taaaatgcat	atgagccatt	cagttttact	ccattacctc	240
tctggcttag	aatgaactat	-cagtagaatt	aacaaaaatt	gcatcataga	gttggagaat	300
tgccaccaag	gaagtgttct	agccatacta	cagaaaagat	tctccccatg	ggattacttc	360
tcagtagaat	tcagcaacca	attcctggtg	aatctatcca	agcagagaaa	tgaaaacata	420
tattcactaa	aagacttgaa	cacaaatgct	catagcagcc	ttaatcaaaa	tagagaaaaa	480
ctggaaacat	ttcaaatgtc	tatcaactga	tcaatatata	agcaaaatat	ataaagcatt	540
tgcagacaat	aaaaaacaaa	atattgatat	atactaaaac	atggnatgaa	cctcaaagcc	600
actatactag	atgagagatg	tcagacacaa	acctactgta	tttgcaagat	gecatttact	660
tgaaaaatcc	agaaaagtcg	catttacaga	gacagtaaaa	cagataagtg	ggctgcctgc	720
ggctggggg	ttgnaaaagc	nattttgctg	caaatgaact	tanggaaatt	tttttgngg	780
ggggggngat	anaaaattn					799

<sup>&</sup>lt;210> 36

<220>

<400> 36

ancttggtaa ctgtcagnac caagatttac tcatatcgga tccccaggaa tactattctt 60
taaagactat caatattcta caaagggaaa ttagagttct caattgtgaa cggaaaggaa 120
catcaatggg catgacctaa gacctccttc tacacagtta aacaacaatt tcacaagata 180
tgatttaaga gaaagctttc agggacgcct gggtggctca gtggttgagc gtctgccttc 240
cgctcagggt gtgatcctgg agttccggga ctgagtcccc atggggctcc ctgcatggag 300
cctgcttctc cctctgccta tgtctctgcc tctctctgtg tctcatgaat aaataaataa 360
agnncttatt tttttaaga ttntatttat ttatncatga nagagagaga gaggcng 417

<sup>&</sup>lt;211> 417

<sup>&</sup>lt;212> DNA

<sup>&</sup>lt;213> Canis familiaris

<sup>&</sup>lt;221> misc\_feature

<sup>&</sup>lt;222> (1)..(417)

<sup>&</sup>lt;223> n is a, g, c, or t

<sup>&</sup>lt;210> 37

<sup>&</sup>lt;211> 434

<sup>&</sup>lt;212> DNA

<sup>&</sup>lt;213> Canis familiaris

<sup>&</sup>lt;220>

<sup>&</sup>lt;221> misc\_feature

<sup>&</sup>lt;222> (1)..(434)



<223> n is a, g, c, or t

<400> 37						
tggtaactcg	tcagnaccaa	gatttactca	tatcggcatc	cccaggaata	ctattctta	60
aagactatca	atattctaca	aagggaaatt	agagttctca	attgtgaacg	gaaaggaaca	120
tcaatgggca	tgacctaaga	cctccttcta	cacagttaaa	caacaatttc	acaagatatg	180
atttaagaga	aagctttcag	ggacgcctgg	gtggctcagt	ggttgagcgt	ctgccttecg	240
ctcagggtgt	gatcctggag	ttccgggact	gagtcccaca	tggggctccc	tgcatggagc	300
ctgcttctcc	ctctgcctat	gtctctgcct	ctctctgtgt	ctcatgaata	aataaataaa	360
gtccttattt	tttttaagat	tttatttatt	tattcatgag	agagagagag	agnengngne	420
ntnggcngng	ggng					434

<210> 38

<211> 1425

<212> DNA

<213> Canis familiaris

<220>

<221> misc\_feature

<222> (1)..(1425)

<223> n is a, g, c, or t

<400> 38

enggneggng angattning tegnnaceea tggegaatge etggetngee gaatatteat 60 ggtggaaaat ggccngcttt tctggattca tcgnactgtg nccggctggg tgtggcggac 1.20 cegetatnea gnacatageg ttgggetace engtgataat getgaagage ttggeggneg 180 aatgggetga eegetteete gtgskkkane ggtategeeg etcycegatt egeagegeat 240 cgccttctat cgccttcttg acgagttctt ctgagcggga ctnctggggt tcgaaatgag 300 ctagecetta agtaacgeca ttttgcaagg catggaaaaa tacataactg agaatagaaa 360 agtteatete tgetgtettt ggecattete tetaggeate tgeteatgtg gaggeataag 420 aaaatattga catgetteae attacatttt cagagtatgt tatteatgta atttatttgt 480 adaatctacc aatacaattt occcecaatc aagtaaaact aggtaaaaag atetetgeaa 540 agattagctg aggaagaaac atatgtgagt agaatcagaa tgttaagagc tgacaggtta 600 gcagatagca tgcccatgat tittgtgggt tiggccccit igtigaagci aaatcitaca 660 gagaggccca accctagagg taaaatgatt aaaacagatg tgctgcagtt ggcggggagg 720 gtgctgcgcc aggggaagcc caagactgct gctggctgcc ttccctectg aycttatecc 780 atgtctcatt tgaaaaccaa tagttgaaaa actctcaatt ttcagatgag aacgaaaaca 840 aaaatgcaaa gaaggcaaat gattcaytca aarwtactca gtgaatkrga sccawsatgt 900

# WO 2004/070002 PCT/US2003/037143

gggaatacaa	ctctggcctt	ctgtttctga	atctagtggt	atttocaggc	<b>t</b> cacaggaag	960
cttcctgtac	cttgctccac	tgtgtgtgtt	£ttggatggc	cctggtgttt	gattacctyt	1020
cgtggcaggc	ccaacagccc	ttgctaaggc	acagactgca	tatttgctga	tccctgaggn	1080
ggaaagctgt	gattcagact	ttgaggtcta	agaattgcag	acttagtttc	tagtctoccg	1140
atgaaactgc	taatctgggt	gccagtggtg	tttctgctac	acggacacct	gcccacacag	1200
catgattaga	aattataatg	atgacggcga	tgagtcttcc	aggacaccta	cgttctttgc	1260
aagatatttc	tgctaatcgt	ctctaccaga	atcagttgga	gaacttttt	tagtttttt	1320
tttttttt	taatttcccc	ctttctaagt	caagtaaaaa	tactagttta	attnetggtg	1380
tagggtaatg	atttgtcctc	accattactg	atgtgtcatt	ttttg	•	1425

<sup>&</sup>lt;210> 39

<220>

<221> misc\_feature

<222> (1)..(674)

<400> 39

caaaaaatga cacatcagta atggtgagga caaatcatta ccctacacca gnaattaaac 60 tagtatttt acttgactta gaaaggggga aattaaaaaa aaaaaaaaa aactaaaaaa 120 agttetecaa etgattetgg tagagaegat tageagaaat atettgeaaa gaaegtaggt 180 gtcctggaag actcatcgcc gtcatcatta taatttctaa tcatgctgtg tgggcaggtg 240 tccgtgtagc agaaacacca ctggcaccca gattagcagt ttcatcggga gactagaaac 300 360 taagtotgca attettagac otcaaagtot gaatcacago tttcccctca gggatcagca 420 aatatgcagt ctgtgcctta gcaagggctg ttgggoctgc cacgagaggt aatcaaacac cagggccatc caaaaacaca cacagtggag caaggtacag gaagcttcct gtgagcctgg 480 aaataccact agattcagaa acagaaggcc agagttgtat toccacatga tggctctaat 540 tcactgagta actttgaatg aatcatttgc cttctttgca tttttgtttt cgttctcatc 600 tgaaaattga gagtttttca actattggtt ttcaaatgag acatgggata agatcaggag 660 ggaaggcagc cagc 674

<sup>&</sup>lt;211> 674

<sup>&</sup>lt;212> DNA

<sup>&</sup>lt;213> Canis familiaris

<sup>&</sup>lt;223> n is a, g, c, or t

<sup>&</sup>lt;210> 40

<sup>&</sup>lt;211> 666

<sup>&</sup>lt;212> DNA

<sup>&</sup>lt;213> Canis familiaris

480

**-** · · · ·

	<b>4220</b> 2							
	.,		_feature .(666)					
		• •	.(666) a, g, c, c	or t				
,				-				
		40						60
	cccatga	ıgca	aaaaatgaca	catcagtaat	ggtgaggaca	aatcattacc	ctacaccagn	60
•	aattaaa	rcta	gtatttttac	ttgacttaga	aagggggaaa	ttaaaaaaaa	aaaaaaaaa	120
•	ctaaaaa	aag	ttctocaact	gattctggta	gagacgatta	gcagaaatat	cttgcaaaga	180
	acgtagg	tgt	cctggaagac	tcatcgccgt	catcattata	atttctaatc	atgctgtgtg	240
	;					ttagcagttt		300
						atcacagett		360
	gatcago	caaa	tatgcagtct	gtgccttagc	aagggctgtt	gggcctgcca	cgagaggtaa	420
	tcaaaca	acca	gggccatcca	aaaacacaca	cagtggagca	aggtacagga	agcttcctgt	480
	gageet	ggaa	ataccactag	actcagaaac	agaaggccag	agttgtattc	ccacatgatg	540
	gctctaa	attc	actgagtaac	tttgaatgaa	tcatttgcct	tctttgcatt	tttgttttcg	600
	ttctca	tctg	aaaattgaga	gtttttcaac	tattggtttt	caaatgagac	atgggataag	660
	atcagg		• •					666
	<210> <211> <212> <213>	41 603 DNA Can		is				
	<220> <221> <222> <223>	(1)	c_feature (603) .s.a, g, c,	or t		·		
	<400>	<b>41</b>	aaaaatgaca	-catcagtaat	: ggtgaggaca	a aatcattaco	: ctacaccaga	60
					;		a aaaaaaaac	120
						•	c ttgcaaagaa	180
							tgctgtgtgg	240
							c atcgggagac	300
							t cccctcaggg	360
							c gagaggtaat	420
	accaye	Jaual	. arguagect	, cycetage		990009000	- 3-3-35	

caaacaccag ggccatccaa aaacacacac agtggagcaa ggtacaggaa gcttcctgtg

WO,2004/070002	PCT/US2003/037143
agectggaaa taccactaga tecagaaaca gaaggecaga get	tgtattcc cacatgatgg 540
ctctaattca ctgagtaact ttgaatgaat catttgeett ett	ttgcattt ttgttttcgt 600
tet	603
.<210> 42 .<211> 749	
<pre>&lt;&lt;212&gt; DNA </pre> <pre>&lt;&lt;213&gt; Canis familiaris</pre>	
in .	
<220> <221> misc_feature	
<pre> &lt;222&gt; (1)(749)  &lt;223&gt; n is a, g, c, or t </pre>	
<400> 42	
ggtnactgtn cgnaccagtt tactncatat ncggntnccc at	gagcaaaa aatgacacat 60
cagtaatggt gaggacaaat cattacccta caccagnaat ta	aactagta tttttacttg 120
acttagaaag ggggaaatta aaaaaaaaaa aaaaaaacta aa	aaaagttc tccaactgat 180
tctggtagag acgattagca gaaatatctt gcaaagaacg ta	ggtgtcct ggaagactca 240
tcgccgtcat cattataatt tctaatcatg ctgtgtgggc ag	gtgtccgt gtagcagaaa 300
caccactggc acccagatta gcagtttcat cgggagacta ga	aactaagt ctgcaattct 360
tagaceteaa agtetgaate acagetttee eeteagggat ca	gcaaatat gcagtctgtg 420
ccttagcaag ggctgttggg cctgccacga gaggtaatca aa	caccaggg ccatccaaaa 480
acacacacag tggagcaagg tacaggaagc ttcctgtgag co	tggaaata ccactagatt 540
cagaaacaga aggocagagt tgtattccca catgatggct ct	aattcact gagtaacttt 600
gaatgaatca tttgccttct ttgcattttt gttttcgttc tc	catctgaaa attgagagtt 660
tttcaactat tggttttcaa atgagacatg ggataagatc ag	ggagggaag gcagccagca 720
gcagtettgg getteeectg gegcageae	749
<210> 43	
<211> 1778 <212> DNA	
<213> Canis familiaris	
<220>	
<pre>&lt;221&gt; misc_feature &lt;222&gt; (1)(1778)</pre>	
<223> n is a, g, c, or t	
<400> 43 gkggtagngn reggtaaaca atttneacae ageaattnee ee	ctotonaaa etocettoac 60
gryytagnym rogytaaata attenpatat aytaattNCC 4CC	ceyeghada eegeeeegae 00

ttggtgcctt ttttggaggg gtggagttgt ttccaetttg acaaattttt atatttctcc

120



catoctaatt ggactaattt gottttatat otottotgtg gttattttgt taatogtatt 180 ttaggaaagt cacctatttc aaattgattt gcatggagct aaataatttc ttccaatttt 240 ttcatttcct ttgtgtttat ggttatttct acattattag tgaaagtttt gtggttttgt 300 gttttagttc tctatctcct cttttgatta gtttcacaga gtttagttgt tatttttca 360 420 gaaaacaget ettgeactta tttategget etactgttet taatttgete etaaaaattg tcaataatat gtttctttg ctttgcccgg gctcattttg ttgtttttct aattgtttga 480 gettgaetet taatteatet attittgitt etgettitit gitaatgiaa attiaaaaaa 540 600 tgcgagatcc aattagaata agcctcaccg gacaagaacc tgtctgtgca cttcgagact accataatgc ctatcacata gcaggtgctt aagcaaaatt tttgtatgaa taaataaacc 660 octatgaaat aattatggga tttgtgtgac agccctcgtt cttctctgct gtctttggsc 720 780 aytototota ggcatotgot catgtggagg cataagaaaa tattgacatg ottoacatta 840 cattttcaga gtatgttatt catgtattta tttgtaaaat ctaccaatac aatttcccc 900 caatcaagta aaactaggta aaaagatctc tgcaaagatt agctgaggaa gaaacatatg 960 tgagtaraat caraatgtta agagctrmca ggttarcaga tagcatgccc atgatttttg tgggkttggc ccctttgttg aagctaaatc ttacagagag gcccaaccct agaggtaaaa 1020 1080 tgattaaaac agatgtgctg cagttggcgg ggagggtgct gcgccarggg aagncccaag actgctgctg gctgccttcc ctccntgatc ttatcccatg tctcatttga aaaccaatag 1140 1200 ttgaaaaact ctcaattttc agatgagaac gaaaacaaaa atgcaaagaa ggcaaatgat 1260 tcattcaaag ttactcagtg aattagagcc atcatgtggg aatacaactc tggccttctg 1320 tttctgaatc tagtggtatt tccaggctca caggaagctt cctgtacctt gctccactgt 1380 gtgtgttttt ggatggccct ggtgtttgat tacctctcgt ggcaggccca acagcccttg ctaaggcaca gactgcatat ttgctgatcc ctgaggggaa agctgtgatt cagactttga 1440 ggtctaagaa ttgcagactt agtttctagt ctcccgatga aactgctaat ctgggtgcca 1500 1560 gtggtgtttc tgctacacgg acacctgccc acacagcatg attagaaatt ataatgatga cggcgatgag tcttccagra cacctacgtt ctttgcaaga watttctgct aatcgnttnc 1620 1680 tctaccagaa tcagttggag aactttttt agttttttt tttttttt aatttecccc tttctaagtc aagtaaaaat actagtttaa ttctggtgta gggtaatgat ttgtcctcac 1740 1778 -cattacttga aagaccccac ctgtaggttg gcaagcgg

<210> 44

<211> 868

<212> DNA

#### PCT/US2003/037143 WO,2004/070002

<213> Canis familiaris

<220>

<221> misc\_feature

<222> (1)..(868)

<223> n is a, g, c, or t

<400> 44 tbeetgagae ngettgeeaa acetacaggt ggggtettte aagtaatggt gaggacaaat 460 cattacccta caccagaatt aaactagtat ttttacttga cttagaaagg gggaaattaa 120 aaaaaaaaaa aaaaaactaa aaaaagttct ccaactgatt ctggtagaga cgattagcag 180 aaatatettg caaagaacgt aggtgteetg gaagaeteat egeegteate attataattt 240 ctaatcatgc tgtgtgggca ggtgtccgtg tagcagaaac accactggca cccagattag 300 cagtttcatc gggagactag aaactaagtc tgcaattctt agacctcaaa gtctgaatca 360 cagctttccc ctcagggatc agcaaatatg cagtctgtgc cttagcaagg gctgttgggc 420 ctgccacgag aggtaatcaa acaccagggc catccaaaaa cacacagt ggagcaaggt 480 acaggaaget teetgtgage etggaaatae caetagatte agaaacagaa ggecagagtt 540 gtattcccac atgatggctc taattcactg agtaactttg aatgaatcat ttgccttctt 600 tgcatttttg ttttcgttct catctgaaaa ttgagagttt ttcaactatt ggttttcaaa 660 tgagacatgg gataagatca ggagggaagg cagccagcag cagtcttggg cttccctggc 720 gcagcaccnt cccgccaact gcagcacatc tgtttaatca tttaacctct aggntgggcc 780 tttctgtaag atttagcttn acaangggcc aaacccaaaa aatcatgggc atgcttctgc 840 868 tacctgncan tntaacattt gattntac

<210> 45

<211> 1237

<212> DNA

<213> Canis familiaris

<220>

<221> misc\_feature

(1) . . (1237) <222>

<223> n is a, g, c, or t

<400> 45

ggtatcgccg ctcccgattc gcaccgcatc gccttctatc gccttcttga cgagttcttc 60 tgagcgggac tctggggttc gaaatgagct agcccttaag taacgccatt ttgcaaggca 120 tggaaaaata cataactgag aatagaaaag ttcatctctg ctgtctttgg ccattctctc 180 taggcatctg ctcatgtgga ggcataagaa aatattgaca tgcttcacat tacattttca 240 gagtatgtta ttcatgtatt tatttgtaaa atctaccaat acaatttccc cccaatcaag 300



taaaactagg taaaaagatc totgcaaaga ttagotgagg aagaaacata tgtgagtaga 360 atcagaatgt taagagetga caggttagca gatagcatgc ccatgatttt tgtgggtttg 420 geceettigt tgaagetaaa tettacagag aggeecaace etagaggtaa aatgattaaa 480 acagatgtgc tgcagttggc ggggagggtg ctgcgccagg ggaagcccaa gactgctgct 540 ggctgccttc cctcctgatc ttatccccat gtctcatttg aaaaaccaat agttgaaaaa 600 ctctcaattt tcagatgaga acgaaaacaa aaatgcaaag aaggcaaatg attcattcaa 660 agttactcag tgaattagag ccatcatgtg ggaatacaac tetggcette tgtttetgaa 720 tctagtggta tttccaggct cacaggaagc ttcctgtacc ttgctccact gtgtgtgttt 780 ttggatggcc ctggtgtttg attacetete gtggcaggcc caacagecet tgctaaggca 840 cagactgcat atttgctgat ccctgagggg aaagctgtga ttcagacttt gaggtctaag ,900 . aattgcagac ttagtttcta gtctcccgat gaaactgcta atctgggtgc cagtggtgtt 960 totgotacac ggacacetgo ccacacagoa tgattagaaa ttataatgat gacggogatg 1020 agtettecag gacacetacg teetttgcaa gatatttetg etaategtet etaecagaat 1080 cagttggaga actttttta gtttttttt ttttttta atttcccct ttctaagtca 1140 agtaaaaata ctagtttaat totggtgtag ggtaatgatt tgtoctcacc attactgatg 1200 1237 tgccattttt tgctcatggg atccgatatg agtaaac

<211> 703 <212> DNA

<213> Canis familiaris

<220>

<221> misc\_feature

<222> (1)..(703)

<223> n is a, g, c, or t

<400> 46

ecctgtgaaa etgeettgae ttggtgeett ttttggaggg gtggagttgt ttecaetttg 60 acaaattttt atatttctcc catcotaatt ggactaattt gcttttatat ctcttctgtg 120 gttattttgt taatcgtatt ttaggaaagt cacctatttc aaattgattt gcatggagct 180 aaataatttc ttccaatttt ttcatttcct ttgtgtttat ggttatttct acattattag 240 tgaaagtttt gtggttttgt gttttagttc tctatctcct cttttgatta gtttcacaga 300 gtttagttgt tatttttca gaaaacagct cttgcactta tttatcggct ctactgttct 360 taatttgctc ctaaaaattg tcaataatat gtttcttttg ctttgcccgg gctcattttg 420 ttgttttct aattgtttga gettgaetet taatteatet atttttgttt etgetttttt 480

WO 2004/070002 PCT	F/US2003/037143
gttaatgtaa atttaaaaaa tgcgagatcc aattagaata agcctcaccg gaca	agaacc *540
tgtctgtgca cttcgagact accataatgc ctatcacata gcaggtgctt aagc	aaaatt 600
tttgtatgaa taaataaacc cctatgaaaa aattatggga tttgtgtgac agcc	ectcgtt 660
cttctctgct gnctttggcc attctctcta ggcatctgct cat	703
<210> 47 <211> 304 <212> DNA <213> Canis familiaris	
<220>	
<221> misc_feature	
<222> (1)(304) <223> n is a, g, c, or t	
<400> 47 ctagcttgcc aaacctacag gtggggtctt tcaagtaatg gtgaggacaa atc	attaccc 60
tacaccagaa ttaaactagt attttactt gacttagaaa gggggaaatt aaa	aaaaaaa 120
aaaaaaaact aaaaaaagtt ctccaactga ttctggtaga gacgattagc aga	aatatct 180
tgcaaagaac gtaggtgtcc tggaagactc atcgccgtca tcattataat ttc	taatcat 240
gctgtgtggg caggtgtccg tgtagcagaa acaccactgg ncccccagat nag	agttttc 300
ttgg	304
<210> 48 <211> 735 <212> DNA <213> Canis familiaris	
<pre>&lt;220&gt; &lt;221&gt; misc_feature &lt;222&gt; (1)(735) &lt;223&gt; n is a, g, c, or t</pre>	
<400> 48 agcttgccaa acctacaggt ggggtctttc aagtaatggt gaggacaaat ca	ttacccta 60
caccagaatt aaactagtat ttttacttga cttagaaagg gggaaattaa aa	aaaaaaaa 120
aaaaaactaa aaaaagttct ccaactgatt ctggtagaga cgattagcag aa	atatcttg 180
caaagaacgt aggtgtcctg gaagactcat cgccgtcatc attataattt ct	aatcatgc -240
tgtgtgggca ggtgtccgtg tagcagaaac accactggca cccagattag ca	gtttcatc 300
gggagactag aaactaagte tgeaattett agaceteaaa gtetgaatea ca	gettteec 360
ctcagggatc agcaaatatg cagtctgtgc cttagcaagg gctgttgggc ct	gccacgag 420

aggtaatcaa acaccagggc catccaaaaa cacacacagt ggagcaaggt acaggaagct

wo	2004	/0700	002

tcctgtgagc	ctggaaatac	cactagattc	agaaacagaa	ggccagagtt	gtattcccac	· 540
atgatggctc	taattcactg	agtaactttg	aatgaatcat	ttgccttctt	tgcatttttg	600
ttttcgttct	catctgaaaa	ttgagagttt	ttcaactatt	ggttttcaaa	tgagacatgg	660
gataagatca	ggagggaagg	cagccagcag	cagtcttggg	ctttccctgg	cgcaaaaccn	720
teccegeaac	tggag					735

<210> 49

<211> 1412

<212> DNA

<213> Canis familiaris

<220>

<221> misc\_feature

<222> (1)..(1412)

<223> n is a, g, c, or t

<400> 49

cttcccacct nnnacccntg gnecttaaca gneacnnncc tttggagata gctaactcct -60 acneatteaa cateagtgnn anggntetee teeagaagge tteetenace ettteaatte 120 ccacttacnt gtaagcctag gatgcctcct ctcagattca gactggttgn cncagtgttt 180 aagaacttna gctgtacagc canagagttt gtattggaaa ataatctctg tggttttttg 240 tengeatgat ettggaegag ttatttaace eecteagtnt agtttettea tecatataat 300 ctggcaaatg atagtnonca gtccatacaa ttgtnagcac taaacaaaat aatgtacacg 360 agcetggcac actgaaggan eccagtgaaa ggtggttgtg attactnaca gteettetea 420 ttctctagca tagcacttac cgtgttgcgt tccgattttc tgtctgcatg tctacctgca 480 tgtcggtttg catgcagact atgaactgga agctgaatcc ccagtgcctg gtacaatgtg 540 agaccccata neagtteatt gaatgaatte agacacttea gtttttecat aaattteage 600 cttcttcaat attttgctcc tattttctag aagtttctga aagagcagct tggaatatgt 660 720 cagcaatttc taatttctta gettttcagt gtgtgtgege gtgtgtgegt gtgtgtttga 780 tattttctgc tgtggaaacc gctggactta gatgatcagn ctgtgagata caggcaggac anagataaga agtaggagga gggctncgat gatgaagctt aggcactgaa gcaactcagc 840 cacccaccag gaageetcag tneeetgaar aggtggacce tkkcasscyg wggtgaacca 900 ttgtgggcca aagaggccca gtgcatgcat gaggcagacc tecetetaca gggaggettt 960 geoctactgg gatttatttc cttgctgctt aaggacctgg ctttgctcct gcctttcctt 1020 gtccccttca tetgattete tggccttatt ttggccagca gattgcattt gcctgtccag 1080 tttaccatat aaatgcattc tectecteat gacetettet cageetgetg gtetaaggga 1140

### WO<sub>2</sub>2004/070002

ggagetetgt ttettgatee tgeeetetga etaaatttee tettget	get ettecettte 1200
ctgatgattc agtacagaca octgcocaat tccacttttt ctcttca	etct ccaattattt 4260
ggtggtcaag actgtttact caaatatgca tctggtttaa tcacgag	cca cgactetyae 1320
taaagtagcc tgattatatg gttctttaag ggatagctga ctttcac	caaa cctaagaaaa 1380
gttnottaaa gtggtgtnot aagggnoota ca	1412

<210> 50

<211> 866

<212> DNA

<213> Canis familiaris

<220>

<221> misc\_feature

<222> (1)..(866)

<223> n is a, g, c, or t

<400> 50 ttnngggacn gcttgccaaa cctacaggtg gggtctttca agatctgctg acagtgaagc 60 taaatctggc ggaagcaaag gattcacttt ctcataatgg attaactcat cctatttgcc 120 tettaaacaa tgggtatttt aaagacagaa gttgaaggaa gtccaagtat ecaattttaa 180 ggatgcctat tagagcagtt ataagagagt gtctctcttt ctctcttc tttcttctc 240 ttggtaggag tatgcaggag gtcatttaaa agccagatag tgatacaaat cacaatgcag 300 aaaaacatcc ccgtggactc ctccctgtcc tatgtttgac attcttaaaa tctatgtccc 360 aggtettgaa atetttaaat aatetaceat gttetttgge etgeeetggg aaatetattt 420 cagtaccaga gctatgctgg ttacacacct tttctgactc atgttcccaa gtgattttat 480 tecagatacg atttggggac agttacgtgt actgttetga tatetteeta aaaggaaatt 540 attttggaag taaagtcact gataaaatca actcaggaaa atgcactttg taaatattaa 600 aatataaaca ttattaaagg ccatgctgta aaaatactaa ttgattttcc tgtgtagcag 660 ttacaataga acaacgatag atctctaagg ggagagtgaa aggacctcaa tttgagaaac 720 gtgaggcagg aaaagtttca aataattata ttcagagtgn tacctaagtt gttacttaaa 780 gacattetet acgtaaaana aacaataagg ccaaatgaag gaatgagagt tatgttateg 840 866 cagaaacaan gtaancggnt tntttt

<sup>&</sup>lt;210> 51

<sup>&</sup>lt;211> 597

<sup>&</sup>lt;212> DNA

<sup>&</sup>lt;213> Canis familiaris

	WO 2004/070002		PCT/US2003/0371	43
	<220> <221> misc_feature			
	<222> (1)(597)			
	<223> n is a, g, c, or t			
	<400> 51		•	
	acacagcaat tcattncaat gaactgttat ggggtctcac	attgtaccag	gcactgggga	60
	ttcagcttcc agttcatagt ctgcatgcaa accgacatgc	aggtagacat	gcagacagaa	120
	aatcggaacg caacacggta agtgctatgc tagagaatga	gaaggactgt	cagtaatcac	180
	aaccaecttt cactgggtte cttcagtgtg ccaggctcgt	gtacattatt	ttgtttagtg	240
	ctcacaattg tatggactgt gtactatcat ttgccagatt	atatggatga	agaaactaga	300
	ctgagggggt taaataactc gtccaagatc atgcagacaa	aaaaccacag	agattatttt	360
	ccaatacaaa ctctctggct gtacagctca agttcttaaa	cactgggcca	accagtctga	420
	atctgagagg aggcattcta aggcttacag gtaagtggga	attgaaaggg	ttgagggaag	480
•	ccttctggag gagatgccat tacactgaat gttgaatgag	taggagttag	ctatctccag	540
	aggggtagtg gctgtgaagg ggcgaggggt agagggtggg	aaggggatga	tggaagg	597
	<210> 52			
	<211> 875	•		
	<212> DNA		•	
	<213> Canis familiaris			
	<220>		·	
	<221> misc_feature			
	<222> (1)(875)			
	<223> n is a, g, c, or t			
	<400> 52		٠	
	cgcttgccaa cctacaggtg gggtctttca agatctgctg	acagtgaagc	taaatetgge	60
	ggaagcaaag gattcacttt ctcataatgg attaactcat	cctatttgcc	tcttaaacaa	120
	tgggtatttt aaagacagaa gttgaaggaa gtccaagtat	ccaattttaa	ggatgcctat	180
	tagagcagtt ataagagagt gtctctcttt ctctctctc	tttctttctc	ttggtaggag	240
	tatgcaggag gtcatttaaa agccagatag tgatacaaat	cacaatgcag	aaaaacaccc	300
	ccgtggactc ctccctgtcc tatgtttgac attcttaaaa	tctatgtccc	aggtcttgaa	360
	atctttaaat aatctaccat gttctttggc ctgccctggg	aaatctattt	cagtaccaga	420

gctatgctgg ttacacacct tttctgactc atgttcccaa gtgattttat tccagatacg

atttggggac agttacgtgt actgttctga tatcttccta aaaggaaatt attttggaag

taaagtcact gataaaatca actcaggaaa atgcactttg taaatattaa aatataaaca

ttattaaagg ccatgctgta aaaatactaa ttgattttcc tgtgtagcag ttacaataga

480

540

600

660

		_
WO 2004/070002	•	PCT/US2003/037143

acaacgatag atctctaagg ggagagtgaa aggacctcaa tttgagaaac gtgaggcagg	720
aaaagtttca aataattata ttcaagagtg ttacctaagt tgttacttaa agacattttc	780
tacgtaaaat aaacacataa ggocaaanga agggaatgag anttangtta tngcaggana	840
aaaggtaaat eggnttttt ttgtateeat tgeaa	875
<210> 53 <211> 612	
<212> DNA <213> Canis familiaris	
<220> <221> misc_feature	
<222> (1)(612) <223> n is a, g, c, or t	•
<400> 53 agcggataac aatttcacac agnaattcat tcaatgaact gttatggggt ctcacattgt	€0
accaggcact ggggattcag cttccagttc atagtctgca tgcaaaccga catgcaggta	120
gacatgcaga cagaaaatcg gaacgcaaca cggtaagtgc tatgctagag aatgagaagg	180
actgtcagta atcacaacca cetttcactg ggtteettca gtgtgccagg ctcgtgtaca	240
ttattttgtt tagtgctcac aattgtatgg actgtgtact atcatttgcc agattatatg	300
gatgaagaaa ctagactgag ggggttaaat aactcgtcca agatcatgca gacaaaaaac	360
cacagagatt attiticcaat acaaactitic tggctgtaca gctcaagttc ttaaacactg	420
ggccaaccag tetgaatetg agaggaggea ttetaagget tacaggtaag tgggaattga	480
aagggttgag ggaagcette tggaggagat gccattacae tgaatgttga atgagtagga	540
gttagctatc tccagagggg tagtggctgt gaaggggcga ggggtagagg gtggnaaggg	600
atgatngaaa gg	612
<210> 54	
<211> 732	
<212> DNA <213> Canis familiaris	
<220> <221> misc_feature	
<222> (1)(732)	
<223> n is a, g, c, or t	
<400> 54 agettgecaa acetacaggt ggggtettte aagatetget gacagtgaag etaaatetgg	60
cggaagcaaa ggattcactt totcataatg gattaactca toctatttgc ctottaaaca	120
atgggtattt taaagacaga agttgaagga agtccaagta tccaatttta aggatgccta	180



بخ	tagagcagt	tataagagag	tgtctctctt	tetetett	ctttctttct	cttggtagga	-240
g	tatgcagga	ggtcatttaa	aagccagata	gtgatacaaa	tcacaatgca	gaaaaacatc	300
C	ccgtggact	cctccctgtc	ctatgtttga	cattcttaaa	atctatgtcc	caggtettga	360
а	atctttaaa	taatctacca	tgttctttgg	cctgccctgg	gaaatctatt	tcagtaccag	420
a	gctatgctg	gttacacacc	ttttctgact	catgttcnca	agtgatttta	ttocagatac	480
g	atttgggga	cagttacgtg	tactgttctg	atatetteet	aaaaggaaat	tattttggaa	540
g	taaagtcac	tgataaaatc	aactcaggaa	aatgcacttt	gtaaatatta	aaatataaac	600
,a	ttattaaag	gccatgctgt	aaaaaactaa	ttgattttcc	tgtgtagcag	ttacaataga	660
ļa	cacgatgat	ctctaagggg	agagtgaaag	gaccttattt	ggtaaccgtg	aggcagnaaa	720
g	tttcaaata	tt			•		732

<210> 55

<211> 697

<212> DNA

<213> Canis familiaris

<220>

<221> misc\_feature

<222> (1)..(697).

<223> n is a, g, c, or t

### <400> 55

ctagcttgcc aaacctacag gtggggtctt tcaagatctg ctgacagtga agctaaatct 60 ggcggaagca aaggaticac titctcataa tggattaact catcctatit gcctcttaaa 120 caatgggtat tttaaagaca gaagttgaag gaagtccaag tatccaattt taaggatgcc 180 tattagagca gttataagag agtgtctctc tttctctctc ttctttcttt ctcttggtag 240 gagtatgcag gaggtcattt aaaagccaga tagtgataca aatcacaatg cagaaaaaca 300 teccegtgga etectecetg tectatgttt gacattetta aaatetatgt eccaggtett 360 gaaatettta aataatetae catgttettt ggeetgeeet gggaaateta ttteagtaee 420 agagetatge tggttacaca cethttetga etcatgttee caagtgattt tattecagat 480 acgatttggg gacagttacg tgtactgttc tgatatcttc ctaaaaggaa attattttgg 540 aagtaaagtc actgataaaa tcaactcagg aaaatgcact ttgtaaatat taaaatataa 600 acattattaa aggccatgct gtaaaatact aattgatttt cctgtgtagc agttacaata 660 gaacacgata gatctctang gggagagtga aaggact 697

<210> 56

<211> 617

#### WO 2004/070002

<212> DNA

<213> Canis familiaris

<220>

<221> misc\_feature

<222> (1)..(617)

<223> n is a, g, c, or t

<400> 56 tggattgcga gcggataaca atttcacaca gaattcattc aatgaactgt tatggggtct 60 cacattgtac caggcactgg ggattcagct tccagttcat agtctgcatg caaaccgaca 120 tgcaggtaga catgcagaca gaaaatcgga acgcaacacg gtaagtgcta tgctagagaa 180 tgagaaggac tgtcagtaat cacaaccacc tttcactggg ttecttcagt gtgecagget 240 cgtgtacatt attttgttta gtgctcacaa ttgtatggac tgtgtactat catttgccag 1300 attatatgga tgaagaaact agactgaggg ggttaaataa ctcgtccaag atcatgcaga 360 caaaaaacca cagagattat tttecaatac aaactetetg getgtacage teaagttett 420 aaacactggg ccaaccagtc tgaatctgag aggaggcatt ctaaggctta caggtaagtg 480 ggaattgaaa gggttgaggg aagcettetg gaggagatge cattacactg aatgttgaat 540 600 gagtaggagt tagctatctc cagaggggta gtggctgtga aggggcgagg ggtagagggt 617 ggnaagggga tgaattg

<210> 57

<211> 603

<212> DNA

<213> Canis familiaris

<220>

<221> misc\_feature

<222> (1)..(803)

<223> n is a, g, c, or t

<400> 57 cctgcagcta gcttgccaaa cctacaggtg gggtctttca agatctgctg acagtgaagc 60 taaatctggc ggaagcaaag gattcacttt ctcataatgg attaactcat cctatttgcc 120 tottaaacaa tgggtatttt aaagacagaa gttgaaggaa gtocaagtat ccaattttaa 180 ggatgcctat tagagcagtt ataagagagt gtctctcttt ctctctttc tttcttctc 240 300 ttggtaggag tatgcaggag gtcatttaaa agccagatag tgatacaaat cacaatgcag aaaaacatee eegtggaete eteeetgtee tatgtttgae attettaaaa tetatgteee 360 aggicitigaa atcittaaat aatciaccat gitcitiggc cigccciggg aaatciatti 420 cagtaccaga gctatgctgg ttacacacct tttctgactc atgttcccaa gtgattttat 480

# WO 2004/070002

# PCT/US2003/037143

786

cccagatacg	atttggggac	agttacgtgt	actgttctga	tatottccta	aaaggaaatt	540
áttttggaag	taaagtcact	gataaaatca	actcaggaaa	atgcactttg	taaatattaa	600
aatataaaca	ttattaaagg	ccatgctgta	aaaatactaa	ttgattttcc	tgtgtagcag	660
ttacaataga	acaacgatag	atctctaagg	ggagagtgaa	aggacctcaa	tttgagaaac	720
gcgaggcagg	aaaagtttca	aatattatat	<b>tcaagagtgt</b>	acctaagttg	ttacttaaag	780
acaattctnc	acttaaataa	acc				803

<210> 58 <211> 786 <212> DNA

<213> Canis familiaris

<220>
<221> misc\_feature
<222> (1)..(786)
<223> n is a, g, c, or t

<400> 58 gngnggnaat gtgcagncgg ntaacaattt cacacagnaa ttccatttcc ctcaacaagc 60 aggagaaatt ttctcaagag tttaccagaa gtcactctta acgtcaggct tgcaaatttt 1-20 aaaaagcatg aaaaagaacg tctactacat aatcctccag gcacattcca acacgctgcc 180 aacagtatte etgaaaatee tetgteaaae eesteeataa ateatageet cagagetetg 240 tgtgtgtggc tgcagcaggc tcgtagctgc agagcacttg catggaggag acatgcgctc 300 aggaactgca ccgccgcatt ccgcagaagc cacgcgactt acttccctct gctgcatgtt 360 aacctgtgct atgttctaga tcttacttta gttagtaatt caacaacagg agtcatgtgg 420 gctggcaagt agtcagctga aaactaacat gtgaacagaa ctctcagggg caggcctcca 480 gcaageteec accegagtea gtactgetee egeetteeet teagettgtg ggtgggtaet 540 accttctgaa gcctcacaaa acccccatct gaaagaagag gaaactgaga cacggtgaga 660 catggtgccc ctcgcccaaa gtctgacagt ttgatatggt agagccagga atccatccca 720 gggnagtggg ccagaaggta gtggctgact gccatgcccg aggacgtccc caggagctgc 780

<210> 59 <211> 837 <212> DNA <213> Canis familiaris

cgtgaa

<220>
<221> misc\_feature

# WO,2004/070002

1, <222> (1)..(837) 4 <223> n is a, g, c, or t

<400> 59 tetggnnece	cgggacgtnn	ttgggagctg	ccctgagete	ccacctgctg	ctgccagtac	160
tagcacaggg	tecteaagtg	atggctgctg	gtgaattatt	tagaatetee	atgggcaggg	120
cattctgctt	tttagcactg	tgtcttgacc	tgttccaaga	ccatcttcca	aggagagcca	180
gcagctggtg	ttgtaagttc	ttcccatgac	aaataagccc	aagaceteae	ttaggaaaca	240
tacaatgatt	atatgatctt	gggagtcagc	cctagaaggg	cccttcttct	cttgcttcaa	300
gctaaaaaga	ctctggacaa	caaaagaggc	agtggctgct	aagtaacttg	caactaccac	360
ttcagtctca	ctgcagctgc	aaagatagga	acagagaagt	tttaggtgag	aaactccttt	420
ttcccaagaa	actgtgatga	accagtgtta	cagtttaggg	agagagetet	gtagacaagg	480
agggacctaa	ggacccccag	gactcaccac	cccacacct	agctcccctg	gtcacctggt	540
acgtaagcag	gtaggctctg	cttagcatag	tgctaagato	acatcttgct	cagagtgtac	600
aaactcagga	aagctggcat	taggtagta	cacaagtgaa	a aaaataccto	: aaccagtggc	660
cattggaagt	gcggaagtac	atgccatac	t cactgcaag	ttctccattc	cagctgccgt	720
actgtgtaat	acgacttaat	: atcttcaga	g natcaaggt	t aatttcaaat	t ttgtgtcttc	780
aaagaacatt	tettttnn	t tettttggg	g ncagtactg	c gcacatttt	a actagga	837

PCT/US2003/037143

<211> 866

<212> DNA

<213> Canis familiaris


<220>

<221> misc\_feature

<222> (1)..(866)

<223> n is a, g, c, or t

<400> 60 ttgtcgagcg gataacaatt tcacacagna attccagcac catgcactct ctgagacagg 60 tgaggatttt gcagcagctg ataaggacac aagtgaacag gagcataata atgaaaacac 120 aaagactagt tagctgttac tacttgcttc tagggcttct agtgttetct gttgtgatac 180 ttggtcaaat gttgtttggg agtcactgaa gaatgcttca tcatttgcaa agataggacc 240 ctaacttgta agccccttaa attaaaagaa tgctttttag tacaaaatta atgatottag 300 tcacaaaaag caaagaagaa atcaaaatca caaagtcatc attcaaagtt gtattcttta 360 tagcaaaaat ggggcaagct acaggattgc caaaagtctt ataaaacagg aggaaggttt 420 atgaaatgat gctcagagag aatgcagaat gtgctattag cacaaatcct ttctgaaatg 480 gaacctgagc aaagtgatgg catttgatgt agaggaatag ccaccatcac atatgtgtga 540



gagaaaatag	tttgctttgg	ggatgaacaa	taccaccgtt	gtacaaagca	tgaataagca	*600
cttggaaaat	gtatagtatg	tataacagag	ggacttttat	ctgtttggca	ttgaaaatca	660
atgecattaa	aagtaggaac	aattggttat	tgggnctgat	tttttaaaag	aattcattta	720
tttnttttng	gggganagaa	nnececcec	cctntnaccc	cnggggaaan	annnaggggn	780
aaaaaanaat	ntnnagecna	ctnttttctt	nntgggnccc	-cgggnggggg	ctttancnca	840
aancccngna	aannannntn	ngnccn				866

<210> 61 <211> 886

<212> DNA

<213> Canis familiaris

<220>

<221> misc\_feature

· <222> (1)..(886)

<223> n is a, g, c, or t

<400> 61

ttgngaaccc gcttgccaaa cctacaggtg gggcctttca agaacataag cccaaataag 60 cactggcaca tagtaggage agcataaacg ctcccctcc tattcctaac ccaccaagaa 120 ttctagattg acagtttttt ctttgagtat tttaaagatg ctgcttcctt gacttcttgt 180 ttgcaaattt ctgatgagaa atctgctgtc attttatctt ccttcctttg cataatgatg 240 tatettttte tetetgettt taagatttte attitateae tggttetaag caatttaatt 300 atgatgttcc ttggtatagt gctcttcata tttctattag gagtttgttg agcttcttgg 360 atttgtgagt ttatagtttt tatcaaattt ggcaagtttt cagctactat ttcttcaact 420 tttttttcc tgtcctccct tgactcctcc tcattcccat atttctcctg tccttcaggg 480 actecagtta tetgtatgtt aageteattg ataccetatt tgtgtatatt ttaaggettt 540 ttattccctg tatttcattt tggatagttt ctactgcaat gttttcaggt tctttaacct 600 660 ctttttttt ttccccccag taatgtctaa tctgctcttc atcccaaaga catgtagtgg tgtgtgtgct aaaaatccca gacaatgttt ttatgattcc taggtatttg ctttggggct 720 tttcaaagat tttccatatt tctacttcct tggccatata gaatgcggnt attattattt 780 tttagnggcc tatgctacta aatcctataa ttnctgggac tccnttgatt nagnntnncc 840 tttttattta ttnattaagn anggttttat tgggagttng attncc 886

<210> 62

<211> 728

<212> DNA

<213> Canis familiaris

480

# WO 2004/070002

<pre>&lt;220&gt; &lt;221&gt; misc_feature &lt;222&gt; (1)(728) &lt;223&gt; n is a, g, c, or t</pre>	
<pre>&lt;400&gt; 62 ggattgtcag cggataacaa tttcacacag aattcccagg acccagcatg atgcctggtg</pre>	·60
tgcacatggg tgggccctcc tatgtaagcg tcaccactcg ggagcagtgg cggggatgcc	120
tggatgcgcc ggctcctgcg tgtagggtgc tatcaggaca ttgctgggtt gccacctctg	180
tctgaggctc cagagagcga ggggacaccc cacatcatga atgccctgtg gggttaccag	240
tgggggcaat tacctgcatt gctcctgggc ctcagcggcc tcatctgtga aatgggtaca	300
ttcatatcac gtatgggaga gggctgccgt ggggtttaat ggaggcaacc catttgagcg	360
ctgggcccgg caccgctcct gctcttactg tgactatggc cagcgtcact gttgcagggc	420
cttgaccggc cggggtggac gctggtgcca ccgttgctct ctcccagggt gggaggagac	480
aggeetgegg ggeggaetea eegtggegtt gaeggtgage tggtaggeet gegtggtete	540
gtagtccagc tcgcggacca ccgtgacgat gccgcgggcg ctgtcgatgg cgaacaacgg	600
ggaccggggc tggaaggagt acaggacgct gccccctgca ccaagtcggg gtccgtggcg	660
ttacgataaa atgggtgtcc ccaccggcgt gttctggggg ccaagcaaac aaccaaggtg	720
agtgggct	728
<210> 63 <211> 785	
<212> DNA	
<213> Canis familiaris	
<220>	
<221> misc_feature <222> (1)(785)	ė
<223> n is a, g, c, or t	
<400> 63	×0
attgtcgagc ggataacaat ttcacacaga attcctaaaa cccttactgt tgttttata	60
tggcacttcc tgatgtgatt gcaggctttt agcaaagcca tttttgttaa caaaaaatga	120
tttaaattot tttaaacaag tgtttagtga caagtcagta tttagtcato tagttattga	180
tacagcaccc ataaaattta tcactgaggg gagggatcag gaggaaatgt gggcattcta	240
acttaatgat taataatatg tgtctataac aaatgtgatg gctaagttat aaaatattta	300
aaaaattttt tettgeaggt atttataaca geaatgatgt ageagtatea tttocaaatg	360
tggtatetgg ctcaggatet agcaeteetg tetecagtte teatttacet cagcagtett	420

ctgggcattt gcaacaagtg ggagcactct ccccatcagc agcatcatct gcaacccctg

ctgttgctac	aactcaggta	atcattacag	tgctatgaag	taacctgtag	atggctttgt	540
cgtttttgaa	agtgagtttg	attggagaag	aaagaaacct	-tgtatagaaa	ccttcctata	ъ00
	taggaattta	taagtatctc	catttgttt	gacacgttag	tggatataat	660
agacatttt	atgtgatatt	catgagaaag	gacaaaagaa	tacattggca	ttaactgatt	720
ctttecagtt	tctgagtttc	taatttttcc	tgaagatgna	aacaaaaatt	tgggġggaac	780
tttta						785

<2'10> 64

<211> 981

<212> DNA

<213> Cercopithecus aethiops

<220>

<221> misc\_feature

(1)..(981) <222>

<223> n is a, g, c, or t

aaaaattttt tttttnggnt n

<400> 64 ttggnaancg tcagaccaag tttactcata tcggatccaa agtgcttgag actgcatttt 60 tttcaaattt tgcaatattt gcattataat taccagttaa gcatccgtaa tccaaaaatc 120 180 ctaaacctac aatgctctaa taaatatttc ctttggctgt gttggtgcaa aaaatgtttt ggattttgga agacttcaaa tttcacatta gggataccct gagtggaaaa aatagttttt 240 gtttttaaga ttctttcact caacaacaat caacaaggta gacttctgtg atcaaatgtg 300 tgaggatttc tccccaccaa taagcaatca attctgcagc agacaccaag tgggtatcct 360 ccaattcaag totgacatta octaootgga gaaagogtca gatotcacag gttgatggot 420 cagtoccaca agactgetee etacttetga tgtcaateae aagecacagt ttgttttace 480 tgtgcttcta actgactgga tataaactgg gaatctcatg agcccctctt tgggttcggt 540 600 taatttgcta gagtggctca cagaactcag ggaatcacat ttattagttt attataaagg 660 atatacagtt gaagagatac acatggcaag gtatgccctc cctgggaaca ccactctcca ggaacetnet titgttoctg tecagaaget citegaatec tetectetig ggeettitat 720 780 ggagacttna ttagatgggc atgactgaca cacatgtaga aatgtgactg gagaaaaaat atatgateta atattaatag actggggaaa etcancaggg eetgtntgtt caaattntte 840 900 nggncntttt gggtagcatt ncttnctcca gggttngggg gngnacnttt ttgaaagaaa gtntttgacc ctanncaaaa gngggggaag annaantnct ctttnggcag nnaaaaaaaa 960 981

tgtgcttcta actgactgga tataaactgg gaatctcatg agcccctctt tgggttcggt

taatttgcta gagtggctca cagaactcag ggaatcacat ttattagttt attataaagg

atatacagtt gaagagatac acatggcaag gtatgccctc cctgggaaca ccactctcca

ggaacetnet tttgtteetg teeagaaget ettegaatee teteetettg ggeettttat

ggagacttna ttagatgggc atgactgaca cacatgtaga aatgtgactg gagaaaaaat

atatgateta atattaatag actggggaaa ctcancaggg eetgtntgtt caaattntte

nggnentttt gggtageatt nettneteea gggttngggg gngnaenttt ttgaaagaaa

gtntttgacc ctanncaaaa gngggggaag annaantnct ctttnggcag nnaaaaaaaa

60

120

180

240

300

360

420

480

540

600

660

720

780

840

900

960

981

WO,2004/070002 <210> 65 <211> 981 <212> DNA <213> Cercopithecus aethiops <220> <221> misc\_feature (1)..(981) **<222>** <223> n is a, g, c, or t <400> 65 ttggnaancg tcagaccaag tttactcata tcggatccaa agtgcttgag actgcatttt tttcaaattt tgcaatattt gcattataat caccagttaa gcatccgtaa tccaaaaatc ctaaacctac aatgctctaa taaatatttc ctttggctgt gttggtgcaa aaaatgtttt ggattttgga agacttcaaa tttcacatta gggataccct gagtggaaaa aatagttttt gtttttaaga ttctttcact caacaacaat caacaaggta gacttctgtg atcaaatgtg tgaggatttc tccocaccaa taagcaatca attctgcagc agacaccaag tgggtatcct ccaattcaag totgacatta cotacotgga gaaagogtca gatotcacag gttgatggot cagtoccaca agactgotoc ctacttotga tgtcaatcac aagccacagt ttgttttacc

<210> 66 <211> 1005 <212> DNA

aaaaattttt tttttnggnt n

<213> Cercopithecus aethiops

<220> <221> misc\_feature <222> (1)..(1005) <223> n is a, g, c, or t

<400> 66 ctnagctngc ttgccaaacc tacaggtggg gtctttcaaa aaacagacat gcagacttta 60

PCT/US2003/037143

150	gcaagagctt	actcgagaaa	ttatgtattt	ggttttccgt	aggtttttga	acagataata
180	gcaatggctc	gggctggagt	tctgtcgecc	ggagtttcgc	tttttgagac	tatttattta
240	teteaacete	gattctccca	gggttcaagc	tetgeeteec	cactgaaacc	-catctcgtct
300	taaaaatgca	ataaaaatac	ccacgcctgt	gcgcgcgacg	gggattacag	ccgagtagct
360	aactccaggc	atgttggcga	gcgtttcatc	agtagagatg	ttgtattttt	aaaataattt
420	gctgggatta	ctcccaaagt	ccgcctcggc	ggtgatctgc	ccctgacctc	tggtctcgaa
480	aagcagactt	atggaaaacg	ctttataaag	cggccaagag	ccaecgcgac	caggcgtgag
540	_catatatagc	tgaaatctta	tacactactt	ggataaggat	ccatgetttt	tctgcccaag
600	cctttaacat	gcaattattc	ttcactaatt	tgcacaaacc	ctatcaaaac	acttggccaa
660	aatacattca	accaggtaat	tttagtgccc	acaaaacaag	cecaatecgc	ctcgagttac
<sup>'</sup> 720	tttttctac	aaaaacatac	aactacagag	gacgtttaag	tccaagaaca	ggaaaataat
780	atttatattt	tgttagcatg	nccttatctc	agtaccaggg	cttagaggac	aagaaaaaat
840	anatagaaag	tagccanggc	tntaaancna	actgctncat	tggcccagtc	cacgtaacgt
.900	cctggcaaac	ggnaacaaan	tttttacca	ngggtttaaa	ttgacngcna	tctgaacana
960	agggctttga	aagmaaacgg	gggtccctgg	tgctggnctn	ggtgcccaaa	tgccancang
1005	•	tnttc	ttnggcnaan	ngncnnggnt	ntttnggaac	attttttcc

<210> 67

<211> 863

<212> DNA

<213> Cercopithecus aethiops

<220>

<221> misc\_feature

<222> (1)..(863)

<223> n is a, g, c, or t

<400> 67

nttttgggng nntancttnt ananatnngc caattattgg ggggnacctt catcataagt 60 attaatataa taataataat aagtaatagt aactagtaac aacaataaaa aggaaatcag 120 cggaaagtca ggaaaaatgt taaaaaaaaa ttggaataac ttactgtagc tgaagatcaa 180 aaaaatctca ctgtaaaaaa acaaaaataa aaatagccca gattagaaaa acgggaggtg 240 caaaaatgtc aagtcagtaa agttcatttc ttttctcttt ccaaaagcag tttccacaaa 300 aaccgcaagg ataaagtttt cagtagcaga caagcaaagc cctttcgaca tcatcaatca 360 atcttaaaaa tacacgagga agtagagagg tcagtttatg agaggctaaa aggctcctcc 420 tectetaace caactgetge agaaaaaata gaaatagaaa tettaaaaat tacatettaa 480

WO 2004/070002	PCT/US2003/03714	13
atcaggtcc cggttttgga aacaattaaa aaaaaaacac ctgtacattt	gccgtagtgc	540
acaccaagtt gcatcattat gtttaaaatg totttataaa atcagttttg	gaatggaatg	600
tgtgtgttct ggaagggtgg ggaagggagg ttaaaaatca aagctgagct	ccagtgagta	660
gggatggggt tegeettget geeetgtgaa agggaaagga cagatnagte	aanttnctaa	720
aaatgintgc cctaancccn anaaaaaact tignnitting aantaaaaaat	ttggtaagct	780
ttaaatteee tgggngggaa neenentaaa nacetttnea ngnnngntta	aaattttaan	840
aaaangggnn naaaaaaaaa ncc		863
14010x 60		
<pre>'&lt;210&gt; 68 '&lt;211&gt; 918</pre>		
<212> DNA		
<213> Cercopithecus aethiops		
<220>		
<221> misc_feature		
<222> (1)(918)		
<223> n is a, g, c, or t		
<400> 68		~^
cnnnttctgg nngatnaaan tnnttnnnna nttcnccaat nnattggggg		60
tcataagtat tnatataata ataataataa gtaatagtaa ctagtaacaa	-caataaaaag	120
gaaatcagcg gaaagtcagg aaaaatgtta aaaaaaaatt ggaataactt	: actgtagctg	180
aagatcaaaa aaatctcact gtaaaaaaaac aaaaataaaa atagcccaga	ttagaaaaac	240
gggaggtgca aaaatgtcaa gtcagtaaag ttcatttctt ttctctttcc	aaaagcagtt	300
tccacaaaaa ccgcaaggat aaagttttca gtagcagaca agcaaagcc	c tttcgacatc	360
atcaatcaat cttaaaaata cacgaggaag tagagaggtc agtttatgag	g aggctaaaag	420
geteeteete etetaaeeea aetgetgeag aaaaaataga aatagaaat	t ttaaaaatta	480
catcttaaat ccaggtcccg gttttggaaa caattaaaaa aaaaacacc	t gtacatttgc	540
cgtagtgcac accaagttgc atcattatgt ttaaaatgtc tttataaaa		<b>600</b>
atggaatgtg tgtgttctgg aagggtgggg aagggaggtt aaaaatcaa	a gctgagctcc	660
agtgagtagg gatggggttc gccttgctgc cctgtgaaag gagaaggga	c agattgagtc	720

<210> 69

acnaancect gnnaattn

agagtteete aaaaatgttg tgeectaaac eeccaagaca gaaacatett gtttattntn

gctaacacaa tntttntgna naatnatnaa cctecccngg ggagggnacn ccctnnnnaa


aannneeett neeanggant gnnttnaaan tittinaana tnantggggg nanaaaatna

780

840

900

918



<211> 887 <212> DNA

<220>

<221> misc\_feature

<222> (1).,(887)

<223> n is a, g, c, or t

<400> 69

ŧ	ncantettt	nnnnggcnna	nacgcgcgnc	nantegecaa	tnactggggg	ggnancttca	60
t	cataagtat	taatataata	ataataataa	gtaatagtaa	ctagtaacaa	caataaaaag	120
g	aaatcagcg	gaaagtcagg	aaaaatgtta	aaaaaaaatt	ggaataactt	actgtagctg	180
а	agatcaaaa	aaatctcact	gtaaaaaaac	aaaaataaaa	atageceaga	ttagaaaaac	240
g	ggaggtgca	aaaatgtcaa	gtcagtaaag	ttcatttctt	ttetetttee	aaaagcagtt	, 300
t	ccacaaaa	-ccgcaaggat	aaagttttca	gtagcagaca	agcaaagccc	tttcgacatc	3€0
a	tcaatcaat	cttaaaaata	cacgaggaag	tagagaggtc	agtttatgag	aggctaaaag	420
Q	ctectecte	ctctaaccca	actgctgcag	aaaaaataga	aatagaaatt	ttaaaaatta	480
C	atcttaaat	ccaggtcccg	gttttggaaa	caattaaaaa	aaaaacacct	gtacatttgc	540
c	gtagtgcac	accaagttgc	atcattatgt	ttaaaatgtc	tttataaaat	cagttttgga	€00
a	atggaatgtg	tgtgttctgg	aagggtgggg	aagggaggtt	aaaaatcaaa	gctgagetcc	660
ε	agtgagtagg	gatggggttc	gccttgctgc	cctgtgaaag	gagaagggac	agattgagtc	720
ē	agagttcctc	agaaatgttg	tgccctaacc	·cccaagacag	aaacatctgt	ctttgcagct	780
ε	acacatttt	ggnaagcatn	acatncactg	ggatggacag	ccncntaaaa	aaccttnncn	840
ľ	ngnennnttt	naantttaa	nnnaaagggg	nnnaaataan	naacccn		887

<210> 70

<211> 897

<212> DNA

<213> Cercopithecus aethiops

<220>

<221> misc\_feature

<222> (1)..(897)

<223> n is a, g, c, or t

<400> 70

ctttggggng tnnttcanac nttttancac nntnntcgcc antcencttg aggggnaaac 60
ccatcgcctt ctatcgnctt cttgacgagt tcttctgagc gggactctgg ggttcgaaat 120
gagctagccc ttaagtaacg ccattttgca aggcatggaa aaatacataa ctgagaatag 180
aaaagttcag atcgaggtca ggaacagatg gaacagggtc gaccggtcga ccggtcgacc 240



	ctagagaacc	atcagatgtt	tccagggtgc	cccaaggacc	tgaaatgacc	ctgtgcctta	300
	tttgaactaa	ccaatcagtt	cgcttctcgc	ttctgttcgc	gcgcttctgc	tccccgagct	360
	caataaaaga	gcccacaacc	cctcactcgg	ggcgccagtc	ctccgattga	ctgagtcgcc	420
	cgggtacccg	tgtatecaat	aaaccctctt	gcagttgcat	ccgacttgtg	gtctcgctgt	480
	tecttgggag	ggtctcctct	gagtgattga	ctacccgtca	gegggggtet	ttcaatgatg	540
	gtgatgatga	tgatgataat	gacactgatg	attttaacc	ggattaaaat	cgagtttttc	600
	tgaatgtttc	taagaatttc	tccggectcc	tgattgactt	tggagttttg	catettggga	660
	gagaaagcga	aggcattagt	attttaagt	ggattgatca	cataaacctt	ttctctccca	720
	accccaccct	tgcccttatc	cccttcccca	cactgaacag	aattttactg	gctgntaagt	780
	ctatgacctt	attttttct	gatctttaac	ttaactgntt	tagagcatct	ntggacgncn	1840
,	ggattttnaa	atttttnat	tttnggnttt	ttnntttnaa	annttnnatt	gggaaan	897

<sup>&</sup>lt;210> 71

<220>

<221> misc\_feature

<222> (1)..(878)

<223> n is a, g, c, or t

#### <400> 71


teggggngnn etecaetnnt gntgennnte nnegeeante enettgnggg gnaaaceate 60 gcettetate gnettettga egagttette tgagegggae tetggggtte gaaatgaget 120 agcccttaag taacgccatt ttgcaaggca tggaaaaata cataactgag aatagaaaag 180 ttcagatcga ggtcaggaac agatggaaca gggtcgaccg gtcgaccggt cgaecctaga 240 gaaccatcag atgtttccag ggtgccccaa ggacctgaaa fgaccctgtg cttatttga 300 actaaccaat cagttegett etegettetg ttegegeget tetgeteece gageteaata 360 aaagageeca caacceetca eteggggege cagteeteeg attgactgag tegecegggt 420 accogtgtat ccaataaacc ctcttgcagt tgcatccgac ttgtggtctc gctgttcctt 480 gggagggtct cctctgagtg attgactacc cgtcagcggg ggtctttcaa tgatggtgat 540 gatgatgatg ataatgacac tgatgatttt taaccggatt aaaatcgagt ttttctgaat 600 gtttctaaga atttctccgg cctcctgatt gactttggag ttttgcatct tgggagagaa 660 agegaaggea ttagtatttt taagtggatt gateacataa aeettttett tnecaacece 720 780 accettgeed thateceett deceacactg aacagaattt tactggetgn caagtetatg

<sup>&</sup>lt;211> 878

<sup>&</sup>lt;212> DNA

<sup>&</sup>lt;213> Cercopithecus aethiops

acctatttt toctgatett taactnactg ntttagannt ctctggacgn eggnntttna	840
aattinttat titgggttit tantitaaan citnatin	878
<210> 72 <211> 964 <212> DNA <213> Cercopithecus aethiops	
<pre>&lt;220&gt; &lt;221&gt; misc_feature &lt;222&gt; (1)(964) &lt;223&gt; n is a, g, c, or t</pre>	
<pre>&lt;400&gt; 72  cttctgggnn gannnaanca nttcgnncan nnctccneca atctacttgn ggggcaaacc</pre>	<b>€</b> 0
categoette tategttett ettgaegagt tettetgage gggaetetgg ggttegaaat	120
gagetagece ttaagtaacg eeattttgea aggeatggaa aaatacataa etgagaatag	180
aaaagttcag atcgaggtca ggaacagatg gaacagggtc gaccggtcga ccggtcgacc	240
ctagagaacc atcagatgtt tccagggtgc cccaaggacc tgaaatgacc ctgtgcctta	300
tttgaactaa ccaatcagtt cgcttctcgc ttctgttcgc gcgcttctgc tccccgagct	360
caataaaaga geecacaace eeteaetegg ggegeeagte eteegattga etgagtegee	420
egggtaceeg tgtatecaat aaaceetett geagttgeat eegaettgtg gtetegetgt	480
teettgggag ggteteetet gagtgattga etaecegtea gegggggtet tteaatgatg	540
gtgatgatga tgatgataat gacactgatg atttttaacc ggattaaaat cgagttttc	€00
tgaatgttte taagaattte teeggeetee tgattgaett tggagttttg catettggga	€60
gagaaagega aggeattagt attittaagt ggattgatea cataaacett tittiticea	720
acccaccct tgnccttatn cccttnccca cactgaacag aaanttactg gctggnannn	780
natganecta nttttnengn nettnaanta aenggnnnna anaaahenng genneebgnn	840
nnnaaaaaan ttnnnnnnng nngntttttt naaaaaancnt nnttnnaaaa ntaaaancgg	900
nnnnaaaaa nggggggggn ennennanen tnannnnggg ngggttttee nnnaanentt	960
ttcc	964
<210> 73 <211> 986 <212> DNA <213> Cercopithecus aethiops	
<220> <221> misc_feature <222> (1)(986)	٠



<223> n is a, g, c, or t

٠,٠							
	<400> 73 catenttetg	nnnngnaana	aacgtncnnn	nnnennetee	cnaatttaac	€¢ggggggn	60
	aaaancatcg	ccttctattt	ttcttcttga	-cgagttcttc	tgagcgggac	tetggggtte	120
	gaaatgagct	agecettaag	taacgccatt	ttgcaaggca	tggaaaaata	cataactgag	180
:	aatagaaaag	ttcagatcga	ggtcaggaac	agatggaaca	gggtcgaccg	gtcgaccggt.	240
; ;	cgaccctaga	gaaccatcag	atgtttccag	ggtgccccaa	ggacctgaaa	tgaccetgtg	300
	ccttatttga	actaaccaat	cagttcgctt	ctcgcttctg	ttcgcgcgct	tetgetecee	360
	gageteaata	aaagagocca	caacccctca	ctcggggcgc	cagtoctccg	attgactgag	420
_	tegeeegggt	acccgtgtat	ccaataaacc	ctcttgcagt	tgcatecgac	ttgtggtctc	480
	getgtteett	gggagggtct	cctctgagtg	attgactacc	cgtcagcggg	ggtctttcaa	540
	tgatggtgat	gatgatgatg	ataatgacac	tgatgatttt	taaccggatt	aaaatcgagt	600
	ttttctgaat	gtttctaaga	atttctccgg	cctcctgatt	gactttggag	ttttgcatct	660
	tgggagagaa	agcgaaggca	ttagtatttt	taagtggatt	gatcacataa	accttttctc	720
	teccaaeeee	accettgeec	ttatcccctt	cccacactg	aacagaattt	tactggctgt	780
	taagtctatg	accttattt	tcctgatctt	taacttaact	gntttanago	atctntggac	840
	gnnngnattt	naaannttt	tatttnggnt	ttnattta	aannttnatt	ngnaaanntt	900
	naactgggct	gnanaaaagg	gnggggncta	-ctnaaantnn	nnacgggagg	gntttncctg	960
	nanncanttn	ctccnnttcc	ntgaan				986

<sup>&</sup>lt;210> 74

<220>

×400> 74

tttttgent taeegtateg eegetnnega ttegeagege ategeettet ategeettet 60

tgaegagtte ttetgagegg gaetetgggg ttegaaatga getageeett aagtaaegee 120

attttgeaag geatggaaaa atacataaet gagaatagaa aagtteagat egaggteagg 180

aacagatgga acagggtega eeggtegaee ggtegaeeet agagaaeeat eagatgtte 240

cagggtgeee caaggaeetg aaatgaeeet gtgeettatt tgaaetaaee aateagtteg 300

ettetegett etgttegege gettetgete eeegagetea ataaaagage eeacaaeeee 360

<sup>&</sup>lt;211> 748

<sup>&</sup>lt;212> DNA

<sup>&</sup>lt;213> Cercopithecus aethiops

<sup>&</sup>lt;221> misc\_feature

<sup>&</sup>lt;222> (1)..(748)

<sup>&</sup>lt;223> n is a, g, c, or t



accetettge agttgeatee gaettgtggt etegetgtte ettgggaggg teteetetga	<del>-4</del> 80
gtgattgact accogtcago gggggtottt caatgatggt gatgatgatg atgataatga	540
cactgatgat ttttaaccgg attaaaatcg agtttttctg aatgtttcta agaatttctc	600
cggcctcctg attgactttg gagttttgca tcttgggaga gaaagcgaag gcattagtat	660
ttttaagtgg attgatcaca taaaccnEtt tntcttccaa ccccaccctt gcccttatnc	720
ecttneceae actgaacaga attttact	748
<210> 75 <211> 881 <212> DNA <213> Cercopithecus aethiops	•
<220> <221> misc_feature <222> (1)(881) <223> n is a, g, c, or t	
<400> 75 tnetttgegg acceptateg cegetteega ttegeagege ategeettet ategeettet	60
attttgcaag gcatggaaaa atacataact gagaatagaa aagttcagat cgaggtcagg	180 .
aacagatgga acagggtcga ccggtcgacc ggtcgaccct agagaaccat cagatgtttc	240
cagggtgccc caaggacctg aaatgaccct gtgccttatt tgaactaacc aatcagttcg	300
cttctcgctt ctgttcgcgc gcttctgctc cccgagctca ataaaagagc ccacaacccc	360
teactegggg egecagteet eegattgact gagtegeeeg ggtaceegtg tatecaataa	420
accetettge agttgcatec gacttgtggt etegetgtte ettgggaggg teteetetga	480
gtgattgact acccgtcagc gggggtcttt caatgatggt gatgatgatg atgataatga	540
cactgatgat ttttaaccgg attaaaatcg agtttttctg aatgtttcta agaatttctc	600
cggcctcctg attgactttg gagttttgca tcttgggaga gaaagcgaan gccttantat	660
tttttagngg gtnggnnaca tataaccttt tttttccaa neeccectt neectttnc	720
cctttcccc actgaaaaaa attttacngg ctgnnaannn tnnnaccntn ttttnccnnn	780
ncttnannna annggttnaa gaccnnnnng ggccnnnggn tttnaaantt ttttntttng	840
ggnttttnnt tnnaancnnn cnttggnaaa ntttnaanng g	881

<sup>&</sup>lt;210> 76 <211> 906 <212> DNA <213> Cercopithecus aethiops

<220> <221> misc_feature <222> (1)(906) <223> n is a, g, c, or t	
<400> 76. cannnttctg gggngtnnnn aactnannnn nnnnatcgcn nccacantnn nnttgggggg	60
aaaaacctga atacabttgt ngttatttcc cttagatctt ttttttttt tttttttt	120
ttgagacatc tcactctgtc acccaggcta gagtgaagtg gcacaatctc tggctcactg	180
caacccccac ctgcctggtt caagcgattc tectgcctca gcttcccgag tagctggtac	240
tataggtgtg caccaccaca cctggctaat ttttttaaaa aatatttta gtggagatgg	300
ggtttcacca tgttgaccag gctggtctca aactcctgac ctcaaaggat ccacctgcct	• 360
tggcctccca aagtgctggg attataagca tgagccacca tgccagcctg tttcttttag	420
atcttgattt gatattctgg atatgaatga aagaaaatta atgagtgttt caaagtctaa	480
ataaggaagc tccacagata atattaacat ttctctgatc tagtcatatt tattattgtg	540
tttcaattag aagtggctgt aggctctgaa agacacacta taaataaagc ctcccctca	600
tacacectea etcacaceca caettacace aatgeaattt ttagacagaa acacaageaa	660
gaaataggat agatttttt taaaaaatgg gcattggtta aattttctgg tcatattaaa	720
aaanntnttt nagaacteee aangggggge cattaataga gaeetnatte aetgnnggaa	780
nnaaannggn aaattnenan aattnetnae aatntttagg ganttgangn aaaatnttnn	840
gtnnntgnna ctttcctagn ggncnnnttn ngccctatnc ccaggnnttt tatnctaaac	900
ccentc	906
<210> 77 <211> 909 <212> DNA <213> Cercopithecus aethiops	
<220> <221> misc_feature <222> (1)(909) <223> n is a, g, c, or t	٠
<400> 77 cntcttnngg gngttnaanc tgncntnnaa tgcntcacat tnattnnggg gaaaaccgta	<b>1</b> 60
ctgacttatt atgagaggtt tetgetettg ttaggateca gtaggtttga ggtgcaasta	120

180

240

tteetetact ttaetettee accteecaga gaactetgee aagaaceatg ttaagaetge

tttctgcttt aactactaat agtcttgatt ataggaacgg aatttgtgta tcaagtaggt

tctaagaact	taacataaaa	actggctatt	aatgcatttg	caaaatttgc	attttaaatc	300
ceaggcaaga	acaggtcagg	caaaaatgga	atccaaacac	caaattgtta	aaagttotaa	360
gtccatttct	cttgttagtt	tgcaacttaa	attactaatt	ctctaatgtt	t-tagagcaga	420
agttggtaaa	ttgtttctgt	aaaaaaattg	tttctttaaa	ttgtttcata	atcaaaattt	480
taggttgtgt	aggtgatact	gtttctgttg	aaattattta	atctaaataa	atggacatag	540
ctgtgttcta	acaaaacttt	atgattaacc	tgacaggeca	gatttgaaat	gttagcaggt	600
ttgcacaccc	ctactttaga	aaaactcagt	ctttatagct	tecagttaca	agatgtatct	<b>1</b> 660
etetetet	ttttttaaa	taagacagta	ttattncaaa	tgtcgggtgg	cecataccna	720
aatttgtttc	ccenttettn	anttttcnaa	angtggggcc	caaanacttn	aaaaggtngn	780
annentttnn	nntaanaaaa	nanccattta	ggggnttntn	caaccectnn	aaaaantttt	840
tttcttnaaa	aanaantnca	naaaannntn	ctnaaaaaan	naaaggggcc	caccentent	900
tttaaaac		•				909

<210> 78

<211> 890

<212> DNA

<213> Cercopithecus aethiops

<220>

<221> misc\_feature

<222> (1)..(890)

<223> n is a, g, c, or t

<400> 78

gnnntnenne tttnnnngat eageegenee neagnneece accaateena ettggtgtaa 60 120 acccccage agggtettgg getttettte tgetteteea aaatgggeet ggetteecag gagacageeg agagegeete geceetgetg gaagggeage etgggagetg gagttggeaa 180 acgggaggg acgggaggag gcccagggga gggggggtet tecettaget tteagegaca 240 300 tctgctggcc gtgcgctgaa ctgccgctac cccagaggcc agctggagac caattttgag ttgtgagcag ggaaagagag gaggggttcc aggacaatca ggtctggagc ttccagaaac 360 attecaaaaa cacagtttag getttttaat tgtteactea gteattetee eggggtetag 420 ggagaaatcg gactcagact cggatctttg gggacctacc gcagcatgat aacccaggtg 480 tacctggggc tcatgggggc ctgggggatca gggaggcccc tcacctgcat tcactgtgtg 540 ccaagcactg gcctacatca ctgacatttg ctgtctcgct gcgggtgctg tgatcttgct 600 gctgtgctca tttgacagat gaaaacgctc aggttgtgag agaaccccaa agccagagga 660 ttcccttgat cactecectt ccttcatgcc catagtcaat ccttcttcaa agcctatccg 720

WO 2004/070002	PCT/US2003/037143

teccacetee	aaagcacacc	atggatgccc	atccttggcc	catcatcgtt	acectctnag	780
tgccagcctg	cctgancccc	tcanttnaag	teecgeteec	tggccttttg	cagaagcatc	840
ccaccagaat	ctncaagcca	eccetecena	nttententt	cccaaatggc		890

<210> 79
<211> 965
<212> DNA

<213> Cercopithecus aethiops

<220>
<221> misc\_feature
<222> (1)..(965)
<223> n is a, g, c, or t

<400> 79 ntttctggnn gtnacagang gggngccnnn ccccccatn aactgggggn aaacncnccc .60 agccccaagg tggccattgt cagggaggtg cttgctatgc agatgtgccg ttcaaaggca 120 tgcagatatg aaagcatcgc tccctcaggt gggagacaat gggaaggtcg agagcactgt 180 ggttaggagc aaggetttgg aattagcagt coetgeatte aaateetage tttacttgee 240 tcatgacage egtetgteet tgagcaaaat tgtttaaeet etetggacet gtetatatet 300 gtaaaaaggg ccaacatggt gtacccaaaa gccttgtcgt ggtgatctca ttaagatatt 360 420 tcatgtgaat atgtgctgag tggcctcacg taggaggtgc ttactgactt ctcccaagcc 480 controlled categoract georgeotyc gtatecteca geotoctece acgettecte 540 tractgract tittgggggt gagggaggre attictgagt carttgreec tggacttgat gaattccatt cgtgtggcgg gggcagcagg gcccagtgtg aaccagcagc tccccaaccc 600 660 tgcccactat accactcaag tgagtccaag ctgtgatgcc cctggctgcc tcccccactt 720 cccttgagcg agctgggagg acaaagattg gactctgagg atcagcctga gacttaagat ggaggetgtg ttcccgagag cccagggtgg gcatgccagg aagcactctg gctccacgga 780 atgctgcact gccccggggc tggcanacca ncacttcctt gtnttnctgg gtctnacagn 840 cncancetgg eetgggetgt tittgentgn tgnacetgee tnaaannggn aaancetggn 900 ancetggagn cttccnaggt ttngnttttc caanenceca aaattangne naacengnet 960 965 nnggc

<220>

<sup>&</sup>lt;210> 80

<sup>&</sup>lt;211> 891

<sup>&</sup>lt;212> DNA

<sup>&</sup>lt;213> Cercopithecus aethiops



<221> misc\_feature
<222> (1)..(891)
<223> n is a, g, c, or t

**≮400> 80** tttggtaact gtcagaccaa gttttactca tatcggatcc tctctatcag attgatctgc 60 aggtgagggt gtccagagat gtcttgcaaa tggcaatgtc ccaggccatg gaaacaggaa 120 tatgggetea aatecattta tggeeaggea tggtggetea tgeetgtaat cecaacaett 180 tgggaggtca aggcaggagg attgcttaag cecaggagtt caagaccgtc tgggcaacgg 240 300 agaggagacc ctgtctctac aaataattaa aaaattatct gagcatagtg gcacatgcgt gtggtcccag ctactcggga ggctgaagtg ggaggatcgc ttgaggccaa gaggtcaagg 360 ctgcagtgaa ctgtgatcat accacggcac ttgagcctgg gcgacagagc aagaccctgt 420 ctttctttt tttttcaaa aaaaaaaaat ccatttataa tttaacatgg gagcctcacg 480 ggaaagagtt ettgteettgt tgagtggtee agtgttttgg atgggetgga aetttgeaet 540 tgatgtgttg taattcattt tctagagtct atgtcgtgaa ggtccttggg gtgatagagc 600 cttggaaaaa tgttgtttcc ctgtggatta tctaaactag atccaagaac atgaaagacc 660 atccctcagg gagetggcat ttgtctaaaa accancattn cctgggccat ttgattgggg 720 ntcttgcttc actgcaaang ggggacttgc aaaattttac tnatgncccn nttgttnttt 780 ttntccaagg ggnttttana aaatttttct tnncnntttt ncnnaanacc ccnttnnant 840 891 tntnttttnc nnccccnttt nttntaacna nggggggntt ttnaacnnec n

<210> 81

<211> 803

<212> DNA

<213> Cercopithecus aethiops

<220>

<221> misc\_feature

<222> (1)..(803)

<223> n is a, g, c, or t

400> 81

tggtaactgt cagaccaagt ttactcatat cggatccctt ctggtcccac atcactcagg 60
caactctctc ttcccacctg cccccaaac tcccttccac ctccctccac atgtatcctc 120
ccactcctt ccactcatgt aatgagaggt gctgatgagt cacaggagag gtagccctag 180
ataaccaaca gactgcaaaa cggacagtcc ctggatgtct gagccagtgt ttgtgcactg 240
cattgactgg ctcctcgtag tttttccctg tagttgctaa agcctgtaag gtctgtgtga 300
tgaatattt ctaacacatc ttagaagaac ataatgcaag acagaatgaa aaactagaga 360
ggcagaaacc cccaaagtaa gtagtgggaa attaccaggt atataatagg tcaagcctgc 420

#### PCT/US2003/037143

# WO,2004/070002

torgraggag etcaagggat tgtagcatte ttateecaaa ecactgaate etggges	aaa 460
ataagaagtc gectaatttt agtattaeca getteecaac .cccgggeatt etteate	tta 540
ctcaagetgt ccagaggece cagggtgact ccctataagt cccatgggtg getgag	etct 600
atttagaggc acaagggtat ctccttataa gtcccatggg tggctgagat ctatga	gaag 660
catcttgggg agagtgcctc tggccaccag catgtggccc tgaatctttc atgtgc	aact 720
ggecagggaa ggaaattatg gaaatagtea teetgeacat ntgeaaatga gatgea	aatc 780
ctggaagete ttetaaaaaa aaa	803

**<sup>&</sup>lt;210> 82** 

<220>

<221> misc\_feature

<222> (1)..(763)

<223> n is a, g, c, or t

<400> 82 tegtgettta eggtategee geteeegatt egeagegeat egeettetat egeettettg 60 acgagttett etgageggga etetggggtt egaaatgage tageeettaa gtaacgeeat 1-20 tttgcaaggc atggaaaaat acataactga gaatagaaaa gttcagatcg aggtcaggaa 180 cagatggaac agggtcgacc ggtcgaccgg tcgaccctag agaaccatca gatgttteca 240 300 gggtgcccca aggacctgaa atgaccctgt gccttatttg aactaaccaa tcagttcgct tetegettet gttegegege ttetgetece egageteaat aaaagageee acaacecete 360 acteggggeg ccagtectee gattgactga gtegeeeggg taceegtgta tecaataaac 420 ectettgcag ttgcatecga ettgtggtet egetgtteet tgggagggte teetetgagt 480 gattgactac ccgtcagcgg gggtctttca gtagcccttc ctttgtagca aagacagaca 540 gatggtgatc caagagatac gcaagaagag gaccgtgtgt gtaatggttg agctctaaaa 600 660 agagaaatca cttggatgga aatgaaggag aggaaaaggc tgatgtggat ggctgggaag aggitegatg gitacettgg caacegaget tetteteat eccatecett ecctagiect 720 763 tgtcttaaaa gatttttttn tatgtccctt ccctcccaag ggg

<sup>&</sup>lt;211> 763

<sup>&</sup>lt;212> DNA


<sup>&</sup>lt;213> Cercopithecus aethiops

<sup>&</sup>lt;210> 83

<sup>&</sup>lt;211> 861

<sup>&</sup>lt;212> DNA

<sup>&</sup>lt;213> Cercopithecus aethiops



<220> <221> misc_feature <222> (1)(861) <223> n is a, g, c, or t	
<400> 83 ttggggganc ctgtcagnac canttttact catateegga teetgaeeta catteagtgt	60
tctagattga aatcacagat tttggataga gaaaaaaaaa tattctctgc aatctaataa	120
aaccaacttt ttttttttt tttttttt ttgagacaga gtcttgctcc atggcccagg	180
ctagagtgca gtagcacgat ctcggcttgc tgcaacctct gcctgtcggg ttcaaccgat	240
totootgoot cotgtotoot geoccagoot ntcaagtago agggattaca ggcatgtgoo	300
atgatgccca gctagttttt tgtatttta gtagagatgg ggtcttgcca tgttgcccag	360
getggaettg aacteetgae etcaggtgat caggecatet tggeetecca aagtgttggg	420
attacaggcg tgagccatcc tgcctggcca aaaccagcat atttatgga taggaaattg	480
gaccaaaggc gaatctttta ttgcaggctg tgggnttttt ccatgtggct ggtggnacac	600
tgcaccaagc agcacacaca ctaggccagt ttnctttgca gacccagttg caatcccatc	660
tntnagccag gattctatta ggtctcnaca accnatggga atttagggng ctcanagntt	720
nngggtggga aaaggggact aacctncntg ggttnanggn tttnnaantg gncncnncct	780
ttggancngg ganatttatt necaaaanng gnngggntng tnttngggnn anaaaccaaa	840
-tttgggaaa aaancntttt t	861
<210> 84 <211> 767 <212> DNA <213> Cercopithecus aethiops	
<220> <221> misc_feature <222> (1)(767) <223> n is a, g, c, or t	
<pre>&lt;400&gt; 84 ggnattgncn ageggntaac aattteacac agnaatteeg tatttgaaat ttggggacaa</pre>	€0
togottgaat ottaaaatta ottttotggt cacgogogoo gaaggtotaa goatttgtga	180
aatgtetttt tteececce ecacecettg atgetgttet etttgggetg tettaattae	240
acaggggttg agaaaccaaa ttaaaattag gcgtgtctgg tcaacagtga tcacgttgca	300
tgcttttagc tttgcttgtt gaagttgctt ctoctccctg agtggctttc ctccttttt	360

tttttttt tttatttaa aaaggaaata tcataagctc tttcagaaat actcacagga

agtgagtgtc	cgtatgctgg	ttactcacca	gcaactgant	geeggeagge	ggagaatget	480
accgcanccn	cccanacaga	tctgcaaact	ggecentine	agangatnaa	aacagggtgc	540
gtggaantan	ggtttttgnn	naaangcant	ttnaaagnaa	atgggcactg	cattnnnttc	600
naggggggg	anttaagnaa	cangnttggg	gtnaaaaagn	ncntgnttcc	attnnggngg	660
tnetgeteet	ttnaaanggg	nggnnggttt	naaaaaaaag	ggccccncnc	cccanaaaaa	720
aattttttgg	nggaaaacct	nccaaaaaaa	anaccecncn	ttttgn		767
						-

<210> 85 <211> 761

<212> DNA

<213> Cercopithecus aethiops

<220>

<221> misc\_feature

**<222>** (1)..(761)

<223> n is a, g, c, or t

<400> 85

cngcttgcca acctacaggt ggggtctttc aaaatattgc gttacaaata tcattttggt . 60 gtatgtatgt caaaaccaaa actgccttta tgtcaatatg ctgtaaaaat ctatcagaat 120 atatettaat tettaaettt cattgttgte tgtgggttgt ettgtataat tattateaea 180 tctacagtat tttctgtagg taaatatgaa atgtattata aatgtaccag ggggaaaatg 240 ccctttaata agcctttccc tagacaaagc accatttagg cgtttagaag caagaactag 300 360 tgaaatcaga aattgctgtc atacatactc acctgtgaat ggtcgtacaa aggatcccaa gcgcaggact tgtcctggaa gcagaggatc ggattccacc aggaaaagag gcaagtagaa 420 atgecaaatg ecagegetee etttneecag eteatettat ttgtaggeae teagattttg 480 gaateeteea ggactaacat taaaaceeca etagggngtt tneetaatne egggaaanga 540 gncagtaggn caaacaactt atccccncna nanaggaaca attccttgag ctccccncct €00 gtttcngaaa ccctnttccc ttntgggncc ctgnanaagg nctgcccnaa tgctngggag 660 ncencenggt tttnatgaaa accatntnaa aatneeenaa agttneeece eeaaggnaan 720 761 nttccnttta aanttttggg aaaaaaaancc ccntnanaaa n

<210> 86

<211> 791

<212> DNA

<213> Cercopithecus aethiops

**∠220>** 

<221> misc\_feature

<222> (1)..(791)

#### PCT/US2003/037143

**WO 2004/070002** 

<223> n is a, g, c, or t

≼400> 86						
tnggggacca	gcttgccaaa	tctacaggtg	gggtctttca	aaatattgcg	ttacaaatat	60
cattttggtg	tatgtatgtc	aaaaccaaaa	ctgcctttat	gtcaatatgc	tgtaaaaatc	120
taccagaata	tatcttaatt	cttaactttc	attgttgtct	gtgggetgte	ttgtataacn	180
attatcacat	ctacagtatt	tectgtaggt	aaatatgaaa	tgtattataa	atgtaccagg	240
gggaaaatgc	cctttaataa	gectttccct	agacaaagca	ccatttaggc	gtttagaagc	300
aagaactagt	gaaatcagaa	attgctgtca	tacatactca	ectgtgaatg	gtcgtacaaa	360
ggateceaag	cgcaggactt	gtcctggaag	cagaggatcg	gattccacca	ggaaaagagg	420
caagtagaaa	tgccaaatgc	cagegetece	tttccccagc	tcatcttatt	tgtaggcact	480
cagattttgg	aatcctccag	gactaacaat	aaaaaccaca	ctaggttgtt	ttcctaattc	540
ctgtgaaatg	agtcagtagg	tcaaacaact	tatccactcc	agagagagaa	caattccttg	600
agctacactc	cctgtttcca	gtaacectat	tecetetetg	tgtccctgga	taaagtgctg	6 <del>6</del> 0
ncnacaatgc	atgganagec	cccgggttct	gatgaaancn	atngaaagat	ngcanaaagt	720
agctgcctta	agggaangtt	cccttngaaa	tttaggnaaa	aaaanccnnt	aaaaanacng	780
gnggtcggtt	t					791

<210> 87

<211> 783

<212> DNA

<213> Cercopithecus aethiops

<220>

<221> misc\_feature

<222> (1)..(783)

<223> n is a, g, c, or t

<400> 87 ttgggganca gcttgccaan tctacaggtg gggtctttca aaatattgcg ttacaaatat 60 cattttggtg tatgtatgtc aaaaccaaaa ctgcctttat gtcaatatgc tgtaaaaatc 120 tatcagaata tatcttaatt cttaactttc attgttgtct gtgggttgtc ttgtataatt 180 attatcacat ctacagtatt ttctgtaggt aaatatgaaa tgtattataa atgtaccagg 240 300 gggaaaatgc cctttaataa gcctttecct agacaaagca ccatttaggc gtttagaagc aagaactagt gaaatcagaa attgctgtca tacatactca cctgtgaatg gtcgtacaaa 360 ggatoccaag cgcaggactt gtcctggaag cagaggatcg gattccacca ggaaaagagg 420 caagtagaaa tgccaaatgc cagcgctccc tttccccagc tcatcttatt tgtaggcact 480 cagattttgg aatcetecag gactaacaat aaaaccacac taggtnggtt teetaattee 540

#### PCT/US2003/037143

# WO,2004/070002

:	tgtgaaatga	gtcagtaggn	caannantta	thenetecag	agagagaaca	attccttgng	600
٠	ctecactccc	tgtttcnnna	acconattno	ctttctgngn	ccctgganaa	aggggtgccc	660
	•		ccggntcttg				720
•	anceteente	nanggaagnt	teecetttta	aattttnggn	naaaaaannc	ccttnaanta	780
(	ann						783

<210> 88 <211> 769 <212> DNA <213> Cercopithecus aethiops

<220>
<221> misc\_feature
<222> (1)..(769)
<223> n is a, g, c, or t

**∠400> 88** 60 ttggnattgn ccagcggnta acaatttcac acagnaattc cgtatttgaa atttggggac aaacaaacat aactettet ettteettga agggttaatg etecaaecag eetcagattg 120 gttcgcttga atcttaaaat tacttttctg gtcacgcgcg ccgaaggtct aagcatttgt 180 gaaatgtett ttttcccccc ccccacccct tgatgctgtt ctctttgggc tgtcttaatt 240 300 acacaggggt tgagaaacca aattaaaatt aggcgtgtct ggtcaacagt gatcacgttg 360 catgetttta getttgettg ttgaagttge tteteeteec tgagtggett teeteetttt 420 ttttttttt tttttatttt aaaaaggaaa tatcataagc tctttcagaa atactcacag 480 gaagtgagtg teegtatget ggttaeteac cageaactga gtgttggeag gtggagaatg 540 ctaccgcagc cgcccagaca gatctgcaga ctggccccat tgcagangat tagacacagg 600 gtgcgtggat catangggtt tttgtacaga aggcagtttt aagangaaan tgggcactgc atgtcatctc nanggggngg tgattcangg ancanggctg ggggtnaaaa gcacctggct 660 gccattnngg agntcctgct aatttttaaa nggcagggtg gttttaaaaa aaaagctccc 720 ccccccaa aaannnnttt tttggaggna naacttccaa aangaanga 769

<210> 89 <211> 754 <212> DNA <213> Cercopithecus aethiops

<220>
<221> misc\_feature
<222> (1)..(754)
<223> n is a, g, c, or t.



<400> 89 cagettgeca acctaeaggt ggggtettte aaaatattge gttacaaata teattttggt **\*60** gtatgtatgt caaaaccaaa actgccttta tgtcaatatg ctgtaaaaat ctatcagaat 120 atatcttaat tettaaettt cattgttgte tgtgggttgt ettgtataat tattateaca 180 tctacagtat tttctgtagg taaatatgaa atgtattata aatgtaccag ggggaaaatg 240 300 ccctttaata agcctttccc tagacaaagc accatttagg cgtttagaag caagaactag tgaaatcaga aattgctgtc atacatactc acctgtgaat ggtcgtacaa aggatcccaa 360 gcgcaggact tgtcctggaa gcagaggatc ggattccacc aggaaaagag gcaagtagaa 420 atgecaaatg ecagegetee ettteeceag eteatettat tigtaggeae teagatitig 480 gaatocteca ggactaacaa taaaaaccac actaggttgt totcctaatt cetgtgaaat 540 600 gagtcagtag gtcaaacaac ttatccactc cagagagaga acaattcctt gagctacact ccctgtttnc agtaacccta ttccctctct gtgtccctgg ataaagtgct gcnacaatgc 660 atggggagnc caccgggttc tgaatgagac aatcgtaaan atngccaaaa nttagctgcc 720 754 ntcangggaa anttnecntt tgaaatttaa gnaa

<210> 90

<211> 866

<212> DNA

<213> Cercopithecus aethiops

<220>

<221> misc\_feature

<222> (1)..(866)

<223> n is a, g, c, or t

<400> 90 tnggggaacc ctgnccagna cetttttac tcatatecgg atectgacet acatteagtg 60 120 ttctagattg aaatcacaga ttttggatag agaaaaaaaa atattctctg caatctaata aaaccaactt tttttttttt tttttttt tttgagacag agtcttgctc catggcccag 180 gctagagtgc agtagcacga tctcggcttg ctgcaacctc tgcctgtngg gttcaaccga 240 tteteetgee teetgtetee tgeeccagee inteaagtag cagggattae aggeatgtge 300 catgatgccc agctagtttt ttgtattttt agtagagatg gggtcttgcc atgttgccca 360 ggctggactt gaactectga cetcaggtga tcaggecate ttggceteec aaagtgttgg 420 gattacaggc gtgagccatc ctgcctggcc aaaaccagca \*tattttatgg ataggaaatt 480 gaggettaga tggggggaga aaaacattac acagattaaa ccacagetaa tgtcaagtgg 540 600 tgaccaaagg cgaatctttt attgcaggct gtgggttttt ccatgtggct ggtggtacac

WO 2004/070002	PCT/US2003/037143
··· • #004/0/0002	2 02,000.00.00

tgcaccaagc	agcacacaca	ctaggccagt	ttcctttgca	gacccagttg	caatcecatc	660
tntaanccag	gatactatta	ggtetenaca	ncctatggna	ttttagggtg	ctcanagttt	720
agggtgggaa	aaggggacta	anctncttgg	nttaaggtnt	ntccactggn	ccctcncttt	780
nggneenggg	antttnatgc	ccaeaancgg	tngggctttt	ttgggggnan	aannecaane	840
cnngggaaaa	aaacntttt	gttang				866
,				•	•	
<210> 91	**					
<211> 783						
<2'12> DNA			•			-
<213> Cer	copithecus	aethiops				
1		m crr opp				

<220>

<221> misc\_feature

<222> (1)..(783) <223> n is a, g, c, or t

<400> 91

tgggnntgnc cagcggnt	aa cantttcaca	cagaattccg	tatttgaaat	ttggggacaa	<b>€0</b>
acaaacataa ctctttct	ct ttccttgaag	ggttaatgct	ccaaccagcc	tcagattggt	120
tcgcttgaat cttaaaat	ta cttttctggt	cacgcgcgcc	gaaggtctaa	gcatttgtga	180
aatgtettt tteecee	ec ecaeccettg	atgctgttct	ctttgggctg	tcttaattac	240
acaggggttg agaaacca	aa ttaaaattag	gcgtgtctgg	tcaacagtga	tcacgttgca	300
tgcttttagc tttgcttg	tt gaagttgctt	ctectecetg	agtggctttc	ctccttttt	360
tttttttt tttattt	aa aaaggaaata	tcataagctc	tttcagaaat	actcacagga	420
agtgagtgtc cgtatgct	gg ttactcacca	gcaactgagt	gttggcaggt	ggagaatgct	480
accgcagccg cccagaca	aga tctgcagact	ggccccattg	cagaggatta	gacacagggt	540
gcgtggatca tanggtt	tt gtacagaagg	cagttttaag	aggaaattgg	tcactgcatg	600
tcatctcgag gggtggt;	gat tcaaggagca	gggctngggg	gtcanaangc	acntggctgc	660
catctcgggg gttcctg	ctc acttntnaaa	gggcaggctg	gcttntaaaa	anaaatgctn	7-20
ccttcacccc caaanag	gga tttttttgc	agngaataac	ttcccaaaaa	tgaatngccc	780
«cna					783

<sup>&</sup>lt;210> 92

<sup>&</sup>lt;211> 775

<sup>&</sup>lt;212> DNA

<sup>&</sup>lt;213> Cercopithecus aethiops

<sup>&</sup>lt;220>

<sup>&</sup>lt;221> misc\_feature

<sup>&</sup>lt;222> (1)..(775)



<223> n is a, g, c, or t

<400> 92 ttggggaanc agcttgccaa anctacaggt ggggtctttc aaaatattgc gttacaaata 60 tcattttggt gtatgtatgt caaaaccaaa actgccttta tgtcaatatg ctgtaaaaat 120 ctatcagaat atatcttaat tcttaacttt cattgttgtc tgtgggttgt cttgtataat 180 tattatcaca tctacagtat tttctgtagg taaatatgaa atgtattata aatgtaccag 240 300 ggggaaaatg ccctttaata agcctttccc tagacaaagc accatttagg cgtttagaag caagaactag tgaaatcaga aattgctgtc atacatactc acctgtgaat ggtcgtacaa 360 aggatoccaa gcgcaggact tgtcctggaa gcagaggatc ggattccacc aggaaaagag 420 480 gcaagtagaa atgccaaatg ccagcgctcc ctttccccag ctcatcttat ttgtaggcac tcagattttg gaatcctcca ggactaacaa taaaaaccac actaggttgt tttcctaatt 540 cctgtgaaat gagtcagtag gtcaaacaac ttatccactc cagagagaga acaattcctt 600 gagetacact ceetgtttee agtaacceta tteeetett gtgteeetgg ataaagtget 660 gccaanaatg catggagagn cccccgggtt ttgaatgana cccatcgtaa agatngccaa 720 775 aagntagctg ccttcaaggg aagttnccnt ttganattta gnagaaaaag tccnt

<400> 93

60 ttngggganc tagcttgcca aanctacagg tggggtcttt caaaatattg cgttacaaat atcattttgg tgtatgtatg tcaaaaccaa aactgccttt atgtcaatat gctgtaaaaa 120 tctatcagaa tatatcttaa ttcttaactt tcattgttgt ctgtgggttg tcttgtataa 180 ttattatcac atctacagta ttttctgtag gtaaatatga aatgtattat aaatgtacca 240 gggggaaaat gccctttaat aagcctttcc ctagacaaag caccatttag gcgtttagaa 300 gcaagaacta gtgaaatcag aaattgctgt catacatact cacctgtgaa tggtcgtaca 360 aaggateeca agegeaggae ttgteetgga ageagaggat eggatteeac caggaaaaga 420 ggcaagtaga aatgecaaat gecagegete eetttnocca geteatetta titigtaggea 480 ctcagatttt ggaatcctcc aggactaaca ntaaaacccc actagggggn ttncnnantc 540 ctgngaaatg agtcagtagg ncaaacannt ttncheteca nanannnaan anteentggn 600

<sup>&</sup>lt;210> 93

<sup>&</sup>lt;211> 837

<sup>&</sup>lt;212> DNA

<sup>&</sup>lt;213> Cercopithecus aethiops

<sup>&</sup>lt;220>

<sup>&</sup>lt;221> misc\_feature

<sup>&</sup>lt;222> (1)..(837)

<sup>&</sup>lt;223> n is a, g, c, or t

ntacnetece tgnttcagna accenattce etnentgggn cenggnaaaa gggegneeca	660
aatggnnggg ngncccccgg nttntnanga aacccatnnt aaaattnccc aaaantttnc	720
ncccnnann gaaannnncc nttttaaatt ttngganaaa aaancoccnt naaaaaaana	780
ngggggcggn tttnttttn aaagaaanaa anatttttt ttnngggagg ggttnnt	837
<210> 94 <211> 837 <212> DNA <213> Cercopithecus aethiops	
<220> <221> misc_feature <222> (1)(837) <223> n is a, g, c, or t	ı
<400> 94 ttggggnacc ctgncagncc antittactc atatcggatc ctgacctaca ttcagtgttc	60
tagattgaaa tcacagattt tggatagaga aaaaaaaata ttctctgcaa tctaataaaa	120
ocaacttttt tttttttt tttttttt gagacagagt cttgctccat ggcccaggct	180
agagtgcagt agcacgatct eggettgetg caacetetge etgtegggtt caacegatte	240
tectgeetee tgteteetge eccageetet caagtageag ggattacagg catgtgecat	300
gatgcccagc tagttttttg tatttttagt agagatgggg tcttgccatg ttgcccaggc	360
tggacttgaa ctcctgacct caggtgatca ggccatcttg gcctcccaaa gtgttgggat	420
tacaggegtg agecatectg cetggecaaa aecageatat tttatggata ggaaattgag	480
gettagatgg ggggggaaaa anentineee aaattaanee acagettatg tnaagiggitg	<b>-540</b>
gncccaggcg gnccnnnctt tggnccnttt tcttttggaa cccngntgca atcccctttt	660
taanceggga atettttggg ttteneneec ettgggnatt nngggggeec caantinngn	720
nggggnaagg ggnaaaaacc cctttggntn agggntttaa aangggnccc ccctttggnc	· 780
cngggnnttt tntnccnaan ngggnggggt ttttttgngg annaacncnn acnnggn	837
<210> 95 <211> 812 <212> DNA <213> Cercopithecus aethiops  <220> <221> misc_feature <222> (1)(812) <223> n is a, g, c, or t	
•	

#### PCT/US2003/037143

		_
WO:	2004/0	70002

ttagggttag	gagcggntaa -	cantiticaca.	cagaatteeg	tatttgaaat	ttggggacaa	60
Salah Baran	ctctttctct					120
tegettgaat	cttaaaatta	ctttbctggt	cacgcgcgcc	gaaggtetaa	gcatttgtga	180
acaggggttg	agaaaccaaa	ttaaaattag	gcgtgtctgg	tcaacagtga	tcacgttgca	300
tgcttttagc	tttgcttgtt	gaagttgctt	ctectccctg	agtggctttc	ctccttttt	360
tttttttt	ttatttaa	aaaggaaata	tcataagctc	tttcagaaat	actcacagga	420
agtgagtgtc	cgtatgctgg	ttactcacca	gcaactgagt	gttggcaggt	ggagaatgct	480
accgcagccg	cccagacaga	tctgcagact	ggececattg	cagaggatta	gacacagggt	540
gcgtggatca	tagggttttt	gtacagaagg	cagttttaag	angaaattgg	tcactgcatg	600
tcatctcgag	gggtggtgat	tcanggagca	gggctggggg	tcanaangca	cgtggctgca	660
teteggnggt	nctgctcant	tttaaagggn	ngctggnttt	aaaaataang	ntncttcacc	720
ccaaaangaa	ttttttgcag	gnaaannttc	naaaaganna	cccnantttt	tgnnaaaacn	780
tgggaaancc	ccntttnaan	ggnggnttta	an			812

<sup>&</sup>lt;210> 96

<220>

<221> misc\_feature

<222> (1)..(805)

<223> n is a, g, c, or t

**<400> 96** 

ttgggganen gettgeeaan tetacaggtg gggtetttea aaatattgeg ttacaaatat 60 cattttggtg tatgtatgtc aaaaccaaaa ctgcctttat gtcaatatgc tgtaaaaatc 120 tatcagaata tatcttaatt cttaactttc attgttgtct gtgggttgtc ttgtataatt 180 attatcacat ctacagtatt ttctgtaggt aaatatgaaa tgtattataa atgtaccagg 240 gggaaaatgc cctttaataa gcctttccct agacaaagca ccatttaggc gtttagaagc 300 aagaactagt gaaatcagaa attgctgtca tacatactca cctgtgaatg gtcgtacaaa 360 ggatcccaag cgcaggactt gtcctggaag cagaggatcg gattccacca ggaaaagagg 420 caagtagaaa tgccaaatgc cagcgctccc tttccccagc tcatcttatt tgtaggcact 480 cagattttgg aatcctccag gactaacaat aaaaaccaca ctaggttgtt ttcctaattc 540 ctgtgaaatg agtcagtagg tcaaanaact tatccactcc agagagngaa caattccttg 600

<sup>&</sup>lt;211> 805

<sup>&</sup>lt;212> DNA

<sup>&</sup>lt;213> Cercopithecus aethiops

WO 2004/070002		PCT/US2003/03	7143
agetacacte cetetteag naaccetatt eceteteteg	gtecctggat	aaagggctgc	660
cacaatgcat ggggageeee enggntnttg atggnaacae	tcntaaaaat	tgccaaaagn	720
tnnctgcctn aangaaaant nccctttnaa tttttggana	aaaaanccct	<pre>tnaanaaacn</pre>	780
ggggggggt ttttcnttaa agaaa			805
<210> 97			
<211> 854			•
<212> DNA <213> Cercopithecus aethiops		•	
<213> Cercopithecus aethiops		•	
<220>			
<pre>&lt;221&gt; misc_feature   &lt;222&gt; (1)(854)</pre>			
<223> n is a, g, c, or t	i		
<400> 97			
ttggggaacn ngcttgccaa ntctacaggt ggggtctttc	: aaaatattgc	gttacaaata	60
tcattttggt gtatgtatgt caaaaccaaa actgccttta	tgtcaatatg	ctgtaaaaat	120
ctatcagaat atatcttaat tottaacttt cattgttgto	tgtgggttgt:	cttgtataat	180
tattatcaca tctacagtat tttctgtagg taaatatgaa	a atgtattata	aatgtaccag	240
ggggaaaatg ccctttaata agcctttccc tagacaaag	accatttagg	cgtttagaag	300
caagaactag tgaaatcaga aattgctgtc atacatact	e acctgtgaat	ggtcgtacaa	360
aggateceaa gegeaggaet tgteetggaa geagaggate	ggattccacc	aggaaaagag	420
gcaagtagaa atgccaaatg ccagcgctcc ctttcccca	g ctcatcttat	ttgtaggcac	480
tcagattttg gaatceteca ggactaacaa taaaaacca	c actaggttgn	tttcctaatt	540
cctgtgaaat gagtcagtag gtcaaacaac ttatccact	c cagagagaga	acattteett	600
gagetacact neetgnttee agtaacceta tteeetete	t gggteeetgg	g ataaagggct	660
gccnacaatg catngggggg ccccccgggt tntgaanga	a aannntnntt	: aaaaatngcc	720
aaaanntaac tneecteaan ggnnannnne eeettttna	a ntttttgggr	i aaaaaaaanc	780
ceentnaaaa aananagggg gggnggnttt tetttinna	a aanaanaanr	aannttttt	840
tttggggnan annt			854
<210> 98			
<211> 912	•		
<212> DNA <213> Cercopithecus aethiops			
-2137 Cercopronecus decurops			
<b>&lt;220&gt;</b>			
<221> misc_feature			
<222> (1)(912)			



<223> n is a, g, c, or t

<400>	98						
		ggggnntgna	gcgncggctn	aactttttg	cacacagaaa	ntcacaggaa	€0
cacagga	igtc	agtttcttca	gcaangtctt	gcttgtecng	ttntgaacgg	taggatnttg	120
tcgctat	att	tgnacacatg	agggacctnt	gtggagcttc	caaatagtgc	gctnggcgca	180
atatnna	acaa	ganacagece	ttagcgantg	gcttgttgnt	gggngagatg	ntgetetgtg	240
ngatgaa	attn	acanatcaca	gagtttttn	tttgnntgct	tgttteetgt	tntnaacggt	300
ggattt	gtgn	·tttggacca	tgggatntct	atgggctnan	agangteeta	tgtgngaata	360
nggcaa	tgta	ctgcctttna	naactggaat	gangetnggt	gagaanctgc	tetgtgttet	420
gtgant	tecg	tactntgaaa	tttggggacn	aacaaacata	netettttt	ctttecttg	480
aagggn	taat	tgctccaacc	ccgccncaga	ttgggntngc	ttgaatetta	naattnettt	,540
tctggt	cccg	cccgccgang	gntnagcttt	tgngnaaatg	gtntttttc	-cececececa	600
cccctt	ggtg	gngggtnttt	ttgggcttgg	nnttnanntn	ccccggggg	nntngnnnna	660
ccnatt	ttnn	attttgggnn	nttttgggnc	ncangggttc	cnnnnnnnn	gnctntnann	720
cttggc	ttgn	nngaangntg	nttntcccc	cccggggggg	tteccecent	tttttttt	780
tttntt	ttt	tttnnagggg	anttttntng	tcttttnna	annenenegg	gntggggggn	840
tenntt	ttt	gttttnncn	nnnnttggnn	nnggggggg	gganntttct	ctnnneccc	900
cnnnnt	ttnn	gc					912

<sup>&</sup>lt;210> 99

<220>

<221> misc\_feature

<222> (1)..(807)

<223> n is a, g, c, or t

<400> 99

ctgcttgcca anctacaggt ggggtctttc aaaatattgc gttacaaata tcattttggt 60 gtatgtatgt caaaaccaaa actgccttta tgtcaatatg ctgtaaaaat ctatcagaat 120 atatcttaat tcttaacttt cattgttgtc tgtgggttgt cttgtataat tattatcaca 180 tctacagtat tttctgtagg taaatatgaa atgtattata aatgtaccag ggggaaaatg 240 ccctttaata agcctttccc tagacaaagc accatttagg cgtttagaag caagaactag 300 tgaaatcaga aattgctgtc atacatactc acctgtgaat ggtcgtacaa aggatcccaa 360 gcgcaggact tgtcctggaa gcagaggatc ggattccacc aggaaaagag gcaagtagaa 420

<sup>&</sup>lt;211> 807

<sup>&</sup>lt;212> DNA

<sup>&</sup>lt;213> Cercopithecus aethiops

atgccaaatg ccagcgctcc ctttncccag ctcatcttat ttgtaggcac tcagattttg	480
gaateeteca ggaetaacan taaaaeeeea etaggttgnt tteetaatte etgtgaaatg	540
agtcagtagg tcaaanannt ttncnctcca ganaggaaca attccttgag ctanctccct	600
gtttcaggaa ccctattccc ttntgggncc ctggaaaang gctgccacan tgctgggaag	660
ccccgggtt tnaangnaaa aatcnnaaaa ttgccaaaan tancnncccn agggnnggtn	720
cccttanant tttnggaaaa aanceccnta aaaaancngg ggncgnnttt tnttaaaana	780
aaanaaattt tintingggn gnittinn	807
<210> 100 <211> 814 <212> DNA <213> Cercopithecus aethiops	1
<220> <221> misc_feature <222> (1)(614) <223> n is a, g, c, or t	
<220> <221> misc_feature <222> (1)(814) <223> n is a, g, c, or t	
<400> 100 ttggnattgn ccagcggnta acaatttcac acagnaattc caggcacagt tggctgttaa	60
ctagaatagt aagtggcttc ctaggctctg tcactcctaa actgtagggg gcttccagcc	120
toggagatta oggaagtagt actiticatt agcaagotca agaagaagtg toaaaatagg	180
atgacacttt cctagtcgct ctgcaaaaaac ccaaaaaaacc agaaggggtg tcatctagac	240
actectaagt ctatgeaggt gteageetge ceteaceeaa caceageeag cagegtgeae	300
cattcaacca tatcttaact tgccccttac aaattgacac ttacactaac aagccctttg	360
atctcatttg tttaaaatga cagatataca accetcacgg gggtteccac tcaaggeett neagcetneg neetgeeeet gneeaceece aaacetacac acgtgttage eegacacegg	420 480
ccccaccggg teccacgtge acctggteta acacactnee cacgtgtggg egecceacgg	540
getttetnan gtagetgang gneeceecat gaeeceeggt tntecaaaan aaaaaaaegg	600
gaaggacaag ggcccttttc nccgnggncc caaccntngg ggggggnggt ccaaccctt	660
tnttnnntat aaaceccaaa aaananaaag ggeeeggggn cenneceee eettnaaaaa	720
ncecgncccc cnttttnccc cccnaaaaaa nggggggaaa aaaaaaattt aaaaaaannc	780
	01.4

<210> 101

nttttttnt tttnnccccc ccnncatnta nata

814

```
756
       DNA
 <212>
 <213> Cercopithecus aethiops
 <220>
- <221> misc_feature
 <222> (1)..(756)
 <223> n is a, g, c, or t
 <400> 101
                                                                   120
 tggtcccaga gtctaaatag gagccccaaa ctaatcactg tatggtagtc gaacttcccg
                                                                   180
 gcacttcccc gacaatctac aaccccatcc aaaggggtca gaaactggta ataaaatacc
 agetatgage etnteettee ceteaagaga tetateaatt eggeeteace tteecacete
                                                                   240
                                                                   300
 tagcctgcgg gaacaacat cccaggatcc cgggcggttt cgattgacgt tacttecggg
                                                                   360
 aaaagtaacc ttgcttcggc ggttgcgggc ctgaaaagct ctcgcgacat ttcctcccgc
                                                                    420
 nagatetget tgeteactgt agegatgaca tectectect ectecegge geetttegge
                                                                    480
 aatcttcgcc agtcccagcc ccgaccaatc tgtactcaga tggcatggat cagggtctcc
  cctcgaaccc cggttcgcac ggggcgtcag gtggcagcgg cggggtgcga gctgcgcgag
                                                                   540
  gecnaengea geggeaetge gggtggeeng gggeaggeea caageantga ntgtnggeeg
                                                                    600
  ggecgggggn aacccaeccg ngtagegget enantgntte tggeetgget ttngngeeet
                                                                    660
  tttctccccc ccncangggt tcccgggnnc ctgttncgnt tctttaann ggggaaaggg
                                                                    720
                                                                    756
  geeccecce cecengneca angeceennn aennnt
  <210> 102
  <211> 804
  <212> DNA
  <213> Cercopithecus aethiops
  <220>
  <221> misc_feature
  <222> (1)..(804)
  <223> n is a, g, c, or t
  <400> 102
  tgggntgncc agcggntaac antttcacac agaattccaa ttatggggaa caagacatct
                                                                     60
  120
  gtttctgtct ttgcttcctg tettttcttc cacettactc ctccttcccc ttccccttcc
                                                                    180
  ccttcccctt ccccatcttt gctaccaaaa aaaaatctag agaagccttc tattaacctg
                                                                    240
  aaccecttaa agaagteaga acaaaggeac cacttgeege tttttgggat gtegtgtttt
                                                                    300
```

360

otttatggag tittcaagag taatgggcag atgctttag gtotacagtt ctgctttcct

WO 2004/070002	•	PCT/US2003/037	143
gtattgcact acctgattct ttgacttttg	gagataccag aaattacctt	gtaccatyag	420
aggatttggc tttggcatgt gtaatggcag	atgagageta caaagttaag	agtggctgaa	480
gatggtttac atgaagtggt cttaggtggt	ttagctgagc tcccaggaag	ttgttgtcta	540
ggatcccaat tctagttcag aggtgcattc	ctattattat tatcattact	attggtggtg	600
ntgntattat tttgagacag agtcttgctc	tgttacccca ggctggagtc	etetggcacc	660
attacgggtn actggagcct naanttccag	gctncagaga tectecttt	annetennag	720
tagtgggacn canangnngg nneccccaa	cnnannnatt tttgnncttt	tgnaanaann	780
gggtttgntt tttngncnnn ntgn			804
<210> 103 <211> 795 <212> DNA <213> Cercopithecus aethiops			
<220>			
<pre>&lt;221&gt; misc_feature &lt;222&gt; (1)(795)</pre>			
<223> n is a, g, c, or t			
<400> 103			
ggnattgncn agcggntaac aatttcacac	agnaattetg gagttaggtt	gtctgggcta	€0
ttcaattagt ttctatgtgt ctgacacatg	g gcagaaactt attaaatgct	: tgaatgaata	120
cataaagcaa gatgacagtt tcagaatgna	,		180
aaatttattt tagtctacac agaagtgaag	y taacactaaa atctgggcat	: ttaccaggtg	240
atggcaagta ttcatttcca tcatccagc	c cgttacctgg cacatagtta	a ctgccctatg	300
taaatgetta teacageaat caateaatg	a aatgtttttc tcatagagt	cggtgaataa	360
ctcacgacag catactcaca gaggattca	a agagtatttg acttgtata	t attgttttaa	420
acagttggaa cctgataatg cagttttct	a aaatacagtg aaagggctt	g tectaaaggg 	480
catgtcagga tatgtgtgag aaaggatga	a cttgtcctgt gaagacaac	c ttgcattagc	540
tctagcagaa tgagccattg cctacctgg	g ctggggaagg cggcacctc	a gtatctccct	600
cacctgetee etggeacttt aaateeete	t gtgaagangt cagttgtaa	t tttcagtaag	660
attgaaggtt tcaaagcact gacccctgg	g gggaatggat tngcttaag	t tggctctgaa	720
ngaagngget gggatnnget ntetganaa	a eccgggattg tgaggnaat	g gagacngeeg	780
ggagggtnna anaaa			795

<210> 104

<211> 641 <212> DNA

# <213> Cercopithecus aethiops

₹220>			
<221>	misc_feature		
<222>	(1)(641)		
·<223>	n is a, g, c,	or	ŧ

<400> 104 tgggggnacc cagcggntaa cattttcaca cagaaatctc attcaatgaa ctgttatggg 60 gtotoacatt gtaccaggoa otggggatto agottocagt toatagtotg catgoaaaco 120 gacatgcagg tagacatgca gacagaaaat cggaacgcaa cacggtaagt gctatgctag 180 agaatgagaa ggactgtcag taatcacaac cacetttcac tgggttcctt cagtgtgcca 240 ggctcgtgta cattattttg tttagtgctc acaattgtat ggactgtgta ctatcatttg 300 ccagattata tggatgaaga aactagactg agggggttaa ataactcgtc caagatcatg 360 cagacaaaaa accacagaga ttattttcca atacaaactc tctggctgta cagctcaagt 420 480 tottaaacac tgggccaacc agtotgaatc tgagaggagg cattotaagg ottacaggta 540 agtgggaatt gaaagggttg agggaagcct tctggaggag atgccattac actgaatgtt gaatgagtag gagttagcta tctccagagg ggtagtggct gtgaaggggc gaggggtana 600 641 gggtgggaag gggatgatgg aaggtggtag agtggnnaca g

<210> 105 <211> 757 <212> DNA <213> Cercopithecus aethiops

<220>
<221> misc\_feature
<222> (1)..(757)
<223> n is a, g, c, or t

cngncttgcc aacctacagg tggggtcttt caagatctgc tgacagtgaa gctaaatctg 60 gcggaagcaa aggattcact tectcataat ggattaactc atcctatttg cctcttaaac 120 aatgggtatt ttaaagacag aagttgaagg aagtccaagt atccaatttt aaggatgcct 180 attagagcag ttataagaga gtgtctctct ttctctctt tctttctttc tcttggtagg 240 agtatgcagg aggtcattta aaagccagat agtgatacaa atcacaatgc agaaaaacat 300 ccccgtggac tcctccctgt cctatgtttg acattcttaa aatctatgtc ccaggtcttg 360 aaatetttaa ataatetaee atgttetttg geetgeeetg ggaaatetat tteagtaeea 420 qagctatgct ggttacacac cttttctgac tcatgttccc aagtgatttt attccagata 480 cgatttgggg acagttacgt gtactgttct gatatcttcc taaaaggaaa ttatttttgg 540

WO 2004/070002	PCT/US2003/037143
( o o o	101,002000000

위험하다	
agtaaagtc actgataaaa tcanctcagg aaaatgcact ttgtaaatat taaaatataa	600
actititaa ggnentgetg gaaaanacta attgattite etgggnagea giteeainga	660
acancgatng atctttaggg ggnagtgaan ggccccnatt tgaaaaangg gggcgggaaa	720
ngttcaaata ntttttccaa angggnncct anntnnt	757
(<210> 106 (<211> 640	
<212> DNA " <213> Cercopithecus aethiops	
VELUE CERCOPTENECUS decintops	
<220>	
<221> misc_feature <222> (1)(640)	
<223> n is a, g, c, or t	
<400> 106 ttggggnanc gagcggntaa cattttcaca cagaaattca ttcaatgaac tgttatgggg	60
	120
totcacattg taccaggoac tggggattca gottocagtt catagtotgc atgcaaaccg	180
acatgcaggt agacatgcag acagaaaatc ggaacgcaac acggtaagtg ctatgctaga	
gaatgagaag gactgtcagt aatcacaacc acctttcact gggttccttc agtgtgccag	.240
gctcgtgtac attattttgt ttagtgctca caattgtatg gactgtgtac tatcatttgc	300
cagattatat ggatgaagaa actagactga gggggttaaa -taactcgtcc aagatcatgc	360
agacaaaaaa ccacagagat tattttccaa tacaaactct ctggctgtac agctcaagtt	420
cttaaacact gggccaacca gtctgaatct gagaggaggc attctaaggc ttacaggtaa	480
gtgggaattg aaagggttga gggaagcett ctggaggaga tgccattaca ctgaatgttg	540
aatgagtagg agttagctat ctccanaggg gtagtggctg tgaangggcn aggggtaaag	600
ggtgggaagg ggatnatgga aggggtnnaa tnggnncnng	640
<210> 107	
<211> 818	
<212> DNA <213> Cercopithecus aethiops	
<220>	
<pre>&lt;221&gt; misc_feature &lt;222&gt; (1)(818)</pre>	
<223> n is a, g, c, or t	
<400> 107	
ttggggacca gcttgccaat tctacaggtg gggtctttca agatctgctg acagtgaagc	60
taaatetgge ggaageaaag gatteaettt eteataatgg attaaeteat eetatttgee	120

#### PCT/US2003/037143 WO 2004/070002

tcttaaacaa	tgggtatttt	aaagacagaa	gttgaaggaa	gbccaagtat	ccaattttaa	180
ggatgcctat	tagagcagtt	ataagagagt	gtctctctt	ctctctctc	tttctttctc	240
ttggtaggag	tatgcaggag	gtcatttaaa	agccagatag	tgatacaaat	cacaatgcag	300
aaaaacatcc	ccgtggactc	ctecetgtcc	tatgtttgac	attettaaaa	tctatgtccc	360
aggtcttgaa	atctttaaat	aatctaccat	gttctttggc	ctgccctggg	aaatctattt	420
cagtaccaga	gctatgctgg	ttacacacct	tttctgactc	atgttcccaa	gtgattttat	480
tccagatacg	atttggggac	agttacgtgt	actgttctga	tatcttccta	aaaggaaatt	540
attttggaag	taaagtcact	gataaaatca	actcaggaaa	atgcactttg	taaatattaa	600
aatataaaca	ttattaaagg	ccatgctgta	aaaatactaa	ttgattttcc	tgggtagcag	660
ttacaataga	acancgatng	atctctaagg	ggagagtgaa	aggacctcan	tttganaaac	720
gtgaggcagg	aaaagnttca	aatnattatt	tncaanaggg	ntecetaagt	tgttncttaa	780
anaaaatttt	tttcntnaaa	aaaaaacnnt	aanggcca			818

<210> 108 <211> 608 <212> DNA

<213> Cercopithecus aethiops

<220> <221> misc\_feature <222> (1)..(608) <223> n is a, g, c, or t

<400> 108 ttgggaccct gtcagaccan ttttactcat atcggatccc ctgaggtcgg gagatcaaga ccaccetggc caacatggtg aaaccetgte tetactaaaa tacaaaaatt agccaggcgt 120 180 ggtggcaggc gcctgtaatc ccagctactc aaaggctgag gcaggagaat cgcttgaacc taggaggcag aggtggaagt gagccgagat cataccactg cactccagcc tgggcatcag 240

agocagacto tgtogcaaaa aaaaaaaaaa aaaaaaaaaa attagotaco totoccatoo

**60** 

300

540

600

608

anaaatgaga gtcgaggctt ctgacttccc gggctcaatt tatcctcccg -cctcagectc 360 ttgaggaact gggactacag acgtgcacta tcacacttgg ctaatttttt tgagatgatg 420 tettgetetg tgeecagget ggagtacagt gacacaatet cageteactg caaceteege 480

ccccacaacg tccagntatt tttgtatttn aagnagagac nggggnnncc cctgttggnc

ctnctgggtt caaccgattc tnttgcttca gcctcccaag tagctgggat tacaggcgtg

ngggnggg

<210> 109

# WO 2004/070002

<211> 516 <212> DNA

<213> Cercopithecus aethiops

<220>

<221> misc\_feature

<222> (1)..(516)

<223> n is a, g, c, or t

<400> 109 ngggancetg necagnacet tettactgca tateggatee tgagaagete etgatettee 60 ctcaagccta aggcaaagta gtattcagaa cctcctatcc cactgactcc gagagoctgt 120 cctccgatat ctccaagaga gcctatcctc cgataggagg ggaagcccct ccaacctgca 180 ggtatectec ecagaeteae catttetece acceeacaet ggtggettec aaacttteee 240 300 teteataaca aggegeeetg teacceagae tgetteeete ggettgagga ggaggggaag gcgcacgaag taggaaggaa cttggggaga gggcgggcgg agggtgggcg aagcactgag 360 gggagggcgg tgaagaaggc agaagtcagg cagtgagagg gagaagcggc gggggcaggt 420 gagggcgggg gagtggggat ggggccgggg aaaggggccg agaggacgcg gagggggcag 480 516 aggtagggna caggagggga ggggaggggg agggcc

<210> 110

<211> 802

<212> DNA

<213> Cercopithecus aethiops

<220>

. . . . . .

<221> misc\_feature

<222> (1)..(802)

<223> n is a, g, c, or t

<400> 110 tnggggaacc tgccagacct tttttactca tatcggatcc ttattgcctg gctatttcag 60 cctgggaggg gtttggctgg aatatccctg gggaggcagg ctctcagggc taaaatagtg 120 ggagaaaaga ttaaaccttt aggaaactgg tacacatcag cgctaagtgt gactcaggga 180 gaaacaagaa ctaggacact tattactcca aaggagttgt atttggttca actcttgtat 240 tttcttatta aaacttttgc aaagtgggtt gagaagaaag tgttacttcc agtgttacac 300 ceteaacact tittectgtg gagactecag catgiteatt atgittectg aagecatgge 360 actgtagtac tettecattg ttgttattat tatttaataa tataaaatga gacatttttg 420 ctccattttt cattcatatt tttgtcctaa ttacttttta aatatattct ggtgtcaggt 480 caatatttat agtctaacgt ttaagactta gactttggtt cttaggatgt tatttttgaa 540 tcagctgcgt ctggtaaggt aatagatatt gaaagtgcct tgtaaattgt ccagtggcat 600 WO 2004/070002

# PCT/US2003/037143

aaaagtattg teatatettt atgacataaa agaaaantgt tttettett ttagcatgga	660
aaactttaca anccatttgc tggtgacngg ngangncctn ggggttggat ttcatgattt	720
tggggtccct tgagggtoca aantaccntt ctaanagngg aaanttttca nnaattcatg	780
antgreetna ttnaaanann tt	802
<210> 111 <211> 851	
<212> DNA <a href="mailto:color: red;">&lt;212&gt; Cercopithecus aethiops</a>	
<b>&lt;220&gt;</b>	
<pre>&lt;221&gt; misc_feature &lt;222&gt; (1)(851)</pre>	
<223> n is a, g, c, or t	
<400> 111 '	
tactttttt tgggggnncc aagncggnta acattttcac acagaaatct ccaagttccn	60
naggaccgca gnatectece cagaaccect gngaccaagt cactgtggtt ggntgtgetg	120
ggcatccctg aggcccagcc actcaacttt actggctcca ggattctata gaaagggaaa	180
ggggtagaaa ateteaaaag gettetteet tteagggagg gggtteeete teageggett	240 <sup>.</sup>
ctggaatete tacceactee ageegaettt tgaggeeatg tggteetgga acaaggeece	300
tctgagggcg gcagatgggg caggcggccc aggcacacag catggttggc tctgcggccc	360
agggcccaca aaagccttat tgagtcacca ccagcccccg gcagaggctg aggtggcagt	420
ggcgccgagc gcctgccacc taatgactgt cctggcacag ccagatgttc cgcagacctc	480
cggagcagcg ggaccaaggg cccgcccggg ccagccggca ccngannagg ccactttaa	540
tttccaatta accagntttc agnntgancn aaanaggggg gcagtnggtg gncccacccc	600
cgggcnagta ngccccggcc cnnaaaannc cttncgaagt tntaanactn ccanatntga	660
aaccnccacc ncccngaatt cccnatggaa aaantggccc ccagccangg gcaagggntt	720
gggncctttc ttttctttgg aaaaggaaat tttggttntt ttnacnaagg ccccccaang	780
aacccnatt t	851
<210> 112 <211> 773	
<211> //3 <212> DNA	
<213> Cercopithecus aethiops	
<220>	
<221> misc_feature	
<222> (1)(773)	

77

, <223> n is a, g, c, or t

<400> 112 cagettgeca antitacagg tgggantett teaagageag taaaaegace tatecaagga 60 aactcagcta gtaaaggcag ggacagggta tcgcaggctc tcggaactca cgagtcoccg 120 ccaggegeat ggeegeteet treecceggt gggegtggee aggeeaggee egteecetee 180 cctgagegeg ttcctggcag cccggeegge egtttnetge etgegteget gggegegegg 240 gcgggcgggc agcccatctg gcggcccccg cggggcggcg cggggaggcg gcccagactt 300 gctggagcca ggcgcctgcc cgggggcccc cctgcccgcc tggagaaccc aggtgtggcc 360 420 gggcaggatg cagecteete eegteetete eteggeetee geeteeegeg eeetggeeeg 480 540 gaatcctgga gggaatccaa acgcggggcg gggaggccgg ggcaggcccc tgaggccccg cccctgatag ccatttaata ccaccgcaag tcttgaccgt atttttgggg tgacccanct 600 tecetgettg ggcaagacca getgaactet gacetnetgg anggeegatt ttacettget 660 ectcagggac cennaaatga tegtaggaac engnnteact actgetgtaa gecananege 720 773 ttganatatn caattattca gcggnttcaa gtcccggaag cggntttna cna

<210> 113

<211> 807

<212> DNA

<213> Cercopithecus aethiops

<220>

<221> misc\_feature

<222> (1)..(807)

<223> n is a, g, c, or t

<400> 113

60 ttggggttgc gagcggntaa cantttcaca cagaattctt cagtgaattt cttaagccct gagcatette tttgtattet getttaagaa ettgtttgtt tetgtattte atacteagtg 1.20 gctctggcgc ttggatgccc tggtcccaca gaaggccttg aatactgaat ctgaggatgg 180 ggettgetta taaggacett actoectgte ttaaccagat tgtgttttaa cettteatet 240 cactttttac ttttcattca tggatagtgt ttgtcactgt gtgtgtgtgt gtgtgtgtat 300 gaatgagtga atgaatatet etcacaetet aaattettt aaaggeagga agtaetgtte 3'60 tettgtttgc tattttatcc actetgcctc tactgggtct ggcacataat aaagaaagaa 420 tgaacaggac aaacacccat totgaaagtg aacttototg gcaattgtog tttgtacata 480 ccagctggag catagacaat tggcttttaa tgtggtaagg gaaaaggtca aaaaaagaat 540 cgtcattgac caagggcttc accagatgat tttataatca ntccnaaagg gnctttnaan 600

# PCT/US2003/037143

aaaaaaggcc ttngaggaac aaatttnttc cnnntggaaa antgntttna aatttttntn	<b>660</b>
gaaaaagttt tnanaatttt tgnaaaaccc ccnccccnnt gaaaacntnt aaancnngna	720
annngnnnng ggcggggttt naaaaaaaaa aantnccccc cnnnnaanng ggnctttnaa	780
aaannnngn ntnctaaaaa aangggg	807
<210> 114	
<211> 836	
<212> DNA <213> Cercopithecus aethiops	
(213) Cercoprenetus decirrops	
<220>	
<221> misc_feature	
<223> n is a, g, c, or t	
400. 114	·
<400> 114 ttggggacca gcttgccaan tctacaggtg gggtctttca gtatgtgtca agagtcagaa	60
tttaaagaag ataagaaaat taaatacact gagaacaatg catctcntga cattcaaaat	120
atgtaagtgc agcaaccagc agtaattcca taggcctttt atcaaccttt gccaaaacct	180
ataaaaagaa tatctaaaat tgctttttta tgaaagttcc tatttattct tgtttccctt	240
accagagage ctgettteec ettactgatg agaacacagg gggteetggg taaagagtee	300
ataanattta aaaaggagta tgccttggcc tcccatgacc ctcttacttc acaataaggc	360
catcttttac ctggtttaga tttgcagact aggtccatta gatacgttgt cattaaatac	420
ctatactata ccctaatatt tgtaatcttg acaggtatta ttttcatttt atagacagat	480
ctaggaaaat tacatgactt atcggaatcc cttcaaatat cacagagcaa agtcatgatt	540
ttaacttgtg tttgccactc tgaaactcac actggaattc gagactagtg tgcgtaacat	600
ggcgaaaccc catctctatt tnttnttttc aaaatntntt tttccaaaat ttgctggggg	660
tgttggtgtg tgcctgtant ncagcctnct tgggaggctn aannggngga cngcttgacc	720
ctgggngnaa aggctaaatn gnctttnttn geecctggan ttaacenngg ggaaaaangg	780
aacecttntc aaaataaatt ttaaattaaa naangccnag gtttccccna aaaaat	836
<210> 115	
<211> 839	
<212> DNA	•
<213> Cercopithecus aethiops	
<220>	
<221> misc_feature	
<222> (1)(839)	
<223> n is a, g, c, or t	

<400>	115						~^
11.5		gagcggntaa					*60
aacaca	agtt	aaaatcatga	ctttgctctg	tgatatttga	agggattecg	ataagtcatg	120
taattt	tcct	agatetgtet	ataaaatgaa	aataatacct	gtcaagatta	caaatattag	180
ggtata	gtat	aggtatttaa	tgacaacnta	tctaatggac	ctagtctgca	aatctaaacc	240
aggtaa	aaga	tggccttatt	gtgaagtaag	agggtcatgg	gaggccaagg	catactcctt	300
tttaas	tttt	atggaçtett	tacccaggac	cccctgtgtt	-ctcatcagta	aggggaaagc	360
aggcto	tctg	gtaagggaaa	caagaataaa	taggaacttt	cataaaaaag	caattttaga	420
tattct	ttt	ataggtttg	gcaaaggttg	ataaaaggcc	tatggaatta	ctgctggttg	480
·    ctgcad	cttac	atattttgaa	tgtcttgaga	tgcattgttc	: tcagtgtatt	taattttctt	540
atctt	cttta	aattctgact	cttgacacat	actgaaagac	: cccacctgta	ggtttggcaa	600
gctage	ctgag	gatogtttcg	catgattgaa	caagatggat	: tgcacgctgg	ttctecggcc	660
gcttg	ggtgg	agaggctatt	cggctatgac	tgggcacaca	a gacanteggn	tgctctgatg	720
cegee	gtgtt	: cggctgtcan	cncagggcnc	cegnttttt	tgnaanaccn	nctgnccggg	780
		ctgnngacaa				•	839
	_						

<sup>&</sup>lt;210> 116

<220>

<400> 116 tnggggacca gcttgccant tctacaggtg gggtctttca gtatgtgtca agagtcagaa 60 tttaaagaag ataagaaaat taaatacact gagaacaatg catctcaaga cattcaaaat 120 atgtaagtgc agcaaccagc agtaattcca taggcctttt atcaaccttt gccaaaacct 180 ataaaaagaa tatctaaaat tgcttttta tgaaagttcc tatttattct tgtttccctt 240 300 accagagage etgettteec ettactgatg agaacacagg gggteetggg taaagagtee ataaaattta aaaaggagta tgccttggcc tcccatgacc ctcttacttc acaataaggc 360 catcttttac ctggtttaga tttgcagact aggtccatta gatacgttgt cattaaatac 420 ctatactata coctaatatt tgtaatottg acaggtatta ttttcatttt atagacagat 480 ctaggaaaat tacatgactt atcggaatcc cttcaaatat cacagagcaa agtcatgatt ttaacttgtg tttgncactc tgaaactcac actggaattn tgngggaaat nntatccgnt €00

<sup>&</sup>lt;211> 815

<sup>&</sup>lt;212> DNA

<sup>&</sup>lt;213> Cercopithecus aethiops

<sup>&</sup>lt;221> misc\_feature

<sup>&</sup>lt;222> (1)..(815)

<sup>&</sup>lt;223> n is a, g, c, or t

# PCT/US2003/037143



canaatteec ecnacatgag egtnanacec egaaaaaaga acaangatnt ttttggaac	×c 660 .
ntttttttg gggnnaanng gngnngnaaa aaaaaaccnc cnntncnacg ggggtttgt	t 720
ggcgganaan aacnccacct tttttccnaa ggaaangntt tnaaaangcg aanaccaa	aa 780
ntgtcntttt gnnnggccgg gttggncccn cttna	815
<210> 117 <211> 792 <212> DNA <213> Cercopithecus aethiops	
<220> <221> misc_feature <222> (1)(792) <223> n is a, g, c, or t	•
<pre>&lt;400&gt; 117 ttggggganc gagcggntaa cattttcaca cagaaattcc cgacctcaag tgatatate</pre>	cc *60
accttggcct ccaaaagtgc tgggattaca ggcatgagcc accgcgcccg gecccttc	
gcagtttctc tcactccttt cagaatcgag gagtctgcta ttccatcgac atctaacc	
ctcctctaaa ccagcctgca atcccagctg gagaactaca atccaatcag ggattaaa	tc 240
taaatteete eeatetgate actgggatee etacecatte aacteeeete etecteea	ga 300
aatgttacca atcccctaaa gcctccaatc acctgttgag ccaccagcca agcgctta	ct 360
aatocotgto toccaagoto agacactoco tgtaattgat ggacacgcag cattggga	.gc 420
tttcacattg agctcttact ttgaaacttt gaataagaaa agagctgaaa aaagcaga	tc 480
toccaatoto ggtgaaactg tagttaaact ocaagtagaa tacoccaata aatggata	ng 540
aatganaaat ctcatatggg ttatatangc antatttana aattttggaa ttataggn	nt 600
anggatncaa actinnanan tantatteea tiggnntitig gngeneeena ngntaaan	naa 1660
gttnnccnct canaaggaaa nggggngggt nangggctan nccnnaancc annttttg	ign 720
ggntnggnnn aaantttttn ggnccaantt naaanaaann tnntnaaaaa aanggnnc	cn 780
ttttnaaaa aa	792
<pre>&lt;210&gt; 118 &lt;211&gt; 838 &lt;212&gt; DNA &lt;213&gt; Cercopithecus aethiops  &lt;220&gt; &lt;221&gt; misc_feature &lt;222&gt; (1)(838)</pre>	
<223> n is a, g, c, or t	

<400> 118 60 gggnaaccga gcggntaaca ttttcacaca gaaantcgga aagtaaagcc aatcttagag 120 gctgcaggag gtttgggggc agtatctgat tcagacgctg gctaacgttt cacgatcgcg ttoccttttt tottocaact oggtaagtaa aaaggcaaga tgagaaattt acgtgotgaa 180 cttaataaat agttggtgga cgtattgcct ttttttttt tttttggta agggatgaca 240 300 catctcgtga ctacagttct tttgaggaat aacttttctg ctagtttcca aatcggcacg tgaccaaagt cttttcatag gattttagcg tcctgataaa aatcaatggg cagaatttga 360 420 ttgcttttta aaaaatgtgt ttgtcctttg gtctctggca ccattgtaat ggaaaatccc tacattgcct gtactctcag aagctgtcca gtggagcaaa actagagata aagaaacctg 480 gaacgattca gttaggaact tttaagaagc cagcctttag tttttccttt agaagattat 540 600 gcagttatca tgattgcttc tctagaactt cagtgtgtta tttggattcc taaatctaag acaatgctgn ggaagtctgg ggcttttagn attttngggt ctgctgnaga aaatcctcgt 660 720 ttatactaca aagtttctnt tttggaactt tnggaattgg gcattttttn nnttattatt 780 ngnatgntng antnannggc aaaactnagn naaccetttt nggtttgeet enanceggtt nttaaanaaa ngggaaaaan cctnanttta aanttttttc cacccttttt tnttttnt 838

<210> 119 <211> 820 <212> DNA

<213> Cercopithecus aethiops

<220>
<221> misc\_feature
<222> (1)..(820)
<223> n is a, g, c, or t

<400> 119 ttgggganct agcttgccaa ntctacaggt ggggtctttc agtggggggc tgtcctgtag 60 gttatagaat gtttagcagc aaaaattaaa aattaaataa caaaaataaa aataaaaaag 120 aatgtttagc agcatecetg geetetacec actagatgte agcageacet ecettgeeec 180 caggtgtgaa ccaaaaatgc ctgcagacat tgccaaatat ctcctaggag gacaaaattg 240 tectetete caettgagaa etattaetet aaaattaeee agatetgett tgaateeeeg 300 ctccacccca tcacaacctg ggtcatcttg gaaaacagac tgaaccttcc tatgccccc 360 gcaaatteet caactgtaac atggagetet tgetgaagaa atgetatgaa aattaaatga 420 aatgatgtac gtacaggatt tacacgcaca gaatattcac cgcgccagag tgagtgctca 480 ataaatggtc agaaatgagg ggaggctaaa aaaaaataat ttcgagaact caaaaatctt 540

# WO 2004/07000

# PCT/US2003/037143

atotttaggo otecagagta otgtagtota gacagaagaa atggttgaga tagaancaaa	600
agagatgaga gaggttggaa aagaagtgat agaactaagg tattattccc cttatctctt	660
aagaacccgg cttggagtca aagccaatag agggtctact tagttttgnc tattactcta	720
ctttcaaata taacgaaaat tgcccaaacc caaagtntcc aaaaaaaact ttnnnttnan	780
cggggatttc tncncggncn aaaatctaan nccccnctnc	820
<210> 120	
<211> 797	
<212> DNA	
<213> Cercopithecus aethiops	
,	
· !	
<220>	
<221> misc_feature	
<222> (1)(797)	
<223> n is a, g, c, or t	
<400> 120	
ttggggttgc gagcggntaa cantttcaca cagnaattca gctgatgaat gcagatatga	60
	100
accgatggtt caagagetgt agacatacat acctagttta ccacactgat cttcttagta	120
taaaaaaaca agcgttacta agaaacatct actttcagca aatggacatg accagaatga	180
taaaaaaaaa ayeyttatta ayaaacaeet actettayta aatyyacaty atxayaatya	180
tacatagaat gatgcaagaa atttcactct accattcatt ttaatcttta cagtaacagg	240
The state of the s	240
atgattgcta tctcaatctg tcattttacc ttttttttt ttttcagaag ttaaagtgta	300
tccatacaag ttcaacttaa cattgttaag tgcaaagtta acagtgtaca ctttggagat	360
acctttttag gtagaaaatg atttttgtt ttctaataag ttttcccaag taatattaaa	420
gaaggttaaa tatgtcattt acttggagaa aacagaaaac catgagaaag tttgggaaaa	480
tratatatit gagagattaa tatattaana gagbaathaa gagagatta	E 4 0
tgctatattt cagagettaa tatattgaaa cagtaagtaa gacaggaatt ggctacettt	540
taagaacgtt tacaaaaata caaactgann ggaatgcttt tggcaatnaa aatntgacnt	-600
	000
gaaacattca atggcnnaac attcaanaan gnttnagana tenttneett tancatccaa	660
natngttttg ncgncntctc aaaaaantgt ntnttttaaa aaanttaggg ntaaaanttt	720
ctggnagntt nattaanctt tttttgnncc ctnaaatttt nnccnaaagt tcnttnanca	780
aaaaaaaatn cttttt	797
401.05 1.01	
<210> 121	
<211> 828	
<212> DNA <213> Corroritherus aethions	
CALLS COTONIEDOCIE SOFDIANO	

<213> Cercopithecus aethiops

<220>

<221> misc\_feature <222> (1)..(828)

## WO 2004/070002

<223> n is a, g, c, or t

<400> 121 ttggggancn g	scttgecaan	tntacaggtg	gggtctttca	ccttcttgcc	agaaacataa	60
aatgcgatgg a						120
cgcaggcgcc						180
gttocgtttc						240
ctcaattcac						300
tcaagacttg						360
tcataagtgg						420
acatocaatg						480
gccaatagga			•	1		540
					Łtgggagtgg	600
goagoaaa	2222-2-2-2					
egcacttnac	ccgcanttgg	taggtggggg	agaggggaat	: cngggggatn	ctgaatggac	720
aaancggnan	cggcagcaan	tgntgntgcc	cgggtncccg	tgcaantnga	aacntttggn	780
gtggggaang	ggattctagg	caanggnccc	gcnancccna	aaaaaggc		828

<sup>&</sup>lt;210> 122

<220>

<221> misc\_feature

<222> (1)..(842)

<223> n is a, g, c, or t

<400> 122 ttggggancc tagcttgcca antctacagg tggggtcttt caccttcttg ocagaaacat 60 120 aaaatgcgat ggagctacgg cgaccgctgc cgagacaaaa tggcgccgag aacctggttt agegeaggeg cettggaaag accetgeece geceeegtge aageceetgg etgcaattet 180 gggttccgtt tccatgggac actccgccgc caatcctcgt gccgaactgc tcttcctgac 240 ccctcaattc accaatcagt gcccagtcaa gcacatccgg agtcgtctct accaatcatt 300 teteaagaet tgettaetea ataaceaaet eteeaataae gttggtette ggaaaaagee 360 420 aatcataagt ggaagatgtc ctacctgctg tttttcgcac caatccatga agtttcagag 480 ctacatccaa tgaggacggc aggtagcgag gtcctatccg aagctcttcg gcgtcatgaa -cagccaatag gagttcgtgt agaagcgagt ctgctcaaca gettgttatt tggtggattg 540 tggcagtaaa tcggggcgag tggggaaccg ggcgcaggaa-ctgcagccgc ggttgggagt 600

<sup>&</sup>lt;212> DNA

<sup>&</sup>lt;213> Cercopithecus aethiops

815



ggtgctgccc ggacgggggc occacggagg tcagagggga ggaggactct ggagctgaca	660
gcgcgcactt cacccgcagt tggtaggtgg gggagagggg aatcgggggn annotgaatg	720
gacaaanegg caegggnage aantgntgnt geeenggggt eeeggngeaa ttggaanett	780
ttggaggtgg gggnanggna ttctagccaa ngggcccnnc nagcccaaaa aaangggncc	840
nc	842
<210> 123 <211> 815 <212> DNA <213> Cercopithecus aethiops	
<220> <221> misc_feature <222> (1)(815) <223> n is a, g, c, or t	•
<400> 123 ttgggnaacc gagcggntaa cnttttcaca cagaaantee caggeteeat geetgaatag	60
ctgggactac aggcacacag aatcatgccc atctaccttt ttattttttg tagagaagag	120
gtctcactat gatgcccagg ttggtctcaa acacctgtac tcaagagatc ttcccacctt	180
ggcctcccaa agtgccagct ttacaaatgt gagccactgt gggtggccat gaactcttcc	240
aatgaccctt tttcaaaaaa atatttcaac tattcaatgt gagccaagga tgtgccagac	300
atttgctaga tgctatgaat aaaatatgac aaagattcag tctttgtccc catggacttt	360
atagtotagt agtagatgag actoataagt aatatotago caaaaataaa aattaotgta	420
ttatgggaga ataagaatat ggtactaatt tcttcagtgc caatgtatat cttttcatgt	480
tettgtteet tggattetea caacaattga tgaaaaatgt aacaetggat ttgagtttgt	540
agtottattt tocaacatga tgaagttgtt attaagtgtg agatgatcaa gggagactca	· 600
ggaagcagtg ggtaacctca gctaaaagca aacagatagt atattggaag atgaggtaaa	660
caaagagagc aaagctttat gaatctgggc taaaantcag ctataagtnt tcgcanatcc	720
angagaactt tncaacagnt tncaattgaa ancetttnag tttttaaann eetntettn	780

<210> 124 <211> 823

<212> DNA

<213> Cercopithecus aethiops

caaantgncn aaannnttaa caggnttgna atncc

<220>

<221> misc\_feature

## WO 2004/070002

<222> (1)..(823)

<223> n is a, g, c, or t

	<400> 124 ggnnttgcga	gcggntaaca	atttcacaca	gaattcaaac	tccagcttta	ctaccetgtg	60
	accttgggca ggggacctgg	ggtcacttca gtttgcagga	catttctcag agaaaacttc	gctggtttcc cttacactga	agtctggctg ataattattg	cctttgggga ccttgttaga	120 180
	aatttttac	catgtgcaca	tattactttt	cctaaatatt	tgcacccaat	ttaattgatt	240
	taattgggga	aaaatgaaca	taggaaaaat	aatgacctct	tcctcagggt	tattaaaagg	300
	tttcaaaata	aagtatgtag	ctagtaaagg	tgcatagtat	atgcttaatc	aatagagtgg	360
	·tgacagggtg	gagggaggtg	ggaggcaggc	tcattcctgc	cctggggccc	agaggagaac	420
	atgtggtaca	gaagtcccag	cctacagcca	gctcctagca	ttaaggcagg	tgcccattca	480
	gctagagcct	cangggggtg	cnagttgagg	gagetgetee	tancctggnc	cccatgccct	<b>'54</b> 0
,	ttnctttgtg	gtggancctt	aagaageccn	ttttcctgan	naanneetgg	gnttananaa	,200
	ttcacctttg	ncaattncca	agnneceggn	gnaattntcc	ntnttgggng	aaacccnttn	660
	nntttaaggg	tgnntnttng	ggattngnac	cnnnttttg	gggeneneec	ngnttttnn	720
	ttttttt	aaannccnnn	aaaanaaaaa	aaaaanntnn	gngneennaa	anneceenn	780
	gggggggaa	aaaaaaaaa	antttttccc	cocccccnc	c -cúc	•	823

<210> 125

<211> 691

<212> DNA

<213> Cercopithecus aethiops


<400> 125 cctaatccac caacccccaa ctactatagt gggagcctga ggtcacagca tggcccccc 60 gtgttgtgag aaaaatctcc acaggattct cccactgttt cctaagtgtg ctctgggatc 120 ctecgtgact agtgtggaat tttgagecag tgatttetee ccacaggttt caattaaate 180 atctgtcaaa tgaggatgac cacatcttct ttacctcacc actgagctgt gaaatgaacc 240 agaggeetta eetttteece etgaacteee agteateeet ggaacaeeaa tttgaacate 300 atctcccact ttcccagcca gttagcagct ctgtcctctg gatttcaaag agaaatgtct 360 ctagcatcat ccctgtttcc ttgcactgtc ctactttctt tttcccccca gagccaggaa 420 tgtcttaaac agaatgagat gctcccaagg ggccaccaac tcacaattag gagttcaata 480 aatactgact taagagtgaa tgaacgatcc ccgtgtcttt gtccacattt gtacatgctt 540 acatgattct gcaaagaatc taaatttctc tttacattaa caaacaaggg ggctgggcat 600 ggtggctcat gactgtaatc tcagcatttt tgttaaccag gacagtcctg atgaaataac 660 691 tgggaaagtt cctttttggg gggtggggtg g

126 748

<210>

<212> DNA <213> Cercopithecus aethiops <400> 126 -ccategeett actattgeet tettgaegag ttettetgag egggaetetg gggttegaaa 60 tgagctagcc cttaagtaac gccattttgc aaggcatgga aaaatacata actgagaata 120 gaaaagttca gatcqaggtc aggaacagat ggaacaggt cgaccggtcg accggtcgac 180 240 cctagagaac catcagatgt ttocagggtg ccccaaggac ctgaaatgac cctgtgcctt atttgaacta accaatcagt tegetteteg ettetgtteg egegettetg etecoegage 300 tcaataaaag agcccacaac ccctcactcg gggcgccagt cctccgattg actgagtcgc 360 ccgggtaccc gtgtatccaa taaaccctct tgcagttgca tccgacttgt ggtctcgctg 420 ttccttggga gggtctcctc tgagtgattg actacccgtc agcgggggtc tttcagcagg 480 gcccggggcc acagaaggaa aacatctctg tggaatgtgg aaatgcagaa ctctactggg 540 cccgtttaga aagcacagaa aagcatggaa gaaagggaga ggcgagaagc ctagaaaatt **600** accctagatc ttaggtatgg atatatcgac ctaaaagaaa gaagatgggg caaagttaat 660 gcaagcagag agtttatttg gggtcaagct tgaggattgc accccaggag catagattca 720 agttgccctg aatttacact gattagca 748 <210> 127 <211> 708 <212> DNA <213> Cercopithecus aethiops <400> 127 gccaaaccta caggggggt tetttcactg ccagtcagcg aaccgcgaag ccggcaggca 60 cttcggcggt ctccagcett tgoctgaaaa gageteggca agetagetag aggtcagace 120 ccaggaccca gtcgttttag ctcagggaaa ggaagcgccg gacgccagcc tgcaagcttc 180 actgcgcagc cgtggacacc gccccacgtc gtagggccgt ggaccctgac aacgccggaa 240 300 cccggcgtcc ggtgcgtgcg cttggcggac cagaatggct aacgtaccgc catgccgcga ggcccacgta gaggcggaag ttgatgggac ggacgcagat ggggggaacct tgcctcgatg 360 geactitiest greegegact eegeceeege cagagggget aggeteeggg titeaagatg 420 gaggegetga gtegagetgg geaggagatg ageetggegg eeetgaagea acaegaceet 480 tacatcacca gcatcgcaga cetcacggge caggttgete tgtacacett etgececaag 540 gecaaccagt gggtgagtge egeetggete tgaggaegge egeeeggeeg etgeggtete 600

ttaaaggggc cgtgcgtgtt gctgtggggt gggggacaca gcaagagcca gggagg	tgaa 660
gacggggcca gggactgccg agaagccgac cagaaccaga ggggttgt	708
<210> 128 <211> 741 <212> DNA <213> Cercopithecus aethiops	•
<220> <221> misc_feature <222> (1)(741) <223> n is a, g, c or t	
<400> 128 taacaatttt cacacagaaa ttcaatccaa caaacaanta catattattt tctaag	rttgt 60
aaagcctgta accgaatgag ttaattagga agggtcaatt acaagaaagt gggaaa	ttat 120
gctagttgtt tttaaacaac taacaaagct tcaagcaggg gctaacgaga atcagt	gaac 180
agactgaatg taacttttcg gaccctctcc agtgcacgaa aagccagaaa gtactg	gagtc 240
tgaggggaac attcagagat gacatcacca gcatcatagg tggaacaaaa cacatt	ctaca 300
gggtctctct tgtttgtaca aaggtcttcg gggatctagt gaacatggaa gccctt	sttcc 360
taagtgeett gaaatetttt eegaaaetgt gtagttegat taaageegga eecac	egcac 420
tocccettee aagaategaa actaattgga ttttaagett taaateeaaa tgace	tctga 480
gaaaggggct ctcatttacg tctgccgggg gagaggagga gtgtttattt tatag	acaat 540
gtatatgcaa tttatctaat aatccgcaaa gcctcaaaca caagctttca ggcac	bottt 600
tgaccccacc ggtctcataa ctoccaatgt atctgcaaag aaggcaggtc gccca	cgtcc 660
ccaaacccga cgccaaggga ctgatcctgc tccaatcctc cctcactggc ttttc	cttgg 720
ggatgtgtnc agcccacttc t	741
<210> 129 <211> 694 <212> DNA <213> Cercopithecus aethiops	
<220> <221> misc_feature <222> (1)(694) <223> n is a, g, c or t	
<400> 129 ccgccaacet acagggtggg gttettteae tgccagtaca gcgaacegeg aagee	ggcag 60
gcacttegge ggtetecage etttgeetga aaagageteg geaagetage tagag	
accccaggac ccagtcgttt tagctcaggg aaaggaagcg ccggacgcca gcctg	



١.,							
. 1	tcactgcgc	agecgtggac	accgccccac	gtcgtagggc	cgtggaccct	gacaacgccg	240
Ç	gáacccggcg	teeggtgegt	gcgcttggcg	gaccagaatg	gctaacgtac	cgccatgccg	300
	cgaggcccac	gtagaggcgg	aagttgatgg	gacggacgca	gatgggggaa	ccttgcctcg	360
	atggcacttt	ectgtccgcg	acteegeecee	cgccagaggg	gctaggctcc	gggtttcaag	420
: •	acggaggcgc	Łgagtcgagc	tgggcaggag	atgagectgg	cggccctgaa	gcaacacgac	480
	ccttacatca	ccagcatcgc	agacctcacg	ggccaggttg	ctctgtacac	cttctgcccc	540
i	aaggccaacc	agtgggtgag	tgccgcctgg	ctctgaggac	ggccgctccg	gccgctgcgg	600
;	tctcttaaag	gggccgtgcg	tgttġctgtg	gggtgggga	cacagcaaga	ggccagggga	660
4	ggtgaagacg	gggccaaggg	actgncgaaa	agcc			694
	<210> 130 <211> 678 <212> DNA <213> Cerc	copithecus a	aethiops	·	;		
	-400- 120		•				
	<400> 130 ccctttactg	ccagacagcg	aaccgcgaag	~ccggcaggca	cttcggcggt	ctccagectt	60
	tgcctgaaaa	gagctcggca	agctagctag	aggtcagacc	ccaggaccca	gtcgttttag	120
	ctcagggaaa	ggaagcgccg	gacgccagcc	tgcaagcttc	actgcgcagc	cgtggacacc	180
	gececaegte	gtagggccgt	ggaccctgac	aacgccggaa	cccggcgtcc	ggtgcgtgcg	-240
	cttggcggac	cagaatggct	aacgtaccgc	catgccgcga	ggcccacgta	gaggcggaag	300
	ttgatgggac	ggacgcagat	gggggaacct	tgcctcgatg	gcactttcct	gteegegaet	360
	ccgccccgc	cagaggggct	aggeteeggg	tttcaagatg	gaggegetga	gtcgagctgg	420
	gcaggagatg	agcctggcgg	ccctgaagca	acacgaccct	tacatcacca	gcatcgcaga	480
	cctcacgggc	caggttgctc	tgtacacctt	ctgccccaag	gccaaccagt	gggtgagtgc	540
	cgcctggctc	tgaggacggc	cgcccggccg	ctgcggtctc	: ttaaagggggc	cgtgcgtgtt	600
	gctgtggggt	gggggacaca	gcaagaggcc	agggaagttg	aagacggggc	caagggaact	660
	ggccgaaaag	ccaagcca			·		⁺678
	<210> 131 <211> 712 <212> DNA <213> Cer <400> 131	copithecus	aethiops				
			gtettteact	occantacac	T COBBCCOCOS	accoacaaa	-60

cccgccagcc tacaggtggg gtctttcact gccagtacag cgaaccgcga agccggcagg 60 cactteggae ggtetecage etttgeetga aaagageteg geaagetage tagaggteag £20

WO 2004/07000	02 PCT/US2003/0	37143
accccaggac	ccagtcgttt tagctcaggg aaaggaagcg ccggacgcca gcctgcaagc	180
	agccgtggac accgccccac gtcgtcgggc cgtggaccct gacaacgccg	240
<b>9</b> 0 克 1	teeggtgegt gegettggeg gaccagaatg getaaegtae egecatgeeg	300
	gtagaggcgg aagttgatgg gacggacgca gatggggggaa cettgcctcg	360
•	cctgtccgcg actccgcccc cgccagaggg gctaggctcc gggtttcaag	420
. 1	tgagtcgagc tgggcaggag atgagcctgg cggccctgaa gcaacacgac	480
	ccagcatcgc agacctcacg ggccaggttg ctctgtacac cttctgcccc	540
•	cagtgggtga gtgccgcctg gctctgagga cagccgcccg gccgctgcgg	<b>7600</b>
1	gggcccgtgc gtgttgctgt gggggtgggg gaacacagca agaggccagg	660
•	accggggcca gggacctggc gaaaagcccg aaccagaagc cc	712
<210> 132	,	
<211> 738		
<212> DNA		
<213> Cer	copithecus aethiops	
<220>		•
	c_feature	
<222> (1)	(738)	
<223> n i	sa, g, c or t	
<400> 132	: aggggggggt ctntcactgc acagtacagc gaaccgcgaa gccggcaggc	60
	tetecageet ttgeetgaaa agagetegge aagetageta gaggteagae	120
	agtcgtttta gctcagggaa aggaagcgcc ggacgccagc ctgcaagctt	180
	g ccgtggacac cgcccacgt cgtagggccg tggaccctga caacgccgga	240
	c cggtgcgtgc gcttggcgga ccagaatggc taacgtaccg ccatgccgcg	
	t agaggoggaa gttgatggga oggaogoaga tgggggaaco ttgcotogat	
	c tgtccgcgac tccgcccccg ccagaggggc taggctccgg gtttcaagat	
	g agtcyaycty gycaygayat gaycctyycy yccctyaayc aacacyacco	
	c agcategeag aceteaeggg ecaggitget etgtacacet tetgeeceaa	
	g tgggtgagtg ccgcctggct ctgaggacgg ccgcccggcc gctgcggtct	
	g ccgtgcgtgt ttgctgtggg gtgggggaca cagcaagagg ccagggaggt	
gaagacngg	g gccagggnac tggcgaagag ccgagccaaa gccagagggg tgtcgggtcc	
acctgggaa	t tgggggaa	738

<210> 133 <211> 757

480

540

WO 2004/070002 PCT/US2003/0				
	<212> DNA <213> Cercopithecus aethiops			
	<400> 133 cgccaaacct acagggggg tetttcactg ccagacagcg aaccgcgaag	ccggcaggca	60	
	cttcggcggt ctccagcctt tgcctgaaaa gagctcggca agctagctag	aggtcagacc 1	20	
	ccaggaccca gtcgttttag ctcagggaaa ggaagcgccg gacgccagcc	tgcaagcttc 1	80	
	actgcgcagc cgtggacacc gccccacgtc gtagggccgt ggaccctgac	aacgccggaa 2	40	
	cccggcgtcc ggtgcgtgcg cttggcggac cagaatggct aacgtaccgc	catgccgcga 3	00	
	ggcccacgta gaggcggaag ttgatgggac ggacgcagat gggggaacct	tgcctcgatg 3	60	
	geactiteet greegegact eegeeeeege cagagggget aggeteeggg	tttcaagatg 4	20	
	gaggegetga gtegagetgg geaggagatg ageetggegg ecetgaagea	acacgacect 4	80	
	tacatcacca gcatcgcaga cctcacgggc caggttgctc tgtacacctt	ctgccccaag 5	40	
	gccaaccagt gggtgagtgc cgcctggctc tgaggacggc cgcccggccg	ctgcggtetc 6	00	
	ttaaaggggc cgtgcgtgtt gctgtggggt gggggacaca gcaagaggcc	aggggaggtg 6	б0	
	aagacggggg ccaggggact ggcgaagagc ccgagccaga gccagagggg	tgtcgggtcc 7	20	
	acctgggatt ggggggatag gaagtgagaa gaagtgg	. 7	57	
	<210> 134 <211> 668 <212> DNA <213> Cercopithecus aethiops			
	<220> <221> misc_feature <222> (1)(668) <223> n is a, g, c or t			
	<400> 134 ccagcctaca ggggggggtt ctttcactgc cagtacagcg aaccgcgaag		60	
	cttcggcggt ctccagoctt tgcctgaaaa gagctcggca agctagctag	aggtcagacc 1	20	
	ccaggaccca gtcgttttag ctcagggaaa ggaagcgccg gacgccagcc	tgcaagcttc 1	80	
	actgcgcagc cgtggacacc gccccacgta gtagggccgt ggaccctgac	aacgeeggaa 2	40	
	cocggegtee ggtgcgtgcg cttggcggac cagaatggct aacgtaccgc	catgccgtga 3	00	
	ggcccacgta gaggcggaag ttgatgggac ggacgcagat gggggaacct	tgcctcgatg 3	60	
	geactiteet gteegegact eegeecoege eagagggget aggeteeggg	tttcaagatg 4	<b>30</b>	

gaggcgctga gtcgagctgg gcaggagatg agcctggcgg ccctgaagca acacgaccct

tacatcacca gcatcgcaga cctcacgggc caggttgctc tgtacacctt ctgccccaag

gccaaccagt gggtgagtgc cgcctggctc tgaggacggc ccgcccggcc gctgncggtc	600
ntcttaaaag gggcccganc gtgtttgctg tgggggtggg gggacncaag caagaaggcn	660
cagggagg	668
<210> 135 <211> 752 <212> DNA <213> Cercopithecus aethiops	
<220> <221> misc_feature <222> (1)(752) <223> n is a, g, c or t	
<400> 135 gcttgccaaa cctacagggg gggtctttca ctgccagaca gcgaaccgcg aagccggcag	60
gcacttcggc ggtctccagc ctttgcctga aaagagctcg gcaagctagc tagaggtcag	120
accccaggac ccagtcgttt tagctcaggg aaaggaagcg ccggacgcca gcctgcaagc	180
ttcactgcgc agccgtggac accgccccac gtcgtagggc cgtggaccct gacaacgccg	240
gaacccggcg teeggtgcgt gegettggcg gaccagaatg getaacgtae egecatgeeg	300
cgaggcccac gtagaggcgg aagttgatgg gacggacgca gatgggggaa ccttgcctcg	360
atggcacttt cctgtccgcg actccgcccc cgccagaggg gctaggctcc gggtttcaag	420
atggaggege tgagtegage tgggeaggag atgageetgg eggeeetgaa geaacaegae	480
cettacatea ecageatege agaceteaeg ggeeaggttg etetgtacae ettetgeeee	540
aaggccaacc agtgggtgag tgccgcctgg ctctgaggac ggccgcccgg ccgctgcggt	<b>√600</b>
ctcttaaagg ggccgtgcgt gttgctgtgg ggtgggggac acagccagga ggccaaggga	660
ggtgaagacn ggggccaggg actggcgaag agccgagcca ganccagagg ggtgtcgggt	720
tcacctggga ttgggggata ggagtgagag aa	752
<210> 136 <211> 739 <212> DNA <213> Cercopithecus aethiops	
<220> <221> misc_feature <222> (1)(739) <223> n is a, g, c or t	
<400> 136 ctttcactgc cagnacagcg aaccgcgaag ccggcaggca cttcggcggt ctccagcct	t 60
tgcctgaaaa gagctcggca agctagctag aggtcagacc ccaggaccca gtcgttta	g 120

. . . . . . .

ctcagggaaa	ggaagcgccg	gacgccagcc	tgcaagcttc	actgcgcagc	cgtggacacc	180
gcccacgtc	gtagggccgt	ggaccctgac	aacgccggaa	ceeggegtee	ggtgcgtgcg	240
cttggcggac	cagaatggct	aacgtaccgc	catgccgcga	ggcccacgta	gaggcggaag	300
ttgatgggac	ggacgcagat	gggggaacct	tgcctcgatg	gcactttcct	gtccgcgact	360
cegececege	cagaggggct	aggctccggg	tttcaagatg	gaggcgctga	gtcgagctgg	420
gcaggagatg	agcctggcgg	ccctgaagca	acacgaccct	tacatcacca	gcatcgcaga	480
cctcacgggc	caggttgctc	tgtacacctt	ctgccccaag	gccaaccagt	gggtgagtgc	540
cgcctggctc	tgaggacggc	cgcccggccg	ctgcggtctc	ttaaaggggc	cgtgcgtgtt	<b>600</b>
gctgtggggt	gggggacaca	gcaagaggcc	agggaggtga	agacggggcc	agggactggc	660
gaagagccga	gccagagcca	gaggggtgtc	gggtccacct	gggattgggg	gataggggtg	720
agagaagngg	ctgganaat					739

<210> 137 <211> 707

<212> DNA

<213> Cercopithecus aethiops

<220>

<221> misc\_feature

<222> (1)..(707)

<223> n is a, g, c or t

<400> 137

gecaaaccta caggtgggat ctttcactgc cagacagcga accgcgaagc cggcaggcac 60 ttcggcggtc tccagccttt gcctgaaaag agctcggcaa gctagnttag aggtcagacc 120 ccaggaccca gtcgttttag ctcagggaaa ggaagcgccg gacgccagcc tgcaagcttc 180 actgcgcagc cgtggacacc gccccacgtc gtagggccgt ggaccctgac aacgccggaa 240 cccggcgtcc ggtgcgtgcg cttggcggac cagaatggct aacgtaccgc catgccgcga 300 ggcccacgta gaggcggaag ttgatgggac ggacgcagat gggggaacct tgcctcgatg 360 420 geactiteet greegegaet eegeeceege eagagggget aggeteeggg titeaagatg gaggcgctga gtcgagctgg gcaggagatg agectggcgg ccctgaagca acacgaccct 480 540 tacatcacca gcatcgcaga cetcacgggc caggttgete tgtacacett etgecccaag 600 gocaaccagt gggtgagtgc cgcctggctc tgaggacggc cgcccggccg ctgcggtctc ttaaaggggc cgtgcgtgtt gctgtggggt gggggacaca gcaagaggcc agggaggtga 660 707 agacggggcc agggactggc gaagagccga gccagagcca gaggggt

# WO,2004/070002

<210> 138 <211> 818 <212> DNA <213> Cercopithecus aethiops

<220>

<221> misc\_feature

<222> (1)..(818)

<223> n is a, g, c or t

<400> 138 tcacacagaa ttcagnaaag cacagctgtc taggcgtttg geteetgaca aatggttgcc 60 tgcccctcac ctcaccagcc tctccagaca cctctgcatc acacagcact gatgaccgcc 120 teccagecca acacecaete tgettaetet gtgeegeeag getetgattg tgtttgggag 180 gtaaagtget cageeceaag actggecaaa ettggeeete ateateceat teeteettge 240 cagtggttta tctaggaata gatatggggc cctgttcagg tcagtgaaat gtaagggtga 300 gttagttcag gaatttctga gaaagattct cctctgtaat aaagcagaga gtcacatgac 360 tagaaaatct tittgitgit gitgitgitt taccaccacc ccticcitcc igcittggaa 420 ateggtttat gatgtgatgc ctggagctgt ggcagctgtt ttatgaccat gagagaaggc 480 ttctccagtg tgctaggatt caggggagga aatacagaat gaatgtcagc cctcgatgac 540 actgccgagc cctaaaccaa ctctgagaat ttaagacttt ttgttctgta agaaatgaga 600 660 tttatttatt gtttaagact ctgttgggta ttctgttatc tgtggcccan aatattttaa ataatataat ttctttttgc aataatacat ctcagatgga cattccocaa agtctaagac 720 tttgagagaa gtcatctctg aagagccaag cattcataat tagaaacttg gccaggtgca 780 818 gtggctcacg cctgtgatcc cagcactttg ggaggcca

<210> 139 <211> 581 <212> DNA <213> Cercopithecus aethiops

•

<220>

<221> misc\_feature

<222> (1)..(581)

<223> n is a, g, c or t

0 200	.,				1 (1,052005,05,	145
cctgge	ctgg gtggccctcc	tcagagcaga	cccaatcccc	accggcccct	cactgggcac	300
agcaac	cctt ccaagggctg	aagggcctgt	acctgcttct	tgaggtcagc	cacctetgca	360
gaagtc	togt tocacageto	ataggggatg	tecateacea	ccttgaccc	*ttgtgtacc	420
aggttg	tgta atgtctcaaa	ggtctctgac	atgecetgga	agaagcgacc	agacatggga	480
ggcaga	gete cettetetec	ctcctaccct	cctctcccag	tggggcctat	gaactcagct	540
gtaaga	ccaa tgcccaatgc	cctctgagga	tcctcaaacc	t		581
<210>	140					
<211>	630				••	
<212>	DNA					
<213>	Cercopithecus	aethiops				
<400>	140				•	

tcacacagaa ttccatgttc agtaaccagg tgctacaaat gcagttcaag gctctaggtc ' 60 · atgacaatgt cacagatate teaggteeag teaceaagge aacatgtgge ttgggtettt 120 ttctggtttc aagactgcat ctgtattctc tcacctccct gggcccacag attccctaaa 180 tcatagcttg gtctaagagc aatgcttcaa attcaggtcc cttgtctcag gtgggtagac 240 300 ttcctgtcac ccagccaccg ccacctgatt ctggacctgg agccggcagg cccgtggctt cagecegact cactettttg tattetgttg cttactatea tetttttttt ttttggtett 360 gaacteegea gtgteattit tittitetag titateeate titgeeatgt gittggggaa 420 480 gaatggcaat gcgaaagtgt gaacttccag tcccggctta ttagaagccc acagctgttt taaaaaaaat ctaccttgct atcctttccc ttttctgtga cacacaagtg actgttaatt 540 agtacctagg ccatgggctg tcatgcttaa aaactgaatg gaattttttg ttcttttagc 600 aatgttagga tgactggctg attataaaaa 630

<210> 141
<211> 737
<212> DNA

<213> Cercopithecus aethiops

<220>
<221> misc\_feature
<222> (1)..(737)
<223> n is a, g, c or t

acacagaatt cttacttaat acatataaac agaacatttc taggtcagtg aacaaaaata 60
taacctgaat cataaaaaca gagttataac tcctccatca atttccagac atcagccagt 120
ttacaaatcc agaacccctt aaatgaagaa caagcttgat gcccttgagg aagggcccta 180
gtacactgcc caaaatctgt acatttaatt ttcctcctaa tcttcccaaa agggacatat 240

Contract of the contract of th						
gtccttttac	cagtgaaact	gctcatttgg	gtaattgaaa	ataatcaaat	caggtactac	300
tggaccctgg	ctacgaactg	atgcaaattc	caggagacct	aacatgccat	ggtggtccac	360
aaagacagtg	cttatgggaa	tcaggtgatc	catggagttt	taagttgggt	ccaactcaca	420
tttgaataaa	tatactcatg	ctgacagaat	ctccataatg	gttccctgac	ctgtaaagtg	540
aggtgcatta	tggtgggtaa	tggcaaatgg	aagccagtag	aaacacctct	atctaggaaa	*600
aatagtaaag	caaatgcaat	attttcatct	-ccgtagggat	tgcagacatt	agttgccacc	660
atcaagggct	tgaaaaatga	ccagggggtg	attcccacca	acattctnca	ttcagctttg	720
tctattnggg	ccttgcc					737
	•		•			
<210> 142 <211> 768	•		•	i		
<211> 700 <212> DNA						
	copithecus	eethiops				
/213> CGE	coprenectab	مر د د د د د د د د د د د د د د د د د د د				
<400> <b>142</b>						
		atgctatgaa	acatatette	actgttcgtg	tttgtctctt	60
tctgaatcca	caagtgatgg	acacatgaat	ctactactac	tgttctctt	tcttctttt	120
ecgtettect	ctcccttccc	acccctagtt	cctgacgttt	gectaeteta	tcatgtctgc	180
	•	•		•		
agtgttgcat	accactctgc	atcctcatct	gtctgagaca	cattcaacca	ctaggteete	300
agctgcttca	a ctgctgcctg	atgttctttg	aagtccagta	taagagaga	a cattctattt	360
tgctaaaact	aaaagactac	cctttatctt	: tgctgagaat	: atgtaaaga	a aaggggaatg	420
actagatcaç	g aaggettatt	ctgaggtata	a tagtaatgtt	: aattttaa	a taattgttag	480
gtgttcttc	t tcattaggta	ttcaccttca	gttttccaag	g actatggaa	a gcaccattgg	540
tgcatgtag	t taacagcago	: ttgactcaga	a cgtagaactg	g cagecagga	c ocatctgttc	600
cccattact	c cctgctgcca	gttttgcaad	c cagaacctag	g gagtgattt	a toccatectc	660
aattttgct	c aggactcago	agaagaagga	a tectgggaca	a caagacttt	t cagtggcttc	720

aaacttggga gagttctttg gcaatgcaca ggtttgacct atgaactg

768

<sup>&</sup>lt;210> 143

<sup>&</sup>lt;211> 450

<sup>&</sup>lt;212> DNA

<sup>&</sup>lt;213> Cercopithecus aethiops

<sup>&</sup>lt;220>

<sup>&</sup>lt;221> misc\_feature

<sup>&</sup>lt;222> (1)..(450)

<sup>&</sup>lt;223> n is a, g, c or t

geetgtg:		ccatctggnc	ctggactttt	tttggttggn	aggctatcaa	cttattgcct	€0
caatttc	aga	gcctactatt	ggtctattca	gggatctcaa	ctncttcctg	gctttagtct	120
tggaaga	gtg	taagtgtcca	ggaaatctat	ccatcttctt	ctagattttc	cagtttattn	180
cgcgcag	agg	cgttcacagc	agcctctgat	ggtagttcga	atttctgagg	ggncggcggn	240
gatatoc	cct	ttatcattnt	naatngcgnc	gatnagacnc	ttetetettn	tettetetat	300
aagcact	cng	ctagecggec	ngccaatntc	gnngangctt	ntcaaaaaac	caactoctgg	360
attcatc	gat	tncnntggag	ggtctntttg	ngtctctatc	tccttcagtn	actgcnctga	420
tcttagn	ata	tttcntgccn	tctgctagct			•	450

<210> 144

<211> 729

<212> DNA

<213> Cercopithecus aethiops

<221> misc\_feature

<222> (1)..(729)

<223> n is a, g, c or t

<400> 144 cacacagaat taccettete geetteeaag gggaaaccag geeactitge tettettggg 60 · gaaggaggat aattgtccag tgctgggagg tgacagcagc tactgccagc acgaggtggg 1-20 gccctgcag tgtggttcct caggtctgag aggggttccc tctgccttcc tccctcctgc 180 teccetttee tettteetet acetgttttt teettetete acatetetee tgetteecea 240 300 caatccctga catttactgc aggeteccga agagecatga cactttatac cetcaacete 360 atttaattct caggaaaccc cacaaggccg tgcaattctc accccaggta ccaagtgagc 420 cagttcaggt gcacagagac tgccccttgc ccagagatcc tagcacgagg gctctgtact ggttagggtc tccagagaaa cagctccaat agaatgtgca gatgctgggt gcagtggctc 480 acccctgtaa tcccagcact ttgggaggcc gaggcgggcg gatcatgagg tcaggagatc 540 600 gagaccatec tggetaacac ggtgaaacce catetetact aaaaatacaa aaacattage cgggccgtgg tggcgggncg cctgtagtcc cagctacttg ggaggctgag ggcaggagaa 660 720 tqqcatgaag ccganaggca nagcttgcag tgagccaaga tcacatggca ctccaacctg 729 ggcgacaaa

<210> 145

<211> 755

<212> DNA

<213> Cercopithecus aethiops

<220>	:	1
<221> misc_fe	ature	
<222> (1)(7	55)	
<223> n is a,	g, c or t	
,		
<b>&lt;400&gt; 145</b>		eggeetecca 60
aacaattttc aca	cagaatt acctggtctc aaagtgtatc ctccatgctt.	eggececca 60
	turner become a tatomattot	ggtggaaget 120
aagtattgtg att	acaggag tgacccaccc tgcccggccc tctagcttat	ggrggaaget 120
h	ttagaca tttcttcttc ctttttttcc caagaaacag	ggtcttgctc 180
taaacaacca ytt	teagaca tececocco eccecoco	
taccaccac act	ggaatga agtggtgcaa tcatagctga ttgcaacctc	aaactoctta 240
		•
actcaatcaa too	eteccace tragecttte aaatagetgg gactacagtg	cgtaagccac 300
		1
cgcacctggc ctc	cttettte taatataagt atttaatatt ataaaattte	ctctaagatc 360
		404
taaacactgc tt	tagetgea acteacaaat titgatatgt igtatitita	tttatatccc 420
		ttagaagtgt 480
attaaaaata cag	gtattagt teeegtgtga tttettettt gaeccatgge	ttagaagtgt 401
	ccaaattt gggggcattt tccagatatc tttctcttat	ttatttgtaa 540
geegeetage et	ccaaacce gggggcacce tecagacace tecetocat	Courtegedd 52
tttaattoto st	gtggtcga ggagcacgtt ctgtttgctt acaatcctcg	taaatttatt 600
tttaattety tt	geggeega ggageaegee eegeegee	
atgacttott tt	atggccca gcatagggtc tgtttggcga gtgttccatg	tgcatctgaa 66
acgaeetgee ee		
aagaatgtgt at	tctgtagt tgtgcagggt atttttaaaa ttttattctt	ttcactgana 72
caaaatagct gt	ncatattt agagggtaca tgcga	75
	•	
<210> 146		
<211> 795		
<212> DNA	oithecus aethiops	
<213> Cercop	Tenecus accinops	
<400> 146		
	acaaagaa aagctcgtac cattcatgct gaaactactc	caaaaagttg 6
aggagaagga aa	itectecet agettattet acaaagetag cateacactg	rctaccaaaac 12
ctgacagagt ca	acaacaaca aaaattecag acatatatto ttgatgaaca	ttgatgcaaa 18
		- L-L
gtagtcaaca aa	atacttgc aaaccaaatt cagcagcaca tcaaaaagct	tatecateat 24
	All been been been waters and best and a sector of the sec	a atcaataaat 30
gatcaagtag go	etttateee tgggatgeaa ggttggttea acatetgeaa	a accaacaaa
etestasta se	cataaatac cactaaagac aaaaaaacca catgattato	tcaacagatg 36
gegaeveace at	,araaarac tactaaayac aaaaaaaacca tacyarcaac	
יכשתששששתתר ליו	tttgataaa atccaatacc ccttcatgtt aaaaactctc	c aataaactag 42
-agaaaaggo C		-
gtattgaagg as	acatacete aaagtaataa gaaceaeeta taaaaaaeee	c acagecaaca 46
		•
tcatattgaa to	gggcaaaag ctggaagcaa teeeettgaa aactggagga	a agacaagaat 5

600

accettett accaetecta tecaacataa tateggaagt eetggeeagg acaageagge

WO 2004/070002 PCT/US2003/0	37143
aagagaaaga aagaaaggca teecaatagg aagaaaggga agteaaaeta teectgtttg	660
cagacaaaat gateetatag etagaaacee catagtetea geecaaaget tttaagetga	7-20
tanacacttt cagcaagcct cagcatacaa aatcatgtgc aaaagtcagt acattttgta	780
caccaccaac agtca	795
<pre>&lt;210&gt; 147 &lt;211&gt; 704</pre>	
<212> DNA	
<213> Cercopithecus aethiops	. •
<220>	
<pre>&lt;221&gt; misc_feature &lt;222&gt; (1)(704)</pre>	
<223> n is a, g, c or t	
<400> 147	
geatectece tecteggeet gggegtggge tegeaaaacg etgggattee eggtattaca	60
ggcgggcgcg ccacgccagg agcaaacact tcctgcttta aaaattcagt gttgtgattg	120
gctgccattc agcattatgc taattaagca tgcctgtttt ttttaagctt cttaaaacaa	180
ttttttaaaa ttccgtttcc acctaaaacg ttaaaatttg tcaagtgata atattcgaga	240
agatgttgtt gccaaactat ttttctattt gtttcctaat ggcatcggaa atagcgaaag	300
tatetegeca ttagttaaaa gttggcagca gatgtagace eegcagagge tgegagtggg	360
ctgttaagac tatactttca gggatcattt ctatagtttg ttactagaga agttetetet	420
gaacgtgtag agcaccgaaa accacgagga agagacgtag cgttttctcc tgagcgtgaa	480
gegggegttt ggtgttgett egetgeaact gecateagee attgatgate gttettetet	540
ccgctttgga gagnaagagg gagagaacgc ggtctgagtg gtttttcttt tttgcgnggt	600
tagaacgaca gactgtacag cgaccgtntc ccggcttgnc tntgtgcttg nntgnccncc	660
ngaggccnaa gngagttgcc ttattttgtt tcacnanccg ntgt	704
<210> 148 <211> 650	
<212> DNA	
<213> Cercopithecus aethiops	
<220>	
<221> misc_feature	
<222> (1)(650) <223> n is a, g, c or t	
•	
<400> 148 atcgccttct atcgccttct tgacgagttc ttctgagcgg gactctggggg ttcgaaatga	. 60
•	

1-20

gctagecett aagtaacgee attttgcaag gcatggaaaa atacataact gagaatagaa

## WO, 2004/070002

aagttcagat	cgaggtcagg	aacagatgga	acagggtcga	ccggtcgacc	ggtcgaccct	180
agagaaccat	cagatgtttc	cagggtgccc	caaggacctg	aaatgaccct	gtgccttatt	240
tgaactaacc	aatcagttcg	cttetegett	ctgttcgcgc	gcttctgctc	cccgagetca	300
ataaaagagc	ccacaacecc	tcactcgggg	cgccagtcct	ecgattgact	gagtcgcccg	360
ggtacccgtg	tatccaataa	accetettge	agttgcatcc	gacttgtggt	ctcgctgttc	420
cttgggaggg	tctcctctga	gtgattgact	acccgtcagc	gggggtcttt	cagttaagac	480
tatactttca	gggatcattt	ctatagtttg	ttactagaga	agtttctctg	aacgtgtaga	540
gcaccgaaaa	ccacgaggaa	gagacgtagc	gttttctcct	gagcgtgaag	cgggcgtttg	600
gtgttgcttc	gctgcactgc	catcanccat	tgatgatcgt	ttentnteeg		650

<210> 149

<211> 671

<212> DNA

<213> Cercopithecus aethiops

<220>

<221> misc\_feature

<222> (1)..(671)

<223> n is a, g, c or t

<400> 149 aactttaact aatggcgaga taccttcgct attgccgatg ccattaggaa acaaatagaa 60 120 aaatagtctg gcaacaacat cttctcgaat attatcactc gacaaattat aacgttttag gtggaaacgg aactttaaaa aattgtttta agaagcggaa aaaaaacagg catgcataat 180 tagcataatg ctgaatggca gccaatcaca aactgaatct ccaaagcagg aagtgtttgc 240 tectggegtg gegegeege etgtaateeg ggaateecag egtttagega geecacgeee 300 aggecgagga gggaggatec tttgttccac gagategaca ecagectagg caatatagca 360 gaatcctggt ggtgacggaa atgccctatc ttgagcttat caatgccaaa accccggtca 420 tataacttta ttggatatca gtggggaaaa ctgagtaaaa ggtgcaaatg tataactcag 480 tataaacccc aagaacgaaa cgcaaaacct accattctct gaaagaaatg ttttgtacat 540 atatttacac agaaacacat acatcatgat caaaaaaatga catcattcgt aaaaaaaaat 600 aacaaaaagt gtaaaagaac ccatcgcccg gaaaggaagg gccctgtgag accggatccc 660 671 caaaaccaaa c

<210> 150


<211> 704

<21:2> DNA

<213> Cercopithecus aethiops

600

660



<220> <221> misc\_feature <222> (1)..(704)<223> n is a, g, c or t <400> 150 tcattaacag cccactegea geetetgegg ggtetacate tgetgeeaac ttttaactaa . 60 tggcgagata ctttcgctat ttccgatgcc attaggaaac aaatagaaaa atagtttggc 120 **180** aacaacatct totogaatat tatoacttga caaattttaa cgttttaggt ggaaacggaa ttttaaaaaa ttgttttaag aagettaaaa aaaacaggca tgcttaatta gcataatgct 240 300 gaatggcagc caatcacaaa ctgaattttt aaagcaggaa gtgtttgctc ctggcgtggc 360 gegeeegeet gtaateeggg aateeeageg ttttgegage ceaegeeeag geegaggagg gaggatectt tgttecaega gttegaeace agectaggea atatageaga attetgtgtg 420 aaattgttat ccgctcacaa ttccacacaa catgagcgtc agaccccgaa gaaaagatca 480 **-540** aaggatette ttgagateet ttttttetge gegtaatetg etgettgeaa acaaaaaaae 600 caccgctacc agcggtggtt tgtttgccgg atcaagagct accaactctt tttccgaagg ~660 taactggctt cagcagagcg cagataccaa atactgtcct totagtgtag ccgtagttag gecenecact teaagaacte tgtageaceg ectacatace tega 704 . <210> 151 <211> 705 <212> DNA Cercopithecus aethiops <400> 151 qctatattgc ctaggctggt gtcgaactcg tggtaacaaa ggatcctccc tcctcggcct 60 gggcgtgggc tcgcaaaacg ctgggattcc cggattacag gcgggcgcgc cacgccagga 120 gcaaacactt cctgctttaa aaattcagtt tgtgattggc tgccattcag cattatgcta 180 attaagcatg cctgtttttt ttaagcttct taaaacaatt ttttaaaatt ccgtttccac 240 ctaaaacgtt aaaatttgtc aagtgataat attcgagaag atgttgttgc caaactattt 300 360 ttctatttgt ttcctaatgg catcggaaat agcgaaagta tctcgccatt agttaaaagt tggcagcaga tgtagacccc gcagaggctg cgagtgggct gttaatgaaa gaccccacct 420 gtaggtttgg caagctagct gaggatcgtt tcgcatgatt gaacaagatg gattgcacgc 480 tggttctccg gccgcttggg tggagaggct attcggctat gactgggcac aacagacaat 540

eggetgetet gatgeegeeg tgtteegget gteagegeag gggegeeegg ttetttttgt

caagaccgac ctgtccggtg ccctgaatga actgcaggac gaggcagcgc ggctatcgtg

# WO 2004/070002 PCT/US2003/037143 getggccacg acgggegtte ettgegcace tgtgctegae gttgt 705

geoggeoracy acgustic consustant agosticate surjections	
<210> 152 <211> 673 <212> DNA <213> Cercopithecus aethiops	٠
<400> 152 tttcattaac ageccactcg cagcctctgc ggggtctaca tctgctgcca actttaact	60
aatggcgaga tactttcgct atttccgatg ccattaggaa acaaatagaa aaatagtttg	120
gcaacaacat cttctcgaat attatcactt gacaaatttt aacgttttag gtggaaacgg	180
aattttaaaa aattgtttta agaagcttaa aaaaaacagg catgcttaat tagcataatg	240
ctgaatggca gccaatcaca aactgaattt ttaaagcagg aagtgtttgc tcctggcgtg	300
gegegeeege etgtaateeg ggaateeeag egttttgega geeeacgeee aggeegagga	360
gggaggatee tttgtteeac gagttegaca ecageetagg caatatagca gaatteatet	420
cacagagtta catctttccc ttcaagaagc ctttcgctaa ggctgttctt gtggaattgg	480
caaagggata tttggaagcc catagagggc tatggtgaaa aaggaaatat cttccgttca	540
aaactggaaa gaagctttct gagaaactgc tctgtgttcc tctgaattct ggaagaaaac	600
aaacacatca ttcttgtctc caagagctta aatttctgtt tgggcaattt atttataaaa	<b>660</b>
acacaactta gcc	673
<210> 153 <211> 709 <212> DNA <213> Cercopithecus aethiops  <220> <221> misc_feature	
<222> (1)(709) <223> n is a, g, c or t	
<400> 153 tttcattaac agcccactcg cagcctctgc ggggtctaca tctgctgcca acttttaact	60
aatggcgaga tactttcgct atttccgatg ccattaggaa acaaatagaa aaatagtttg	120
gcaacaacat cttctcgaat attatcactt gacaaatttt aacgttttag gtggaaacgg	180
aattntaaaa aaagttitta agaagcttaa aaaaaacagg catgcttaat tagcataatg	240
ctgaatggca gccaatcaca aactgaattt ttaaagcagg aagtgtttgc tcctggcgtg	300
gcgcgcccgc ctgtaatccg ggaatcccag cgttttgcga gcccacgccc aggccgagga	360

420

460

gggaggatcc tttgttccac gagttcgaca ccagcctagg caatatagca gaattctgtg

tgaaattgtt atccgctcac aattccacac aacatgagcg tcagaccccg aagaaaagat

NW 1						
caaaggatct 4	cttgagatc	ctttttttc	tgcgcgtaat	ctgctgcttg -	caaaacaaaa	540
aaaccaccgc	accageggt	ggtttgtttg	cncgggatca	agagtctacc	aacctcttt	600
ttacgaaagg (	nactgggct	tcaggcagga	gccgcanatt	nccaaaataa	ttggnccctt	660
ccaagnggnn	anceegenag	gnttagggcc	cnoccaactt	tenaaggae		709
<210> 154 <211> 574						
<212> DNA <213> Cerc	opithecus a	ethiops				
1	<u>.</u>	_				
<220> <221> misc	_feature					
<222> (1).	 .(574) a, g, c ox	. <u>.</u>				
	' ' '	. •	,	;		
	ggcgtgggct	cgcaaaacgc	tgggattccc	ggattacagg	cgggcgcgcc	<b>₹</b> 60
acgccaggag	caaacacttc	ctgctttaaa	aattcagttt	gtgattggct	gccattcagc	120
attatgctaa	tnaagcatgc	ctgtttttt	taagcttctt	aaaacaattt	tttaaaattc	180
cgttaccacc	taaaacgtta	aaatttgtca	agtgataata	ttcgagaaga	tgttgttgcc	240
aaactatttt	tctatttgnt	tcctaatggc	atcggaaata	gcgaaagtat	ctcgccatta	300
gttaaaagtt	ggcagcagat	gtagaccccg	cagaggctgc	gagtgggctg	ttaatgaaag	360
accccacctg	taggtttggc	aagcatagct	gaggatcgtt	: tcgcatgntt	gaacaagatg	420
gattgcacgc	tggntctccg	geegetngng	tggagaggct	atteggntat	gactgggcac	480
aacagacaaa	tcgggctgnt	ctgatgccgc	cgtgttccgg	ntgtaagcgc	aggggcgccc	540
cngtttcttt	tttgnaaaga	ccganctgta	acg <del>g</del>			574
<210> 155						
<211> 794				•		
<212> DNA		••				
<213> Cere	copithecus	aethiops				
<220>						
<221> mis	_					
<222> (1)		<b></b>				
	sa, g, co	rt				
<400> 155	<b></b>			+ n+an=+=n=+	- ashbassbab	·60
aceccggaga	tatgaggcct	. agctccatco	; tecttett	ı accacceagt	cattcaatct	700
ttgcttggaa	tacatgaact	aataatttc	aatattacc	t gacatggato	cactttaggg	120

aagacacaag atatgaaaga aaggataaag totgaaagtt agaagtaaca caactacaga 180

WO 2004/070002 PCT/US2003/037	143
aaatagatta atgtggattg ttatageeat teatacaatg acateeteaa egteaaaace tttttgtact etttacagat tecarateea ageagaatte tatttaatgt getttetaac	240 300
aatcagattc ctgacaaatg tgttcataaa gtaataaaag cagcaaaatc ttaaatgttt	360
tatactaaca tagtagacaa aatacaaata ctctgaacac taatatcaca gaaaccctta	420
aaaaaaagat tgaggggagg taataacata cctaatacaa atagaaataa ggaggaacct	480
ttgaggtttg ctatgctttg aacgtgtccc caaggttcac atgttggaaa cttaatccct	540
gaagcaacag tgatgagaag tgggaccttt aagaggtgag taggtcacga gggctctgct	600
ctgccacatg aatggattaa tgctattacc agaggagtgg ggaatgggtt ccagatagaa	660
gaccgagttt ggectectec ttatntnteg etetetngee tteegeette taccatggga	720
tgatacagca ggaagaccet agataccaca cettgatatg gaetteengt ecenanaect	780
tgantaaata ccag	794
<210> 156 <211> 831 <212> DNA <213> Cercopithecus aethiops	
<221> misc_feature <222> (1)(831) <223> n is a, g, c or t	
<400> 156 cgcatcgcct tctatcgcct tcttgacgag ttcttctgag cgggactctg gggttcgaaa	60
tgagctagcc cttaagtaac gccattttgc aaggcatgga aaaatacata actgagaata	120
gaaaagttca gatcgaggtc aggaacagat ggaacagggt cgaccggtcg accggtcgac	180
cctagagaac catcatatgt ttccagggtg ccccaaggac ctgaaatgac cctgtgcctt	240
atttgaacta accaatcagt tegetteteg ettetgtteg egegettetg eteceegage	300
tcaataaaag agcccacaac ccctcactcg gggcgccagt cctccgattg actgagtcgc	360
ccgggtaccc gtgtatccaa taaaccctct tgcagttgca tccgacttgt ggtctcgctg	420
tteettggga gggteteete tgagtgattg actaecegte agegggggte ttteaaggte	480
aactgacttt aaacttgeeg tttgatttgt gactttagaa agtagagtta actatattta	540
gcaatatgct taagcatgtg catatcacct catgaaacgt gtgtgtgcat gagaaaagct	600
geetecagta catatacata tgtatataaa cacacataca cacaagcata tatatgtatg	660
tatttcttgn aggaccagtc tcattgtata taatttcaag tgcaggttcc tgatctccan	720
ggatgcgtaa aagactcact gaagttngga agaaanttta nggctactat tntgttggng	780
atchcaccct tcaagtttaa atttgatntg attattctta cngnttgcng g	831

•	<210> <211> <212> <213>	157 637 DNA Cerc	copithecus a	nethiops				
!		(1).	c_feature (637) s a, g, c os	r t				
	<400>		•и_					
			•	gecacttta				60
	ggatcc	tttt	gtacacagct	cctgaaagag	agaaatttt	ttttcaccta	ecgacagaca	120
	tattgg	aagg	ctgctaatat	tetgaetttt	acggactgta	ctccctttaa	cctgggtaca	180
	taccat	aata	ttctttcagt	tgnccacagc	tatagatacc	cctagcataa	cacttcagga	240
	ttcaga	agac	gaatgtacct	ttctgtatct	taacctctct	actccacact	teccacetet	300
	gaaaaa	acaa	caggccaaat	tctcagaacc	taaaaccaag	tcagagtaaa	cactgctaat	360
	acaata	ctga	cacttacata	tttacctggc	ataatctcta	ggattccacc	cacaacctaa	420
	cagato	ctaa	ctctctcata	gagngagaaa	atctgctaaa	atctgacaga	agtccaaatg	480
	aatcct	ttca	gatatatgta	gcttgctaca	cactcagaaa	gnnaagttct	cggaacttga	540
	aagctc	tctg	aaactnttac	cagntacaag	angttncagc	nnatcacact	agcagcatgg	600
	ntaang	gcaa	accagagcag	ctaccggaan	attaaag.			637
		158 656 DNA Cere	copithecus a	aethiops				
	<2,22>	(1)	c_feature (656) s a, g, c o	rt				
	<400>		<b>.</b>				. •	
				gaatgttgtg				60
	aacata	ggaa	catcatttag	cctcttaagc	ttgaacatcc	attaagcggg	aaaaatagtg	120
	cttatt	tect	agaggtttgc	agacattggc	taaccaatag	ttntgattnt	gctggaaagc	180
	aatgtg	caaa	ttttcttaga	tgtgatcgct	tcattttctc	ttacatttta	gattggcagc	240
	agccaa	atgg	gcgttccagc	ccctnatctc	ctgcaagatt	cttctcagtt	tcataaatct	300
	ggtaat	ttt	gagctctttt	cccaacaggg	tgctgcaget	caccaagtgg	aatctacaac	360

W	D <sub>:</sub> 2004/07000	)2				PCT/US2003/03	7143
at	tttctgct	accaggatag •	cagcttgcca	gcaggatata	ctgaaattac	tgggtt <b>b</b> cag	420
ta	tgatgttg	gctggtacga	acntcaatca	tnegaatega	catgcgccca	gecattetea	480
ta	atgaaatg	tntccttctc	ctttcaacat	gttccgcttt	ccagececcc	atcetecntt	540
ta	ttatnttt	tttctttcan	nnaaaagaag	ctttnagnaa	acacnnaaac	ctcttactcc	600
ct	ntagngaa	aggaaaacnt	tcttccnnt	nctrentece	ctttngannc	nocota	656
,	• .						
	10> 159 11> 654	+#					
<2	12> DNA	ionithogus s	ethions				
\ Z	13> Cero	opithecus a	ecniops				
· · <2	20>						
		_feature (654)			,		
		a,'g, c or	t				•
	100> 159						160
					actaactatt		
-tt	gatatttg	gatgtgtaca	gtttgatgct	attataaaat	tcttctaaga	acattettgt	120
ac	atgttcat	tttgtttcgc	taggtcctag	agtctaaggt	atatatccag	aagaggaata	180
go	tgggtatt	atgatagaat	aatgacaaac	tagtttctaa	agtgattgta	ccaattagtg	240
ti	:tecatagg	agaaaagtgt	acagetactg	gaaaaacagt	: ttggaatgat	ctgaagtata	300
ag	<b>jaatgttca</b>	tagcaacaga	atgtgtttct	tgtattccaa	atgttcacct	acagttggtg	360
t	ggtcagtat	aagttgttgt	ttttgtttt	attgtgtgtg	, tgttttttt	atectttggg	420
a	cagggcctc	actttgttat	ccaggctaga	gagcagtggt	acaaacatga	ctcactgcag	480
C	cttagcctc	ccaggctcaa	gcagtcctcc	tgcctcagc	tcctaagtac	: ctgggactac	"5 <b>4</b> 0
a	ggcatgtgc	caccacacct	ggctaatttt	tgtatttni	tgtagagaca	gggtttcacc	600
a	tgttngccc	agtctggtct	agttttaaac	: aaagttgtng	g -cctgnggaaa	tgat	<sup>*</sup> 654
_	210> 160						
<	211> 683					•	
	212> DNA 213> Cer	copithecus	aethiops				
	400> 160						
÷	tactgcato	tgcacacaaa	aacccaccga	a agaaaaaaa	g tgtgaatgc	c atacaatttt	60
t	ttcaatgca	agtatggaac	actgtacato	e actgaaaaa	c agggggaaa	a aaaaaaagga	120
а	aaagaggag	aaccattgaa	gaaagcataa	a aatagcagc	t agetttett	a egtgtgetgg	180
а	attgtgtct	: ttcgggttaa	ccccaaatt	tcctatgct	a tacactett	c tcacattttg	240
					L		300

300

gtcaatacta gcttctgaat tggaagaggc attatcaatt gctttaaaat gttataccta

wo	2004/070002	

aaataaagaa	acactgagtt	agactgtcac	cactttgaat	acccatcagg	agagtgtggc	. 3 <del>6</del> 0
attgcatgcg	aaaatgtatg	tgttcctctt	aggagatgaa	gatcaagtca	gctaacagct	420
gtcaacaaac	ttctagtgta	ggcaagaatt	ttatggccaa	gttgggcttt	cctttattcc	480
ttactggaag	aaagtattca	gaaaatagca	ttttagggga	aaaaagtgtt	aagtaaacag	540
aatcctttta	agcacacaaa	caaaagttga	gcagtgtaaa	ttttgaaact	tagtgccttt	600
tagtatctga	agcaaaatga	taacaagtta	taggatttt	tctttatgaa	gaatgatgta	<b>*6</b> 60
agctcactta	tgaaagaaga	acc				683

<210> 161 <211> 811 <212> DNA

<213> Cercopithecus aethiops

<220>
<221> misc\_feature
<222> (1)..(811)
<223> n is a, g, c or t

<400> ··161

ctttcacgag aattctgtct caaaaaaaaa aaaaaagcca aagtcctcaa aatggcctgc 60 atggcactac attetetggc cetttateag cactetgaca geteteteet ttgettattt 120 tgctcctcat tctagcctct ggatctttgc ccttgctgtt ccttacgctc ttctcccagg 180 gatetgaaag geteacacce teaceteett cagaggtttg etaaaatgte ttetacceag 240 300 tgaageette eccaaceace acattaaaaa cacacaacea geaceegtte tetatettee ttcactttgc atttgtccat tgtgtaacat cacttacata octttaattt ttagtttatt 360 aattcatact gcaaaacaac ttagtttnta ccatgtgcca ggcattgtcc ctagttgctg 420 480 acaatacagt tgaaaataaa atagacaaaa atcccatctt ttgaatcttt tgaaccttac attgggagtg acaggcaaaa acgaggtaaa tcagtaaaat acgtgagaca gaacgctaaa 540 agaaaaaaa gaggaaaggg ctgatttttg tgtctttccc tccanaatgc aagctccctt 600 gaggatacag atttgngtgt tttttaacta ctgnaatnet ceetgacaat agegeeccag 660 tnacatagta agggcatttc gannccaatt ttttaaaaaat gaagaaaact aggccagtta 720 concagttto otggggocca attttoaact ttttaggano ntnaantaco gatataaana 780 811 aaattcggtt acagctaggg ctccgnatna a

<210> 162 <211> 757 <212> DNA <213> Cercopithecus aethiops

:220>	
221> misc_feature	
222> (1)(757)	
223> nisa, g, cort	
<400> 162 ctttcacgag aattetgtet caaaaaaaaa aaaaaageea aagteeteaa aatggeetge	60
ctttcacgag aactctytet cadaadaaa adduudgeed augeeeeduu auegeees	
atggcactac attetetgge cetttateag cactetgaca geteteteet ttgettattt	120
tgctectcat tetagectet ggatetttge cettgetgtt cettaegete tteteceagg	180
	240
gatetgaaag geteacacee teaceteett cagaggtttg etaaaatgte ttetaceeag	540
tgaagcette eccaaceace acattaaaaa cacacaacea gcaceegtte tetatettee	300
tgaagccttc cccaaccacc acattaaaaa tacataacca gcaccegtto soud-	
ttcactttgc atttgtccat tgtgtaacat cacttacata cctttaattt ttagtttatt	· 360
Cocaccing accompany of the second contract of	
aattcatact gcaaaacaac ttagttttta ccatgtgcca ggcattgtcc ctagttgctg	420
	400
acaatacagt tgaaaataaa atagacaaaa atcccatctt ttgaatcttt tgaaccttac	480
' tongtonet acatgages gascactass	540
attgggagtg acaggcaaaa acgaggtaaa tcagtaaaat acgtgagaca gaacgctaaa	
agaaaaaaaa gaggaaaggg ctgatttttg tgtcttccct ccagaatgca agctccttga	600
agadadaa gaggaaaggg a comment of	
·	
taggcattcg atccaatttt aaaatgagat actaggcagt tactcagttt tctgggcaca	720
· · · · · · · · · · · · · · · · · · ·	757
tttcaacttt tagacaataa taccgataag aaaanta	
<210> 163	
<211> 749	
<212> DNA	
<213> Cercopithecus aethiops	
.000	
<220> <222> (1)(749)	
<223> n is a, g, c or t	•
<400> 163	~
ctttcacgag aattctgtct caaaaaaaaa aaaaaagcca aagtcctcaa aatggcctgc	160
and the second sections are sections as the second sections are sections as the second section section sections are sections as the second section section section sections are sections as the second section sec	120
atggcactac attetetgge cetttateag cactetgaca geteteteet ttgettattt	
tgetecteat tetageetet ggatetttge eettgetgtt eettaegete teeteccagg	180
Tyclcctcat totagecoot ggasorogs to tage of the	
gatetgaaag geteacacee teaceteett cagaggtttg etaaaatgte ttotaceeag	240
	200
tgaageette cecaaceace acattaaaaa cacacaacea geaceegtte tetatettee	300
the second second and the second seco	3.60
ttcactttgc atttgtccat tgtgtaacat cacttacata cctttaattt ttagtttatt	300
aattcatact gcaaaacaac ttagttttta ccatgtgcca ggcattgtcc ctagttgctg	420
daticacact yeadaacac teageteeta courgesson good of the courses	
prostrongt toppostage stagecases atrocatett ttgaatettt tgaacettae	48

# WO 2004/07000

# PCT/US2003/037143

$\epsilon h \cdot t'$	
attegggagtg acaggcaaaa acgaggtaaa tcagtaaaat acgtgagaca gaacgctaaa	540
agaaaaaaa gaggaaaggg ctgatttttg tgtcttccct ccagaatgca agctccttga	600
ggatacagat ttgggtgttt tntactactg natctcctga acaatagcgc cccagtacnt	660
aggtaggnca ttcgatccaa nttttnaaaa agaggancct agggccagtt aactnaagtt	720
ttctggggcc ccatttccaa acttttaga	749
<210> 164	
<211> 741 " <212> DNA	
<213> Cercopithecus aethiops	
: !<220>	
<221> misc_feature	
<pre>&lt;222&gt; (1)(741) &lt;223&gt; n is a, g, c or t</pre>	
1225 II 15 d, g, C of C	
<400> 164	
ctttcacgag attctgtctc aaaaaaaaaa aaaaagccaa agtcctcaaa atggcctgca	60
tggcactaca ttctctggcc ctttatcagc actctgacag ctctctcctt tgcttatttt	120
getectcatt etagectetg gatetttgee ettgetgtte ettaegetet teteccaggg	180
atotgaaagg otcacacoot cacotootto agaggtttgo taaaatgtot totaccagt	240
gaageettee ecaaceacea cattaaaaac acacaaceag caceegttet etatetteet	300
tcactttgca tttgtccatt gtgtaacatc acttacatac ctttaatttt tagtttatta	360
attcatactg caaaacaact tagtttttac catgtgccag-gcattgtccc tagttgctga	420
caatacagtt gaaaataaaa tagacaaaaa tcccatcttt tgaatctttt gaaccttaca	480
ttgggagtga caggcaaaaa cgaggtaaat cagtaaaata cgtgagacag aacgctaaaa	540
gaaaaaaaaa gaggaaaggg ctgatttttg tgtcttccct nccagaatgc aagctccttg	600
aggatacaga attngtgtgt tttttnacta ctgnatctcc tgacaatagc ncccagtaca	660
tagtaggcat tcgatccaat tttnaaaaga ganactaggc angtactaag tttntgggcc	720
cattnnactt ttaagacaat a	741
<210> 165	
<211> 727 <212> DNA	
<pre>&lt;212&gt; DNA &lt;213&gt; Cercopithecus aethiops</pre>	

<sup>&</sup>lt;213> Cercopithecus aethiops

<sup>&</sup>lt;220>

<sup>&</sup>lt;221> misc\_feature <222> (1)..(727) <223> n is a, g, c or t

<400> 165						
ctacgataca	tgtaacattc	tacgaacaac	catggtgagt	agaaccatct	ggattttcca	<i>1</i> 60
tcacttcat	ttaaaagact	ctgttgatat	tctaggtact	gattccatat	atcagtatca	120
acaaatttct	caaccaaggg	gataattggt	ttatctgttt	gcaattcatt	ccgtaattta	180
gaaaggagag	aaatagcttt	-cttttcagct	tccacgcctt	cctgcaaaaa	tacaagaaaa	240
accaattgtg	tgtgtgtctg	tgtctgtgtt	tgtgtgtgcg	tgtctatgca	attectetag	300
ggtaacatat	ttttacagac	ttaagaagaa	aagaaaaatg	ttcaaactac	attatacttc	360
tttaaacatt	acatttagaa	ctcttaaact	gaaaatcaaa	aaacacacac	agateteata	420
tgaacataat	catgccttat	ctatctaagt	tctggccttt	ctgtgtcttc	ggtgatcatt	480
: actacagagg	gaaaggaacc	cctgacagat	tttccatgtc	: tttcatgctt	ccatacacat	540
tettettea	ccattgacac	cactagaaaa	gaaactgtgg	cctttctgag	gtttettttg	600
gtagctcaat	tttttttt	aacttgtttt	ccactgagtt	ctagctaggt	gagagatgag:	660
atatgctgac	atacaaggcg	ctacaatata	teteacatga	a caggccanto	g ggagtgggga	720
naaatgt		•				727

<210> 166

<211> 713

<212> DNA

<213> Cercopithecus aethiops

<220>

<221> misc\_feature

<222> (1)..(713)

<223> n is a, g, c or t

<400> 166 cacgagaatt ctgtctcaaa aaaaaaaaaa aagccaaagg tcctctaaaa tggcctgcat 60 ggcactacat tetetggccc tttatcagca etetgacage teteteettt gettattttg 120 ctcctcattc tagcctctgg atctttgccc ttgctgttcc ttacgctctt otcccaggga 180 tetgaaagge teacaccete aceteettea gaggtttget aaaatgtett etacceagtg 240 aageetteee caaccaccac attaaaaaca cacaaccage accegttete tatetteett 300 cactttgcat ttgtccattg tgtaacatca cttacatacc tttaattttt agtttattaa 360 ttcatactgc aaaacaactt agtttttacc atgtgccagg cattgtccct agttgctgac 420 aatacagttg aaaataaaat agacaaaaat cocatctttt gaatcttttg aaccttacat 480 tgggagtgac aggcaaaaac gaggtaaaat cagtaaaata cgtgagacag aacgctaaaa 540 gaaaaaaaa aggaaagggc tgatttttgt gtcttcccct ccagaatgca agctcccttg 600 aggatacaga titnggntgt titttacta cigtatcicc tgacaanagg egeccagtaa 660



## cataggtang gcattcgatn ccaatttttn aaaatgagan actaggcagt tac 713 <210> 167 <211> 714 <212> DNA <213> Cercopithecus aethiops <220> <221> misc\_feature <222> (1)..(714) <223> n is a, g, c or t <400> 167 ctttcacgag aattctgtct caaaaaaaaa aaaaaagcca aagtcctcaa aatggcctgc :60 atggeactac attetetgge cetttateag cactetgaca geteteteet ttgettattt 120 tgctcctcat tctagcctct ggatctttgc ccttgctgtt ccttacgctc ttctcccagg 180 gatctgaaag gctcacaccc tcacctcctt cagaggtttg ctaaaatgtc ttctacccag 240 tgaageette eecaaceace acattaaaaa cacacaacca gcaceegtte tetatettee 300 ttcactttgc atttgtccat tgtgtaacat cacttacata cctttaattt ttagtttatt 360 aattcatact gcaaaacaac ttagttttta ccatgtgcca ggcattgtcc ctagttgctg 420 acaatacagt tgaaaataaa atagacaaaa atcccatctt ttgaatcttt tgaaccttac 480 attgggagtg acaggcaaaa acgaggtaaa tcagtaaaat acgtgagaca gaacgctaaa 540 agaaaaaaaa gaggaaaggg ctgatttttg tgtcttccct ccaaaatgca agctccttga 600 ggatacagat ttngtgtgtt ttttanttac tgtatctcct gacaatagcg ccccagntcc 660 atagtaaggc attcgatcca atttttaaaa atggagatac tagggcagtt tact 714 <210> 168 <211> 792 <212> DNA <213> Cercopithecus aethiops <220> <221> misc\_feature <222> (1)..(792)<223> n is a, g, c or t <400> 168 ctttcacgag attctgtctc aaaaaaaaaa aaaaagccaa agtcctcaaa atggcctgca 60 tggcactaca ttctctggcc ctttatcagc actctgacag ctctctcctt tgcttatttt 120 getectcatt ctagectctg gatetttgcc cttgctgttc cttacgctct tctcccaggg 180 atotgaaagg ctcacaccct cacctccttc agaggtttgc taaaatgtct tctacccagt 240

WO <sub>1</sub> 2004/070002 PCT/US2003/037	143
gaagoottoo ccaaccacca cattaaaaac acacaaccag caccegttot ctatottoot	300
reactitigea titiguecati gigiaacate actiacatae etitaatiti tagiitatia	360
attcatactg caaaacaact tagtttttac catgtgccag gcattgtccc tagttgctga	420
caatacagtt gaaaataaaa tagacaaaaa toocatottt tgaatotttt gaacottaca	480
ttgggagtga caggcaaaaa cgaggtaaat cagtaaaata cgtgagacag aacgctaaaa	540
gaaaaaaaaa aggaaagggc tgatttttgt gtctbccctc cagaatgcaa gctccttgag	600
gatacagatt tgtgtgtttt ttactactgt atctcctgac aatagcgccc agtacatagt	660
aggeattega tecaattttt aaaatgtgat actaggeagt tacteagttt etgggeacat	720
ttnaactttt agacnataat accgattaaa aaaancggtt ncagctaggc tacgatncaa	780
gananaactg tn	792
<210> 169 <211> 691 <212> DNA <213> Cercopithecus aethiops	
<220> <221> misc_feature <222> (1)(691) <223> n is a, g, c or t	
<400> 169 ctacgaacaa ccatggtgag tagaaccatc tggattttcc atcactttca tttaaaagac	60
totgttgata ttotaggtac tgattocata tatcagtatc aacaaatttc tcaaccaagg	120
ggataattgg tttatctgtt tgcaattcat tccgtaattt agaaaggaga gaaatagctt	180
tetttteage ttecaegeet teetgeaaaa atacaagaaa aateaattgt gtgtgtgtet	240
gtgtctgtgt ttgtgtgtgc gtgtctatgc aattcctcta gggtaacata tttttacaga	300
cttaagaaga aaagaaaaat gttcaaacta cattatactt ctttaaacat tacatttaga	360
actettaaac tgaaaateaa aaaacacaca cagateteat atgaacataa teatgeetta	420
tctatctaag ttctggcctt tctgtgtctt cggtgatcat tactacagag ggaaaggaac	480
-ccctgacaga ttttccatgt ctttcatgct tccatacaca ttcttctttc accattgaca	540
ccactagaaa agaaactgtg gcctttctga ggtttctttt ggtagctcaa ttttttttn	600
aacttgtttt ccactgagtt ctagctaggt gagagatgag atatgctgac atacaaggcg	660

<210> 170


<211> 699 <212> DNA

300

360

420

480



# <213> Cercopithecus aethiops

<220> <221> misc_feature <222> (1)(699)	
<400> 170 ctcaaaaaaa aaaaaaaagc caaagteete aaaacggeet geatggeact acattetetg	60
geeetttate ageactetga cagetetete etttgettat tttgeteete attetageet	120
ctggatcttt geecttgetg tteettaege tetteteeca gggatctgaa aggetcacae	180
cctcacctcc ttcagaggtt tgctaaaatg tcttctaccc agtgaagcct tccccaacca	240
ccacattaaa aacacacaac cagcacccgt tetetatett cetteaettt geatttgtee	300
attgtgtaac atcacttaca tacctttaat ttttagttta ttaattcata ctgcaaaaca	360
acttagtttt taccatgtgc caggcattgt ecctagttgc tgacaataca gttgaaaata	420
aaatagacaa aaatcccatc ttttgaatct tttgaacctt acattgggag tgacaggcaa	480
aaacgaggta aatcagtaaa atacgtgaga cagaacgcta aaagaaaaaa aagaggaaag	540
ggctgatttt tngtgtcttc cctccagaat gcaagctcct ttgaggatac agatttgngt	600
gtttattact actgaatctc cnggacaaat agcgcccagc acatnagtan gccattcnat	660
ccaatttttn aaaatgagat actagggcag tnactccaa	699
<210> 171 <211> 767 <212> DNA <213> Cercopithecus aethiops	
<220> <221> misc_feature <222> (1)(767) <223> n is a, g, c or t	
<400> 171 catctcacag agttacatct ticccttcaa gtaatccttt cgctaaggct gttcttgtgg	·60
	. 120
aattggcaaa gcgatatttg gaagcccgta gagggctatg gtgaaaaagg aaatatcttc	
cgttcaaaac tggaaagaag ctttccgaga aactgctctg tgttctgtga attcctcttt	180
tagaattttc ttcagaactt gtggcacatc attaaacctc cgtcagtgat cacatatctt	240

catcetttgg agteaattta tttttggaaa cagteaaaag teacteggag tgactteagt

agaatgaagt gtgtgatcaa attggataaa aactttttt tttaatcaaa aatgagtaac

taaaaaaaaa agaagactaa attttctttt tgaggcatgt aaactggctc tgaaagaagt

tecaaataat teaaagatgg ttttagcaat ggeageaetg etgaaateea teagtetete

# PCT/US2003/037143 WO 2004/070002

aaggtgactt	aaaaggataa	atatcattcg	gatgcataga	gccaatccgg	tecaccaect	540
gttttgtctg	actcacatgc	taagagtggt	ttttatattt	ttgaatggct	gaaaacaaaa	600
gtgaaagaaa	agtagtattt	tgtgatacat	gaaattcaaa	tttcagtgtt	cattaaataa	660
agntttcttt	agaacacagc	catgctcatt	cttacatatt	atttaaggct	gcttttcaca	720
ctacaacgac	aggntecage	agctgcaana	aaaaccacat	ggcceca		767

<210> 172 <211> 769 <212> DNA <213> Cercopithecus aethiops

<220> <221> misc\_feature <222> (1)..(769) <223> n is a, g, c or t

ctttcacgag attctgtctc aaaaaaaaaa aaaaagccaa agtcctcaaa atggcctgca **\*60** tggcactaca ttctctggcc ctttatcagc actctgacag ctctctcctt tgcttatttt 120 geteeteatt etageetetg gatetttgee ettgetgtte ettaegetet teteceaggg 180 atctgaaagg ctcacaccct cacctccttc agaggtttgc taaaatgtct tctacccagt 240 . gaageettee ecaaceacea cattaaaaae acacaaceag caceegttet etatetteet 300 360 tcactttgca tttgtccatt gtgtaacatc acttacatac ctttaatttt tagtttatta attcatactg caaaacaact tagtttttac catgtgccag gcattgtccc tagttgctga 420 caatacagtt gaaaataaaa tagacaaaaa toocatottt tgaatotttt gaacottaca 480 ttgggagtga caggcaaaaa cgaggtaaat cagtaaaata cgtgagacag aacgctaaaa 540 gaaaaaaaag aggaaagggc tgatttttgt gtcttccctc cagaatgcaa gctccttgag 600 gatacagatt tgtgtgtttt ttactactgt atctcctgac aatagcgccc agtacatagt 660 aggeattega tecnattttt taaatgagat actaggeagt taeteagttt netgggeeca 720 769

tttcaacttt tagacaataa taccgatnag aaaaacggtt acagctagg

<210> 173 <211> 769 <212> DNA <213> Cercopithecus aethiops

<220> <221> misc\_feature <222> (1)..(769) <223> n is a, g, c or t <400> 173

WO 2004/07000					PCT/US2003/0	037143
cagagaacac	agnagtcagt	ttctcagaaa	gettettee	agttttgaac	ggcaagatat	60
tecetete	accatagecc	tctatgggct	tccaaatatc	gctttgccaa	ttecacaaga	120
acagccttag	cgaaaggctt	cttgaaggga	aatatgtaac	tctgtgagat	gaattctacg	180
atacatgtaa	cattctacga	acaaccatgg	tgagtagaac	catctggatt	teccatcact	240

cacaaga 120 180 ttctacg 240 catcact ttcatttaaa agactetgtt gatattetag gtactgatte catatateag tateaacaaa 300 tttctcaacc aaggggataa ttggtttatc tgtttgcaat tcattccgta atttagaaag 360 gagagaaata gctttctttt cagcttccac gccttcctgc aaaaatacaa gaaaaatcaa 420 ttgtgtgtgt gtctgtgtct gtgtttgtgt gtgcgtgtct atgcaattcc tctagggtaa 480 catattttta cagacttaag aagaaaagaa aaatgttcaa actacattat acttctttaa 540 acattacatt tagaactctt aaactgaaaa tcaaaaaaca cacacagatc tcatatgaac 600 ataatcatgc cttatctatc taagttctgg cctttctgtg tcttcggtga tcattactac 660 agagggaaag gaacccctga cagattttcc atgtttttca tgcttccata cacattcttt 720 769 tttcaccatt gacaccactn gaaaagaaac tgtggccttt ctgaggttt

60

<210> 174

<211> 784

<212> DNA

<213> Cercopithecus aethiops

<220>

<221> misc\_feature

<222> (1)..(784)

<223> n is a, g, c or t

<400> 174

120 cttcaaatgt tgaaaaagag ctgaaatgct gcacagctga atgaaggatc ttctcaaggc 180 tctcctggcg cgagccaatc ccagcctcat gaacgagaga gatcctgaca cccacagatg 240 ggcacctcac agccacatgg agacagagac aggctcggtg accagccacc ctcacagcca cacggggaca ggctcggtga ccagccacc tcacagtcac acggggacag cctcggtgac 300 cagocaccot cacagocaca tgggacaggo toggtgacca gocaccotca cagocacacg 360 gggacaggct cggtgaccag ccaccctcac agccacacgg ggacaggctc ggtgaccagc 420 cacceteaca gteacaeggg gacageeteg gtgaccagee acceteagag ceacaegggg 480 acaggetegg tgaccaggea ceeteacage cacaegggga caggettggt gaccagecae 540 cctcacagcc acacggggaa cagctctcgg tgaccagcca ccctnagagt aacatgggga 600 caggeteggt tanecageca ececteacag neacaegggg gaengggete ggtgaecage 660 cnacnetnae agneaeaceg gggaeaggge tnngtttaee ageecaeece teacagaeen 720

11, 21, 11, 11, 11, 11, 11, 11, 11, 11,	700
cacqggggac agggtttcgt ngaccagccc acccettaca ntccacacgg nggnacagcc	780
cticg	784
<210> 175 <211> 733	
<pre>&lt;211&gt; 733 </pre> <pre>&lt;212&gt; DNA</pre>	
<pre>&lt;213&gt; Cercopithecus aethiops</pre>	
<220>	
<221> misc_feature	
<222> (1)(733)	
<223> n is a, g, c or t	
<400> 175	
aatgtgggaa atgcatcatt tgaaacattt taatggagag actagtattt gatatataa	60
tgttaggttc ctcccagaac ttaattttta aaatttttat ccaaacttat tttacttaat	120
tatcaccatt tattgaatac attaattgaa atageteage tettetgace tgtggageaa	180
aggnntgacc ctcaggatct cctggaagct gccctcaact aagcagaact cagaggaaac	240
ttttgactga gaaactgagg tggtcaaatt gtgctaatgt taaaatacat aaaatagaac	300
atttettea atcagaacta etgacactat tacatggcae aggttgecag ttactetgat	360
tagaaatact aaacagaaaa aagaaaacac ttggcttgga tccttaaaga ggtatttacg	420
gaaggtgttg ccaacacagc ccatcccaat gtctggtgag atttcctgtc tgggagaggt	480
ctatgggatc tcacccaaac accacagacc ccagtagcat ttcctggact aatgttcttg	540
tetttteaca gtgetetget gatttggtet ttagataaen tggtetteet teetetteat	600
aggnatetat acccectgaa gtgtgggtee ttagaeteag ggggettett caaaageeet	<b>*6</b> *60
tttggattca gnanaaaaag aancetggge acttaactgg ggetnaaaga aacaettetn	720
eegggtteen caa	733
<210> 176	
<211> 729	
<212> DNA <213> Cercopithecus aethiops	
(213) Cercopronous dominage	
<220>	
<pre>&lt;221&gt; misc_feature &lt;222&gt; (1)(729)</pre>	
<223> n is a, g, c or t	
<b>&lt;4</b> 00> 176	
catgteettt teagtaacat ggatgtaatt ggaageeatt attetaageg acattaatge	60
aggaaaagaa aatccaatac cacatgttct ctcctgtaaa tcggagctaa acattgggta	120



cccagggaca	caaagatggg	aacaatagac	attggggatt	ccaaaatatg	ggatgtaggg	180
aggagggaaa	ggatttataa	agtgtctatt	gggtactacg	tttagtacct	gggtg&cgag	240
atcatttgta	ccctaaacgt	cagcattatg	caacatacca	atgtaacaaa	cctgcacatg	300
tagactctga	atctgaaagt	tgaaatactt	tttaaaagtc	tattatatta	tcacacaatg	360
accccataaa	caacaacaaa	aaaaagtgaa	agtaaaaaaa	cgcaaggtct	ttagacgtag	420
gaatcagaat	gatataaaga	aggaaaagag	atttatacta	atatagaacc	tttttagaca	480
tgaattttaa	aaaaatgata	cctaggttat	caagttactt	ttgtgtccac	ctaatattta	540
tacactgtat	ccctaaccac	aattggctgt	attttgaaga	cagageeete	aaaggaagta	600
attcaggttn	tggtgtccct	ataaggagga	gaacactagn	agnateteag	cttctctcca	660
«cccacccc	aacccccaca	aaaacatgtt	aaagaaagnc	tttatnttgn	gggacacagt	720
nggagaaaa						729

<210> 177

<211> 679

<212> DNA

<213> Cercopithecus aethiops

<220>

<221> misc\_feature

<222> (1)..(679)

<223> n is a, g, c or t

#### <400> 177

catgcaaggt caggtgcagg catctcttcc aatagggcag tgtctaccag gtagggtctt 60 120 teteetetta gaateattna tggaaatata atteacacaa cataaaatte accetttaaa actatactac acacacaca acacacacac acacacgaat aaaccatatc ccattagcag 180 ttattcaaca cactotgocc ctttgacccc tggaaataat cactaatcta ctggctggta 240 300 ttatggattt gcttattctg gacaaatcat agaaattgaa tcattaaaca tttggttatt ttgaatctat cttcttcac ttggcataat gtttgcaagg tttatccatg ttgcagcaag 360 taccaatact catteettt tatgetteea taatatteea tggatatatt ataattttag 420 tcaattttta agtcggtgaa catttacact gtttctcctt tttagctatt atgaataatc 480 tigotatgaa tattoatgta caagttitig cataaacacg titncaatto totattatgo 540 acctagaagt ggaattggta ggtcatatgg taattctatg ntnaactttt gngaatatat 600 gccaaactat tttccaaagc aactgcaccc atttngtatt accaccatta aggnataaaa 660 679 ngttectact ttcttcaca

<210> 178

<211> 737 <212> DNA <213> Cercopithecus aethiops <220> <221> misc\_feature <222> (1)..(737) <223> n is a, g, c or t <400> 178 ctttcataat gaaaagaaaa aaatgaattt caactagtat cgatttttcg gtgtgtgggg gcagggcatt taagggtatt attectagt aatgatcact tagattctaa gccttaaaca 120 tgattcaaat gcagcagaaa tcaggaaaga agcaacagat acggtggtgc atatcgaatg 180 tctagactac aaggcaaaac ccaaatacca aagaagcatc catgtgtcaa accagcataa 240 300 aaaatctagg aggggtaacc agaaggtcaa ccccagttca caggaactgg gaagaagcta 360 geogttacce tgtgacatet teetgageag ettecteege agecagetee ecageeteet 420 tacaatgttt ccaaaaggcc caactcccta aacatttgct tcttcaaggt catcctaaga 480 taaggcagtg aataaccacc aaacactgag tcacggatac ctttcggcta aaaaagatcc 540 cccttcccaa aatcattaca taaatacttt aaatgccaag agggttttct ccggaactcc 600 accagaaact cccagnactt taatttagat tgggcaacta aatgtgttca anttttgcgc 660 cataaaatat taaaggettt teaggtetgg caantneagt teaaaacagg tgettteagt 720 737 gtacgctgaa taacagg <210> 179 <211> 759 <212> DNA <213> Cercopithecus aethiops <220> <221> misc\_feature (1)..(759) <222> <223> n is a, g, c or t cagatttttc tttaagaatt ttgtttattg caataggatt atcaaagtaa aaattaaaaa 60 gtaatgaaaa aattaaaaaa ataattttgt agctaccctt cctataaaac ttatccagat tacttcttga octatacttt gagagcagag gaaatctagc tacattaact cagtagctct 180 gcaacttcta ggtaatttct tacctgaaca gtatatccta agtactgtaa ttectgcatt gettgeacat tegagettat tattecatee etgtattaca ataaatatte tetacataaa

360

ctttcaagag aaaaagcatt caaggtatat gtgtgtgtac acacttatat atatgtgtat

	-	
WO	2004/070062	
•		

atacactect	gtaaaccata	attggagttt	aaaaaatata	tggtatttgc	aattttetet	420
téttectete	tgtetetete	tetetetete	tetetete	tetetette	tttcgatgga	480
gtcttgctct	gtcacccagg	ttggagtgca	gtggtgtgat	ttcagcttac	tgcaacctcc	540
aactcctggg	ttcaagtgat	teteetgeet	cagactccca	agtagctagg	actacaggtg	600
cgtgccacca	tgcccggcta	attttttgt	atttttagta	gagatggggt	ttcaccatgc	660
tgnccagact	gntcttgaac	tccctgacct	tetgatecae	ccgcctcgtc	ctccnaagtg	720
ctgggataca	ggncatgagc	caccaccccc	gccggtatt			759

<210> 180 <211> 770

<212> DNA

<213> Cercopithecus aethiops

<220>

<221> misc\_feature

<222> (1)..(770)

<223> n is a, g, c or t

<400> 180

cagcttttat atatgctgag ttcaagacac ataagtacat atagataant aatgtacact 60 tettetgtaa gaagacatat aagactgtaa tecatgagag agggaagtet aagatgacat 120 gtttgggaat cctttatatg gacatgatag atgaagccaa agagaacaat gaaatgattc 180 atgttgagtt atttgacatt ttaaaaagta tataagtatt ttaatagtgt gaccatttgt 240 gtctggaaat tttgaaaagc acaaagatct acaatgattt atttatctct atactgatct 300 gtaggaagtt tttggcatgg gaaattgtgc taatgagtat ttggaaacaa gtgtattaag 360 taagggttta caagatcatt agactttcat tttgcagact caatcagatc tgttcactat 420 agtotoctgt tggcataatt ggtttoctga ggacttatta cotgtagatg cacaattttt 480 cattccaaca atgitctgca ttccttttgg actitcctgt cttgaggatc tctttaaaga 540 gctaaaacct caggaacttc ttctacttgt ttctttaaag tcaggatgag agacagaata 600 aggeatecag ceatgatggt ttttecceag gttettetet catgetaage cetttatggt 660 acgatgtgcc tctcaaagga gaatgcagat ctaatactat tgcaccactc tgaaagaagt 720 atgaggagaa ggcanaagag ctatgaaaag aaaaacatcc tgatctttt 770

<210> 181

<211> 706

<212> DNA

<213> Cercopithecus aethiops

## WO 2004/070002

<220>
<221> misc\_feature
<222> (1)..(706)

<223> n is a, g, c or t

ctttcatgcc tagtaaagag tggggcttgg cctggagagg gaggcctcat gggccagata 60 agggagatgc tggcccatct gggcacgcat gtgcccgtag gctttccctg tcgagatgat 120 180 caactggaaa ggcagagaat gcggcctgga ggctcagaaa catccttgaa gccatatecc 240 cagglectag tectaactge caetetttte tttttttgaa atggggtett getatgttge tcaggctgga ctccaactcc tgggcttaag cgttcctcct gcctcaactg cccaagcagc 300 360 cacaaaccac acctggcctc ttcctgccac ttctagctta gcaggtggct tcatctgtat acggggatga cgtgactgct tgggggaatg agctgagccc ttggtggaat catggttcat 420 gcaagaggtc tccggcaaaa tgctccaggc ttggagtctg ctgggcgctt ctacccctga 480 540 caatcogttt acttaccacc accetetgtt cagacaggga agttettec atcaggatta 600 tagcgaggat tggtcttcat ggcacccttg gcatccgagc acgtgttgtt ggagctgttc 660 tacgagccag gacacaccag ggaacggttn cccgcaataa acacccgtct cttcctcgta 706 ctcaagttct tcggggttgc aacattctga gagcttgtcc ttcatt

<210> 182 <211> 740

<212> DNA

<213> Cercopithecus aethiops

<220>

<221> misc\_feature

<222> (1)..(740)

<223> n is a, g, c or t

<400> 182

engngneteg ategtteete ecaceteage eteccaaagt getgtgttae aggtgggage 60 cactagaccc agctgaatta tggattttta aggctgcttt atgtcaaaca ttgcgggttc 120 180 tritaatatt gitticcaga titaagatti titictitta agcittgiat aattiatagi aatttggtaa agtacttttg aaaacaaaaa tgaaaacatt tgcttttctt ctctacctga 240 accetecaga atttagaage aatttatgat tattettatt tttacageaa catggttatt 300 tgcataggtt cagtaagaat ctgttctctg tecaggcaca gtggctcaca cctataatcc 360 cagaactttg ggaggctgag gcaggcagat cacttgagat caggagttca agactagcct 420 ggccaacatg gcgaaaccct gtctctaccg aaaatacaaa aattagcctg gcgtgttggg 480 catgtgcctg gaateccage tactagggag getgagteag gagaateact tgaacetgeg 540

WO 2004/070002	PCT/US2003/037143

aggtggaggt	tgctgtaagc	tgagattgta	ccactgcact	ccagcotggg	tgacagagtg	600
agattttgtc	tcaaaaaaaa	aaggagggcc	aggcatagtg	geteatgeet	gtaattccag	660
cactttggga	gaccangggg	agcgaatcac	anggtcagtt	cgaggtgact	ntaggganaa	720
aattatgttt	naatagaaaa					740

<210> 183 <211> 720

<212> DNA

<213> Cercopithecus aethiops

<220>

<221> misc\_feature

<222> (1)..(720)

<223> n is a, g, c or t

<400> 183

aaacagtaaa aaataaggaa ttttactttc tctggggctc ccaggctctc tggttgggtc 60 agggcccaag tggagcaggg aagaaggggc cactctttct gaagtctccc tgcatgaatg 120 aaaataacag ttgagtggca gtcacacact tagaagcaaa tcattctgat tttgccttct 180 agagcagaga tgtctccct aagatccatt ttaccccagc agaaaaagcc cgggttgtct 240 ggattgtagc aacgctgttt tgacagaaag ccctatgatt tttctcacaa acttccctaa 300 360 ggatgctate tttcagctac acatacttag attattett etceetcace aactcaatet aatgttgcta aggggttcag tactttctct ctgctgctta cctcgtccca acccccaagt 420 tettteecaa atteeageag etgggaceag tetetgggae agageagaaa taacatggaa 480 540 attgggggta gggttaaaca catctatcag tctaggaaca ggtagaaaag caacaccccc gtgactacaa gtttggtagt gggcaacaat tttcttatcc atcatgggtg gtggtgtggg 600 660 tagtnattga gcataanttt atttgtagag gtgaatttgt ttactgggct ntnaagggtc 720 acatggaggc tgtccaagga aaganattcn ataatnaatg gaaatttatt ataattaat

<210> 184

775 <211>

<212> DNA

<213> Cercopithecus aethiops

<220>

<221> misc\_feature

(1)..(775) <222>

<223> n is a, g, c or t

annnnactna nnnnnnnat tggctnnttn nnttgggggg naanccagta cttcaaaact 60 ttgtattatt taataaatga tactgactag ttggctaaac atttgaacaa aagataaatc 120

WO.2004/070002	PCT/US2003/037143

tccaaaccat	tctacccacc	aaaataaatt	ctagaaatga	acaaagacct	caaagtaaga	180
agtaatccac	aaaagtacgg	aagaaaacaa	tcttaaattg	gagaaggact	ttctaaacat	240
ggcaccaaag	gtagaaacca	aaaggaatca	cttgcaggtt	tcatcacata	aagatttaa	300
aatttctata	catecaaage	actacaatgt	tcagctcaag	atggcaggct	aggcacattt	360
gcctttcatc	tttagagaac	catttaaata	aaaagacgga	ggtacaatga	ggaaaaactg	420
taacagggaa	gagacgggct	ggaacgacag	gaagcagatg	agccagctgg	gagatgaacc	480
agctgaaaga	gctgcagtgg	agatgaaagc	ctgtcctgtg	canactgtgg	aggaaggagt	540
gaaagacccc	acctgtaggt	ttggcaagct	agctgaggat	cgttncncat	gattgaacaa	600
natggattgc	acnetggttn	-tccngccnnt	tgggtggana	ggctnttnnn	ntttnantgg	660
nccaacanac	antnnnntgt	ttnatnccnc	cnnntnengn	tnnnannnan	gggcncccnn	720
ttttttttnt	ananccacct	nnnennnnee	cnnatnaact	nnnncnang	nnnnn	775

<210> 185

<211> 400

<212> DNA

<213> Cercopithecus aethiops

<220>

<221> misc\_feature

<222> (1)..(400)

<223> n is a, g, c or t

#### <400> 185

ggggggaaan nneccecee ettennnnn tettennng nnnnngnnae aggetetet 120
negnggggat nnenttance ceannnett nnneagnnng gnnnneanne nnnecagenn 180
ggnngnannn tgetnneetg enegnnneea geeegnetet tnneetgnta eagnnnnnte 240
etnattgnae eteegnetnt ntatntaaat ggntetetaa agangaaagg eaaatnettt 300
teteetgeea teteggeng aacattgnng ngetnnggat gnatagaaat tntaaaanet 360
tnnegtgang aaacengeaa gegntetett tnnggnneet 400

<210> 186

<211> 951

<212> DNA

<213> Cercopithecus aethiops


<220>

200403000242 1 -

<221> misc\_feature

<222> (1)..(951)

<223> n is a, g, c or t



<400> 186 ccgccnggtg ntgggaaaga cnnnggacgc ttcagaccac aggnaggtac catcctggaa 60 cetggaatct ggaacctcag gggctgacct ggcactgggt gggcctggaa cctgtatctg 120 cageecagaa geagggtetg caggtgeaag eetgatgeea ggetgeaggg gacageegng 180 agenggtttt tnttgaggea ggggntgata angecageag geecaaagea aagnetaggg 240 cnnatntntg tctcctaccc ccatgcngag gatacctnnn ttnaagctgc ggagccngag 300 gaagggaggg ggcgcangca agagaatgtc anaactancc ttncnnacct nctncagngc 360 nacctccagg ngctgtaanc actcactagg anaccettaa ggncnnactg aaaggagent 420 ccctangagn gatggnagca aaaaananga nacgacactn cgactgcnng gngacgtgca 480 acntggaaag actotgnncc ctncancacc tegggnanac tatnacaaag angnccccca 540 **'**600 ncacctncan aatgaaagna aangtgancg ngcnanacca acnncgacnn ccctnggcca agagaacacc aataacnaga ntagganatc caaaagcggn aaanacnaca gngctatnng 660 gaatgcncaa gccaccatnn cttgcantgg nncaacagnt gnaatcnaaa nctacnnccn 720 cnatacactg gagagacaan naccnagcnc cantaaagcg nnaaaaanga gaaaacgnaa 780 aaaancgcgc anngnngcng ncnaatngcc cnnaccntaa ccctccnnan aaaaannaat 840 enngaacetg gnnacgaenn nenaagngge neaaneenee encaggegne tenneeneet 900 951 gecaenanca eccengagee nenneagagn reacengeetn aeneaecean e

<211> 450

<212> DNA

<213> Cercopithecus aethiops

<220>

<221> misc\_feature


<222> (1)..(450)

<223> n is a, g, c or t

<400> 187

tnctnntttn ggggtnnnan nnnnnnnnn anntccncca atnnnnntgg gggggaannc 60 ctggtttect geactetece tettttecae teatgtegee aggetteeca aatgtteect 120 gactattett teeetttttt gtgeecaect gtgeeceagg cacagcatgt gacctagtee 180 tgggagtccg cggtggcaga actgcaggcc gttggggcct ccaagtagac catgcaagtt 240 tcacagecat attnetetga tatcagaage taaggagteg tgeetggeea gtactaggat 300 gggggtecgn ctgggaacac tgggtgatgt aggetttttg cttacagnnc cetecetetn 360 tececetnea gnngnetnga tneacaacca tneeetgact ntnntntnen ntnnnnneac 420 ccaactgcat ncnanacaca nncngngact 450 WO 2004/070002 PCT/US2003/037143

<210> 188 <211> 338 <212> DNA <213> Cercopithecus aethiops	
<220> <221> misc_feature <222> (1)(338) <223> n is a, g, c or t	
<400> 188 tncnnettnt ggnggannna nnennnnnnn nnnntecene etnnnntggg gggggaanne	60
gnncacntnc nntttangaa agagacgacg cttncgagga agaaggtttn tgggacgcgg	120
gactgggnag agctccagag ccccagcagc ccggctcaag gncccctgcg cataggcgcc	180
ccaccgngac gncagggacg cgactneegn gangeceege gegeegnnng ancecaggeg	240
cgggcnnaga ctgngatcnn ggagnngccc ngngccnnnc ngacggngcg nnnnggnggn	300
cnngggcgcg ggcnnngnga nnggacagnc nggagcnt	338
<210> 189 <211> 936 <212> DNA <213> Cercopithecus aethiops <220>	
<221> misc_feature <222> (1)(936) <223> n is a, g, c or t	
<400> 189 ttttnngggg gaannnnnn nggngtangn nnnnnnnccn ccgcggttnn necttggggg	°60
gggaannnee nnneeangtn nettttteat gnaaagngna egacgntete egaggaagaa	120
ggeteeggga egegggaetg ggtagagete cagageeeca geageeegge teaaggteee	180
etgegeatag gegeeceace gtgaegteag ggaegegaet ecegegatge ecegegegee	240
gtetgatece aggegegge teannntttt ateteggagt teeeetgege etteetgaeg	300
gtgcgttctg gcggcctcgg gcgcgggctc tgcgatcgga cagcctggag cctttggcct	360
cgatttacat gggaggcccc tcgaaacagg gcacgtcact tgcccccggt cacctgcgga	420
cggggagact ctcgggttga ctccaaggcc tgacattccc ctccggtttt caccgaggag	480
gatgaggatg ttgtcaggag ctgcggcaag gctggaggag cttgcgttgn gtccacccnc	540
ctctgnacag gccttagcat ncacccncag tttctccctt gacttntgaa cccnaactcc	600
ttacccccgc aagtnnennc cctgtttnga ttgctgaaac tgcaagtgac ggaagantaa	660
aatgtttgcc naagcntnat gcttnanggn ggntgccngg gtataaggtc angggttggg	720



ggecettnne	-cctgnngggt	nggcnttaag	ntaacccagg	gnncntggca	nttnantnnt	780
attcaanana	tgccanggnn	nteggnntnn	aanggntntt	tnnanaaaat	nnttneeett	840
nttannctnt	annccnnagg	gaaanccntn	gggtettgtt	±ngccctgna	aanacnatna	900
aaggggtaat	nnecenenet	tnaatntnnn	gnence			936

<210> 190 <211> 936 <212> DNA

<213> Cercopithecus aethiops

<220>

<221> misc\_feature

<222> (1)..(936)

<223> n is a, g, c or t

<400> 190

tttttnngng gannnennnn gtttntngnn nnececeece ceatnnnttt ngggggggaa 60 120 nncccnnnca cgtcctcntn atgaaagaga cgacgcctcc gagaagaagg ctctgggtac 180 gcgggactgg gtagagctcc agagccccag cagcccggct caaggtcccc tgcgcatagg 240 cycccaccy tyacytcagy gacycgactc ccycgatycc ccycgcyccy tctgatccca ggcgcgggct cagantnnna tctcggagtt cccctgcgcc ttcctgacgg tgcgttctgg 300 cggcctcggg cgcgggctct gcgatcggac agcctggagc ctttggcctc gatttacatg 360 ggaggecect cgaaacaggg cacgteactt geeceeggte acetgeggae ggggagaete 420 tegggttgae tecaaggeet gacatteece teeggtttte accgaggagg atgaggatgt 480 tgtcaggage tgcggcaagg ctggaggage ttgcgttggg tccacccgcc tctggacagg 540 cettageatt caccegeagt ttetecetga etttgaacce aaacteeeta eeceegeaag 600 660 tectteeetg tittgattge tgaactgeaa gtgacggaag aattaagtgt tggeeggaaag 720 ctgatgcttc agggggtgca ggntagaggt caggggtggg ggcctngcct tgnggngngc atantgtanc ccanggtccn gcactgantn ttnnaggaat gcanggaatn gnatannang 780 gtnctaanaa anthtccccc tannaactga taccnnagna accntngggc tgnntgancn 840 900 tqaaaaaccc annagggtaa ngcctnnctt atnngggccc cnntntcnag annaaangcc 936 ctggggtttc anngaaaacc cnnnnanaaa ntntgg

<210> 191

<211> 951

<212> DNA

<213> Cercopithecus aethiops

WO 2004/070002 PCT/US2003/037143

<220> <221> misc_feature <222> (1)(951) <223> n is a, g, c or t	
<400> 191 ttttnngng gancnnncng gttgttgnnc entecegege attecettgg gggggnaace	60
ecennneang thectnttna tgaaagagae gaegenteeg agaagaagge tetgggaege	120
gggactgggt agagetecag ageeecagea geeeggetea aggteocetg egeataggeg	180
ccccaccgtg acgtcaggga cgcgactccc gngatgcccc gcgcgccgtc tgatcccagg	240
egegggetea nanttnnate teggagttee eetgegeett eetgaeggtg egttetggeg	300
gcctcgggcg cgggctctgc gatcggacag cctggagect ttggcctcga tttacatggg	360
aggcccctcg aaacagggca cgtcacttgc ccccggtcac ctgcggacgg ggagactctc	420
gggttgactc caaggcctga cattcocctc cggttttcac cgaggaggat gaggatgttg	480
tcaggagetg eggeaagget ggaggagett gegttgggte caccegeete tggacaggee	540
ttagcattca eccgcagttt etecetgact ttgaacccaa actecetace eccgcaagte	600
-cttccctgtt tgattgctga actgcaagtg acggaagaat taagtgttgg cgaaagctga	660
tgcttcaggg ggntgcaggg tagaggtcag gggtgggggc ctcgccttgt ggngtgcata	720
tgtageecag ggtentggea etgattntta ttaggaatge aggganttng attagatggt	780
ttettagaaa atateeeetn tgnanetgnt acetgagnaa eegetggget ggeatnacet	840
tgnaaaaccc agaanggtta nngccctttc ttantngtgg cccnattttt tcaggacnaa	900
angggeentg gntttneaat gnaatenent ttgeneaaan nnetggttte t	951
<210> 192 <211> 938 <212> DNA <213> Cercopithecus aethiops	
<220> <221> misc_feature <222> (1)(938) <223> n is a, g, c or t	
<400> 192 ttcnnggntc ttnntgntan attttccccc ccattttttg ggggggaanc cnacncanca	60
aaaggtagaa attattgata aantntaaat gttacaaact gcngctaaaa gaagcaaaag	1-20

180

240

300

agaacatgct gtatgatcct ttttttttt tttttttt ttttttttt

actettgttg eccaggetgg agtacaatgg cacaateteg geteaceaca acetetgeet

-cnnnttttca agcaattttt ntnncttann etecetagta getgggatta taggeatgtg

WO 2004/07000Z PCT/US2003/037143

ccaccaggcc	cagctaattt	tgtatettta	gtagagacgg	ggtttctcca	tgttggtcag	360
gctggtcttg	aacteeegae	ctcaggtgat	ccaaccgcct	cggcctccca	aagtgctggg	420
accacagacg	tgagccactg	tgcccggcaa	tetttttet	taattttaaa	tttttagag	480
acaaagtctg	gcttttctag	tnccaggctg	gagggcagtg	gagccatoct	ggctcactgc	540
ancettenne	teccaggete	aagccatect	nctaccttaa	ncttcctgag	tngctggnaa	600
ctacaggtac	acaccaccat	gtcagnctaa	tttttttt	tttttttt	ttgaaaccna	660
atttttcnt	tgttcacccc	tnntgganan	ncaggnngna	nnanctetnn	cenentenae	720
cccttacnnc	naagnncaat	atnaantatc	nncetaennn	cccnagntct	tnnnntttta	780
annnannttn	-tatttttntt	nnttatantt	tacctnnntn	tetenennen	ctnanccctn	840
ntncactnnt	nnactantct	ttttccacnt	attettetet	nennetntne	tnatatenen	900
nnccnnnctc	tetettntne	ttctttnttt	ctnnnatn	,		938

<210> 193

<211> 804

<21.2> DNA

<213> Cercopithecus aethiops

<220>

<221> misc\_feature

<222> (1)..(804)

<223> n is a, g, c or t

<400> 193


tntngggggt nnnaaaacnt tncnnacata atcgccncaa tacaanttgg gnggggaaaa 60 annetgnnte attecteent gnacecatet ceatgeogtg naagcatete etnettggae 120 ttgcactatc tggtcccata gcccttgctt attcttaaat gggagtcact ctgacttgca 180 ttgtggggaa gggtatacct ggggcacagt cetctgggat ggacacttcc ataggaaggg 240 gcagttatac gtggacttat gtcctcctac actctcatcc agaaccatcc acccagaagc 300 aggagttgtt tcttttagaa accagccggc ccaatcagcc cattttatag gtgaaggcag 360 tgaagcccag agagataaag catcttgtcc aaggtcacag agccagacct agactaggct 420 geotggetee tagtteaggg eteateceae ectageegge ttetggetag acagaateta 480 cccatcctgg cccagactct ctggtgggaa gtcagggatg cagnggtcag gatgggcatc 540 agagocagca ggccctgagc acggntcacc caagtggaac atgaacttcc taaactccag 600 nggaagttag aaatggcana ttgatcagng ctaatgagct taaaacaccc agggattaaa 660 aaaaaaaaca tgaanaagct ntacttnaag cataaatntg ntnaacanaa agganaccng 720 780 getnenennt ntntnanann naennnntgg aggetnaggg ggnnngnnea tnnggggngn

420

# WO 2004/070002

ganattngnn tengnaaggg gnnt	804
that he	·
<210> 194 <211> 560	
<212> DNA	
<pre>&lt;&lt;213&gt; Cercopithecus aethiops</pre>	
<pre>&lt;220&gt; </pre> <pre>&lt;221&gt; misc_feature</pre>	
<222> (1)(560)	
<223> n is a, g, c or t	
<400> 194 ttctanttnn nnnggtnnna ancannnnnn ncatnntcgn cncatnnnnn ttgggaggga	<b>6</b> 0
	120
aannnaatna ataatcaaan ttagnaattg aatttagaat ttcatttatg aataaaaagg	120
ctgggaggaa acaçacccca accgacacag tggatgcgat aggataagac tatgagcaga	180
ttttgttctt ccttttcacc gtctgtattt tccatcaatt atttgtatga ttaaaatcaa	240
tcatttcaga caagagggac attgtgagct atctgtgaga aatgtcttct atctgtttcc	300
agatagaagg ggctccagct cggtttgggg aaagtcccaa tgccattctc ttaaccaaga	3.60
ggtttectac ctcatctaat gtggagattc tacttacccg ggaagactcc cctcctgtta	420
cctcaagtct gcagccggcc tcccagactt ctgcctnctn ctaaccacag cctgcctggn	480
tgcaggncgg ngggaaagga gggcatangg ggctgnatne cgnanaggce ctnncactce	540
tngactnang cagggnnctg	560
·	
<210> 195 <211> 977	
<212> DNA	
<213> Cercopithecus aethiops	
<220>	
<221> misc_feature	
<222> (1)(977) <223> n is a, g, c or t	
<400> 195	
ennececeng gntneceneg ggnnnnnnn nnnnececee eenannettt gggggggaan	€0
nncnnncctt tnggngnatt gnngggnana annengtnet teennaatag natgnggeng	120
canttcaact negetaatta aeggaacage aggetngnaa ttetgacaac ageaggacae	180
aaanggggen gggateagea etgaatgeeg gegaageatg eeneeeeee ttaagaagaa	240
gcacaacacc cacgacccac attnnntntn gggncaggtc catgaaggng cnaecctnga	300
tttagttana ngcnetnece tgcagcaact ccaagggene agggttttta aaatgnenee	360

tcaggccttc ttnagaggna gcaagccngc cccaactggc ctttttcnna aaaaagangg



aaacaggnct gngattggtc nagagcagga nncgcccagc continggct ccccngggcc 480 540 acacngnaag aaaaagaatn gnnttggacc acacagaaaa cacaccaana ctaangacag ctgaaaagct caaaaaaaaa atcgcnaaaa aatccctcaa tgctcnaaga agtccncaaa 600 nnegeegngn gaengnnaca cagetneeng geengeanga ennenggggn neacaggnng 660 720 cnacaccag gaccagnagn taatatcnna aaagggtaac aanaaaancc ctaataccaa 780 aaangcnatg anaatggaag cnnnacntcc tncaaaagac aagccctang gaaancntcn 840 cncnacecnn neeceaacen ggeanneggg ceeceaecea aaaggggggn neegeeeegg aannnaaaan ccnacnnngg ggaaaaanng accnnaance ngaaanngte tatancecca 900 960 engneenaaa aceteecang neaatnacee enceeteeta aaaggntagg annaanaene 977، nggngcaaag ncnncca

<210> 196 <211> 868 <212> DNA

<213> Cercopithecus aethiops

<220>
<221> misc\_feature
<222> (1)..(868)
<223> n is a, g, c or t

<400> 196 60 gaanneenne nnaaaaaacn nnnnneecee neeceatann nettgggggg gaaannneec ccccacaagn natantnagn aggnaggaaa acacanttaa tatateteac tageneteat 120 ttecetecce cacceteate ceactecact getaagagag agaaatnnea geactgetat 180 cetgttntat tatacattnt ecettnngag tnaaggattn naagattnng aaagtaacag 240 aatagaaacc aaaagtnnta ctcaactncc aatttggctt aaaaagagag aaataatnat 300 tattncctat gnnacccaaa actnattctg nnaataacag ntataattat atattcaaan 360 naataaatga agatcgccaa aatcacctna atataatngn nagcagctaa agaacaaaaa 420 tnnnnncat nngctnctat aagnagacat cacatganna ctnctatnga ccagnaagaa 480 actagnaaaa ncaggcagnc acccaccatn cnnnnctaac anncnnnnnc nnannctatn 540 caaccnnnnc ggnatannen naagaageca aatcaagaaa nnagacenne atgeetaaaa 600 aaaaanngng nnatcnnaan acatcangaa caggaaccng nngnanataa cacaggnann 660 720 caaagcnnna ncgncaannn cnagaacccn naaacanaaa ggcagennan anncaagann 780· agaaacngaa nncacanaac acanagcann nncncanaaa gcnnnnnnca nnnnngaacg aagaaannnc nnnnnaccaa aggecncaag ggcnnncaaa nnccnnngcc aannnaaaaa 840

# WO 2004/070002

aaaccnanca aaggcncnng anggaaaa	868
<210> 197 <211> 260 <212> DNA <213> Cercopithecus aethiops	
<220> <221> misc_feature <222> (1)(260) <223> n is a, g, c or t	
<400> 197 ttttcnggng gannnnnnn nnnnnnnnn nccncnccgn tnnnnttggg ggggaaannc	60
nnnncacang nnathttngn ggaggaaaac acatttaata nanctcatta gccctcattt	120
ecetececa eceteatece actecaengn taagagagag aaatnneage actgntatee	180
tgnnnnatna tacatttncc ctnnngagtn aaggatnnna agatnnngaa agnaacagaa	240
nagaaaccaa atntttttt	260
nagaaaceaa acneeeeeee	•
<210> 198 <211> 901 <212> DNA <213> Cercopithecus aethiops	
<220> <221> misc_feature <222> (1)(901) <223> n is a, g, c or t	
<400> 198 gggnancnnn agnngnaana nnccaacccc gccaanatnt anggggggan actntcacaa	60
gtatacaaga ggaggaaaac acaattaata tateteacta gcatteattt eceteoceca	120
ccctcatccc actccactgc taagagagag aaatttnggc actgctatcc tgttntatna	180
tacatnttcc cttttgagtn aaggattnna agattntgaa agtaacagaa tagaaaccaa	240
aagtttnoto aactnocaan nnggotaaaa agagagaaat aatnattatt tootatgnna	300
cccaaaactn annongnnaa taacagntat aattatatat ncaaatcaat aaatgaagan	360
cgccaaaatc accttaatat aattgncagc agctaaagaa caaaaannen nencannngc	420
nncnataagn anacatcaca tgatnactnc tatngaccag naagaaacta gnaaaancag	480
gcagncaccc acccacnenn nnetaacatt cnnnnnenna nnenanceaa cetnnnnegg	540
natatnenna agaageeaaa neaagaaaan nagaeennea ngeenaaaaa aaaaengngn	600
nancnnaaac atcangaaca ggaaaccagn ngnaaaataa cacagggnat ncaaaagcnn	660

WO 2004/0700	02				PCT/US2003/037	143
tanceggean	nnnnccaaaa	acccctaaac	anaaaaggcn	gneccagaac	ccangaaana	720
gaaaaccnga	aanncccngg	nnaanccegg	cancnncecc	caatccacaa	ceccegnna	780
naancnecen	aaacccancc	aaaacanaaa	accengngge	naaaaaggcn	ccccnaaaaa	840
aanggnnccc	cggnccggcg	gncgaacncc	cnagggncaa	nannggggng	nagncaaaaa	900
<b>a</b> .						901
<210> 199 <211> 885 <212> DNA <213> Cerc	" copithecus a	aethiops				
<222> (1)	c_feature (885) s a, g, c o	r t				
<400> 199 ttttttnggn	ggntttnnnc	nnttttnntc	nnnnncecc	cccgattnnn	nttngggggg	60
aaannnccnn	nccanaagnn	atnttagnag	gaggaaaaca	canttaatat	atctcactag	120
cattcatttc	cctccccac	cctcatccca	ctccactgct	aagagagaga	aatttcagca	180
ctgctatect	gttttattat	acattttccc	ttttgagtta	aggattttaa	gattttgaaa	240
gtaacagaat	agaaaccaaa	attttnntca	acttccaatt	tggctnaaaa	agagagaaat	300
aattattatt	tectatgtta	cccaaaactt	attctgttaa	taacagttat	nattatatat	360
tcaaattaat	aaatgaagat	cgccaaaatc	accttaatat	aattgttago	agctaaagaa	420
caaaaatttt	tttcatttgc	ttctataagt	agacatcaca	tgattacttc	tattgaccag	480
taagaaacta	gtaaaatcag	gcagtcaccc	accattctt	tctaacatto	ttttncttat	540
tctatncaac	ctttncngta	tattcttaan	aagccaaatc	aanaaatnan	accttcatgc	600
ctaaaataaa	attgtgntat	cttatacatn	atgaacagga	acctgtngta	tataacacaa	660
nntatnncaa	agctttatcn	cantttctan	aacccttaaa	caaaaangca	nnctcanatt.	720
nnaanattan	aaaactnaat	tctggaccca	antgtanatt	aactctnnar	acatttttnn	780
gtgnattaan	naaaaactgg	nnncetated	ttaactttaa	naggtcanco	caaanttntn	840
nnanaacaan	ncctnnnnan	aancaantta	tatnaaacca	nctan		885
				•		

<210> 200 <211> 941 <212> DNA <213> Cercopithecus aethiops

<220>

## WO,2004/070002

<221> misc\_feature <222> (1)..(941)

<223> n is a, g, c or t

<400> 200 ttttnggggg anntananng nnnnnnnnn nnccnngnnn nnattggggg gaaannnccn 60 nnettngnat ttagaggagg aaaacacntt taatggatet tattagette attteeetee 120 cccacectca teccacteca engntaagag agagaaattt cageactget atectgtttt 180 atnatacatt ttccpttttg agtnaaggat nntaagattn ngaaagtaac agaanagaaa 240 ccaannittt tittcaactg gnaatinggc tcaaaaagag agaaataatt ainaintect 300 latgitaceca aaacinatee ignnaataac agitaintii atalaticaa attaataaat 360 gaagatcgcc aaaatcacct taatataatn gncagcanan aaagaacaaa aatnctttca 420 nnongottna ataangnnga catonocatg atcacotnot attgaccagn aagnaaacta 480 gnnnnaatna ggchanncac ncacnanann nanncnaanc accannnnna cnaannncna 540 600 ttcaacannt nannggnana ntnncnnaat aagccnaaat aanananann gccccnanan 660 gcctaannan nancgaggna atgcnnnncc caannttnaa caggnatncc nggcagngnt tntaacanng annatttcan angnnnnanc cggnaatact nnnanaannc cnannaaann 720 780 naaaggnnan tennaatnea angttnaana aaangnaatn enecennnnn antantaaat aangnonnna ntannannnn notancaton onchonatgo acnnnnnaaa ntnnnnnntn 840 900 acnnncnnnc nnngnnaaan nttnaangga nnncnnnntn ancacannnn cncannaang nnnnnaana necacaanne aacacatnan caancacnaa t 941

<210> 201

<211> 886

<212> DNA

<213> Cercopithecus aethiops

<220>

<221> misc\_feature

<222> (1)..(886)

<223> n is a, g, c or t

<400> 201

tttteeenng gntnnnnnt nnnnannnn nnteceeeee catnnnttt gggggggaaa 60
ancacagnaa cacagngttt nngnnetcag naaagetttt tteeagtttt gaacgtaaga 120
tattteettt tteaccatat eeetetatgg getteeaaat ateeetttge caatteeaca 180
agaacageet tagegaaagg ettettgaag ggaaagatgt aactetgtga gatgaattea 240
cagaacacaa ageagtttt ttagaaaget tettetagt tttgatetga gaatattee 300
etttteacca tagaceteta tgggetteea aatateacgt tggaaatte acaagaacag 360

WO 2004/070002		PCT/US2003/037143

tgttagcgaa	aagcttcttg	agggaaaagc	tataactctg	tgagatgaat	tctacgatac	420
atgtaacatt	ctacgaacaa	ccatggtgag	tagaaccatc	tggattttcc	atcactttca	480
tttaaaagac	tctgttgata	ttctaggtac	tgattccata	tatcantatc	aacaaatttc	540
tcaaccaagg	ggataattgg	ttnatctgnt	tgcaaantca	ttccgtnatt	tnanaaaagg	600
agagaaaata	gctttctntt	cancttneca	cgccttncct	gccaaaaatn	ccaanaaaaa	660
ancaatngng	nngnggngcc	ncgnntnntg	nngnttngng	tgtnccntgn	nctntccnan	.720
tecenntnag	ggnnaacnaa	tttttncnga	ctttaanaaa	naaaanaaaa	aanngnncaa	780
accaenttnn	aaactnnttt	aaanntncca	tnnnaaacct	taaancnnaa	aaccaaaaaa	840
ancececaen	ancnnnnnnn	nanananann	nnnecentan	ttnttt	•	886

<210> 202

<211> 925

<212> DNA

<213> Cercopithecus aethiops

<220>

<221> misc\_feature

<222> (1)..(925)

<223> n is a, g, c or t

#### **<400> 202**

tittnitggng gannneinni nnnnnnntin nneceeneet annneiing ggggaannnn 60 120 cnncocactt agnatttttt ncncaaaaaa aaaaaaatag ccaaagtcct caaaacggcc tgcatggcac tacattotot ggccctttat cagcactotg acagetotot cotttgctta 180 240 ttttgctcct cattctagcc tctggatctt tgcccttgct gttccttacg ctcttctccc 300 agggatetga aanntttttt teeeteacet eetteagagg titgetaaaa tgtettetae 360 ccagngaage ettececaac caccacatta aaaacacaca acenttteec gttetetate 420 ttccttcact tngcatatgt ccattgngta acatcactta cataccttna attntnagct natnaatnca tactncaaaa caccttatnt nttaccatgt necaagcatt gncecntant 480 tgcttnacan tacancncna anatnaaatt cnacanaaaa tcccatnctt tttgaatntt 540 tttgaacctt acattngnaa gtnncannca aaatccnang ttaaancata aaaatncccn 600 660 tgnanacnna acccctnaaa naaanaaaat angaaganag gggcctgaat tnnngngcnc 720 ttteecetee caaantnean acnteetngn angnaacenn atetnnnnng nnntnnnnte 780 actneegtht ntteeegaca anaancheee ennnneeeth ntnngeeett ecatneenat 840 tnttnaaana ttaaaanccc cccncnctcn ctaanttnct ngggnccnat ttcaaacttt 900 tnaacnaann annoccnnce nnnaaaaacn nonncencec tnngnnnece annonaaate

925

60

#### atconnente nnetectent etcen

y<sup>th</sup> in

<210> 203
<211> 895
<212> DNA
<213> Cercopithecus aethiops

<220>

<221> misc\_feature

<222> (1)..(895)

<223> n is a, g, c or t

<400> 203

ttttttcgng gattnctnnt ntnnnnntnn ntccccccat tnnncttggg gggnaannnc 60 120 nacgattcan gtnttatnnc tacgaacaac cattgtgagt agaaccatct ggattttnca tractitrat traaaagact cigitgatat ictaggiact gattroatat atcagtatra 180 acaaatttct caaccaaggg gataattggt ttatctgttt gcaattcatt ccgtaattta 240 300 gaaaggagan anntttettt etttteaget teeaegeett eetgeaaaaa tacaagaaaa atcaattgtg tgtgtctg tgtctgtgtt tgtgtgtgcn tgtctatgca attcctctag 360 420 ggtaacatat ttttacagac ttaagaagaa aagaaaaatg ttcaaactac attatacttc 480 tttaaacatt acatttagaa etettaaact gaaaatcaaa aaacacacac agatetcata tgaacataat catgccttat ctatctaagt tctggccttt ctgtgtcttc ggtgatcatt 540 600 actacagagg gaaaggaacc cctgacagat tttccatgtn ttttcatgct tccatacaca tinticitic accatigaca conactanaa aaagaaacon giggneetti cigaggitti 660 ttttttngnn anntnaattn nttttttta aacttggntt ttccncctna attnttancn 720 taggntnana aaangaaana ntgcctnnna tnaaaanggn ncctncaatn ntatnttacn 780 cnnanaagnc cnattggnna gggngcanaa antntnanng ggnnacnaaa ataaaannaa 840 895 aaataactct nnnanccttt ggttttacat taacnaaana nntctncccc caana

```
<210> 204
```

<213> Cercopithecus aethiops

<220>

<221> misc\_feature

<222> (1)..(887)

<223> n is a, g, c or t

<400> 204

ttttcnngng gntnnnnnnn nnnnnnnnn nnaccccncg tnnnnntngg ggggaannac

cnncccacga gnatttttnn ctcaaaaaaa aaaaaaaagc caaagtcctc aaaatggcct 120

<sup>&</sup>lt;211> 887

<sup>&</sup>lt;212> DNA

60

600

660



gcatggcact	acattctctg	gecetttate	agcactctga	cagctctctc	ctttgcttat	180
tttgctcctc	attctagcct	ctggatcttt	gcccttgctg	ttecttacgc	tettetecca	240
gggatctgaa	aggnttacac	cctcacctcc	ttcagaggtt	tgctaaaatg	tettetacee	300
agngaagect	tecccaacca	ccacattaaa	aacacacaac	cagcacccgt	tetetatett	360
ccttcacttt	gcattngncc	attgngtaac	atcacttaca	taccttnaat	tnttagttna	420
ttaattcata	ctgcaaaaca	acttantttt	taccatgtgc	caggcattgn	ccctagttgc	480
tgacaataca	gnngaaaata	aaatagacaa	aaateccatc	tttngaatct	ttngaacctt	540
acattgggag	tgacaggcaa	aaacgaggna	aatcagnaaa	atacgtgaga	cagaacgcta	600
aaagaaaaaa	aagaggaaag	ggctganntt	ngngnettee	ctccanaatg	caagctcctn	660
gagaatacag	annngngngn	nnnnacnac	ngnatctccn	gacaatagcn	cccannacan	,720
annangcatt	ncnacccaan	tnnaaaaang	annaacnang	gcannnnccn	aannnengge	780
cacatnncaa	ccntaaaaca	anaanaccca	anaaaaaaac	ngnnncagen	aggncacnaa	840
nnaagaaana	nccgnncnna	attnnnggng	caggeentna	aanneca		887

<sup>205</sup> <210>

<220>

accccccca tnnnnttggg ggggaaaaac canccagtaa nagttttgnn gcaaggnngg tggctcttaa tcatcagggg caaggtagat ttaattctcc attatccatt aattatttaa 420 tgaacaccaa cagtgggatt gcaagtggga ggtttagaac aacagggctc tgtggcaaag 180 240 actactagac catggtatca ctagggacag ctagttgggg aggcnttnng ggtattactt ggcttataaa accaaaatag accaacagca gattattaaa atgctggtgt tggctgccaa 300 gtggaacgta ataatcacac atctggtttt ccaaattgaa cagttcttag atccagaatc 360 ctgtgattga tagagatgct agatcctttt gcagaaaatc ttataatgcc ccaatgaatt 420 tatagtagta atttccccaa tccttctcca aaagaatcta tgctgcagaa aataaaatac 480 540 ctgmacagng ngcattacat tgngcactac agagatgaaa gtagccaaat atttcaagtg

ctgnngaatc canagttnga gatgacacca ataccagaga aaacaaaaac catcatgatg

ccctggntag ggngggtgtg ngaaanccan gnggaaaaan aaagnettgg geeenacant

<sup>843</sup> 

<sup>&</sup>lt;212> DNA

<sup>&</sup>lt;213> Cercopithecus aethiops

<sup>&</sup>lt;221> misc\_feature

<sup>(1)..(843)</sup> <222>

<sup>&</sup>lt;223> n is a, g, c or t

## WO 2004/070002 PCT/US2003/037143

-]	ncanatataa	atgnncaaag	agnenggena	cccnccccgn	naanaaggnn	agggnenetg	720
;	nnggocnaaa	nnaggnnngg	aagcaccnaa	anaannngaa	anaaccccc	accaaaaccc	780
	ccgngcnccn	gaccnggana	ggggggnncc	cntncncann	ccaaaanggc	ccannggnnn	840
	nec						843

<210> 206 <211> 927 <212> DNA

<213> Cercopithecus aethiops

<220>

<221> misc\_feature

<222> (1)..(927)

<223> n is a, g, c or t

<400> 206 nenececeng gnaaneeeen ggngtaannn nnnneeeeee ecaatanntt tgggggggna **€0** annnecennn canagtgnaa tantaagnaa neaaaggeag engagteagn accaaaacta 120 acagnanaat aacagnaaaa nnnccaccac catatgaaag caggggaaaa atatatggaa 180 acagatatgg ccaaaaaaaa ggatgcagac aacgaagnaa gcggacagaa gcccgagaag 240 aaaaacgggg ncgggggaga aaggagacta tnaataggaa aaangaaaaa gcanacacag 300 ggcgactgag caatacagaa agcaaagang cnggataaaa agcagggccc tagagtggga 360 gtggcncaac acgaagaggg gcatccagag ggggaataca gcgcngggng acaggagggg 420 480 gnccaaaang gaggaaaagc gcccnncnca gagaaccanc aggcgcggcc caccccgggg 540 cggcagccgg ggaggggcc cacagangng ggngagaagc caagaaacnc agcgganggn 600 agggaancac nggcccangc gcaggggaca ccccccagaa gccnaggaca gagggagggg caaggngcac actaagganc cnnnaangaa cggccagagg ngcaggancc cacannagaa 660 gnaccengaa ggggeaggng caggeaagne eeegengean gaggacaaaa enggeengen 720 780 gaaaanggne geecenneae ecencengne ennaaceeae ngeaaceaee agnennnaae 840 annaancccn aaaacacaaa ngnccccacn nnanccancc cganaaaaagg cnaanaacca 900 ggngnaance nacecaceng gneegnanga eeenggaaac ennnanneea nnennaannn 927 nnacccnaaa ccaaaagnnc gannacc


<220>

<sup>&</sup>lt;210> 207

<sup>&</sup>lt;211> 940

<sup>&</sup>lt;212> DNA

<sup>&</sup>lt;213> Cercopithecus aethiops



<<221> misc\_feature

<222> (1)..(940)

<223> n is a, g, c or t

4 .	<400> 207		-		•		
(* )		ntttctgtnt	nntnetnnne	cccccetta	ttttgggggg	ggaannneen	60
	nnncntnnnn	nnntttneca	ccnaaaacta	ttententnc	tnncccgcct	atcctccaaa	120
÷	ctagcaatan	tteggttett	ecctettget	ctcgggcgga	ttcctgaaag	tcgtttattc	180
;	tcttaattaa	tacgecgete	cagccccgcc	cgttcagctc	attctcttaa	tcgcattacc	240
:•	ctggctgcng	nnncttttt	tttttccac	ctgctgccac	-ccacccagac	accgcctncg	300
	getettteeg	gaccatetea	gtttctcctc	cttccccngn	cccaattttc	tttaggctat	360
	ttctggctcc	cgtaggtttn	tcatgctctc	gttagcccca.	-ccccatcacc	accancggct	420
	ctttttcggc	teteteeegn	cncctcctgt	ctcctgctca	ggctcttttc	cagctattnn	480
	cgactcccct	cntactcacc	ctttgccttc	ngaaactntc	ccaccngecc	ttcaggcaaa	540
	tcngtctcna	cccctantc	ccgcacgtga	acacagnect	nccccctccg	ccttcttaga	600
	naccccctct	caccnnnncc	ctttccnncc	catcctcaaa	actananggn	tgggtacngg	660
	cenancence	cnttttggtg	nnnaanneen	gaategeegn	caaggneeeg	gtnentnece	720
	ngaaaancct	atngncnggn	cacaaacang	ggaaacannn	ttcncacecn	ttntccactg	780
	ancenettee	cccntcaccc	ttnaaanaca	tenteennnt	ttatctaaaa	cent-teanee	840
	eccnectect	tcggncacct	cnttnctant	ncccatatan	ccccntagnt	natnentnea	900
	atneengeae	cnnntntnta	tctaatnaaa	ccccaacccc			940

<210> 208

<211> 881

<212> DNA

<213> Cercopithecus aethiops

<220>

<221> misc\_feature

<222> (1)..(881)

<223> n is a, g, c or t

<400> 208

tttttccnng gnnattcnnt gtnnaatntn ntntccccc cattntttgg gggggaanac 60 cognantiga aattinggga caaacaaaca tanctotto tottocottg aagggttaat 120 gctccaacca gcctcagatt ggttcgcttg aatcttaaaa ttactttct ggtcacgcgc 180 gccgaaggtc taagcatttg tgaaatgtct tttttccccc cccccacccc ttgatgctgt 240 tctctttggm ntttttaat tacacagggg ttgagaaacc aaattaaaat taggcgtgtc 300 tggtcaacag tgatcacgtt gcatgctttt agctttgntt gttgaagttg cttctcctcc 360 WO,2004/070002 PCT/US2003/037143

1,0							
çtg	agtggct	ttectecttt	<del>tttttttt</del> t	ttttttattt	taaaaaggaa	atatcataag	420
cte	tttcaga	aatacecaca	ggaagtgagt	gtccgtatgc	tggttactca	ccancaactg	480
agt	gttggca	ggtggagaat	gctaccgcag	ccgcccagac	agatctgcag	actggcccca	540
ttg	cagagga	ttagacacag	ggtgcgtgga	tcatagggtt	tittgtacaga	angcagtttt	600
aag	aggaaat	tggtcactgc	atgtcatctc	gaggggtggt	gattcangga	gccaggcctn	660
<b>ggg</b>	gttcana	aagnacgttg	ctngccatct	tnggaggttt	cctgctcact	tntcaaangg	720
nca	ggctngc	cttttaaaaa	tcaatgttcc	ttccacccc	aaaagggntt	ctttttgcag	780
tga	atcanct	nccaaaataa	atageceen	tttttttgga	aaagaacgtt	tgnaaatccc	840
ncn	ttttaat	ggnangtttt	naattngggg	gttnantcaa	а		881

<210> 209

<211> 896

<212> DNA

<213> Cercopithecus aethiops

<220>

<221> misc\_feature


<222> (1)..(896)

<223> n is a, g, c or t

<400> 209 tttttccngg atnttnattt ntanacttat ccccnccatt attttanggg ggnaanccct 60 120 nncanaatat tgtnttacaa atatcatttt ngtgtatgta tgtcaaaacc aaaactgcct ttatgtcaat atgctgtaaa aatctatcag aatatatctt aattcttaac tttcattgtt 180 gtctgtgggt tgtcttgtat aattattatc acatctacag tattttctgt aggtaaatat 240 300 gaaatgtttt tttnatgtac cagggggaaa atgcccttta ataagccttt ccctagacaa agcaccattt aggcgtttag aagcaagaac tagtganntc agaaattgct gtcatacata 360 420 ctcacctgtg aatggtcgta caaaggatcc caagcgcagg acttgtcctg gaagcagagg atoggattoc accaggaaaa gaggcaagta gaaatgccaa atgccagcgc tecetteecc 480 cageteatet tattigtagg caeteagatt titggaatee teeaggaeta acaaatanaa 540 accacactag gttgtttttc ctaattnoct gtgaaatgag tcangtangt caaacanctt 600 atecacteca gagagagaac caatteettt gagetacact ceetgtttte cagtnacect 660 aatneeetet ntggtgteee ttgaanaaag ggnntgeena «ceantgeatt ggagageeea 720 ccgggtttnt gaatgaagan nattgtnaaa antnnccaaa aagttaannn gccttcaagg 780 gganagttin ccttintgaa nattnaagna ggaaaaatcc cannitaaaa tacctgggnt. 840

896

congttttt nntaaaaaan cnnnnnactt tttttggnc naangntttt ttttt



<210> 210 <211> 869 <212> DNA <213> Cercopithecus aethiops	
<220> <221> misc_feature <222> (1)(869) <223> n is a, g, c or t	,
<400> 210 nnecttetaa ttttntagtt tnnnagetea ettataaane aggetaeagt gttattetta	60
agtattcatt gttgtataac acactaccc caaaatttag gagcttaaaa taacagcaaa	120
cacttattat ctctcatggt tctgtgtgtt gactagacat ttcggctcct gtgcagatgg	180
ctggagcact gagctntttt ttnggtctac agtgctctcg cttacatagt aggcactagt	240
gttggctgct ggtagcaagc tcagttgggt gtgttgacca gannnnttgg ttctgctcta	300
greggetgee ggrageaage teagetgggt grgtegatea gammmetgg teetgetea	300
gagcattgta atantgagca tttcaacagt attaacccaa catgcaaaca ctcactatag	420
taagcaaaat aaaataaaat aaagcccccc cccagatatc tatgctctaa aacttccaaa	480
cgtatgaata tgtnacctta aatagcaaaa ggcactntgc agtgtgattn angcaagatg	540
gggcagagtg tctgggaata tccangtgga acccaataat gcaaataaaa aaaatcnttt	∘600
tataanangg naggtaggaa ntaanacatc tgntcancat taccgctgcc nggttettng	660
aaaaanaaaa ttnggaagaa aggggccnca agccaaggga atnccaggca tttcnctaan	720
tnggecaaaa caanannatn aaaantente eecennnnne ennenanaaa aaantgnaac	780
cctgggcgnc cncnttgatt tttnnnccca angancctnc ctnaccaana nantnaaaaa	840
aaaatctntt gntcgnnttt nancnaaan	869
<210> 211 <211> 874 <212> DNA <213> Cercopithecus aethiops	
<220> <221> misc_feature <222> (1)(874) <223> n is a, g, c or t	
<400> 211 tttttngggg atttecettn tanantnnan ecceecett anttgggggg gaaatæenne	·60
ecattaacag tittactege ageetetget ingictacat etgetgeeaa etittaacta	120
atggcgagat actttcgcta tttccgatgc cattaggaaa caaatagaaa aatagtttgg	180



caacaacatc ttctcgaata ttatcacttg acaaatttta acgttttagg tggaaacgga 240 attttaannt tttgttttaa gaagcttaaa aaaaacaggc atgcttaatt agcataatgc 300 360 tgaatggcag ccaatcacaa actgaatttt taaagcnnga agtgtttgct cctggcgtgg 420 cgcgcccgcc tgtaatccgg gaatcccagc gttttgcgag cccacgccca ggccgaggag 480 ggaggatect ttgttecaeg agttegaeae eageetagge aatatageag aatteagtte aatgactcta ggctttagcc atgcagtatt aacaaatggg atattaacaa tattaacaaa 540 600 tgggataaaa accaagaact tgacaaatgt gttaatttcc tatttctgtt ttaatacatt acacaaaact aactgcctga aaacaaaaca aaagntntta tttttatagt tctctaaatc 6.60 agaanttttc attggggcnt aaaatcaagg tnntctgcaa ggctgcattc tttntgnagg 720 780 ctgtagggga naaatttcat tgtccttgnt ngncctttaa naaagcctgt tttnccttgg cttggngncc cctttttcaa ttcatttta aaaccccnan nnnatnngnn ccnntttctn 840 874 cctccncctc cncnttaaaa natttttnt gngn

<210> 212

<211> 866

<212> DNA

<213> Cercopithecus aethiops

<220>

<221> misc\_feature

<222> (1)..(866)

<223> n is a, g, c or t

<400> 212

annnnennnn nnnnnnnec ecengatann ttggggggga aannenenca tttgagtgnt 60 ncagggcaaa accaacagta aaccagacta ctaaagattt acttgtggaa ttttttgca 120 aagtgtcaaa gggcttatag agaaaatgaa acagttcttt aaagatgttc ttgagcgagg 180 240 ttttttttt tttaacttac taaaagactt tatgttttag aacagttttt gtttacgttn agcacgtagg acgtccccac tacacacaca gnttctctta ttaatagata ttagtatggt 300 acattngntg caactaatga accagtaatg ataaattatt aactaagatc catagntnat 360 tectgettee teacattnta tetaaagnee tetntetgnt ecaggateee agetaggaga 420 tngaaagacc ccacctgnag gttnggcaag ctagctgagg atcgnnncgc atgatngaac 480 540 aagatggatn gcacgctggn tctccggccg ctngggngga gaggctatnc ggctatgact 600 gggcacaaca gacaancggc tgctctgatg ccgccgngnn ccggctgnca gcgcaggggc gcccggnncn tttnggnaan accgaccngn ccggngcccn gaangaacng caggacnagg 660 720 canngcggnn ategnggntg gccacgacgg gegnnecnng cgcannnggg cncnacgnng

wo	2004	/0700	102

nnacngaaac	gggaagggna	-ccggcngnna	nngggncaaa	angeegggge	aggaaccncn	780
gnnaannaaa	ccnggnnccn	gccnnnaang	aaccanaang	ggngnnnnaa	agnggngggn	840
ngnananccc	ngnaaccggn	nnecce				866

<210> 213 <211> 998 <212> DNA <213> Cercopithecus aethiops

<220> <221> misc\_feature **<222>** (1)..(998) <223> n is a, g, c or t

<400> 213

ttcgggggtc tanaangtnt nntnntncan nececcecn tttttggggg gnaannnenn <del>-</del>60 120 nccagtttnn natttggnnn nggagcataa attnagtcgn ctctctcacc taaaactcat ggtctggtgg aggctccgcc tcctttgtcc cctttcatgt ttctgtctca gcatgcctgg 180 creettaagg ntetteatet titgeaggtt tateteaagn eteaatigaa eegeeneete 240 ctgncaggcn tttttnnnct gggaggtgag cagnngggtc cgggaatgtg ggagctaagg 300 · 360 gcatagatgt gaggaccncc ctatgaanag gaaaaggann cnnctggaat gcanacctgg 420 gactgtctgt atacctgcct ggtcactaaa tttctctgag aggcatcaac agnnaaaanc 480 ctganagggt tatngccaag agcatngatg gggtctgctt tetgggangc agggaataaa ggnngtgata cccanaggga ttatntctca gccaggnecc tecttecent gtangannag 540 tecettgage encenmena etnanenntn tittnaatna aacneeetn tnnnegggae 600 aacgggaann teectatann ceteceanne tnggttgnnn aanneeeggn getaaaagea 660 atennentn necntnggte theacaaaan ggetnagaat naccangttg nageeeentn 720 ntnecetant ecceetgna nnnetatnat ttnttecaan taaccaatna naceeeccan 780 aacccannat acancacaac atngaccecc ntcaaaacca acanccnnnt agacnttntn 840 ocnacntnnt aggneatnng enaacegnaa gentttgttn tngaanetan ecaagggeet 900 cncnaacaan ttcaaaaana agtggtgntt cccccancct naaccccgng cccccacnnt 960 998 caacanannt aaaaannaan acccacnncc nntngtng

<210> 214 <211> 956 <212> DNA <213> Cercopithecus aethiops

#### WO 2004/070002

<220>

<221> misc\_feature

<222> (1)..(956)

<223> n is a, g, c or t

<400> 214 tttttcggn ggattnctnn tttnnttnnt tnnncccccc ngttnnttgg gggggaannc 60 cancettetn netatteet tettgacgag tinttetgag egggactetg gggttenaaa 120 tgagctagcc cttaagtaac gccattttgc aaggcatgga aaaatacata actgagaata 180 gaaaagttca gatcgaggtc aggaacagat ggaacagggt cgaccggtcg accggtcgac 240 cctagagaac nnttttntgt ttccagggtg ccccaaggac ctgaaatgac cctgtgcctt 300 atttgaacta accaatcagt tegetteteg ettetgttet ntegettetg etcecegage 360 tcaataaaag agcccacaac cectcacteg gggegecagt cetcegattg actgagtege 420 480 ccgggtaccc gtgtatccaa taaaccctct tgcagttgca tccgacttgt ggtctcgctg ttccttggga gggtctcctc tgagtgattg actacccgtc agcgggggtc tttcaatctg 540 attgcctctt gcttgacggc aaggagtccc gaccactgaa cactgatgac ctcatctggt 600 gtgattgtct cttgcttgac ggcgaggagc cccgacgact gaacatggat agtcgccgcc 660 acagcacggt gatcanaagg ctttcgttcg acttatgant ccgacgntcc ggggagttca 720 840 aagccccttt tcnactccnt gggncctttt ngtnnttntc ttgnccacct ttcttgactt cttnaanttt gcttctggan tgntaatnen natennaaan eettgtttgn aaaanentgg 900 ccccnggncc cngnttcntt nacccccann tantgnttta ngncccnttt tggaaa 956

<210> 215

<212> DNA

<213> Cercopithecus aethiops

<220>

<221> misc\_feature

<222> (1)..(915)

<223> n is a, g, c or t

<400> 215

concaacett ngagacecta aagacattgg agcagececa tacacetect cecagggeac 60
acaaaggeec etgacatgee catggeagte caaggeetee aattggagee atetttggta 120
aatetgggge ecateageec ecaetgeeet teetggtace etgageatge tggeaagggg 180
actnnttttt geateceate ttgtntcata tacecacagn acetgatgtg gacatgacte 240
aceetggggt ectgtgagte aataagggtg tntgantaag gggeagagea ttteaaceta 300
gteecataac ecatgagete attaageaaa tattacecat geetagattt ggggeeagte 360

•						
WO 2004/070002					PCT/US2003/0	37143
actacccact g	gaggctgtg	ggctccaagg	tatggcagca	ggggaggœa	gecaggente	420
tgeccagete a	eccttecct	gtgaggatgg	acnecageca	ggcctcccac	ctccacecct	480
agactggggg a	cccggggtt	ggggggcaag	aaaggggacc	tgaaagtggn	tgtctnggag	540
ntaageceat t	tncttnata	ctccnccaat	aggganccaa	gaaggngggt	tnagagttac	•600
cccaanaact c	accccaacc	cantntnaac	gctgtggggt	ctcaangggg	acangcnaaa	660
acnaaaantn a	nacnggccc	aaaaaagaac	aggtncggnc	ctnccccnan	ggaccttttn	720
ttttctacca c	ettacccan	nanaatnett	gaccaggggc	ntttccccaa	acncngnaaa	780
anctttcaag c	ntngncact	ntnnanaccc	ngggcnnnnn	aaggnttagn	gcctcttnnn	840
anchetntgn c	nggttncca	tngnntaaaa	accecaangn	aactcctcca	aanaacaagn	900
ancenntetn g	gttn					915
		٠	•	•		
<210> 216 <211> 949	·					
<211> 949 <212> DNA						
	pithecus a	ethiops				
		•				
<220>						
	feature				•	
<222> (1) <223> n is	(949) a, g, c or	<b>~                                    </b>				
~225° 11 15	a, g, c oi			•		
<400> 216	enntttnta	naassnaatt	22222222			~0
neatestat t						120
ncatcgttct t						120
atgagetage e						180
agaaaagttc a						240
ccctagagaa c	ctttntatg	tttccagggt	gccccaagga	cctgaaatga	cectgtgcct	300
tatttgaact a	accaatcnn	ttcgcttctc	gcttctgttc	negegettet	geteeecgag	360
ctcaataaaa g	agcccacaa	ccctcactc	ggggcgccag	tcctccgatt	gactgagtcg	420
cccgggtacc c	gtgtateca	ataaaccctc	ttgcagttgc	atccgacttg	tggtctcgct	480
gttccttggg a	gggtctcct	ctgagtgatt	gactacccga	gtggggaacg	ggggcagggc	540
gggtgggagg a	gggcgcagg	aggctgagac	agcccaggtg	agagagggcc	aagcttgaaa	÷600
ggttttccca g	gctłgggga	gaggccctgg	tcaggatgtg	tatgggtaag	gggtgagaga	660
cagaggtncn t	ggggcangc	ccggacctgt	tttttngnc	cagtntcagt	tetgnttene	720
ttgnecctga g	accccacgt	tcanagaggg	ttggnncggt	tgnggggnga	cnnttanccc	780

840

catctgatcc catggtggnn ntganganan gggctaannc nnanccentn cagtecettn

WO.2004/070002	PCT/US2003/037143
.YY (.) /2004/0 /0002	1 C1/052000.00.310

ttgcccncac	ccgggccccn	atcnnggnga	agagggagnc	cgctcgneec	nececcagga	900
agggnnengg	nanaccggnn	gneceegnng	caaccngnaa	ccaacnnan		949

'<210> 217

<211> 999

<212> DNA

<213> Cercopithecus aethiops

<220>
<221> misc\_feature
<222> (1)..(999)
<223> n is a, g, < or t</pre>

<400> 217 ttttcccgng gannnnnntg nnnnttnnnn nttnccccc cocatnnnnc attggggggg 60 aaatneecc catntaggee tttnngenaa agacecagtn ntetgeecet gggtneecne 120 agganetetg caatggggaa gtgageeete etgaggeetg getggeagga ggetetteaa 180 ggtcatgtgg acttccccca acacctcgag tttctgcaca gcagccacgg agacgggcct 240 300 gggggctggc gggaaatttt tnnnaaggca atgtttneet gagtgggctg aaacetgaga 360 tgaggaaatg agaagacgtc aggtggctgg aggacacggg ctttaggaca gccagcaccc agecetgtag etgaggeete eggagggage eagagggaaa gggagteece teecegegge 420 ctgagtctct gccagtgccc agcactccca aaggatccac cccaacctga gagaccctaa 480 540 agacattgga gcagceccag acacetecte ecagggecae aaaggeeeet gacatgeeca 600 tggcagtcca aggcctncaa ttggagccat cttttggtaa atctggggcc catcagcccc cactgenect teetggtace etgageatge tggcaagggg actggaaact geateceate 660 ttgtctcana tacccacagn acctgatgtg ggacatgact caccctgggg tcctgtgagt 720 caataagggt gtttgantaa ngggcagaac nnttnaactt antnccanaa acccatgagc 780 .\_ tcattaannc aaanttaccc tgcctanaat nggggccant nactaccnac tggaaggttg 840 900 tggcttcang natggntnag ggaagneene nggcttteee aannnneet tneettngag gnggacccac cagcetecan enececenna actgggaace nngngnggea anaagggeng 960 999 aaanggtttt gantaaccna tttntanncc cnnggnaaa

<210> 218

<211> 962

<212> DNA

<213> Cercopithecus aethiops

<220>

<221> misc\_feature

<222> (1)..(962)



<223> n is a, g, c or t

<400> 218 .60 nnneceeggn aetttennnt anngnannee eeceetnat teggggggna anneaeannn 120 ttannnattt nnnnnngaca aagetttttt ccagggnntg aacngengga tattteetnn ancaccatag ccgnctatgg gcttccaaat atccctttgc catttccaca agaactgcct 180 tatcgaaagg cttcttgaag ggaaagatgt aactctgnga gatgaatnct ccagaggaat 240 cctggatnnt nnccataggn angnetnaac ctgttcactc enganettng ggagggtgca 300 cetggaagca agetetgggg teectgggag agaaagcaca geecetgeec tggagacact 360 caaagcctgg aagggaaggg cagngggctg gacagagacc acaggtgtga cggtcctagg 420 480 tgggaggtgg gagetcagag ggggeaceta accecattgg geagagtget canggaagge tttgagtagc gccncagagg atgcngnaga ananccccag gaggagagcg acngnatgna 540 gagggaanag catttaccgn ngcctgggag tgngagaggg ctggcnggag aaaaaagagc 600 tccangaagc cacaaancct cannagnngc gtccacagen cgatnetena neacenacaa 660 cananccecg concatanaa agngonecaa nocatonnto aengaangaa nnaacaaaat 720 780 qaaanaaggg agatcaccna agggaganac gcngacaccc ccccnncccn accnganaac cacnncanaa entnnacece geanacenaa ganecatgaa ganttnagea eggnanggee 840 900 cannnaaaag ncataaanan aacngnagga aaagggaccg gacacccnan tnactacccc cacnnntacc caaaaccaca ncnncngeen gggcgnaacn cccnacnacc aaccancccc 960

<210> 219 <211> 891

<212> DNA <213> Cercopithecus aethiops

<220>

<221> misc\_feature

<222> (1)..(891)

<223> n is a, g, c or t

<400> 219

tttttngggg ntmmnnggg gmnngmmnt eccgectmnc ettngggggn anneetmme 60
agttgggaat tmatttaaag aagggaetta agggagatta ttaaagagee agnaacgeaa 120
aggagagetg eggeaatega caactacega agaegegaag cacatteaeg aagegtteee 180
tteaateege acactacact eccaegacee geeeetteeg eccaeagage eegeeaette 240
egeeteanan ntmaegeeeg etetgtgete etaagggeet teeegegget gateagaege 300
eccgeeeett ageegeaaea gaageegtaa agetttetee egtegegatg eagegeteaa 360

WO 2004/070002 PCT/US2003/037143

	ggegeetgeg	cagaccctga	aaagcggcca	gggtggcccc	gagetteect	tttccggttg	420
	cagcgccgcg	cggttaggtt	ctctcgttct	«gctcgcagc	catgccgtcc	aagggcccgc	480
,	tgcagt <del>c</del> ggt	gcaggtcttc	ggacgcaagg	tgagctagac	gccagatggg	aaggggaggg	540
	gaaggagaag	gtcagggtct	gggagaggac	ggtgggcagg	aatacagggg	gcaacatggg	600
	agctggatcc	cgagctcacg	gggccacact	ctcttgtatc	ccacagaaga	cagecacage	660
	tgtggcgcac	tgcaaacgcg	gcaatggtct	catcaaggtg	aacgggcggc	ccctggagat	720
	gattgagccn	cgcacgctnc	aatacaaggt	gnttggcatt	gggncattcg	ncgttgantt	780
	ggattggagg	acctntngga	nataatagta	gctnnttgaa	agcttgaggg	ggcnggntnt	840
	cancancegg	gnttttnana	anttngnttn	gtntnnnnaa	aagggggttt	t	891

<210> 220

<211> 902

<212> DNA

<213> Cercopithecus aethiops

<220>

<221> misc\_feature

. <222> (1)..(902)

<223> n is a, g, c or t

<400> 220

tttttnnngg nntataattt ganntatnta tcccncccat aaaccttggg ggggaanaca 60 120 aggnetnaag tittitagga tigtgetaet glacteeagg gigagigaea geaagtatae tgttcttaaa aaaagaacct tatatattaa aaaaaaattt ttttttaact gaccctgcaa 180 tgcacatatg cttcctttta aaagtagtaa acttcagaag gggcagaaat cagactctgg 240 300 tttcttcca ttttnagcca aagaaactga nagtnccaaa cagggaacag aagaaccct 360 ttcacaagca agcatttaaa cagacccaaa ttcggccgcg cggctcacca ggctggtcag .. 420 gagttctaga ccagcctggc cgacatggtg aaaccacgtc tctcctgaaa atacaaacat tagecggccg tggtggtgt cgcctatagt cccagccacc cgggaggctg aggcaagaga 480 attgettgaa ceeggagggt ggaggttgea gegateegag ategtgeeac tgeactetee 540 600 agcctgggcg acagagcgag actccctctc aaacaaataa atngaaaaaa aaataaacag 660 acccaaattc aagctatttc aatacttact gagcacttac aatgtctaaa acgctgcttt tagacgcctt ggggttttnt taaggatnaa aacacttgnt ncttngtgaa aatnaaanct 720 atgaaaactg ggtgttcctt caancetttn gggntccccc ccggnttccc cnnttnaaat 780 gaacettnet aaacattnee aattttnaaa agneaneece nttaattntt taanaeneec 840 900 ccaattinaa nntittaaan tittininaa acnntaaanc cccgggtiit titincnaa

902

```
<210> 221
<211> 907
<212> DNA
<213> Cercopithecus aethiops
```

<220>
<221> misc\_feature
<222> (1)..(907)

<223> n is a, g, c or t


<400> 221 concanniget agricogoto goottoogoo ttgtaagong gaaaggtgot togogaggto 60 togeottegg ggteegacat ggtgaeegga tttagagaeg etaaageaga gaeaategaa 120 gaaaagetgg agaaceteta tetggttetg gtttgtggaa geteegtete ttagcaaceg 180 cgagacgann ttttcagcga tttccggttc cgtccctgtc tggcaagggc ccggattctg 240 ggtgcaacct gccggcgtgc gcgtgcgcca gttctntnnn gcaccgggcc ggagagtgat 300 gagtgcgtgg ctggcggctg agctccttag tgtttgctgt tgcacgctcc ttcggttctc 360 tctggagtta ctgcgtgaaa aggctgcctt gtaagacagc caagaaaaca ggaagagggt 420 tggaggcaaa gttccnaata gggattgaaa gaccocacct gtnggttttg gcaagctagc 480 tgaggatcgt tcgcatgatt gaacaagatg gattgcacgc tggtttcttc ggccgcttgg 540 gtggagaggc tatttegget atgactgggc acacagacat teggetnett ttantgeene 600 cngngtneng getgtnageg naggggaegn ceegggttet tintignaaa gaeeenaeeg 660 ttccggtgcc cttaatnaan ctgnanggac gagnnnancc cngntttatt ttgntgggcn 720 ncaacggnen tteettnnac ancingnien neanentigt nanttaacen gnaanggnne 780 840 tngntngttt tggncnaaat annccgggca aggaactccn nnnnannccc ccgtgtnnnt neccacaaan tatenattng ggtanenaan engggnnnnn tnacennnae eegnnnneeg 900 907 ccnanct

```
<210> 222
<211> 955
<212> DNA
<213> Cercopithecus aethiops
```

```
<220>
<221> misc_feature
<222> (1)..(955)
<223> n is a, g, c or t
<400> 222
```

ttttteeggg ggaannnnn nnggnnnaa nnnnteecc neeccatnn ecttnggggg 60

WO,2004/070002 PCT/US2003/037143



<210> 223

<211> 927

<212> DNA

<213> Cercopithecus aethiops

<220>

<221> misc\_feature

<222> (1)..(927)

<223> n is a, g, c or t

<400> 223 nnnntttta aanacnnanc coccccanta ntttgggggg gaaaacecec agcatgeeca 60 cntateatnn cecateactg ggtaatatte acagnateaa attateetee etaacceagt 1-20 cetgtgaata tteteattga teetcaaact caetttggee teagtgatee ecaacageet 180 ectttacaac cttacaacat ccaagtteet gttetgtgag agttteetet cgaaacacaa 240 cattecgtac aatteagtet etcactecgt caatecteta cattggcagt gagacettat 300 tttgtgaccc tttactttac agcagccatt tcaaagagac attctctagc ctgaaagggc 360 tecagattet tteaacttte tattatgtat geattgeeaa tattgaattt geactatett 420 atcaactatt ctaaaactac tgacatttgc agaaactggt catttgttct tagggaaaat 480 gtctgtgtta tccaaaaatg gagattaaaa acttgcacac attcctactt gatttccaca 540

		)
WO	2004/070002	

gngacctgat	ctatggtatc	tagcntcctt	cccctctgcc	ccaagttcac	atttccatca	600
gctcatatat	actetteect	ttctactcct	gctgacaggg	tccaaggata	ctgcctcaaa	660
aactctataa	aaganaataa	aaactnatta	actggctttn	ctatcnaaaa	nctttcnact	720
agnaatatta	anaaangntt	ttcaaccggt	nggatccgaa	ancatccnaa	gnagggntna	780
ngccnaaaaa	aaaaataatn	nntttccccn	aaaaannaaa	aaatagnntn	tnangggggc	840
cengnnentn	gnaaaagaaa	naanneeggn	cntnnaaana	nnannaaaaa	nntcenengg	900
nttnannnnn	aaaaancatn	aancnnn				927

<210> 224

<211> 936

<212> DNA

<213> Cercopithecus aethiops

<220>

<221> misc\_feature

<222> (1)..(936)

<223> n is a, g, c or t

<400> 224

60 titticgng gnanntannn nittanacti nnccccccc attictiggg gggggaanac 120 cccccacag nnccacttcg cggctgccag gcagtcaggc aaagnaggcc gaagcaaagc 180 cctagaagca aagccacagg aataagtcag ctttcccaga ggtcaaagaa ggctgtaggg -ccacctgcca cgcctcccga ccccggccgc gcggcctggg cccgctcccc aaccaaagag 240 300 qeecqaatte agagannttt tageagttte acagaaaget tettteeagt tetgaacgga 360 agatatttcc tttttcaccg taggcctcta tgggcttcca aatatccctt tgccaattcc 420 acaagaacag ccttagcgaa aggcttcttg aagggaaaga tgtaactctg tgaaatgaat 480 tctgcttata ggtcttgaga taaagtcacc gatctcatat catggattat aaggttttcc ttctattttc tggcattttg gatatgtaat gatgagcatc agaaagttta atcatattta 540 600 attittagaa ttattaaata ctcctgaggt cattitggtt gattitgngt ggctttcaac 660 cataaagaga tcaatgcctt gcagatataa agctttcctt ttccttcttt aataattnta 720 aactctgaat tnatgnctac agatatntaa tngatcataa atganaaatg ngatactatt 780 cnctacctcc ttatctgttc tcggaanaga ctatacancc ctgcaannat ngaagttnan 840 gattgcttnt acgaaannna aaaaaaattn acttnttttt nggcaanana aaatgcttcc 900 tecgttgnna acteccetca nggngtntta gggggnanne tacettnaan tecentngne 936 ctggnnncng tnnnaggnan tgcaaanngn tttctt

# WO 2004/070002

<210> 225 <211> 605 <212> DNA <213> Cercopithecus aethiops

<220>

<221> misc\_feature

<222> (1)..(605)

<223> n is a, g, c or t

<400> 225 ttttnccnng nnntacnnct tnnnnanttn anncccccc attatttng gggggaaacc 60 tagnaaaaat aatantgtac aagattttat ttttgtcttt aaccagaatg atgtatttgg 120 ttaagaagat agtccaagtt aaaggcatac attcaagcta gtggcacatt cggaagagca 180 gacaaagata gttggttgca aatgggaaat ttaagccatg atcttaaaag gacagaatgg 240 atatttgtta cttttnctat gggaataatt gattttttc accttccctt tcttggattt 300 tttttttt ttaaattagt ttggttactt taaccttact gtcggttata ttggttctct 360 ttttatgtct gagttttttt tttttttga gacggagtct tgctctgtcg cccaggctgg . 420 agtgcagtgg ccggatctca gctcactgca agctctgcct cccgggttta caccattctc 480 ctgectcage ctnetgagta getaggacta caggegeeeg ecacetngee eggetagttt 540 tttgtatttt ttagtagaga cgggtttnna cccnnntnnn ncanatggtt tnnntctnct 600 605 ntcct

<210> 226

<211> 654

<212> DNA

<213> Cercopithecus aethiops

<220>

<221> misc\_feature

<222> (1)..(654)

<223> n is a, g, c or t

<400> 226
tttntngggg nnnnnnnngn attgnnnntc cccccgtnn nttggggggn aanneennee 60
antactgttt gaggaaagac tgaggnteag atggcagagg ctccntagag gaaggagget 120
acagcettga gggcateage tteecacaet cccaacetge tgeetetete tgetggaatg 180
aggaggggec teetggetgg gggteteeag ggtggaggga ggageteaca ttettageat 240
teetnttnee etgagttgea aggaagaeet ggtgageatg etgaceeeag aggagtgaet 300
caggeeeatg getegagtge etgaggagg aceagggteg gggatggge atgagteage 360
etggcaggte ecataagaag ggaagggaag ggagagaaat gggggetgea eaggtgtgag 420

WO 2004/070002

# PCT/US2003/037143

ggtctgtgca tgtctgtgtg gtgtggggg gtgtctggat atccgngtgt tctggatctg	480
agtgttagtg tatccgncag cacaacetet gtgtgagggt gtgtctnggc gagggtgggc	540
ttctgtggat gtcccntgtg tggnatgtgt gngtgtgtgt gtgngngact aanntatnnc	600
cttcaacnng ggntctnncc caangngnnt ntggatctnc atannatgtc tetc	654
<210> 227 <211> 2635 <212> DNA <213> homo sapiens	
<220> <221> CDS <222> (285)(1679)	
<400> 227	1
ggccgacgcg agcgccgcgc ttcgcttcag ctgctagctg gcccaaggga ggcgaccgcg	<b>*60</b>
gagggtggcg agggggggcc aggacccgca gccccggggc cgggccggtc cggaccgcca	120
gggagggcag gtcagtgggc agatcgcgtc cgcgggattc aatctctgcc cgctctgata	180
acagtecttt teeetggege teaettegtg eetggeacee ggetgggege eteaagaeeg	240
ttgtctcttc gatcgcttct ttggacttgg cgaccatttc agag atg tct tcc aga Met Ser Ser Arg 1	<b>296</b>
agt acc aaa gat tta att aaa agt aag tgg gga tcg aag cct agt aac Ser Thr Lys Asp Leu Ile Lys Ser Lys Trp Gly Ser Lys Pro Ser Asn 5 10 15 20	344
tcc aaa tcc gaa act aca tta gaa aaa tta aag gga gaa att gca cac Ser Lys Ser Glu Thr Thr Leu Glu Lys Leu Lys Gly Glu Ile Ala His 25 30 35	392
tta aag aca tca gtg gat gaa atc aca agt ggg aaa gga aag ctg act Leu Lys Thr Ser Val Asp Glu Ile Thr Ser Gly Lys Gly Lys Leu Thr 40 45 50	440
gat aaa gag aga cac aga ctt ttg gag aaa att cga gtc ctt gag gct Asp Lys Glu Arg His Arg Leu Leu Glu Lys Ile Arg Val Leu Glu Ala 55 60 65	488
gag aag gag aag aat get tat caa ete aca gag aag gac aaa gaa ata Glu Lys Glu Lys Asn Ala Tyr Gln Leu Thr Glu Lys Asp Lys Glu Ile 70 75 80	536
cag cga ctg aga gac caa ctg aag gcc aga tat agt act acc gca ttg Gln Arg Leu Arg Asp Gln Leu Lys Ala Arg Tyr Ser Thr Thr Ala Leu 85 90 95 100	584
ctt gaa cag ctg gaa gag aca acg aga gaa gga gaa agg agg	°632
gtg ttg aaa gcc tta tct gaa gag aaa gac gta ttg aaa caa cag ttg	680

,	Val	Lev	. Łj		Ala 1 L20	Leu '	Ser ﴿	Glu (	Glu i	Lys <i>1</i> 125	Asp V	/al I	Leu I	Lys (	Gln · 130	Gln	Lev	1	
	tct Ser	gct Ala	A	ca a la 1 35	acc : Thr :	tca Ser	cga Arg	Ile .	gct ( Ala ( 140	gaa 4 Glu 1	ctt ( Leu 1	gaa ( Glu (	agc a Ser i	aaa Lys 145	acc Thr	aat Asn	aca Thi	a r	728
	ctc Leu	cg Arg	j L	ta : eu :	tca Ser	cag Gln	act Thr	gtg Val 155	gct Ala	cca Pro	aac Asn "	Cys	ttc Phe 160	aac Asn	tca Ser	tca Ser	ata Il	e e	776
•	aat Asn 165	As	t a n I	itt . :le	cat His	gaa Glu	atg Met 170	gaa Glu	ata Ile	cag Gln	Leu	aaa Lys 175	gat Asp	gct Ala	ctg Leu	gag Glu	aa Ly 18	8	824
	aat Asn	ca Gl	g c	ag Sln	tgg Trp	ctc Leu 185	gtg Val	tat Tyr	gat Asp	cag Gln	cag Gln 190	egg Arg	gaa Glu	gtc Val	tat Tyr	gta Val 195	гу	S	872
	gga	ct Le	t (	ta Leu	gca Ala 200	aag Lys	atc Ile	ttt Phe	gag Glu	ttg Leu 205	gaa Glu	aag Lys	aaa Lys	acg Thr	gaa Glu 210	aca Thr	gc Al	t la	920
	gct Ala	ca A Hi	s	tca Ser 215	ctc Leu	cca Pro	.cag Gln	cag Gln	aca Thr 220	aaa Lys	aag Lys	cct Pro	gaa Glu	tca Ser 225	GIU	ggt	: ta	at /r	<b>968</b>
٠.	cti Lei	u G	aa ln 1	gaa Glu	gag Glu	aag Lys	cag Gln	aaa Lys 235	Cys	tac Tyr	aac Asn	gat Asp	ctc Leu 240	Leu	gca Ala	agt Sei	ge c A	ca la	1016
	aa Ly 24	s L	aa ys	gat Asp	ctt Leu	gag Glu	gtt Val 250	Glu	cga Arg	caa Gln	acc Thr	ata Ile 255	act Thr	-cag Gln	cto Lev	g agt	ב צ	tt he 60	1064
	ga G1	a c u L	tg eu	agt Ser	gaa Glu	ttt Phe 265	Arç	aga J Arg	aaa Lys	tat Tyr	gaa Glu 270	GIU	acc Thr	: -caa : Glr	a aaa n Lys	a ga s G1 27	u v	tt al	1112
	ca Hi	ıc a .s A	at .sn	tta Leu	aat Asr 280	ı Glı	n Lev	j ttg 1 Lei	1 Туз	r Ser	Glr	Arg	a agg g Arg	1 TI	a ga a As 29	p va	g c	aa In	1160
	ca Hi	at o	tg eu	gas Glu 295	ı Ası	t ga p As	t agg	g cat g Hi	t aas S Lys 300	s Thi	a gaq r Glu	g aag	g ata s Ila	a ca e Gl: 30	и гу	a ct	c a	agg Arg	<b>1208</b>
	g:	lu (	gag Slu S10	aat Ası	ga n As	t at p Il	t gc e Al	t ag a Ar 31	g Gl	a aaa y Lys	a cti s Lei	t gaa u Gl	a gaa u Glu 32	u GI	g aa u Ly	g as s Ly	ig 8 7s j	aga Arg	1.256
	S	cc ( er ( 25	gaa Glu	gag	g ct u Le	c tt u Le	a tc u Se 33	r Gl	g gt n Va	c ca 1 Gl:	g tt n Ph	t ct e Le 33	t ta u Ty 5	c ac r Th	a to r Se	t ct er Le	eu .	cta Leu 340	1304
	a L	ag ys	cag Gln	ca: Gl:	a ga n Gl	a ga u Gl	u Gl	a ac n Th	a ag r Ar	g gt g Va	a gc l Al 35	a Le	g tt u Le	g ga u Gl	a "ca lu Gl	LIL G	ag ln 55	atg Met	1352
	√C •G	ag ln	gca Ala	tg Cy	t ac	t te	a ga eu As	ic tt	t ga æ Gl	a aa .u As	t ga n Gl	a .aa .u <b>L</b> y	a ct 's Le	c ga	ac -ce	gt c rg G	aa ln	cat His	1400

360 365 370

yal Gln His Gln Leu Leu Val Ile Leu Lys Glu Leu Arg Lys Ala Arg 375 380 385	1448
aat caa ata aca cag ttg gaa tcc ttg aaa cag ctt cat gag ttt gcc Asn Gln Ile Thr Gln Leu Glu Ser Leu Lys Gln Leu His Glu Phe Ala 390 395 400	1496
atc aca gag cca tta gtc act ttc caa gga gag act gaa aac aga gaa  Ile Thr Glu Pro Leu Val Thr Phe Gln Gly Glu Thr Glu Asn Arg Glu 405 410 420	1544
aaa gtt gcc gcc tca cca aaa agt ccc act gct gca ctc aat gaa agc Lys Val Ala Ala Ser Pro Lys Ser Pro Thr Ala Ala Leu Asn Glu Ser 425 430 435	1592
ctg gtg gaa tgt ccc aag tgc aat ata cag tat cca gcc act gag cat Leu Val Glu Cys Pro Lys Cys Asn Ile Gln Tyr Pro Ala Thr Glu His 440 445 450	1640
cgc gat ctg ctt gtc cat gtg gaa tac tgt tca aag tag caaaataagt Arg Asp Leu Leu Val His Val Glu Tyr Cys Ser Lys 455 460	1689
atttgttttg atattaaaag attcaatact gtattttctg ttagcttgtg ggcattttga	1749
attatatatt tcacattttg cataaaactg cctatctacc tttgacactc cagcatgcta	1809
gtgaatcatg tatcttttag gctgctgtgc atttctcttg gcagtgatac ctccctgaca	1869
tggttcatca tcaggctgca atgacagaat gtggtgagca gcgtctactg agactactaa	1929
cattttgcac tgtcaaaata cttggtgagg aaaagatagc tcaggttatt gctaatgggt	1989
taatgcacca gcaagcaaaa tatttatgt tttgggggtt tgaaaaatca aagataatta	2049
accaaggate ttaactgtgt tegeatettt tatecaagea ettagaaaac etacaateet	2109
aattttgatg tocattgtta agaggtggtg atagatacta ttttttttt catattgtat	2169
ageggttatt agaaaagttg gggattttct tgatctttat tgctgcttac cattgaaact	2229
taacccagct gtgttcccca actctgttct gcgcacgaaa cagtatctgt ttgaggcata	2289
atcttaagtg gccacacaca atgttttctc ttatgttatc tggcagtaac tgtaacttga	2349
attacattag cacattotgo itagotaaaa ttgttaaaat aaactttaat aaacccatgt	2409
agecetetea titgatigae agtatittag tiatititigg cateettaaa getgggeaat	2469
gtaatgatca gatctttgtt tgtctgaaca ggtattttta tacatgcttt ttgtaaacca	2529
aaaactttta aatttettea ggttttetaa eatgettace aetgggetae tgtaaatgag	2589
aaaagaataa aattatttaa tgttttaaaa aaaaaaaa	2635

<210> 228 <211> 464

<212> PRT

<213> homo sapiens

<400> 228

. 1

Met Ser Ser Arg Ser Thr Lys Asp Leu Ile Lys Ser Lys Trp Gly Ser 1 10 15

Lys Pro Ser Asn Ser Lys Ser Glu Thr Thr Leu Glu Lys Leu Lys Gly
20 25 30

Glu Ile Ala His Leu Lys Thr Ser Val Asp Glu Ile Thr Ser Gly Lys
35 40 45

Gly Lys Leu Thr Asp Lys Glu Arg His Arg Leu Leu Glu Lys Ile Arg 50 55 60

Val Leu Glu Ala Glu Lys Glu Lys Asn Ala Tyr Gln Leu Thr Glu Lys 65 70 75 80

Asp Lys Glu Ile Gln Arg Leu Arg Asp Gln Leu Lys Ala Arg Tyr Ser 85 90 95

Thr Thr Ala Leu Leu Glu Gln Leu Glu Glu Thr Thr Arg Glu Gly Glu
100 105 110

Arg Glu Gln Val Leu Lys Ala Leu Ser Glu Glu Lys Asp Val Leu 115 120 125

Lys Gln Gln Leu Ser Ala Ala Thr Ser Arg Ile Ala Glu Leu Glu Ser 130 135 140

Lys Thr Asn Thr Leu Arg Leu Ser Gln Thr Val Ala Pro Asn Cys Phe 145 150 155 160

Asn Ser Ser Ile Asn Asn Ile His Glu Met Glu Ile Gln Leu Lys Asp 165 170 175

Ala Leu Glu Lys Asn Gln Gln Trp Leu Val Tyr Asp Gln Gln Arg Glu 180 185 190

Val Tyr Val Lys Gly Leu Leu Ala Lys Ile Phe Glu Leu Glu Lys Lys 195 200 205

Thr Glu Thr Ala Ala His Ser Leu Pro Gln Gln Thr Lys Lys Pro Glu 210 215 220 Ser Glu Gly Tyr Leu Gln Glu Glu Lys Gln Lys Cys Tyr Asn Asp Leu 225 230 235 240

Leu Ala Ser Ala Lys Lys Asp Leu Glu Val Glu Arg Gln Thr Ile Thr 245 250 255

Gln Leu Ser Phe Glu Leu Ser Glu Phe Arg Arg Lys Tyr Glu Glu Thr 260 265 270

Gln Lys Glu Val His Asn Leu Asn Gln Leu Leu Tyr Ser Gln Arg Arg 275 280 285

Ala Asp Val Gln His Leu Glu Asp Asp Arg His Lys Thr Glu Lys Ile 290 295 300

Gln Lys Leu Arg Glu Glu Asn Asp Ile Ala Arg Gly Lys Leu Glu Glu 305 310 315 320

Glu Lys Lys Arg Ser Glu Glu Leu Leu Ser Gln Val Gln Phe Leu Tyr 325 330 335

Thr Ser Leu Leu Lys Gln Gln Glu Gln Thr Arg Val Ala Leu Leu 340 345 350

Glu Gln Gln Met Gln Ala Cys Thr Leu Asp Phe Glu Asn Glu Lys Leu 355 360 365

Asp Arg Gln His Val Gln His Gln Leu Leu Val Ile Leu Lys Glu Leu 370 375 380

Arg Lys Ala Arg Asn Gln Ile Thr Gln Leu Glu Ser Leu Lys Gln Leu 385 390 395 400

His Glu Phe Ala Ile Thr Glu Pro Leu Val Thr Phe Gln Gly Glu Thr 405 410 415

Glu Asn Arg Glu Lys Val Ala Ala Ser Pro Lys Ser Pro Thr Ala Ala 420 425 430

Leu Asn Glu Ser Leu Val Glu Cys Pro Lys Cys Asn Ile Gln Tyr Pro
435 440 445

Ala Thr Glu His Arg Asp Leu Leu Val His Val Glu Tyr Cys Ser Lys 450 455 460


<210> 229 <211> 2635

### WO 2004/070002

<212> DNA

<213> homo sapiens

•	
<220> <221> CDS <222> (285)(1679)	
<400> 229 ggecgacgcg agcgccgcgc ttcgcttcag ctgctagctg gcccaaggga ggcgaccgc	eg 60
gagggtggcg aggggcggcc aggacccgca gccccggggc cgggccggtc cggaccgc	ca 120
gggagggcag gtcagtgggc agatcgcgtc cgcgggattc aatctctgcc cgctctga	ta 180
acagteettt teeetggege teaettegtg eetggeacee ggetgggege eteaagae	cg 240
ttgtctcttc gatcgcttct ttggacttgg cgaccatttc agag atg tct tcc ag Met Ser Ser Ar 1	a 296 g '
agt acc aaa gat tta att aaa agt aag tgg gga tcg aag cct agt aac Ser Thr Lys Asp Leu Ile Lys Ser Lys Trp Gly Ser Lys Pro Ser Asn 5 10 15 20	344
tcc aaa tcc gaa act aca tta gaa aaa tta aag gga gaa att gca cac Ser Lys Ser Glu Thr Thr Leu Glu Lys Leu Lys Gly Glu Ile Ala His 25 30 35	392
tta aag aca tca gtg gat gaa atc aca agt ggg aaa gga aag ctg act Leu Lys Thr Ser Val Asp Glu Ile Thr Ser Gly Lys Gly Lys Leu Thr 40 45 50	440
gat aaa gag aga cac aga ctt ttg gag aaa att cga gtc ctt gag gc Asp Lys Glu Arg His Arg Leu Leu Glu Lys Ile Arg Val Leu Glu Ala 55 60 65	z 488 a
gag aag gag aag aat gct tat caa ctc aca gag aag gac aaa gaa at Glu Lys Glu Lys Asn Ala Tyr Gln Leu Thr Glu Lys Asp Lys Glu Il 70 75 80	a 536 e
cag cga ctg aga gac caa ctg aag gcc aga tat agt act acc gca tt Gln Arg Leu Arg Asp Gln Leu Lys Ala Arg Tyr Ser Thr Thr Ala Le 85 90 95	u
ctt gaa cag ctg gaa gag aca acg aga gaa gga gaa agg agg	g 632 n ·
gtg ttg aaa gcc tta tct gaa gag aaa gac gta ttg aaa caa cag tt Val Leu Lys Ala Leu Ser Glu Glu Lys Asp Val Leu Lys Gln Gln Le 120 125 130	.g 680 eu
tct gct gca acc tca cga att gct gaa ctt gaa agc aaa acc aat ac Ser Ala Ala Thr Ser Arg Ile Ala Glu Leu Glu Ser Lys Thr Asn Th 135 140 145	ca 728 nr
ctc cgt tta tca cag act gtg gct cca aac tgc ttc aac tca tca ac Leu Arg Leu Ser Gln Thr Val Ala Pro Asn Cys Phe Asn Ser Ser I 150 155 160	ta 776 le



٠.,		Asn			gaa Glu												824
					ctc Leu 185												872
					aag Lys												920
•					eca Pro												968
					aag Lys												1016
					gag Glu												1064
					ttt Phe 265												1112
					cag Gln	_	-				_		_	_			1160
		_	_	_	gat Asp				Thr		_			Lys			1208
	-		Asn	_	att Ile	_					-	_		_	_	_	1256
		Glu										Tyr				cta Leu 340	1304
					gaa Glu 345						Leu						1352
										Glu					Gln	cat His	1400
				Gln					Leu					Lys		aga Arg	1448
			Ile					Ser					His			gcc Ala	1496
	ato	: aca	gag	cca	tta	gtc	act	ttc	-caa	gga	gag	act	gaa	aac	aga:	gaa	1544

# WO 2004/070002 PCT/US2003/037143

Ile Thr Glu 405	Pro Leu Val Thr 410		Glu Thr Glu <i>I</i> 415	Asn Arg Glu 420	
aaa gtt gcc Lys Val Ala	gcc tca cca aaa Ala Ser Pro Lys 425	agt ccc act Ser Pro Thr 430	gct gca ctc a Ala Ala Leu 1	aat gaa agc Asn Glu Ser 435	1592
ctg gtg gaa Leu Val Glu	tgt cec aag tgc Cys Pro Lys Cys 440	aat ata cag Asn Ile Gln 445	Tyr Pro Ala '	act gag cat Thr Glu His 450	1640
cgc gat ctg Arg Asp Leu 455	ctt gtc cat gtg Leu Val His Val	gaa tac tgt Glu Tyr Cys 460	tca aag tag Ser Lys	caaaataagt	1689
atttgttttg	atattaaaag attca	atact gtattt	ctg ttagcttg	tg ggcattttga	1749
attatatatt 4	tcacattttg cataa	aactg cctatc	tacc tttgacac	tc cagcatgcta	1809
gtgaatcatg	tatcttttag gctgo	tgtgc atttct	cttg gcagtgat	ac ctccctgaca	1869
tggttcatca	tcaggctgca atgad	agaat gtggtg	agca gcgtctac	tg agactactaa	1929
cattttgcac	tgtcaaaata cttg	gtgagg aaaaga	tagc tcaggtta	ett gctaatgggt	1989
taatgcacca	gcaagcaaaa tatt	tatgt tttggg	ggtt tgaaaaat	ca aagataatta	2049
accaaggatc	ttaactgtgt tcgc	atttt tatcca	agca cttagaaa	ac ctacaatcct	2109
aattttgatg	tccattgtta agag	gtggtg atagat	acta ttttttt	tt catattgtat	2169
agcggttatt	agaaaagttg ggga	ttttct tgatct	ttat tgctgct	tac cattgaaact	2229
taacccagct	gtgttcccca actc	tgttct gcgcac	gaaa cagtatc	tgt ttgaggcata	2289
atcttaagtg	gccacacaca atgt	tttctc ttatgt	tatc tggcagt	aac tgtaacttga	2349
attacattag	cacattetge ttag	ctaaaa ttgtta	aaat aaacttt	aat aaacccatgt	2409
agccctctca	tttgattgac agta	ttttag ttatt	ttgg cattctt	aaa getgggeaat	2469
gtaatgatca	gatctttgtt tgtc	tgaaca ggtati	ttta tacatgc	ttt ttgtaaacca	2529
aaaactttta	aatttcttca ggtt	ttctaa -catgc	ttaec actgggc	tac tgtaaatgag	2589
aaaagaataa	aattatttaa tgtt	ttaaaa aaaaa	aaaaa aaaaaa		2635

<210> 230

<211> 464

<212> PRT

<400> 230

Met Ser Ser Arg Ser Thr Lys Asp Leu Ile Lys Ser Lys Trp Gly Ser 1 5 10 15

Lys Pro Ser Asn Ser Lys Ser Glu Thr Thr Leu Glu Lys Leu Lys Gly . 20 25 30

- Glu lle Ala His Leu Lys Thr Ser Val Asp Glu lle Thr Ser Gly Lys
  40
  45
- Gly Lys Leu Thr Asp Lys Glu Arg His Arg Leu Leu Glu Lys Ile Arg
  - Val Leu Glu Ala Glu Lys Glu Lys Asn Ala Tyr Gln Leu Thr Glu Lys 65 70 75 80
  - Asp Lys Glu Ile Gln Arg Leu Arg Asp Gln Leu Lys Ala Arg Tyr Ser 85 90 95
  - Thr Thr Ala Leu Leu Glu Glu Leu Glu Glu Thr Thr Arg Glu Gly Glu
    100 105 110
  - Arg Arg Glu Gln Val Leu Lys Ala Leu Ser Glu Glu Lys Asp Val Leu 115 120 125
  - Lys Gln Gln Leu Ser Ala Ala Thr Ser Arg Ile Ala Glu Leu Glu Ser 130 135 140
  - Lys Thr Asn Thr Leu Arg Leu Ser Gln Thr Val Ala Pro Asn Cys Phe 145 150 155 160
  - Asn Ser Ser Ile Asn Asn Ile His Glu Met Glu Ile Gln Leu Lys Asp 165 170 175
  - Ala Leu Glu Lys Asn Gln Gln Trp Leu Val Tyr Asp Gln Gln Arg Glu 180 185 190
  - Val Tyr Val Lys Gly Leu Leu Ala Lys Ile Phe Glu Leu Glu Lys Lys
    200
    205
  - Thr Glu Thr Ala Ala His Ser Leu Pro Gln Gln Thr Lys Lys Pro Glu 210 215 220
  - Ser Glu Gly Tyr Leu Gln Glu Glu Lys Gln Lys Cys Tyr Asn Asp Leu 225 230 235 240
  - Leu Ala Ser Ala Lys Lys Asp Leu Glu Val Glu Arg Gln Thr Ile Thr 245 250 255
  - Gln Leu Ser Phe Glu Leu Ser Glu Phe Arg Arg Lys Tyr Glu Glu Thr 260 265 270

· 1

Gin Lys Glu Val His Asn Leu Asn Gln Leu Leu Tyr Ser Gln Arg Arg 285 285

Ala Asp Val Gln His Leu Glu Asp Asp Arg His Lys Thr Glu Lys Ile 290 295 300

Gln Lys Leu Arg Glu Glu Asn Asp Ile Ala Arg Gly Lys Leu Glu Glu 305 310 315 320

Glu Lys Lys Arg Ser Glu Glu Leu Leu Ser Gln Val Gln Phe Leu Tyr 325 330 335

Thr Ser Leu Leu Lys Gln Gln Glu Glu Gln Thr Arg Val Ala Leu Leu 340 345 350

Glu Gln Gln Met Gln Ala Cys Thr Leu Asp Phe Glu Asn Glu Lys Leu 355 360 365

Asp Arg Gln His Val Gln His Gln Leu Leu Val Ile Leu Lys Glu Leu 370 375 380

Arg Lys Ala Arg Asn Gln Ile Thr Gln Leu Glu Ser Leu Lys Gln Leu 385 390 395 400

His Glu Phe Ala Ile Thr Glu Pro Leu Val Thr Phe Gln Gly Glu Thr 405 410 415

Glu Asn Arg Glu Lys Val Ala Ala Ser Pro Lys Ser Pro Thr Ala Ala 420 425 430

Leu Asn Glu Ser Leu Val Glu Cys Pro Lys Cys Asn Ile Gln Tyr Pro
435 440 445

Ala Thr Glu His Arg Asp Leu Leu Val His Val Glu Tyr Cys Ser Lys 450 460

<210> 231

<211> 6829

<212> DNA

<213> HOMO SAPIENS

<220>

<221> CDS

<222> (89)..(6274)

<400> 231

cttetetece agggeggtge gaeeeggage tecagegeee gagteteeae ttegtttget




gaaacttgct ttctaccagc taagaacc atg ctg cga gtg att gtg gaa bet Met Leu Arg Val Ile Val Glu Ser 1 5	112
gcc agc aat atc cct aaa acg aaa ttt ggc aag ccg gat cct att gtt Ala Ser Asn Ile Pro Lys Thr Lys Phe Gly Lys Pro Asp Pro Ile Val 10 15 20	160
tct gtc att ttt aag gat gag aaa aag aaa aca aag aaa gtt gat aat Ser Val Ile Phe Lys Asp Glu Lys Lys Lys Thr Lys Lys Val Asp Asn 25 30 35 40	508
gaa ttg aac cct gtc tgg aat gag att ttg gag ttt gac ttg agg ggt Glu Leu Asn Pro Val Trp Asn Glu Ile Leu Glu Phe Asp Leu Arg Gly 45 50 55	256
ata cca ctg gac ttt tca tct tcc ctt ggg att att gtg aaa gat ttt Ile Pro Leu Asp Phe Ser Ser Leu Gly Ile Ile Val Lys Asp Phe 60 65 70	304
gag aca att gga caa aat aaa tta att ggc acg gcg act gta gcc ctg Glu Thr Ile Gly Gln Asn Lys Leu Ile Gly Thr Ala Thr Val Ala Leu 75 80 85	<b>'352</b>
aag gac ctg act ggt gac cag agc aga tcc ctg ccg tac aag ctg atc Lys Asp Leu Thr Gly Asp Gln Ser Arg Ser Leu Pro Tyr Lys Leu Ile 90 95 100	<b>400</b>
tcc ctg cta aat gaa aaa ggg caa gat act ggg gcc acc att gac ttg Ser Leu Leu Asn Glu Lys Gly Gln Asp Thr Gly Ala Thr Ile Asp Leu 105 110 115 120	448
gtg atc ggc tat gat ccg cct tct gct cca cat cca aat gac ctg agc Val Ile Gly Tyr Asp Pro Pro Ser Ala Pro His Pro Asn Asp Leu Ser 125 130 135	496
ggg ccc agc gtg cca ggc atg gga gga gat ggg gaa gaa gat gaa ggt Gly Pro Ser Val Pro Gly Met Gly Gly Asp Gly Glu Glu Asp Glu Gly 140 145 150	544
gat gaa gac agg ttg gac aat gca gtc agg ggc cct ggg ccc aag ggg Asp Glu Asp Arg Leu Asp Asn Ala Val Arg Gly Pro Gly Pro Lys Gly 155 160 165	592
cca gtt ggg acg gtg tcg gaa gct cag ctt gct cgg agg ctc acc aaa Pro Val Gly Thr Val Ser Glu Ala Gln Leu Ala Arg Arg Leu Thr Lys 170 175 180	640
gta aag aac agc cgg cgg atg ctg tca aat aag cca cag gac ttc cag Val Lys Asn Ser Arg Arg Met Leu Ser Asn Lys Pro Gln Asp Phe Gln 185 190 195 200	688
atc cgc gtc cga gtg att gag ggc cga cag tta agt ggt aac aac ata Ile Arg Val Arg Val Ile Glu Gly Arg Gln Leu Ser Gly Asn Asn Ile 205 210 215	736
agg cct gtg gtc aaa gtt cac gtc tgt ggc cag aca cac cga aca aga Arg Pro Val Val Lys Val His Val Cys Gly Gln Thr His Arg Thr Arg 220 225 230	784
atc aag aga gga aac aac cot tit tit gat gag tig tit tic tac aat	832

WO 2004/070002 PCT/US2003/037143

Ile	Lys	Arg 235	Gly	Asn	Asn	Pro	Phe 240	Phe	Asp "	Glu -	Leu	Phe : 245	Phe	Tyr	Asn	
	aac Asn 250															. 880
	tat Tyr															928
	att īle															976
	aag Lys															1024
	ggt Gly															1072
	cct Pro 330	Pro										ĄzĄ				1120
	aat Asn					Ala										1168
	rctg Leu				Arg					Pro					Ala	1216
				Val					Gly					Lys	aaa Lys	1264
			Asp			· Val		Val			Ala		y . Tys		gtt Val	1312
tg:	t aca s Thr 410	Asn	ata Ile	att Ile	gag Glu	aaa Lys 415	Asr	gca Ala	aac Asn	e cca	gag Glu 420	ı Trç	aat Asr	caç Glr	g gtc n Val	1360
	l Ası					Phe					Gli				a cta s Leu 440	1408
	•															
ac Th	a ata	a tat	gac Asp	tgg Trp 445	Ası	e egt Arg	ctt Lev	act Thr	aaa Lys 450	s Asr	ga4 n As	t gta p Val	a gta L Val	gg L Gl; 45	a aca y Thr 5	1456
Th	a ata	Tyr	Asp	445 ctc	Asp tet	Arg	Let ati	Thr gct	Lys 450 gco Ala	Asr ) c tot	a Asi	p Val	l Val	45 45 a gt	y Thr	1456 1504

۲.		•	4.75					400					403			•	
	gga Gly	gaa Glu 490	aca Thr	gag Glu	gta Val	ggc Gly	ttt Phe 495	gtt Val	cca Pro	acg Thr	ttt Phe	gga Gly 500	ect Pro	tgt Cys	tac Tyr	ctg Leu	1600
•	aat Asn 505	Leu	tat Tyr	gga Gly	agc Ser	ccc Pro 510	agg Arg	gag Glu	tac Tyr	acg Thr	gga Gly 515	ttc Phe	<i>c</i> ca Pro	gac Asp	ecc Pro	tat Tyr 520	1648
	gat Asp	gag Glu	ctg Leu	Asn	act Thr '525	gga Gly	aag Lys	Gly ggg	gaa Glu	gga Gly 530	gtt Val	gcc Ala	tac Tyr	aga Arg	ggc Gly 535	agg <b>Ar</b> g	1696
									ctt Leu 545								1744
									gac Asp								1792
	cag Gln	cga Arg 570	agg Arg	.cgg Arg	aag Lys	tac Tyr	agc Ser 575	ctg Leu	tct Ser	gcc Ala	gŁg Val	ttt Phe 580	cat His	tca Ser	gcc Ala	acc Thr	1840
	atg Met 585	Leu	caa Gln	gat Asp	gtt Val	ggt Gly 590	Glu	gcc Ala	att Ile	cag Gln	ttt Phe 595	Glu	gtc Val	agc Ser	att Ile	600 61Å 888	1888
	aac Asn	tat Tyr	ggc	aac Asn	aag Lys 605	ttt Phe	gac Asp	acc	acc Thr	tgt Cys 610	Lys	ect Pro	ttg Leu	gca Ala	tca Ser 615	Thr	<b>1936</b> .
					Arg					Gly					Tyr	ttg Leu	1984
				His					Val					Туг		gag Glu	2032
	gat Asp	att Ile 650	Sex	cat His	cgc Arg	ctg Lev	gat Asp 655	Ala	g gtg a Val	aac Asr	act Thi	Lev 660	ı Lev	gct Ala	atg Met	gca : Ala	<b>-2080</b>
	G1u 665	Arg	, Lev	Glr	Thi	670	ı Ile	e Glı	ı Ala	. Lei	675	s Sei	Gl)	/ Ile	∋ Glr	ggt Gly 680	2128
	aaa Lys	att Ile	e ect	gca Ala	a aac a Ası 689	ı Glı	g ctg n Len	g gci 1 Ala	t gaa a Glu	tto Lei 690	ı Txy	g cto o Lei	ı Ly:	g cto	g ata u Ila 699	a gat e Asp	2176
	Glu	' Val	l Ile	700	Asp O	Thi	r Arq	TY:	r Thi 705	Let	ı Pro	o Lei	u Thi	710	u Gly O	a aaa y <b>Ly</b> s	2224
	gcc Ala	aak Ası	gto 1 Va: 71	l Thi	a gti r Vai	t cto	c gai u Asj	t ac p Th 72	r Gli	g ate	e Ar	a aag g Ly:	g cto s Leo 72	u Ar	g too g Se:	c agg r Arg	2272

											٠.						0200
	Ser	ccc Leu 730	tcc Ser	caa Gln	ata Ile	cat His	gag Glu 735	gcg Ala	gct Ala	gtg Val	agg Axg	atg Met 740	agg Arg	tcg Ser •	gaa Glu	gcc Ala	2320
	aca Thr 745	gat Asp	gtg Val	aag Lys	tcc Ser	aca Thr 750	ctg Leu	gca Ala	gaa Glu	att Ile	gag Glu 755	gac Asp	tgg Trp	ctt Leu	gat Asp	aaa Lys 760	2368
•	tta Leu	atg Met	cag Gln	ctg Leu	act Thr 765	gaa Glu	gag Glu	cca Pro	cag Gln	aac Asn 770	agc Ser	atg Met	cct Pro	gac Asp	atc Ile 775	atc Ile	2416
	atc Ile	tgg Trp	atg Met	atc Ile 780	cgg Arg	gga Gly	gag Glu	aag Lys	aga Arg 785	ctg Leu	gcc Ala	tat Tyr	gca Ala	cga Arg 790	att Ile	ccc Pro	2464
	gca Ala	cat His	cag Gln 795	gtc Val	ttg Leu	tac Tyr	tcc Ser	acc Thr 800	agt Ser	ggt Gly	gag Glu	aat Asn	gca Ala 805	tct Ser	gga Gly	aaa Lys	2512
	tac Tyr	tgt Cys 810	GJA aaa	aaa Lys	acc Thr	caa Gln	acc Thr 815	atc Ile	ttt Phe	ctg Leu	aag Lys	tat Tyr 820	Pro	cag Gln	gag Glu	aaa Lys	2560
	aac Asn 825	Asn	GJA aaa	cca Pro	aag Lys	gtg Val 830	Pro	gtg Val	gag Glu	ttg Leu	cga Arg 835	Val	aac Asn	atc Ile	tgg	cta Leu 840	2608
	Gly	tta Leu	agt Ser	gct Ala	gtg Val 845	Glu	aag Lys	aag Lys	ttt Phe	aac Asn 850	Ser	tto Phe	gca Ala	gaa Glu	gga Gly 855	Thr	2656
	ttc Phe	acc	gto Val	ttt L Phe 860	. Ala	gaa Glu	atg Met	tat Tyr	gaa Glu 865	Asn	cas Glr	gct Ala	ctc Leu	atg Met 870	Phe	gga Gly	2704
	aaa Lys	tgg Trp	gg: Gl; 87!	y Thi	tct Ser	gga Gly	tta Lev	gta Val	L G17	a cgt y Arg	cat His	aag Lys	Phe 885	Ser	gat As <u>r</u>	gtc Val	2752
	aca Thr	gga Gl <sub>2</sub> 890	Ly	a ata s Ile	a aaa e Lys	tete Lev	aag Lys 895	Arg	g gaa g Glu	a ttt 1 Phe	tti Phe	cto Lev 900	1 Pro	r cca	aaa Ly:	a ggc s Gly	2800
	tgg Trg 905	Glu	tg Tr	g gaa p Gl	a gga u Gly	a gaq Y Glv 910	ı Tr	g ata	- a gt: e Va:	t gad l Asy	Pro 91	o Gli	a aga u Arq	ago g Sei	Lei	g ctg u Leu 920	2848
	act Thi	gag Gli	g gc u Al	a ga a As	t gca p Ala 92	a Gl	t cae	c ac	g gag r Gl	g tto u Pho 930	e Th	t ga r As	t gaa p Glu	a gto ı Val	ta: L Ty: 93:	t cag r Gln 5	2896
	aa As:	c ga a Gl	g ag u Se	c cg r Ar 94	g Ty	c .cc r Pr	c gg o Gl	λ <b>C</b> J a aæ	c ga y As; 94	p Tr	g aa p Ly	g cc s Pr	g gc	gaç a Glu 950	ı As	c acc p Thr	2944
	ta Ty:	c ac r Th	g ga r As 95	p Al	g aa a As	c gg n Gl	c ga y As	t aa p Ly 96	s Al	a gc a Al	a tc a Se	a cc r Pr	c age o Se: 96	r Gl	g tt u <b>L</b> e	g act u Thr	2992



Cys	ect Pro 970	.cca Pro	ggt Gly	tgg g Trp G	lu T	gg ga rp Gi 75	aa g lu A	at ga sp A	at gca sp Ala	a tgg a Trj 989	p Se	t ta r Ty	t ga r As	c ata p Ile	30.40	
aat Asn 985	cga Arg	gcg Ala	gtg Val		gag a Slu L 190	aa g	gc t ly T	rp G	aa ta lu Ty: 99	r G1;	a at y Il	c ac e Th	c at r Il	t cct e Pro 1000	3088	
cct Pro	gat Asp	cat His	aag Lys	occ Pro 1005	aaa Lys	tcc Ser	tgg Trp	Val	gca Ala 1010	gca Ala	gag Glu	aaa Lys	atg Met	tac Tyr 1015	3133	
cac His	act Thr	cat His	aga Arg	cgg Arg 1020	.cga Arg	agg Arg	ctg Leu	Val	cga Arg 1025	aaa Lys	cgc A <b>rg</b>	aag Lys	aaa Lys	gat Asp 1030	3178	
tta Leu	aca Thr	cag Gln	act Thr	gċt Ala 1035	tca Ser	agc Ser	acc Thr	Ala	agg Arg 1040	gcc Ala	atg Met	gag Glu	gaa Glu	ttg Leu 1045	3223	
caa Gln	gac Asp	caa Gln	gag Glu	ggc Gly 1050	tgg Trp	gaa Glu	tat Tyr	gct Ala	tct Ser 1055	cta Leu	att Ile	Gly ggc	tgg Trp	aaa Lys 1060	3268	
ttt Phe	cac His	tgg Trp	aaa Lys	caa Gln 1065	cgt Arg	agt Ser	tca Ser	gat Asp	acc Thr 1070	ttc Phe	cgc Arg	cgc Arg	aga Arg	cgc Arg 1075	3313	
				atg Met 1080	Ala										3358	
atc Ile	ttt Phe	aaa Lys	ctt Leu	gaa Glu 1095	Gly	gcc Ala	ctt Leu	Gly	gca Ala 1100	gac Asp	act Thr	acc Thr	gaa Glu	gat Asp 1105	3403	
GJA aaa	gat Asp	gag Glu	aag Lys	agc Ser 1110	Leu	gag Glu	aaa Lys	cag Gln	aag Lys 1115	cac His	agt Ser	gcc Ala	acc Thr	act Thr 1120	3448	
gtg Val	tto Phe	gga Gly	gca Ala	aac Asn 1125	Thr	-ccc Pro	att Ile	gtt Val	tcc Ser 1130	Cys	aat Asn	ttt Phe	gac Asp	aga Arg 1135	3493	
gto Val	tac Tyr	ato : Ile	tac Tyr	cat His 1140	Leu	cgc Arg	tgc Cys	tat Tyr	gtc Val 1145	Tyr	-Caa Gln	gcc Ala	aga Arg	aac Asn 1150	3538 :	
cto Lev	ttg Lei	g gct 1 Ala	tta Lei	a gat 1 Asp 1155	Lys	gat Asp	agc Ser	ttt Phe	tca Ser 1160	Asp	cca Pro	tat Tyr	gct Ala	cat His 1165	3583	
ato Ile	c tg( e Cy:	t tto s Phe	c cto e Leu	cat His 1170	Arg	agc Ser	aaa Lys	acc Thr	act Thr 1175	Glu	ato Ile	ato : Ile	cat His	tca Ser 1180	<b>3628</b> 	
Thi	r Lei	u Ası	n Pro	acg Thr 1189	Trp	Asp	Gln	Thr	11e 1190	Ile	Ph∈	e Asp	Glu	1195	3673	
gaa	a at	c tai	t ggg	g gaa	CCC	caa	aca	gtt	cta	-cag	aat	CCE	cc	aaa.	3718	į

									•	_		•		<b>D</b>	T	
	Glü		Tyr	Gly	Glu 1200	₽ro ⁴	Gln	Thr	Val	Leu 1205	GIn	ASN	PEO	5±0	1210	
	gtt Val	atc Ile	atg Met	gaa Glu	ctt Leu 1215	Phe	gac Asp	aat Asn	gac Asp	caa Gln 1220	Val	ggc Gly	aaa Lys	gat Asp	gaa Glu 1225	3763
	ttt Phe	tta Leu	gga Gly	.cga Arg	agc Ser 1230	Ile	ttc Phe	tct Ser	cct Pro	gtg Val 1235	Val	aaa Lys	ctg Leu	aac Asn	cca Ser 1240	3808
•	gaa Gl¦u	atg Met	gac	atc Ile	e aca Thr 1245	Pro	aaa Lys	ctt Leu	ctc Leu	tgg Trp 1250	His	cca Pro	gta Val	atg Met	aat Asn 1255	3853
	gga Gly	gac Asp	aaa Lys	gcc Ala	tgc Cys 1260	Gly	gat Asp	gtt Val	ctt Leu	gta Val 1265	Thr	gca Ala	gag Glu	ctg Lev	att Ile 1270	3898
	ctg Leu	agg Arg	Gly	aag Lys	g gat s Asp 1279	Gly	Ser	aac Asn	ctt Leu	ecc Pro 1280	116	ctt Lev	ecc Pro	ect Pro	caa Gln 1285	3943
	agg Arg	gcg Ala	Pro	a aat	t cta n Leu 129	Tyr	atg Met	gtc : Val	ecc Pro	cag Gln 129	G13	g ato 7 Ile	agg Arg	g ect	gtg Val 1300	3988
	gtc Val	caç Glr	g cto 1 Le	cac uTh	t gcc r Ala 130	Ile	gag Glu	g att	cta Lev	gct Ala 131	Tr	o Gli	c tta y Lem	a ag	a aat g Asn 1315	4033
	atç Met	g aas Lys	a aa s As	c tt n Ph	c cag e Gln 132	Met	g gc	t tct a Sei	t ato	c aca e Thr 132	Se	c cc r Pr	c ag o Se	t ct r Le	t gtt u Val 1330	4078
	gtç Val	g ga l Gl	g tg u Cy	t gg s Gl	a gga y Gly 133	Gli	a ag	g gte g Va	g gaa	a tcg u Ser 134	· va	g gt l Va	g at 1 Il	c aa e Ly	a aac s Asn 1345	4123
	ct: Le:	t aa u Ly	g aa s Ly	rs Th	a ccc ar Pro 135	) Ası	n Ph	e Pr	o Se	r Ser	. Va	t ct l Le	c tt u Ph	c at e Me	g aaa t Lys 1360	4168
	gt Va	g tt l Ph	c tt e Le	g co eu Pi	cc aag co Lys	s Gl	g ga u Gl	a tt .u Le	g ta u Ty	c ato r Mei 13	e Pi	ec co	a ct	g gt	g atc al Ile 1375	4213
	aa Ly	g gt s Va	c at	cc ga le A	ac cae sp Hi:	s Ar	g Ca	ag tt In Ph	t gg ie Gl	g cgg ly Arg 13	a T7	ag co ys Pa	ct gt co Va	c ga al Va	te ggc al Gly 1390	<b>4258</b>
	<b>c</b> a Gl	g to n Cy	jc ad /s T	oc a hr I	tc ga le Gl	u Ar	g Le	tg ga eu As	ac co	gc tt rg Ph 14	e A	gc to	gt ga ys A	ec c sp P	ct tat ro Tyr 1409	<b>4303</b> 5
	gc Al	a gg la Gl	gg a Ly L	aa g ys G	lu As	c at p II 10	c gi le Vi	tc co al Pi	ca ca ro Gi	In Le	c a u L 15	aa g ys A	cc to la S	cc c er L	tt ctg eu Leu 142	
	to Se	et go	cc c la P	ca c	ca tg ro Cy	c co	gg ga	ac a sp I	tc g	tt at al Il	.c g .e .G	aa a lu M	tg g et G	aa g lu A	ac acc sp Thr	4393

1425	14	130	1435
	Leu Thr Gl	na aag gag gaa ga .u Lys Glu Glu Gl 145	
	Tyr Ala Se	cc tca ggg gaa ca er Ser Gly Glu Hi 160	
 _	Lys Gly Ty	at toc aag ctc aa yr Ser Lys Leu Ly 175	<u> </u>
	Val Ala Gl	aa ttt gag ggc c lu Phe Glu Gly Le 190	
	Leu Tyr Ar	ga ggc aag tcg ga rg Gly Lys Ser As 505	
	Gly Glu Ph	tt aag ggc tcc to he Lys Gly Ser Pl 520	
	Pro Ser Va	tg cca gcc cct c al Pro Ala Pro P 535	
 _	Ser Val Pa	ca cag gaa tgc a ro Gln Glu Cys T 550	
	Leu Glu Le	tc cag ccc cag g eu Gln Pro Gln A 565	
	Ile Lys I	ta aca ctg ggc a le Thr Leu Gly L 580	
 	Tyr Ile P	cc aac act ctc a ro Asn Thr Leu A 595	
 	Leu Ser C	gc tac tta cct c ys Tyr Leu Pro G 610	
	Tyr Asp T	at gac acc ttt a yr Asp Thr Phe T 625	
	Ile Ile A	at ctg gaa aac c sp Leu Glu Asn A 640	
	Cys Gly I	ta cca gag gag t le Pro Glu Glu T 655	

. ;

gtt : Val	tct Ser	gga Gly	gt. Va	l A	at .sn 665	acc Thr	tgg Txp	cga Arg	gat Asp	-caa Gln 1670	ctg Leu	aga Arg	cca Pro	aca Thr	cag Gln 1675	5113
ctg Leu	ctt Leu	caa Gln	aa As	n V	tc al .680	gcc Ala	aga Arg	ttc Phe	aaa Lys	ggc Gly 1685	Phe	cca Pro	caa Gln	Pro	atc Ile 1690	5158
ctt Leu	tcc Ser	gaa Glu	ga As	p G	199 195 1695	agt Ser	aga Arg	atc Ile	aga Arg	tat Tyr 1700	GJA	gga Gly	cga Arg	gac Asp	tac Tyr 1705	5203
agc Ser	ttg Leu	gat Asp	ga Gl	.u I	tt Phe 1710	gaa Glu	gcc Ala	aac Asn	aaa Lys	atc Ile 1715	Leu	cac	cag Gln	cac His	ctc Leu 1720	5248
.GJA aaa	gcc Ala	ect	ga G]	lu (	gag Glu 1725	cgg Arg	ctt Leu	gct Ala	ctt Leu	cac His 1730	Ile	ctc Leu	agg Arg	act Thr	cag Gln 1735	5293 '
ggg ggg	ctg Lev	gto Va	c co L Pi	ro (	gag Glu 1740	cac His	gtg Val	gaa Glu	aca Thr	agg Arg 1749	Thr	ttg Leu	cac His	agc Ser	acc Thr 1750	~5338
£tc Phe	cag Glr	r CC	c aa	sn	att Ile 1755	tec Ser	cag Gln	gga Gly	aaa Lys	ctt Leu 176	Glr	atg Met	tgg Tr	g gtg Val	gat Asp 1765	5383
gtt Val	tto Phe	e ec	c a o L	ys `	agt Ser 1770	Leu	G17 . aaa	r eca	a -cca Pro	a ggc o Gly 177	Pro	ect Pro	tto Phe	c aac e Ası	atc 11e 1780	5428
aca Thr	ecc Pro	c cg	g a g L	aa ys	gcc Ala 1785	Lys	aaa Ly:	a tac	c tac r Ty:	c ctg r Leu 179	Ar	t gtg g Vai	g ato	c ato e Ilo	e tgg e Trp 1795	5473
aac Asr	ace Th	c aa r Ly	gg	ac	gtt Val 1800	Ile	tt:	g ga u As	c ga p Gl	g aaa u Lys 180	Se	c ater Ile	c ac e Th	a gg r Gl	a gag y Glu 1810	*5518
gaa Glu	a at 1 Me	g ag t Se	jt g	ysb Igc	atc Ile 1815	Ty	c gt r Va	c aa 1 Ly	a gg s Gl	c tgg y Tri 182	ı Il	t cc e Pr	t gg o Gl	c aa y As	t gaa n Glu 1825	5563
gaa Gl	a aa u As	c as n Ly	aa ( /s (	cag Sln	aaa Lys 183	Th	a ga r As	t gt p Va	c ca 1 Hi	t tac is Tyr 183	: Ar	a to g Se	t tt er Le	g ga eu As	t ggt p Gly 1840	<b>5608</b> . ,
gaa	a gg u Gl	g aa .y As	at (	ttt Phe	aac Asn 184	Tr	g cg p Ar	a tt g Ph	et gt ne Va	t tte al Pho 18	e Pa	g tt o Ph	t ga ne As	ic ta sp Ty	c ctt r Leu 1855	5 <b>65</b> 3
.cc Pr	a go o Al	c g la G	aa 4 lu 7	caa Gln	ctc Leu 186	Су	t at	c gt Le Va	et go	cg aa la Ly 18	s Ły	aa ga /s Gl	ag ca Lu Hi	at ti is Pl	c tgg ne Trp 1870	5698
ag Se	t at	t g le A	ac . sp :	caa Gln	acg Thr 187	G1	a ti u Pl	et co	ga a rg I	tc cc le Pr 18	o Pi	cc ag	gg c	tg at eu I	c att le Ile 1889	<b>5743</b>

Ţ				-										_		
ca G1	g a n l	ica [le	tgg Trp	gac Asp	aat Asn 1890	gac Asp	aag Lys	ttt Phe	tct Ser	ctg Leu 1895	gat Asp	gac Asp	tac Tyr	ttg Leu	ggt Gly 1900	57 <del>8</del> 8
196	٠,	rta	gaa Glu	ctt Leu	gac Asp 1905	ttg Leu	cgt Arg	cac His	acg Thr	atc Ile 1910	att Ile	ect Pro	gca Ala	aaa Lys		5833
CC Pi	ca ro	gag Glu	aaa Lys	tgc •Cys	agg Arg 1920	ttg Leu	gac Asp	atg Met	att Ile	ccg Pro 1925	gac Asp	ctc Leu	aaa Lys	gcc Ala	atg Met 1930	5878
a: A:	ac sn	ccc Pro	ctt Leu	aaa Lys	gcc Ala 1935	Lys	aca Thr	gcc Ala	tcc Ser	ctc Leu 1940	Phe	gag Glu	-cag Gln	aag Lys	tcc Ser 1945	5923
a M	tg et	aaa Lys	gga Gly	tgg Trp	tgg Trp 1950	Pro	tgc Cys	tac Tyr	gca Ala	gag Glu 1955	Lys	gat Asp	Gly	gcc Ala	cgc Arg 1960	5968
g V	ta al	atg Met	gct Ala	ggg	aaa Lys 1965	Val	gag Glu	atg Met	aca Thr	ttg Leu 1970	Glu	atc Ile	cto Lev	aac Asn	gag Glu 1975	6013
a	ag ys	gag Glu	gcc	gac Asp	gag Glu 1980	Arc	rca Pro	gec Ala	Gly	aag Lys 1989	Gly	g cgg	gad J Asj	gaa Glu	ecc Pro 1990	6058
F	ac Asn	atç Met	aac : Ası	c ccc	aag Lys 1995	Let	g gac ı Asp	tta Leu	eca Pro	a aat o Asn 2000	Arg	a ccá g Pro	a gaa	a acc	tcc Ser 2005	6103
ţ	ttc Phe	cto	tgg 1 Tæj	g tto p Pho	acc Thr 2010	Ası	c cca	tgo Cys	aaq Ly:	g acc s Thr 201	Me	g aaq t Lyn	g tt s Ph	c ato e Ilo	c gtg e Val 2020	6148
1	tgg Trp	CG(	c cg g Ar	c tt g Ph	t aag e Lys 202	Tr	g gte p Va	c ato	e ate	c ggc e Gly 203	Le.	g ct u Le	g tt u Ph	c ct e Le	g ctt u Leu 2035	<sup>6</sup> 193
•	ato Ile	ct: Le	g ct u Le	g ct u Le	c ttc u Phe 204	٧a	g gc	c gtg a Vai	g ct l Le	c ctc u Leu 204	Ty	c tc r Se	t tt r Le	g cc u Pr	g aac o Asn 2050	6238
					g aag t Lys 205	Il	t gt e Va	a aag l Ly	g .cc s Pr	a aat o Asn 206	. Va	g ta 1	a -ca	aagg	caaa	6284
	ggo	ttc	attt	caa	.gagtc	at c	cago	aatg	a ga	gaato	ctg	ccto	tgta	aga «	caacatcca	6344
	gto	jtga	ttt	gtg	tctga	ga c	caca	cccc	a gt	agcag	gtt	acgo	cat	gtc a	ccgagcccc	6404
	ati	tgat	tece	aga:	gggtc	ett a	igtee	tgga	a ag	rtcagg	jeca	acaa	igca	acg t	ttgcatcat:	6464
	gt	tato	tctt	aag	jtatta	aa a	igttt	tatt	t to	taaag	g <b>tt</b> t	aaat	cat	gtt 1	ttcaaaata	6524
	tt	ttt	aagg	g tgg	ctggt	tc «	attt	aaaa	a to	catct	tttt	atal	tgŁg	tct 1	ecggttctag	6584
															gaggtgatat	6644 :
	ac	ttca	atat	t tgl	taatca	aac 4	tgaaa	agago	t g	tgcat	tata	.aàa	tcag	tta (	gaatagttag	670 <u>4</u>

aacaattett atttatgeee acaaceattg etatattttg tatggatgte ataaaagtet 6764
atttaacete tgtaatgaaa etaaataaaa atgttteace tttaaaaaaa aaaaaaaaaa 6824
aaaaa

<210> 232

(<211> 2061

<212> PRT

<213> HOMO SAPIENS

<400> 232

Met Leu Arg Val Ile Val Glu Ser Ala Ser Asn Ile Pro Lys Thr Lys
1 5 10 15

Phe Gly Lys Pro Asp Pro Ile Val Ser Val Ile Phe Lys Asp Glu Lys 20 25 30

Lys Lys Thr Lys Lys Val Asp Asn Glu Leu Asn Pro Val Trp Asn Glu 35 40 45

Ile Leu Glu Phe Asp Leu Arg Gly Ile Pro Leu Asp Phe Ser Ser Ser 50 55 60

Leu Gly Ile Ile Val Lys Asp Phe Glu Thr Ile Gly Gln Asn Lys Leu 65 70 75 80

Ile Gly Thr Ala Thr Val Ala Leu Lys Asp Leu Thr Gly Asp Gln Ser 85 90 95

Arg Ser Leu Pro Tyr Lys Leu Ile Ser Leu Leu Asn Glu Lys Gly Gln 100 105 110

Asp Thr Gly Ala Thr Ile Asp Leu Val Ile Gly Tyr Asp Pro Pro Ser 115 120 125

Ala Pro His Pro Asn Asp Leu Ser Gly Pro Ser Val Pro Gly Met Gly
130 135 140

Gly Asp Gly Glu Glu Asp Glu Gly Asp Glu Asp Arg Leu Asp Asn Ala 145 150 155 160

Val Arg Gly Pro Gly Pro Lys Gly Pro Val Gly Thr Val Ser Glu Ala 165 170 175

Gln Leu Ala Arg Arg Leu Thr Lys Val Lys Asn Ser Arg Arg Met Leu 180 185 190

Ç

∢.

Ser Asn Lys Pro Gln Asp Phe Gln Ile Arg Val Arg Val Ile Glu Gly 195 200 205

Arg Gln Leu Ser Gly Asn Asn Ile Arg Pro Val Val Lys Val His Val 210 225 220

Cys Gly Gln Thr His Arg Thr Arg Ile Lys Arg Gly Asn Asn Pro Phe 225 230 235 240

Phe Asp Glu Leu Phe Phe Tyr Asn Val Asn Met Thr Pro Ser Glu Leu 245 250 255

Met Asp Glu Ile Ile Ser Ile Arg Val Tyr Asn Ser His Ser Leu Arg 260 265 270

Ala Asp Cys Leu Met Gly Glu Phe Lys Ile Asp Val Gly Phe Val Tyr 275 280 285

Asp Glu Pro Gly His Ala Val Met Arg Lys Trp Leu Leu Leu Asn Asp 290 295 300

Pro Glu Asp Thr Ser Ser Gly Ser Lys Gly Tyr Met Lys Val Ser Met 305 310 315 320

Phe Val Leu Gly Thr Gly Asp Glu Pro Pro Pro Glu Arg Arg Asp Arg 325 330 335

Asp Asn Asp Ser Asp Asp Val Glu Ser Asn Leu Leu Leu Pro Ala Gly 340 345 350

Ile Ala Leu Arg Trp Val Thr Phe Leu Leu Lys Ile Tyr Arg Ala Glu 355 360 365

Asp Ile Pro Gln Met Asp Asp Ala Phe Ser Gln Thr Val Lys Glu Ile 370 375 380

Phe Gly Gly Asn Ala Asp Lys Lys Asn Leu Val Asp Pro Phe Val Glu

Val Ser Phe Ala Gly Lys Lys Val Cys Thr Asn Ile Ile Glu Lys Asn 405 410 415

Ala Asn Pro Glu Trp Asn Gln Val Val Asn Leu Gln Ile Lys Phe Pro 420 425 430

Ser Val Cys Glu Lys Ile Lys Leu Thr Ile Tyr Asp Trp Asp Arg Leu 435 440 445

Thr Lys Asn Asp Val Val Gly Thr Thr Tyr Leu His Leu Ser Lys Ile 450 455 460

Ala Ala Ser Gly Gly Glu Val Glu Asp Phe Ser Ser Ser Gly Thr Gly 465 470 475 480

Ala Ala Ser Tyr Thr Val Asn Thr Gly Glu Thr Glu Val Gly Phe Val
485 490 495

Pro Thr Phe Gly Pro Cys Tyr Leu Asn Leu Tyr Gly Ser Pro Arg Glu 500 505 510

Tyr Thr Gly Phe Pro Asp Pro Tyr Asp Glu Leu Asn Thr Gly Lys Gly 515 520 525

Glu Gly Val Ala Tyr Arg Gly Arg Ile Leu Val Glu Leu Ala Thr Phe 530 535 540

Leu Glu Lys Thr Pro Pro Asp Lys Leu Glu Pro Ile Ser Asn Asp 545 550 555 560

Asp Leu Leu Val Val Glu Lys Tyr Gln Arg Arg Arg Lys Tyr Ser Leu 565 570 575

Ser Ala Val Phe His Ser Ala Thr Met Leu Gln Asp Val Gly Glu Ala 580 585 590

The Gln Phe Glu Val Ser Ile Gly Asn Tyr Gly Asn Lys Phe Asp Thr 595 600 605

Thr Cys Lys Pro Leu Ala Ser Thr Thr Gln Tyr Ser Arg Ala Val Phe 610 620

Asp Gly Asn Tyr Tyr Tyr Tyr Leu Pro Trp Ala His Thr Lys Pro Val 625 630 635

Val Thr Leu Thr Ser Tyr Trp Glu Asp Ile Ser His Arg Leu Asp Ala 645 650 655

Val Asn Thr Leu Leu Ala Met Ala Glu Arg Leu Gln Thr Asn Ile Glu
560 665 670

Ala Leu Lys Ser Gly Ile Gln Gly Lys Ile Pro Ala Asn Gln Leu Ala

680

685

Glu Leu Trp Leu Lys Leu Ile Asp Glu Val Ile Glu Asp Thr Arg Tyr 690 695 700

Thr Leu Pro Leu Thr Glu Gly Lys Ala Asn Val Thr Val Leu Asp Thr 705 710 715 720

Gln Ile Arg Lys Leu Arg Ser Arg Ser Leu Ser Gln Ile His Glu Ala 725 730 735

Ala Val Arg Met Arg Ser Glu Ala Thr Asp Val Lys Ser Thr Leu Ala
740 745 750

Glu Ile Glu Asp Trp Leu Asp Lys Leu Met Gln Leu Thr Glu Glu Pro
755 760 765

Gln Asn Ser Met Pro Asp Ile Ile Ile Trp Met Ile Arg Gly Glu Lys
770 775 780

Arg Leu Ala Tyr Ala Arg Ile Pro Ala His Gln Val Leu Tyr Ser Thr 785 790 795 800

Ser Gly Glu Asn Ala Ser Gly Lys Tyr Cys Gly Lys Thr Gln Thr Ile 805 810 815

Phe Leu Lys Tyr Pro Gln Glu Lys Asn Asn Gly Pro Lys Val Pro Val 820 825 830

Glu Leu Arg Val Asn Ile Trp Leu Gly Leu Ser Ala Val Glu Lys Lys 835 840 845

Phe Asn Ser Phe Ala Glu Gly Thr Phe Thr Val Phe Ala Glu Met Tyr 850 855 860

Glu Asn Gln Ala Leu Met Phe Gly Lys Trp Gly Thr Ser Gly Leu Val 865 870 875 880


Gly Arg His Lys Phe Ser Asp Val Thr Gly Lys Ile Lys Leu Lys Arg 885 890 895

Glu Phe Phe Leu Pro Pro Lys Gly Trp Glu Trp Glu Gly Glu Trp Ile

Val Asp Pro Glu Arg Ser Leu Leu Thr Glu Ala Asp Ala Gly His Thr 915 920 925

Glu Phe Thr Asp Glu Val Tyr Gln Asn Glu Ser Arg Tyr Pro Gly Gly 930 935 940

- Asp Trp Lys Pro Ala Glu Asp Thr Tyr Thr Asp Ala Asn Gly Asp Lys 945 950 955 960
- Ala Ala Ser Pro Ser Glu Leu Thr Cys Pro Pro Gly Trp Glu Trp Glu 965 970 975
- Asp Asp Ala Trp Ser Tyr Asp Ile Asn Arg Ala Val Asp Glu Lys Gly 980 985 990
- Trp Glu Tyr Gly Ile Thr Ile Pro Pro Asp His Lys Pro Lys Ser Trp 995 1000 1005
- Val Ala Ala Glu Lys Met Tyr His Thr His Arg Arg Arg Arg Leu 1010 1015 1020
- Val Arg Lys Arg Lys Lys Asp Leu Thr Gln Thr Ala Ser Ser Thr 1025 1030 1035
- Ala Arg Ala Met Glu Glu Leu Gln Asp Gln Glu Gly Trp Glu Tyr 1040 1045 1050
- Ala Ser Leu Ile Gly Trp Lys Phe His Trp Lys Gln Arg Ser Ser 1055 1060 1065
- Asp Thr Phe Arg Arg Arg Arg Trp Arg Arg Lys Met Ala Pro Ser 1070 1075 1080
- Glu Thr His Gly Ala Ala Ala Ile Phe Lys Leu Glu Gly Ala Leu 1085 1090 1095
- Gly Ala Asp Thr Thr Glu Asp Gly Asp Glu Lys Ser Leu Glu Lys 1100 1105 1110
- Gln Lys His Ser Ala Thr Thr Val Phe Gly Ala Asn Thr Pro Ile 1115 1120 1125
- Val Ser Cys Asn Phe Asp Arg Val Tyr Ile Tyr His Leu Arg Cys 1130 1135 1140
- Tyr Val Tyr Gln Ala Arg Asn Leu Leu Ala Leu Asp Lys Asp Ser 1145 1150 1155



- Thr Thr Glu Ile Ile His Ser Thr Leu Asn Pro Thr Trp Asp Gln 1175 1180 1185
  - Thr Ile Ile Phe Asp Glu Val Glu Ile Tyr Gly Glu Pro Gln Thr 1190 1195 1200
  - Val Leu Gln Asn Pro Pro Lys Val Ile Met Glu Leu Phe Asp Asn 1205 1210 1215
  - Asp Gln Val Gly Lys Asp Glu Phe Leu Gly Arg Ser Ile Phe Ser 1220 1225 1230
    - Pro Val Val Lys Leu Asn Ser Glu Met Asp Ile Thr Pro Lys Leu 1235 1240 1245
    - Leu Trp His Pro Val Met Asn Gly Asp Lys Ala Cys Gly Asp Val 1250 1255 1260
    - Leu Val Thr Ala Glu Leu Ile Leu Arg Gly Lys Asp Gly Ser Asn 1265 1270 1275
    - Leu Pro Ile Leu Pro Pro Gln Arg Ala Pro Asn Leu Tyr Met Val 1280 1285 1290
    - Pro Gln Gly Ile Arg Pro Val Val Gln Leu Thr Ala Ile Glu Ile 1295 1300 1305
    - Leu Ala Trp Gly Leu Arg Asn Met Lys Asn Phe Gln Met Ala Ser 1310 1315 1320
    - Ile Thr Ser Pro Ser Leu Val Val Glu Cys Gly Gly Glu Arg Val 1325 1330 1335
    - Glu Ser Val Val Ile Lys Asn Leu Lys Lys Thr Pro Asn Phe Pro 1340 1345 1350
    - Ser Ser Val Leu Phe Met Lys Val Phe Leu Pro Lys Glu Glu Leu 1355 1360 1365
    - Tyr Met Pro Pro Leu Val Ile Lys Val Ile Asp His Arg Gln Phe 1370 1375 1380
    - Gly Arg Lys Pro Val Val Gly Gln Cys Thr Ile Glu Arg Leu Asp


1385

DAIGNOCKE JAMO 200407000242 I S

1390

1395

- Arg Phe Arg Cys Asp Pro Tyr Ala Gly Lys Glu Asp Ile Val Pro 1400 1405 1410
  - Gln Leu Lys Ala Ser Leu Leu Ser Ala Pro Pro Cys Arg Asp Ile 1415 1420 1425
- Val Ile Glu Met Glu Asp Thr Lys Pro Leu Leu Ala Ser Lys Leu 1430 1435 1440
  - Thr Glu Lys Glu Glu Glu Ile Val Asp Trp Trp Ser Lys Phe Tyr 1445 1450 1455
  - Ala Ser Ser Gly Glu His Glu Lys Cys Gly Gln Tyr Ile Gln Lys 1460 1465 1470
  - Gly Tyr Ser Lys Leu Lys Ile Tyr Asn Cys Glu Leu Glu Asn Val 1475 1480 1485
  - Ala Glu Phe Glu Gly Leu Thr Asp Phe Ser Asp Thr Phe Lys Leu 1490 1495 1500
  - Tyr Arg Gly Lys Ser Asp Glu Asn Glu Asp Pro Ser Val Val Gly
  - Glu Phe Lys Gly Ser Phe Arg Ile Tyr Pro Leu Pro Asp Asp Pro 1520 1525 1530
  - Ser Val Pro Ala Pro Pro Arg Gln Phe Arg Glu Leu Pro Asp Ser 1535 1540 1545
  - Val Pro Gin Glu Cys Thr Val Arg Ile Tyr Ile Val Arg Gly Leu 1550 1555 1560
  - Glu Leu Gln Pro Gln Asp Asn Asn Gly Leu Cys Asp Pro Tyr Ile 1565 1570 1575
  - Lys Ile Thr Leu Gly Lys Lys Val Ile Glu Asp Arg Asp His Tyr 1580 1585 1590
  - Ile Pro Asn Thr Leu Asn Pro Val Phe Gly Arg Met Tyr Glu Leu 1595 1600 1605
  - Ser Cys Tyr Leu Pro Gln Glu Lys Asp Leu Lys Ile Ser Val Tyr 1610 1615 1620



- Asp Tyr Asp Thr Phe Thr Arg Asp Glu Lys Val Gly Glu Thr Ile 1625 1630 1635
- Ile Asp Leu Glu Asn Arg Phe Leu Ser Arg Phe Gly Ser His Cys 1640 1645 1650
- Gly Ile Pro Glu Glu Tyr Cys Val Ser Gly Val Asn Thr Trp Arg 1655 1660 1665
- Asp Gln Leu Arg Pro Thr Gln Leu Leu Gln Asn Val Ala Arg Phe 1670 1675 1680
- Lys Gly Phe Pro Gln Pro Ile Leu Ser Glu Asp Gly Ser Arg Ile 1685 1690 1695
- Arg Tyr Gly Gly Arg Asp Tyr Ser Leu Asp Glu Phe Glu Ala Asn 1700 1705 1710
- Lys Ile Leu His Gln His Leu Gly Ala Pro Glu Glu Arg Leu Ala 1715 1720 1725
- Leu His Ile Leu Arg Thr Gln Gly Leu Val Pro Glu His Val Glu 1730 1735 1740
- Thr Arg Thr Leu His Ser Thr Phe Gln Pro Asn Ile Ser Gln Gly 1745 1750 1755
- Lys Leu Gln Met Trp Val Asp Val Phe Pro Lys Ser Leu Gly Pro 1760 1765 1770
- Pro Gly Pro Pro Phe Asn Ile Thr Pro Arg Lys Ala Lys Lys Tyr 1775 1780 1785
- Tyr Leu Arg Val Ile Ile Trp Asn Thr Lys Asp Val Ile Leu Asp 1790 1795 1800
- Glu Lys Ser Ile Thr Gly Glu Glu Met Ser Asp Ile Tyr Val Lys 1805 1810 1815
- Gly Trp Ile Pro Gly Asn Glu Glu Asn Lys Gln Lys Thr Asp Val 1820 1825 1830
- His Tyr Arg Ser Leu Asp Gly Glu Gly Asn Phe Asn Trp Arg Phe 1835 1840 1845
- Val Phe Pro Phe Asp Tyr Leu Pro Ala Glu Gln Leu Cys Ile Val

1850

1855

1860

- Ala Lys Lys Glu His Phe Trp Ser Ile Asp Gln Thr Glu Phe Arg 1865 1870 1875
- Ile Pro Pro Arg Leu Ile Ile Gln Ile Trp Asp Asn Asp Lys Phe 1880 1885 1890
- Ser Leu Asp Asp Tyr Leu Gly Phe Leu Glu Leu Asp Leu Arg His 1895 1900 1905
- Thr Ile Ile Pro Ala Lys Ser Pro Glu Lys Cys Arg Leu Asp Met 1910 1915 1920
- Ile Pro Asp Leu Lys Ala Met Asn Pro Leu Lys Ala Lys Thr Ala 1925 1930 1935
- Ser Leu Phe Glu Gln Lys Ser Met Lys Gly Trp Trp Pro Cys Tyr 1940 1945 1950
- Ala Glu Lys Asp Gly Ala Arg Val Met Ala Gly Lys Val Glu Met 1955 1960 1965
- Thr Leu Glu Ile Leu Asn Glu Lys Glu Ala Asp Glu Arg Pro Ala 1970 1975 1980
- Gly Lys Gly Arg Asp Glu Pro Asn Met Asn Pro Lys Leu Asp Leu 1985 1990 1995
- Pro Asn Arg Pro Glu Thr Ser Phe Leu Trp Phe Thr Asn Pro Cys 2000 2005 2010
- Lys Thr Met Lys Phe Ile Val Trp Arg Arg Phe Lys Trp Val Ile 2015 2020 2025
- Ile Gly Leu Leu Phe Leu Leu Ile Leu Leu Phe Val Ala Val 2030 2035 2040
- Leu Leu Tyr Ser Leu Pro Asn Tyr Leu Ser Met Lys Ile Val Lys 2045 2050 2055

pro Asn Val 2060

<210> 233 <211> 16

..... ....

<212>	TNITA		
	Artificial sequer	200	
	WITTIGTHI Sedner	.ce	
<220>			
<223>	nrimer		
-2237	br mer		
<400>	222		
	caaa cctaca		.6
•	caaa cccaca		.0
1. 2. 1.			
<210>	234		
<211>			
<212>			
	Artificial seque	nce	
1240	increase sodes.		•
<220>	•		
	primer		
	,		
<400>	234		
	tctg gcaagc		L6
-555	,		
	•		•
<210>	235		
<211>			
<212>			
	Artificial seque	nce '	
		•	
<220>			
<223>	primer		
<400>	225		
	ttca atcatgcg		18
		•	18
atctto	rttca atcatgcg		18
atcttg <210>	rttca atcatgcg 236		18
<210><211>	236		18
<210> <211> <212>	236 16 DNA		18
<210> <211> <212>	236	nce	18
<210> <211> <212> <213>	236 16 DNA	nce	18
<210> <211> <212> <213> <220>	ttca atcatgcg  236  16  DNA  Artificial seque	nce	18
<210> <211> <212> <213> <220>	236 16 DNA	nce	18
<210> <211> <212> <213> <223>	236 16 DNA Artificial seque	nce	18
<210> <211> <212> <213> <223> <400>	236 16 DNA Artificial seque primer	nce	
<210> <211> <212> <213> <223> <400>	236 16 DNA Artificial seque	nce	18
<210> <211> <212> <213> <223> <400>	236 16 DNA Artificial seque primer	nce	
<210> <211> <212> <213> <223> <400> gggtc	236 16 DNA Artificial seque primer 236 cgacg ctcatg	nce	
<210> <211> <212> <213> <220> <223> <400> gggtc	236 16 DNA Artificial seque primer 236 Egacg ctcatg	nce	
<210> <211> <212> <213> <220> <223> <400> gggtc <210> <211>	236 16 DNA Artificial seque  primer 236 cgacg ctcatg	nce	
<210> <211> <212> <213> <220> <223> <400> gggtcf <210> <211> <212>	236 16 DNA Artificial seque  primer 236 cgacg ctcatg  237 16 DNA		
<210> <211> <212> <213> <220> <223> <400> gggtcf <210> <211> <212>	236 16 DNA Artificial seque  primer 236 cgacg ctcatg		
<210> <211> <212> <213> <220> <223> <400> gggtcf <210> <211> <212>	236 16 DNA Artificial seque  primer 236 cgacg ctcatg  237 16 DNA Artificial seque		
<pre>&lt;210&gt; &lt;211&gt; &lt;211&gt; &lt;212&gt; &lt;213&gt; &lt;220&gt; &lt;223&gt; &lt;400&gt; gggtcf</pre> <210> <211> <212> <213> <210> <213>	236 16 DNA Artificial seque  primer 236 cgacg ctcatg  237 16 DNA Artificial seque		
<pre>&lt;210&gt; &lt;211&gt; &lt;211&gt; &lt;212&gt; &lt;213&gt; &lt;220&gt; &lt;223&gt; &lt;400&gt; gggtcf &lt;210&gt; &lt;211&gt; &lt;212&gt; &lt;213&gt;</pre>	236 16 DNA Artificial seque  primer 236 cgacg ctcatg  237 16 DNA Artificial seque		
<pre>&lt;210&gt; &lt;211&gt; &lt;211&gt; &lt;212&gt; &lt;213&gt; &lt;220&gt; &lt;223&gt; &lt;400&gt; gggtcf</pre> <210> <211> <212> <213> <210> <213>	236 16 DNA Artificial seque primer 236 cgacg ctcatg  237 16 DNA Artificial seque		
<pre>&lt;210&gt; &lt;211&gt; &lt;212&gt; &lt;213&gt; &lt;223&gt; &lt;400&gt; gggtcf  &lt;210&gt; &lt;211&gt; &lt;212&gt; &lt;213&gt; &lt;400&gt; &lt;210&gt; &lt;211&gt; &lt;212&gt; &lt;213&gt; &lt;400&gt;</pre>	236 16 DNA Artificial seque  primer 236 cgacg ctcatg  237 16 DNA Artificial seque		
<pre>&lt;210&gt; &lt;211&gt; &lt;212&gt; &lt;213&gt; &lt;223&gt; &lt;400&gt; gggtcf  &lt;210&gt; &lt;211&gt; &lt;212&gt; &lt;213&gt; &lt;400&gt; &lt;210&gt; &lt;211&gt; &lt;212&gt; &lt;213&gt; &lt;400&gt;</pre>	236 16 DNA Artificial seque primer 236 cgacg ctcatg  237 16 DNA Artificial seque		16
<pre>&lt;210&gt; &lt;211&gt; &lt;212&gt; &lt;213&gt; &lt;223&gt; &lt;400&gt; gggtcf  &lt;210&gt; &lt;211&gt; &lt;212&gt; &lt;213&gt; &lt;400&gt; &lt;210&gt; &lt;211&gt; &lt;212&gt; &lt;213&gt; &lt;400&gt;</pre>	236 16 DNA Artificial seque  primer 236 cgacg ctcatg  237 16 DNA Artificial seque		16
<pre>&lt;210&gt; &lt;211&gt; &lt;212&gt; &lt;213&gt; &lt;223&gt; &lt;400&gt; gggtcf  &lt;210&gt; &lt;211&gt; &lt;212&gt; &lt;213&gt; &lt;400&gt; &lt;210&gt; &lt;211&gt; &lt;212&gt; &lt;213&gt; &lt;400&gt;</pre>	236 16 DNA Artificial seque  primer 236 cgacg ctcatg  237 16 DNA Artificial seque  primer 237 237 237 237 248 237 237 248 237 237 248 237 248 237 248 248 248 248 258 268 268 268 268 268 268 268 268 268 26		16
<pre>&lt;210&gt; &lt;211&gt; &lt;212&gt; &lt;213&gt; &lt;223&gt; &lt;400&gt; gggtcf &lt;210&gt; &lt;211&gt; &lt;212&gt; &lt;213&gt; &lt;400 gggtcf</pre>	236 16 DNA Artificial seque  primer 236 cgacg ctcatg  237 16 DNA Artificial seque  primer 237 gtgcc tcactg		16
<pre>&lt;210&gt; &lt;211&gt; &lt;212&gt; &lt;213&gt; &lt;223&gt; &lt;400&gt; gggtcf  &lt;210&gt; &lt;211&gt; &lt;212&gt; &lt;213&gt; &lt;400 gggtcf &lt;210&gt; &lt;211&gt; &lt;212&gt; &lt;213&gt; &lt;210&gt; &lt;210&gt; &lt;211&gt; &lt;212&gt; &lt;213&gt; &lt;210&gt; &lt;221&gt; &lt;213&gt; </pre>	236 16 DNA Artificial seque  primer 236 cgacg ctcatg  237 16 DNA Artificial seque  primer 237 gtgcc tcactg		16

WO 200	4/070002		•	PCT/US2003/037143
	Artificial			
<220 <b>&gt;</b>				
	Rab9 siRNA			
,<400>	238			10
gggaag	agtt cacttatga	•		19
•				
-210-	220			
<210> <211>				•
<211>				
<213>	Artificial			
<220>	•			
<b>≮223&gt;</b>	Rab9 siRNA			
. 1				
<400>				19
tcacaa	agct tecagaact	•		19
	,		•	
<210>	240			
<211>				
<212>				
	Artificial			
		·		
<220>				
<223>	Rab9 siRNA			
<400>	240			ŕ
	aagat tgacataag	•		19
gcaac			•	
<210>				
<211>				
<212>				
<213>	Artificial			
<220>				
	Rab9 siRNA			
12001				
	241		•	
ggaag	tggat ggacatttt			19
J010-	242			
<210> <211>		•		
	RNA			
	Artificial Sequence			
	-			
<220>				
<223>	RNAi molecule			
	242			
	· 242 agagcu ggaggauuu			19
gguca	iyaycu yyayyauuu			
	· 243			
<211>				
	RNA			
<213>	> Artificial Sequence			

## WO 2004/070002

:220>				•			
	RNAi molecule						
	10200220						
<400>	243						
	agga gacccguua						19
,							
	•						
<210>	244						
	19			•			
	RNA						
	Artificial Sequence			•			
<220>							
	RNAi molecule			•			
<400>	244					•	
ссаада	agau cuacaaugg						19
	-					•	
							t
<210>	245						
<211>	19	•					
<212>	•						
<213>	Artificial Sequence				•		
1							
<220>							
<223>	RNAi molecule	•					
			•				
<400>	245						
ggaacu	igcau gcugaauga					٠	19
				•			
					•		
<210>							
<211>						•	
<212>							
<213>	Artificial Sequence						
<220>	m.m. 1					,	
<223>	RNAi molecule						
400	0.4.5						
<400>	246						27
uagaco	cugcu cagccuucug gauacuu						21
					_		
<210>	247						
<211>	-						
<212>							
	Artificial Sequence				•		
\Z13/	Metiterar pedacue			•			
<220>							
	RNAi molecule						
-663-	THE MOLCOLLO						
<400>	247						
	cauaa uugaaguggu ugucguu						27
<210>	248						
<211>							
<212>							
	Artificial Compande						

; · · WO,2004/070002	PCT/US2003/037143
., <220> <223> RNAi molecule	
່ ວຸນຽນຽນເວັນເວັນເຂັ້ນຂອນພອນນຽລ ຂອງນອງເນັ້ນ	27
<210> 249	·
<211> 27	
<212> RNA	
<213> Artificial Sequence	
in the	
<220>	
<223> RNAi molecule	
<del>\</del> 400> 249	
cgcugugugu ucuucaugug ugacguu	27
egeagagaga acaacaagag a garaga	
	1
<210> 250 ,	
<211> 27	
<212> RNA	
<213> Artificial Sequence	•
<220>	
<223> RNAi molecule	
	·
<400> 250	
agaccugcuc agccuucugg auacuuu	27
•	
-010> 051	
<210> 251 <211> 27	
<211> 27 <212> RNA	
<213> Artificial Sequence	
<220>	
<223> RNAi molecule	
<400> 251	27
ccucuugaga ucagguuggc agucauu	
<210> 252	
<211> 27	•
<212> RNA	•
<213> Artificial Sequence	·
•	
<220>	
<223> RNAi molecule	
<400> 252	
gaccugcuca gccuucugga uacuuuu	27
<210> 253	
<211> 27	$\cdot$ .
<212> RNA	
<213> Artificial Sequence	
<220>	
<223> RNAi molecule	

wo	2004/070002	

<400> 25 ccgauuuu	53 aa uccucuugcu ucaauuu	27
<210> 29	_	
<211> 2' <212> RI		
	rtificial Sequence	
	- · · · · · · · · · · · · · · · · · · ·	
<220>	NAi molecule	
<223> R	NAI MOIECUIE	
	54	27
uccgauuu	ua auecucuuge uucaauu	2,
<210> 2		
<212> P		ı.
<213> A	Artificial Sequence	
<b>&lt;220&gt;</b>		
	RNAi molecule	
<400>	255	27
cagauca	uga aucgacucaa accucuu	
04.0		
<210>		
<211>		
<212>	RNA Artificial Sequence	
<b>~213</b> × .	Wittercraft podecines	
<220>		
<223>	RNAi molecule	
<400>	256	27
accugcu	cag ccuucuggau acuuuuu	21
<210> <211>	257 27	
<211> <212>	RNA	
<213>	Artificial Sequence	
<220>		
	RNAi molecule	
	,	
<400>	257	-27
agaucu	uuuc caccgcugug uguucuu	
<210>		
<211>		
<212>	RNA	
<213>	Artificial Sequence	
<220>		
<223>	RNAi molecule	

WO 200	4/070002			PCT/US2003/0371	143
	777002			101/002	
	258				27
guguug	ugag gucacaacag uacacuu				21
<210> <211>					
<212>					
<213>	Artificial Sequence				
<220>			•		
	RNAi molecule				
<400>	259				
	ccga uuuuaauccu cuugcuu		•		27
<210>	260				
<211>				•	
<212>	RNA Artificial Sequence				•
. ~213/	Artificial bequence	•			
<220>				•	
<223>	RNAi molecule		•		
<400>					
gcagcu	uuug uuucuaugua caguguu	•			27
<210>					
<211> <212>			•		
	Artificial Sequence				
<220> <223>	RNAi molecule				
<400>	261				27
auaya	cauug gcagauauau cggccuu				
<210>	262				
<211>					
<212>	RNA				
<213>	Artificial Sequence				
<220>					
<223>	RNAi molecule				
<400>	262				
	guguu cuucaugugu gacguuu				27
	263				
<211>					
	RNA Artificial Sequence				
~613/					
<220>					
<223>	RNAi molecule				
<400>	263				

WO 2004/070002	PCT/US2003/037143
	27
ugaguguugu gagecuucac aaguguu	2.
<210> 264	
<211> 27	
<212> RNA	·
<213> Artificial Sequence	
eteΩia Nacionale	
<220>	·
<223> RNAi molecule	
<400> 264	
ugacguuugu uuuucuuggu ucauuuu	27
•	
<210> 265	
<b>K211&gt; 27</b>	
<pre> &lt;212&gt; RNA &lt;213&gt; Artificial Sequence</pre>	
<5513> Willificial pedirence	
<220>	;
<223> RNAi molecule	
<400> 265	27
gugacguuug uuuuucuugg uucauuu	-27
•	
<210> 266	
<211> 27	
<211> 27 <212> RNA	
<213> Artificial Sequence	
<220>	
<223> RNAi molecule	
.400- 066	
<400> 266 ugugacguuu guuuuucuug guucauu	27
agagacgada gadadadaag gadaaaa	
•	
<210> 267	
<211> 27	
<212> RNA	•
<213> Artificial Sequence	•
<220>	
<223> RNAi molecule	•
<400> 267	27
acaacaguac acuuucuuga uccucuu	21
<210> 268	
<210> 266 <211> 27	
<212> RNA	
<213> Artificial Sequence	
<220>	
<223> RNAi molecule	
<400> 268	
gccucggaac guguggaccu uaaaguu	27
Accredance and addition access.	

WO,2004/070002 PCT/US2003/037143

<b>&lt;210&gt;</b>	260	
<211>		
<212>		
	Artificial Sequence	•
<220>		
·<223>	RNAi molecule	
<400>	269	
	guac agugujuauca agccauc	27
	111	
•		
<210>	270	
₹211>		
<b>&lt;212&gt;</b>		
	Artificial Sequence	
\Z13/	With the second	
<220>	•	
	RNAi molecule	
<223>	KNAI molecule	
	050	
<400>		27
uucuce	uaau ugaagugguu gucguug	
	•	
<210>		
<211>		
<212>		
<213>	Artificial Sequence	
<220>		
<223>	RNAi molecule	
<400>	271	
cagug	uuauc aagccaucug ucaccag	27
<210>	272	
<211>	27	
<212>		
	Artificial Sequence	
	•	
<220>		
	RNAi molecule	
4000		
<400>	272	
	acguu caauccacag ucugagc	27
agaga		
-210ء	273	
<211>		
	RNA	
<213>	Artificial Sequence	
'-		
<220>		
<223>	RNAi molecule	
	· 273	20
uguac	agugu uaucaagcca ucuguca	27

WO 2004/070002

PCT/US2003/037143

<210>	274					
<211>	27		•			
<212>						
<213>	Artificial Sequence					
<220>						
<223>	RNAi molecule	•				
<400>	274					
aguguua	auca agccaúcugu caccaga					27
-010-	0.75					
<210> <211>	275 27	-				
<211>						
	Artificial Sequence			•		
\Z1J/	Artiriciai bequeixe					
<220>					•	
	RNAi molecule					
<400>	275	•				
guacag	uguu aucaagecau cugucac					27
	·					
<210>	276					
<212>	RNA	•				•
<213>	Artificial Sequence					
<220>						
	RNAi molecule					
~2237	AMAI MOZECUIE		·			
<400>	276				•	
	acgu ucaauccaca gucugag					27
<210>	277					
<211>						
<212>						
<213>	Artificial Sequence					
~220						
<220>	RNAi molecule					
\EZ3/	RVAI MOIECUIE					
<400>	277					
	uaca guguuaucaa gccaucu					27
<b>3</b>						
<210>	278					
<211>	27					
<212>						
<213>	Artificial Sequence					
<220>						
<223>	RNAi molecule					
400-	270					
<400>						27
ucauaa	uuga agugguuguc guugugu					41

<210> 279

WO 200	4/070002			PCT/US2003/037	143
<211> <212> <213>		:			
<220> <223>	RNAi molecule				
<400>	279 aauu gaagugguug ucguugu				27
<210> <211> <212> <213>	27				
<220> <223>	RNAi molecule			•	,
<400> aauuga	280 agug guugucguug uguguga				27
<210><211><212><212><213>	27				
<220> <223>	RNAi molecule			•	
<400> cuguc	281 accag aucaugaauc gacucaa				.27
<210> <211> <212> <213>	27				
<220> <223>	RNAi molecule				-
	282 guuau caagccaucu gucacca				27
<211: <212:			·		
<220: <223:	> RNAi molecule				
	> 283 guguua ucaagecaue ugucaec				27
	> 284 > 27				

WO 200	4/070002	PCT/US2003/03714	3
<212>	RNA		
	Artificial Sequence		
<220>			
	RNAi molecule		
	•		
<400>	284		
uuccac	cgcu guguguucuu caugugu	:	27
•			
1. 2			
<210>	285		
<211>			
<212>			
<213>	Artificial Sequence		
<220>			
	RNAi molecule		
. 1			
<400>	285		
uaugua	cagu guuaucaagc caucugu		27
-		``	
	·		
<210>			
<211>			
<212>			
<213>	Artificial Sequence		
<220>		·	
	RNAi molecule		
<400>	286		
auaauu	gaag ugguugucgu ugugugu		27
-010-	207		
<210> <211>			
<212>			
	Artificial Sequence	·	
<220>			
<223>	RNAi molecule		
<400>			
ucuucu	icaua auugaagugg uugucgu		27
<210>	288		
<211>			
<212>			
	Artificial Sequence		
<220>			
<223>	RNAi molecule		
-400-	200		
<400>	288 ucuc auaauugaag ugguugu		-27
guguet	reart appearant allegan		_ /
<210>			
-211	27		

<211> 27 <212> RNA

WO 2004	/070002		PCT/US2003/037143
<213>	Artificial Sequence		
<220> <223>	RNAi molecule		
<400>	289 ucau aauugaagug guugucg		27
_			
<210>	290		
<211>			
<212>			
<512>	Artificial Sequence		•
<220> <223>	RNAi molecule		
<400>	290		,
	uaga cauuggcaga uauaucg		. 27
<210>	291	·	
<211>			,
<212>			
<213>	Artificial Sequence		•
<220>		•	
	RNAi molecule		
<400>	291		·
ucugu	cacca gaucaugaau cgacuca		27
<210>			
<211>			
<212>	RNA Artificial Sequence		
<b>\213</b> /	Willian pedaewe		•
<220>			
<223>	RNAi molecule		
<400>			
auuga	agugg uugucguugu gugugag		-27
	000		
<210> <211>			
	RNA		
	Artificial Sequence		
<220>			
	RNAi molecule		
	293		<b></b>
uugaa	guggu ugucguugug ugugagg		27
<b>∠210</b> ≥	294	•	
<211>	· 27		
<212>	RNA		
<213>	Artificial Sequence		

-0.00-	•	
<220>		
	DND i malagula	
~××3>	RNAi molecule	
<400>	294	
ququaco	guuc aauccacagu cugagca	27
19 C	·	
	AAP	
<210>		
<211>	27	
<212>	RNA	
	Artificial Sequence	
\L		
<220>	•	
<223>	RNAi molecule	
	·	
<b>₹400&gt;</b>	295	
		27
ccaccg	cugu guguucuuca uguguga	
<210>	296	<b>`</b>
<211>	•	
<212>		
<213>	Artificial Sequence	•
<220>	•	
<223>	RNAi molecule	
1000		•
.400-	204	•
	296	
gaauuu	lauuu caguagauau cgaacug	27
	,	
<210>	207	
<211>	•	
<212>		
<213>	Artificial Sequence	
	<u>-</u>	
<220>		
	DVI i malagula	
<223>	RNAi molecule	
<400>	297	
chedan	laaua caagcgaacu ccaaguu	27
	· · · ·	
.644	000	
<210>		
<211>	27	
<212>	RNA	
	Artificial Sequence	
~2±3×	uterran pedagine	
<220>		
<223>	RNAi molecule	
<400>	298	
		.27
ucacci	ucauc uauauuacau ucauguu	.27
<210>	299	
<211>		
<212>		
<213>	Artificial Sequence	

WO,200	_		PCT/US2003/037143
<220> <223>	RNAi molecule		
<b>≈400&gt;</b>	200		
. ' '1	uguu acaaguccaa gagaauu		27
, unuugu	ague doddgeood geganne		
<210>			
<211>			
<212>	Artificial Sequence	•	
	m signature		
<220>	18		
<223>	RNAi molecule		
1.400-	300		
<400>	sauu aauuguugga uaguguu		27
aaccac	Cada agaagaaga aagagaa		
<210>		`	
<211>			
<212>	RNA Artificial Sequence		
<b>₹₹13</b> >	Aftilicial Sequence	•	
<220>			
<223>	RNAi molecule		
<400>	ucuau auuacauuca uguucuu		27
.ccucai	Chan annacannea nàmean		
		·	•
<210>		·	
<211>			
<212>			
<213>	Artificial Sequence		
<220>			
<223>	RNAi molecule		•
.400	200		
<400>	302 uauuc accucuucau caagguu		27
aauua	dadde deededdad oddaggaa	•	•
-	303		
<211>			
	RNA Artificial Sequence	•	
\21J>	Willician poducies		
<220>		•	•
<223>	RNAi molecule		
44005	303		
	caccu cuucaucaag guuacuu		27
uuuu		•	
	304		
	• 27		
	<ul><li>RNA</li><li>Artificial Sequence</li></ul>		
<2132	Writherar poduction		
<220	•		


WO 2004	1/070002	PCT/US2003/037143
<223>	RNAi molecule	
<400>		27
aayaug	uauc cuauauccuu cacucuu	_,
<210> <211>		
<212>	RNA	
<213>	Artificial Sequence	
<220>	nyn i malamala	
<223>	RNAi molecule	
<400>	305	
aacugg	agug uguggaggaa uuauauu	<b>27</b>
<210>	306	•
<211>		t
<212>	RNA Artificial Sequence	
, ~215>	A COLLEGE AND A	
<220>		
<223>	RNAi molecule	
<400>	306 .	
ucggua	auac aagcgaacuc caaguuu	27
	·	•
<210>		
<211>		
<212>	RNA Artificial Sequence	
12201		
<220>	RNAi molecule	
<223>	RNA1 molecule	
<400>	307	
gagaa	cuuca auaauucuug uaucauu	27
<210>		·
<211> <212>		
	Artificial Sequence	
<220>	RNAi molecule	
<400>		27
ucaac	cucug gaaguccauu agauguu	2,
<210>	309	
<211>	27	
	RNA	
<213>	Artificial Sequence	
<220>		
<223>	RNAi molecule	

	309		27
gcaguug	nua aaauaggaaa ucagauu		~.
<210>	310		
<211>	27		
	RNA		
	Artificial Sequence		
		·	
<220>			
<223>	RNAi molecule		
<400>	310		
ccagau	cauc uuccauuugu aauacuu	<u>.</u>	27
<210>		1	
<211>			•
<212>			
<213>	Artificial Sequence		
<220>	•		
	RNAi molecule	•	
\ZEJ/	MAL MOLECULE		
<400>	311		
	auca ccagaucauc uuccauu		27
	•		
		•	
<210>	312 .	· · · · · · · · · · · · · · · · · · ·	
<211>	27		
<212>			
<213>	Artificial Sequence		
<220>	mm / 2 2 -		
<223>	RNAi molecule		
<400>	312		
	lauga aaucaccaga ucaucuu		27
ucuguo	augu uuucucugu uuuu-		
<210>	313		
<211>	27		•
<212>		·	
<213>	Artificial Sequence		
	-	•	
<220>			
<223>	RNAi molecule	•	
-4005	212		
<400>			27
guucu	ucuuc ugauuuaagc auggauu		_,
<210>	314		
<211>			
<212>			
	Artificial Sequence		
	_	<i>:</i>	
<220>			
	Page 2 2 2 -		

WO 200	4/070002	•		PCT/US2003/	037143
<400>	314				
gaaugga	uaa ucguucuucu ucugauu				27
•					
<210>					
<211> <212>					
	Artificial Sequence				
<220>					
<223>	RNAi molecule				
· · · · ·					
<400>					27
uucuga	aggu ugaucacuug cagaauu				
	•			•	
<b>&lt;210&gt;</b>	316				
<211>	27				
<212>					
<213>	Artificial Sequence	•	1		
<220>	•				
	RNAi molecule				
\DD5					
<400>	316				
cuaaua	aaaa ugugauccaa gaaacuu	•			27
	•			•	
<210>	217				
<211>					
<212>					
	Artificial Sequence				
<220>					
<223>	RNAi molecule				
<400>	317				
	acaga gaacuucaau aauucuu				-27
		•			
	24.0				
<210>					
<211> <212>			•		
	Artificial Sequence				
	-				
<220>					
<223>	RNAi molecule				
-400>	318				
	cuaua uuacauucau guucuuu	•			27
Cucuu					
	319				
<211>					
	RNA Artificial Sequence				
<213>	wicitional sedmence				
<220>	•		•		
	RNAi molecule				

<400> 319

. WO 200	4/070002			PCT/US	2003/037143
	and discounting interests				27
Cauuuu	icac cucaucuaua uuacauu				
<b>&lt;210&gt;</b>	320				
<211>					
<212>	RNA				
	Artificial Sequence				
<220>	RNAi molecule				
	Ideal morocaro				
<400>					27
uangaa	aaau guugucauuc agaaguu				_,
	•				
<210>					
<b>&lt;211&gt;</b>					
<212>	Artificial Sequence				
<213>	Artificial Sequence	•		,	
<220>					
<223>	RNAi molecule				
<400>	321		•		
acucgo	ruaau acaagcgaac uccaagu 🕟				27
<210>	322				
<211>		•			
<212>	RNA				
<213>	Artificial Sequence		•		
<220>					
	RNAi molecule				
-400-	222				
<400>	guaau acaagcgaac uccaag				26
4449	9-0-0-0-0-0-0-0-0-0-0-0-0-0-0-0-0-0-0-0				
-0105	222				
<210> <211>					
	RNA			-	
	Artificial Sequence				
-000-					
<220>	RNAi molecule				
	•				
	323				-27
ccau	lagaug uuacaagucc aagagaa				
	> 324				
	> 27				
	> RNA				
<213:	> Artificial Sequence				
<220			•		
	> RNAi molecule				
.400	> 324				•
	> 324 uuagau guuacaaguc caagaga				-27
ucca					



<210>	325		
<211>	27		
<212>			
<213>	Artificial Sequence		
-000			
<220>			
<223>	RNAi molecule		
<400>	325		
	uuag auguuacaag uccaaga		27
agucca	day adjudeday accausa		
•			
<210>	326		
<211>			
<212>			
<213>	Artificial Sequence		
		•	
<220>			
<223>	RNAi molecule		
		•	
<400>	326		27
	auua gauguuacaa guccaag		27
٠.			
<210>	227		
	27	•	•
<212>			
	Artificial Sequence		
1220	Implication bodgestor		
<220>	•	·	
<223>	RNAi molecule	•	
<400>	327	•	
gaaguc	cauu agauguuaca aguccaa		27
<210>	220	,	
<210> <211>			
<211>			
	Artificial Sequence		
\Z13>	Willicial pedaence		
<220>		• •	
	RNAi molecule		
<400>	328	•	
guccai	uaga uguuacaagu ccaagag		27
<b>&lt;210&gt;</b>			
<211>	— ·		
<212>			
<213>	Artificial Sequence		
-220			
<220>	RNAi molecule		
<443>	WANT INTERNIE		
<400 <b>&gt;</b>	329		
	cqqua auacaagcga acuccaa	•	27

<210>	330	
	27	
<21.2>	RNA	
<213>	Artificial Sequence	
<220>		
	RNAi molecule	
$T = \overline{V}$	•	
<400>	330	
ucauua	auug uuggauagug uucauaa	27
•	(B	
; .		
<210>	331	
<211>		
<b>&lt;212&gt;</b>		
	Artificial Sequence	
, 220		
<220>		
	RNAi molecule	
\E23>	19417 1102	
<400>	221	
	ucua uauuacauuc auguucu	27
accuca	OCIA NAULACAGO CASAGO	
<210>	332	
<211>		
<211>		
	Artificial Sequence	•
<213>	Wifiticial pedagice	
-000-		
<220>	RNAi molecule	
<223>	RNAI MOIECUIE	
-400-	220	
<400>	332	27
uucac	cucau cuauauuaca uucaugu	
-010-	222	
<210>		
<211>		
<212>	Artificial Sequence	
<213>	Architetat sequence	
.000-		
<220>		
<223>	RNAi molecule	
.400-	222	
	333	27
cauua	auugu uggauagugu ucauaac	
	•	
.046	224	
	334	
<211		
	RNA	
<213:	Artificial Sequence	
<220		
<223	RNAi molecule	
	> 334	27
CAUC	auuaau uguuggauag uguucau	21

WO 200	4/070002			PCT/US2003/0371	143
<210>	225				
<211>					
<212>					
	Artificial Sequence				
				•	
<220>					
<223>	RNAi molecule				
<400>	335				
	uuaa uuguuggaua guguuca				27
<210>					
<211> <212>			•		
	Artificial Sequence	•			
				•	
<220>					
<223>	RNAi molecule			•	,
<400>	33-6				•
	uaca aguccaagag aauucau				27
-1			•		
<210> <211>					
<211>					
	Artificial Sequence				
<220>				•	
<223>	RNAi molecule		•		•
<400>	337			•	
	uuac aaguccaaga gaauuca				27
<210> <211>					
<212>					
<213>	Artificial Sequence				
<220>	nm:lala				
<223>	RNAi molecule				
<400>	338				
	yaugu uacaaguçca agagaau				27
		•		•	
<210>	220		•		
<211>					
<212>					
<213>	Artificial Sequence				
<220>	RNAi molecule				
<223>	WWT MOTECATE				
<400>	339				
	uuaua uucaecucuu caucaag				27
<210>	340				
<21U>	J#U				

	,**		
WO 200	4/070002		PCT/US2003/037143
<211>			
<212>			
<213>	Artificial Sequence		
<220>			
<223>	RNAi molecule		
	•		
<400>	340		
	ccau uagauguuac aagucca		27
00	-		
<210>	341		
<211>			
<212>			
<213>	Artificial Sequence	•	
			•
<220>			
	RNAi molecule		1
,			•
<b>~400&gt;</b>	341		
accucu	iggaa guccauuaga uguuaca	•	27
,			
	•		•
<210>	342		
<211>			
<213>	Artificial Sequence	•	•
<220>			
	RNAi molecule		•
			·
<400>	342		
auguu	acaag uccaagagaa uucauaa		27
٦	_		
<210>	343		
<211>	27		
	RNA	•	
<213>	Artificial Seguence		
<220>			
<223>	RNAi molecule		
•			
<400>	343		
uauau	ucacc ucuucaucaa gguuacu		27
	•	,	
	344		
<211>	<b>27</b> .		
	> RNA		
<213>	Artificial Sequence		
<220	•		
<223	> RNAi molecule		
	> 344		27
uuau	auucac cucuucauca agguuac		
			-
	> 345		
	> 27		
<212	> RNA		

WO 200	04/070002		PCT/US2003/037143
1 1 4 4 1 1	Artificial Sequence		
<220>			
<223>	RNAi molecule		
<400>	345		
	gagu guguggagga auuauau		27
			•
<210> <211>			
<212>			
	Artificial Sequence		
<220>	RNAi molecule		
<223>	RVAI MOIECUIE		
<b>&lt;400&gt;</b>	346		0.7
cuucue	cugug aguugauaag cauucuu		27
		,	
<210>	347		
<211>			·
<212>			
<213>	Artificial Sequence		
<220>	•		
	RNAi molecule		
		•	
<400>			27
cacuu	gccaa gagaucguug uaacauu		
	•		
	348		
<211>			
	RNA Artificial Sequence		
<b>\213</b> /	. Attiticial bequence		
<220>			
<223>	RNAi molecule		
<b>≈</b> 4005	> 348		
	guuggu cucucagucg cuguauu		. 27
~21 <i>0</i> ·	> 349		
	> 27		
	> RNA		
	> Artificial Sequence		• .
<220	> > RNAi molecule		
\ZZJ.	> MAI MOICCAIC		
	> 349		27
cggu	aguacu auaucuggcc uucaguu		27
•			
<210	> 350	•	
	> 27		
	> RNA		
<213	> Artificial Sequence		
		•	

WO<sub>1</sub>2004/070002 PCT/US2003/037143

<220>		
<223>	RNAi molecule	
<400>		27
caaugcg	gua guacuauauc uggecuu	27
-210-	261	
<210> <211>	351 27	
<211>		
	Artificial Sequence	
-,	•	
<220>		
<b>&lt;223&gt;</b>	RNAi molecule	
1		
<400>	351	27
cugauc	auac acgagecacu geugauu	
<210>	352	
<211>		
<212>		
<213>	Artificial Sequence	
<220>	RNAi molecule	
<223>	KNAI molecule	
<400>	352	
	nuga uaagcauucu ucuccuu	27
-3-5-3		
<210>		
<211>		
<212>	Artificial Sequence	
\Z13>	UTCTTTOTOT PARMITTE	
<220>		
<223>	RNAi molecule	
<400>		-27
uugaa	gauaa ccuucugauu caggcuu	,
<210>	354	
<211>		
<212>	RNA	
<213>	Artificial Sequence	
<220>		
<223>	RNAi molecule	
<400>	354	
	cucag ccucaaggac ucgaauu	27
	·	
	355	
<211>		
	RNA - Artificial Sequence	
<5772>	wenting and seducine	

WO 20	04/070002			PCT/US2003/037	143
<220> <223>	RNAi molecule				
<400>	355				
	úcgu ugucucuucc agcuguu			•	27
Cuucuo	4034				
	,			1	
<210>	356				
<211>	27				
<212>	RNA				
<213>	Artificial Sequence			•	
<220>					
<223>	RNAi molecule		•		
<400>				•	27
ucugcu	lucuc uucuugaaga uaaccuu				
				•	
<210>	357				•
<211> <212>		•			
	Artificial Sequence				
<b>42137</b>	William pedagues		•	•	
<220>					
	RNAi molecule				
1220		•			•
<400>	357				
	ucucu gugaguugau aagcauu				.27
				•	
			•		•
<210>				•	
<211>					
<212>					
<213>	Artificial Sequence				
<220>	RNAi molecule				
<223>	RNA1 molecule				
<400>	358				•
	uacac gagecacuge ugauuuu				27
yauca	dacae gagocaeage againe				
				•	
<210>	359				
<211>					
	RNA				
	Artificial Sequence	•			
<220>					
<223	RNAi molecule				
	> 359				27
aucai	lacacg agccacugcu gauuuuu		•		21
-04 A	> 360				
	> 27				
	> RNA			•	
	> Artificial Sequence				
~ZI3	· · · · · · · · · · · · · · · · · · ·	•			
<220	>				
~220					

WO 200	4/070		PCT/US2003/037143
<223>	RNAi molecule		
	360 Laca •cgagecacug -cugauuu		27
.04.0	2-4		
<210>	· <del>-</del>		
<211> <212>			
	Artificial Sequence		
-21J/	Attiticial bequence		
<220>			
	RNAi molecule	•	
		•	
<400>	361		
uucgug	aggu ugcagcagac aacuguu		27
.040.	240		·
<210> <211>	362		1
<211> <212>			
	Artificial Sequence		
1220	inclination poducino		
<220>		•	
<223>	RNAi molecule		
<400>	362		0.7
uuauuu	auug augaguugaa gcaguuu		27
			•
<210>	363	•	
<211>			,
<212>	<del>- ·</del>		
	Artificial Sequence	•	
	_		
<220>			
<223>	RNAi molecule		
400	262		
<400>			27
auuaui	uauu gaugaguuga agcaguu		2,
<210>	364	•	
<211>			
<212>			
<213>	Artificial Sequence		
			•
<220>		,	
<223>	RNAi molecule		
<400>	354		
	ucuug aagauaaccu ucugauu		27
ucucui	unduranter rendura		2,

<400>	365		
ucaaccu	caa gaucuuuuuu ugcacuu	•	27
<210>			
	27		
<212>			•
<213>	Artificial Seguence		
<220>			•
<223>	RNAi molecule		
	18		
<400>	366		07
	ucaa ccucaagauc uuuuuuu		27
1			
. 1			
<210>			
<211>			
<212>	RNA	,	
<213>	Artificial Sequence		
<220>			
	RNAi molecule		
7225			
<400>	367		27
uugucg	juuca accucaagau cuuuuuu		27
	••		
<210>			
<211>		•	
<21-2>	RNA	·	
<220>			
<223>			
1220			
<400>			27
uuugu	cguuc aaccucaaga ucuuuuu		·6/
	•		
	262		
<210>			
<211>	27 RNA	•	
	Artificial Sequence		
~E13>			
<220>	•		
<223>	RNAi molecule		
	•		
	> 369		27
acuug	gecaag agaucguugu aacauuu		
-010.	> 370		
	> 370 > 27	•	
	> RNA		
	> Artificial Sequence		
<220	>		
<223	> RNAi molecule		
-400	<b>~ 370</b>		

guuugu	cguu caaccucaag aucuuuu	27
<210> <211> <212> <213>	27	
<220> <223>	RNAi molecule	
	371 cugu gaguugauaa gcauucu	27
<210> <211> <212> <213>	·	•
<220> <223>	RNAi molecule	
<400> ucucug	372 rugag uugauaagca uucuucu	27
<210> <211> <212> <213>	27	
<220> <223>	RNAi molecule	
<400> uugaua	373 aagca uucuucuccu ucucagc	27
<210> <211> <212> <213>		
≪220> <223>	RNAi molecule	
<400> aagcat	374 uucuu cuccuucuca gccucaa	27
<210> <211> <212> <213>	27	
<220> <223>	RNAi molecule	
<400> uaagc	375 auucu ucuccuucuc agecuca	27

×210>	376		
<211>	27	•	
<212>	RNA		
	Artificial Sequence		
-220-			
<220>	mam 1 1 1		
<223>	RNAi molecule		
•			
<400>		_	
gauaag	cauu cuucuccuuc ucagecu	27	,
•			
<210>	377		
<211>			
<212>			
	Artificial Sequence		
×2137	Writterar seducive		
<220>		<b>;</b>	
<223>	RNAi molecule		
<400>	377		
ugauaa	agcau ucuucuccuu cucagcc	27	1
	ı		
<210>	378		
<211>		·	
<212>			
<512>	Artificial Sequence		
	•		
<220>			
<223>	RNAi molecule		
	·		
<400>	378		
augcgg	guagu acuauaucug gccuuca	2.	7
<210>	379		
<211>			
<212>			
<213>			
_	<del>-</del>		
<220>			
<223>	RNAi molecule		
<400>		_	_
ugcacu	uugcc aagagaucgu uguaaca	2	7
<210>	380		
<211>			
<212>			
	Artificial Sequence		
~£13/			
4000r			
<220>			
<223>	RNAi molecule		
	•		
<400>			_
uugca	cuugc caagagaucg uuguaac	2	7

WO,2004	/070002	PCT/US2003/037143
<210>	381	
×211>	27	
<b>&lt;212&gt;</b>	RNA	
	Artificial Sequence	
, <220>		
. <223>	RNAi molecule	
	201	
<400>	cnnc necnnencad ceneaad	27
√ aycauw	cute decadedcay ecucaay	
:		
<210>	382 "	
<211>	27	
<212>		
	Artificial Sequence	
-000		
<220>	RNAi molecule	
<b>\</b> 2237	MAN MOTECULE	•
<400>	382 '	
	agua cuauaucugg ccuucag	27
<210>	· · · · · · · · · · · · · · · · · · ·	
<211>		
<212>	Artificial Sequence	
<b>\213</b> /	Artificial bequence	
<220>		
<223>	RNAi molecule	
	·	•
	383	27
ucucgu	uguc ucuuccagcu guucaag	27
<210>	384	
<211>		
<212>		
<213>	Artificial Sequence	
<220>	numi malagula	
<423>	RNAi molecule	
<400>	384	
	ugucu cuuccagcug uucaagc	27
<u> </u>		
•		
<210>		
<211>		
<212>		
<213>	Artificial Sequence	
<220>		
	RNAi molecule	
•		
<400>	•	
gcuga	ucaua cacgagccac ugcugau	27
J210×	386	
<41U>	300	

<211>	27				
<212>	RNA				
<213>	Artificial Sequence				
<220>					
<223>	RNAi molecule				
	386				
ugcuga	icau acacgageca cugcuga				27
<210>					
<211> <212>	<del>-</del> -				
<213>	Artificial Sequence				
<220>				•	
	RNAi molecule				
\EE3/	RNAI MOIECULE			•	
<400>	387				•
	uaag cauucuucuc cuucuca				27
aguuga	daay caddcacac cadcaca				2,
<210>	388				
<211>					
<212>					
	Artificial Sequence	•			•
<220>					
<223>	RNAi molecule			•	•
<400>	388				
guugau	aagc auucuucucc uucucag				27
<210>					
<211>					
<212>					
<213>	Artificial Sequence				
<220>					
<223>	RNAi molecule				
-400-	300				
<400>					27
Cuguga	guug auaagcauuc uucuccu				21
<210>	390				
<211>					
<212>					
	Artificial Sequence				
<220>			•		
	RNAi molecule				
	•				
<400>	390				
	gaguu gauaagcauu cuucucc				27
<210>	391				

<211> 27

<212>	RNA			
	Artificial Sequence			
<220>				
<223>	RNAi molecule			
<400>	391			
cuugaa	gaua accuucugau ucaggcu			27
<210>				
<211>				
<212>				
<213>	Artificial Sequence	•		
-000-				
<220>	RNAi molecule			
<b>&lt;223</b> >	MAI molecule			
<400>	392			•
	cuau aucuggccuu caguugg			27
, gaagaa	dua de aggera e agaagg	•		
			,	
<210>	393			
<211>	27			
<212>				
<213>	Artificial Sequence	•		•
<220>				
<223>	RNAi molecule		•	
				•
-400-	202			
<400>			• .	27
	393 augcg guaguacuau aucug <del>g</del> c		٠.	27
			٠.	27
aagca	augcg guaguacuau aucuggc		٠.	27
	augcg guaguacuau aucuggc		٠.	27
aagca:	augcg guaguacuau aucuggc 394 27		* .	27
<210><211><212>	augcg guaguacuau aucuggc 394 27			27
<210><211><212>	augcg guaguacuau aucuggc 394 27 RNA			27
<210> <211> <212> <213> <223>	augcg guaguacuau aucuggc 394 27 RNA Artificial Sequence			27
<210> <211> <212> <213> <223>	augcg guaguacuau aucuggc 394 27 RNA Artificial Sequence			27
<210> <211> <212> <213> <223>	394 27 RNA Artificial Sequence	·		27
<210> <211> <212> <213> <223> <400>	394 27 RNA Artificial Sequence RNAi molecule	·		
<210> <211> <212> <213> <223> <400>	394 27 RNA Artificial Sequence	·		27 27
<210> <211> <212> <213> <223> <400>	394 27 RNA Artificial Sequence RNAi molecule			
<210> <211> <212> <213> <220> <223> <400> caage	394 27 RNA Artificial Sequence  RNAi molecule 394 aaugc gguaguacua uaucugg			
<210> <211> <212> <213> <220> <223> <400> caage	394 27 RNA Artificial Sequence  RNAi molecule 394 aaugc gguaguacua uaucugg			
<210> <211> <212> <213> <220> <223> <400> caagc <210> <211>	394 27 RNA Artificial Sequence  RNAi molecule 394 aaugc gguaguacua uaucugg			
<210> <211> <212> <213> <220> <223> <400> caagc <210> <211> <212>	394 27 RNA Artificial Sequence  RNAi molecule 394 aaugc gguaguacua uaucugg  395 27 RNA			
<210> <211> <212> <213> <220> <223> <400> caagc <210> <211> <212>	394 27 RNA Artificial Sequence  RNAi molecule 394 aaugc gguaguacua uaucugg			
<210> <211> <212> <213> <220> <223> <400> caagc <210> <211> <212>	394 27 RNA Artificial Sequence  RNAi molecule 394 aaugc gguaguacua uaucugg  395 27 RNA Artificial Sequence			
<210> <211> <212> <213> <220> <223> <400> caagc  <210> <211> <212> <213>	394 27 RNA Artificial Sequence  RNAi molecule 394 aaugc gguaguacua uaucugg  395 27 RNA Artificial Sequence			
<pre>&lt;210&gt; &lt;211&gt; &lt;212&gt; &lt;213&gt; &lt;220&gt; &lt;223&gt; &lt;400&gt; caagc  &lt;210&gt; &lt;211&gt; &lt;212&gt; &lt;213&gt; &lt;220&gt; &lt;2213&gt; </pre>	394 27 RNA Artificial Sequence  RNAi molecule 394 aaugc gguaguacua uaucugg  395 27 RNA Artificial Sequence			
<pre> &lt;210&gt; &lt;211&gt; &lt;212&gt; &lt;213&gt; &lt;220&gt; &lt;223&gt; &lt;400&gt; caagc  &lt;210&gt; &lt;211&gt; &lt;212&gt; &lt;213&gt; &lt;400</pre>	394 27 RNA Artificial Sequence  RNAi molecule 394 aaugc gguaguacua uaucugg  395 27 RNA Artificial Sequence  RNAi molecule 395			27
<pre> &lt;210&gt; &lt;211&gt; &lt;212&gt; &lt;213&gt; &lt;220&gt; &lt;223&gt; &lt;400&gt; caagc  &lt;210&gt; &lt;211&gt; &lt;212&gt; &lt;213&gt; &lt;400</pre>	394 27 RNA Artificial Sequence  RNAi molecule 394 aaugc gguaguacua uaucugg  395 27 RNA Artificial Sequence			
<pre> &lt;210&gt; &lt;211&gt; &lt;212&gt; &lt;213&gt; &lt;220&gt; &lt;223&gt; &lt;400&gt; caagc  &lt;210&gt; &lt;211&gt; &lt;212&gt; &lt;213&gt; &lt;400</pre>	394 27 RNA Artificial Sequence  RNAi molecule 394 aaugc gguaguacua uaucugg  395 27 RNA Artificial Sequence  RNAi molecule 395			27
<210> <211> <212> <213> <220> <223> <400> caagc  <210> <211> <212> <213> <400- auucu	394 27 RNA Artificial Sequence  RNAi molecule 394 aaugc gguaguacua uaucugg  395 27 RNA Artificial Sequence  RNAi molecule 395 27 RNA Artificial Sequence  RNAi molecule 395 ucucc uucucagccu caaggac			27
<210> <211> <212> <213> <220> <223> <400> caagc  <210> <211> <212> <213> <400- auucu	394 27 RNA Artificial Sequence  RNAi molecule 394 aaugc gguaguacua uaucugg  395 27 RNA Artificial Sequence  RNAi molecule 395 200 RNAi molecule 395 ucucc uucucagccu caaggac 396			27

<212> RNA

#### WO 2004/070002


<213>	Artificial Sequence	
<220>	mm:legule	
<223>	RNAi molecule	
<400×	306	
	cucc acaucaucac ugucauu	27
auuacu	the acamateae agueraa	
•		
<210>	397	
<211>		
<212>		
	Artificial Sequence	
<220>		
,<223>	RNAi molecule	
!		
<400>	397	
ggaugc	ugau gaucucaucc aucaauu	27
	•	
<210>		
<211>		
<212>		
<213>	Artificial Sequence	
<220>		
	RNAi molecule	
\ZE3>	MAI MOIECUIE	
<400>	398	
	aggu aacaaggucc aaacguu	27
<b></b>		
<210>	399	
<211>	27	
<212>		
<213>	Artificial Sequence	
<220>		
<223>	RNAi molecule	
-4005	399	
<400>	aggaa caaagccuac cucuguu	27
aacgut	nggaa caaageeuae cucuguu	
<210>	400	
<211>		
<212>		
	Artificial Sequence	
<220>		
<223>	RNAi molecule	
	•••	
<400>		20
agauce	cugec ucuguaggea acuccuu	27
•		
,00 A.	401	
<210> <211>		
<211> <212>		
	Artificial Sequence	
~をエン>	er erretar hedactoe	

WO<sub>2</sub>2004/070002 PCT/US2003/037143

19, 25							
20205							
<223>	RNAi molecule				•		
<400>	401						
	cuuu uuaucuggug gugucuu						27
, cucaug							
•							
<210>	402						
<211>							
<212>							
	Artificial Sequence						
~2,10-	THE CLEAN TO A CONTRACT		•				
<220>							
<223>	RNAi molecule	• •	•				
•							
×400>	402						
	aaca aauccaacau caaucuu						27
44544					;		
	1				'		
<210>	403						
<211>							
<212>							
	Artificial Sequence						
4220							
<220>							
	RNAi molecule						
<400>	403						
	auguu guuccaacua caucauu					•	27
				•			
<210>	404						
<212>							
	Artificial Sequence						
<220>				•			
<223>	RNAi molecule			•			
<400>	404						
uucuu	aucug cauugccucc aaauauu			•			27
	•			•			•
<210>							
<211>							
<212>	RNA						
<213>	Artificial Sequence						
<220>							
<223>	RNAi molecule						
	405						0.7
gugud	uucuc aagaaaagug gcuaauu						27
•							
	406						
	<b>27</b>						
	- RNA						
<213	Artificial Sequence						
₹220	•			•			

WO 2004	/070002		PCT/US2003/	037143
<223>	RNAi molecule			
<400>	406			
	cuga agauugacga ccugauu			27
<210>				
<211> <212>				
	Artificial Sequence			
<220>				
	RNAi molecule			
<400>	407			
aagccu	accu cuguuucucc uguguuu		•	27
<210>			•	1
<211> <212>		,		
	Artificial Sequence			
<220>				
	RNAi molecule			
<400>	408			•
auccac	gaga uuuuucuuau cugcauu		,	27
<210>				
<211> <212>				
	Artificial Sequence			
<220>				
<223>	RNAi molecule		,	
<400>				
aacuud	cuaca aaaggaucca cgagauu			27
<210>				
<211> <212>				
	Artificial Sequence			
<220>	•			
	RNAi molecule			
<400>	410			
uucuca	aacaa ccagcagguc aucauuu			27
<210>				
<211>				
<212> <213>	RNA Artificial Sequence		•	
<220>				
	RNAi molecule			

10			
<400>	411		
uuucuca	411 laca accagcaggu caucauu	2.	7
30 W			
<210>	.412		
<211>			
<212>			
<213>	Artificial Sequence		
		•	
<220>			
<223>	RNAi molecule		
:			
	412		
aaacaa	aucc aacaucaauc uuaaauu	2	7
:			
<210>	413		
<211>	27		
<212>		•	
	Artificial Sequence		
<220>			
	RNAi molecule		
\ZZ3/	MAI MOICCUIC		
-400-	413		
<400>		2	7
auuuua	gaga gguguagaua uguuguu		•
<210>			
<211>			
<212>			
<213>	Artificial Sequence		
<220>			
<223>	RNAi molecule		
<400>	414	•	
•	ucau gacagcaugg ccagguu	2	:7
	• • • • • • • • • • • • • • • • • • • •		
<210>	415		
<211>	27		
<212>			
	Artificial Sequence		
<b>-213</b> >	Arciliciai Sequence		
<220>	•		
	mand malamile		
<223>	RNAi molecule	·	
	415	_	٠.
cugaag	gaung acgaccugan nccacuc	4	27
<210>			
<211>	27		
<212>	RNA		
	Artificial Sequence		
	· •	•	
<220>			
-022	DNA: malamile		



<400> acucúco	416 caca ucaucacugu cauuauc	•	27
<210>			•
<211>	27		
<212>			
<213>	Artificial Sequence		
<220>		•	
<223>	RNAi molecule		
<400>	417	•	
uaauuc	aacc aagauccugc cucugua	•	27
	•	••	
	418		
<211>	27		
<212>			1
<213>	Artificial Sequence		
<220>			
<223>	RNAi molecule		
<400>	418		
ucacug	ucau uaucacgauc ucgucuc		. 27
		•	
<210>	419		
<211>	27		
<212>			
<213>	Artificial Sequence		
<220>			
<223>	RNAi molecule		
<400>	419	•	
caucac	rugue auuaucaega ueuegue	•	-27
<210>	420		
<211>	27		
<212>			•
<213>	Artificial Sequence		
<220>		•	
<223>	RNAi molecule	•	
<400>	420		
gaagaı	lugac gaccugauuc cacucug		27
<210>	421	•	
<211>			
<212>	RNA		
<213>	Artificial Sequence		
<220>		•	
	RNAi molecule		
~400 <b>&gt;</b>	421	•	
-ano-	# · 1		

## 27 ugaagauuga cgaccugauu ccacucu <210> 422 <211> 27 <212> RNA <213> Artificial Sequence <220> <223> RNAi molecule <400> 422 27 ucugaagauu gacgaccuga uuccacu <210> 423 <211> 27 <212> RNA <213> Artificial Sequence <220> <223> RNAi molecule <400> 423 27 aaguggcuaa uucaaccaag auccugc <210> 424 <211> 27 <212> RNA <213> Artificial Sequence <220> <223> RNAi molecule <400> 424 27 aucacuguca uuaucacgau cucgucu <210> 425 <211> 27 <212> RNA <213> Artificial Sequence <220> <223> RNAi molecule <400> 425 27 ucaucacugu cauuaucacg aucucgu <210> 426 <211> 27 <212> RNA <213> Artificial Sequence <220> <223> RNAi molecule <400> 426 27 ocacaucauc acugucauua ucacgau

WO 2004/070002

<210>	427	
×211>		
<212>		
	Artificial Sequence	
2237	Michigan bequence	
-220-		
<220>	mm i malacula	
<223>	RNAi molecule	
.400-	407	
<400>	427	
uccacai	ncan cacugucann ancacga	27
-	100	
<210>		
: <211>		
<212>		
<213>	Artificial Sequence	
<220>		
<223>	RNAi molecule	
<400>		
ucueca	cauc aucacuguca uuaucac	27
	·	
<210>		
<211>		
<212>		
<213>	Artificial Sequence	
<220>		
<223>	RNAi molecule	
	•	
<400>		
cucucc	acau caucacuguc auuauca	27.
<210>		
<211>		
<212>		
<213>	Artificial Sequence	
<220>		
<223>	RNAi molecule	
<400>		
cuccac	auca ucacugucau uaucacg	27
<210>		
<211>		
<212>		
<213>	Artificial Sequence	
	•	
<220>		
<223>	RNAi molecule	
<400>	431	
	agau ugacgaccug auuccac	27

1.0			
<210>	432	•	
<211>			
<212>			
	Artificial Sequence		
<220>			
	RNAi molecule		
	MAIL MOTOGRE		
<400>	132		
	caac caagauccug ccucugu	2	7
Cuaauu	""	_	•
; .	19		
<210>	422		
<211 <i>&gt;</i>			
<211> <212>	Z /		
<212>	Artificial Sequence		
, <b>&lt;213&gt;</b>	Arcificial Sequence		
-000-			
<220>	nuni malagula	· • • • • • • • • • • • • • • • • • • •	
<223>	RNAi molecule		
.400-	422		
<400>		2	27
gucauv	auca cgaucucguc ucucagg	•	, ,
	434		
<210>		•	
<211>			
<212>			
<213>	Artificial Sequence		
	•		
<220>		•	
<223>	RNAi molecule		
<400>			27
aagauı	igacg accugauucc acucugg	•	<i>.</i> ,
	40.5		
<210>			
<211>			
<212>			
<213>	Artificial Sequence		
.<220>			
<223>	RNAi molecule		
<400>		•	27
acauc	aucac ugucauuauc acgaucu	Y	21
<210>			
<211>			
	RNA		
<213>	Artificial Sequence	•	
		•	
<220>			
<223>	RNAi molecule		
<400>	436	•	_
uacuc	uccac aucaucacug ucauuau		27

.-....

WO 2004/070002 PCT/US2003/037143			
<210>	437		
<211>			
<212>			
<213>	Artificial Sequence		
<220>		•	
<223>	RNAi molecule		
<400>	437		
aauuacı	ucuc cacaucauca cugucau	2	7
	•	_	
<210>	438		
<211>	27	•	
<212>			
<213>	Artificial Sequence		
<220>	•		
	RNAi molecule	1	
<400>	438	1	
aucauc	acug ucauuaucac gaucucg	2	7
		-	•
<210>	439		
<211>	27		
<212>	RNA	•	
<213>	Artificial Sequence		
<220>	·		
<223>	RNAi molecule		
<400>	439		
ucauua	ncac gaucucgucu cucagga	2	7
<210>			
<211>	27		
<212>	RNA Artificial Sequence		
<213>	Artificial Sequence		
<220>			
<223>	RNAi molecule		
<400>	440		
ugucau	uauc acgaveucgu cucucag	2	7
<210>			
<211>			
<212>			
<213>	Artificial Sequence		
<220>			
	RNAi molecule		
<400>	441		
	nnan cacdanched nenenca	•	_
cagaca	was sayarered watter	2	7

<210> 442

<211>	27	
<212>	RNA	
<213>	Artificial Sequence	
<220>		
<223>	RNAi molecule	
	•	
< <b>400</b> >	442	
	cauu aucacgaucu cgucucu	27
<210>	443	
<211>	27	
<212>	RNA	
<213>	Artificial Sequence	
<220>		
<223>	RNAi molecule	
,		1
<400>	443	
	acca agauccugcc ucuguag	27
<210>	444	
<211>		
<212>		•
<213>	Artificial Sequence	
<220>		
<223>	RNAi molecule	
•		
<400>	444	
uagaga	ggug uagauauguu guuccaa	27
<210>	445	
<211>	27	
<212>	RNA	
<213>	Artificial Sequence	
<220>		
<223>	RNAi molecule	
<400>	445	
uuagag	yaggu guagauaugu uguucca	27
	·	
		•
<210>		
<211>		
<212>		
<213>	Artificial Sequence	
<220>		
<223>	RNAi molecule	
	***	
<400>	•	
cacuug	gccaa gagaucguug uaacauu	27
010	447	
<210>		
<211>	<b>4</b> 1	

<212	> RNA	
<213	> Artificial Seguence	
<220		
<223		
	rand molecule	
<b>-</b> 400	447	
cuga	ucauac acgagecacu geugauu	27
1 1. 1		
	> 448	•
<211	> 27	
<212	> RNA "	
	> Artificial Sequence	
,<220	>	
	> RNAi molecule	
1-223	> MANT MOTECATE	
-400	> 448	
uuga	agauaa ccuucugauu caggcuu	27
	1	
<210	> 449	
<211	> 27	•
<212	> RNA	
<213	> Artificial Sequence	•
	_	
<220	> ·	•
	> RNAi molecule	•
		•
-400	> 449	
uuat	aagcaa uugaugcugc acauguu	27
		·
	> 450	
	> 27	
	> RNA	
<213	> Artificial Sequence	
	•	
<220	<b> &gt;</b>	
<223	> RNAi molecule	
<400	> 450	•
	cuccuu aagaauuaca agcaauu	27
22-:	, corres angus acou agouaca	
-216	)> 451	•
	.> 27	
	•	·
	> RNA	
<21.	> Artificial Sequence	
	•	
<220		
<22:	> RNAi molecule	•
<401	)> 451	
-cgga	ucucuu cuucucuucu ucaaguu	27
	<b>3</b>	
<211	)> 452	
	> 27	
	P RNA .	

<213>	Artificial Sequence	
-2205		
<220> <223>	RNAi molecule	
<400>	452	
		7
		•
<210>		
<211>		
<212>		
<213>	Artificial Sequence	
<220>		
	RNAi molecule	
<b>1000</b>	1242 110200420	
<4.00>	453	
		27
_		
<210>	·	
<211>	<del></del>	
<212>		
<213>	Artificial Sequence	
<220>		
	RNAi molecule	
~2237	WAI MOIECUIE	
<400>	454	
		27
<210>		
<211>	<del></del>	
<212>		
<213>	Artificial Sequence	
<220>		
	RNAi molecule	
<400>	455	
uucgug	gaggu ugcagcagac aacuguu	27
	45¢	
<210> <211>		
<211> <212>	<del></del>	
	Artificial Sequence	
7225	messaceus bequesice	
<220>	· ·	
<223>	RNAi molecule	
<400>		
gaugeu	ngcac auguugacgg ucgaguu	27
•		
<210>	AS7	
<21U>	•	
<212>		
	Artificial Sequence	

WO 2004	4/070002		PCT/US2003/037143
<220>	•		
<223>	RNAi molecule		
<400>	457		
acuuge	caag agaucguugu aacauuu		27
<210>	458		
<211>	27		
<212>			
<213>	Artificial Sequence		
;	•••		
<220>		. :	•
<223>	RNAi molecule		
1			
· <b>/&lt;400&gt;</b>	458		
agauaa	gage ucuucggaue ucuucuu		27
		•	
<210>			,
<211>	**		
<212>			
<213>	Artificial Sequence	•	
		•	•
<220>			
<223>	RNAi molecule		•
	459		. 27
cuaaag	maca ugccugcauc uguuguu		27
<210>	460		
<210> <211>			
		·	
<212> <213>	Artificial Sequence		
<213>	Attiticial Sequence		
<220>			
	RNAi molecule		
~2237	Ideil morecare		
<400>	460		
	aaagu acaugccugc aucuguu	•	27
252500			
<210>	461		
<211>			
<212>			
	Artificial Sequence		
	-		
<220>			
<223>	RNAi molecule		
<400>			
ugaúc	auaca cgagccacug cugauuu		27
•			
<210>	•		
<211>			
<212>			
<213>	Artificial Sequence		

WO,2004	1/070002	PCT/US2003/037143	
( ) ( )	.,.,.,	- 0 21 002000.00 , 240	
<220>			
<223>	RNAi molecule		
1.00			
<b>∠400&gt;</b>	462		
, ,,	laag agcucuucgg aucucuu	27	
<210>	463		
<211>	27		
<212>			
<z13></z13>	Artificial Sequence		
	•••		
<220>			
<223>	RNAi molecule		
<b>;</b>	•		
. ≮400>	463		
gugagg	uugc agcagacaac uguuguu	. 27	
<210>	464		
<211>	27		
<212>			
<213>	Artificial Sequence	•	
<220>	•	•	
	RNAi molecule		
4225	12012 110107220		
<400>	464		
	lauug augaguugaa gcaguuu	27	
duaudo			
-010-	ACE		
<210>			
<211>			
<212>			
<213>	Artificial Sequence		
<220>			
<223>	RNAi molecule		
<400>	465	07	
auuauı	uauu gaugaguuga agcaguu	27	
	•		
<210>	466		
<211>	27		
<212>			
	Artificial Sequence		
	-	•	
<220>			
	RNAi molecule		
-223	· · · · · · · · · · · · · · ·		
<400>	466		
	ucuug aagauaaccu ucugauu	-27	
acaca	anang aagaaaanna anagaaa		
	467		
<211>			
	RNA		
<213>	Artificial Sequence		
<b>&lt;220&gt;</b>			

WO 2004	/070002	PCT/US2003/037143	
<223>	RNAi molecule		
<400>	467		
	ucaa gaucuuuuuu ugcacuu	27	
<210>	468 .		
<211>		•	
<212>	RNA		
	Artificial Sequence		
<220>			
	RNAi molecule		
<400>	468		
	ucaa ccucaagauc uuuuuuu	. 27	
	•	ı	
<210>		•	
<211>	-· · ·		
<212>			
<213>	Artificial Sequence		
<220>			
<223>	RNAi molecule		
<400>			
uugucg	uuca accucaagau cuuuuuu	27	
<210>	470	•	
<211>			
	Artificial Sequence		
<220>			
	RNAi molecule		
<400>	470		
uuuguo	eguuc aaccucaaga ucuuuuu	27	,
J010+	471		
<210>			
<211>			
<212>	Artificial Sequence		
<213>	Wiffilligial Sedimence		
<220>			
<223>	RNAi molecule		
<400>	471		
aguac	augee ugeaucuguu guueeaa	27	7
<210>			
<211>			
<212>			
<213>	Artificial Sequence		
<220>			
≈223>	RNAi molecule		

	P.GT/(152002/027142
WO 2004/070002	PCT/US2003/037143
<400> 472	
ucggagcucc uuaagaauua caagcaa	27
<210> 473	·
<211> 27	
<212> RNA	
<213> Artificial Sequence	
	•
<220> <223> RNAi molecule	
(ZE) MAI MOZOGULO	
<400> 473	27
gcacuugcca agagaucguu guaacau	
·	
<210> 474	
<211> 27	
<212> RNA	<b>'</b>
<213> Artificial Sequence	
<220>	
<223> RNAi molecule	
1	
<400> 474	27
ugcacuugcc aagagaucgu uguaaca	
	•
<210> 475	•
<211> 27	
<212> RNA <213> Artificial Sequence	·
(SI)> With Indian	
<220>	
<223> RNAi molecule	
<400> 475	
uugcacuugc caagagaucg uuguaac	27
•	
-010 A76	
<210> 476 <211> 27	•
<212> RNA	
<213> Artificial Sequence	
.000-	
<220> <223> RNAi molecule	
<400> 476	27
aaguacaugc cugcaucugu uguucca	
<210> 477	
<211> 27	•
<212> RNA	
<213> Artificial Sequence	
<220>	
<223> RNAi molecule	
	·
<400> 477	•

aaguga	cuaa uggcucugug auggcaa	-27
<210>	478	
	27	
<212>		
	Artificial Sequence	
	Wettietar poducino	
<220>		
<22U>	RNAi molecule	
<223>	RNA1 molecule	
1	480	
· <400>	478	0.7
guacau	geen geaucuguug uuccaac	27
	•	
<210>		
	27	
	RNA	
<213>	Artificial Sequence	
<220>	.1	
<223>	RNAi molecule	
<400>	479	
	caua cacgagccac ugcugau	27
0 - 10 - 11		
<210>	480	
<211>		
	Artificial Sequence	
1020		
<220>		
<223>	RNAi molecule	
1225		
<400>	480	
	ucau acacgagcca cugcuga	27
-55-		
<210>	481	
<211>	27	
<212>		
	Artificial Sequence	
1020		
<220>		
	RNAi molecule	
7225		
<400>		
	agaa uuacaagcaa uugaugc	27
accuae	augua uuucuugcuu uuguugc	
<210>	482	
<211>		
<211>	•	
<512>	Artificial Sequence	
-000s		
<220>		
<223>	RNAi molecule	
. 4 6 6	400	
<4.00>		^-
geucei	uuaag aauuacaagc aauugau	27
	· · · · · · · · · · · · · · · · · · ·	

, WO,200	4/070002	PCT/US2003/037143
<b>A</b>		
<210>	483	
<211>		
<212>		
	Artificial Sequence	
, \223>	Attiticial Sequence	
<220>		
	RNAi molecule	
<400>	483	
	uuaa gaauuacaag caauuga	27
-5,55		
•		
<b>&lt;210&gt;</b>	484	
<211>		•
<212>		
<213>	Artificial Sequence	
		i
<220>	1	
<223>	RNAi molecule	
<400>	484	
cuugaa	gaua accuucugau ucaggcu	27
		•
<210>		
<211>		
<212>		
<213>	Artificial Sequence	
<220>		·
	RNAi molecule	
<b>\223</b> >	RNAL MOZECUTE	
<400>	485	
	eucu ucuucucuuc uucaagu	. 27
acggat	20200 0022000000 0000032	
<210>	486	
<211>		
<212>	RNA	•
<213>	Artificial Sequence	
<220>		
<223>	RNAi molecule	
	•	
<400>		
uucgg	aucuc uucuucuu cuucaag	27
-040-	407	
<210>		
<211> <212>		
	Artificial Sequence	
72137	TETETAL Deficence	
<220>		
	RNAi molecule	
~2237		
<400>	487	
	gaucu cuucuucucu ucuucaa	27

WO 2004/070002

<210>	488	
<211>	27	
<212>		
<213>	Artificial Sequence	
-220-		
<220>		
<223>	RNAi molecule	
<400>		
acaagc	aauu gaugcugcac auguuga	27
<210>		
<211>		•
<212>		
<213>	Artificial Sequence	·
<220>		•
<223>	RNAi molecule	F.
		•
<400>	489	·
uucgga	gcuc cuuaagaauu acaagca	27
	•	
1		
<210>	490	
<211>	27	•
<212>	RNA	
<213>	Artificial Sequence	
<220>		•
<b>≪223</b> >	RNAi molecule	•
		•
<400>	490	
aagcaa	nugcg guaguacuau aucuggc	27
<210>	491	
<211>	27	
<212>	RNA	
<213>	Artificial Sequence	
<220>		
<223>	RNAi molecule	
<400>	491	
caagc	aaugc gguaguacua uaucugg	27
<210>	492	
<211>	27	
<212>		
	Artificial Sequence	
	-	•
<220>		
	RNAi molecule	
<400>	492	. •
	auuga ugcugcacau guugacg	2.
~~=		

WO 2004	/070002		PCT/US2003/037143
<210>			
<211> <212>			
	Artificial Sequence		
	-		
<220>			
<223>	RNAi molecule		
<400>	493		
	auug augcugcaca uguugac		27
:	181		
<210>			
<211>		* **:	
<212>			
	Artificial Sequence		
: <220>	·		
	RNAi molecule		
	t		
<400>			27
ucucgu	uguc ucuuccagcu guucaag		21
<210>		•	
<211>			•
<212>	RNA Artificial Sequence		
<543>	William Seguence		
<220>	• •		•
<223>	RNAi molecule	•	
<400>	495		
	uugu cucuuccagc uguucaa		27
		•	
<210>	496		
<211>	27		
<212>	RNA		
<220>	·		
	RNAi molecule		
<400>			ວາ
	gaacc uggaucuccu gacuguu		27.
	·		
<210>		•	
<211>			
<212>			
<213>	Artificial Sequence		
<220>			
<223>	RNAi molecule		
<400>	497		
	caagc uguauauaga gccaauu		27
22309			
	400		
<210> <211>			
<b>KZ11&gt;</b>	£ 1		

WO 2004	1/070002		PCT/US2003/03714	3
<212> <213>	RNA Artificial Sequence			
<220>				
<223>	RNAi molecule			
<400>	498			
cucueca	auca gucaccacaa uggccuu			27
<210>				
<211> <212>				
	Artificial Sequence			
<220>				
	RNAi molecule	•		
	499		•	27
ucauca	uauu cagaaccucu uacucuu		•	27
<210>	500			
<211>				
<212>				
	Artificial Sequence			
<220> <223>	RNAi molecule			
<400>	500		•	
	auug aaugugcaau acugguu			27
			·	
<210>	501			
<211>				
<212>	RNA Artificial Sequence			
<220>	in the second		·	
	RNAi molecule			
<400>	501			
	gaca ucuucuggcc augcauu			27
<210>				
<211> <212>				
	Artificial Sequence			
<220>				
	RNAi molecule			
<400>	502			
ccaca	ecag aaugacaggc agacauu			27
<210>			•	
<211>				
<212>	RNA			

# WO 2004/070002 PCT/US2003/037143 <213> Artificial Sequence <220> <223> RNAi molecule <400> 503 27 ucaccacaau ggccuugaug acaucuu <210> 504 <211> 27 <212> RNA <213> Artificial Sequence <220> <223> RNAi molecule <400> 504 caugaauguu caauugcugu cucucuu 1.27 <210> '505 <211> 27 <212> RNA <213> Artificial Sequence <220> <223> RNAi molecule <400> 505 **27** ' aaugacaggc agacauucuu gaggauu <210> 506 <211> 27 <212> RNA <213> Artificial Sequence <220> <223> RNAi molecule <400> 506 27 guucaggaga cgaaaugcau ucacauu <210> 507 <211> 27 <212> RNA <213> Artificial Sequence <220> <223> RNAi molecule <400> 507 27 gecguaguec aauguagagu ggaucuu <210> 508 <211> 27 <212> RNA

<213> Artificial Sequence

			•
<220>			
<223>	RNAi molecule		
	508		
agaccu	gcaa cugcaacaga ugcuguu	23	7
•			
<210>			
<211>			
<212>		•	
<213>	Artificial Sequence		
<220>	4 66		
	RNAi molecule		
1000			
:<400>	509		
guggca	acaa uccaugaaug uucaauu	2'	7
<210>			
<211>			
<212>			
<213>	Artificial Sequence		
<220>			
	RNAi molecule	•	
72837	Tent mozocazo		
<400>	510		
	agcu guauauagag ccaauuu	2	7
_			
<210>		·	
<211>			
<212>			
<213>	Artificial Sequence		
<220>			
<223>	RNAi molecule		
	Turia morocuro		
<400>	511		
	rugge aacaauccau gaauguu	2	7
_			
<210>			
<211>	<del>-</del> -		
<212>	Artificial Sequence		
<213>	Artificial Sequence	•	
<220>		•	
	RNAi molecule		
4220			
<400>	512		
	aucau cauauucaga acc <del>uc</del> uu	2	27
	_	•	
<210>			
<211>			
<212>			
<213>	Artificial Sequence		
<220>			
ヘゼビリン			

WO 2004	/070002	PCT/US2003/037143
	RNAi molecule	
<400>	513	
ugaauu	guc caaaaaauca ucauauu	27
1.57		
<210>	514	
<211> <212>	27	,
	Artificial Sequence	
	• • • • • • • • • • • • • • • • • • • •	
<220>		
<223>	RNAi molecule	
<400>	agua acuccucauu uucgguu	27
, peduda	agua acuccucada daoggan	
•		
<210>	515	
<211>		
<212>		
<213>	Artificial Sequence	
<220>	·	
	RNAi molecule	
		•
<400>		<b>27</b> .
guggav	cuuu aaguaacucc ucauuuu	27 .
	· ·	
<210>	516	
<211>		
<212>		
<213>	Artificial Sequence	
<220>		
	RNAi molecule	
<400>		0.7
agugga	aucuu uaaguaacuc cucauuu	27
	·	
<210>	517	
<211>		
<212>	RNA	
<213>	Artificial Sequence	
<220>	RNAi molecule	
\&&J>	MAI MOICCUIC	
<400>	517	
ucauc	auuga augugcaaua cugguuu	27
401.0s	510	
<210> <211>		
	RNA	
	Artificial Sequence	
<220>		
<223>	RNAi molecule	

# WO 2004/070002

<b>≈400&gt;</b>	518	
cugaaua	aagg caauucaugc cauacuu	27
<210>	519	
<211>	27	
<212>		
<213>	Artificial Sequence	
<220>		
<223>	RNAi molecule	
<400>	519	
gagaag	auac cugucaaagu cagaguu	27
	•	•
<210>	520	
<211>	27	•
<212>	RNA	· ·
<213>	Artificial Seguence	
	·-	•
<220>		
	RNAi molecule	•
,		
<400>	520	
	gaau gacaggcaga cauucuu	27
	5	
<210>	521	
<211>		
<212>		
	Artificial Sequence	
-220		
<220>		
<223>	RNAi molecule	•
		•
<400>	521	
	cugg aucuccugac uguugaa	27
	•	
<210>	522	
<211>	27 .	
<212>		
	Artificial Sequence	
<220>		•
	RNAi molecule	
		•
<400>	522	
	accug gaucuccuga cuguuga	2'
		_
<210>	523	
<211>		
<212>		
	Artificial Sequence	
~223/	Janabana Doguesec	
<220>		
	RNAi molecule	
~		

<b>&lt;400&gt;</b>	523	
cucuaa	gaac -cuggaucucc ugacugu	27
-010-	£0.4	
<210>		
<211> <212>	•	
<213>	Artificial Sequence	
<220>		
	RNAi molecule	
1225		
<400>	524	
	auua agagaagaua ecuguca	27
•		
<210>		
<211>		
<212>		1
<213>	Artificial Sequence	
<220> <233>	RNAi molecule	
<b>\</b> 2237	WAT MOISCALE	
<400>	525	
	proag augucagoac ucuauaa	.27
<210>	526	
<211>		
<212>		
<213>	Artificial Sequence	
.000		
<220> <223>	RNAi molecule	
<b>&lt;223</b> >	RWAI MOIECUIE	
<400>	526	
	acucu aagaaccugg aucuccu	27
<210>		
<211>		
<212>		
<213>	Artificial Sequence	
<220>		
	RNAi molecule	
\&&J/	NAMI WOJECUIE	•
<400>	527	
	auguc agaugucagc acucuau	27
<210>		
<211>		
	RNA	
<213>	Artificial Sequence	
2000-		
<220>	RNAi molecule	
~EEJ/		
<400>	528	

WO 2004/070002

augcau	ngag aacugaagca auaugcc	27
<b>&lt;210&gt;</b>	529	
	27	
<212>		
<213>	Artificial Sequence	
<220>		
	RNAi molecule	
<400>		27
uauucas	gaac cucuüacucu ucucugc	2/
,		
:<210>	530	
<211>		
<212>	RNA Artificial Sequence	
\Z13>	Artificial Sequence	
<220>		
<223>	RNAi molecule	
400	<b>700</b>	
<400>	aaga accuggaucu ccugacu	27
uacucu	adda accaddada coadaca ,	4,
<210>		
<211><212>		
	Artificial Sequence	
1020		
<220>		
<223>	RNAi molecule	
<400>	<b>5</b> 31	
	cucu ccaucaguca ccacaau	27
-010-	520	
<210> <212>		
	Artificial Sequence	
<220>	musi malamula	
<223>	RNAi molecule	
<400>	532	
auucag	aacc ucuuacucuu cucugec	27
<210>	- 	
<211>		
<212>		
<213>	Artificial Sequence	
J000-		
<220> <223>	RNAi molecule	
-005-		
<400>		
cuacuc	uaag aaccuggauc uccugac	27

<210>	534		
<211>	27		
<212>		•	
<213>	Artificial Sequence		
<220>	•		
	RNAi molecule		
\LLJ>	THE MOLOGIC		
<400>	534		
ucugge	caug cauugagaac ugaagca	+	27
<b>≪210&gt;</b>	626	•	
<211>	27		
<212>		•	
	Artificial Sequence		
<220>		ı	
<223>	RNAi molecule	•	
<400>	535		
	gcuc uccaucaguc accacaa		27
٥,			
<210>			
<211> <212>			
	Artificial Sequence	•	
4220			
<220>			
<223>	RNAi molecule		
-4005	536		
<400>	gcaag cuguauauag agccaau		27
ccuco:	·		
<210>			
<211>			
<212> <213>			
	Withitan pedacuce		
<220>		•	
<223>	RNAi molecule		
<400>	ucucu geeguaguee aauguag	·	27
acucu	ucucu geeguaguee aauguag		-
<210>	538		
<211>			
	RNA		
<213>	Artificial Sequence	•	
<220>			
	RNAi molecule		
<400>			_
aucau	auuca gaaccucuua cucuucu		2

<210>	539	
<b>~211&gt;</b>		
<b>&lt;212&gt;</b>		
75132	Artificial "Sequence	
<220>		
<b>&lt;223&gt;</b>	RNAi molecule	
<400>	539	
		27
uqueau	cauu gaaugugcaa uacuggu	2,
<210>	540	
<211>	27	
<212>	RNA	
×213>	Artificial Sequence	
1		
<220>		
<223>	RNAi molecule	
<400>	540 '	
auauca	ucau ugaaugugca auacugg	27
	· ·	
<210>	E41	
	· ·	
<211>		
<212>		
<213>	Artificial Sequence	
<220>		
,	RNAi molecule	
<400>	541	
uccuug	aaua ucaucauuga augugca	27
	•	
	•	
<210>	542	
<211>	27	
<212>		
	Artificial Sequence	
~2132	viciticiat pedreuce	
<220>		
<223>	RNAi molecule	
<400>	542	
uuccuu	ngaau aucaucauug aaugugc	27
	·	
<210>	F.4.2	
<211>		
<212>		
<213>	Artificial Sequence	
<220>		
	RNAi molecule	
-2120		
-400-	542	
<400>		
gaucca	auuaa gagaagauac cugucaa	27
<210>	544	

	•	
<211>	27	
<212>		
	Artificial Sequence	
	TETTIOTAL DOGUMENT	
<220>		
2223	RNAi molecule	
, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	10tt11 morecule	
<400>	544	
	caau ugcugucucu cuuccag	27
·, -		
1		
<210>	545 "	
<211>		
<212>		
	Artificial Sequence	
•	•	
<b>&lt;220&gt;</b>		
<223>	RNAi molecule	
<400>	545 .	
gaaugu	lucaa uugcugucuc ucuucca	27
<210>		
<211>		
<212>		
<213>	Artificial Sequence	
000	•	
<220>	RNAi molecule	•
<223>	RNAI MOIECUIE	
<400>	546	
	acucc acggugaacu cugacuu	27
agagas		
<210>	547	
<211>		
<212>	RNA	
<213>	Artificial Sequence	
<220>		
<223>	RNAi molecule	
<400>		27
gacau	cugug augaugaugg ccaaguu	27
-04.0	540	
	548	
<211>	RNA	
	Artificial Sequence	
<b>\613</b> /	the present policies	
<220>		
	RNAi molecule	
-263/		
<400>	→ <b>548</b>	
	auguug gugcuguaag gcagguu	27
33-		
	<b>→ 549</b>	
	<b>→</b> 27	
		•

****	7070002	1 617 652 665 745
<212>	RNA	
	Artificial Sequence	
<220>		
<223>	RNAi molecule	
. 400-	540	
	549 cuug ücuugaucug uggcguu	27
ccuggu	cada acadaacaa aaacaa	<u> </u>
<210>	550	
<211>		
<212>		
<213>	Artificial Sequence	
<220>		
	RNAi molecule	·
	550	. 27
cagcag	guau guaucaaaga agugguu	ı <b>27</b>
		•
<210>	551	
<211>	27	
<212>	RNA	
<213>	Artificial Sequence	
-000-		·
<220> <223>	RNAi molecule	
1225-	.dum moroure	
<400>	551	
agaaug	cucg uagauguugg ugcugua	27
<210>	552	•
<211>	27	
<212>	RNA	
<213>	Artificial Sequence	
<220>		
<223>	RNAi molecule	•
******		
<400>		
aacuc	cacgg ugaacucuga cuugguc	.27
<210>	553	
<211>		
<212>		
<213>	Artificial Sequence	
<220>	•	
	RNAi molecule	
===	-	
<400>		•
gagaa	cucca cggugaacuc ugacuug	23
<210>	554	
<211>	27	
<212>	RNA	

<213>	Artificial Sequence	
-000-		
<220>	man / malamila	
<223>	RNAi molecule	
-400-	CCA	
<400>		27
uugucui	ugau cuguggcguu gaccgug	
<210>	555	
<211>		
<212>		
	Artificial Sequence	
	•	
<220>		
<223>	RNAi molecule	
<400>		
ggagga	gaau gcucguagau guuggug	' 27
	•	
•		
<210>		
<211>		
<212>		
<213>	Artificial Sequence	
<220>		
	RNAi molecule	
<b>~</b> 223>	WANT INSTEGRIE	
<400>	556	
	cuugu cuugaucugu ggcguug	27
Cuggue	,	
<210>	557	
<211>		
<212>		
<213>	Artificial Sequence	
<220>		
<223>	RNAi molecule	
<400>	ce7	
		27
yyaya	augcu cguagauguu ggugcug	
<210>	558	
<211>	•	
<212>	•	
<213>	Artificial Sequence	
<220>		
<223>	RNAi molecule	
<400>		2
uccau	guccu ggacaucugu gaugaug	2
-240-	559	
<210> <211>		
	RNA	
	Artificial Sequence	

\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \		
<220>		
<223>	RNAi molecule	
. 24.00-	cen :	
	559 gguc agcacuccgc ugaugua	27
,	ggac agraencege agaagaa	
• • • • • • • • • • • • • • • • • • • •		
<210>	560	
<211>	27	
<212>	RNA .	
<213>	Artificial Sequence	
000	•	
<220>	RNAi molecule	
<b>4227</b>	WAI INTEGRIG	
<b>₹400&gt;</b>	560	
	gcug aucagcaggu auguauc	27
<210>	561	
<211>		
<212>	Artificial Sequence	
<b>4213</b> >	Artificial Sequence	
<220>	,	
	RNAi molecule	
<400>		
guguco	cucge ugaucageag guaugua	27
<210>	562	
<211>		
<212>	•	
<213>	Artificial Sequence	
<220>	nm /	
<223>	RNAi molecule	
<400>	562	
	aguca ggaugaagcc auggcug	27
		•
<210>		
<211>		
<212>	Artificial Sequence	
<213>	wretterar bedreine	
<220>		
	RNAi molecule	
· <u>-</u>		
<400>		-
acauc	uguga ugaugauggc caaguug	5.
<210>	564	
<211>		
	RNA	

<213> Artificial Sequence

WO 2004	/070002		PCT/US2003/037143
<220>			
<223>	RNAi molecule		
<400>	564		
andrec	ugga caucugugau gaugaug		27
, , ,			21
<210>	<b>*565</b>		
<211>			•
<212>	Artificial Sequence		
. <2132	Artificial Sequence		
<220>			
<223>	RNAi molecule		
1			
<400>	565		27
gugcug	uaag gcagguugau gaagaug		27
		,	
<210>		·	
<211>			
<212>			
<213>	Artificial Sequence	•	
<220>		•	
<223>	RNAi molecule		•
-400		•	
<400>			27
auguug	gugc uguaaggcag guugaug		27
			•
<210>			
<211>			
<212>			
<213>	Artificial Sequence		
≪220>		•	
<223>	RNAi molecule		•
.400			
<400>	567		27
uagaug	uugg ugcuguaagg cagguug		27
		•	
<210>		•	
<211>			
<212>	RNA Artificial Sequence		
~413/	werrerer bednetke		
<220>			
<223>	RNAi molecule		
<400>	540		
	agaa cuccacggug aacucug		27
-94649	, accuragely accuracy		21
<210>			
<211>			
<212>	RNA Artificial Sequence		
~6137	werracial pedience		
<220>			

WO 2004	7070002		PCT/US2003/037143
<223>	RNAi molecule		
<400> accugga	569 lugu ucaccuuccg ugugauc		27
<210> <211> <212> <213>	27		
<220> <223>	RNAi molecule		
<400>	570		
cacagu	cagg augaagccau ggcugua		. 27
<210> <211> <212> <213>	27 RNA	·	
<220>	••		
<b>&lt;223&gt;</b>	RNAi molecule		
	571 ccac ggugaacucu gacuugg	*	27
<210> <211> <212> <213>	RNA		
<220> <223>	RNAi molecule		
<400> aaugcu	572 cgua gauguuggug cuguaag		27
<210><211><211><212><213>	27		
<220>	RNAi molecule		
<400> gaaugo	573 ucgu agauguuggu gcuguaa		27
<210> <211> <212> <213>	27		
<220> <223>	RNAi molecule		

, WO <sub>2</sub> 2004/	070002	PCT/US2003/037143
		2 20, 222
	en.	
4400>	574 uag auguuggugc uguaagg	27
adgedeg	and and and and an	
<210>		
<211> <212>		
	Artificial Sequence	
<220>		
<223>	RNAi molecule	
<400>	575	
	acg gugaacucug acuuggu	27
. 1		•
.04.0	rne.	
<210> <211>		
<212>		i
	Artificial Sequence	
<220>	RNAi molecule	·
\Z23>	ideal molecule	
<400>	576	
ugucuuq	gauc uguggcguug accguga	27
•		
<210>	577	
<211>		
<212>		
<213>	Artificial Sequence	
<220>		
	RNAi molecule	
400	con	
<400>	uuga ucuguggcgu ugaccgu	27
caagac		
		·
<210> <211>		
<211> <212>		
	Artificial Sequence	
<220>	RNAi molecule	
<223>	KNAI MOIECUIE	•
<400>	578	
	cuug aucuguggcg uugaccg	5.
<210>	579	
<211>		
<212>	RNA	
<213>	Artificial Sequence	
<220>	•	
	RNAi molecule	

<b>WO</b> 2004	/070002	PCT/US2003/037143
<400>	579	
gaggaga	aug cucguagaug uuggugc	27
<210>	580	•
<211>	27	
<212>	·	
<213>	Artificial Sequence	
<220>		•
	RNAi molecule	
1000		
<400>	580	27
cggagg	agaa ugcucguaga uguuggu	.61
	•	
<210>	581	
<211>		
<212>		
<b>&lt;213&gt;</b>	Artificial Sequence	·
<220>	·	
<223>	RNAi molecule	
~400-	F01	
	581 gcuc guagauguug gugcugu	27
gagaau	acre arranging andered	
	582	
<211> <212>		
<212> <213>	Artificial Sequence	
<b>\Z13</b> /	Willicial Beducine	·
<220>		
<223>	RNAi molecule	
<400 <b>&gt;</b>	582	
	laugc ucguagaugu uggugcu	27
~22~20		
<210>	502	
<210> <211>		
<211>	·	
	Artificial Sequence	
-0407		
<220>		
<223>	RNAi molecule	

RNA Artificial Sequence
RNAi molecule

ggucuugucu ugaucugugg cguugac

<400> 583

<210> 584 <211> 27

<400> 584

27

WO 2004	1/070002	•	PCT/US2003/037143
ugcucgi	ıaga uguuggugcu guaaggc		27
<210>			•
<211> <212>			
	Artificial Sequence		
<220>			
<223>	RNAi molecule		
<400>	585		
cauguc	cugg acaucuguga ugaugau		27
<210>	586		
<211>	27		
<212>			
	Artificial Sequence		•
<220>	mand malamala		
	RNAi molecule		:
	586		22
ceuege	ugau cagcagguau guaucaa		
<210>.			
<211>			•
<212>	RNA	·	
<213>	Artificial Sequence		
<220>	mara 2 1 1 .		
<223>			
<400>	587		27
uccuc	gcuga ucagcaggua uguauca		
<210>			
<211>			
<212>			•
	Artificial Sequence		
<220>	RNAi molecule		
<400>		•	. 27
ngncc	ucgcu gaucagcagg uauguau		27
	589		
<211>			
	RNA		
<b>~213&gt;</b>	Artificial Sequence		

27

<220>

<400> 589

<223> RNAi molecule

aacucugacu uggucucucu guccagu

<b>≮210&gt;</b>	590				
	27				
<212>					
	Artificial Seguence				
<220>					
	RNAi molecule				
<400>	590				
	ngnc nnashcnana acannas				27
aggaca	agae aagaagagaga				
:				•	
<210>	<b>~</b> 91				
×211>					
<b>K212&gt;</b>					
	Artificial Sequence				
<220>		•	1		
	RNAi molecule			٠	
<400>	591	•			
	aucu gugaugauga uggccaa				27
•					
<210>	· <b>592</b>				
<211>	27				
<212>	RNA				
<213>	Artificial Sequence				
	·				
<220>	· ·				
<223>	RNAi molecule				
	·				
<400>	592				
ccaugi	ccug gacaucugug augauga				27
			•		
<210>					
<211>					
<212>					
<213>	Artificial Sequence				
<220>					
<223>	RNAi molecule	•			
	593				27
gucca	ugucc uggacaucug ugaugau	•			2,
-04.0	£04				
<210>					
<211>					
<212>					
<213>	Artificial Sequence				
<220>					
	RNAi molecule				
<243>	MANT MOTECUTE				
-400-	594				
<400>	cuase mamenene narecsa				2.

. '''			
<b>₹210&gt;</b>	<b>595</b>		
<211>	27		
<212>		·	
, <b>&lt;213&gt;</b>	Artificial Sequence		
-000-			
<220>	RNAi molecule		
<223>	RNAI molecule		
<400>	<b>&lt;</b> 95		
	eggu gaacucugae uuggueu		27
acucca	iii		
<210>	596		
	27		
	RNA		
<213>	Artificial Sequence		
<220>			
<223>	RNAi molecule		
	506		
	596		27
ugugui	lagaa cuccucuugc cuauguu		
	•		•
<210>	597		
<211>			
<212>			
	Artificial Sequence		
	• •		
<220>		•	
<223>	RNAi molecule		
	•		
<400>			27
uguac	gaaau guguuagaac uccucuu		21
<210>	508		
<211>			
	Artificial Sequence	•	
1020		•	
<220>			
<223>	RNAi molecule		
	· 598		27
caugo	nuccu gecaageace auuccuu		27
	•		
	500	·	
	599		
	> 27 > RNA		
	Artificial Sequence		
<213	- INCATACINE DOGUCIOCO		
<220	•		
	> RNAi molecule		
-200-			
<400	> 599		
	acauaa uugugcugag uggaguu		-27
		•	
<210	> 600		

250

# WO 2004/070002

<211>	27				
<212>					
<213>	Artificial Sequence				
-000-					
<220>	RNAi molecule				
<b>\ZZ</b> 3/	RIAL MOISCUIE				
<400>	600				
	aagu auaaaaggau ucuacuu				27
	•			•	
<210> <211>					
<211>					
	Artificial Sequence		•		
<220>					
<223>	RNAi molecule				
-400-	C01				,
<400>					27
uacaau	uuuu cagcuucaca cauaauu	•			
<2,10>			•		
<211>					
<212>					
<213>	Artificial Sequence				
<220>					•
	RNAi molecule				
<400>	602				
aaaaag	gaac caaaguauaa aaggauu				27
<210>	603				
<211>					
<212>	RNA			•	
<213>	Artificial Sequence				
-000-				•	
<220>	RNAi molecule				
\L.Z.	THE INCICUAL				
<400>	603				
guguu	agaac uccucuugcc uauguua				27
<210>	604				
<211>					
<212>					
<213>	Artificial Sequence				
<220>					
<223>	RNAi molecule				
<b>~400&gt;</b>	604				
	guuag aacuecucuu gecuaug				27
<210>	605				

WO 2004	/070002		PCT/US2003/037143
<212> <213>	RNA Artificial Sequence		
<220> <223>	RNAi molecule		
<400> gaaaug	605 uguu agaacuccuc uugccua		27
<210> <211> <212> <213>	27		
<220> <223>	RNAi molecule		
<400> acuggu	606 ucug cagcucugga auggaug		27
<210> <211> <212> <213>	27		
<220> <223>	RNAi molecule		
<400> guacga	607 laaug uguuagaacu ccucuug	•	27
<210><211><212><213>	27	·	
<220> <223>	RNAi molecule		
<400> auggu	608 uccug ccaagcacca uuccuuc		27
<220> <223>	RNAi molecule		
	609 guaua aaaggauucu acuucua		27
<211>	610 27 RNA	· ·	

# WO 2004/070002

<213>	Artificial Sequence		
≮220> <b>≮223</b> >	RNAi molecule		
* W			
<400>			27
aaccaa	agua uaaaaggauu cuacuuc		• • • • • • • • • • • • • • • • • • • •
<210>	611		
<211>			
<212>	RNA		
<213>	Artificial Sequence	•	
-1			
<220>	mam 2 2 2 2		
<223>	RNAi molecule		
!< <b>400&gt;</b>	611		
•	ccuc uugccuaugu uaaaaug		27
aguada			
		``	
<210>			
<211>	= :		
<212>	•		
<213>	Artificial Sequence		
<220>			
	RNAi molecule		
<400>			
cagcuu	icaca cauaauugug cugagug		27
	•	•	
<210>	612		
<211>			
<212>			
	Artificial Sequence		
<220>			
<223>	RNAi molecule		
<400>	613		
	cugca gcucuggaau ggaugug	·	27
aggaa	cagea geacaggana ggaagag		
<210>			
<211>			
	RNA .		
<213>	Artificial Sequence		
<220>			
	RNAi molecule		
-3			
<400>	614		
cucua	caauu uuucagcuuc acacaua		27
<210>	615		
<210> <211>		;	
	RNA		
	Artificial Semence		

# WO 2004/070002

<220>				
<223>	RNAi molecule			
<400>	615			
	ngccu auguuaaaau gugaaug			27
.04.0-				
<210>				
<211> <212>				
	Artificial Sequence			
	•			
<220>				
<b>≺223</b> >	RNAi molecule		•	
<400>	616		•	
	cucuu gccuauguua aaaugug		•	. 27
				•
-010-				
<210> <211>				
<211>		•		
	Artificial Sequence			
<220>				
<223>	RNAi molecule			
<400>	617			
	aaucu ugcagaggcc uccagug	•		. 27
			•	
<210>	. 618			
<211>				
<212>				
<213>	Artificial Seguence			
<b>-000</b>	•			
<220>	RNAi molecule			
4225				
<400>				0.5
aauuu	uucag cuucacacau aauugug			27
<210>	<b>619</b>			
<211>	> 27			
<212>				
<213>	> Artificial Sequence			
<220>	•			
	> RNAi molecule			
<400>				27
acaau	uuuuuc agcuucacac auaauug			21
	•			
	> 620			
<211>				
	> RNA > Artificial Sequence			
<ペエコ>	- viriticial pedimence			

254

ו כפכתתקוות מונה יחורתיםונם

Section 18		
<220>		
<223>	RNAi molecule	
7/2/2		
<400>		27
	aacc aaaguauaaa aggauuc	21
<210>	621	
<211>		
₹212>	RNA	
<213>	Artificial Sequence	
•		
<220>	1H	
<223>	RNAi molecule	
<400>	£21	
	nada acrecenand cenaran	27
dagaga	daga acuccucuug ccuaugu	
:		
<210>	622	
<211>	27	
<212>		
<213>	Artificial Sequence	
<220>	DID i mologulo	
<223>	RNAi molecule	
<400>	622	
	ucag uuagagcucc acgaagg	27
,		
<210>		
<211>		
<212>		
<213>	Artificial Sequence	
<220>		
	RNAi molecule	
<400>	623	
uguuag	gaacu ccucuugecu auguuaa	27
	•	
J010:	624	
<210> <211>		
<211>	<del>-</del> ·	
-616/		
<220>	•	
<223>	RNAi molecule	
<400>		
uacga	aaugu guuagaacuc cucuugc	27
<210>	625	
<210> <211>		
<212>		
	Artificial Sequence	
<220>		
-222	PNNi mologula	

# <400> 625 27 · Cgaaaugugu uagaacuccu cuugccu <210> 626 <211> 27 <212> RNA <213> Artificial Sequence ( <220> : <223> RNAi molecule <400> 626 27 acgaaaugug uuagaacucc ucuugcc <210> 627 <211> 27 <212> RNA <213> Artificial Sequence <220> <223> RNAi molecule <400> 627 27 gacugguucu gcagcucugg aauggau <210> 628 <211> 27 <212> RNA <213> Artificial Sequence <220> <223> RNAi molecule <400> 628 27 uuguacgaaa uguguuagaa cuccucu <210> 629 27 <211> <212> RNA <213> Artificial Sequence <220> <223> RNAi molecule <400> 629 27 aauugugcug aguggaguuu ugacaac <210> 630 <211> 27 <212> RNA <213> Artificial Sequence <220>

WO,2004/070002

PCT/US2003/037143

<223> RNAi molecule

# WO 2004/070002

<400>	<del>-</del> 630		
	cac acauaauugu gcugagu		-27
_			
<210>	631		
<211>			
<212>			
<213>	Artificial Sequence		
<220>			
	RNAi molecule		
~2237	NWI morecure		
<400>	631		
	uuca cacauaauug ugcugag		27
<210>	632	·	
<211>			
<212>		•	
<213>	Artificial Sequence		1
, <220>	nund melegule		
<223>	RNAi molecule	•	
<400>	632		
	cuga guggaguuuu gacaacc		27
aaagag			
<210>	633		
<211>	27		
<212>			
<213>	Artificial Sequence	. <b>'</b>	
<220>		•	
<223>	RNAi molecule		
<400>	633		
	icaug gcuaguucau ccugugg		27
Counge	.oug goneganon congagg		
<210>	634		
<211>	27	••	
<212>			
<213>	Artificial Sequence		
<220>			
<223>	RNAi molecule	•	
<400>	634	·	
	icuge ageucuggaa uggaugu		27
Cuggu	acago agoaoaggaa agga-g-		
<210>	635		
<211>		•	
<212>	RNA		
	Artificial Sequence		
<220>			
<223>	RNAi molecule		
	<b></b>		
<400>			25
aaagu	auaaa aggauucuac uucuacc		27

<210>	636				
<211>	27			•	
<212>	<del>-</del> -				
<213>	Artificial Sequence				
	·				
<220>					
<223>	RNAi molecule				
400-	***				٠
	636				27
Caaagu	auaa aaggauucua cuucuac				2,
<210>	637	•			
<211>	27			•	
<212>					
	Artificial Sequence			ı	
	-				1
<220>					
<223>	RNAi molecule	,			
<400>	637				
accaaa	guau aaaaggauuc uacuucu				27
	<b></b>	•			•
<210>	638				
<211>					
<212>				•	
<213>	Artificial Sequence	•			
<220>				•	
<223>	RNAi molecule		•		
\22JZ	MAT MOTECULE				
<400>	638				
	cuccu cuugccuaug uuaaaau				27
				•	
<210>	639	•			
<211>	27				
<212>					
<213>	Artificial Sequence				
<220>					
<223>	RNAi molecule				
<400>	639				
	•			•	27
uuaya	ecucc ucuugecuau guuaaaa	•			
	Q				
<210>	640				
<211>					
<212>			-		
	Artificial Sequence				
	-				
<220>					
	RNAi molecule				
<400>	640				
20100	ucuua ecuaumuaa aaumida				27

# WO 2004/070002

<210>	641		
<211>	27		
<212>	RNA		
<213>	Artificial Sequence		
<220>			
<223>	RNAi molecule		
<i>i</i> 3,		·	
<400>			27
gaacuc	cucu ugccuauguu aaaaugu		21
•	18		
i	•		
<210>			
<211>	27		
<212>			
<b>≺213</b> >	Artificial Sequence		
:	•		
<220>	_		
<223>	RNAi molecule	` <b>\</b>	
	1		
<400>			27
guuaga	acuc cucuugccua uguuaaa		21
	• •		
<210>			
<211>	27	•	
<212>			
<213>	Artificial Sequence		
<220>			
<223>	RNAi molecule		
<400>			27
aaaug	uguua gaacuccucu ugccuau		
	·		•
<210>			
<211>			
<212>			
<213>	Artificial Sequence		
<220>			
<223>	RNAi molecule		
. 4 0 0 -	C A A	•	•
	644		27
uaauu	gugcu gaguggaguu uugacaa		
040-	- E15		
<210>	645		
	RNA Artificial Sequence		
<213>	MECTITOTAL Seductice	•	
.000			
<220			
<223	RNAi molecule		
.400	CAE		
	> 645		27
auaai	uugugc ugaguggagu uuugaca		

WO,2004	/070002		PCT/US2003/037143
<210>	-646		
<211>	27		
<212>	RNA		
<213>	Artificial Sequence		
3 B			
<220>			
<223>	RNAi molecule		
<400>	CAC		
<i>.</i>	geca ucaugugacu ucgaauu		27
. uuguugi	oca deaugugueu ueguuuu		
•			
<210>	647 "		
<211>	27		
<212>			
,<213>	Artificial Sequence		
1			
<220>	RNAi molecule		
<553>	RNAI molecule		
<400>	647	,	
ucauug	cgga uguuaugcuc aauuauu		27
_			
	·	•	
<210>			
<211>			•
<212>			•
<213>	Artificial Sequence		
<220>			
	RNAi molecule		
<400>	648		
uagaac	ucgc uuguagaugg cugaauu		27
			:
<210>	649		
<211>			
<212>			
	Artificial Sequence		
<220>			
<223>	RNAi molecule		
<400>	619		
	ggaa caucagcuuc augucuu		27
Cuuucc			
<210>			
<211>			
<212>			
<213>	Artificial Sequence		
<220>			
	RNAi molecule		
4223°			
~400>	650		
uaacuı	cucc aggauaugug caucauu		27
.040	4E1		
<210>	100		

WO 200	4/070002		PCT/US2003/037143
<b>~211&gt;</b>	27		
<212>	RNA		
	Artificial Sequence		
<220>	,		
<b>~223&gt;</b>	RNAi molecule		
<400>	651		27
aguccu	caac cauagaguca auaucuu		21
<210>	452		
<211>			
<212>			
	Artificial Seguence	,	
<220>			
<223>	RNAi molecule		ı
<400>	652		<b>' 27</b>
aacauc	agcu ucaugucuuc uaucauu		
<210>	653		
<211>		·	
<212>			
<213>	Artificial Sequence		•
<220>			
	RNAi molecule		•
<400>	653	•	
	aguca auaucuuggu acuuguu		27
<210>	654		
<211>	27		
<212>			
<213>	Artificial Sequence		•
<220>			
<223>	RNAi molecule		
<400>			27
uucaa	gucca uuggcuccaa gaugauu		
<210>	655		
<211>			
<212>			
<213>	Artificial Sequence		
≤220>			
	RNAi molecule	•	
	655		•
uggcu	cucga gcuucaagaa caacauu		2*
.04 O:	656		
<210> <211>	• 656 • 27		
~~***	* **		

W 0/2007	70 7000 <b>2</b>	101,002000,007140
Vi.		
<212>	RNA	
<213>	Artificial Sequence	
<220>	,	
<223>	RNAi molecule	
, , ,	Her morocare	
<400>	<56	•
		27
cgauau	cguc ucuccuggca agcucuu	27
• '.'		
<210>		
<211>	27 "	
<212>	RNA	
<213>	Artificial Sequence	
<220>		
	RNAi molecule	
<400>	657	
		27
gcuuca	agaa caacauugaa uaagauu	2,
	450	
<210>		
<211>		
<212>		
<213>	Artificial Sequence	•
<220>		
<223>	RNAi molecule	
<400>	658	
	ccauc augugacuuc gaauuuu	27
355-		
	·	
<210>	<b>650</b>	
<211>		
<212>		
<213>	Artificial Sequence	
<220>		
<223>	RNAi molecule	
<400>	659	
uguug	gccau caugugacuu cgaauuu	27
<210>	660	
<212>		
	Artificial Sequence	·
~2237	·	
<220>		
	RNAi molecule	
<443>	WAT MOTECATE	
400	(60	
	660	
agaaa	ugeca cucuuccuac ucageuu	27
	661	
<211>		
<212>	RNA	
	Artificial Sequence	
	-	



<220>		
<223>	RNAi molecule	
<400>	661	27
ugguacı	uugu uggeeaueau gugaeuu	L
<210>	·662	
<211>		
<212>		
<213>	Artificial Sequence	
-2205		
<220> ~223>	RNAi molecule	
<b>\£</b> ZJ/	MMI morecure	
<400>	662	
aauaag	auuu ucauucgcug cuuucuu	27
	•	
.010-		· ·
<210> <211>		
<212>		
	Artificial Sequence	
-,	•	
<220>		
<223>	RNAi molecule	
<400>		
	uuca uagaccucau uuaguuu	27
uacage	augusta augusta	
<210>		
<211>		
<212>	RNA Artificial Sequence	
<b>&lt;213</b> >	Attilitial bequence	
<220>		
<223>	RNAi molecule	
	664	27
uucuuı	nacag cuucauagac cucauuu	21
		•
<210>	665	
<211>		
<212>		
<213>	Artificial Sequence	
<220>		
	RNAi molecule	
~225		
<400>	665	
uuguc	auuge ggauguuaug eucaauu	27
-210-	666	
<210><211>		
<212>		

<213> Artificial Sequence

WO 2004/070002		_	PCT/US2003/037143
<220> <223>	RNAi molecule		
<400>	666		
uagacc	icau uuaguuucug cugcauu		27
<210>			
<211>			
<212>	Artificial Sequence		
<b>\213</b> >	Wifilitiai peddence		
<220>			
<223>	RNAi molecule		
<400>	667		•
guucuu	uaca gcuucauaga ccucauu		27
			,
<210>			
<211>		•	
<212>	Artificial Sequence		
1	Morrioral podemoc	•	
<220>	DVB: melogulo		
<223>	RNAi molecule		
<400>			
uggeca	lucau gugacuucga auuuuuu		. 27
•		,	•
<210>			•
<211> <212>			
	Artificial Sequence		
<220>	RNAi molecule		
\LE5>	· ·		
<b>≪4</b> 00>			22
uuggc	cauca ugugacuucg aauuuuu		· 27
	CD0		
<210> <211>			
<212>		•	
	Artificial Sequence		:
<220>			
	RNAi molecule		
.4005	670		
<400>	uucuu cuuugccugc auaacuu		27
90204			_,
<210>	671		
<211>		•	•
<212>	RNA		
<213>	Artificial Sequence		
~220>			

<b>WO 2004</b>	/07000z	PCT/US2003/037143
<223> R	NAi molecule	
14,14,	74	
<400> 6	cu ucuccaggau augugca	27
uugaguaa	cu deuceaggaa aegese	
<210> 6		
<211> 2		
<212> F	NNA Artificial Sequence	
<513> F	Affiteign pedacuse	
<220>		
<223> I	NAi molecule	
<400>	572	
	aac uucuccagga uaugugc	27
1	•	
. 1		
<210>		
<211> <212>		
<213>	Artificial Sequence	
<220>		
<223>	RNAi molecule	
<400>	673	0.7
	gcc aucaugugac uucgaau	27
<210>	674	•
<211>		
<212>	RNA	
<213>	Artificial Sequence	
<220>		
	RNAi molecule	
-525		
<400>	674	27
acuugu	uggc caucauguga cuucgaa	
<210>	675	
<211>		
<212>	RNA	
<213>	Artificial Sequence	
<220>	•	
	RNAi molecule	
.444	675	
<400>	nugg ccaucaugug acuucga	27
uacuug		
<210>	676	
<211> <212>		
<212>	RNA	

<213> Artificial Sequence

<220> <223> RNAi molecule

خ400 <i>&gt;</i>	£76	
	augcu gucuccgucc ucgauau	27
	augen gueuceguee meganna	2.
	677	
<213>	Artificial Sequence	
(		
<220>		
<223>	RNAi molecule	
•		
<400>		
gcauuc	ccgga acaucagcuu caugucu	27
• 1		
-010-	670	
<210> <211>		•
<212>		•
	Artificial Sequence	
~425	m trreams ordenise	
<220>		
		•
<400>	678	
uggcau	uuccg gaacaucagc uucaugu	27
	• •	
<210>	•	
<211>		·
<212>		
<213>	Artificial Sequence	
<220>		
<223>		
\22J/	Must morecate	
<400>	679	
	cacuc uuccuacuca gcuugag	27
_		
	·	
<210>		
<211>		
	RNA	
<213>	Artificial Sequence	
نام ممیر		
<220>	RNAi molecule	
<223>	RNAI molecule	
<400>	680	
	igucuc cguccucgau aucgucu	27
5	.gggg <del>-</del>	
<210>	<b>681</b>	
<211>		
	> RNA	
<213>	> Artificial Sequence	
<220>		
<223>	> RNAi molecule	

WO 2004/070002	PCT/US2003/037143
<400> 681 ucaugcuguc uccguecucg auaucgu	27
ucauguigue necytecuteg adabegu	
<210> 682	
<211> 27	•
<212> RNA	
<213> Artificial Sequence	
<220>	
<223> RNAi molecule	
<400> 682	
aucaugcugu cuccguccuc gauaucg	27
	·
<210> 683	•
<211> 27	
<212> RNA <213> Artificial Sequence	·
<5513> Vicialitial Seductice	•
<220>	
<223> RNAi molecule	
<400> 683	
ggagaageca ugucaucauc aucagge	27
<210> 684	
<211> 27	
<212> RNA	•
<213> Artificial Sequence	
<220> <223> RNAi molecule	
(223) KWAI molecule	
<400> 684	0.7
gaacaucage uucaugucuu cuaucau	27
<210> 685	
<211> 27	
<212> RNA	
<213> Artificial Sequence	
<220>	
<223> RNAi molecule	
<400> '685	
uuagaacucg cuuguagaug gcugaau	27
<u> </u>	
<210> 686	
<211> 27	
<212> RNA	
<213> Artificial Sequence	
.000	
<220> <223> RNAi molecule	
JUNET THE THE TIME OF THE TAXABLE TO	

<400> 686

WO 2004/0	70002	PCT/US2003/037143		
ggaacauc	ag cuucaugucu ucuauca		27	
<210> 6 <211> 2 <212> F	27			
	Artificial Sequence			
<220> <223> F	RNAi molecule			
<400> 6 guaacuud	587 cuc caggauaugu gcaucau		27	
<210> 6		•		
<212> 1	RNA	•		
<213> 1	Artificial Sequence		•	
<220> <223>	RNAi molecule			
	688		07	
aguaacu	ucu ccaggauaug ugcauca		27	
<210>				
<211> <212>		·		
	Artificial Sequence	• .		
<220> <223>	RNAi molecule			
<400>	689			
ugaguaa	cuu cuccaggaua ugugcau	·	27	
<210>			•	
<211> <212>				
	Artificial Sequence			
<220> <223>	RNAi molecule			
<400>			0.7	
auaguag	guca ggcaacucag aucuaga		27	
<210>				
<211> <212>				
	Artificial Sequence			
<220>		•		
	RNAi molecule			
<400> ocggaa	691 cauc agcuucaugu cuucuau		27	

<210>	692		
<211>			
<212>	RNA		
	Artificial Sequence		
<220>			
	RNAi molecule		
. 7		•	
<400>	692		
	aaca ucagcuucau gucuucu		-27
uuccgg	ill		
<210>	693		
<211>			
<212>		•	
	Artificial Sequence	_	
~21J/	With the second	·	
<220>			
	RNAi molecule	•	
<b>\</b> 4437	MAI MOIECUIE		
<400>	602		
			-27
uaguag	rucag gcaacucaga ucuagag		2,
		•	
<210>	604		
<211>			
<212>			
<213>	Artificial Sequence		
-000-			
<220>	myn dawal a mala		
<223>	RNAi molecule	•	
.400-	604		
<400>	694	•	27
gauagu	laguc aggcaacuca gaucuag		L
-010-	COE		
<210>			
<211>			
<212>			
<213>	Artificial Sequence		
-000-			
<220>	RNAi molecule		
<225>	RNA1 molecule		
4 0 0 5	605		
<400>			27
guacu	uguug gccaucaugu gacuucg	•	£,
	-00		
<210>			
<211>			
<212>			
<213>	Artificial Sequence		
<220>			
<223>	RNAi molecule		
<400>			
ugacc	agcau caucagauca augaucu		.27

#### WO 2004/070002

<210>	<b></b> 7697				
<211>	27				
<212>	RNA	•		• .	
<213>	Artificial Sequence				
<220>	•				
<223>	RNAi molecule				
400	607				
	697				27
caugga	cuuc accuucuuca ccaecuu				_,
<210>	698	•			
<211>	27	•			
<212>	RNA			·	
	Artificial Sequence				
			•	•	
<220>					•
<223>	RNAi molecule				
<b>&lt;400&gt;</b>	698				27
gaacau	cugc auggacuuca ccuucuu		•		2,
<210>	699	,			
<211>	27				
<212>	RNA				
	Artificial Sequence				
		•			
<220>					
<223>	RNAi molecule				
<400>	699				
acugua	aaugu ggaacuuggc cuugguu				27
.010	500				
<210><211>	700				
<211> <212>	27 RNA				
	Artificial Sequence				
\Z137	Wettierer pedagues				
<b>&lt;220&gt;</b>					
	RNAi molecule				
<400>		•			
aaucg	gugca ccucggaacu ugguguu				27
	504				
<210>					
<211><212>					
	Artificial Sequence				
<213>	viciriciar pednence				
<220>					
<223>					
<400>	701				
	uguuc agcaccacga ccagcuu				27

<210>	702				
<211>	27				
<b>&lt;212&gt;</b>	RNA				
<213>	Artificial Sequence				
	-				
<220>					
	RNAi molecule				
<400>	702				
	uge ugecugueue uuueeuu			•	27
	rage ageragaeae adaeeaa				
· ·					
<210>	703 "				
<211>					
<211>					
2213>	Artificial Sequence				•
1.000					
:<220>					
<223>	RNAi molecule				
		•	;		
<b>~400&gt;</b>				•	22
guggaa	cauc ugcauggacu ucaccuu				-27
•	•		•		
<210>					
<211>					
<212>					
<213>	Artificial Sequence	•	•		
<220>					
<223>	RNAi molecule				
<400>	704				
aggcaa	ucug gccgaucaca aggcauu				27
<210>	705				
<211>	27				
<212>	RNA				
	Artificial Sequence				
	•				
<220>					
	RNAi molecule				
<400>	705				
	aggu aagaggucua uuuuguu				27
	•				
<210>	706	·			
<211>					
<212>		•			
	Artificial Sequence				
~2137	varavau poqueine				
<220>					
	RNAi molecule				
	WANT MOTOCRIS				
.4005	706				
<400>					27
cuuuc	cuuca gguaagaggu cuauuuu				21

<210> 707

WO 200	1/070002		PCT/US2003/037143
<212>			
<213>	Artificial Sequence		
<220>			
	RNAi molecule		
<400>	707		
cauuuu	auca auugcugccu gucucuu		27
1 ( )			
<210>	708 '"		
<211>			
<212>			
	Artificial Sequence		
·	Withful poducino		
<220>	•		
	RNAi molecule		
<b>&lt;223</b> >	MAI MOIECULE		
-4005	708	,	
<400>			27
ggucuu	cugc auuuucuugg ucauuuu		~2.7
<210>	700		
<211>			
<212>			•
<213>	Artificial Sequence		
<220>			
	RNAi molecule		
\ZZ3/	MAI MOIECULE	•	
<400>	709		
	naua ggcuccuggu caaaguu	•	27
guccas	dada gycaccagga caaagaa		
<210>	710		
<211>			
<212>			
	Artificial Sequence		
<220>			
	RNAi molecule		
<400>	710		
	aucaa uugcugccug ucucuuu		27
		•	
<210>	711		
<211>	27		
<212>			
	Artificial Sequence		
	_		
<220>			
<223>	RNAi molecule		
•			
<400>	711		
	uccuu cagguaagag gucuauu		27
<210>			
·<21 <b>1</b> >	27		

	RNA				
<213>	Artificial Sequence				
<220>					
	RNAi molecule				
	712			2	7
cuguaai	igug gaacuuggee uugguuu				
<210>	713				
<211>					
<212>	RNA Artificial Sequence			•	
<213>	Aftilitiat beguance				
<220>			•		
<223>	RNAi molecule				
.4005	712			•	
<400>	713 uuca ecuucuucae caecuug			' a	27
aaggao					
1		•			
<210> <211>					
<211> <212>					
	Artificial Sequence				
<220>	RNAi molecule				
<b>&lt;223</b> >	RIVAL MOLECULE		•		
<400>	714				27
gguaua	aaucg gugcaccucg gaacuug			•	۷,
<210>	715				
<211>					
<212>	RNA Artificial Sequence				
<213>	Aftiticial Sequence				
<220>					
<223>	RNAi molecule				
.400-	715				
	uggag caggacugaa gaacauc				27
		•			
<210> <211>					
	RNA				
<213>	Artificial Sequence				
		•			
<220> <223>					
<b>&lt;</b> 223>	MANT WOTCOME				
<400>	716				-
uggaa	caucu gcauggacuu caccuuc				27
		•			
<210>	- 717				
<211>					
<212	> RNA				

# PCT/US2003/037143 WO 2004/070002 <213> Artificial Sequence <220> <223> RNAi molecule <400> 717 aacaucugca uggacuucac cuucuuc 27 <210> 718 <211> 27 <212> RNA <213> Artificial Sequence <220> <223> RNAi molecule <400> 718 uuggucacau cgaugaecag caucauc ' 27 <210> 719 <211> 27 <212> RNA <213> Artificial Sequence <220> <223> RNAi molecule <400> 719 uuuguucagc accacgacca gcuucug 27 <210> 720 <211> 27 <212> RNA <213> Artificial Sequence <220> <223> RNAi molecule <400> 720 auaaucggug caccucggaa cuuggug 27 <210> 721 <211> 27 <212> RNA <213> Artificial Sequence <220> <223> RNAi molecule <400> 721 aucgugcaga aguaggcauu ccuuccu 27 <210> 722 <211> 27 <212> RNA

274

<213> Artificial Sequence

יו בעניייניני ייוור ייווי ייווי אויייייני

WO 2004/070002

<220>		
<223>	RNAi molecule	
<400>	722	
• .	uccg aaguaauecu ecucauu	27
<210>	702	
<211>		
<212>		
: <213>	Artificial Sequence	
	th ·	
<220>		
<223>	RNAi molecule	
<400>	723	
ugcauc	aaug aucaacugaa uuacauu	27
	-	
<210>	724	
<211>		
<212>		
	Artificial Sequence	
<213>	ALCITICIAL Sequence	
<220>	man /	
<223>	RNAi molecule	
<400>	724	27
uuggav	icuga guaavauccu cuggcuu	21
<210>	725	
<211>	27	
<212>		
	Artificial Sequence	
<220>		
	RNAi molecule	
\ZZ3>	MAN MOTECULE	
<400>	725	
		27
gaagg	auaau cauaauaaug gcucauu	_,
	RO.C	
<210>		
<211>		
<213>	Artificial Sequence	
<220>		
<223>	RNAi molecule	
<400>	726	
	acuga auuacauugc uagaauu	27
2		
<210×	727	
<211>		
	RNA	
<213>	Artificial Sequence	
	•	
~220s		

WO 200	04/070002	PCT/US2003/037143
<223>	RNAi molecule	
<400>	727	
	uaau guuccuacug cugacuu	27
-99-		•
<210>	728	
<211>	27	
<212>		
<213>	Artificial Sequence	
<220>	_	
<223>	RNAi molecule	
<400>	728	
	laaug uaaggcauca cagucuu	. 27
-5-5-		
<210>		•
<211>		
<212>		•
<213>	Artificial Sequence	
<220>		•
<223>	RNAi molecule	
<400>	729	•
	uugua aacaggcuga aauucuu	27
<210>	730	•
<211>		•
<212>	RNA	
<213>	Artificial Sequence	·
-000-		
<220>	RNAi molecule	
\EEJ>	Ideal morocard	
<400>		27
ucauc	acauc gugcagaagu aggcauu	Ε,
-1040م	- 731	
	· /31 · 27	
	NA RNA	
	Artificial Sequence	•
<220	> RNAi molecule	• •
<223	RWAI MORECUIE	
	> 731	
cuga	guaaua uccucuggcu ugagcuu	27
<210	> 732	
	> 27	
	> RNA	•
<213	> Artificial Sequence	
<220	>	
	> RNAi molecule	

<400>	732	
	gcuc auuguguaca uauuauu	27
	-	
\$ W		
<210>	733	
<211>	. ·	
<212>	RNA	
<213>	Artificial Sequence	
<220>		•
<223>	RNAi molecule	
	410	
<400>	733	
•	auca gaucuguucc aagacuu	27
:		•
<210>	734	
<211>	27	
<212>	RNA	
<213>	Artificial Sequence	•
<220>		
<223>	RNAi molecule	•
		·
<400>	734	,
guccga	agua auccuccuca uuucauu	. 27
	_	
	•	
<210>	735	•
<211>	27	
<212>	RNA	•
<213>	Artificial Sequence	
<220>		
<223>	RNAi molecule	
		•
<400>	735	
ugaagu	iccga aguaauccuc cucauuu	27
<210>	736	•
<211>	27	•
<212>		
<213>	Artificial Sequence	
		•
<220>		
<223>	RNAi molecule	
<400>		0.5
cugge	uugag cuucucugcu guuccuu	27
	500	
<210>		
<211>		
<212>		
<213>	Artificial Sequence	
<220>		
<223>	RNAi molecule	

WO 2004/070002	PCT/US2003/037143
S. O. C.	

<b>.</b>		
<b>&lt;</b> 400>	737	
, accucu	ggcu ugagcuucuc ugcuguu	27
12 y		
<210>	738	
· <211>	27	
<212>	RNA	
	Artificial Sequence	
72137	writterar sequence	
₹220>		
<223>	RNAi molecule	
	16	
<400>	738	
	uucc uguaaaaaug uugaauu	27
	and of the state o	21
:		
1-010-	720	
<210>		
<211>		
<212>		
<213>	Artificial Sequence	
	'	
<220>		
	RNAi molecule	
\EZ3/	WAT MOTECUTE	
	739	
caacaa	guuc auuaaauacu ucuccuu	27
<210>	740	
<211>	•	
<212>		
<213>	Artificial Sequence	
<220>		
<223>	RNAi molecule	
<400>	740	
	gcaa aaccaacugc ugugguu	22
addada	gedd ddeeddedge dguggud	27
.040	744	
<210>	741	
<211>		
<212>		
<213>	Artificial Sequence	
	-	
<220>		
	RNAi molecule	
\ZZJ/	WAI WOISCULE	
.400	B44	
<400>		
cacauc	gugc agaaguaggc auuccuu	27
	•	
<210>	742	
<211>		
<212>		
<213>	Artificial Sequence	
<220>		
<223>	RNAi molecule	
<400>	742	

<b>WO 2</b> 00	4/070002	PCT/US2003/037143
cuugcau	ngau ggcaucgaaa -ccaccuu	. 27
<210>	7.4.3	
<211>		
<212>		
	Artificial Sequence	
<220>		
<223>	RNAi molecule	
<400>		27
auaaua	augg cucauugugu acauauu	2.7
<210>	744	
<211>		•
<212>	· ·	
	Artificial Sequence	•
<220>		·
	RNAi molecule	
<400>	744	
ccuuua	uuag uaagacugag cacauuu	27
	545	
<210> <211>		
<212> <213>	Artificial Sequence	
<220> <223>	RNAi molecule	
	•	
<400>		27
uccuui	uauua guaagacuga gcacauu	
	746	
<210> <211>		
	RNA	
	Artificial Sequence	
<220>		
<223>	RNAi molecule	
<400>	746	
cauco	rugcuc augucacuca auucauu	27
~21 <i>0</i> ~	· 747	
<211>		
	RNA	
	Artificial Sequence	
<220>	> RNAi molecule	
-400-	. 747	

27

<400> 747

cucaauuaag ugguccuucu cauccuu

<b>∼210&gt;</b>	748	
<211>	27	
<212>		
	Artificial Sequence	
72132	Wichiteral pedience	
<220>	•	
	RNAi molecule	
7227	MAI morecare	
<400>	748	
	rugg uccuucucau ecuuguu	27
aauuaa	gagg accumencat ceangua	41
-210>	749	
<210>	·	
<211>	27	
<212>		
<513>	Artificial Sequence	
	·	1
<220>		'
<223>	RNAi molecule	
	2.2	
<b>&lt;400&gt;</b>	749	
guauag	ucgc ucaauuaagu gguccuu	27
'		
<210>	750	•
	27	
<212>		
<213>	Artificial Sequence	
	•	
<220>		
<223>	RNAi molecule	
<400>	750	
cugauc	ucuc uguauagucg cucaauu	27
<210>	751	
<211>	27	
<212>		
<b>&lt;213&gt;</b>	Artificial Sequence	
<220>		
<223>	RNAi molecule	
<400>	751	
gguacu	ccau cuugguucuu agcaguu	27
	•	
<210>	752	
<211>	27	
<212>	RNA	
<220>		
<223>	RNAi molecule	
<400>	752	
	cuca uccuuguuca caccauu	27

WO 200	04/070002		PCT/US2003/037143
<210>	753		
	27		
<212>			
<213>	Artificial Sequence		
1			
<220>			
	RNAi molecule		
~~~~	IMIT WOLCOTTO		
<400>	753		
	cege uugaaguacu geagguu		27
	cyc auguaganoa gonggan		
, ·			
<210>	754 "		
<211>			
•			
<212>	Artificial Sequence		
<\Z13>	Wifilitias seddence		
<220>			
<220>	RNAi molecule		
<223>	KNAI molecule		
	BC4	;	
<400>			27
aacugg	aaaa aguuguucac gucacuu		
	ner		
<210>			•
<211>			
<212>			
<213>	Artificial Sequence		
<220>			
<223>	RNAi molecule		
<400>	755		· 27
guacuo	cauc uugguucuµa gcaguuu		
	•		
<210>			
<211>	27		
<212>	RNA		
<213>	Artificial Sequence		
<220>	municum la mula		
<223>	RNAi molecule		
<400>	756		27
ggagu	ugaau acuguuugga agagguu		
	•		•
.04.0	757		
<210>			
<211>			
<212>	RNA		
<213>	Artificial Sequence		
<220>			
	RNAi molecule		
	0.50		
<400>	757	•	27
uuggv	iguggu acuccaucuu gguucuu		<i>4. 1</i>

**<210> 758** 

	004/070002	PCT/US2003/037143	3
and the second	22		
<211> <212>			
-213>	Artificial Sequence		
72.1	Writtergray podlamen		
<220>			
	RNAi molecule		
<40Ò>		-2	7
uccagg	uagu caaacaucuc cacuguu	<b>~</b>	•
( '			
	·		
<210>			
<211>			
<212>	Artificial Sequence		
•	Withtern podemen		
<220>			
<223>	RNAi molecule		
		<b>\</b>	
<400>			27
gguuge	cugga gcgguagaac agaucuu	•	<i>. ,</i>
.000		•	
<210> <211>			
<211>			
	Artificial Sequence	•	
/L13/			
<220>			
<223>	RNAi molecule		
<400>			27
ggcau	ccaug uccaugaggu cauccuu		
-210>	761		
<211>			
	- RNA	·	
	Artificial Sequence		
	•		
<220>			
<223>	> RNAi molecule		
	0.01		
	> 761		27
ugaai	uacugu uuggaagagg uugaguu		
	•		
<210	> 762	,	•
	> 27		
	> RNA		
<213	> Artificial Sequence		
<220			
<223	> RNAi molecule		
-A00	> 762		
	ccaaag augucaucaa acuuguu		27
acuy			
	> 763		
<211	.> 27		

WO 2004	1/070002		PCT/US2003/037143	3
<212> <213>	RNA Artificial Sequence			
<220>				
	RNAi molecule			
<400>	763			
	geca aagaugucau caaacuu		2	27
<210>				
<211>				
<212>				
<213>	Artificial Sequence			
<220>				
≈223>	RNAi molecule			
<400>				27
auccuu	guuc acaccauuuu gacuguu		,	<b>.</b> ,
<210>	765			
<211>				
<212>				
	Artificial Sequence			
<220>				
<223>	RNAi molecule			
<400>	765			
	nuaga acagaucuuu caacuuu			27
<210>	766			
<211>				
<212>				
	Artificial Sequence			
<220>				
<223>	RNAi molecule			
<400>				27
ccuuc	ucauc cuuguucaca ccauuuu			- 21
<210>	767			
<211>				
<212>				
	Artificial Sequence			
<220>				
	RNAi molecule			
<400>	767			
	cucau ccuuguucac aocauuu			·27
<210>	· 768			
<211>				
	RNA			
<213>	Artificial Sequence			

110,1		
<220>		
.<223>	RNAi molecule	
. <400>		
agucuu	caug uuuucuagcu gugccuu	27
•		
<210>	769	
<211>		
<212>		
<213>	Artificial Sequence	
-000-		
<220>	DVI 411 -	
;<223>	RNAi molecule	
<400>	769 ·	
ggagegi	guag aacagaucuu ucaacuu	27
<210>	770	
<211>	· · ·	
<212>		
	Artificial Sequence	
72137	Werricial pedagive	
<220>		
	RNAi molecule	
<400>	770	
	caga gaguecuuca ggacguu	27
3		2,
		•
<210>	771	
<211>	27	
<212>	RNA	
<213>	Artificial Sequence	
<220>		
<223>	RNAi molecule	
	· 	
	771	
acaucc	ugcu caugucacuc aauucau	27
-910-	770	
<210> <211>		
<211> <212>		
<213>	Artificial Sequence	
<220>		
	RNAi molecule	
~663~	ARM HINTERATE	
<400>	772	
	agug guccuucuca uccuugu	27
	-3-3 3	41
<210>	773	
<211>		
<212>		
	Artificial Sequence	

	WO 2004/070002				PCT/US2003/037	143
	<220> <223> RNAi molecui	le				
	CSSD MAN WOLCOM	20				
	<400> 773					27
	ucucuguaua gucgcuc	aau uaagugg				
	<210> 774					
	<211> 27					
	<212> RNA	<b>0</b>				
	<213> Artificial	Sequence				•
	<220>					
	<223> RNAi molecu	ıle				
				•		
	<400> 774 aagugguccu ucucauc	sciii giucaca	•			27
	aagugguccu acacaa	,our grasses			•	
	<210> 775				•	1
	<211> 27 <212> RNA					
	<213> Artificial	Sequence				
		<del>-</del> ,				
	<220>	<b>3</b> -		•		
	<223> RNAi molec	ите				
	<400> 775		٠			
	gcucaauuaa gugguc	cuuc ucauccu				27
•	<210> 776					
	<211> 27					
	<212> RNA					
	<213> Artificial	Sequence				
	<220>					
	<223> RNAi molec	cule		•		
		•				
	<400> 776 gguugaguuc acacud	-cado naducaa				27
	ggugaguuc acaca	Joags anguests				
	<210> 777					
	<211> 27 <212> RNA					
	<213> Artificia	1 Sequence				
			•			
	<220>	au1a				-
	<223> RNAi mole	Cale				
	<400> 777					27
	agguugaguu cacac	uccag guaguca				Z/
	<210> 778					
	<211> 27					
	<212> RNA					
	<213> Artificia	al Sequence				
	<220>		•			

<223>	RNAi molecule			
<400>				27
caugue	aug aggucauccu ucucuag			L
<210>	770			
<210> <211>				
<21-2>				
	Artificial Sequence			
<220>		•		
<223>	RNAi molecule			
<400>	770			
(400>	gguc cuucucaucc uuguuca		•	27
uuuugu	9940 044040444			
			'	•
<210>			'	•
<211>		•		
<212>	RNA Artificial Sequence			
<512>	Artificial bequeixe		•	
<220>				
	RNAi molecule			
<400>	780			27
auaguo	egcuc aauuaagugg uccuucu			
		•		,
<210>	781		•	
<211>				
<212>				
<213>	Artificial Sequence			
<220>				
<223>				
1220			•	
<400>				27
uguau	agucg cucaauuaag ugguccu			
<210×	782			
<211>				
<212>	RNA			
<213>	Artificial Sequence			
<220>	RNAi molecule			
<2232	RIVAT MOTECUTE			
<400	> 782			22
acuga	aucucu cuguauaguc gcucaau			27
_				
	703			
	> 783			
	> 27 > RNA			
	> Artificial Sequence			
<220				
<223	> RNAi molecule			

<400	> 783	
	eccuge ucaugucacu caauuca	-27
• • • •	accuse accusate consists	
18 W	•	
10.1		
, <210	> 784	
<211	> 27	
	> RNA	
<213	> Artificial Sequence	
<220	>	
	> RNAi molecule	
\L'L'J	100	
-400	704	
	> 784	27
uggu	acucca ucuugguucu uagcagu	2,
1		
. 1		
<210	> 785	
<211	> 27	
<212	> RNA	
	> Artificial Sequence	
-220		
<220	<b>.</b>	
<223	> RNAi molecule	
<400		27
uaag	jugguee uucucauceu uguucae	21
	•	
<210	)> 786	
	<b>&gt;</b> 27	
	> RNA	
	3> Artificial Sequence	
<213	Millicial pedgesce	
	·	
<220		
<223	3> RNAi molecule	
<400	0> 786	
ague	cgcucaa uuaagugguc cuucuca	27
_		
<21	0> 787	
	1> 27	
	2> RNA	
<21	3> Artificial Sequence	
	•	
<22		
<22	3> RNAi molecule	
<40	0> 787	
uuc	uagcugu gecuucaauc cacugau	27
٠٥٩	0> 788	
	2> RNA	
<21	3> Artificial Sequence	
	10>	
<22	3> RNAi molecule	
-40	00~ 700	

			-
· ; ;			
14.00			27
' ucugaav	gag ocgcuugaag uacugca		Z1
(数)。			
<210>	789		
	27		
, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			
	RNA		
<213>	Artificial Sequence		
• .			
1 32 1			
<b>: &lt;220&gt;</b>			
<223>	RNAi molecule		
,			
<400>	789		
ggaucu	yaau gagccgcuug aaguacu	•	27
55	,		
;			
<b>&lt;210&gt;</b>	790		
	27		
			•
<212>			
<213>	Artificial Sequence	•	
	1		
<220>			
<223>	RNAi molecule		
	,		
<400>	790		^=
ameen	ucuc auccuuguuc acaccau		27
99			
<210>	791		
	27		
<211>			
<212>	RNA		
<213>	Artificial Sequence		
1020			
<220>	·	•	
<223>	RNAi molecule		
4000			
<400>	791		07
1100110	uucu cauccuuguu cacacca	•	27
25520	, <b>44</b> 0		
,			
<210>	792		
<211>			
<212>	RNA		
<213>	Artificial Sequence		
<220>			
<223>	RNAi molecule		
<400>	792		
മസത്ത	uccuu cucauccuug uucacac		27
agagg			
<b>&lt;210&gt;</b>	793		
<211>			
<212>	RNA		
	Artificial Sequence		
~2137	in creating and amount		
<220>			
	RNAi molecule		
<b>~</b> 443>	WANT WOTECUTE	•	
<b>&lt;400&gt;</b>	793		
	aauua agugguccuu cucaucc		27
cycuc	aaraa aguggubbaa babaab		

WO<sub>1</sub>2004/070002

<210>	794		
<211>	27		
	RNA	•	
<213>	Artificial Sequence	•	
<220>	mam !33 .		
<223>	RNAi molecule		
<400>	794		
	caug gcagaacuuc cagcaga		27
ggaaca	caug gengeneeue engenge		
		•	
<210>	795	•	
<211>	27		
<212>	RNA	·	
<213>	Artificial Sequence		
		•	
<220>			•
<223>	RNAi molecule		
		•	
<400>	795		27
ugaaug	agcc gcuugaagua cugcagg	•	21
-210	796		
<210> <211>	27	•	
<211><212>	RNA		
<213>			
<b>\213</b> /	Westergian pedagues		
<220>			
	RNAi molecule	•	
<400>	796		
cagcau	lagcg uccaacuugg ugucauu		27
<210>	797		
<211>			
<212>			
<213>	Artificial Sequence		
<220>			
<223>	RNAi molecule		
~2237	Idea moreoare	•	
<400>	797		
	ucucc uucuccgugc cgcaguu		27
<210>	798		
<211>			
<212>			
<213>	Artificial Sequence		
<220>			
<223>	RNAi molecule	•	
	700		
<400>			27
acaud	ququu qaaquecaqq auggcuu		Z/

<210>	799	
<211>	27	
<212>		
<213>	Artificial Sequence	
<220>	RNAi molecule	
<223>	RNAI molecule	
~400>	799	22
	ccaug aucucagaca ugguguu	27
_		
<210>		
<211> <212>		
<213>	Artificial Sequence	
4020	•	1
<220>		•
<223>	RNAi molecule	
,	000	
<400>	gcucc uccuuaacga ggucguu	27
guucas	GCACC Accadada 33-03-0	
<210>	801	•
<211>		
<212>	RNA	
<213>	Artificial Sequence	•
<220>		
	RNAi molecule	·
12201		
<400>		27
ucaau	ucacau cuucuaaggu gacgauu	
<210>	> 802	
<211>		
	> RNA	
<213>	> Artificial Sequence	
<220	> RNAi molecule	
<223	> KWAI molecule	
<400	> 802	27
	laacuug gugaggaaga ugguguu	.27
_		
	003	
	)> 803	
	L> 27 2> RNA	
	> NNA 3> Artificial Sequence	
~243	· · · · · · · · · · · · · · · · · · ·	
<220		
<223	3> RNAi molecule	
	,	
<400	0> 803	2

X (mark)					
<210>	804				
<211>					
<212>					
<213>	Artificial Sequence				
<220>					
<223>	RNAi molecule				
<400>	804				
annigai	igau uucuucaauc acaucuu				<del>2</del> 7
(	-gua				
· ·					
<210>	805 "				
<211>					
<212>					
	Artificial Sequence				
	Artificial bequence				
- 1					
<220>	mm: melomile				
<423>	RNAi molecule				
.400-	005		•	•	
<400>					27
gaugcg	cuug gcguaauucu ucuccuu				
<210>	·				
<211>					
<212>					
<213>	Artificial Sequence	•			
<220>					
<223>	RNAi molecule				
		·			
<400>	806				27
cacgai	lagcc aggugagauu uaccuuu				2,
<210>				÷	
<211>					
<212>					
<213>	Artificial Sequence		j		
<220>					
<223>	RNAi molecule				
<400>					27
gcacg	auagc caggugagau uuaccuu				Li
	•				•
		·			
<210>					
<211>					
	RNA				
<213>	Artificial Sequence				
<220>					
<223>	RNAi molecule				
•					
	808				~~
gucga	gcagg auggugagcg ugguguu				. 27
-210	000				

# PCT/US2003/037143 WO 2004/070002 <211> 27 <212> RNA <213> Artificial Sequence <220> <223> RNAi molecule <400> 809 27 uuggcguaau ucuucuccuu cuccgug <210> 810 <211> 27 <212> RNA <213> Artificial Sequence <220> <223> RNAi molecule <400> 810 27 , aucucuccga agaugacgau accgaug <210> 811 <211> 27 <212> RNA <213> Artificial Sequence <220> <223> RNAi molecule <400> 811 27 ggcacgaucu cuccgaagau gacgaua <210> 812 <211> 27 <212> RNA <213> Artificial Sequence <220> <223> RNAi molecule <400> 812 27 aauucuucca gcauagcguc caacuug <210> 813 <211> 27 <212> RNA <213> Artificial Sequence <220> <223> RNAi molecule <400> 813 27 agcauagcgu ccaacuuggu gucauug

<210> 814 <211> 27

<b>~212&gt;</b>				
	Artificial Seguence			
erio di per				
<220>				
<223>	RNAi molecule			
<400>	814			
	cucu ccaugaucuc agacaug			27
7.3				
<210>	915			
<211>				
<212>				
-212>	Artificial Sequence			
<5 <sup>1</sup> 13>	Artificial Seguence			
.000	•			
<220>				
<223>	RNAi molecule			
;				
	815			27
uuccag	caua gcguccaacu ugguguc	•	,	27
	•			
<210>	816			•
<211>	27			
<212>	RNA			
<213>	Artificial Sequence	•		
<220>				
<223>	RNAi molecule			
<400>	816			
	agca uagcguccaa cuuggug			27
<210>	817			
<211>				
<212>				
	Artificial Sequence		•	
~2137	William pedagge			
<220>				
	RNAi molecule			
<223>	MAI MOIECUIE			
<400>	017			
				27
ucucc	gaaga ugacgauacc gauggug			E /
	04.0			
<210>				
<211>				
<212>				
<213>	Artificial Sequence			
<220>				
<223>	RNAi molecule			
<400>	818			
gaugu	ucage uccuecuuaa egaggue			27
	•			
<210>	819			
<211>				
<212>		•		
-616/	****			

, WO 2004/070002	PCT/US2003/037143
( A () ( ) ( )	101.002
<213> Artificial Seguence	
<pre>&lt;213&gt; Artificial Sequence</pre>	
<220>	·
<223> RNAi molecule	
<400> 819	27
caugaucuca gacauggugu ugaaguc	
\<210> 820	
<211> 27	
<212> RNA "	
<213> Artificial Sequence	
<220>	
<pre></pre>	
<400> 820	. 27
ccuuggauga uguucagcuc cuccuua	,
·	
<210> 821	•
<211> 27	•
<212> RNA <213> Artificial Sequence	
<213> Aftilitial Sequence	
<220>	
<223> RNAi molecule	
.400- 001	
<400> 821 cucuccgaag augacgauac cgauggu	27
concedual addances in	•
<210> 822	
<211> 27 <212> RNA	
<213> Artificial Sequence	
<220>	•
<223> RNAi molecule	
<400> 822	
guageegeue uccaugaueu cagacau	27
<210> 823 <211> 27	
<212> RNA	
<213> Artificial Sequence	
222	
<220> <223> RNAi molecule	
CERS. IGNT MOTOCOTO	
<b>&lt;4</b> 00> 823	27
uguageegeu cuccaugaue ucagaea	21
<210> 824	
<211> 27	

<212> RNA <213> Artificial Sequence

# WO 2004/070002

<220>		
	RNAi molecule	
~2637	MAI MOIECGIE	
<400>	824	
gaucuci	ecg aagaugacga uaccgau	27
	•	
<210>	825	
<211>	27	
<212>		
	Artificial Sequence	
-E1J/	Artificial pequence	
-220-		
<220>		
<223>	RNAi molecule	
<400>	825	
gaugau	guuc agcuccuccu uaacgag	-27
		•
		•
<210>	826	
<211>		•
<212>	_	
	Artificial Sequence	
<b>\Z13</b> >	Artificial Sequence	
<220>		
<223>	RNAi molecule	•
<400>	826	
uggcgu	aauu cuucuccuuc uecgugc	. 27
<210>	827	•
<211>		
<212>		
	Artificial Sequence	
<b>\Z13</b> /	Artificial Sequence	
-000-		
<220>		•
<223>	RNAi molecule	
		•
<400>	827	
ucucuc	cgaa gaugacgaua ccgaugg	27
<210>	828	
<211>		
<212>		
	Artificial Sequence	
~213/	THE CANADAGE DEGREENCE	
<220>		
	namill-	
<223>	RNAi molecule	
<400>		
cgaucu	cucc gaagaugacg auaccga	· <b>5</b> .
<210>	829	
<211>	27	
<212>		
	Artificial Sequence	

# PCT/US2003/037143 WO 2004/070002 <220> <223> RNAi molecule <400> 829 27 acgaucucuc cgaagaugac gauaccg <210> 830 <211> 27 <212> RNA <213> Artificial Sequence <220> <223> RNAi molecule <400> 830 27 cacgaucucu ccgaagauga cgauacc <210> 831 <211> 27 <212> RNA <213> Artificial Sequence <220> <223> RNAi molecule <400> 831 27 gcacgaucuc uccgaagaug acgauac <210> 832 <211> 27 <212> RNA <213> Artificial Sequence <220> <223> RNAi molecule <400> 832 27 aacuugguga ggaagauggu guuggcc <210> 833 <211> 27 <212> RNA <213> Artificial Sequence <220> <223> RNAi molecule <400> 833 27 cauagcgucc aacuuggugu cauugaa <210> 834 <211> 27 <212> RNA <213> Artificial Sequence

<220>

. . . . . . . .

WO 2004	1/020003		PCT/US2003/037143
WO 2004	707002		FC1/632003/03/143
	RNAi molecule		
<400>	834		
cúugac	guaa uucuucuccu ucucegu		-27
		•	
<210>			
<211>			
<212>			
<213>	Artificial Sequence		
.000			•
<220>	mm: malamala		
<223>	RNAi molecule		
<400>	835		
	acau gguguugaag uccagga		27
;			
• !			
<210>	836		
<211>	27		
<212>		•	•
<213>	Artificial Sequence		
<220>	nm /11 -		
<223>	RNAi molecule		
<400>	836		
	igaca ugguguugaa guccagg		27
440400	.9404 4554544544 5400055		
•			
<210>	837		
<211>	27		
<212>			
<213>	Artificial Sequence		
-000			
<220> <223>	RNAi molecule		
<b>\</b> 2237	AWAI MOTESTATE		
<400>	837		
	gegue caacuuggug ucauuga		27
<210>			
<211>			
<212>			
<213>	Artificial Sequence		
<220>	•		
	RNAi molecule		
<400>			
uucuu	ccage auagegueca acuuggu		27
	020		
<210>			
<211>			
	RNA Artificial Sequence		
<413>	uterrorar seducine		

<220> <223> RNAi molecule

<b>≼400&gt;</b>	839				
	ccag cauagcgucc aacuugg				27
		•			
<210>					
<211>					
<212>	RNA				
<213>	Artificial Sequence			*	
-220-				•	
:<220>	RNAi molecule				
<223>	RNAI molecule				
<400>	840			•	
	ucuc cuucuccgug ccgcagu				27
•					
• 1					
<210>	841				
<211>		•	,		
<212>					
<213>	Artificial Sequence				
<220>	mm !		•		
<223>	RNAi molecule				
<400>	841				
	anca cennenceda decesad			•	27
uaauuc	erefere afternooned and				
•					
<210>	842				
<211>					
<212>	RNA		•		
<213>	Artificial Sequence				
	·				
<220>					
<223>	RNAi molecule				
-4005	842		•		
<400>					27
guaau	ucuuc uccuucuccg ugccgca				
<210>	843				
<211>				•	
<212>					
<213>	Artificial Sequence				
		•			
<220>					
<223>	RNAi molecule	•		•	
<b>&lt;400&gt;</b>	0.42				
	gegua auucuucuee uucueeg				27
geuug	gegua audeudeuce udeuceg				
<210>	844				
<211>					
	RNA				
	Artificial Sequence				
	-				
<220>					
<223>	RNAi molecule				

<400> 844 ccagcauage guccaacuug gugucau	27
•	
<210> 845	
<211> 27	
<212> RNA .	
<213> Artificial Sequence	
<220>	•
<223> RNAi molecule	
<400> 845	0.7
uccagcauag cguccaacuu gguguca	27

# This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

# **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

BLACK BORDERS

IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

FADED TEXT OR DRAWING

BLURRED OR ILLEGIBLE TEXT OR DRAWING

SKEWED/SLANTED IMAGES

COLOR OR BLACK AND WHITE PHOTOGRAPHS

GRAY SCALE DOCUMENTS

LINES OR MARKS ON ORIGINAL DOCUMENT

REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

OTHER:

# IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.